type
stringclasses 1
value | question
stringlengths 13
210
| answer
stringlengths 5
521
| golden_answers
listlengths 1
22
| ideal_answer
stringlengths 9
22.1k
| documents
listlengths 1
133
| snippets
listlengths 0
125
| asq_challenge
int64 5
13
| folder_name
stringclasses 6
values | concepts
listlengths 0
23
⌀ | triples
listlengths 0
4.35k
⌀ | id
stringlengths 24
24
| __index_level_0__
int64 6
5.4k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
factoid
|
Which disease can be treated using Tezepelumab?
|
['severe asthma']
|
[
"severe asthma",
"severe persistent asthma",
"chronic severe asthma",
"refractory asthma",
"difficult-to-treat asthma"
] |
['Tezepelumab can be used to treat severe asthma.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/34572294",
"http://www.ncbi.nlm.nih.gov/pubmed/33368307",
"http://www.ncbi.nlm.nih.gov/pubmed/34572466",
"http://www.ncbi.nlm.nih.gov/pubmed/34606305",
"http://www.ncbi.nlm.nih.gov/pubmed/34608100"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34608100",
"endSection": "abstract",
"offsetInBeginSection": 449,
"offsetInEndSection": 630,
"text": "SUMMARY: Clinical trials demonstrated that tezepelumab, an anti-TSLP monoclonal antibody, is a promising alternative treatment for asthma that is effective also in nontype 2 asthma."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34606305",
"endSection": "abstract",
"offsetInBeginSection": 60,
"offsetInEndSection": 132,
"text": "Tezepelumab in adults and adolescents with severe, uncontrolled asthma. "
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34606305",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 101,
"text": "In severe, uncontrolled asthma, tezepelumab reduced exacerbations and improved asthma control at 1 y."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34572294",
"endSection": "abstract",
"offsetInBeginSection": 970,
"offsetInEndSection": 1141,
"text": "Tezepelumab and other anti-alarmins are thus likely to become, in the near future, valuable therapeutic options for the biological treatment of uncontrolled severe asthma."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34572466",
"endSection": "abstract",
"offsetInBeginSection": 1010,
"offsetInEndSection": 1221,
"text": "Omalizumab, dupilumab, and tezepelumab can directly modulate the ASM in asthma, by specifically blocking the interaction between IgE, IL-4, and TSLP, and their receptors are located on the surface of ASM cells. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34572466",
"endSection": "abstract",
"offsetInBeginSection": 1409,
"offsetInEndSection": 1761,
"text": "AHR has been suggested as the main treatable trait towards precision medicine in patients suffering from eosinophilic asthma, therefore, well-designed head-to-head trials are needed to compare the efficacy of those mAbs that directly target ASM contractility specifically against the AHR in severe asthma, namely omalizumab, dupilumab, and tezepelumab."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33368307",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 309,
"text": "Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, an epithelial cytokine involved in asthma pathogenesis. In the phase 2b PATHWAY study (ClinicalTrials.gov identifier: NCT02054130), tezepelumab significantly reduced exacerbations in adults with severe, uncontrolled asthma. "
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33368307",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 124,
"text": "Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33368307",
"endSection": "abstract",
"offsetInBeginSection": 1496,
"offsetInEndSection": 1663,
"text": "These results support the selection of 210 mg every 4 weeks subcutaneously as the dose for phase 3 studies of tezepelumab in adults and adolescents with severe asthma."
}
] | 12
|
BioASQ-training12b
| null | null |
61f7c904882a024a10000027
| 4,957
|
factoid
|
Chromatin is tightly packed into what structure inside the nucleus?
|
['Nucleosome']
|
[
"Nucleosome",
"Nucleosomal core particle",
"Nucleosome core",
"Histone octamer",
"DNA-histone complex"
] |
['Chromatin, a complex of DNA and proteins, is tightly packed into a highly organized structure called the nucleosome inside the nucleus. Nucleosomes are the fundamental repeating units of chromatin and consist of approximately 147 base pairs of DNA wrapped around an octamer of histone proteins, which include two copies each of histone H2A, H2B, H3, and H4. The nucleosomes are connected by linker DNA and further compacted through interactions with additional histone proteins such as histone H1. This organization allows for efficient packaging of the long DNA molecules within the confined space of the nucleus while still permitting access to genetic information for processes like transcription, replication, and repair. The degree of chromatin compaction can vary depending on cellular context and regulatory mechanisms, ultimately influencing gene expression patterns in response to various signals or environmental cues.', 'DNA in eukaryotes is packed into a nucleoprotein complex called chromatin in a manner that enables it to be rapidly accessed during genomic processes. The basic component of chromatin is the nucleosome consisting of DNA wrapped around a histone octamer. Inside the cell nucleus, chromatin is folded into higher-order structures through various mechanisms, including repositioning of nucleosomes along the DNA, packing of nucleosomes into more condensed 3-dimensional configurations, looping of chromatin fibers, and tethering of chromosomal regions to nuclear structures.', 'Chromatin is the complex of DNA and proteins that make up the chromosomes within the nucleus of eukaryotic cells. The basic unit of chromatin is the nucleosome, which consists of DNA wrapped around a histone octamer. Chromatin is folded into higher-order structures through various mechanisms, including repositioning of nucleosomes along the DNA, packing of nucleosomes into more condensed 3-dimensional configurations, looping of chromatin fibers, and tethering of chromosomal regions to nuclear structures. These higher-order structures play important roles in regulating gene expression and other genomic processes. Overall, chromatin provides a means for tightly packaging genetic information while still allowing it to be rapidly accessed during cellular processes.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/23109894",
"http://www.ncbi.nlm.nih.gov/pubmed/28058066",
"http://www.ncbi.nlm.nih.gov/pubmed/34255854",
"http://www.ncbi.nlm.nih.gov/pubmed/20444609",
"http://www.ncbi.nlm.nih.gov/pubmed/15868422"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/20444609",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 345,
"text": "Our genetic information is tightly packaged into a rather ingenious nucleoprotein complex called chromatin in a manner that enables it to be rapidly accessed during genomic processes. Formation of the nucleosome, which is the fundamental unit of chromatin, occurs via a stepwise process that is reversed to enable the disassembly of nucleosomes."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/15868422",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 464,
"text": "DNA in eukaryotes is packed into chromatin. The basic component of chromatin is the nucleosome consisting of DNA wrapped around a histone octamer. Inside the cell nucleus, chromatin is folded into higher-order structures through various mechanisms, including repositioning of nucleosomes along the DNA, packing of nucleosomes into more condensed 3-dimensional configurations, looping of chromatin fibres, and tethering of chromosomal regions to nuclear structures."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/15868422",
"endSection": "abstract",
"offsetInBeginSection": 147,
"offsetInEndSection": 464,
"text": "Inside the cell nucleus, chromatin is folded into higher-order structures through various mechanisms, including repositioning of nucleosomes along the DNA, packing of nucleosomes into more condensed 3-dimensional configurations, looping of chromatin fibres, and tethering of chromosomal regions to nuclear structures."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34255854",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 90,
"text": "Chromatin is a tightly packaged structure of DNA and protein within the nucleus of a cell."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28058066",
"endSection": "abstract",
"offsetInBeginSection": 138,
"offsetInEndSection": 272,
"text": "The basic unit of chromatin is the nucleosome, which consists of a short piece of DNA wrapped around a core of eight histone proteins."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28058066",
"endSection": "abstract",
"offsetInBeginSection": 273,
"offsetInEndSection": 469,
"text": "In addition to their role in packaging DNA, nucleosomes impact the regulation of essential nuclear processes such as replication, transcription, and repair by controlling the accessibility of DNA."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23109894",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 179,
"text": "DNA repair in eukaryotic cells takes place in the context of chromatin, where DNA, including damaged DNA, is tightly packed into nucleosomes and higher order chromatin structures."
}
] | 12
|
BioASQ-training12b
| null | null |
644ef78f57b1c7a315000084
| 4,968
|
factoid
|
What is the cause of Facioscapulohumeral Muscular Dystrophy type 2 (FSHD2)?
|
['autosomal dominant disease', 'ectopic expression of the transcription factor DUX4 in skeletal muscle', 'mutations in the protein regulating the methylation status of chromatin - SMCHD1']
|
[
"autosomal dominant disease",
"dominant genetic disorder",
"dominant inheritance disorder",
"ectopic expression of DUX4",
"ectopic DUX4 expression",
"DUX4 ectopic expression",
"DUX4 expression in skeletal muscle",
"mutations in SMCHD1",
"SMCHD1 mutations",
"mutations in the SMCHD1 gene",
"SMCHD1 gene mutations",
"protein regulating chromatin methylation - SMCHD1"
] |
['FSHD2 is caused by mutations in the protein regulating the methylation status of chromatin - SMCHD1.', 'Facioscapulohumeral Muscular Dystrophy type 2 (FSHD2) is an autosomal dominant disease that is caused by the mutations in the protein regulating the methylation status of chromatin - SMCHD1tha leads in the ectopic expression of the transcription factor DUX4 in skeletal muscle.', 'FSHD2 is caused by mutations in the SMCHD1 gene which regulates the methylation status of chromatin.', 'Facioscapulohumeral Muscular Dystrophy type 2 (FSHD2) is caused by mutations in the genes SMCHD1, DNMT3B, and LRIF1.', 'FSHD2 is caused by mutations in the SMCHD1 protein, which regulates the methylation status of chromatin.', 'The cause of FSHD2 is mutations in the protein regulating the methylation status of chromatin - SMCHD1.', 'FSHD2 is caused by mutations in the SMCHD1 gene, which regulates the methylation status of chromatin, affecting the muscle function.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/29980640",
"http://www.ncbi.nlm.nih.gov/pubmed/34711481",
"http://www.ncbi.nlm.nih.gov/pubmed/30871534",
"http://www.ncbi.nlm.nih.gov/pubmed/24128691",
"http://www.ncbi.nlm.nih.gov/pubmed/30923442",
"http://www.ncbi.nlm.nih.gov/pubmed/29402602",
"http://www.ncbi.nlm.nih.gov/pubmed/30327220",
"http://www.ncbi.nlm.nih.gov/pubmed/28915324"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30871534",
"endSection": "abstract",
"offsetInBeginSection": 12,
"offsetInEndSection": 212,
"text": "Facial-scapular-humeral myodystrophy Landouzy-Dejerine (FSHD) is an autosomal dominant disease, the basis of its pathogenesis is ectopic expression of the transcription factor DUX4 in skeletal muscle."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30871534",
"endSection": "abstract",
"offsetInBeginSection": 480,
"offsetInEndSection": 584,
"text": "FSHD2 is caused by the mutations in the protein regulating the methylation status of chromatin - SMCHD1."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24128691",
"endSection": "abstract",
"offsetInBeginSection": 1116,
"offsetInEndSection": 1325,
"text": "Given the previous report of SMCHD1 mutations in FSHD2 and the clinical presentations consistent with the FSHD phenotype, we conclude that the SMCHD1 mutation is the likely cause of the disease in this family."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24128691",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 96,
"text": "Exome sequencing identifies a novel SMCHD1 mutation in facioscapulohumeral muscular dystrophy 2."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24128691",
"endSection": "abstract",
"offsetInBeginSection": 275,
"offsetInEndSection": 373,
"text": "Recently, mutations in SMCHD1 combined with a permissive 4q35 allele were reported to cause FSHD2."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34711481",
"endSection": "abstract",
"offsetInBeginSection": 140,
"offsetInEndSection": 318,
"text": "Facioscapulohumeral muscular dystrophy type 2 (FSHD2) accounts for approximately 5% of all cases of FSHD and describes patients without a D4Z4 repeat contraction on chromosome 4."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30923442",
"endSection": "abstract",
"offsetInBeginSection": 256,
"offsetInEndSection": 491,
"text": "Type 1 facioscapulohumeral muscular dystrophy (FSHD) is caused by contraction of D4Z4 repeats on 4q35, whereas type 2 FSHD is associated with mutations of the SMCHD1 or DNMT3B gene in the presence of a disease-permissive 4qA haplotype."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30327220",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 215,
"text": "Facioscapulohumeral muscular dystrophy (FSHD) 2 is caused by a combination of heterozygous structural maintenance of chromosomes flexible hinge domain containing 1 (SMCHD1) mutation plus DNA hypomethylation on D4Z4."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28915324",
"endSection": "abstract",
"offsetInBeginSection": 808,
"offsetInEndSection": 1037,
"text": "The less common form of the disease, FSHD2, results from haploinsufficiency of the SMCHD1 gene in individuals carrying a permissive 4qA allele, also leading to the derepression of DUX4, further supporting a central role for DUX4."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29402602",
"endSection": "abstract",
"offsetInBeginSection": 463,
"offsetInEndSection": 613,
"text": "iduals and 1-10 repeats in patients), and FSHD2 is caused by mutations in SMCHD1 or DNMT3B. Here, we present clinical features and results of genetic "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29980640",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 367,
"text": "OBJECTIVE: To determine whether congenital arhinia/Bosma arhinia microphthalmia syndrome (BAMS) and facioscapulohumeral muscular dystrophy type 2 (FSHD2), 2 seemingly unrelated disorders both caused by heterozygous pathogenic missense variants in the SMCHD1 gene, might represent different ends of a broad single phenotypic spectrum associated with SMCHD1 dysfunction"
}
] | 12
|
BioASQ-training12b
| null | null |
644298cc57b1c7a315000062
| 4,975
|
factoid
|
What is the cause of Facioscapulohumeral Muscular Dystrophy type 1 (FSHD1)?
|
['autosomal dominant disease', 'partial deletion of the D4Z4 repeats on the 4th chromosome', 'ectopic expression of the transcription factor DUX4 in skeletal muscle']
|
[
"autosomal dominant disease",
"dominant genetic disorder",
"autosomal dominant disorder",
"hereditary disease",
"partial deletion of the D4Z4 repeats on the 4th chromosome",
"D4Z4 repeat deletion",
"ectopic expression of the transcription factor DUX4 in skeletal muscle",
"DUX4 ectopic expression",
"ectopic DUX4 expression"
] |
['Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is caused by contraction of the D4Z4 repeat array.', 'Facioscapulohumeral Muscular Dystrophy type 1 (FSHD1) is caused by the loss of DNA repetitive elements (D4Z4 repeats) in the subtelomeric region of chromosome 4q, leading to decreased methylation and epigenetic derepression of the toxic protein DUX4.', 'FSHD1 is an autosomal dominant disease that is caused by partial deletion of the D4Z4 repeats on the 4th chromosome, affecting the expression of DUX4.', 'Facial-scapular-humeral myodystrophy Landouzy-Dejerine (FSHD) is an autosomal dominant disease, the basis of its pathogenesis is ectopic expression of the transcription factor DUX4 in skeletal muscle.', 'FSHD1 is caused by partial deletion of the D4Z4 repeats on the 4th chromosome.', 'The cause of FSHD1 is a partial deletion of the D4Z4 repeats on the 4th chromosome, which affects the expression of DUX4.', 'The cause of Facioscapulohumeral Muscular Dystrophy type 1 (FSHD1) is a partial deletion of the D4Z4 repeats on the 4th chromosome, which affects the expression of DUX4.', 'FSHD1 is caused by a partial deletion of the D4Z4 repeats on chromosome 4.', 'FSHD1 is caused by a partial deletion of D4Z4 repeats on chromosome 4, which affects the expression of the transcription factor DUX4 in skeletal muscle.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/31518905",
"http://www.ncbi.nlm.nih.gov/pubmed/14634647",
"http://www.ncbi.nlm.nih.gov/pubmed/24882751",
"http://www.ncbi.nlm.nih.gov/pubmed/30871534",
"http://www.ncbi.nlm.nih.gov/pubmed/27822859",
"http://www.ncbi.nlm.nih.gov/pubmed/24755953",
"http://www.ncbi.nlm.nih.gov/pubmed/29436205",
"http://www.ncbi.nlm.nih.gov/pubmed/30122154",
"http://www.ncbi.nlm.nih.gov/pubmed/32703466",
"http://www.ncbi.nlm.nih.gov/pubmed/32576599",
"http://www.ncbi.nlm.nih.gov/pubmed/24075187",
"http://www.ncbi.nlm.nih.gov/pubmed/24128691",
"http://www.ncbi.nlm.nih.gov/pubmed/23593020"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30871534",
"endSection": "abstract",
"offsetInBeginSection": 213,
"offsetInEndSection": 470,
"text": "There are two types of the disease: FSHD1 (MIM:158900) and FSHD2 (MIM: 158901), which have different genetic causes but are phenotypically indistinguishable. In FSHD1, partial deletion of the D4Z4 repeats on the 4th chromosome affects the expression of DUX4"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30871534",
"endSection": "abstract",
"offsetInBeginSection": 12,
"offsetInEndSection": 212,
"text": "Facial-scapular-humeral myodystrophy Landouzy-Dejerine (FSHD) is an autosomal dominant disease, the basis of its pathogenesis is ectopic expression of the transcription factor DUX4 in skeletal muscle."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24128691",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 206,
"text": "FSHD2 is a rare form of facioscapulohumeral muscular dystrophy (FSHD) characterized by the absence of a contraction in the D4Z4 macrosatellite repeat region on chromosome 4q35 that is the hallmark of FSHD1."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27822859",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 152,
"text": "The myopathy facioscapulohumeral muscular dystrophy type 1 (FSHD1) is caused by copy number variation of the D4Z4 macrosatellite repeat on chromosome 4."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/14634647",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 151,
"text": "The autosomal dominant myopathy facioscapulohumeral muscular dystrophy (FSHD1, OMIM 158900) is caused by contraction of the D4Z4 repeat array on 4qter."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24075187",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 144,
"text": "Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is caused by contraction of the D4Z4 repeat array on chromosome 4 to a size of 1-10 units."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24755953",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 225,
"text": "Facioscapulohumeral muscular dystrophy 1 (FSHD1) is caused by a contraction in the number of D4Z4 repeats on chromosome 4, resulting in relaxation of D4Z4 chromatin causing inappropriate expression of DUX4 in skeletal muscle."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31518905",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 207,
"text": "Facioscapulohumeral dystrophy type 1 (FSHD1) is caused by contraction of the D4Z4 repeat array on chromosome 4q resulting in sporadic misexpression of the transcription factor DUX4 in skeletal muscle tissue."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24882751",
"endSection": "abstract",
"offsetInBeginSection": 287,
"offsetInEndSection": 526,
"text": "Autosomal dominant FSHD1 (95% of patients) is characterized by chromatin relaxation induced by pathogenic contraction of a macrosatellite repeat called D4Z4 located on the 4q subtelomere (FSHD1 patients harbor 1 to 10 D4Z4 repeated units)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23593020",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 258,
"text": "Facioscapulohumeral dystrophy (FSHD) is a progressive muscular dystrophy caused by decreased epigenetic repression of the D4Z4 macrosatellite repeats and ectopic expression of DUX4, a retrogene encoding a germline transcription factor encoded in each repeat."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30122154",
"endSection": "abstract",
"offsetInBeginSection": 137,
"offsetInEndSection": 331,
"text": "tal muscle. The genetic cause of FSHD1 is contraction of the D4Z4 macrosatellite array on chromosome 4 alleles associated with a permissive haplotype causing infrequent sporadic expression of th"
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30122154",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 162,
"text": "Sporadic DUX4 expression in FSHD myocytes is associated with incomplete repression by the PRC2 complex and gain of H3K9 acetylation on the contracted D4Z4 allele."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29436205",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 104,
"text": "Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is caused by contraction of the D4Z4 repeat array."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27822859",
"endSection": "abstract",
"offsetInBeginSection": 41,
"offsetInEndSection": 191,
"text": " dystrophy type 1 (FSHD1) is caused by copy number variation of the D4Z4 macrosatellite repeat on chromosome 4. In unaffected individuals the number o"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32576599",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 175,
"text": "Facioscapulohumeral muscular dystrophy (FSHD) is caused by the loss of repression at the D4Z4 locus leading to aberrant double homeobox 4 (DUX4) expression in skeletal muscle."
}
] | 12
|
BioASQ-training12b
| null | null |
6442933f57b1c7a315000060
| 4,979
|
factoid
|
What is CHARMS with respect to medical review of predictive modeling?
|
['CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS).']
|
[
"CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies",
"CHARMS"
] |
['CHARMS stands for CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS).', 'CHARMS stands for Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies. It is a tool used to assess the quality of systematic reviews of predictive modeling studies in the medical field.', 'CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS).']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/35321760",
"http://www.ncbi.nlm.nih.gov/pubmed/32978532",
"http://www.ncbi.nlm.nih.gov/pubmed/28284255",
"http://www.ncbi.nlm.nih.gov/pubmed/31439598",
"http://www.ncbi.nlm.nih.gov/pubmed/32453803",
"http://www.ncbi.nlm.nih.gov/pubmed/25314315",
"http://www.ncbi.nlm.nih.gov/pubmed/33407048",
"http://www.ncbi.nlm.nih.gov/pubmed/35633976",
"http://www.ncbi.nlm.nih.gov/pubmed/35493941",
"http://www.ncbi.nlm.nih.gov/pubmed/31762119",
"http://www.ncbi.nlm.nih.gov/pubmed/35934199",
"http://www.ncbi.nlm.nih.gov/pubmed/31090660",
"http://www.ncbi.nlm.nih.gov/pubmed/33492724",
"http://www.ncbi.nlm.nih.gov/pubmed/33364802",
"http://www.ncbi.nlm.nih.gov/pubmed/35196337",
"http://www.ncbi.nlm.nih.gov/pubmed/34413828",
"http://www.ncbi.nlm.nih.gov/pubmed/32583899",
"http://www.ncbi.nlm.nih.gov/pubmed/35395724",
"http://www.ncbi.nlm.nih.gov/pubmed/31441567"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35633976",
"endSection": "abstract",
"offsetInBeginSection": 452,
"offsetInEndSection": 569,
"text": "CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35321760",
"endSection": "abstract",
"offsetInBeginSection": 1208,
"offsetInEndSection": 1359,
"text": "We will extract data based on the Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS), "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35196337",
"endSection": "abstract",
"offsetInBeginSection": 688,
"offsetInEndSection": 807,
"text": "Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS-PF)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35493941",
"endSection": "abstract",
"offsetInBeginSection": 892,
"offsetInEndSection": 993,
"text": "Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS)"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32583899",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 267,
"text": "The CHARMS (critical appraisal and data extraction for systematic reviews of prediction modelling studies) checklist was created to provide methodological appraisals of predictive models, based on the best available scientific evidence and through systematic reviews."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31762119",
"endSection": "abstract",
"offsetInBeginSection": 53,
"offsetInEndSection": 298,
"text": "However, these models should be developed appropriately (CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modeling Studies [CHARMS] and Prediction model Risk Of Bias ASsessment Tool [PROBAST] statements)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31439598",
"endSection": "abstract",
"offsetInBeginSection": 621,
"offsetInEndSection": 842,
"text": "tudies with model updating. Data was extracted following the Checklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS) checklist.PRIMARY AND SECONDARY OUTCOME MEA"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32453803",
"endSection": "abstract",
"offsetInBeginSection": 693,
"offsetInEndSection": 931,
"text": "Data collection was guided by the checklist for critical appraisal and data extraction for systematic reviews (CHARMS) and applicability and methodological quality assessment by the prediction model risk of bias assessment tool (PROBAST)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31090660",
"endSection": "abstract",
"offsetInBeginSection": 351,
"offsetInEndSection": 509,
"text": "Studies were assessed using the checklist for critical appraisal and data extraction for systematic reviews of prediction modeling studies (CHARMS) checklist."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35395724",
"endSection": "abstract",
"offsetInBeginSection": 321,
"offsetInEndSection": 688,
"text": "methods in oncology. We used the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) statement, Prediction model Risk Of Bias ASsessment Tool (PROBAST) and CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS) to assess the methodological conduct of i"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33492724",
"endSection": "abstract",
"offsetInBeginSection": 372,
"offsetInEndSection": 591,
"text": "inclusion criteria). We followed the CHARMS recommendations (Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies), extracting the information from its 11 domains (Source of data"
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25314315",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 116,
"text": "Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28284255",
"endSection": "abstract",
"offsetInBeginSection": 678,
"offsetInEndSection": 847,
"text": "The CHARMS (Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies) checklist was used for data extraction and quality assessment."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35934199",
"endSection": "abstract",
"offsetInBeginSection": 190,
"offsetInEndSection": 1256,
"text": "ion making. Systematic reviews of prognostic model studies can help identify prognostic models that need to further be validated or are ready to be implemented in healthcare.OBJECTIVES: To provide a step-by-step guidance on how to conduct and read a systematic review of prognostic model studies and to provide an overview of methodology and guidance available for every step of the review progress.SOURCES: Published, peer-reviewed guidance articles.CONTENT: We describe the following steps for conducting a systematic review of prognosis studies: 1) Developing the review question using the Population, Index model, Comparator model, Outcome(s), Timing, Setting format, 2) Searching and selection of articles, 3) Data extraction using the Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies (CHARMS) checklist, 4) Quality and risk of bias assessment using the Prediction model Risk Of Bias ASsessment (PROBAST) tool, 5) Analysing data and undertaking quantitative meta-analysis, and 6) Presenting summary of findings, inte"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33407048",
"endSection": "abstract",
"offsetInBeginSection": 1028,
"offsetInEndSection": 1211,
"text": "te, or status of the publication. To carry out the systematic review, the CHARMS (Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies) guidel"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32978532",
"endSection": "abstract",
"offsetInBeginSection": 1042,
"offsetInEndSection": 1457,
"text": "The authors did not put any restrictions on the models included in their study regarding the model setting, prediction horizon or outcomes.Data extraction and synthesis Checklists of critical appraisal and data extraction for systematic reviews of prediction modelling studies (CHARMS) and prediction model risk of bias assessment tool (PROBAST) were used to guide developing of a standardised data extraction form."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34413828",
"endSection": "abstract",
"offsetInBeginSection": 764,
"offsetInEndSection": 1015,
"text": "We critically appraised these models by means of criteria derived from the CHARMS (CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modeling Studies) and PROBAST (Prediction model Risk Of Bias ASsessment Tool)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31762119",
"endSection": "abstract",
"offsetInBeginSection": 116,
"offsetInEndSection": 266,
"text": "ist for critical Appraisal and data extraction for systematic Reviews of prediction Modeling Studies [CHARMS] and Prediction model Risk Of Bias ASsess"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31439598",
"endSection": "abstract",
"offsetInBeginSection": 690,
"offsetInEndSection": 840,
"text": "t for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS) checklist.PRIMARY AND SECONDARY OUTCOME M"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33492724",
"endSection": "abstract",
"offsetInBeginSection": 405,
"offsetInEndSection": 555,
"text": "the CHARMS recommendations (Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies), extracting the information"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32583899",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 150,
"text": "The CHARMS (critical appraisal and data extraction for systematic reviews of prediction modelling studies) checklist was created to provide methodolog"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31090660",
"endSection": "abstract",
"offsetInBeginSection": 389,
"offsetInEndSection": 539,
"text": "ist for critical appraisal and data extraction for systematic reviews of prediction modeling studies (CHARMS) checklist. In total 89,959 citations wer"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35493941",
"endSection": "abstract",
"offsetInBeginSection": 864,
"offsetInEndSection": 1014,
"text": "acted the data. We used the Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS) checklist for the ri"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33364802",
"endSection": "abstract",
"offsetInBeginSection": 517,
"offsetInEndSection": 667,
"text": "ical appraisal and data extraction for systematic reviews of prediction modeling studies (CHARMS) and the prediction model risk of bias assessment too"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31441567",
"endSection": "abstract",
"offsetInBeginSection": 461,
"offsetInEndSection": 611,
"text": "nalysed (domains of CHARMS, Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies) the following: source of da"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31439598",
"endSection": "abstract",
"offsetInBeginSection": 690,
"offsetInEndSection": 850,
"text": "t for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS) checklist.PRIMARY AND SECONDARY OUTCOME MEASURES: P"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33492724",
"endSection": "abstract",
"offsetInBeginSection": 405,
"offsetInEndSection": 624,
"text": "the CHARMS recommendations (Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies), extracting the information from its 11 domains (Source of data, Participants, etc). We determin"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35493941",
"endSection": "abstract",
"offsetInBeginSection": 864,
"offsetInEndSection": 1020,
"text": "acted the data. We used the Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS) checklist for the risk of "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33364802",
"endSection": "abstract",
"offsetInBeginSection": 517,
"offsetInEndSection": 764,
"text": "ical appraisal and data extraction for systematic reviews of prediction modeling studies (CHARMS) and the prediction model risk of bias assessment tool (PROBAST) were used for the data extraction process and critical appraisal.RESULTS: From the 29"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31441567",
"endSection": "abstract",
"offsetInBeginSection": 461,
"offsetInEndSection": 821,
"text": "nalysed (domains of CHARMS, Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies) the following: source of data, participants, outcome to be predicted, candidate predictors, sample size, missing data, model development, model performance, model evaluation, results and interpretation and discussion.RESULTS: We found tw"
}
] | 12
|
BioASQ-training12b
| null | null |
640f857d201352f04a00002b
| 4,984
|
factoid
|
What is the target of Litifilimab?
|
['BDCA2']
|
[
"BDCA2",
"Blood dendritic cell antigen 2",
"CD303",
"BDCA-2"
] |
['Litifilimab is a humanized monoclonal antibody against BDCA2 that is being developed for treatment of cutaneous lupus erythematosus.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/35939578",
"http://www.ncbi.nlm.nih.gov/pubmed/36069871"
] |
[
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35939578",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 75,
"text": "Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35939578",
"endSection": "abstract",
"offsetInBeginSection": 193,
"offsetInEndSection": 406,
"text": "Whether treatment with litifilimab, a humanized monoclonal antibody against BDCA2, would be efficacious in reducing disease activity in patients with cutaneous lupus erythematosus has not been extensively studied."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36069871",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 74,
"text": "Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36069871",
"endSection": "abstract",
"offsetInBeginSection": 258,
"offsetInEndSection": 420,
"text": " The safety and efficacy of subcutaneous litifilimab, a humanized monoclonal antibody that binds to BDCA2, in patients with SLE have not been extensively studied."
}
] | 12
|
BioASQ-training12b
| null | null |
63eef3ebf36125a42600000a
| 4,987
|
factoid
|
What is AUROC in context of predictive modeling?
|
['area under the receiver operator characteristics curve']
|
[
"area under the receiver operating characteristic curve",
"AUC",
"area under ROC curve",
"area under the ROC curve",
"AUC-ROC"
] |
['. The area under the receiver operator characteristics curve (AUROC)', "AUROC is an evaluation metric used to measure the performance of a predictive model. It is calculated by measuring the area under the receiver operating characteristic curve, which is a graphical representation of the model's true positive rate and false positive rate.", 'AUROC stands for Area Under the Receiver Operating Characteristic Curve. It is a metric used to evaluate the performance of a predictive model by measuring the trade-off between true positive rate and false positive rate at various threshold levels. A higher AUROC value indicates better model performance.', '. AUROC stands for the area under the receiver operator characteristics curve (AUROC)', 'area under receiver operator curve [AUROC]']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/25885260",
"http://www.ncbi.nlm.nih.gov/pubmed/21958955",
"http://www.ncbi.nlm.nih.gov/pubmed/31093546",
"http://www.ncbi.nlm.nih.gov/pubmed/23620757",
"http://www.ncbi.nlm.nih.gov/pubmed/31437918",
"http://www.ncbi.nlm.nih.gov/pubmed/31094792",
"http://www.ncbi.nlm.nih.gov/pubmed/30842277",
"http://www.ncbi.nlm.nih.gov/pubmed/33203588",
"http://www.ncbi.nlm.nih.gov/pubmed/34908548",
"http://www.ncbi.nlm.nih.gov/pubmed/34865209",
"http://www.ncbi.nlm.nih.gov/pubmed/35438215",
"http://www.ncbi.nlm.nih.gov/pubmed/25958031",
"http://www.ncbi.nlm.nih.gov/pubmed/31807867",
"http://www.ncbi.nlm.nih.gov/pubmed/31509205",
"http://www.ncbi.nlm.nih.gov/pubmed/34154565",
"http://www.ncbi.nlm.nih.gov/pubmed/35426141",
"http://www.ncbi.nlm.nih.gov/pubmed/35610482",
"http://www.ncbi.nlm.nih.gov/pubmed/31967640",
"http://www.ncbi.nlm.nih.gov/pubmed/17309939",
"http://www.ncbi.nlm.nih.gov/pubmed/28323524",
"http://www.ncbi.nlm.nih.gov/pubmed/28860560",
"http://www.ncbi.nlm.nih.gov/pubmed/33088899",
"http://www.ncbi.nlm.nih.gov/pubmed/35879562",
"http://www.ncbi.nlm.nih.gov/pubmed/35509018",
"http://www.ncbi.nlm.nih.gov/pubmed/31304302",
"http://www.ncbi.nlm.nih.gov/pubmed/26592354",
"http://www.ncbi.nlm.nih.gov/pubmed/31932807",
"http://www.ncbi.nlm.nih.gov/pubmed/32930711",
"http://www.ncbi.nlm.nih.gov/pubmed/35505048",
"http://www.ncbi.nlm.nih.gov/pubmed/36329470"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35610482",
"endSection": "abstract",
"offsetInBeginSection": 847,
"offsetInEndSection": 915,
"text": ". The area under the receiver operator characteristics curve (AUROC)"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35426141",
"endSection": "abstract",
"offsetInBeginSection": 1513,
"offsetInEndSection": 1556,
"text": "area under receiver operator curve [AUROC] "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35438215",
"endSection": "abstract",
"offsetInBeginSection": 819,
"offsetInEndSection": 927,
"text": "The model performance was evaluated using the area under the receiver operating characteristic curve (AUROC)"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31932807",
"endSection": "abstract",
"offsetInBeginSection": 478,
"offsetInEndSection": 672,
"text": "Our models predict GDM with high accuracy even at pregnancy initiation (area under the receiver operating curve (auROC) = 0.85), substantially outperforming a baseline risk score (auROC = 0.68)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32930711",
"endSection": "abstract",
"offsetInBeginSection": 858,
"offsetInEndSection": 1147,
"text": " prediction of pancreatic cancer. Two popular models were evaluated: logistic regression and a recurrent neural network.RESULTS: For logistic regression, using UMLS delivered the optimal area under the receiver operating characteristics (AUROC) results in both dengue hemorrhagic fever (81"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21958955",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 102,
"text": "Area under the receiver operating characteristics (AUROC) curve is often used to evaluate risk models."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31093546",
"endSection": "abstract",
"offsetInBeginSection": 117,
"offsetInEndSection": 271,
"text": "stic tests. Rather, researchers use the area under the receiver operating characteristic (AUROC) as the key metric to gauge and report predictive performa"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28860560",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 175,
"text": "Area under a receiver-operating-characteristic (AUROC) curve is widely used in medicine to summarize the ability of a continuous predictive marker to predict a binary outcome."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/17309939",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 258,
"text": "The c statistic, or area under the receiver operating characteristic (ROC) curve, achieved popularity in diagnostic testing, in which the test characteristics of sensitivity and specificity are relevant to discriminating diseased versus nondiseased patients."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34908548",
"endSection": "abstract",
"offsetInBeginSection": 1598,
"offsetInEndSection": 1949,
"text": "-day mortality, respectively. When using only baseline variables to predict mortality, all algorithms except SVM (area under the receiver operator characteristic curve [AUROC], 0.83 [95% confidence interval {CI}, 0.69-0.97]) had AUROC >0.9: GBM (AUROC, 0.96 [0.94-1.0]), RF (AUROC, 0.96 [0.92-1.0]), CNN (AUROC, 0.96 [0.92-0.99]), and logistic regress"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31437918",
"endSection": "abstract",
"offsetInBeginSection": 99,
"offsetInEndSection": 361,
"text": "We assessed model performance using two metrics, the area under the receiver operating characteristic curve (AUROC) and the area under the precision-recall curve (AUPRC), to illustrate the differences in information they convey in the setting of class imbalance."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30842277",
"endSection": "abstract",
"offsetInBeginSection": 777,
"offsetInEndSection": 958,
"text": "The two approaches were explored and validated within the context of mRNA expression level prediction and have the area under the ROC curve (auROC) values ranging from 0.75 to 0.94."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26592354",
"endSection": "abstract",
"offsetInBeginSection": 862,
"offsetInEndSection": 1132,
"text": ".4%) and validation (47.4%) cohorts. The FibroGENE-DT yielded the area under the receiver operating characteristic curve (AUROCs) of 0.87, 0.85 and 0.804 for the prediction of fast fibrosis progression, cirrhosis and significant fibrosis risk, respectively, with compara"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31094792",
"endSection": "abstract",
"offsetInBeginSection": 1711,
"offsetInEndSection": 1952,
"text": "ement (oral or IV) was 41.1%. Independent predictors using history alone were female sex, decreasing age, surgical history, and non-Caucasian ethnicity (model area under the receiver operating characteristic curve [AUROC], 0.59 [95% confiden"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33088899",
"endSection": "abstract",
"offsetInBeginSection": 808,
"offsetInEndSection": 1084,
"text": " reduction of at least I° MR. One-year mortality was 28.2%.In Kaplan-Meier analysis, one- year mortality was significantly higher in RVD-pts (34.8% vs 2.8%, p = 0.009).Area under the Receiver Operating Characteristic (AUROC) for SHFM and MAGGIC were comparable for both scores"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23620757",
"endSection": "abstract",
"offsetInBeginSection": 1371,
"offsetInEndSection": 1584,
"text": "Using a standard multivariate approach to combine predictors, the PPIN model achieved an AUROC (area under the receiver operating characteristic curve) of 0.81 with a sensitivity of 48% given a specificity of 90%."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35879562",
"endSection": "abstract",
"offsetInBeginSection": 360,
"offsetInEndSection": 510,
"text": "cognitive impairment was evaluated using area under the receiver operating characteristic curve (AUROC), and multivariate logistic regression was appl"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32930711",
"endSection": "abstract",
"offsetInBeginSection": 1005,
"offsetInEndSection": 1155,
"text": "ssion, using UMLS delivered the optimal area under the receiver operating characteristics (AUROC) results in both dengue hemorrhagic fever (81.15%) an"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25958031",
"endSection": "abstract",
"offsetInBeginSection": 1325,
"offsetInEndSection": 1475,
"text": "s). Sensitivity, specificity, predictive values and area under receiving operating curves (AUROC) of RBUS for VCUG abnormalities were determined.RESUL"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34865209",
"endSection": "abstract",
"offsetInBeginSection": 598,
"offsetInEndSection": 748,
"text": "ys). Model performance was assessed using area under the receiver operator characteristic curve (AUROC). Pre-N8-GP prophylaxis models learned from dat"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34154565",
"endSection": "abstract",
"offsetInBeginSection": 536,
"offsetInEndSection": 686,
"text": "agnostic threshold were evaluated using area under the receiver operating characteristic curve (AUROC). Stratification analysis by age and MP-IgM tite"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35505048",
"endSection": "abstract",
"offsetInBeginSection": 543,
"offsetInEndSection": 693,
"text": " learning algorithms was assessed by the area under the receiver operating characteristic curve (AUROC). The conventional scoring models had various p"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33203588",
"endSection": "abstract",
"offsetInBeginSection": 471,
"offsetInEndSection": 621,
"text": "sing PubMed, MEDLINE, and Scopus databases. Papers with area under the receiver operating curve (AUROC) scores reported were included in the analysis."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36329470",
"endSection": "abstract",
"offsetInBeginSection": 837,
"offsetInEndSection": 987,
"text": "nstruct the prediction model. Finally, the area under the receiver operating characteristic (AUROC) curve was used to compare the model performance.RE"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31304302",
"endSection": "abstract",
"offsetInBeginSection": 1029,
"offsetInEndSection": 1179,
"text": "cy for tasks such as predicting: in-hospital mortality (area under the receiver operator curve [AUROC] across sites 0.93-0.94), 30-day unplanned readm"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31093546",
"endSection": "abstract",
"offsetInBeginSection": 112,
"offsetInEndSection": 262,
"text": "rognostic tests. Rather, researchers use the area under the receiver operating characteristic (AUROC) as the key metric to gauge and report predictive"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32930711",
"endSection": "abstract",
"offsetInBeginSection": 1005,
"offsetInEndSection": 1216,
"text": "ssion, using UMLS delivered the optimal area under the receiver operating characteristics (AUROC) results in both dengue hemorrhagic fever (81.15%) and pancreatic cancer (80.53%) tasks. For recurrent neural netw"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25958031",
"endSection": "abstract",
"offsetInBeginSection": 1325,
"offsetInEndSection": 1466,
"text": "s). Sensitivity, specificity, predictive values and area under receiving operating curves (AUROC) of RBUS for VCUG abnormalities were determi"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33203588",
"endSection": "abstract",
"offsetInBeginSection": 471,
"offsetInEndSection": 577,
"text": "sing PubMed, MEDLINE, and Scopus databases. Papers with area under the receiver operating curve (AUROC) sc"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36329470",
"endSection": "abstract",
"offsetInBeginSection": 837,
"offsetInEndSection": 955,
"text": "nstruct the prediction model. Finally, the area under the receiver operating characteristic (AUROC) curve was used to "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31093546",
"endSection": "abstract",
"offsetInBeginSection": 112,
"offsetInEndSection": 266,
"text": "rognostic tests. Rather, researchers use the area under the receiver operating characteristic (AUROC) as the key metric to gauge and report predictive per"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35879562",
"endSection": "abstract",
"offsetInBeginSection": 360,
"offsetInEndSection": 706,
"text": "cognitive impairment was evaluated using area under the receiver operating characteristic curve (AUROC), and multivariate logistic regression was applied to evaluate predictive accuracy of biomarkers on cognitive impairment; 178 subjects (41 PD, 31 VaD and 106 normal controls) were included. In multiple linear regression analysis of PD patients"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25885260",
"endSection": "abstract",
"offsetInBeginSection": 652,
"offsetInEndSection": 945,
"text": "of outcome (AC), sensitivity (SN), specificity (SP), and area under receiver-operating curve (AUROC) were compared between 3 models: KCC (INR, creatinine, coma grade, pH), CART analysis using only KCC variables (KCC-CART) and a CART model using new variables (NEW-CART).RESULTS: Traditional KC"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31807867",
"endSection": "abstract",
"offsetInBeginSection": 652,
"offsetInEndSection": 941,
"text": "models of the EGFR mutation status (Model 1: area under the receiver operating characteristic curve [AUROC] = 0.910, 95% CI 0.861-0.945; Model 2: AUROC = 0.859, 95% CI 0.803-0.904; Model 3: AUROC = 0.711, 95% CI 0.643-0.773). A testing set (n = 50) and temporal validation data set (n = 70"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31304302",
"endSection": "abstract",
"offsetInBeginSection": 1029,
"offsetInEndSection": 1371,
"text": "cy for tasks such as predicting: in-hospital mortality (area under the receiver operator curve [AUROC] across sites 0.93-0.94), 30-day unplanned readmission (AUROC 0.75-0.76), prolonged length of stay (AUROC 0.85-0.86), and all of a patient's final discharge diagnoses (frequency-weighted AUROC 0.90). These models outperformed traditional, c"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35509018",
"endSection": "abstract",
"offsetInBeginSection": 838,
"offsetInEndSection": 1056,
"text": " matrix, accuracy, precision, recall, F1 score, and Area under the Receiver Operating Characteristics (AUROC) were used to evaluate the performance of predictive models.RESULTS: Ability of prediction was between 68.6% "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35509018",
"endSection": "abstract",
"offsetInBeginSection": 846,
"offsetInEndSection": 1064,
"text": " accuracy, precision, recall, F1 score, and Area under the Receiver Operating Characteristics (AUROC) were used to evaluate the performance of predictive models.RESULTS: Ability of prediction was between 68.6% and 61.5"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31509205",
"endSection": "abstract",
"offsetInBeginSection": 1023,
"offsetInEndSection": 1173,
"text": "s), positive predictive values (PPVs), and area under the receiver operating characteristic curve (AUROC), of machine learning models when predicting "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28323524",
"endSection": "abstract",
"offsetInBeginSection": 645,
"offsetInEndSection": 838,
"text": "ance of prediction, accuracy of discrimination (area under the receiver operating characteristic curve [AUROC]), calibration, and validity of the two predictive models were investigated. The co"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31967640",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 734,
"text": "The area under the receiver operating characteristic (ROC) curve (AUC) is commonly used for assessing the discriminative ability of prediction models even though the measure is criticized for being clinically irrelevant and lacking an intuitive interpretation. Every tutorial explains how the coordinates of the ROC curve are obtained from the risk distributions of diseased and non-diseased individuals, but it has not become common sense that therewith the ROC plot is just another way of presenting these risk distributions. We show how the ROC curve is an alternative way to present risk distributions of diseased and non-diseased individuals and how the shape of the ROC curve informs about the overlap of the risk distributions."
}
] | 12
|
BioASQ-training12b
| null | null |
64136fbf201352f04a00003d
| 4,988
|
factoid
|
When was Keytruda approved by the FDA for the treatment of metastatic non-small cell lung cancer?
|
['October 24, 2016']
|
[
"October 24, 2016",
"10/24/2016",
"10-24-2016",
"24th October 2016",
"24/10/2016"
] |
['On October 24, 2016, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for treatment of metastatic non-small cell lung cancer.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/28835513"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28835513",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 713,
"text": "On October 24, 2016, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda; Merck & Co., Inc., https://www.merck.com) for treatment of patients with metastatic non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1) as determined by an FDA-approved test, as follows: (a) first-line treatment of patients with mNSCLC whose tumors have high PD-L1 expression (tumor proportion score [TPS] ≥50%), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations, and (b) treatment of patients with mNSCLC whose tumors express PD-L1 (TPS ≥1%), with disease progression on or after platinum-containing chemotherapy. "
}
] | 12
|
BioASQ-training12b
| null | null |
6415c53e690f196b51000012
| 4,997
|
factoid
|
What is the estimated reduction in time when using online genetic counseling?
|
['8%']
|
[
"8 percent",
"eight percent",
"0.08",
"0.08 fraction",
"8/100"
] |
['The estimated reduction in the required time through online counseling is about 8%.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/26785833"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26785833",
"endSection": "abstract",
"offsetInBeginSection": 1548,
"offsetInEndSection": 1645,
"text": "We estimated reduced time and costs by online counseling with about 8% and 10-12%, respectively. "
}
] | 12
|
BioASQ-training12b
| null | null |
6415bc8d690f196b5100000f
| 5,009
|
factoid
|
Which company produces Keytruda?
|
['Merck & Co., Inc.']
|
[
"Merck & Co., Inc.",
"Merck Sharp & Dohme Corp.",
"MSD",
"Merck",
"Merck & Co."
] |
['Keytruda is produced by Merck & Co., Inc..']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/28835513"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28835513",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 712,
"text": "On October 24, 2016, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda; Merck & Co., Inc., https://www.merck.com) for treatment of patients with metastatic non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1) as determined by an FDA-approved test, as follows: (a) first-line treatment of patients with mNSCLC whose tumors have high PD-L1 expression (tumor proportion score [TPS] ≥50%), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations, and (b) treatment of patients with mNSCLC whose tumors express PD-L1 (TPS ≥1%), with disease progression on or after platinum-containing chemotherapy."
}
] | 12
|
BioASQ-training12b
| null | null |
6415c599690f196b51000013
| 5,020
|
factoid
|
Cereblon (CRBN) has been identified as the target for what type of drug?
|
['Immunomodulatory drugs (IMiDs)', 'Thalidomide', 'pomalidomide', 'lenalidomide']
|
[
"Immunomodulatory drugs (IMiDs)",
"Thalidomide",
"pomalidomide",
"lenalidomide",
"IMiDs",
"Thalomid",
"Revlimid",
"Pomalyst"
] |
['Immunomodulatory drugs (IMiDs) thalidomide, lenalidomide, and pomalidomide. IMiDs bind to CRBN and recruit neo-substrates for their ubiquitination and proteasome-mediated degradation', 'Cereblon (CRBN) has been identified as the target for thalidomide and its derivatives such as IMiDs (immunomodulatory drugs).', 'Cereblon (CRBN) has been identified as the target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.', 'Cereblon (CRBN) has been identified as the target for immunomodulatory drugs (IMiDs) such as thalidomide, lenalidomide, and pomalidomide.', 'Cereblon (CRBN) has been identified as the target for thalidomide and its derivatives, known as immunomodulatory drugs (IMiDs), such as lenalidomide and pomalidomide.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/33777938",
"http://www.ncbi.nlm.nih.gov/pubmed/26990986",
"http://www.ncbi.nlm.nih.gov/pubmed/26186254",
"http://www.ncbi.nlm.nih.gov/pubmed/26002965",
"http://www.ncbi.nlm.nih.gov/pubmed/34316334",
"http://www.ncbi.nlm.nih.gov/pubmed/21207098",
"http://www.ncbi.nlm.nih.gov/pubmed/32333926",
"http://www.ncbi.nlm.nih.gov/pubmed/35831190",
"http://www.ncbi.nlm.nih.gov/pubmed/24328678",
"http://www.ncbi.nlm.nih.gov/pubmed/28978850",
"http://www.ncbi.nlm.nih.gov/pubmed/29530986",
"http://www.ncbi.nlm.nih.gov/pubmed/35045330",
"http://www.ncbi.nlm.nih.gov/pubmed/23565715",
"http://www.ncbi.nlm.nih.gov/pubmed/35780831",
"http://www.ncbi.nlm.nih.gov/pubmed/26117057",
"http://www.ncbi.nlm.nih.gov/pubmed/22966948",
"http://www.ncbi.nlm.nih.gov/pubmed/27294876",
"http://www.ncbi.nlm.nih.gov/pubmed/22552008",
"http://www.ncbi.nlm.nih.gov/pubmed/31187860",
"http://www.ncbi.nlm.nih.gov/pubmed/33938033",
"http://www.ncbi.nlm.nih.gov/pubmed/36252444",
"http://www.ncbi.nlm.nih.gov/pubmed/25626321",
"http://www.ncbi.nlm.nih.gov/pubmed/34033753",
"http://www.ncbi.nlm.nih.gov/pubmed/31202702"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36252444",
"endSection": "abstract",
"offsetInBeginSection": 128,
"offsetInEndSection": 195,
"text": "Cereblon is a well-known target of thalidomide and its derivatives."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36252444",
"endSection": "abstract",
"offsetInBeginSection": 399,
"offsetInEndSection": 580,
"text": "We have identified novel CRBN inhibitors, namely DHFO and its analogs, with structural features that are slightly different from thalidomide but stronger cereblon-binding affinity. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35045330",
"endSection": "abstract",
"offsetInBeginSection": 98,
"offsetInEndSection": 338,
"text": " It additionally modulates the anti-myeloma effect of the immunomodulatory drugs (IMiDs) thalidomide, lenalidomide, and pomalidomide. IMiDs bind to CRBN and recruit neo-substrates for their ubiquitination and proteasome-mediated degradation"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34316334",
"endSection": "abstract",
"offsetInBeginSection": 162,
"offsetInEndSection": 443,
"text": ". Cereblon (CRBN)-targeting immunomodulatory agents (IMiDs®) lenalidomide (LEN) and pomalidomide (POM) play a central role in combination regimens due to their pleiotropic antitumor/immunomodulatory mechanisms that synergize with many anti-myeloma approved or developmental agents."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31202702",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 293,
"text": "Thalidomide, well known for its potent teratogenicity, has been re-evaluated as a clinically effective drug for the treatment of multiple myeloma. Although the direct target of thalidomide had been unclear until recently, we identified cereblon (CRBN) as a primary direct target of this drug b"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31187860",
"endSection": "abstract",
"offsetInBeginSection": 815,
"offsetInEndSection": 1076,
"text": "The molecular mechanism of action of IMiDs remained unclear for a long time until 2010 when the protein cereblon (CRBN) was identified as a primary direct target. IMiDs binds to CRBN and alters the substrate specificity of the CRBN E3 ubiquitin ligase complex, "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29530986",
"endSection": "abstract",
"offsetInBeginSection": 974,
"offsetInEndSection": 1307,
"text": "These results strongly suggest that increased BK channel activity is the pathological mechanism of intellectual disability in CRBN mutations.SIGNIFICANCE STATEMENTCereblon (CRBN), a well known target of the immunomodulatory drug thalidomide, was originally identified as a gene that causes human intellectual disability when mutated."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22552008",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 123,
"text": "Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26990986",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 208,
"text": "Cereblon (CRBN), a substrate receptor for the cullin-RING ubiquitin ligase 4 (CRL4) complex, is a direct protein target for thalidomide teratogenicity and antitumor activity of immunomodulatory drugs (IMiDs)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22552008",
"endSection": "abstract",
"offsetInBeginSection": 1246,
"offsetInEndSection": 1409,
"text": "Our biophysical, biochemical and gene silencing studies show that CRBN is a proximate, therapeutically important molecular target of lenalidomide and pomalidomide."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26117057",
"endSection": "abstract",
"offsetInBeginSection": 586,
"offsetInEndSection": 899,
"text": "CRBN has been identified as a direct target for immunomodulatory drugs (IMiD) and plays a significant role in anti-proliferation, pro-apoptotic effects, anti-angiogenic activities, immunomodulatory activities and intervention of cell surface adhesion molecules between myeloma cells and bone marrow stromal cells."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33938033",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 265,
"text": "Thalidomide and its derivatives lenalidomide and pomalidomide, known as immunomodulatory drugs, (IMiDs) bind directly to cereblon (CRBN), a substrate receptor of an E3 ubiquitin ligase, resulting in the rapid ubiquitination and degradation of the substrate protein."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28978850",
"endSection": "abstract",
"offsetInBeginSection": 268,
"offsetInEndSection": 321,
"text": "Cereblon (CRBN) is a common primary target for IMiDs."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27294876",
"endSection": "abstract",
"offsetInBeginSection": 241,
"offsetInEndSection": 397,
"text": "Cereblon (CRBN), a substrate receptor of the CRL4 ubiquitin ligase complex, is the primary target by which IMiDs mediate anticancer and teratogenic effects."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23565715",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 161,
"text": "Cereblon (CRBN) has recently been identified as a target for immunomodulatory drugs (IMiDs) and its downregulation has been linked to resistance to lenalidomide."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34033753",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 138,
"text": "Cereblon (CRBN), originally identified as a gene associated with intellectual disability, was identified as primary target of thalidomide."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26186254",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 270,
"text": "Clinical interest in the measurement of Cereblon (CRBN), the primary target of the IMiDs immunomodulatory drugs lenalidomide and pomalidomide, has been fueled by its essential requirement for antitumor or immunomodulatory activity of both drugs in multiple myeloma (MM)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32333926",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 133,
"text": "Cereblon (CRBN), a substrate receptor for Cullin-ring E3 ubiquitin ligase (CRL), is a major target protein of immunomodulatory drugs."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26002965",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 162,
"text": "Cereblon (CRBN), a substrate receptor of the Cullin 4 RING E3 ubiquitin ligase complex, is the target of the immunomodulatory drugs lenalidomide and pomalidomide."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25626321",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 240,
"text": "Cereblon was identified as a direct target of thalidomide by Prof. H. Handa, and this pioneering work triggered active research on IMiDs (immunomodulatory drugs), which include thalidomide-derivatives, such as lenalidomide and pomalidomide."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35780831",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 169,
"text": "The Cullin-RING ligase 4 E3 ubiquitin ligase component Cereblon (CRBN) is a well-established target for a class of small molecules termed immunomodulatory drugs (IMiDs)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21207098",
"endSection": "abstract",
"offsetInBeginSection": 636,
"offsetInEndSection": 750,
"text": " We identified a thalidomide-binding protein, cereblon (CRBN), as a primary target for thalidomide teratogenicity."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35831190",
"endSection": "abstract",
"offsetInBeginSection": 359,
"offsetInEndSection": 567,
"text": " Although the direct target of thalidomide was largely debated until recently, our groups discovered cereblon (CRBN), a substrate receptor of an E3 ubiquitin ligase as a primary target of thalidomide in 2010."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28978850",
"endSection": "abstract",
"offsetInBeginSection": 267,
"offsetInEndSection": 321,
"text": " Cereblon (CRBN) is a common primary target for IMiDs."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33777938",
"endSection": "abstract",
"offsetInBeginSection": 172,
"offsetInEndSection": 322,
"text": "d previously demonstrated that cereblon (CRBN) is the target of thalidomide embryopathy and acts as a substrate receptor for the E3 ubiquitin ligase c"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22966948",
"endSection": "abstract",
"offsetInBeginSection": 333,
"offsetInEndSection": 483,
"text": "dy recently identified cereblon (CRBN) as a primary target of thalidomide teratogenicity. Subsequently it was demonstrated that CRBN is also required "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23565715",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 150,
"text": "Cereblon (CRBN) has recently been identified as a target for immunomodulatory drugs (IMiDs) and its downregulation has been linked to resistance to le"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24328678",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 150,
"text": "Cereblon (CRBN), the molecular target of lenalidomide and pomalidomide, is a substrate receptor of the cullin ring E3 ubiquitin ligase complex, CRL4(C"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22552008",
"endSection": "abstract",
"offsetInBeginSection": 163,
"offsetInEndSection": 313,
"text": "eblon (CRBN) has been identified as the primary teratogenic target of thalidomide. Our studies demonstrate that thalidomide, lenalidomide and another "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24328678",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 156,
"text": "Cereblon (CRBN), the molecular target of lenalidomide and pomalidomide, is a substrate receptor of the cullin ring E3 ubiquitin ligase complex, CRL4(CRBN) ."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28978850",
"endSection": "abstract",
"offsetInBeginSection": 242,
"offsetInEndSection": 392,
"text": "cluding multiple myeloma. Cereblon (CRBN) is a common primary target for IMiDs. It works as a substrate receptor of CRL4. Accumulating evidence has sh"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36252444",
"endSection": "abstract",
"offsetInBeginSection": 92,
"offsetInEndSection": 242,
"text": "ubiquitin ligase complex component. Cereblon is a well-known target of thalidomide and its derivatives. Cereblon is involved in multiple myeloma cell "
}
] | 12
|
BioASQ-training12b
| null | null |
6414638c201352f04a000047
| 5,022
|
factoid
|
What is the difference between dermatillomania and skin picking disorder?
|
['None']
|
[
"None",
"null",
"naught",
"nothing",
"zero",
"nil",
"no one",
"not any"
] |
['Dermatillomania is also known as skin picking disorder (SPD).']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/33808008"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33808008",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 241,
"text": "Dermatillomania or skin picking disorder (SPD) is a chronic, recurrent, and treatment resistant neuropsychiatric disorder with an underestimated prevalence that has a concerning negative impact on an individual's health and quality of life. "
}
] | 12
|
BioASQ-training12b
| null | null |
6414c4cf690f196b51000006
| 5,026
|
factoid
|
What causes Japanese Spotted Fever?
|
['Rickettsia japonica']
|
[
"Rickettsia japonica",
"Rickettsia japonica (Japanese spotted fever)",
"Rickettsia japonica (Rickettsial disease)",
"Rickettsia japonica (Rickettsiosis)"
] |
['Japanese Spotted Fever is caused by Rickettsia japonica.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/35507925",
"http://www.ncbi.nlm.nih.gov/pubmed/36016429",
"http://www.ncbi.nlm.nih.gov/pubmed/32863353"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32863353",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 189,
"text": "Non-pathogenic Rickettsia species LON strains closely related to an agent of Japanese spotted fever (JSF), R. japonica, were isolated in Japan from Haemaphysalis longicornis ticks in 2001. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36016429",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 221,
"text": "Severe fever with thrombocytopenia syndrome (SFTS) and Japanese spotted fever (JSF; a spotted fever group rickettsiosis) are tick-borne zoonoses that are becoming a significant public health threat in Japan and East Asia."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35507925",
"endSection": "abstract",
"offsetInBeginSection": 153,
"offsetInEndSection": 288,
"text": "Rickettsia japonica is a member of SFG rickettsiae causing Japanese spotted fever (JSF) and can transmit to humans via infected ticks. "
}
] | 12
|
BioASQ-training12b
| null | null |
63eefa3bf36125a426000012
| 5,027
|
factoid
|
Olokizumab is tested for which disease?
|
['rheumatoid arthritis']
|
[
"rheumatoid arthritis",
"RA",
"chronic inflammatory arthritis",
"rheumatoid disease",
"rheumatoid joint disease"
] |
['Olokizumab, a monoclonal antibody against interleukin 6, improves outcomes of rheumatoid arthritis.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/34344706",
"http://www.ncbi.nlm.nih.gov/pubmed/36001712"
] |
[
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34344706",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 240,
"text": "Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34344706",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 154,
"text": "OBJECTIVE: To evaluate the efficacy and safety of olokizumab (OKZ) in patients with active rheumatoid arthritis despite treatment with methotrexate (MTX)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34344706",
"endSection": "abstract",
"offsetInBeginSection": 1387,
"offsetInEndSection": 1586,
"text": "CONCLUSIONS: Treatment with OKZ was associated with significant improvement in signs, symptoms and physical function of rheumatoid arthritis without discernible differences between the two regimens. "
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36001712",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 64,
"text": "Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36001712",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 245,
"text": "BACKGROUND: The cytokine interleukin-6 is involved in the pathogenesis of rheumatoid arthritis. Olokizumab, a humanized monoclonal antibody targeting the interleukin-6 cytokine directly, is being tested for the treatment of rheumatoid arthritis."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36001712",
"endSection": "abstract",
"offsetInBeginSection": 2389,
"offsetInEndSection": 2722,
"text": "CONCLUSIONS: In patients with rheumatoid arthritis who were receiving maintenance methotrexate, olokizumab was superior to placebo and noninferior to adalimumab in producing an ACR20 response at 12 weeks. Larger and longer trials are required to determine the efficacy and safety of olokizumab in patients with rheumatoid arthritis. "
}
] | 12
|
BioASQ-training12b
| null | null |
63eef60ef36125a42600000c
| 5,033
|
factoid
|
What disease can be treated with Lenacapavir?
|
['HIV-1']
|
[
"HIV-1",
"Human Immunodeficiency Virus type 1",
"HIV",
"AIDS virus",
"LAV (Lymphadenopathy-Associated Virus)",
"HTLV-III (Human T-lymphotropic Virus type III)"
] |
['Lenacapavir is a long-acting, highly potent HIV-1 capsid (CA) inhibitor that is approved for treatment of HIV-1.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/36272024",
"http://www.ncbi.nlm.nih.gov/pubmed/34871187",
"http://www.ncbi.nlm.nih.gov/pubmed/36190128",
"http://www.ncbi.nlm.nih.gov/pubmed/36202818"
] |
[
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36190128",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 91,
"text": "Structural and Mechanistic Bases of Viral Resistance to HIV-1 Capsid Inhibitor Lenacapavir."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36190128",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 79,
"text": "Lenacapavir (LEN) is a long-acting, highly potent HIV-1 capsid (CA) inhibitor. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36202818",
"endSection": "abstract",
"offsetInBeginSection": 803,
"offsetInEndSection": 1012,
"text": "The investigational drug lenacapavir accesses unoccupied hydrophobic pockets in the complex to potently impair HIV-1 inside the nucleus without displacing the tightly bound cellular cofactor from virus cores. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36272024",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 145,
"text": "Lenacapavir (Sunlenca®) is a long-acting capsid inhibitor of human immunodeficiency virus type 1 (HIV-1) being developed by Gilead Sciences Inc. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36272024",
"endSection": "abstract",
"offsetInBeginSection": 301,
"offsetInEndSection": 696,
"text": "In August 2022, lenacapavir received its first approval in the EU for use in combination with other antiretroviral(s) in adults with multi-drug resistant HIV infection, for whom it is otherwise not possible to construct a suppressive anti-viral regimen. This article summarizes the milestones in the development of lenacapavir leading to this first approval for the treatment of HIV-1 infection."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34871187",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 53,
"text": "Lenacapavir: a first-in-class HIV-1 capsid inhibitor."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34871187",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 496,
"text": "PURPOSE OF REVIEW: This review summarizes available data for lenacapavir, an investigational first-in-class agent that disrupts functioning of HIV capsid protein across multiple steps in the viral life cycle.RECENT FINDINGS: Lenacapavir demonstrated picomolar potency in vitro with no cross resistance to existing antiretroviral classes and potent antiviral activity in persons with HIV-1. In persons with HIV-1, there was no preexisting resistance to lenacapavir regardless of treatment history."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34871187",
"endSection": "abstract",
"offsetInBeginSection": 600,
"offsetInEndSection": 1015,
"text": "In heavily treatment-experienced persons with multidrug-resistant HIV-1 and in treatment-naive persons with HIV-1, lenacapavir in combination with other antiretroviral agents led to high rates of virologic suppression and was well tolerated.SUMMARY: Ongoing studies are evaluating long-acting dosing of lenacapavir for treating HIV-1 in combination with other antiretrovirals and preventing HIV-1 as a single agent."
}
] | 12
|
BioASQ-training12b
| null | null |
63f03fc8f36125a426000021
| 5,036
|
factoid
|
What cells proliferate in Mantle Cell Lymphoma
|
['B cells']
|
[
"B cells",
"B lymphocytes",
"B-lymphocytes",
"B-cell",
"B-cell lymphocyte"
] |
["Mantle cell lymphoma is a subtype of B-cell non-Hodgkin's lymphoma, where B-cells proliferate uncontrollably.", 'Mantle Cell Lymphoma is characterized by the proliferation of mantle cells, which are a type of B-cell lymphocytes.', 'Mantle Cell lymphoma is an aggressive (fast-growing) type of B-cell non-Hodgkin lymphoma', "Mantle cell lymphoma (MCL) is a subtype of B-cell non-Hodgkin's lymphoma seen predominantly in males.", 'Mantle cell lymphoma is a type of B-cell non-Hodgkin lymphoma characterized by the proliferation of malignant B-cells in the mantle zone of the lymph node.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/33197439",
"http://www.ncbi.nlm.nih.gov/pubmed/22555177",
"http://www.ncbi.nlm.nih.gov/pubmed/8277026",
"http://www.ncbi.nlm.nih.gov/pubmed/10463985",
"http://www.ncbi.nlm.nih.gov/pubmed/10942246",
"http://www.ncbi.nlm.nih.gov/pubmed/8649059",
"http://www.ncbi.nlm.nih.gov/pubmed/28203581",
"http://www.ncbi.nlm.nih.gov/pubmed/32774275",
"http://www.ncbi.nlm.nih.gov/pubmed/26604506"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32774275",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 129,
"text": "Mantle cell lymphoma (MCL) is a relatively rare B-cell non-Hodgkin lymphoma, typically presenting with extensive lymphadenopathy,"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28203581",
"endSection": "abstract",
"offsetInBeginSection": 207,
"offsetInEndSection": 483,
"text": "Activity has been demonstrated in many subtypes of B-cell lymphoma, including diffuse large cell lymphoma, follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), lymphocyte-predominant Hodgkin lymphoma, and Waldenström macroglobulinemia (WM)"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26604506",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 102,
"text": "Mantle cell lymphoma (MCL) is a subtype of B-cell non-Hodgkin's lymphoma seen predominantly in males. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22555177",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 189,
"text": "Mantle cell lymphoma is an aggressive, non-curable B-cell lymphoma, characterized by the translocation t(11;14)(q13;q32) involving CCND1 and a high number of additional genetic alterations."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/10942246",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 126,
"text": "Mantle cell lymphoma (MCL) is a B cell non-Hodgkin's lymphoma, characterized by a poor response to therapy and short survival."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/8649059",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 173,
"text": "Mantle cell lymphoma is a B cell lymphoproliferative disorder cytogenetically characterized by the t(11;14)(q13;q32) which at molecular level involves the Bcl-1/PRAD-1 gene."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/8277026",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 131,
"text": "BACKGROUND: Mantle zone lymphoma (MZL) is a B-cell proliferation regarded as the follicular variant of intermediate lymphocytic lym"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/10463985",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 150,
"text": "BACKGROUND: Mantle cell lymphoma is a mature, virgin B-cell neoplasm characterized immunologically by a panB+, CD5+, CD23-, cyclin D1+ phenotype and g"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/10463985",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 231,
"text": "BACKGROUND: Mantle cell lymphoma is a mature, virgin B-cell neoplasm characterized immunologically by a panB+, CD5+, CD23-, cyclin D1+ phenotype and genetically by t(11;14)(q13;q32) with overexpression of the cyclin D1 (bcl-1) gene"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33197439",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 286,
"text": "Mantle cell lymphoma (MCL) is a unique subtype of B-cell non-Hodgkin lymphoma with a generally aggressive and heterogeneous clinical course. Chemokines are one of the complex components in the tumor microenvironment (TME), and they play a vital role in tumor progression and metastasis."
}
] | 12
|
BioASQ-training12b
| null | null |
640c85e9201352f04a000026
| 5,043
|
factoid
|
What is the estimated cost reduction when using telegenetics?
|
['10-12%']
|
[
"10-12%",
"ten to twelve percent",
"10 to 12 percent",
"10% to 12%",
"10 percent to 12 percent"
] |
['The estimated cost reduction by online counseling is about 10-12%.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/26785833"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26785833",
"endSection": "abstract",
"offsetInBeginSection": 1548,
"offsetInEndSection": 1644,
"text": "We estimated reduced time and costs by online counseling with about 8% and 10-12%, respectively."
}
] | 12
|
BioASQ-training12b
| null | null |
6415bb3c690f196b5100000e
| 5,044
|
factoid
|
What is the target of BI 1015550?
|
['phosphodiesterase 4B']
|
[
"phosphodiesterase 4B",
"PDE4B",
"cAMP-specific phosphodiesterase 4B",
"phosphodiesterase 4B isoform",
"PDE4B1",
"PDE4B2",
"PDE4B3",
"PDE4B4"
] |
['BI 1015550 is a preferential phosphodiesterase 4B inhibitor that is used for patients with idiopathic pulmonary fibrosis.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/35569036",
"http://www.ncbi.nlm.nih.gov/pubmed/35517783",
"http://www.ncbi.nlm.nih.gov/pubmed/36299369"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35569036",
"endSection": "abstract",
"offsetInBeginSection": 181,
"offsetInEndSection": 402,
"text": "METHODS: In this phase 2, double-blind, placebo-controlled trial, we investigated the efficacy and safety of BI 1015550, an oral preferential inhibitor of the PDE4B subtype, in patients with idiopathic pulmonary fibrosis."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36299369",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 143,
"text": "Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36299369",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 101,
"text": "Introduction: BI 1015550 is a phosphodiesterase 4 (PDE4) inhibitor that has antifibrotic properties. "
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35517783",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 118,
"text": "BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35517783",
"endSection": "abstract",
"offsetInBeginSection": 351,
"offsetInEndSection": 441,
"text": "BI 1015550 is a novel PDE4 inhibitor showing a preferential enzymatic inhibition of PDE4B."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35517783",
"endSection": "abstract",
"offsetInBeginSection": 2098,
"offsetInEndSection": 2401,
"text": "In summary, the unique preferential inhibition of PDE4B by BI 1015550 and its anticipated improved tolerability in humans, plus its anti-inflammatory and antifibrotic potential, suggest BI 1015550 to be a promising oral clinical candidate for the treatment of IPF and other fibro-proliferative diseases."
}
] | 12
|
BioASQ-training12b
| null | null |
63f03ae6f36125a42600001d
| 5,045
|
factoid
|
Beremagene Geperpavec is tested for which disease?
|
['recessive dystrophic epidermolysis bullosa']
|
[
"recessive dystrophic epidermolysis bullosa",
"RDEB",
"dystrophic epidermolysis bullosa",
"recessive dystrophic EB",
"recessive dystrophic epidermolysis bullosa (RDEB)",
"epidermolysis bullosa dystrophica recessiva"
] |
['Beremagene Geperpavec was tested for recessive dystrophic epidermolysis bullosa.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/35347281"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35347281",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 393,
"text": "Recessive dystrophic epidermolysis bullosa (RDEB) is a lifelong genodermatosis associated with blistering, wounding, and scarring caused by mutations in COL7A1, the gene encoding the anchoring fibril component, collagen VII (C7). Here, we evaluated beremagene geperpavec (B-VEC), an engineered, non-replicating COL7A1 containing herpes simplex virus type 1 (HSV-1) vector, to treat RDEB skin. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35347281",
"endSection": "abstract",
"offsetInBeginSection": 1370,
"offsetInEndSection": 1528,
"text": "These studies show that B-VEC is an easily administered, safely tolerated, topical molecular corrective therapy promoting wound healing in patients with RDEB."
}
] | 12
|
BioASQ-training12b
| null | null |
63eeeaaaf36125a426000004
| 5,048
|
factoid
|
Hairpatches is a single gene mutation associated with what disease?
|
['alopecia and renal failure']
|
[
"alopecia",
"hair loss",
"renal failure",
"kidney failure",
"chronic kidney disease",
"acute kidney injury",
"kidney dysfunction",
"alopecia and renal failure"
] |
['Hairpatches is a single gene mutation associated with progressive renal failure and alopecia in mice, and may be a potential model for a newly described heritable human disorder.', 'Hairpatches is a single gene mutation associated with progressive renal disease and alopecia.', 'Hairpatches is a single gene mutation characterized by progressive renal disease and alopecia in the mouse', 'Hairpatches, a single gene mutation characterized by progressive renal disease and alopecia in the mouse. A potential model for a newly described heritable human disorder.', '"Hairpatches" (Hpt) is a naturally occurring, autosomal semi-dominant mouse mutation. Hpt/Hpt homozygotes die in utero, while Hpt/+ heterozygotes exhibit progressive renal failure accompanied by patchy alopecia.', '"Hairpatches" (Hpt) is a naturally occurring, autosomal semi-dominant mouse mutation. Hairpatches, a single gene mutation characterized by progressive renal disease and alopecia in the mouse.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/23301070",
"http://www.ncbi.nlm.nih.gov/pubmed/1836514"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23301070",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 212,
"text": "\"Hairpatches\" (Hpt) is a naturally occurring, autosomal semi-dominant mouse mutation. Hpt/Hpt homozygotes die in utero, while Hpt/+ heterozygotes exhibit progressive renal failure accompanied by patchy alopecia. "
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/1836514",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 171,
"text": "Hairpatches, a single gene mutation characterized by progressive renal disease and alopecia in the mouse. A potential model for a newly described heritable human disorder."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23301070",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 167,
"text": "Retrotransposon insertion in the T-cell acute lymphocytic leukemia 1 (Tal1) gene is associated with severe renal disease and patchy alopecia in Hairpatches (Hpt) mice."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/1836514",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 105,
"text": "Hairpatches, a single gene mutation characterized by progressive renal disease and alopecia in the mouse."
}
] | 12
|
BioASQ-training12b
| null | null |
64138ce8201352f04a000042
| 5,049
|
factoid
|
What is the alternative microexon splicing by RBFOX2 and PTBP1 associated with?
|
['colorectal cancer metastasis']
|
[
"colorectal cancer metastasis",
"metastatic colorectal cancer",
"metastatic colon cancer",
"metastatic rectal cancer",
"colorectal carcinoma metastasis",
"CRC metastasis",
"colon cancer metastasis",
"rectal cancer metastasis"
] |
['Alternative microexon splicing by RBFOX2 and PTBP1 is associated with metastasis in colorectal cancer']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/36394206",
"http://www.ncbi.nlm.nih.gov/pubmed/34346508"
] |
[
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36394206",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 107,
"text": "Alternative splicing of HSPA12A pre-RNA by SRSF11 contributes to metastasis potential of colorectal cancer."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34346508",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 102,
"text": "Alternative microexon splicing by RBFOX2 and PTBP1 is associated with metastasis in colorectal cancer."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34346508",
"endSection": "abstract",
"offsetInBeginSection": 638,
"offsetInEndSection": 1073,
"text": "RNA interference-mediated knockdown experiments identified two splicing factors, RBFOX2 and PTBP1, as regulators of microexon splicing in CRC cells. RBFOX2 and PTBP1 were found to directly bind to microexon-containing pre-mRNAs and to control their splicing in such cells. Differential microexon splicing was shown to be due, at least in part, to altered expression of RBFOX2 and PTBP1 in CRC tissue compared to matched normal tissue. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34346508",
"endSection": "abstract",
"offsetInBeginSection": 1178,
"offsetInEndSection": 1320,
"text": "Our data thus suggest that altered expression of RBFOX2 and PTBP1 might influence CRC metastasis through the regulation of microexon splicing."
}
] | 12
|
BioASQ-training12b
| null | null |
63f9cd0b33942b094c000010
| 5,050
|
factoid
|
Which gene is implicated in Canavan disease?
|
['ASPA']
|
[
"ASPA",
"aspartoacylase",
"aspartoacylase enzyme",
"aspartate N-acyltransferase",
"N-acetylaspartate acylase"
] |
['Canavan disease is an inherited leukodystrophy resulting from mutations in the gene encoding aspartoacylase (ASPA).']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/36267868",
"http://www.ncbi.nlm.nih.gov/pubmed/35636725",
"http://www.ncbi.nlm.nih.gov/pubmed/35637731",
"http://www.ncbi.nlm.nih.gov/pubmed/35929936"
] |
[
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36267868",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 102,
"text": "Cribriform Appearance of White Matter in Canavan Disease Associated with Novel Mutations of ASPA Gene."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36267868",
"endSection": "abstract",
"offsetInBeginSection": 652,
"offsetInEndSection": 837,
"text": "Genetic analysis revealed novel mutations in the aspartoacylase or ASPA gene that possibly accounts for the severe form of Canavan disease, which probably explains the imaging findings."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35636725",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 121,
"text": "Canavan disease (CD) is an inherited leukodystrophy resulting from mutations in the gene encoding aspartoacylase (ASPA). "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35637731",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 290,
"text": "Canavan disease (CD) is a devastating neurological disease that lacks effective therapy. Because CD is caused by mutations of the aspartoacylase (ASPA) gene, we introduced the wild-type (WT) ASPA gene into patient iPSCs through lentiviral transduction or CRISPR/Cas9-mediated gene editing. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35929936",
"endSection": "abstract",
"offsetInBeginSection": 1284,
"offsetInEndSection": 1453,
"text": "The compound heterozygous variants of the ASPA gene probably underlay the Canavan disease in this patient, and the result has enabled prenatal diagnosis for this family."
}
] | 12
|
BioASQ-training12b
| null | null |
63f56f7533942b094c000002
| 5,051
|
factoid
|
What disease can be treated with Glofitamab?
|
['DLBCL']
|
[
"DLBCL",
"Diffuse Large B-cell Lymphoma",
"Diffuse Large B Cell Lymphoma",
"DLBCL lymphoma",
"Large B-cell lymphoma"
] |
['Glofitamab is being tested for treatment of DLBCL after CAR T-Cell Therapy']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/35626120",
"http://www.ncbi.nlm.nih.gov/pubmed/34941996",
"http://www.ncbi.nlm.nih.gov/pubmed/36198538"
] |
[
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35626120",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 78,
"text": "Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35626120",
"endSection": "abstract",
"offsetInBeginSection": 361,
"offsetInEndSection": 624,
"text": "In this study, we evaluated the safety and efficacy of a monotherapy with the bispecific CD20xCD3 antibody glofitamab in patients who progressed after CAR T treatment. We report nine consecutive patients with progressive DLBCL after preceding CAR T-cell therapy. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35626120",
"endSection": "abstract",
"offsetInBeginSection": 1106,
"offsetInEndSection": 1284,
"text": "Our data suggest that glofitamab treatment is well tolerated and effective in patients with DLBCL relapsing after CAR T-cell therapy and can enhance residual CAR T-cell activity."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36198538",
"endSection": "abstract",
"offsetInBeginSection": 674,
"offsetInEndSection": 976,
"text": "Bispecific antibodies such as epcoritamab, mosunetuzumab, and glofitamab, anti-CD19 antibody drug tafasitamab combined with lenalidomide, CD19 antibody drug conjugate loncastuximab tesirine, oral selective inhibitor of nuclear export selinexor, and several new agents have been investigated for DLBCL. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34941996",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 200,
"text": "Glofitamab, a novel CD20xCD3, T-cell-engaging bispecific antibody, exhibited single-agent activity in Study NP30179, a first-in-human, phase 1 trial in relapsed/refractory B-cell non-Hodgkin lymphoma."
}
] | 12
|
BioASQ-training12b
| null | null |
63eeeb70f36125a426000005
| 5,057
|
factoid
|
Which molecule is targeted by upadacitinib?
|
['Janus kinase 1']
|
[
"Janus kinase 1",
"JAK1",
"JAK-1",
"Janus kinase-1",
"Janus kinase 1 (JAK1)"
] |
['Upadacitinib is a Janus kinase 1 inhibitor under development for the treatment of several inflammatory disorders including rheumatoid arthritis.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/28503781",
"http://www.ncbi.nlm.nih.gov/pubmed/29908670",
"http://www.ncbi.nlm.nih.gov/pubmed/30500075",
"http://www.ncbi.nlm.nih.gov/pubmed/29672874",
"http://www.ncbi.nlm.nih.gov/pubmed/29688617",
"http://www.ncbi.nlm.nih.gov/pubmed/28765121",
"http://www.ncbi.nlm.nih.gov/pubmed/30394138",
"http://www.ncbi.nlm.nih.gov/pubmed/28762476",
"http://www.ncbi.nlm.nih.gov/pubmed/29908669",
"http://www.ncbi.nlm.nih.gov/pubmed/29076110"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28765121",
"endSection": "abstract",
"offsetInBeginSection": 1255,
"offsetInEndSection": 1554,
"text": "We summarise the development and recent application of Janus kinase (JAK) inhibitors in the treatment of IMIDs, including first-generation pan-JAK inhibitors (tofacitinib, baricitinib, ruxolitinib, peficitinib) and second-generation selective JAK inhibitors (decernotinib, filgotinib, upadacitinib)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28762476",
"endSection": "abstract",
"offsetInBeginSection": 353,
"offsetInEndSection": 463,
"text": "Upadacitinib is a Janus kinase 1 inhibitor currently being evaluated in phase III rheumatoid arthritis trials."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29076110",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 171,
"text": "BACKGROUND AND OBJECTIVES: Upadacitinib is a janus kinase (JAK) 1 inhibitor being developed for the treatment of rheumatoid arthritis (RA) and other inflammatory diseases."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29672874",
"endSection": "abstract",
"offsetInBeginSection": 932,
"offsetInEndSection": 1163,
"text": "RESULTS: In randomised controlled trials primary efficacy endpoints were met for tofacitinib (JAK 1/3 inhibitor-phase III), upadacitinib (JAK 1 inhibitor-phase II) and AJM300 (α4-integrin antagonist-phase II) in ulcerative colitis."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29688617",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 150,
"text": "Upadacitinib is a Janus kinase 1 inhibitor under development for the treatment of several inflammatory disorders including rheumatoid arthritis (RA). "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30394138",
"endSection": "abstract",
"offsetInBeginSection": 249,
"offsetInEndSection": 371,
"text": "Upadacitinib selectively inhibits Janus Kinase 1 (JAK1) which could potentially reduce JAK2 and JAK3-related side effects. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29908670",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 184,
"text": "BACKGROUND\nPhase 2 studies with upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor, have shown safety and efficacy in the treatment of patients with active rheumatoid arthritis."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29908669",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 163,
"text": "BACKGROUND\nUpadacitinib is a selective inhibitor of Janus kinase 1 and was efficacious in phase 2 studies in patients with moderate-to-severe rheumatoid arthritis."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30500075",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 133,
"text": "Upadacitinib is a novel selective oral Janus kinase 1 (JAK) inhibitor being developed for treatment of several inflammatory diseases."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29076110",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 170,
"text": "BACKGROUND AND OBJECTIVES\nUpadacitinib is a janus kinase (JAK) 1 inhibitor being developed for the treatment of rheumatoid arthritis (RA) and other inflammatory diseases."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28503781",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 136,
"text": "AIMS\nUpadacitinib (ABT-494) is a selective Janus kinase 1 inhibitor being developed for treatment of auto-immune inflammatory disorders."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29672874",
"endSection": "abstract",
"offsetInBeginSection": 938,
"offsetInEndSection": 1168,
"text": "RESULTS\nIn randomised controlled trials primary efficacy endpoints were met for tofacitinib (JAK 1/3 inhibitor-phase III), upadacitinib (JAK 1 inhibitor-phase II) and AJM300 (α4-integrin antagonist-phase II) in ulcerative colitis."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28503781",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 136,
"text": "AIMS Upadacitinib (ABT-494) is a selective Janus kinase 1 inhibitor being developed for treatment of auto-immune inflammatory disorders."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29908669",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 163,
"text": "BACKGROUND Upadacitinib is a selective inhibitor of Janus kinase 1 and was efficacious in phase 2 studies in patients with moderate-to-severe rheumatoid arthritis."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30394138",
"endSection": "abstract",
"offsetInBeginSection": 194,
"offsetInEndSection": 316,
"text": "Upadacitinib selectively inhibits Janus Kinase 1 (JAK1) which could potentially reduce JAK2 and JAK3-related side effects."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30394138",
"endSection": "abstract",
"offsetInBeginSection": 1117,
"offsetInEndSection": 1321,
"text": "Expert commentary: Upadacitinib has displayed a rapid and favorable efficacy profile in RA but despite being a selective JAK1 inhibitor appears to have a similar safety profile to less-selective Jakinibs."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29076110",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 170,
"text": "BACKGROUND AND OBJECTIVES Upadacitinib is a janus kinase (JAK) 1 inhibitor being developed for the treatment of rheumatoid arthritis (RA) and other inflammatory diseases."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29688617",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 149,
"text": "Upadacitinib is a Janus kinase 1 inhibitor under development for the treatment of several inflammatory disorders including rheumatoid arthritis (RA)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30394138",
"endSection": "abstract",
"offsetInBeginSection": 338,
"offsetInEndSection": 463,
"text": "Areas covered: In this paper, we review a newly developed oral selective JAK inhibitor, upadacitinib for the treatment of RA."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30394138",
"endSection": "abstract",
"offsetInBeginSection": 215,
"offsetInEndSection": 337,
"text": "Upadacitinib selectively inhibits Janus Kinase 1 (JAK1) which could potentially reduce JAK2 and JAK3-related side effects."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28503781",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 144,
"text": "<b>AIMS</b>: Upadacitinib (ABT-494) is a selective Janus kinase 1 inhibitor being developed for treatment of auto-immune inflammatory disorders."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30394138",
"endSection": "abstract",
"offsetInBeginSection": 1138,
"offsetInEndSection": 1342,
"text": "Expert commentary: Upadacitinib has displayed a rapid and favorable efficacy profile in RA but despite being a selective JAK1 inhibitor appears to have a similar safety profile to less-selective Jakinibs."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28503781",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 149,
"text": "Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28503781",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 131,
"text": "Upadacitinib (ABT-494) is a selective Janus kinase 1 inhibitor being developed for treatment of auto-immune inflammatory disorders."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30394138",
"endSection": "abstract",
"offsetInBeginSection": 317,
"offsetInEndSection": 442,
"text": "Areas covered: In this paper, we review a newly developed oral selective JAK inhibitor, upadacitinib for the treatment of RA."
}
] | 8
|
BioASQ-training8b
| null | null |
5c7039207c78d69471000065
| 5,058
|
factoid
|
What type of extracolonic tumors does the PMS2 germline mutation cause?
|
['endometrial cancer', 'ovarian cancer', 'gastric cancer', 'small bowell cancer', 'ureter cancer', 'urothelial cancers']
|
[
"endometrial cancer",
"uterine cancer",
"ovarian cancer",
"fallopian tube cancer",
"gastric cancer",
"stomach cancer",
"small bowel cancer",
"small intestine cancer",
"ureter cancer",
"ureteral cancer",
"urothelial cancers",
"bladder cancer",
"transitional cell carcinoma"
] |
['The PMS2 gene is one of the mismatch repair genes that play a crucial role in maintaining genomic stability. Germline mutations in the PMS2 gene can lead to Lynch syndrome, which is an autosomal dominant disorder characterized by an increased risk of developing colorectal and other types of cancer. However, compared to other MMR genes such as MLH1 and MSH2, PMS2 germline mutations are less common and associated with a lower risk of cancer development. , Extracolonic tumors associated with PMS2 germline mutations include endometrial, gastric, small bowel, biliary tract, pancreatic, brain (usually glioblastoma), sebaceous skin tumors, and transitional cell carcinomas of the ureter and renal pelvis. However, it is important to note that the risk of developing extracolonic tumors in individuals with PMS2 mutations is lower than in those with MLH1 or MSH2 mutations. , It is also worth mentioning that PMS2 germline mutations have be', 'PMS2 is one of the four DNA mismatch repair proteins, which plays a significant role in maintaining genomic stability. PMS2 germline mutation results in Lynch syndrome, which predisposes to various extracolonic tumors, including endometrial, ovarian, gastric, and urothelial cancers.', 'The PMS2 germline mutation causes extracolonic tumors, including endometrial cancer and colorectal and endometrial cancer.', "Lynch syndrome, which can be caused by PMS2 germline mutations, predisposes to various extracolonic cancers including endometrial cancer, ovarian cancer, stomach cancer, renal pelvis and ureteral cancer, small bowel cancer, hepatobiliary tract cancer, pancreatic cancer, glioblastoma multiforme (in Turcot's variant), sebaceous skin tumors (in Muir-Torre variant), and more recently identified, breast and prostate cancers.", 'The PMS2 germline mutation does not cause any extracolonic tumors.', 'The PMS2 germline mutation causes a severe colorectal cancer and multiple adenoma phenotype without extraintestinal cancer. The patient presented with multiple gastrointestinal tumors, which could not be distinguished clinically from cases with attenuated familial adenomatous polyposis or MUTYH-associated polyposis. In addition, the cumulative incidence of extracolonic tumors was higher in females than males (p = 0.001), including uterus and breast cancers. However, path_MLH1 variants are significantly more associated with the development of colorectal cancer than extracolonic tumors, while path_MSH2 variants show a greater frequency of extracolonic cancers, including ovarian cancer.', 'PMS2 is a mismatch repair gene that plays a critical role in maintaining genomic integrity. A germline mutation in PMS2 is associated with Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer syndrome). This mutation increases the risk of colorectal cancer and other extracolonic malignancies such as endometrial, ovarian, gastric, small bowel, pancreatic, ureter, and renal pelvis cancer', 'The PMS2 germline mutation is associated with a slightly increased risk for colorectal and endometrial cancer. However, it does not appear to increase the risk for any other types of cancer associated with Lynch syndrome.', 'Based on the provided abstract, a study was conducted to determine the age-specific cumulative risk (penetrance) of various cancers for carriers of heterozygous pathogenic PMS2 variants. The research involved a large dataset from a global collaboration and used modified segregation analysis while considering both genotyped and nongenotyped relatives. , The results showed that PMS2 mutation carriers had an increased risk for colorectal cancer and endometrial cancer compared to the general population. However, there was no clear evidence of an elevated risk for ovarian, gastric, hepatobiliary, bladder, renal, brain, breast, prostate, or small bowel cancer. , In conclusion, the PMS2 germline mutation primarily causes an increased risk for colorectal and endometrial cancers. The study did not find a significant association between PMS2 germline mutations and other Lynch syndrome-associated extracolonic tumors.', 'The PMS2 germline mutation is associated with an increased risk of developing various extracolonic malignancies, including but not limited to endometrial cancer, ovarian cancer, stomach cancer, small intestine cancer, hepatobiliary tract cancers (liver and bile duct), urinary tract tumors (kidney and ureter), brain tumors such as gliomas, skin cancers like melanoma, and pancreas cancer. The exact spectrum of extracolonic tumors can vary among different studies and populations, but these are the most commonly reported types associated with PMS2 mutations.', 'PMS2 is a gene associated with Lynch syndrome, which is a hereditary predisposition to colorectal and extracolonic cancers. The extracolonic tumors associated with PMS2 germline mutation include gynecologic (endometrial and ovarian), urologic (urinary tract and renal pelvis), small bowel, pancreas, stomach, biliary tract, and skin (sebaceous neoplasms).', 'The PMS2 germline mutation is predominantly associated with colorectal and endometrial cancer within the Lynch tumor spectrum. However, there is no clear evidence of an increased risk of other extracolonic tumors such as ovarian, gastric, hepatobiliary, bladder, renal, brain, breast, prostate, or small bowel cancer.', 'The PMS2 germline mutation can cause several extracolonic tumors. These include cancers of the ovary, stomach, liver and biliary system, bladder, kidney, brain, breast, and prostate, as well as small bowel cancer. It is essential to monitor individuals with PMS2 mutations closely for these potential malignancies.', 'The PMS2 germline mutation is associated with an increased risk of developing extracolonic tumors, specifically endometrial cancer.', 'PMS2 germline mutation causes extracolonic tumors in regions such as the endometrium, ovary, urinary tract, lymphoma, stomach, pancreas small bowel and brain.', 'Germline mutations of the PMS2 gene are associated with an increased risk of colorectal cancer in individuals with hereditary nonpolyposis colorectal cancer (HNPCC) syndrome. However, PMS2 germline mutations are rarely associated with extracolonic tumors in familial aggregation of colorectal cancers.', 'The PMS2 germline mutation is associated with a slightly increased risk for colorectal and endometrial cancer. However, it does not appear to increase the risk for any other types of cancer associated with Lynch syndrome. Lynch syndrome is a genetic disorder that increases the risk of many types of cancer, particularly cancers of the colon (colorectal cancer) and endometrium.', 'Heterozygous PMS2 mutation carriers were at small increased risk for colorectal and endometrial cancer but not for any other Lynch syndrome-associated cancer.', 'The PMS2 germline mutation leads to café-au-lait macules, colonic polyps, and a unique range of tumors.', 'The PMS2 germline mutation is associated with an increased risk of colorectal and endometrial cancer, but not with other Lynch syndrome-associated cancers. Heterozygous PMS2 mutation carriers have a small increased risk for colorectal and endometrial cancer. However, the mutation does not seem to increase the risk of other extracolonic tumors. Therefore, the answer is that PMS2 germline mutation causes colorectal and endometrial cancer, but not other Lynch syndrome-associated cancers.', 'The PMS2 germline mutation is associated with an increased risk of developing colorectal cancers (CRCs) that differ from sporadic CRCs in genetic and histologic features. In addition, tumors from patients with PMS2-associated Lynch syndrome have been found to be distinct from colorectal tumors associated with defects in other mismatch repair genes. , However, the PMS2 germline mutation does not cause extracolonic tumors, such as brain tumors, haematological malignancies, and signs of neurofibromatosis type 1, which are more commonly associated with biallelic MMR gene mutations. , In summary, the PMS2 germline mutation is primarily linked to the development of colorectal cancers with unique genetic and histological features, whereas extracolonic tumors are more frequently observed in individuals with biallelic MMR gene mutations.', 'PMS2 germline mutations are associated with an increased risk of extracolonic tumors, including tumors in regions such as the endometrium, ovary, urinary tract, lymphoma, stomach, pancreas, small bowel, and brain in individuals with Lynch Syndrome.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/29758216",
"http://www.ncbi.nlm.nih.gov/pubmed/18602922",
"http://www.ncbi.nlm.nih.gov/pubmed/18273873",
"http://www.ncbi.nlm.nih.gov/pubmed/19132747",
"http://www.ncbi.nlm.nih.gov/pubmed/30161022",
"http://www.ncbi.nlm.nih.gov/pubmed/31056861",
"http://www.ncbi.nlm.nih.gov/pubmed/25856668",
"http://www.ncbi.nlm.nih.gov/pubmed/26110232",
"http://www.ncbi.nlm.nih.gov/pubmed/31860975",
"http://www.ncbi.nlm.nih.gov/pubmed/17258725",
"http://www.ncbi.nlm.nih.gov/pubmed/15077197",
"http://www.ncbi.nlm.nih.gov/pubmed/34357101",
"http://www.ncbi.nlm.nih.gov/pubmed/15256438",
"http://www.ncbi.nlm.nih.gov/pubmed/22714864",
"http://www.ncbi.nlm.nih.gov/pubmed/27435373"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30161022",
"endSection": "abstract",
"offsetInBeginSection": 1516,
"offsetInEndSection": 1675,
"text": "Heterozygous PMS2 mutation carriers were at small increased risk for colorectal and endometrial cancer but not for any other Lynch syndrome-associated cancer. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22714864",
"endSection": "abstract",
"offsetInBeginSection": 454,
"offsetInEndSection": 569,
"text": "PMS2 mutation carriers had more extracolonic cancers although these differences were not statistically significant."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30161022",
"endSection": "abstract",
"offsetInBeginSection": 247,
"offsetInEndSection": 553,
"text": "pectrum. However, the age-specific cumulative risk (penetrance) of these cancers is still poorly defined for PMS2-associated Lynch syndrome. Using a large data set from a worldwide collaboration, our aim was to determine accurate penetrance measures of cancers for carriers of heterozygous pathogenic PMS2 "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25856668",
"endSection": "abstract",
"offsetInBeginSection": 45,
"offsetInEndSection": 158,
"text": "PMS2 have been shown to cause Lynch syndrome. The penetrance of the cancer and tumor spectrum has been repeatedly"
}
] | 13
|
BioASQ-training13b
| null | null |
65f7736fc4010b4d78000024
| 5,060
|
factoid
|
What proportion of risk is attributable to obesity in colorectal cancer women development?
|
['Hazard Ratio 1.04', '4%', 'HR 1.04 (1.01-1.18) p<0.001']
|
[
"Hazard Ratio 1.04",
"HR 1.04",
"Hazard Ratio",
"HR",
"1.04",
"4%",
"1.04 (1.01-1.18)",
"p<0.001"
] |
['In women, obesity is associated with a 16% increased risk of developing colorectal cancer. This means that approximately 16% of the risk of colorectal cancer in women can be attributed to obesity.', 'The hazard ratio for colon cancer risk in obese women is 1.04 [1.01-1.18], indicating a slight increase in risk associated with obesity.', 'The proportion of risk attributable to obesity in the development of colorectal cancer among women is 1.04 (95% CI: 1.01-1.18).', 'The proportion of risk attributable to obesity in colorectal cancer women development is 1.20 for each 0.1-unit increase in waist-hip ratio.', '1.04 [1.01-1.18]', 'In women, colon cancer risk increased by 16% per 10-cm increase in waist circumference (RR: 1.16; 95% CI: 1.09, 1.23) and by 20% per 0.1-unit increase in waist-hip ratio (RR: 1.20; 95% CI: 1.08, 1.33). Obese women had a 4% higher risk of colon cancer compared to non-obese women (hazard ratio = 1.04; 95% CI: 1.01-1.18).', 'The population attributable fraction (PAF) for obesity in colorectal cancer in women is 9%.', 'The proportion of risk attributable to obesity in colorectal cancer development in women is approximately 1.13-1.17 times that of men.', '”BMI and/or the number of CTCs were significantly associated with the risk of CRC (P values of less than 0.001 for all). The proportion of risk attributable to BIM was 31% (95% confidence interval: 27% to 35%). The proportion of risk attributable to the number of CTCs was 49% (95% confidence interval: 43% to 55%).”}</s>', 'The men in the obese/obese group had a higher risk of colon cancer than women (hazard ratio\u2009=\u20091.13 [1.10-1.17] in men, and hazard ratio\u2009=\u20091.04 [1.01-1.18] in women, P\u2009=\u20090.001).', "The specific proportion of risk attributable to obesity in colorectal cancer development in women is not explicitly stated in the provided snippets. However, it is indicated that an increase in waist circumference and waist-hip ratio is associated with an increased risk of colon cancer in women. For every 10-cm increase in waist circumference, the relative risk (RR) increases by 1.16. Similarly, for every 0.1-unit increase in waist-hip ratio, the RR increases by 1.20. Furthermore, women in the obese group had a hazard ratio of 1.04 for colon cancer, indicating a slightly increased risk compared to non-obese women. It's important to note that the association between obesity and colon and rectal cancer risk varies by sex and cancer site", "The exact proportion of risk attributable to obesity in colorectal cancer development in women is not specified in the provided documents. However, they do provide relative risk (RR) values for increases in waist circumference and waist-hip ratio, which are measures often associated with obesity. For every 10-cm increase in waist circumference, the RR is 1.16, and for every 0.1-unit increase in waist-hip ratio, the RR is 1.20. Additionally, the hazard ratio for colon cancer in obese women is 1.04, suggesting that obesity increases the risk of colon cancer in women by 4%. It's important to note that these are not direct measures of the proportion of risk attributable to obesity, but rather indications of the relative risk compared to non-obese individuals.", 'The exact percentage may vary, but providing an approximate range or qualitative description would be helpful. The study found that approximately 10-25% of colorectal cancer cases in women are attributable to obesity.', 'The risk of colon cancer increased with increasing waist circumference (per 10-cm increase) in both men (RR: 1.33; 95% CI: 1.19, 1.49) and women (RR: 1.16; 95% CI: 1.09, 1.23) and with increasing waist-hip ratio (per 0.1-unit increase) in both men (RR: 1.43; 95% CI: 1.19, 1.71) and women (RR: 1.20; 95% CI: 1.08, 1.33). The men in the obese/obese group had a higher risk of colon cancer than women (hazard ratio\\u2009=\\u20091.13 [1.10-1.17] in men, and hazard ratio\\u2009=\\u20091.04 [1.01-1.18] in women, P\\u2009=\\u20090.001).', 'According to the provided information, the proportion of colorectal cancer risk attributable to obesity in women varies by population:\n\n- In Italian women, a decrease in waist-to-hip ratio below 0.82 might reduce colorectal cancer by 19%.\n\n- In Pacific women, the population attributable fraction (PAF) for obesity was 19%. \n\n- In Maori women, the PAF for obesity was 14%.\n\n- In European/other women, the PAF for obesity was 8%.\n\nOverall, obesity increases the risk of colorectal cancer in women by around 19%, but this varies from 8-19% depending on the specific population. The relative risk is estimated to be about 1.5 times higher in obese women compared to normal-weight women.', 'According to the study, the proportion of risk attributable to obesity in colorectal cancer women development is 1.04 (hazard ratio) [1.01-1.18] in women, which means that obesity increases the risk of colorectal cancer in women by 4% (1.04-1.00) compared to non-obese women. This suggests that obesity plays a role in the development of colorectal cancer in women, but the effect size is relatively small compared to other risk factors.', 'Obesity increases the risk of developing colorectal cancer in women by a factor ranging from 1.04 to 1.18.', 'Obesity contributes to an increased risk of colorectal cancer development in women, with a hazard ratio of 1.04 to 1.18. This indicates that a proportion of the risk of colon cancer in women can be attributed to obesity.', 'The proportion of risk attributable to obesity in colorectal cancer development in women varies depending on the cancer site. For colon cancer, a 5-unit increase in body mass index (BMI) is associated with a 12% increased risk in women. However, for rectal cancer, there is a weak or no association between BMI and risk in women. Therefore, the proportion of risk attributable to obesity in colorectal cancer development in women is higher for colon cancer compared to rectal cancer.', 'According to the provided snippets, the risk of colon cancer in women is associated with increasing waist circumference and waist-hip ratio, with a higher risk observed in men compared to women. Specifically, the hazard ratio for colon cancer in women was found to be 1.04 (95% CI: 1.01-1.18) per 10-cm increase in waist circumference, and 1.20 (95% CI: 1.08-1.33) per 0.1-unit increase in waist-hip ratio. However, the proportion of risk attributable to obesity in colorectal cancer women development is not explicitly stated in the provided snippets. , Therefore, we cannot provide a specific proportion of risk attributable to obesity in colorectal cancer women development based on the given information. However, it is clear that obesity is a significant risk factor for colon cancer in both men and women, and that the association between obesity and colon cancer risk varies by sex and cancer site.', "The exact proportion of colorectal cancer risk that is attributable to obesity can vary depending on the study and the population being considered. However, research has consistently shown that there is a positive association between excess body weight and an increased risk of developing colorectal cancer, particularly in women. Studies have estimated that approximately 3-5% of all colorectal cancers may be attributable to obesity among women. It's important to note that these estimates are based on observational studies and can fluctuate due to factors such as study design, sample size, and the specific measures used to define obesity.", 'In women, 1.04 times higher risk of colorectal cancer development is attributable to obesity.', '16% of risk of colorectal cancer in women development is attributable to obesity.', 'The study found that approximately 15.8% of the total costs in obesity-related cancers among women can be reduced, with a significant portion of this reduction coming from post-menopausal breast, liver, and colorectal cancers. However, the study does not provide a specific proportion of risk attributable to obesity in colorectal cancer women development.', 'The population attributable fractions (PAFs) for excess weight were 24.3% for colon and 18.9% for rectum among women. This means that approximately 24.3% of colon cancer cases and 18.9% of rectum cancer cases in women are attributable to obesity.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/19207714",
"http://www.ncbi.nlm.nih.gov/pubmed/27196525",
"http://www.ncbi.nlm.nih.gov/pubmed/30448606",
"http://www.ncbi.nlm.nih.gov/pubmed/37264099",
"http://www.ncbi.nlm.nih.gov/pubmed/12117878",
"http://www.ncbi.nlm.nih.gov/pubmed/20843489",
"http://www.ncbi.nlm.nih.gov/pubmed/17696248",
"http://www.ncbi.nlm.nih.gov/pubmed/17855691",
"http://www.ncbi.nlm.nih.gov/pubmed/28736986",
"http://www.ncbi.nlm.nih.gov/pubmed/30326010",
"http://www.ncbi.nlm.nih.gov/pubmed/21597097",
"http://www.ncbi.nlm.nih.gov/pubmed/32791859",
"http://www.ncbi.nlm.nih.gov/pubmed/22312135",
"http://www.ncbi.nlm.nih.gov/pubmed/29259258",
"http://www.ncbi.nlm.nih.gov/pubmed/28703702",
"http://www.ncbi.nlm.nih.gov/pubmed/11169969",
"http://www.ncbi.nlm.nih.gov/pubmed/33070559",
"http://www.ncbi.nlm.nih.gov/pubmed/23481261",
"http://www.ncbi.nlm.nih.gov/pubmed/17823417",
"http://www.ncbi.nlm.nih.gov/pubmed/32868317"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/17823417",
"endSection": "abstract",
"offsetInBeginSection": 1166,
"offsetInEndSection": 1586,
"text": "Colon cancer risk increased with increasing waist circumference (per 10-cm increase) in both men (RR: 1.33; 95% CI: 1.19, 1.49) and women (RR: 1.16; 95% CI: 1.09, 1.23) and with increasing waist-hip ratio (per 0.1-unit increase) in both men (RR: 1.43; 95% CI: 1.19, 1.71) and women (RR: 1.20; 95% CI: 1.08, 1.33).CONCLUSIONS: The association between obesity and colon and rectal cancer risk varies by sex and cancer site"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37264099",
"endSection": "abstract",
"offsetInBeginSection": 999,
"offsetInEndSection": 1177,
"text": " The men in the obese/obese group had a higher risk of colon cancer than women (hazard ratio = 1.13 [1.10-1.17] in men, and hazard ratio = 1.04 [1.01-1.18] in women, P = 0.001). "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32791859",
"endSection": "abstract",
"offsetInBeginSection": 809,
"offsetInEndSection": 1015,
"text": "Compared with individuals with normal weight, overweight and obese young adults had a significantly higher risk of CRC (relative risks (RR):18%, 95% CI:1.08, 1.28； RR:32%, 95% CI: 1.11, 1.56, respectively)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28736986",
"endSection": "abstract",
"offsetInBeginSection": 1087,
"offsetInEndSection": 1210,
"text": "cant from a BMI of 23.4 kg/m2 [spline analysis]) and women (HR for overweight, 1.54; 95% CI, 1.22-1.93; HR for obesity, 1.5"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21597097",
"endSection": "abstract",
"offsetInBeginSection": 906,
"offsetInEndSection": 1060,
"text": "r association than females. Population attributable fraction for colorectal cancer by BMI ≥ 25 kg/m(2) was 3.62% (95% CI 1.91-5.30) for males and 2.62% (9"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/19207714",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1558,
"text": "OBJECTIVE: Excess body weight, defined by body mass index (BMI), may increase the risk of colorectal cancer. As a prerequisite to the determination of lifestyle attributable risks, we undertook a systematic review and meta-analysis of prospective observational studies to quantify colorectal cancer risk associated with increased BMI and explore for differences by gender, sub-site and study characteristics.METHOD: We searched MEDLINE and EMBASE (to December 2007), and other sources, selecting reports based on strict inclusion criteria. Random-effects meta-analyses and meta-regressions of study-specific incremental estimates were performed to determine the risk ratio (RR) and 95% confidence intervals (CIs) associated with a 5 kg/m(2) increase in BMI.RESULTS: We analysed 29 datasets from 28 articles, including 67,361 incident cases. Higher BMI was associated with colon (RR 1.24, 95% CIs: 1.20-1.28) and rectal (1.09, 1.05-1.14) cancers in men, and with colon cancer (1.09, 1.04-1.12) in women. Associations were stronger in men than in women for colon (P < 0.001) and rectal (P = 0.005) cancers. Associations were generally consistent across geographic populations. Study characteristics and adjustments accounted for only moderate variations of associations.CONCLUSION: Increasing BMI is associated with a modest increased risk of developing colon and rectal cancers, but this modest risk may translate to large attributable proportions in high-prevalence obese populations. Inter-gender differences point to potentially important mechanistic diffe"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/11169969",
"endSection": "abstract",
"offsetInBeginSection": 194,
"offsetInEndSection": 938,
"text": "The proportion of all cancers attributable to overweight has, however, never been systematically estimated. We reviewed the epidemiological literature and quantitatively summarised, by meta-analysis, the relationship between excess weight and the risk of developing cancer at the 6 sites listed above. Estimates were then combined with sex-specific estimates of the prevalence of overweight [body mass index (BMI) 25-29 kg/m(2)] and obesity (BMI > or = 30 kg/m(2)) in each country in the European Union to obtain the proportion of cancers attributable to excess weight. Overall, excess body mass accounts for 5% of all cancers in the European Union, 3% in men and 6% in women, corresponding to 27,000 male and 45,000 female cancer cases yearly."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/20843489",
"endSection": "abstract",
"offsetInBeginSection": 1063,
"offsetInEndSection": 1206,
"text": "s would be avoided by 2040. The population attributable fractions (PAF) for excess weight were much higher for males (between 13.5% and 18.2%) "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29259258",
"endSection": "abstract",
"offsetInBeginSection": 635,
"offsetInEndSection": 1079,
"text": "Among men, when the highest and lowest fifths were compared, BMI (HR = 1.35, 95%CI: 1.13-1.61; Ptrend < 0.0001), waist circumference (HR = 1.66, 95%CI: 1.39-1.99; Ptrend < 0.0001), waist-to-hip ratio (HR = 1.58, 95%CI: 1.31-1.91; Ptrend < 0.0001), total body fat percentage (HR = 1.27, 95%CI: 1.06-1.53; Ptrend = 0.002), and trunk fat percentage (HR = 1.31, 95%CI: 1.09-1.58; Ptrend = 0.002) were associated with greater colorectal cancer risk."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30326010",
"endSection": "abstract",
"offsetInBeginSection": 1632,
"offsetInEndSection": 2377,
"text": "Similar associations were observed among women without a family history of CRC and without lower endoscopy within the past 10 years. Both BMI at 18 years of age and weight gain since 18 years of age contributed to this observation. Compared with women with a BMI of 18.5 to 20.9 at 18 years of age, the RR of early-onset CRC was 1.32 (95% CI, 0.80-2.16) for women with a BMI of 21.0 to 22.9 and 1.63 (95% CI, 1.01-2.61) for women with a BMI of 23.0 or greater at 18 years of age (P = .66 for trend). Compared with women who had gained less than 5.0 kg or had lost weight, the RR of early-onset CRC was 1.65 (95% CI, 0.96-2.81) for women gaining 20.0 to 39.9 kg and 2.15 (95% CI, 1.01-4.55) for women gaining 40.0 kg or more (P = .007 for trend)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30448606",
"endSection": "abstract",
"offsetInBeginSection": 803,
"offsetInEndSection": 948,
"text": " Compared to women with normal BMI, women who were obese had HRs of 1.39 (95%CI 1.12-1.74) and 1.64 (95%CI 1.24-2.16) for CRC and CC respectively"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32868317",
"endSection": "abstract",
"offsetInBeginSection": 712,
"offsetInEndSection": 1475,
"text": " Compared with the reference group (WC 65-75), the HRs [95% confidence interval (CI)] of colorectal cancer in WC <65, 75-85, 85-95, and >95 groups were 1.01 (0.91-1.11), 1.02 (0.97-1.07), 1.09 (1.00-1.18), and 1.31 (1.12-1.52), respectively, in premenopausal women and 1.01 (0.95-1.17), 1.09 (1.07-1.12), 1.19 (1.00-1.18), and 1.30 (1.25-1.35), respectively, in postmenopausal women. Compared with the reference group (BMI 18.5-22.9), HRs (95% CI) for colorectal cancer in BMI <18.5, 23-25, 25-30, and >30 groups were 0.99 (0.87-1.14), 0.99 (0.94-1.06), 0.98 (0.92-1.04), and 1.06 (0.92-1.20), respectively, in premenopausal women. In postmenopausal women, those values were 0.99 (0.93-1.05), 1.05 (1.03-1.08), 1.11 (1.09-1.13), and 1.20 (1.16-1.25), respectively"
}
] | 13
|
BioASQ-training13b
| null | null |
65f7728fc4010b4d78000021
| 5,065
|
factoid
|
What is the relationship between Electroporation (EP) and DNA vaccines?
|
['increase immunogenicity of the vaccine']
|
[
"increase immunogenicity of the vaccine",
"enhance vaccine immunogenicity",
"boost vaccine immunogenicity",
"improve vaccine immunogenicity",
"augment immunogenic response of the vaccine",
"amplify vaccine immunogenicity"
] |
['Yes, electroporation is an effective way to increase the immunogenicity of DNA.', 'Electroporation (EP) is used to enhance the effectiveness of DNA vaccines by increasing their immunogenicity. This means it helps to boost the immune response triggered by the DNA vaccines.', 'Electroporation (EP) is a method of delivering DNA vaccines that significantly increases transfection efficacy and the subsequent vaccine-specific immune responses.', 'Electroporation (EP) is an effective way to increase the immunogenicity of DNA vaccines.', 'Electroporation (EP) is an effective way to increase the immunogenicity of DNA vaccines. EP is used to deliver plasmid DNA vaccines, enhancing the immune response induced by the vaccine.', 'Electroporation (EP) is a physical method used to facilitate the entry of DNA vaccines (plasmid DNA molecules) into cells, significantly improving their efficacy by inducing humoral and cellular immune responses by over 400- and 35-fold respectively.', 'Electroporation (EP) is a method that increases the immunogenicity of DNA vaccines, particularly plasmid DNA vaccines.', 'Electroporation (EP) is a method that has been shown to significantly augment the transfection efficacy and the subsequent vaccine-specific immune responses of DNA vaccines.', 'Electroporation (EP) is an effective way to increase the DNA vaccines immunogenicity.', 'Electroporation (EP) increases the immunogenicity of DNA vaccines.', 'Electroporation (EP) effectively enhances the immunogenicity of DNA vaccines.', 'Electroporation allows efficient delivery of DNA into cells and tissues, improving the expression of therapeutic or immunogenic proteins that are encoded by plasmid DNA, which is used in DNA vaccines.', 'Electroporation (EP) is a technique used to increase the immunogenicity of DNA vaccines. It involves the use of an electric field to create temporary pores in the cell membrane, allowing the DNA to enter the cell and be expressed as antigens, which can stimulate an immune response.', 'Electroporation (EP) is a method used to increase the immunogenicity of DNA vaccines.', 'Electroporation (EP) is an effective way to increase the immunogenicity of plasmid DNA vaccine.', 'Electroporation (EP) is associated with increasing the immunogenicity of DNA vaccines.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/21180650",
"http://www.ncbi.nlm.nih.gov/pubmed/36992261",
"http://www.ncbi.nlm.nih.gov/pubmed/22284894",
"http://www.ncbi.nlm.nih.gov/pubmed/38034030",
"http://www.ncbi.nlm.nih.gov/pubmed/23684840",
"http://www.ncbi.nlm.nih.gov/pubmed/15110305",
"http://www.ncbi.nlm.nih.gov/pubmed/25535102",
"http://www.ncbi.nlm.nih.gov/pubmed/17239494",
"http://www.ncbi.nlm.nih.gov/pubmed/29953259",
"http://www.ncbi.nlm.nih.gov/pubmed/23085605",
"http://www.ncbi.nlm.nih.gov/pubmed/28646234",
"http://www.ncbi.nlm.nih.gov/pubmed/37860767",
"http://www.ncbi.nlm.nih.gov/pubmed/31174938",
"http://www.ncbi.nlm.nih.gov/pubmed/22894954",
"http://www.ncbi.nlm.nih.gov/pubmed/19619001",
"http://www.ncbi.nlm.nih.gov/pubmed/18989354",
"http://www.ncbi.nlm.nih.gov/pubmed/18847301",
"http://www.ncbi.nlm.nih.gov/pubmed/17961089",
"http://www.ncbi.nlm.nih.gov/pubmed/24510831",
"http://www.ncbi.nlm.nih.gov/pubmed/38063059",
"http://www.ncbi.nlm.nih.gov/pubmed/24510835",
"http://www.ncbi.nlm.nih.gov/pubmed/36365078",
"http://www.ncbi.nlm.nih.gov/pubmed/20951666",
"http://www.ncbi.nlm.nih.gov/pubmed/18353952",
"http://www.ncbi.nlm.nih.gov/pubmed/21530212",
"http://www.ncbi.nlm.nih.gov/pubmed/21752954",
"http://www.ncbi.nlm.nih.gov/pubmed/22644389"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/38063059",
"endSection": "abstract",
"offsetInBeginSection": 182,
"offsetInEndSection": 260,
"text": "Electroporation (EP) is an effective way to increase the immunogenicity of DNA"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36992261",
"endSection": "abstract",
"offsetInBeginSection": 228,
"offsetInEndSection": 378,
"text": "n this study, we challenged this concept by characterizing the immunological response induced by a plasmid DNA vaccine delivered using electroporation"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/38034030",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 177,
"text": "Intradermal delivery of DNA vaccines via electroporation (ID-EP) has shown clinical promise, but the use of needle electrodes is typically required to achieve consistent results"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18353952",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 160,
"text": "In vivo electroporation (EP) has been shown to augment the immunogenicity of plasmid DNA vaccines, but its mechanism of action has not been fully characterized."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/19619001",
"endSection": "abstract",
"offsetInBeginSection": 1445,
"offsetInEndSection": 1559,
"text": "These data establish EP as a potent method for stimulating humoral responses induced by DNA vaccination in humans."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/17961089",
"endSection": "abstract",
"offsetInBeginSection": 432,
"offsetInEndSection": 655,
"text": "Electroporation (EP), a promising approach that dramatically enhances expression of the encoded antigen as well as the potency and immunogenicity of DNA vaccines, could facilitate clinical implementation of DNA vaccination."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/15110305",
"endSection": "abstract",
"offsetInBeginSection": 207,
"offsetInEndSection": 347,
"text": "Electroporation (EP) has emerged as an effective method for delivering DNA vaccines, significantly enhancing humoral and cellular responses."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24510831",
"endSection": "abstract",
"offsetInBeginSection": 639,
"offsetInEndSection": 865,
"text": "DNA Electroporation may prove to be the \"missing link\" in the evolution of DNA vaccines allowing for enhanced immune responses from DNA vaccination in humans thereby resulting in protection from disease post-pathogen exposure."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21180650",
"endSection": "abstract",
"offsetInBeginSection": 809,
"offsetInEndSection": 919,
"text": "In vivo EP has the key features of improved DNA uptake, increased antigen expression and a local inflammation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24510835",
"endSection": "abstract",
"offsetInBeginSection": 256,
"offsetInEndSection": 717,
"text": "DNA vaccines have been proposed as a promising approach for introducing foreign antigens into the host for inducing protective immunity against infectious and cancer diseases. Nevertheless, because of their poor immunogenicity, plasmid DNA vaccination strategies need further implementations. Recent data suggest electrotransfer as a useful tool to improve DNA-based vaccination protocols, being able to stimulate both the humoral and cellular immune responses."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22284894",
"endSection": "abstract",
"offsetInBeginSection": 310,
"offsetInEndSection": 561,
"text": "Importantly, EP dramatically enhanced the neutralizing potency of the humoral response, since antibodies induced by low DNA dose (10 μg) were able to highly neutralize DHBV and to recognize ten antigenic regions, including four neutralization epitopes"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18989354",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 233,
"text": "In vivo electroporation of plasmid DNA (DNA-EP) is an efficient and safe method for vaccines resulting in increased DNA uptake, enhanced protein expression and increased immune responses to the target antigen in a variety of species."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37860767",
"endSection": "abstract",
"offsetInBeginSection": 232,
"offsetInEndSection": 488,
"text": "Herein, we report a screening system based on DNA vaccines and a micro-electroporation/electrophoresis system (MEES), which greatly improved the efficacy of DNA vaccines, elevating humoral and cellular immune responses by over 400- and 35-fold respectively"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/17239494",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1010,
"text": "Electroporation can improve intramuscular DNA vaccination efficacy but the exact antigen presentation mechanism remains unclear. We reported here that a similar immuno-potentiation effect was also observed by stimulating the skeletal muscles with electric pulses (EP) a few days prior to DNA inoculation (EP + n days + DNA). The application of EP by itself activated proinflammatory chemokine genes and stress genes. It also triggered an influx of inflammatory monocytes/macrophages (MPs). After DNA inoculation, the plasmids were seen taken up by these inflammatory MPs, which migrated to the draining LNs subsequently. The antibody responses results were fast and strong. Furthermore, MPs isolated from the draining LNs of EP + n days + DNA treated mice were capable of stimulating Ag specific CD4+ T cell proliferation in vitro. Based on these observations, we proposed that the local inflammation resulted from EP treatment played an important role in facilitating antigen presentation of the DNA vaccines."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22644389",
"endSection": "abstract",
"offsetInBeginSection": 209,
"offsetInEndSection": 642,
"text": "One of the uses of EP in vivo is plasmid DNA electrotransfer to the skin for DNA vaccination. EP of tissues induces reduction of blood flow and, in combination with plasmid DNA, induction of an immune response. One of the EP protocols for plasmid DNA electrotransfer to the skin is a combination of high-voltage (HV) and low-voltage (LV) pulses. However, the effects of this pulse combination on skin-vessel blood flow are not known."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28646234",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 357,
"text": "In vivo electroporation (EP) is used to enhance the uptake of nucleic acids and its association with DNA vaccination greatly stimulates immune responses to vaccine antigens delivered through the skin. However, the effect of EP on cutaneous cell behavior, the dynamics of immune cell recruitment and local inflammatory factors, have not been fully described."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25535102",
"endSection": "abstract",
"offsetInBeginSection": 84,
"offsetInEndSection": 484,
"text": "Recent delivery techniques such as the gene gun and in vivo electroporation (EP)/electrotransfer (ET) have completely changed the efficiency of DNA vaccines in humans. In vivo EP exerts multiple effects that contribute to its efficiency. The two central factors are most likely the increased DNA uptake due to the transient membrane destabilization, and the local tissue damage acting as an adjuvant."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22894954",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 661,
"text": "Non-viral in vivo administration of plasmid DNA for vaccines and immunotherapeutics has been hampered by inefficient delivery. Methods to enhance delivery such as in vivo electroporation (EP) have demonstrated effectiveness in circumventing this difficulty. However, the contact-dependent nature of EP has resulting side effects in animals and humans. Noncontact delivery methods should, in principle, overcome some of these obstacles. This report describes a helium plasma-based delivery system that enhanced humoral and cellular antigen-specific immune responses in mice against an intradermally administered HIV gp120-expressing plasmid vaccine (pJRFLgp120)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29953259",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 529,
"text": "The immune responses elicited following delivery of DNA vaccines to the skin has previously been shown to be significantly enhanced by the addition of electroporation (EP) to the treatment protocol. Principally, EP increases the transfection of plasmid DNA (pDNA) into the resident skin cells. In addition to increasing the levels of in vivo transfection, the physical insult induced by EP is associated with activation of innate pathways which are believed to mediate an adjuvant effect, further enhancing DNA vaccine responses."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36365078",
"endSection": "abstract",
"offsetInBeginSection": 262,
"offsetInEndSection": 583,
"text": "Electroporation (EP) is an effective way to enhance the immunogenicity of DNA vaccines, but because of the different configurations of the devices that are used for EP, it is necessary to carefully select the conditions of the procedure, including characteristics such as voltage, current strength, number of pulses, etc."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23684840",
"endSection": "abstract",
"offsetInBeginSection": 188,
"offsetInEndSection": 1039,
"text": "Our laboratory has been evaluating DNA plasmid based Pfs25 vaccine in mice and non-human primates. Previously, we established that in vivo electroporation (EP) delivery is an effective method to improve the immunogenicity of DNA vaccine encoding Pfs25 in mice. In order to optimize the in vivo EP procedure and test for its efficacy in more clinically relevant larger animal models, we employed in vivo EP to evaluate the immune response and protective efficacy of Pfs25 encoding DNA vaccine in nonhuman primates (olive baboons, Papio anubis). The results showed that at a dose of 2.5mg DNA vaccine, antibody responses were significantly enhanced with EP as compared to without EP resulting in effective transmission blocking efficiency. Similar immunogenicity enhancing effect of EP was also observed with lower doses (0.5mg and 1mg) of DNA plasmids."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29953259",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 198,
"text": "The immune responses elicited following delivery of DNA vaccines to the skin has previously been shown to be significantly enhanced by the addition of electroporation (EP) to the treatment protocol."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21752954",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 163,
"text": "In vivo electroporation (EP) has proven to significantly increase plasmid transfection efficiency and to augment immune responses after immunization with plasmids."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23085605",
"endSection": "abstract",
"offsetInBeginSection": 193,
"offsetInEndSection": 404,
"text": "Two main strategies to increase DNA-based vaccine potency are the employment of immuno-adjuvants such as heat shock proteins (HSPs) and a method of improving the delivery of naked plasmid DNA by electroporation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29953259",
"endSection": "abstract",
"offsetInBeginSection": 294,
"offsetInEndSection": 529,
"text": "In addition to increasing the levels of in vivo transfection, the physical insult induced by EP is associated with activation of innate pathways which are believed to mediate an adjuvant effect, further enhancing DNA vaccine responses."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31174938",
"endSection": "abstract",
"offsetInBeginSection": 88,
"offsetInEndSection": 329,
"text": "electroporation (EP) has been shown to generate potent and efficacious immune responses in the clinic. Needle-free jet injection has also been reported to improve DNA vaccine delivery over standard needle and syringe in clinical trials. Here"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21530212",
"endSection": "abstract",
"offsetInBeginSection": 460,
"offsetInEndSection": 685,
"text": "Of these, EP mediated delivery has generated considerable enthusiasm and appears to have had a great impact in vaccine immunogenicity and efficacy by increasing antigen delivery upto a 1000 fold over naked DNA delivery alone."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/20951666",
"endSection": "abstract",
"offsetInBeginSection": 477,
"offsetInEndSection": 818,
"text": "One novel in vivo delivery method for plasmid vaccines is electroporation, which is the application of short pulses of electric current immediately after, and at the site of, an injection of a genetic vaccine. This method has been shown to significantly augment the transfection efficacy and the subsequent vaccine-specific immune responses."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18847301",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 149,
"text": "Electroporation of skeletal muscle induces danger signal release and antigen-presenting cell recruitment independently of DNA vaccine administration."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18353952",
"endSection": "title",
"offsetInBeginSection": 1,
"offsetInEndSection": 177,
"text": "ecruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation."
}
] | 13
|
BioASQ-training13b
| null | null |
65f494d7c4010b4d78000013
| 5,071
|
factoid
|
What type of DMD can golodirsen be used for?
|
['exon 53']
|
[
"exon 53",
"exon 53 (human)",
"exon 53 (mouse)",
"exon 53 (rat)"
] |
['Golodirsen can be used to treat Duchenne muscular dystrophy (DMD) patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.', 'Golodirsen is approved for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.', 'Patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.', 'Golodirsen (Vyondys 53™) is an antisense oligonucleotide designed to induce exon 53 skipping in patients with Duchenne muscular dystrophy (DMD) who have a confirmed mutation of the DMD gene that is amenable to this specific form of therapy.', 'Golodirsen can be used for the treatment of DMD in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.', 'Golodirsen can be used for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.', 'Golodirsen is a drug that can be used for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.', 'Golodirsen is used for treating Duchenne muscular dystrophy that can benefit from exon 53 skipping.', 'Golodirsen can be used for Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.', 'Golodirsen is approved for the treatment of DMD in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.', 'Golodirsen is approved by the FDA for the treatment of Duchenne Muscular Dystrophy (DMD) patients who are amenable to exon 53 skipping.', 'Golodirsen (Vyondys 53™) can be used for treating Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.', 'Golodirsen is used for treating DMD in patients who have a specific mutation that can be treated by skipping exon 53.', 'Golodirsen (Vyondys 53™) is approved for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.', 'Golodirsen can be used for the treatment of Duchenne Muscular Dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.', 'Golodirsen (VYONDYS 53TM) can be used for specific types of Duchenne Muscular Dystrophy (DMD) that are amenable to exon 53 skipping.', 'Golodirsen can be used for DMD with a confirmed mutation amenable to exon 53 skipping.', 'Golodirsen can be used for Duchenne muscular dystrophy (DMD) patients who are amenable to exon 53 skipping.', 'Golodirsen can be used for Duchenne muscular dystrophy (DMD) with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.', 'Golodirsen (Vyondys 53™) can be used for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/32139505",
"http://www.ncbi.nlm.nih.gov/pubmed/36401027",
"http://www.ncbi.nlm.nih.gov/pubmed/34092651",
"http://www.ncbi.nlm.nih.gov/pubmed/32026421",
"http://www.ncbi.nlm.nih.gov/pubmed/33407808",
"http://www.ncbi.nlm.nih.gov/pubmed/34788571",
"http://www.ncbi.nlm.nih.gov/pubmed/33025945",
"http://www.ncbi.nlm.nih.gov/pubmed/32483212",
"http://www.ncbi.nlm.nih.gov/pubmed/30171533",
"http://www.ncbi.nlm.nih.gov/pubmed/32947786"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32026421",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 150,
"text": "Golodirsen (Vyondys 53™), an antisense oligonucleotide of the phophorodiamidate morpholino oligomer (PMO) subclass designed to induce exon 53 skipping"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32026421",
"endSection": "abstract",
"offsetInBeginSection": 251,
"offsetInEndSection": 455,
"text": "In December 2019, intravenous golodirsen received its first global approval in the USA for the treatment of DMD in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping, "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36401027",
"endSection": "abstract",
"offsetInBeginSection": 332,
"offsetInEndSection": 505,
"text": "Two exon 53 skipping PMOs, golodirsen and viltolarsen, have received conditional approval for treating patients due to their ability to restore dystrophin protein expression"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32483212",
"endSection": "abstract",
"offsetInBeginSection": 377,
"offsetInEndSection": 482,
"text": "Eteplirsen and golodirsen, AONs for DMD exons 51 and 53 skipping, have been recently approved by the FDA."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32026421",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 250,
"text": "Golodirsen (Vyondys 53™), an antisense oligonucleotide of the phophorodiamidate morpholino oligomer (PMO) subclass designed to induce exon 53 skipping, has been developed by Sarepta Therapeutics for the treatment of Duchenne muscular dystrophy (DMD)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32026421",
"endSection": "abstract",
"offsetInBeginSection": 251,
"offsetInEndSection": 514,
"text": "In December 2019, intravenous golodirsen received its first global approval in the USA for the treatment of DMD in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping, based on positive results from a phase I/II clinical trial."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30171533",
"endSection": "abstract",
"offsetInBeginSection": 351,
"offsetInEndSection": 649,
"text": "Antisense-mediated exon skipping is most extensively studied in Duchenne muscular dystrophy (DMD) and has developed from in vitro proof-of-concept studies to clinical trials targeting various single exons such as exon 45 (casimersen), exon 53 (NS-065/NCNP-01, golodirsen), and exon 51 (eteplirsen)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36401027",
"endSection": "abstract",
"offsetInBeginSection": 332,
"offsetInEndSection": 506,
"text": "Two exon 53 skipping PMOs, golodirsen and viltolarsen, have received conditional approval for treating patients due to their ability to restore dystrophin protein expression."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33025945",
"endSection": "abstract",
"offsetInBeginSection": 783,
"offsetInEndSection": 901,
"text": "Golodirsen is a provisionally approved PMO-based drug for approx. 8% of all DMD patients amenable to exon 53 skipping."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34788571",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 217,
"text": "The aim of this Phase 1/2, 2-part, multicenter trial was to report clinical safety and efficacy of long-term golodirsen treatment among ambulatory patients with exon 53 skip-amenable Duchenne muscular dystrophy (DMD)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32139505",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 352,
"text": "OBJECTIVE: To report safety, pharmacokinetics, exon 53 skipping, and dystrophin expression in golodirsen-treated patients with Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping.METHODS: Part 1 was a randomized, double-blind, placebo-controlled, 12-week dose titration of once-weekly golodirsen; part 2 is an ongoing, open-label evaluation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32139505",
"endSection": "abstract",
"offsetInBeginSection": 1259,
"offsetInEndSection": 1982,
"text": "Sarcolemmal localization of dystrophin was demonstrated by significantly increased dystrophin-positive fibers (week 48, p < 0.001) and a positive correlation (Spearman r = 0.663; p < 0.001) with dystrophin protein change from baseline, measured by Western blot and immunohistochemistry.CONCLUSION: Golodirsen was well-tolerated; muscle biopsies from golodirsen-treated patients showed increased exon 53 skipping, dystrophin production, and correct dystrophin sarcolemmal localization.CLINICALTRIALSGOV IDENTIFIER: NCT02310906.CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that golodirsen is safe and Class IV evidence that it induces exon skipping and novel dystrophin as confirmed by 3 different assays."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34788571",
"endSection": "abstract",
"offsetInBeginSection": 109,
"offsetInEndSection": 285,
"text": "golodirsen treatment among ambulatory patients with exon 53 skip-amenable Duchenne muscular dystrophy (DMD). Part 1 was a 12-week, randomized, double-blind, placebo-controlled,"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36401027",
"endSection": "abstract",
"offsetInBeginSection": 207,
"offsetInEndSection": 386,
"text": "DMD gene. In particular, PMOs for skipping exon 44 have been developing in clinical trials, such as the drug NS-089/NCNP-02. Two exon 53 skipping PMOs, golodirsen and viltolarsen,"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34092651",
"endSection": "abstract",
"offsetInBeginSection": 898,
"offsetInEndSection": 1078,
"text": "Very recently, golodirsen and viltolarsen, for treatment of DMD patients amenable to skipping exon 53, have been approved by regulatory agencies in the USA and Japan, respectively."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32139505",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 179,
"text": "OBJECTIVE: To report safety, pharmacokinetics, exon 53 skipping, and dystrophin expression in golodirsen-treated patients with Duchenne muscular dystrophy (DMD) amenable to exon 5"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32947786",
"endSection": "abstract",
"offsetInBeginSection": 330,
"offsetInEndSection": 544,
"text": "However, several new personalized therapies, including antisense oligonucleotides eteplirsen for DMD exon 51 skipping and golodirsen and viltolarsen for DMD exon 53 skipping, have been approved in the last 4 years."
}
] | 13
|
BioASQ-training13b
| null | null |
64179034690f196b5100002b
| 5,073
|
factoid
|
What proportion of alteration in NTRK genes are attributable to colorectal cancer?
|
['Less than 0.5%', '0.5%']
|
[
"Less than 0.5%",
"0.5%",
"0.5 percent",
"less than half a percent",
"less than 0.5 percent"
] |
['The proportion of alterations in NTRK genes attributable to colorectal cancer is relatively low, with NTRK gene fusions occurring in approximately 1% of colorectal cancer cases.', 'The rate of alterations in NTRK genes among common cancers is generally below 0.5%, with rare morphological subtypes, colorerectal microsatellite instability (MSI) tumors, and driver mutation exclusion cancers having higher rates. Colorectal cancer specifically has been found to have a higher prevalence of NTRK gene alterations compared to other common cancers, although the exact rate can vary depending on factors such as MSI status and the presence or absence of certain driver mutations.', 'In colorectal cancer, the proportion of alterations in NTRK genes is consistently below 0.5%. However, rare morphological subtypes, colorectal microsatellite instability, and driver mutation exclusion cancers show higher rates of alterations in NTRK genes.', 'The proportion of alteration in NTRK genes attributable to colorectal cancer is not well established in the literature. However, it is known that NTRK gene alterations are relatively rare in colorectal cancer, occurring in approximately 1-3% of cases. Therefore, the proportion of alteration in NTRK genes attributable to colorectal cancer is likely to be small.', 'In common cancers, rates were consistently below 0.5%. Rare morphological subtypes, colorectal microsatellite instability, and driver mutation exclusion cancers had higher rates.', 'The proportion of alteration in NTRK genes attributable to colorectal cancer is 0.0001%.', 'Alterations in NTRK genes attributable to colorectal cancer account for 0.5% of cases, with higher rates observed in rare morphological subtypes and those with microsatellite instability.', 'The prevalence of NTRK gene fusions in colorectal cancer is generally low, ranging from approximately 0.23% to 0.7% in most studies. However, one study found a higher prevalence of around 7% specifically in the microsatellite instability-high (MSI-high) colorectal cancer subgroup.', 'The proportion of alterations in NTRK genes attributable to colorectal cancer is consistently below 0.5%. However, it is important to note that rare morphological subtypes, colorectal microsatellite instability, and driver mutation exclusion cancers may have higher rates of NTRK gene alterations.', 'The text does not provide specific information on the proportion of alteration in NTRK genes attributable to colorectal cancer. It mentions that common cancers have rates consistently below 0.5%, and that rare morphological subtypes, colorectal microsatellite instability, and driver mutation exclusion cancers have higher rates. However, it does not specify the rate for colorectal cancer or NTRK gene alterations.', 'The proportion of alterations in NTRK genes attributable to colorectal cancer is below 0.5%.', 'The proportion of alteration in NTRK genes attributable to colorectal cancer (CRC) is around 10% in the pan-cancer population, and 0.2% of CRCs (9/4569) were positive for Pan-Trk IHC. Additionally, the prevalence of NTRK fusion in CRC was 0.18%, with 46 unique NTRK-fusion partner pairs, of which 33 were not previously reported. TRK positivity was observed in 19% of MLH1-methylated MSI-high CRCs, 17% of sessile serrated lesions with dysplasia (SSLDs), and 4% of sessile serrated lesions (SSLs). However, NTRK gene alterations are not enriched in gastric cancer (GC) with dMMR but are specifically enriched in cases of GAHED.', "Based on the information provided in the snippet, it is not possible to directly determine the proportion of alterations in NTRK genes that are attributable to colorectal cancer. The snippet discusses the rates of cancers in general and mentions rare morphological subtypes, microsatellite instability, and driver mutation exclusion cancers having higher rates, but it does not provide specific details about NTRK gene alterations or their association with colorectal cancer. , However, it is known that NTRK gene fusions can occur across various tumor types, including colorectal cancer, but they are considered rare events. According to a study published in Cancer Discovery, the frequency of NTRK gene fusions in colorectal cancer is estimated to be around 0.18-0.23% (Cancer Discov. 2017 Aug;7(8):824-836). , Therefore, while it's challenging to provide an exact proportion based on the given snippet, it can be inferred that alterations in NTRK genes attributable to colorectal cancer are relatively rare events.", 'According to the literature review, NTRK gene fusions are found in approximately 0.2% to 0.3% of colorectal cancers. This means that out of every 100 colorectal cancers, 2 to 3 cases will have an NTRK gene fusion. Therefore, the proportion of alterations in NTRK genes attributable to colorectal cancer is relatively low, but still significant enough to consider testing for these fusions in certain subgroups of patients.', '0.25% of patients analyzed had NTRK gene fusions and the most common were breast cancer, colorectal cancer (CRC), and sarcoma.', 'According to the systematic review, the proportion of NTRK gene fusions attributable to colorectal cancer is not specifically stated. However, it is mentioned that rare morphological subtypes, such as colorectal microsatellite instability, and driver mutation exclusion cancers have higher rates of NTRK fusions. The review also notes that the prevalence of NTRK fusions in common cancers, including colorectal cancer, is consistently below 0.5%. Therefore, it can be inferred that the proportion of NTRK alterations attributable to colorectal cancer is likely low, but further large-scale, standardized genomic data are needed to characterize NTRK fusion epidemiology in this specific cancer type.', 'The exact proportion of NTRK gene alterations attributable to colorectal cancer (CRC) is not provided in the text. However, the text does mention that NTRK gene fusions are found in approximately 0.16-0.3% of CRCs and that they are more frequent in MMR-deficient/BRAFV600E wild-type tumors (5.3%). Additionally, the study found that 7% of MSI-high CRC cohort had NTRK gene fusions. It is important to note that these frequencies are based on specific patient populations and may not be generalizable to all patients with CRC.', 'In common cancers, rates of NTRK gene alterations were consistently below 0.5%. Rare morphological subtypes, colorectal microsatellite instability, and driver mutation exclusion cancers had higher rates.', "According to the provided text, approximately 7% of colorectal cancers (CRCs) have NTRK gene fusions. This means that about 7% of alterations in NTRK genes are attributable to CRC. However, it's important to note that not all NTRK alterations are necessarily driver mutations or functional, and some may be passengers or non-pathogenic variants. Therefore, the actual proportion of NTRK alterations that contribute to the development and progression of CRC is likely lower than 7%.", 'The rates of NTRK gene alterations were consistently below 0.5% in common cancers. However, colorectal cancers with microsatellite instability had higher rates of NTRK alterations compared to common cancers overall.', 'Rates of NTRK gene alteration were consistently below 0.5% in common cancers, but in rare morphological subtypes and colorectal microsatellite instability, and driver mutation exclusion cancers, higher rates of NTRK gene alteration were reported.', 'Alterations in NTRK genes attributable to colorectal cancer account for approximately 0.5% and are associated with colorectal microsatellite instability.', 'Approximately less than 0.5% of alterations in NTRK genes are associated with colorectal cancer. NTRK gene fusions have been identified as oncogenic drivers across various tumor types; however, they are relatively rare in colorectal cancer, making up a very small proportion of genetic changes observed in this cancer type.', '0.5% or less.', 'The proportion of alteration in NTRK genes attributable to colorectal cancer is below 0.5%.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/34402529",
"http://www.ncbi.nlm.nih.gov/pubmed/36914665",
"http://www.ncbi.nlm.nih.gov/pubmed/31567189",
"http://www.ncbi.nlm.nih.gov/pubmed/36041373",
"http://www.ncbi.nlm.nih.gov/pubmed/36077692",
"http://www.ncbi.nlm.nih.gov/pubmed/28174090"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36914665",
"endSection": "abstract",
"offsetInBeginSection": 975,
"offsetInEndSection": 1154,
"text": " In common cancers, rates were consistently below 0.5%. Rare morphological subtypes, colorectal microsatellite instability, and driver mutation exclusion cancers had higher rates."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36077692",
"endSection": "abstract",
"offsetInBeginSection": 1241,
"offsetInEndSection": 1456,
"text": "The proportion of patients with targets for genetically matched therapies differed among subtypes (salivary duct carcinoma: 82%, adenoid cystic carcinoma 28%, mucoepidermoid carcinoma 50%, acinic cell carcinoma 33%)"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36041373",
"endSection": "abstract",
"offsetInBeginSection": 782,
"offsetInEndSection": 935,
"text": "Of 15,223 patients analyzed, 38 (0.25%) had NTRK gene fusions in 11 tumor types, the most common were breast cancer, colorectal cancer (CRC), and sarcoma"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34402529",
"endSection": "abstract",
"offsetInBeginSection": 945,
"offsetInEndSection": 1135,
"text": "TRK positivity was observed in 11 of 58 (19%) MLH1-methylated MSI-high CRCs, 4 of 23 (17%) sessile serrated lesions with dysplasia (SSLDs), and 5 of 132 (4%) sessile serrated lesions (SSLs)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28174090",
"endSection": "abstract",
"offsetInBeginSection": 772,
"offsetInEndSection": 1020,
"text": "colorectal cancers, prevalence of the NTRK fusions is well below 5%. Selective inhibition of TRK signaling may therefore be beneficial among patients whose tumors vary in histologies, but share underlying oncogenic NTRK gene alterations. Currently,"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31567189",
"endSection": "abstract",
"offsetInBeginSection": 188,
"offsetInEndSection": 298,
"text": "Of the 7008 tumors screened for NTRK expression using a pan-Trk antibody, 16 (0.23%) had Trk immunoreactivity."
}
] | 13
|
BioASQ-training13b
| null | null |
65f77397c4010b4d78000025
| 5,075
|
factoid
|
Cilta-cel was developed for treatment of which disease?
|
['multiple myeloma']
|
[
"multiple myeloma",
"plasma cell myeloma",
"myeloma",
"Kahler's disease",
"myelomatosis"
] |
['Cilta-cel, a BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/37014590",
"http://www.ncbi.nlm.nih.gov/pubmed/34175021",
"http://www.ncbi.nlm.nih.gov/pubmed/37716872",
"http://www.ncbi.nlm.nih.gov/pubmed/37913909",
"http://www.ncbi.nlm.nih.gov/pubmed/37497629",
"http://www.ncbi.nlm.nih.gov/pubmed/36271807",
"http://www.ncbi.nlm.nih.gov/pubmed/37272512",
"http://www.ncbi.nlm.nih.gov/pubmed/36411210",
"http://www.ncbi.nlm.nih.gov/pubmed/37750399",
"http://www.ncbi.nlm.nih.gov/pubmed/36720180",
"http://www.ncbi.nlm.nih.gov/pubmed/36269898",
"http://www.ncbi.nlm.nih.gov/pubmed/34885106",
"http://www.ncbi.nlm.nih.gov/pubmed/35764490",
"http://www.ncbi.nlm.nih.gov/pubmed/34840088",
"http://www.ncbi.nlm.nih.gov/pubmed/37704875",
"http://www.ncbi.nlm.nih.gov/pubmed/35900317"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36411210",
"endSection": "abstract",
"offsetInBeginSection": 1174,
"offsetInEndSection": 1407,
"text": " Additional indirect treatment comparisons conducted separately for ide-cel and cilta-cel have demonstrated that these CAR-T therapies hold promise for substantial clinical benefit relative to currently available treatments for RRMM."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36271807",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 607,
"text": "OBJECTIVE: This study used the latest available data cuts from the CARTITUDE-1 and KarMMa clinical trials to update previously published matching-adjusted indirect treatment comparisons (MAICs) assessing the comparative efficacy of ciltacabtagene autoleucel (cilta-cel) versus the FDA-approved idecabtagene vicleucel (ide-cel) dose range of 300 to 450 × 106 CAR-positive T-cells in the treatment of patients with relapsed or refractory multiple myeloma (RRMM) who were previously treated with a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody (i.e. triple-class exposed)"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36271807",
"endSection": "abstract",
"offsetInBeginSection": 1645,
"offsetInEndSection": 1850,
"text": "CONCLUSIONS: These analyses demonstrate improved efficacy with cilta-cel versus ide-cel for all outcomes over longer follow-up and highlight its therapeutic potential in triple-class exposed RRMM patients."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36269898",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 253,
"text": "PURPOSE: CARTIFAN-1 aimed to evaluate the efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen-targeting chimeric antigen receptor T-cell therapy, in Chinese patients with relapsed/refractory multiple myeloma (RRMM)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36269898",
"endSection": "abstract",
"offsetInBeginSection": 1776,
"offsetInEndSection": 1978,
"text": "CONCLUSION: These data demonstrate a favorable risk-benefit profile for a single infusion of cilta-cel, resulting in early, deep, and durable responses in heavily pretreated patients with RRMM in China."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37497629",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 116,
"text": "Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37497629",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 323,
"text": "Cilta-cel, a BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma, was approved in USA on 28 February 2022, for patients with relapsed or refractory disease who have received ≥4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37913909",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 432,
"text": "Since 2021, 2 B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapies-idecabtagene vicleucel (ide-cel), and ciltacabtagene autoleucel (cilta-cel)-have been approved by the US Food and Drug Administration (FDA) for treating relapsed or refractory multiple myeloma (RRMM) after 4 or more prior lines of therapy, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34840088",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 602,
"text": "BACKGROUND: In the single-arm, phase 1b/2 CARTITUDE-1 study, ciltacabtagene autoleucel (cilta-cel), an anti-B-cell maturation antigen chimeric antigen receptor T-cell (CAR-T) therapy, showed encouraging efficacy in US patients with multiple myeloma (MM) who previously received an immunomodulatory drug, proteasome inhibitor, and anti-CD38 monoclonal antibody (triple-class exposed).PATIENTS AND METHODS: A dataset of US patients refractory to an anti-CD38 monoclonal antibody (MAMMOTH) was used to identify patients who would meet eligibility for CARTITUDE-1 and received subsequent non-CAR-T therapy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37272512",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 204,
"text": "BACKGROUND: Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, is effective in heavily pretreated patients with relapsed or refractory multiple myeloma."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34175021",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 765,
"text": "BACKGROUND: CARTITUDE-1 aimed to assess the safety and clinical activity of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two B-cell maturation antigen-targeting single-domain antibodies, in patients with relapsed or refractory multiple myeloma with poor prognosis.METHODS: This single-arm, open-label, phase 1b/2 study done at 16 centres in the USA enrolled patients aged 18 years or older with a diagnosis of multiple myeloma and an Eastern Cooperative Oncology Group performance status score of 0 or 1, who received 3 or more previous lines of therapy or were double-refractory to a proteasome inhibitor and an immunomodulatory drug, and had received a proteasome inhibitor, immunomodulatory drug, and anti-CD38 antibody."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34885106",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 214,
"text": "Ciltacabtagene autoleucel (cilta-cel) is a Chimeric antigen receptor T-cell therapy with the potential for long-term disease control in heavily pre-treated patients with relapsed/refractory multiple myeloma (RRMM)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37014590",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 410,
"text": "INTRODUCTION: Ciltacabtagene autoleucel (cilta-cel), is a B-cell maturation antigen-directed, genetically modified autologous chimeric antigen receptor T-cell (CAR-T) immunotherapy. It is indicated for treatment for adult patients with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monocl"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35764490",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 557,
"text": "INTRODUCTION: This study estimated the comparative efficacy of ciltacabtagene autoleucel (cilta-cel; CARTITUDE-1), a chimeric antigen receptor (CAR)-T-cell therapy, versus 3 non-CAR-T therapies (belantamab mafodotin [DREAMM-2], selinexor plus dexamethasone [STORM Part 2], and melphalan flufenamide plus dexamethasone [HORIZON]), each with distinct mechanisms of action, for the treatment of patients with relapsed or refractory multiple myeloma (RRMM) who were triple-class exposed to an immunomodulatory drug, proteasome inhibitor, and an anti-CD38 monocl"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37750399",
"endSection": "abstract",
"offsetInBeginSection": 159,
"offsetInEndSection": 528,
"text": "Two BCMA-directed CAR T-cell products - idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) - have received US Food and Drug Administration (FDA) approval for patients with relapsed/refractory MM who underwent four or more prior lines of therapy (including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37913909",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 433,
"text": "Since 2021, 2 B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapies-idecabtagene vicleucel (ide-cel), and ciltacabtagene autoleucel (cilta-cel)-have been approved by the US Food and Drug Administration (FDA) for treating relapsed or refractory multiple myeloma (RRMM) after 4 or more prior lines of therapy, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36720180",
"endSection": "abstract",
"offsetInBeginSection": 118,
"offsetInEndSection": 402,
"text": "nancies. Ciltacabtagene autoleucel (cilta-cel), a second-generation CAR-T cell with double B cell maturation antigen (BCMA) targeting binding domains, showed an 88% overall response rate (ORR) in patients with relapsed/refractory multiple myeloma (MM), which were carried out in our i"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37704875",
"endSection": "abstract",
"offsetInBeginSection": 712,
"offsetInEndSection": 935,
"text": "The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) has approved two BCMA-targeting CAR T cell products, idecabtagene vicleucel (Ide-cel) and ciltacabtagene autoleucel (Cilta-cel), for use in RRMM."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35900317",
"endSection": "abstract",
"offsetInBeginSection": 803,
"offsetInEndSection": 975,
"text": "The autologous CAR-T cell therapy against BCMA (ide-cel and cilta-cel) shows the best efficacy with an overall response rate and a median progression-free survival in RRMM."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37716872",
"endSection": "abstract",
"offsetInBeginSection": 132,
"offsetInEndSection": 413,
"text": "eptor (CAR) T cell therapies, because their engineered cells may include allogeneic T cells. Ciltacabtagene autoleucel (cilta-cel) demonstrated early, deep, durable responses and manageable safety in heavily pretreated relapsed/refractory multiple myeloma patients. We retrospectiv"
}
] | 13
|
BioASQ-training13b
| null | null |
65cfd4b21930410b13000020
| 5,079
|
factoid
|
What is the main cause of spillover events?
|
['The main cause of spillover events is the disruption of habitats of the reservoir species.', 'The main cause of spillover events is the interface between humans, wildlife, and domesticated animals, which is associated with high habitat fragmentation, biodiversity loss through land use change, high livestock densities, agricultural inputs, and wildlife hunting.']
|
[
"spillover events",
"spillover",
"reservoir species",
"wildlife",
"domesticated animals",
"habitat disruption",
"habitat fragmentation",
"biodiversity loss",
"land use change",
"livestock densities",
"agricultural inputs",
"wildlife hunting"
] |
['The main cause of spillover events is the interaction between wildlife, domestic animals, and humans, often influenced by factors such as habitat loss, agricultural practices, and land use for food production. Spillover events occur when pathogens are transmitted from one species to another, leading to potential outbreaks of zoonotic diseases. Factors like habitat destruction and encroachment into wildlife areas can increase the risk of spillover events, highlighting the importance of understanding and managing these interactions to prevent disease transmission.', 'The main cause of spillover events is the disruption of habitats of the reservoir species.', 'The main causes of spillover events include human land modification, domestication, horizontal gene transfer, microbial succession, climate change, biodiversity loss, and globalization.', 'The main cause of spillover events and emerging infectious diseases is cross-species transmission of pathogens, particularly from animals to humans (zoonoses). Key drivers that facilitate this process include:\n\n1. Increased contact and sharing of space between wildlife, humans, and domesticated animals, often due to human intrusion into natural habitats.\n\n2. Agricultural intensification, animal trade, and certain herd management practices.\n\n3. High mutation and recombination rates in some viruses (e.g., coronaviruses) that enable host jumping and adaptation to new species.\n\n4. Specific human behaviors, such as hunting, butchering, and consuming wild animal meat, especially in hotspots like bushmeat markets.\n\n5. Domestication of wild animals as pets or for other purposes, bringing them into close proximity with humans.\n\nIn summary, the growing human-animal interface, coupled with the ability of some pathogens to adapt to new hosts, is the key driver of zoonotic spillover events.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/29466832",
"http://www.ncbi.nlm.nih.gov/pubmed/37019573",
"http://www.ncbi.nlm.nih.gov/pubmed/33052311",
"http://www.ncbi.nlm.nih.gov/pubmed/37007505",
"http://www.ncbi.nlm.nih.gov/pubmed/37000877"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37019573",
"endSection": "abstract",
"offsetInBeginSection": 925,
"offsetInEndSection": 1161,
"text": "the extent of land use for food production and the agricultural practices employed that shape four archetypal food systems, each with a distinct risk profile with respect to zoonotic spillovers and differing dimensions of sustainability"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29466832",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 63,
"text": "Pathogen spillover from wildlife to domestic animals and humans"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29466832",
"endSection": "abstract",
"offsetInBeginSection": 579,
"offsetInEndSection": 651,
"text": "the highest spillover risk occurs at intermediate levels of habitat loss"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37007505",
"endSection": "abstract",
"offsetInBeginSection": 1169,
"offsetInEndSection": 1414,
"text": "We conclude that that the processes of domestication, horizontal gene transfer and microbial succession might be important mechanisms behind the many spillover events driven and accelerated by climate change, biodiversity loss and globalization."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37000877",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 116,
"text": "Human land modification is a known driver of animal-to-human transmission of infectious agents (zoonotic spillover)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37019573",
"endSection": "abstract",
"offsetInBeginSection": 239,
"offsetInEndSection": 461,
"text": "Spillover events are associated to varying degrees with high habitat fragmentation, biodiversity loss through land use change, high livestock densities, agricultural inputs, and wildlife hunting-all facets of food systems."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33052311",
"endSection": "abstract",
"offsetInBeginSection": 149,
"offsetInEndSection": 491,
"text": "The emerging infections that lead to substantive epidemics or pandemics are typically zoonoses that cross species boundaries at vulnerable points of animal-human interface. The sharing of space between wildlife and humans, and their domesticated animals, has dramatically increased in recent decades and is a key driver of pathogen spillover."
}
] | 13
|
BioASQ-training13b
| null | null |
65f8447fc4010b4d78000043
| 5,082
|
factoid
|
What is the cause of Leigh syndrome?
|
['pyruvate dehydrogenase complex, and respiratory chain complexes I, II, III, IV, V defects', 'defects of mitochondrial enzyme complexes', 'mitochondrial DNA mutations', 'nuclear DNA mutations']
|
[
"pyruvate dehydrogenase complex",
"respiratory chain complexes",
"mitochondrial enzyme complexes",
"mitochondrial DNA mutations",
"nuclear DNA mutations",
"defects of mitochondrial enzyme complexes",
"defects of respiratory chain complexes",
"mitochondrial respiratory chain defects",
"mitochondrial dysfunction",
"nuclear genome mutations",
"mtDNA mutations",
"nDNA mutations"
] |
['Leigh syndrome may result from several defects of mitochondrial enzyme complexes, including pyruvate dehydrogenase complex, and respiratory chain complexes I, II, III, IV, V.', 'Leigh syndrome is caused by defects in mitochondrial enzyme complexes. These can include the pyruvate dehydrogenase complex, and respiratory chain complexes I, II, III, IV, and V.', 'Leigh syndrome is caused by various genetic defects, including m.9185T>C MTATP6 variant, Surf1 gene mutations, G8363A mitochondrial DNA mutation, deficiencies in the FAO enzyme short-chain enoyl-CoA hydratase 1 (ECHS1) and defects of 16 mitochondrial DNA (mtDNA) genes and approaching 100 nuclear genes.', 'Leigh syndrome is a severe neurological disorder caused by defects in several mitochondrial enzyme complexes. These include the pyruvate dehydrogenase complex and respiratory chain complexes I, II, III, IV, and V. Additionally, complex V deficiency associated with the NARP point mutation and cytochrome c oxidase deficiency can also lead to Leigh syndrome.', 'Leigh syndrome can result from various defects in mitochondrial enzyme complexes, including pyruvate dehydrogenase complex deficiency, respiratory chain complexes I, II, III, IV, and V deficiencies. Specifically, it can be caused by defects in pyruvate dehydrogenase complex, cytochrome c oxidase deficiency, complex I deficiency, and complex V deficiency associated with the NARP point mutation.', 'Leigh syndrome may result from several defects of mitochondrial enzyme complexes, including pyruvate dehydrogenase complex deficiency, cytochrome c oxidase deficiency, complex I deficiency, complex II deficiency, complex III deficiency, complex IV deficiency, and complex V deficiency associated with the NARP point mutation.', 'Leigh syndrome may result from different enzyme defects, most notably pyruvate dehydrogenase complex deficiency, cytochrome c oxidase deficiency, complex I deficiency, and complex V deficiency associated with the recently described NARP point mutation.', 'Leigh syndrome is caused by various genetic mutations that affect mitochondrial function, leading to impaired energy production and neurodegeneration. These mutations can involve genes related to mitochondrial DNA or nuclear DNA, resulting in deficiencies in oxidative phosphorylation and the accumulation of toxic metabolites. The exact cause of Leigh syndrome can vary among individuals, with over 110 different genes implicated in its development.', 'Leigh syndrome is caused by several defects of mitochondrial enzyme complexes, including pyruvate dehydrogenase complex, and respiratory chain complexes I, II, III, IV, V.', 'Leigh syndrome is caused by defects in mitochondrial enzyme complexes, including pyruvate dehydrogenase complex deficiency, cytochrome c oxidase deficiency, complex I deficiency, complex V deficiency, and the NARP point mutation.', 'The cause of Leigh syndrome is a result of different enzyme defects, most notably pyruvate dehydrogenase complex deficiency, cytochrome c oxidase deficiency, complex I deficiency, and complex V deficiency associated with the recently described NARP point mutation.', 'Leigh syndrome is a rare inherited neurometabolic disorder. It is caused by several defects of mitochondrial enzyme complexes, including pyruvate dehydrogenase complex, and respiratory chain complexes I, II, III, IV, V.', 'Leigh syndrome is a genetically heterogeneous neurodegenerative disorder caused by mutations in nuclear genes or mitochondrial DNA that impair mitochondrial energy metabolism. Over 75 different causative gene mutations have been identified, with approximately 75% being nuclear DNA mutations and 25% mitochondrial DNA mutations. These mutations affect various components of the mitochondrial respiratory chain complexes, pyruvate metabolism, vitamin and cofactor transport and metabolism, mtDNA maintenance, mitochondrial gene expression, protein quality control, lipid remodeling, dynamics, and toxicity.', 'Leigh syndrome may result from several defects of mitochondrial enzyme complexes, including pyruvate dehydrogenase complex.', 'Leigh syndrome can be caused by several defects of mitochondrial enzyme complexes, including pyruvate dehydrogenase complex, respiratory chain complexes I, II, III, IV, and V. Additionally, it can also be caused by cytochrome c oxidase deficiency, complex I deficiency, and complex V deficiency associated with the NARP point mutation.', 'Leigh syndrome is caused by defects in mitochondrial enzyme complexes, including pyruvate dehydrogenase complex, respiratory chain complexes I, II, III, IV, V, and the recently described NARP point mutation.', 'Leigh syndrome can result from defects in mitochondrial enzyme complexes, including pyruvate dehydrogenase complex, and respiratory chain complexes I, II, III, IV, and V. Deficiencies in enzymes such as pyruvate dehydrogenase complex, cytochrome c oxidase, complex I, and complex V can contribute to the development of Leigh syndrome.', 'Leigh syndrome may result from different enzyme defects, most notably pyruvate dehydrogenase complex deficiency, cytochrome c oxidase deficiency, complex I deficiency, and complex V deficiency.', 'Leigh syndrome may result from different enzyme defects, most notably pyruvate dehydrogenase complex deficiency, cytochrome c oxidase deficiency, and complex I deficiency.', 'Leigh syndrome can be caused by defects in mitochondrial enzyme complexes, including deficiencies in pyruvate dehydrogenase complex, cytochrome c oxidase, complex I, and complex V, as well as mutations like the NARP point mutation.', 'Leigh syndrome can be caused by defects in mitochondrial enzyme complexes, such as pyruvate dehydrogenase complex deficiency and respiratory chain complexes I, II, III, IV, V.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/19046652",
"http://www.ncbi.nlm.nih.gov/pubmed/16023078",
"http://www.ncbi.nlm.nih.gov/pubmed/10443880",
"http://www.ncbi.nlm.nih.gov/pubmed/12943968",
"http://www.ncbi.nlm.nih.gov/pubmed/26657515",
"http://www.ncbi.nlm.nih.gov/pubmed/29512743",
"http://www.ncbi.nlm.nih.gov/pubmed/35217561",
"http://www.ncbi.nlm.nih.gov/pubmed/26506407",
"http://www.ncbi.nlm.nih.gov/pubmed/34933094",
"http://www.ncbi.nlm.nih.gov/pubmed/20819849",
"http://www.ncbi.nlm.nih.gov/pubmed/12661941",
"http://www.ncbi.nlm.nih.gov/pubmed/15214016",
"http://www.ncbi.nlm.nih.gov/pubmed/19780766",
"http://www.ncbi.nlm.nih.gov/pubmed/19470250",
"http://www.ncbi.nlm.nih.gov/pubmed/21617257",
"http://www.ncbi.nlm.nih.gov/pubmed/8338207",
"http://www.ncbi.nlm.nih.gov/pubmed/20472868",
"http://www.ncbi.nlm.nih.gov/pubmed/36237717",
"http://www.ncbi.nlm.nih.gov/pubmed/33894360",
"http://www.ncbi.nlm.nih.gov/pubmed/17106447",
"http://www.ncbi.nlm.nih.gov/pubmed/11317352",
"http://www.ncbi.nlm.nih.gov/pubmed/12134275",
"http://www.ncbi.nlm.nih.gov/pubmed/25419155",
"http://www.ncbi.nlm.nih.gov/pubmed/36795052",
"http://www.ncbi.nlm.nih.gov/pubmed/29228836",
"http://www.ncbi.nlm.nih.gov/pubmed/19714555",
"http://www.ncbi.nlm.nih.gov/pubmed/24731534",
"http://www.ncbi.nlm.nih.gov/pubmed/25681084",
"http://www.ncbi.nlm.nih.gov/pubmed/14729820",
"http://www.ncbi.nlm.nih.gov/pubmed/25807530",
"http://www.ncbi.nlm.nih.gov/pubmed/18805359",
"http://www.ncbi.nlm.nih.gov/pubmed/7715756",
"http://www.ncbi.nlm.nih.gov/pubmed/17582259",
"http://www.ncbi.nlm.nih.gov/pubmed/17336115",
"http://www.ncbi.nlm.nih.gov/pubmed/11955926",
"http://www.ncbi.nlm.nih.gov/pubmed/34045482",
"http://www.ncbi.nlm.nih.gov/pubmed/33097395",
"http://www.ncbi.nlm.nih.gov/pubmed/9063742",
"http://www.ncbi.nlm.nih.gov/pubmed/20202874",
"http://www.ncbi.nlm.nih.gov/pubmed/8250532",
"http://www.ncbi.nlm.nih.gov/pubmed/10360771",
"http://www.ncbi.nlm.nih.gov/pubmed/8411720",
"http://www.ncbi.nlm.nih.gov/pubmed/3125426",
"http://www.ncbi.nlm.nih.gov/pubmed/2792954",
"http://www.ncbi.nlm.nih.gov/pubmed/27344648",
"http://www.ncbi.nlm.nih.gov/pubmed/21982779",
"http://www.ncbi.nlm.nih.gov/pubmed/23034978",
"http://www.ncbi.nlm.nih.gov/pubmed/15824269",
"http://www.ncbi.nlm.nih.gov/pubmed/28351484",
"http://www.ncbi.nlm.nih.gov/pubmed/18651330",
"http://www.ncbi.nlm.nih.gov/pubmed/16773507",
"http://www.ncbi.nlm.nih.gov/pubmed/32351444",
"http://www.ncbi.nlm.nih.gov/pubmed/18176892",
"http://www.ncbi.nlm.nih.gov/pubmed/32478789",
"http://www.ncbi.nlm.nih.gov/pubmed/31334367",
"http://www.ncbi.nlm.nih.gov/pubmed/34849584",
"http://www.ncbi.nlm.nih.gov/pubmed/36813320"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18651330",
"endSection": "abstract",
"offsetInBeginSection": 281,
"offsetInEndSection": 443,
"text": "It may result from several defects of mitochondrial enzyme complexes, including pyruvate dehydrogenase complex, and respiratory chain complexes I, II, III, IV, V."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/8338207",
"endSection": "abstract",
"offsetInBeginSection": 2788,
"offsetInEndSection": 3040,
"text": "Leigh syndrome may result from different enzyme defects, most notably pyruvate dehydrogenase complex deficiency, cytochrome c oxidase deficiency, complex I deficiency, and complex V deficiency associated with the recently described NARP point mutation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27344648",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 411,
"text": "Leigh syndrome is a subacute necrotising encephalomyopathy proven by post-mortem analysis of brain tissue showing spongiform lesions with vacuolation of the neuropil followed by demyelination, gliosis and capillary proliferation caused by mutations in one of over 75 different genes, including nuclear- and mitochondrial-encoded genes, most of which are associated with mitochondrial respiratory chain function."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/17582259",
"endSection": "abstract",
"offsetInBeginSection": 143,
"offsetInEndSection": 251,
"text": "Deficiency of pyruvate dehydrogenase complex E1 alpha subunit (PDHA1) is the common cause of Leigh syndrome."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/7715756",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 274,
"text": "Subacute necrotizing encephalomyelopathy (Leigh's syndrome) is a rare neurodegenerative disease in the adult. The precise metabolic defect is unknown, but abnormalities of a mitochondrial enzyme system related to cytochrome-c oxidase or pyruvate dehydrogenase are described."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34933094",
"endSection": "abstract",
"offsetInBeginSection": 164,
"offsetInEndSection": 353,
"text": "Leigh syndrome is the most common clinical presentation of pediatric mitochondrial disease, typically appearing in the first few years of life, and involving severe multisystem pathologies."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/3125426",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 141,
"text": "A new patient with Leigh's syndrome (subacute necrotizing encephalomyelopathy due to pyruvate dehydrogenase complex deficiency) is presented."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21982779",
"endSection": "abstract",
"offsetInBeginSection": 90,
"offsetInEndSection": 288,
"text": "We report a novel m.4296G>A variant in the mitochondrial tRNA isoleucine gene in a child with Leigh syndrome, mitochondrial proliferation, lactic acidosis, and abnormal respiratory chain enzymology."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26506407",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 262,
"text": "Leigh syndrome is the most common pediatric presentation of mitochondrial disease. This neurodegenerative disorder is genetically heterogeneous, and to date pathogenic mutations in >75 genes have been identified, encoded by 2 genomes (mitochondrial and nuclear)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36237717",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 447,
"text": "Leigh syndrome or subacute necrotizing encephalomyelopathy is a rare, rapidly progressive neurodegenerative disorder. In general, symptoms such as shortness of breath and decreased cardiac function usually occur within 1 year of life. It is a serious disease with a mortality rate of 75% in 2-3 years. The cause of Leigh syndrome is DNA mutation. Approximately 75% of patients have nuclear DNA mutations while 25% have mitochondrial DNA mutations."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/20202874",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 96,
"text": "Leigh disease presenting in utero due to a novel missense mutation in the mitochondrial DNA-ND3."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31334367",
"endSection": "abstract",
"offsetInBeginSection": 199,
"offsetInEndSection": 410,
"text": "It can be caused by more than 75 different gene mutations, of nuclear and mitochondrial origin, involving all respiratory chain complexes, with less than 25% of Leigh syndrome having mitochondrial DNA mutations."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29228836",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 216,
"text": "The most common mitochondrial disorder in children is Leigh syndrome, which is a progressive and genetically heterogeneous neurodegenerative disorder caused by mutations in nuclear genes or mitochondrial DNA (mtDNA)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28351484",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 141,
"text": "Leigh syndrome (LS) is a neurogenetic disorder of children caused by mutations in at least 75 genes which impair mitochondrial bioenergetics."
}
] | 13
|
BioASQ-training13b
| null | null |
6451007857b1c7a315000093
| 5,088
|
factoid
|
What is the indication for Alirocumab?
|
['high cholesterol', 'hypercholestoremia']
|
[
"high cholesterol",
"hypercholesterolemia",
"hypercholestoremia",
"elevated cholesterol",
"cholesterol",
"cholesterolemia"
] |
['Alirocumab is primarily used to lower LDL-cholesterol levels.', 'Alirocumab is indicated for the prevention of cardiovascular risk, and for patients with heterozygous familial hypercholesterolemia, atherosclerotic cardiovascular disease, or hypercholesterolemia who require additional LDL-C lowering.', 'Alirocumab is a fully human immunoglobulin G1 monoclonal antibody directed against proprotein convertase subtilisin/kexin type 9 (PCSK9) approved for the treatment of hypercholesterolemia in high-risk patients.', 'Alirocumab is indicated for the treatment of hypercholesterolaemic patients unable to meet LDL-C targets, as an adjunct to diet in addition/alternative to LLT.', 'Alirocumab is a PCSK9 inhibitor that is used to decrease LDL-cholesterol levels in patients who have not been able to achieve target levels with other treatments. It is approved for clinical use by European regulatory authorities.', 'The indication for Alirocumab is lowering LDL cholesterol levels.', 'Alirocumab is indicated for cholesterol and triglyceride metabolism, acting on them.', 'Alirocumab is used for treatment of low-density lipoprotein cholesterol.', 'The indication for Alirocumab is for patients who have high cardiovascular risk from established atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia and who are unable to achieve LDL-C targets with maximally tolerated dose of statins with or without other lipid-lowering drugs.', 'Alirocumab is indicated for the treatment of hypertriglyceridemia.', 'Alirocumab is an anti-PCSK9 monoclonal antibody that is used for the treatment of high cholesterol.', 'Alirocumab is indicated for the treatment of hypercholesterolemia.', 'Alirocumab is indicated for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who require additional lowering of LDL-cholesterol.', 'Alirocumab, sold under the brand name Praluent, is a medication used as a second-line treatment for high cholesterol for adults whose cholesterol is not controlled by diet and statin treatment', 'Alirocumab is indicated for the treatment of hypercholesterolemia in high-risk patients, heterozygous familial hypercholesterolemia, and clinical atherosclerotic cardiovascular disease where low-density lipoprotein cholesterol (LDLC) lowering is insufficient.', 'Alirocumab is indicated for the treatment of hypertriglyceridemia in adults with established cardiovascular disease or diabetes mellitus type 2 and mixed dyslipidemia.', 'The indication for Alirocumab is to reduce LDL cholesterol levels in patients who have not achieved their target LDL cholesterol levels with maximally tolerated statin therapy or in patients who are intolerant to statins.', 'The indication for Alirocumab is to reduce LDL-cholesterol and triglyceride metabolism.', 'Alirocumab is indicated for LDL-cholesterol reduction.', 'Alirocumab is indicated for the reduction of low-density lipoprotein cholesterol (LDL-cholesterol), particularly in patients who have not been able to achieve target LDL-cholesterol levels with traditional treatments.', 'Alirocumab is a PCSK9 inhibitor indicated for lowering LDL cholesterol. It is used in patients who cannot achieve target LDL cholesterol levels with other lipid-lowering therapies.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/26563849",
"http://www.ncbi.nlm.nih.gov/pubmed/26785741",
"http://www.ncbi.nlm.nih.gov/pubmed/26935836",
"http://www.ncbi.nlm.nih.gov/pubmed/26859553",
"http://www.ncbi.nlm.nih.gov/pubmed/26886466",
"http://www.ncbi.nlm.nih.gov/pubmed/29802110",
"http://www.ncbi.nlm.nih.gov/pubmed/28277798",
"http://www.ncbi.nlm.nih.gov/pubmed/26370210",
"http://www.ncbi.nlm.nih.gov/pubmed/37939861",
"http://www.ncbi.nlm.nih.gov/pubmed/28263403",
"http://www.ncbi.nlm.nih.gov/pubmed/35974290",
"http://www.ncbi.nlm.nih.gov/pubmed/26798848",
"http://www.ncbi.nlm.nih.gov/pubmed/29171769",
"http://www.ncbi.nlm.nih.gov/pubmed/28328015",
"http://www.ncbi.nlm.nih.gov/pubmed/36440240",
"http://www.ncbi.nlm.nih.gov/pubmed/28618994",
"http://www.ncbi.nlm.nih.gov/pubmed/26535020",
"http://www.ncbi.nlm.nih.gov/pubmed/28395555",
"http://www.ncbi.nlm.nih.gov/pubmed/25244623",
"http://www.ncbi.nlm.nih.gov/pubmed/28750828",
"http://www.ncbi.nlm.nih.gov/pubmed/27186592",
"http://www.ncbi.nlm.nih.gov/pubmed/27567901",
"http://www.ncbi.nlm.nih.gov/pubmed/35052871",
"http://www.ncbi.nlm.nih.gov/pubmed/27250613"
] |
[
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35052871",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 49,
"text": "Effects of Alirocumab on Triglyceride Metabolism:"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35052871",
"endSection": "abstract",
"offsetInBeginSection": 12,
"offsetInEndSection": 290,
"text": "PCSK9 antibodies strongly reduce LDL cholesterol. The effects of PCSK9 antibodies on triglyceride metabolism are less pronounced. The present study aimed to investigate in detail the effects of alirocumab on triglycerides, triglyceride-rich lipoproteins, and lipase regulators.M"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27250613",
"endSection": "abstract",
"offsetInBeginSection": 290,
"offsetInEndSection": 602,
"text": "To achieve target LDL-cholesterol in these two groups of patients will be possible with new drugs - PCSK9 inhibitors, which decrease LDL-cholesterol by an additional 50-60 %. The first two PCSK9 inhibitors (alirocumab and evolocumab) already had been approved for clinical use by European regulatory authorities."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28395555",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 54,
"text": "Alirocumab for the treatment of hypercholesterolaemia."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28395555",
"endSection": "abstract",
"offsetInBeginSection": 503,
"offsetInEndSection": 867,
"text": "Areas covered: In 2015, the Food and Drug Administration and the European Medicines Agency approved alirocumab (Praluent®; Sanofi), a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9), for the treatment of hypercholesterolaemic patients unable to meet LDL-C targets, as an adjunct to diet in addition/alternative to LLT."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28395555",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 295,
"text": "INTRODUCTION: Prescription of statins for low-density lipoprotein cholesterol (LDL-C) reduction is the standard of care in primary and secondary prevention of cardiovascular disease; nevertheless, a large number of patients treated with statins are unable to reach the recommended LDL-C targets."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27567901",
"endSection": "abstract",
"offsetInBeginSection": 1177,
"offsetInEndSection": 1689,
"text": "Currently, alirocumab is approved by the US Food and Drug Administration (FDA) as an adjunct to diet and maximally tolerated statin therapy for use in adults with heterozygous familial hypercholesterolemia (FH) or those with atherosclerotic CV disease who require additional LDL-C lowering; it has also been recently approved by the European Medicines Agency (EMA) for use in patients with heterozygous FH, non-familial hypercholesterolemia or mixed dyslipidemia in whom statins are ineffective or not tolerated."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28395555",
"endSection": "abstract",
"offsetInBeginSection": 1063,
"offsetInEndSection": 1460,
"text": "Expert commentary: Alirocumab causes a marked reduction in LDL-C, presents good safety and tolerability, and represents a promising approach for LDL-C lowering, particularly in patients with intolerance to statin or elevated LDL-C despite maximal statin therapy; nevertheless, further long-term data on safety and efficacy are necessary, such as data on the improvement of cardiovascular outcomes."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28618994",
"endSection": "abstract",
"offsetInBeginSection": 1063,
"offsetInEndSection": 1621,
"text": "Recently the fully human monoclonal antibodies against proprotein convertase subtilisin/kexin 9 (PCSK9), alirocumab (Praluent®) and evolocumab (Repatha®), which have been shown to decrease LDL-C by up to 70% have been approved in Europe for use in patients with primary hypercholesterolemia not at LDL-C target while on maximally tolerated lipid-lowering therapy and specifically for patients with statin intolerance and in the USA for patients with atherosclerotic cardiovascular disease or familial hypercholesterolemia requiring additional LDL-C lowering."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26886466",
"endSection": "abstract",
"offsetInBeginSection": 272,
"offsetInEndSection": 580,
"text": "Alirocumab (Praluent; Sanofi/Regeneron, Bridgewater, NJ) and evolocumab (Repatha; Amgen, Thousand Oaks, CA) are currently available and approved for use in patients with heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia, and clinical atherosclerotic cardiovascular disease."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25244623",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 58,
"text": "Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28395555",
"endSection": "abstract",
"offsetInBeginSection": 868,
"offsetInEndSection": 1062,
"text": "The authors review the pharmacological features, clinical efficacy, and safety of alirocumab in lowering LDL-C, and discuss its therapeutic perspectives based on the most recent clinical trials."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26370210",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 380,
"text": "Alirocumab (Praluent®) is a fully human monoclonal antibody developed by Regeneron Pharmaceuticals and Sanofi that has been approved in the US as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolaemia (HeFH) or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL-C"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26535020",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 42,
"text": "Alirocumab (Praluent) for high cholesterol"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35974290",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 254,
"text": "BACKGROUND AND OBJECTIVES: Alirocumab is a cholesterol-lowering monoclonal antibody targeting proprotein convertase subtilisin kexin type 9 (PCSK9) indicated in the prevention of cardiovascular risk and exhibiting target-mediated drug disposition (TMDD)."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28277798",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 53,
"text": "Alirocumab for the treatment of hypercholesterolemia."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29171769",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 224,
"text": "INTRODUCTION: Alirocumab is a fully human immunoglobulin G1 monoclonal antibody directed against proprotein convertase subtilisin/kexin type 9 (PCSK9) approved for the treatment of hypercholesterolemia in high-risk patients."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26798848",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 58,
"text": "Alirocumab: targeting PCSK9 to treat hypercholesterolemia."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28277798",
"endSection": "abstract",
"offsetInBeginSection": 924,
"offsetInEndSection": 1309,
"text": "The high cost and the current lack of long-term safety and efficacy data will restrict the use of alirocumab to patients who have high cardiovascular risk from established atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia and who are unable to achieve LDL-C targets with maximally tolerated dose of statins with or without other lipid-lowering drugs."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26935836",
"endSection": "abstract",
"offsetInBeginSection": 1287,
"offsetInEndSection": 1565,
"text": "Thus, alirocumab is a valuable emerging option for use in patients with hypercholesterolemia, particularly patients with statin intolerance or inadequately-controlled LDL-C despite statin therapy; however, more data are needed to establish its potential cardiovascular benefits."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26563849",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 70,
"text": "An evaluation of alirocumab for the treatment of hypercholesterolemia."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37939861",
"endSection": "abstract",
"offsetInBeginSection": 294,
"offsetInEndSection": 571,
"text": "The clinical use of two monoclonal antibodies (alirocumab and evolocumab, approved in 2015) and one small interfering RNA (inclisiran, approved in 2020) which can inhibit PCSK9 function proved that they are very effective in lowering low density lipoprotein cholesterol (LDL-C)"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28395555",
"endSection": "abstract",
"offsetInBeginSection": 504,
"offsetInEndSection": 852,
"text": "reas covered: In 2015, the Food and Drug Administration and the European Medicines Agency approved alirocumab (Praluent®; Sanofi), a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9), for the treatment of hypercholesterolaemic patients unable to meet LDL-C targets, as an adjunct to diet in addition/alte"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29171769",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 210,
"text": "INTRODUCTION: Alirocumab is a fully human immunoglobulin G1 monoclonal antibody directed against proprotein convertase subtilisin/kexin type 9 (PCSK9) approved for the treatment of hypercholesterolemia in high-"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28263403",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 660,
"text": "Alirocumab and evolocumab are 2 human monoclonal antibodies that inhibit the proprotein convertase subtilisin/kexin type 9 (PCSK9). These antibodies can potently lower low-density lipoprotein cholesterol (LDLc) serum concentrations. The aims of this analysis were to develop a pharmacokinetic (PK) and pharmacodynamic (PD) model for both antibodies, to simulate and investigate different dosage and application regimens, and finally, to note the effects on LDLc levels. Alirocumab was clinically studied and approved with 2 doses, 75 and 150 mg every 2 weeks (Q2W), whereas evolocumab was tested and approved with 2 dosing intervals, 140 mg Q2W and 420 mg Q4W."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36440240",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 457,
"text": "Background: Even though the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, have been approved to reduce plasma low-density lipoprotein cholesterol (LDL-C) and the risk of atherosclerotic cardiovascular disease in high-risk patients, real-world data showing comparisons of the lipid-lowering effects between alirocumab and evolocumab are scarce because of the low prescription rates of PCSK9 inhibitors in clinic"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26785741",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 213,
"text": "A new class of lipid-lowering drugs, inhibitors of PCSK9 has been generating impressive clinical trial data over the last several years, and alirocumab (Praluent) has become the first to be approved by the US FDA."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28618994",
"endSection": "abstract",
"offsetInBeginSection": 1063,
"offsetInEndSection": 1619,
"text": "Recently the fully human monoclonal antibodies against proprotein convertase subtilisin/kexin 9 (PCSK9), alirocumab (Praluent®) and evolocumab (Repatha®), which have been shown to decrease LDL-C by up to 70% have been approved in Europe for use in patients with primary hypercholesterolemia not at LDL-C target while on maximally tolerated lipid-lowering therapy and specifically for patients with statin intolerance and in the USA for patients with atherosclerotic cardiovascular disease or familial hypercholesterolemia requiring additional LDL-C lowerin"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27186592",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 485,
"text": "In 2015 the U.S. Food and Drug Administration approved the first two proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, alirocumab (Praluent®; Sanofi/ Regeneron) and evolocumab (Repatha®; Amgen), for use in patients with heterozygous and homozygous familial hypercholesterolemia and for patients intolerant of statins or those with a major risk of cardiovascular disease (CVD) but unable to lower their LDL cholesterol (LDL-C) to optimal levels with statins and ezetimib"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28750828",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 154,
"text": "The proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab has been shown to substantially reduce low-density lipoprotein cholesterol (LDL-C)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35974290",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 171,
"text": "BACKGROUND AND OBJECTIVES: Alirocumab is a cholesterol-lowering monoclonal antibody targeting proprotein convertase subtilisin kexin type 9 (PCSK9) indicated in the preven"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25244623",
"endSection": "abstract",
"offsetInBeginSection": 606,
"offsetInEndSection": 811,
"text": "Alirocumab clinical trials with different doses on different administration schedules were shown to significantly reduce LDL cholesterol both as a mono-therapy and in combination with statins or ezetimibe."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26859553",
"endSection": "abstract",
"offsetInBeginSection": 779,
"offsetInEndSection": 1234,
"text": "Large and comprehensive trials over the last 5 years also indicated good tolerability and safety and resulted in the 2015 regulatory approval in the USA and Europe for the marketing of two mAbs, evolocumab and alirocumab, for the treatment of LDL-C.SUMMARY: The background, clinical trials and approved indications for the current PCSK9 inhibitors are reviewed along with their likely role in the management of LDL-C and cardiovascular disease prevention."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28328015",
"endSection": "abstract",
"offsetInBeginSection": 157,
"offsetInEndSection": 425,
"text": "In 2015 the US Food and Drug Administration approved both alirocumab and evolocumab for high-risk patients with familial hypercholesterolemia (FH) and clinical atherosclerotic cardiovascular disease requiring additional lowering of low-density lipoprotein cholesterol."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29802110",
"endSection": "abstract",
"offsetInBeginSection": 332,
"offsetInEndSection": 557,
"text": "esterol (LDL-C). The currently available PCSK9 inhibitors alirocumab and evolocumab were shown to reduce LDL-C concentrations by approximately 55-60% relative to placebo use when used as monotherapy or added to other lipid-lo"
}
] | 13
|
BioASQ-training13b
| null | null |
65f70b9cc4010b4d7800001c
| 5,094
|
factoid
|
What disease can be treated with Tebentafusp?
|
['uveal melanoma']
|
[
"uveal melanoma",
"choroidal melanoma",
"iris melanoma",
"ciliary body melanoma",
"uveal malignant melanoma"
] |
['Tebentafusp is approved for uveal melanoma.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/37141553",
"http://www.ncbi.nlm.nih.gov/pubmed/37650713",
"http://www.ncbi.nlm.nih.gov/pubmed/37207136",
"http://www.ncbi.nlm.nih.gov/pubmed/36970111",
"http://www.ncbi.nlm.nih.gov/pubmed/36229663",
"http://www.ncbi.nlm.nih.gov/pubmed/37444540",
"http://www.ncbi.nlm.nih.gov/pubmed/35236927",
"http://www.ncbi.nlm.nih.gov/pubmed/36847626",
"http://www.ncbi.nlm.nih.gov/pubmed/38048850",
"http://www.ncbi.nlm.nih.gov/pubmed/36094043",
"http://www.ncbi.nlm.nih.gov/pubmed/35172589",
"http://www.ncbi.nlm.nih.gov/pubmed/37661909",
"http://www.ncbi.nlm.nih.gov/pubmed/36600005",
"http://www.ncbi.nlm.nih.gov/pubmed/37286303",
"http://www.ncbi.nlm.nih.gov/pubmed/31344957",
"http://www.ncbi.nlm.nih.gov/pubmed/31336704",
"http://www.ncbi.nlm.nih.gov/pubmed/36442912",
"http://www.ncbi.nlm.nih.gov/pubmed/35115315",
"http://www.ncbi.nlm.nih.gov/pubmed/34551229",
"http://www.ncbi.nlm.nih.gov/pubmed/34885078",
"http://www.ncbi.nlm.nih.gov/pubmed/37483658",
"http://www.ncbi.nlm.nih.gov/pubmed/37595494",
"http://www.ncbi.nlm.nih.gov/pubmed/37473516",
"http://www.ncbi.nlm.nih.gov/pubmed/35060440",
"http://www.ncbi.nlm.nih.gov/pubmed/36710368",
"http://www.ncbi.nlm.nih.gov/pubmed/36785760",
"http://www.ncbi.nlm.nih.gov/pubmed/36199496",
"http://www.ncbi.nlm.nih.gov/pubmed/34999237",
"http://www.ncbi.nlm.nih.gov/pubmed/36931146",
"http://www.ncbi.nlm.nih.gov/pubmed/35364557",
"http://www.ncbi.nlm.nih.gov/pubmed/37870955",
"http://www.ncbi.nlm.nih.gov/pubmed/35364798",
"http://www.ncbi.nlm.nih.gov/pubmed/36102132",
"http://www.ncbi.nlm.nih.gov/pubmed/32816891",
"http://www.ncbi.nlm.nih.gov/pubmed/37902386"
] |
[
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37444540",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 100,
"text": "Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37444540",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 168,
"text": "BACKGROUND: Tebentafusp has recently been approved for the treatment of metastatic uveal melanoma (mUM) after proving to have survival benefits in a first-line setting."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37444540",
"endSection": "abstract",
"offsetInBeginSection": 1140,
"offsetInEndSection": 1254,
"text": "Treatment with ICI followed by tebentafusp may result in longer PFS/OS compared to the inverse treatment sequence."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37483658",
"endSection": "abstract",
"offsetInBeginSection": 322,
"offsetInEndSection": 446,
"text": "Tebentafusp, a bispecific molecule, has recently become the first treatment in decades to improve overall survival for mUM. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36931146",
"endSection": "abstract",
"offsetInBeginSection": 2309,
"offsetInEndSection": 2563,
"text": "CONCLUSIONS: Tebentafusp achieved the best results compared to combined ICB and other systemic treatments, although these results have to be interpreted with caution due to the approximative methodical approach and high heterogeneity of included studies."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36970111",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 70,
"text": "Tebentafusp: a first-in-class treatment for metastatic uveal melanoma."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36970111",
"endSection": "abstract",
"offsetInBeginSection": 228,
"offsetInEndSection": 460,
"text": "Tebentafusp is both the first bispecific T-cell engager to show efficacy in the treatment of advanced solid cancer and the first anti-cancer treatment to demonstrate an overall survival benefit in patients with uveal melanoma (UM). "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36600005",
"endSection": "abstract",
"offsetInBeginSection": 881,
"offsetInEndSection": 1065,
"text": "These advances have driven the development of a number of novel emerging treatments, including tebentafusp, the first systemic therapy to achieve regulatory approval for this disease. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35060440",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 226,
"text": "INTRODUCTION: Tebentafusp is a novel bispecific immune mobilizing T cell receptor (TCR)-based agent developed for the treatment of metastatic uveal melanoma, a highly fatal disease with no currently approved treatment options."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36847626",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 315,
"text": "On January 25, 2022, the U.S. Food and Drug Administration (FDA) approved the use of tebentafusp, a bispecific glycoprotein 100 (gp100) peptide-human leukocyte antigen (HLA)-directed CD3 T-cell activator, for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM)."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36847626",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 73,
"text": "Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36970111",
"endSection": "abstract",
"offsetInBeginSection": 228,
"offsetInEndSection": 459,
"text": "Tebentafusp is both the first bispecific T-cell engager to show efficacy in the treatment of advanced solid cancer and the first anti-cancer treatment to demonstrate an overall survival benefit in patients with uveal melanoma (UM)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37661909",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 245,
"text": "Tebentafusp, a bispecific T-cell receptor fusion protein directed against gp100 and CD3, can improve survival in patients with metastatic uveal melanoma and was recently approved for the treatment of HLA-A*02:01-positive uveal melanoma patients."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35115315",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 219,
"text": "Tebentafusp, the first drug shown to extend overall survival in people with uveal melanoma, was greenlighted by the FDA in late January to treat patients with inoperable or metastatic forms of the aggressive eye cancer."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31336704",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 79,
"text": "Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/38048850",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 243,
"text": "BACKGROUND: Tebentafusp demonstrated a superior overall survival (OS) benefit (hazard ratio [HR] 0.51) compared to investigator's choice (82% pembrolizumab) in a randomized, Phase 3 trial (IMCgp100-202; N=378) in untreated metastatic uveal mel"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37595494",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 255,
"text": "Tebentafusp is a new T cell receptor bispecific fusion protein and the first approved treatment option for human leucocyte antigen-A*02:01 (HLA-A*02:01) metastatic uveal melanoma, with a proven benefit in overall survival versus the investigator's choice."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35060440",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 212,
"text": "INTRODUCTION: Tebentafusp is a novel bispecific immune mobilizing T cell receptor (TCR)-based agent developed for the treatment of metastatic uveal melanoma, a highly fatal disease with no currently approved trea"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36710368",
"endSection": "abstract",
"offsetInBeginSection": 599,
"offsetInEndSection": 742,
"text": "Using tebentafusp as a case study, a CD3-bispecific approved for uveal melanoma, the model successfully captures the dynamics of five cytokines"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37444540",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 122,
"text": "BACKGROUND: Tebentafusp has recently been approved for the treatment of metastatic uveal melanoma (mUM) after proving to h"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35364557",
"endSection": "abstract",
"offsetInBeginSection": 265,
"offsetInEndSection": 425,
"text": "Tebentafusp was granted full approval on January 25th 2022 in the setting of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36199496",
"endSection": "abstract",
"offsetInBeginSection": 583,
"offsetInEndSection": 751,
"text": "Tebentafusp-tebn is now approved by the US Food and Drug Administration in HLA-A*02:01-positive uveal melanoma patients as first-line therapy in the metastatic setting."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36442912",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 236,
"text": "In January 2022, the US Food and Drug Administration granted regulatory approval to tebentafusp, a bispecific T cell receptor protein that targets melanoma antigen gp100 in the context of the human leucocyte antigen (HLA) A*0201 allele."
}
] | 13
|
BioASQ-training13b
| null | null |
65cec1fb1930410b13000005
| 5,096
|
factoid
|
When was Havana Syndrome first recognized?
|
['2016']
|
[
"2016",
"two thousand sixteen"
] |
['Havana Syndrome is the name given to the group of neurological symptoms that first occurred among the staff at the U.S. embassy in Havana, Cuba in 2016.', 'Havana syndrome is a term that was first coined by US diplomats and intelligence personnel in 2016 in Havana, Cuba, to describe a series of strange symptoms, including dizziness, hearing loss, headaches, and cognitive impairment.', 'Havana Syndrome was first recognized in late 2016 when U.S. diplomatic personnel in Havana, Cuba, reported experiencing unusual symptoms including hearing loss, cognitive issues, and other neurological problems.', 'Havana Syndrome was first recognized in 2016.', 'In 2016, Havana Syndrome was first recognized when U.S. diplomats serving in Havana, Cuba reported hearing strange noises accompanied by a constellation of unexplained health effects.', 'Havana Syndrome is a term used to describe a series of unexplained neurological symptoms experienced by diplomatic personnel serving in Havana, Cuba, beginning in 2016.', 'Since 2016, an array of claims and public discourse have circulated in the medical community over the origin and nature of a mysterious condition dubbed "Havana Syndrome," so named as it was first identified in Cuba.', 'The Havana Syndrome was first recognized in 2016 when U.S. diplomats serving in Havana, Cuba reported hearing strange noises accompanied by a constellation of unexplained health effects.', 'Havana Syndrome was first recognized in Havana, Cuba in late 2016 when several U.S. diplomats and embassy staff reported experiencing unexplained neurological symptoms.', 'Havana Syndrome was first recognized in 2016 when diplomatic personnel serving in Havana, Cuba, reported audible sensory phenomena paired with complex and persistent neurological symptoms consistent with brain injury.', 'Havana Syndrome was first recognized in the year 2016.', ' Havana Syndrome was first recognized in 2016 when U.S. diplomats serving in Havana, Cuba reported hearing strange noises accompanied by a constellation of unexplained health effects.', 'Havana Syndrome was first recognized in late 2016 when several U.S. diplomats stationed in Havana, Cuba, reported experiencing a range of unexplained neurological symptoms.', 'Havana Syndrome was first recognized in 2016 when diplomatic personnel in Havana, Cuba reported experiencing unusual sensory phenomena and neurological symptoms.', 'Havana Syndrome was first recognized in 2016 when U.S. diplomats serving in Havana, Cuba reported hearing strange noises accompanied by a constellation of unexplained health effects.', 'Havana Syndrome was first recognized in 2016 when U.S. diplomats serving in Havana, Cuba began reporting audible sensory phenomena paired with onset of complex and persistent neurological symptoms consistent with brain injury.', 'Havana Syndrome was first recognized in 2016 when diplomatic personnel serving in Havana, Cuba reported audible sensory phenomena paired with complex and persistent neurological symptoms consistent with brain injury.', 'In 2016 diplomatic personnel serving in Havana, Cuba began reporting audible sensory phenomena paired with onset of complex and persistent neurological symptoms consistent with brain injury.', 'Havana Syndrome was first recognized in 2016 when U.S. diplomats serving in Havana, Cuba reported hearing strange noises and experiencing unexplained health effects.', 'Havana syndrome is a term used to describe a cluster of neurological symptoms that have been reported by United States and Canadian diplomats, intelligence officers, and other government employees, mainly in Havana, Cuba, between 2016 and 2018.', 'The phenomenon now known as Havana Syndrome was first recognized in 2016 when U.S. diplomats serving in Havana, Cuba reported hearing strange noises accompanied by a constellation of unexplained health effects.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/37965360",
"http://www.ncbi.nlm.nih.gov/pubmed/32655474",
"http://www.ncbi.nlm.nih.gov/pubmed/30828629",
"http://www.ncbi.nlm.nih.gov/pubmed/35962646",
"http://www.ncbi.nlm.nih.gov/pubmed/37976420"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37965360",
"endSection": "abstract",
"offsetInBeginSection": 13,
"offsetInEndSection": 206,
"text": " In 2016 diplomatic personnel serving in Havana, Cuba, began reporting audible sensory phenomena paired with onset of complex and persistent neurological symptoms consistent with brain injury. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35962646",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 268,
"text": "Since 2016, numerous American and Canadian diplomats and secret (intelligence) agents in Cuba, China, and other places in the world have experienced an abrupt onset of unusual clinical symptoms including, tinnitus, visual problems, vertigo, and cognitive difficulties,"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37976420",
"endSection": "abstract",
"offsetInBeginSection": 268,
"offsetInEndSection": 438,
"text": "This fact was illustrated in 2016 when U.S. diplomats serving in Havana, Cuba reported hearing strange noises accompanied by a constellation of unexplained health effects"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35962646",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 352,
"text": "Since 2016, numerous American and Canadian diplomats and secret (intelligence) agents in Cuba, China, and other places in the world have experienced an abrupt onset of unusual clinical symptoms including, tinnitus, visual problems, vertigo, and cognitive difficulties, after they encountered strange sounds; this has been called \"Havana syndrome\" (HS)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32655474",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 171,
"text": "In late 2016, diplomats in Havana, Cuba, began presenting with a unique symptom complex after perceiving a strange noise and/or feeling a pressure field in their domicile."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37965360",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 205,
"text": "Introduction: In 2016 diplomatic personnel serving in Havana, Cuba, began reporting audible sensory phenomena paired with onset of complex and persistent neurological symptoms consistent with brain injury."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30828629",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 225,
"text": "BACKGROUND: In the Autumn of 2016, diplomatic personnel residing in Havana began to present with symptoms of dizziness, ear pain, and tinnitus that emerged after perception of high frequency noise and/or a pressure sensation."
}
] | 13
|
BioASQ-training13b
| null | null |
65f856a1c4010b4d7800004e
| 5,097
|
factoid
|
Which age group should never be tested for HIV infection?
|
['None.']
|
[
"None"
] |
['There is no age group that should never be tested for HIV infection. HIV testing is recommended for all individuals, regardless of age, as early detection and treatment can improve outcomes and prevent transmission.', 'There is no specific age group that should never be tested for HIV infection. Early testing and diagnosis is crucial for effective treatment and prevention of HIV transmission.', 'No age group should be excluded from HIV testing. Early diagnosis and treatment are crucial in managing HIV infection and preventing its spread. Testing for HIV should be encouraged for all individuals, regardless of age, to ensure timely intervention and appropriate care.', 'There is no age group that should never be tested for HIV infection.', 'There is no age group that should never be tested for HIV infection. The CDC recommends that all adults, adolescents, and pregnant women in health-care settings be offered HIV testing, and that those at high risk for HIV infection be tested at least annually. Additionally, the WHO recommends that all people aged 15-64 years should be offered an HIV test at least once in their lifetime. It is important to note that anyone can be at risk for HIV infection regardless of age, gender, or sexual orientation.', "There is no age group that should never be tested for HIV infection. HIV can affect individuals of all ages, from newborns to older adults. In fact, late diagnosis of HIV is a significant issue, particularly among older individuals, heterosexuals, and non-Europeans. Therefore, it's crucial to get tested regardless of age to ensure early detection and treatment. This can help reduce the burden of late presentation and advanced disease", 'There is no age group that should never be tested for HIV infection. Testing for HIV is important for everyone, regardless of age, to ensure early detection and appropriate care.', 'There is no age group that should never be tested for HIV infection. In fact, the World Health Organization recommends that all people aged 15-64 years old get tested for HIV at least once in their lifetime, and those at high risk of infection get tested annually. Children born to mothers living with HIV also need to be tested regularly as they are at a higher risk of acquiring the virus through mother-to-child transmission. Early diagnosis and treatment of HIV can significantly improve health outcomes and reduce the risk of transmission. Therefore, it is important for all individuals, regardless of age, to know their HIV status and take appropriate measures to protect themselves and their partners.', 'There is no specific age group that should never be tested for HIV infection. HIV testing is recommended for everyone, regardless of age, as early diagnosis and treatment can help prevent the progression of the disease and reduce the risk of transmission to others.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/37993765",
"http://www.ncbi.nlm.nih.gov/pubmed/36629794",
"http://www.ncbi.nlm.nih.gov/pubmed/19940800",
"http://www.ncbi.nlm.nih.gov/pubmed/28796758",
"http://www.ncbi.nlm.nih.gov/pubmed/9611559",
"http://www.ncbi.nlm.nih.gov/pubmed/12126721",
"http://www.ncbi.nlm.nih.gov/pubmed/25283353",
"http://www.ncbi.nlm.nih.gov/pubmed/29583105",
"http://www.ncbi.nlm.nih.gov/pubmed/24964879",
"http://www.ncbi.nlm.nih.gov/pubmed/17129866",
"http://www.ncbi.nlm.nih.gov/pubmed/19303830",
"http://www.ncbi.nlm.nih.gov/pubmed/27435075",
"http://www.ncbi.nlm.nih.gov/pubmed/25960684",
"http://www.ncbi.nlm.nih.gov/pubmed/22908365",
"http://www.ncbi.nlm.nih.gov/pubmed/28883962",
"http://www.ncbi.nlm.nih.gov/pubmed/18685551",
"http://www.ncbi.nlm.nih.gov/pubmed/21279431",
"http://www.ncbi.nlm.nih.gov/pubmed/37632603",
"http://www.ncbi.nlm.nih.gov/pubmed/36589732",
"http://www.ncbi.nlm.nih.gov/pubmed/24789219",
"http://www.ncbi.nlm.nih.gov/pubmed/10224192",
"http://www.ncbi.nlm.nih.gov/pubmed/34949518",
"http://www.ncbi.nlm.nih.gov/pubmed/25303208",
"http://www.ncbi.nlm.nih.gov/pubmed/37720974",
"http://www.ncbi.nlm.nih.gov/pubmed/8655933",
"http://www.ncbi.nlm.nih.gov/pubmed/20685813",
"http://www.ncbi.nlm.nih.gov/pubmed/36630307",
"http://www.ncbi.nlm.nih.gov/pubmed/36630617",
"http://www.ncbi.nlm.nih.gov/pubmed/36729993",
"http://www.ncbi.nlm.nih.gov/pubmed/37729175",
"http://www.ncbi.nlm.nih.gov/pubmed/24849622"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34949518",
"endSection": "abstract",
"offsetInBeginSection": 293,
"offsetInEndSection": 410,
"text": "social and clinical inequalities of more children infected with HIV and more children losing their fight against AIDS"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34949518",
"endSection": "abstract",
"offsetInBeginSection": 475,
"offsetInEndSection": 553,
"text": "two out of five children living with HIV worldwide are unaware of their status"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34949518",
"endSection": "abstract",
"offsetInBeginSection": 862,
"offsetInEndSection": 882,
"text": "maternal HIV testing"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37720974",
"endSection": "abstract",
"offsetInBeginSection": 944,
"offsetInEndSection": 968,
"text": "pregnant people with HIV"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37720974",
"endSection": "abstract",
"offsetInBeginSection": 1645,
"offsetInEndSection": 1741,
"text": "PPHIV experienced higher rates of LBW and VLBW newborns, and higher late pregnancy-related death"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36629794",
"endSection": "abstract",
"offsetInBeginSection": 166,
"offsetInEndSection": 196,
"text": "adults diagnosed late with HIV"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36629794",
"endSection": "abstract",
"offsetInBeginSection": 1545,
"offsetInEndSection": 1720,
"text": "HIV diagnosis could help develop effective strategies to reduce this burden of late presentation - particularly among heterosexual individuals, non-Europeans, and older people"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36629794",
"endSection": "abstract",
"offsetInBeginSection": 926,
"offsetInEndSection": 1010,
"text": "Amongst MSM, those who were older, of an ethnicity other than European, acquired HIV"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36630307",
"endSection": "abstract",
"offsetInBeginSection": 485,
"offsetInEndSection": 581,
"text": "penile cancer within HIV-positive individuals is significantly greater than in those without HIV"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36630307",
"endSection": "abstract",
"offsetInBeginSection": 1000,
"offsetInEndSection": 1109,
"text": "HIV and penile carcinoma, with a higher risk of cancer in Hispanic, compared with Caucasian, HIV-positive men"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36630617",
"endSection": "abstract",
"offsetInBeginSection": 12,
"offsetInEndSection": 149,
"text": "The vulnerability of female sex workers (FSWs) to HIV infection increases if unprotected heterosexual anal intercourse (HAI) is practiced"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37993765",
"endSection": "abstract",
"offsetInBeginSection": 1000,
"offsetInEndSection": 1254,
"text": "Our analysis found that in Cameroon, women in polygamous relationships, Muslim women, married women with inadequate HIV knowledge, those who had never been tested for HIV and women with lower socioeconomic status are less likely to negotiate for safe sex"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18685551",
"endSection": "abstract",
"offsetInBeginSection": 1508,
"offsetInEndSection": 1631,
"text": "Health-care providers should routinely screen all patients aged 13-64 years for HIV in accordance with CDC recommendations."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/12126721",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 843,
"text": "BACKGROUND: The perinatal short-course zidovudine (ZDV) chemoprophylaxis that can reduce HIV-1 vertical transmission by 51% has been widely practiced in developing countries such as Thailand because of its simpler and less cost.OBJECTIVES: To investigate the effects of short-course regimen of oral ZDV for prophylaxis of HIV-1 subtype E vertical transmission among 'break-through' HIV-1 infected infants.STUDY DESIGN: The study analyzed clinical and virological outcomes of 80 infants, whose mothers received ZDV prophylaxis starting at 36 weeks gestation (group Z) and 37 infants whose mothers never received anti-retroviral drugs (group C), at the ages of 1-2, 4-6, and 12 months.RESULTS: Of the 12 HIV-1 infected infants, 5/7 (71.4%) from group Z and 1/5 (20%) from group C progressed to a symptomatic clinical stage by the age 4-6 months."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18685551",
"endSection": "abstract",
"offsetInBeginSection": 540,
"offsetInEndSection": 741,
"text": "To reduce the number of persons with undiagnosed HIV infection, CDC issued recommendations in September 2006 to implement HIV screening as part of routine medical care for all persons aged 13-64 years."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25283353",
"endSection": "abstract",
"offsetInBeginSection": 121,
"offsetInEndSection": 255,
"text": "Yet many adolescents and young adults with high-risk behaviors for HIV are unaware of their HIV status and have never had an HIV test."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21279431",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 110,
"text": "HIV testing was assessed online among men accessing a sexual networking website for men who have sex with men."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29583105",
"endSection": "abstract",
"offsetInBeginSection": 1071,
"offsetInEndSection": 1143,
"text": "An estimated 83.7% of sexually active older adults never tested for HIV."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28883962",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 158,
"text": "BACKGROUND: The human immunodeficiency virus (HIV) infection usually infects persons in the reproductive age group (15-49 years), but elderly people are also "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/19940800",
"endSection": "abstract",
"offsetInBeginSection": 1441,
"offsetInEndSection": 1639,
"text": "d HIV-infected adolescents in Zimbabwe. In resource-poor settings with maturing epidemics, the presence of skin disease should be regarded as a strong indication for HIV testing and especially as it"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/19303830",
"endSection": "abstract",
"offsetInBeginSection": 93,
"offsetInEndSection": 174,
"text": "This is the prime childbearing age group with an increasing mortality due to HIV."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/17129866",
"endSection": "abstract",
"offsetInBeginSection": 386,
"offsetInEndSection": 829,
"text": "No significant difference was observed in the association between HIV infection and gender (chi2=0.58, df = 1, P < 0.05). The highest prevalence of HIV infection (8.9%) was recorded among individuals in the 21-30 years age category, while the least HIV infection prevalence (5.3%) was observed among persons above 40 years old. There was no significant difference in the association between HIV infection and age (chi2=0.68, df = 3, P < 0.05)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28796758",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 334,
"text": "CDC's 2006 recommendations for human immunodeficiency virus (HIV) testing state that all persons aged 13-64 years should be screened for HIV at least once, and that persons at higher risk for HIV infection, including sexually active gay, bisexual, and other men who have sex with men (MSM), should be rescreened at least annually (1)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37729175",
"endSection": "abstract",
"offsetInBeginSection": 1944,
"offsetInEndSection": 2091,
"text": "Providers should target men aged ≤ 34 years, with primary education, visiting facilities for the first time and who have never been tested for HIV."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37632603",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 148,
"text": "The CDC recommends that persons aged 13-64 receive an HIV test at least once in their lifetime and that some groups test annually or more frequently"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36729993",
"endSection": "abstract",
"offsetInBeginSection": 142,
"offsetInEndSection": 408,
"text": "The US Centers for Disease Control and Prevention recommends persons aged 13 to 64 years be tested for HIV at least once as part of routine health care; however, it is unclear how effectively these testing recommendations have been implemented in EHE priority areas."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36589732",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1959,
"text": "HIV testing continues to be a challenge among the young population in Tanzania. As of 2017, only 30% of 15-19-year-olds reported getting tested and receiving their results. This study will examine the demographic and socio-behavioral characteristics associated with HIV testing among adolescents and young adults in Tanzania. Interview data from the 2016-2017 Tanzania HIV Impact Survey (THIS) were analyzed on 10,128 adolescents and young adults 15-24 years of age, representing 10.5 million youth in Tanzania. Weighted logistic regression was used to model the relationship of HIV testing with demographic and socio-behavioral characteristics. Half (50%) of respondents reported ever having been tested for HIV. HIV testing was significantly lower among males compared with females (AOR = 0.5;95% confidence interval [CI] = 0.5-0.6; p<0.001), 15-19 year olds compared with 20-24 year olds (AOR = 0.4;95% CI = 0.4-0.5; p<0.001), no education compared with secondary or post-secondary education (AOR = 0.4;95% CI = 0.3-0.6; p<0.001), rural residents compared with urban residents (AOR = 0.7;95% CI = 0.6-0.9; p<0.001) and those who don't use condoms during sexual intercourse compared with those who do (AOR = 0.6;95% CI = 0.5-0.8; p<0.001). Among HIV-infected youth, younger age group, rural residents, education less than primary, single, high income, and sex workers were significantly associated with never testing for HIV. This study highlights the majority of characteristics affecting HIV testing among young people in Tanzania have not changed over the years, thus it is necessary to re-examine the current approaches to HIV testing. The COVID-19 pandemic will add to this challenge as it collides with the ongoing HIV epidemic and competes for needed medical supplies and health care provider resources. In light of this current situation, intensified and targeted HIV testing programs for at risk young populations in Tanzania should be prioritized."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/17129866",
"endSection": "abstract",
"offsetInBeginSection": 830,
"offsetInEndSection": 1133,
"text": "Mandatory pre-marital HIV screening could generate social stigmatization and infringement of the fundamental human rights of infected individuals. Voluntary counselling and confidential HIV testing and especially pre- and post-test counselling as the basis of pre-marital HIV testing are more desirable."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25303208",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 423,
"text": "The Centers for Disease Control and Prevention recommends routine human immunodeficiency virus (HIV) testing of every client presenting for services in venues where HIV prevalence is high. Because older adults (aged ≥50 years) have particularly poor prognosis if they receive their diagnosis late in the course of HIV disease, any screening provided to younger adults in these venues should also be provided to older adults"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/10224192",
"endSection": "abstract",
"offsetInBeginSection": 526,
"offsetInEndSection": 730,
"text": "HIV-infected children, adolescents, and young adults who are severely immunocompromised (based on age-specific CD4 lymphocyte enumeration) attributable to HIV infection should not receive measles vaccine."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24789219",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 130,
"text": "HIV is often assumed to only affect younger people, and many older people do not realize that they might risk acquiring the virus."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/8655933",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 88,
"text": "The HIV infection primarily affects young adults, but older adults are also susceptible."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25960684",
"endSection": "abstract",
"offsetInBeginSection": 1429,
"offsetInEndSection": 1561,
"text": "Physicians are less likely to discuss sexual risk behaviors with older adults and to test them for HIV compared with younger adults."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/20685813",
"endSection": "abstract",
"offsetInBeginSection": 546,
"offsetInEndSection": 715,
"text": "In 2007 the Centers for Disease Control and Prevention in the United States reported that 16.8% of new diagnoses of HIV that year were in individuals aged over 50 years."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24849622",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 188,
"text": "Adolescents and young adults are the fastest growing age group of human immunodeficiency virus (HIV) positive individuals in the US, and many who are infected do not know their HIV status."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/9611559",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 160,
"text": "Older Americans, 50 years of age and older, account for 10% of the 400,000 reported cases of AIDS nationwide (Centers for Disease Control and Prevention, 1994)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24964879",
"endSection": "abstract",
"offsetInBeginSection": 258,
"offsetInEndSection": 459,
"text": "Since 2006, CDC has recommended that health-care providers screen for HIV all patients aged 13-64 years unless prevalence of undiagnosed HIV infection in their patients has been documented to be <0.1%."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22908365",
"endSection": "abstract",
"offsetInBeginSection": 459,
"offsetInEndSection": 700,
"text": "In 2006, CDC recommended that all persons aged 13–64 years be screened for HIV in health-care settings in which the prevalence of undiagnosed HIV infection is >0.1%, and that persons with increased risk for HIV be retested at least annually."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27435075",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 249,
"text": "Currently, the Centers for Disease Control and Prevention recommends that persons between 15 and 64 years get tested for human immunodeficiency virus (HIV) at least once in their lifetime and persons with HIV risk factors get tested more frequently."
}
] | 13
|
BioASQ-training13b
| null | null |
65f86ba3c4010b4d78000059
| 5,101
|
factoid
|
What does capnography measure?
|
['Carbon dioxide', 'Co2', 'end-tidal carbon dioxide (EtCO2)']
|
[
"Carbon dioxide",
"CO2",
"end-tidal carbon dioxide (EtCO2)",
"carbonic acid gas",
"carbonic anhydride",
"dry ice (solid form)",
"carbon dioxide gas"
] |
['Capnography measures the amount of carbon dioxide in exhaled air, indicating how well CO2 is being eliminated from the body.', 'Capnography measures the amount of carbon dioxide (CO2) in exhaled breath.', 'Capnography is a tool for continuous monitoring of carbon dioxide (CO2) concentration in exhaled gases during anesthesia and respiratory support.', 'Capnography measures carbon dioxide in expired air.', 'Capnography measures the concentration of carbon dioxide at the end of exhalation, and it can detect abnormal breathing patterns or the absence of breath.', 'Capnography is a non-invasive monitoring technique that measures the concentration or partial pressure of carbon dioxide (CO2) in exhaled breath, also known as end-tidal CO2 (EtCO2), over time to assess the adequacy of ventilation and the presence of abnormal ventilation or apnea.', 'Capnography measures carbon dioxide concentration in exhaled air.', 'Capnography is a monitoring tool used in medicine that measures the concentration of carbon dioxide in the respiratory gases. It is often used during cardiopulmonary resuscitation to measure arterial CO2 partial pressure (PCO2). Additionally, it is used for monitoring end-tidal carbon dioxide concentrations.', 'Capnography measures end-tidal carbon dioxide concentrations, which can detect abnormal ventilation or apnoea early during cardiopulmonary resuscitation.', 'Capnography measures the amount of carbon dioxide in expired air.', 'Capnography measures the concentration of carbon dioxide in exhaled air.', 'Capnography is the measurement of carbon dioxide (CO2) concentration in a gas mixture.', 'Capnography measures the end-tidal carbon dioxide (CO2) concentration in exhaled breath. It provides a non-invasive and continuous assessment of ventilation and can detect abnormal ventilation or apnea early during cardiopulmonary resuscitation.', 'Capnography measures the concentration of carbon dioxide in the respiratory gases, which is a vital parameter during anesthesia and intensive care. It is used to monitor the inhaled and exhaled concentration or partial pressure of carbon dioxide. This can help detect abnormal ventilation or apnoea early', 'Capnography measures carbon dioxide, volumetric capnography (VCAP) and arterial CO2 partial pressure, and arterial CO2 partial pressure.', "Capnography measures the concentration of carbon dioxide (CO2) in exhaled breath. It provides real-time monitoring of the patient's ventilation and helps assess the adequacy of respiratory function.", 'Capnography measures the concentration of carbon dioxide (CO2) in exhaled breath as a function of time, known as the capnogram.', "Capnography measures end-tidal carbon dioxide concentrations. This means it monitors the amount of carbon dioxide that is exhaled at the end of each breath. It's a useful tool because it can detect abnormal ventilation or apnoea early.", 'Capnography measures the concentration of carbon dioxide in exhaled breath, which can be used to monitor the effectiveness of cardiopulmonary resuscitation.', 'Capnography provides real-time measurement of carbon dioxide (CO2) in respiratory gases.', 'Capnography measures the concentration of carbon dioxide in the respiratory gases, specifically the end-tidal carbon dioxide concentrations. It is used to monitor the inhaled and exhaled concentration or partial pressure of carbon dioxide.', 'Capnography measures end-tidal carbon dioxide (CO2) concentrations during respiration. It can detect abnormal ventilation or apnea by monitoring CO2 levels in exhaled breath.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/18156957",
"http://www.ncbi.nlm.nih.gov/pubmed/26264607",
"http://www.ncbi.nlm.nih.gov/pubmed/7736268",
"http://www.ncbi.nlm.nih.gov/pubmed/24785676",
"http://www.ncbi.nlm.nih.gov/pubmed/2511789",
"http://www.ncbi.nlm.nih.gov/pubmed/26714621",
"http://www.ncbi.nlm.nih.gov/pubmed/25436022",
"http://www.ncbi.nlm.nih.gov/pubmed/7889801",
"http://www.ncbi.nlm.nih.gov/pubmed/37259022",
"http://www.ncbi.nlm.nih.gov/pubmed/37507472",
"http://www.ncbi.nlm.nih.gov/pubmed/26638570",
"http://www.ncbi.nlm.nih.gov/pubmed/34008907",
"http://www.ncbi.nlm.nih.gov/pubmed/1489871",
"http://www.ncbi.nlm.nih.gov/pubmed/7792768",
"http://www.ncbi.nlm.nih.gov/pubmed/1643689",
"http://www.ncbi.nlm.nih.gov/pubmed/31692301",
"http://www.ncbi.nlm.nih.gov/pubmed/24685942",
"http://www.ncbi.nlm.nih.gov/pubmed/30523011",
"http://www.ncbi.nlm.nih.gov/pubmed/9390853"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37507472",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 198,
"text": "A secondary analysis of a randomized study was performed to study the relationship between volumetric capnography (VCAP) and arterial CO2 partial pressure (PCO2) during cardiopulmonary resuscitation"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37259022",
"endSection": "abstract",
"offsetInBeginSection": 11,
"offsetInEndSection": 140,
"text": " By continually monitoring end-tidal carbon dioxide concentrations, capnography can detect abnormal ventilation or apnoea early. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24685942",
"endSection": "abstract",
"offsetInBeginSection": 139,
"offsetInEndSection": 228,
"text": "Capnography is the measurement and numerical display of end-tidal carbon dioxide (EtCO2)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/9390853",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 101,
"text": "Capnography measures exhaled carbon dioxide and is most useful when applied directly to patient care."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/7736268",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 86,
"text": "Capnography is the measurement of carbon dioxide (CO2) concentration in a gas mixture."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31692301",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 224,
"text": "Capnography, often referred to by emergency clinicians as end-tidal carbon dioxide monitoring, is a noninvasive method of measuring cardiopulmonary and metabolic parameters that can be utilized in many clinical applications."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30523011",
"endSection": "abstract",
"offsetInBeginSection": 494,
"offsetInEndSection": 614,
"text": "Capnography measures exhaled carbon dioxide and provides early identification of airway obstruction and hypoventilation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26264607",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 268,
"text": "An end-tidal CO2 monitor (capnometer) is used most often as a noninvasive substitute for PaCO2 in anesthesia, anesthetic recovery, and intensive care. Additionally, the wide spread on-site use of portable capnometers in emergency and trauma situations is now observed."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/2511789",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 159,
"text": "Capnometers measure carbon dioxide (CO2) in expired air and provide clinicians with a noninvasive measure of systemic metabolism, circulation, and ventilation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/7889801",
"endSection": "abstract",
"offsetInBeginSection": 101,
"offsetInEndSection": 255,
"text": "Capnography provides a continuous and non-invasive measure of arterial partial pressure of carbon dioxide (PaCO2) throughout the entire respiratory cycle."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26638570",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 139,
"text": "MONITORING RESPIRATORY and metabolic function by using capnography to measure end tidal carbon dioxide is standard practice in anaesthesia."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/2511789",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 160,
"text": "Capnometers measure carbon dioxide (CO2) in expired air and provide clinicians with a noninvasive measure of systemic metabolism, circulation, and ventilation. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24785676",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 135,
"text": "PURPOSE OF REVIEW: Volumetric capnography (VCap) measures the kinetics of carbon dioxide (CO2) elimination on a breath-by-breath basis."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/7792768",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 125,
"text": "Capnography measures carbon dioxide concentration or partial pressure of the respiratory gas continuously and non-invasively."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34008907",
"endSection": "abstract",
"offsetInBeginSection": 216,
"offsetInEndSection": 452,
"text": "Capnography is the non-invasive measurement of a sample of the exhaled carbon dioxide which has multiple clinical uses including as a method to confirm placement of a tracheal tube and/or to assess ventilation, perfusion and metabolism."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25436022",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 235,
"text": "BACKGROUND: Capnography provides a continuous, non-invasive monitoring of the CO2 to assess adequacy of ventilation and provide added safety features in mechanically ventilated patients by allowing for quick identification of unplanned"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18156957",
"endSection": "abstract",
"offsetInBeginSection": 277,
"offsetInEndSection": 518,
"text": "Capnography, a noninvasive monitoring technique designed to measure expired carbon dioxide (CO2) levels, has been used previously to identify respiratory placement of nasogastric tubes in adults; however, its use in children is understudied."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/1489871",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 69,
"text": "Capnometers measure carbon dioxide (CO2) in inspired and expired air."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26714621",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 90,
"text": "INTRODUCTION: Capnography is used to monitor the endtidal carbon dioxide tension (EtCO2) i"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/1643689",
"endSection": "abstract",
"offsetInBeginSection": 340,
"offsetInEndSection": 583,
"text": "This review of capnography includes the methods available to determine carbon dioxide in expired air, and an analysis of the physiology of capnograms, which are followed by a description of the applications of capnography in clinical practice."
}
] | 13
|
BioASQ-training13b
| null | null |
65f38059c4010b4d7800000e
| 5,103
|
factoid
|
What is the target of Selpercatinib?
|
['rearranged during transfection (RET) kinase']
|
[
"rearranged during transfection (RET) kinase",
"RET kinase",
"rearranged during transfection kinase",
"rearranged during transfection receptor tyrosine kinase",
"REarranged during Transfection kinase"
] |
['Selpercatinib is an orally-administered, selective inhibitor of rearranged during transfection (RET) kinase approved for the treatment of advanced RET fusion-positive non-small cell lung cancer (NSCLC).']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/37265026",
"http://www.ncbi.nlm.nih.gov/pubmed/36122315",
"http://www.ncbi.nlm.nih.gov/pubmed/32703767",
"http://www.ncbi.nlm.nih.gov/pubmed/32493697",
"http://www.ncbi.nlm.nih.gov/pubmed/37718634",
"http://www.ncbi.nlm.nih.gov/pubmed/37070927",
"http://www.ncbi.nlm.nih.gov/pubmed/37317595",
"http://www.ncbi.nlm.nih.gov/pubmed/37131086",
"http://www.ncbi.nlm.nih.gov/pubmed/32416592",
"http://www.ncbi.nlm.nih.gov/pubmed/36996322",
"http://www.ncbi.nlm.nih.gov/pubmed/33239432",
"http://www.ncbi.nlm.nih.gov/pubmed/31988000",
"http://www.ncbi.nlm.nih.gov/pubmed/37565829",
"http://www.ncbi.nlm.nih.gov/pubmed/36825106",
"http://www.ncbi.nlm.nih.gov/pubmed/33007380",
"http://www.ncbi.nlm.nih.gov/pubmed/32083997",
"http://www.ncbi.nlm.nih.gov/pubmed/35582449",
"http://www.ncbi.nlm.nih.gov/pubmed/36626081",
"http://www.ncbi.nlm.nih.gov/pubmed/37795873",
"http://www.ncbi.nlm.nih.gov/pubmed/36469155",
"http://www.ncbi.nlm.nih.gov/pubmed/36108661",
"http://www.ncbi.nlm.nih.gov/pubmed/37360768",
"http://www.ncbi.nlm.nih.gov/pubmed/32557397",
"http://www.ncbi.nlm.nih.gov/pubmed/36632846",
"http://www.ncbi.nlm.nih.gov/pubmed/35726802",
"http://www.ncbi.nlm.nih.gov/pubmed/37603207",
"http://www.ncbi.nlm.nih.gov/pubmed/34099825",
"http://www.ncbi.nlm.nih.gov/pubmed/37059058",
"http://www.ncbi.nlm.nih.gov/pubmed/37425604",
"http://www.ncbi.nlm.nih.gov/pubmed/34649088",
"http://www.ncbi.nlm.nih.gov/pubmed/35799394",
"http://www.ncbi.nlm.nih.gov/pubmed/35647935",
"http://www.ncbi.nlm.nih.gov/pubmed/33150799",
"http://www.ncbi.nlm.nih.gov/pubmed/33314236",
"http://www.ncbi.nlm.nih.gov/pubmed/36422787",
"http://www.ncbi.nlm.nih.gov/pubmed/34832869",
"http://www.ncbi.nlm.nih.gov/pubmed/33161056",
"http://www.ncbi.nlm.nih.gov/pubmed/34713870",
"http://www.ncbi.nlm.nih.gov/pubmed/35969032",
"http://www.ncbi.nlm.nih.gov/pubmed/34505490",
"http://www.ncbi.nlm.nih.gov/pubmed/37972337",
"http://www.ncbi.nlm.nih.gov/pubmed/35425116",
"http://www.ncbi.nlm.nih.gov/pubmed/38050583",
"http://www.ncbi.nlm.nih.gov/pubmed/37525669",
"http://www.ncbi.nlm.nih.gov/pubmed/36568522",
"http://www.ncbi.nlm.nih.gov/pubmed/34237031",
"http://www.ncbi.nlm.nih.gov/pubmed/36729098",
"http://www.ncbi.nlm.nih.gov/pubmed/33771190",
"http://www.ncbi.nlm.nih.gov/pubmed/35704797",
"http://www.ncbi.nlm.nih.gov/pubmed/33489819",
"http://www.ncbi.nlm.nih.gov/pubmed/36657661",
"http://www.ncbi.nlm.nih.gov/pubmed/36075388",
"http://www.ncbi.nlm.nih.gov/pubmed/32846061",
"http://www.ncbi.nlm.nih.gov/pubmed/35304457",
"http://www.ncbi.nlm.nih.gov/pubmed/37274265",
"http://www.ncbi.nlm.nih.gov/pubmed/36481304",
"http://www.ncbi.nlm.nih.gov/pubmed/36198171",
"http://www.ncbi.nlm.nih.gov/pubmed/35950566",
"http://www.ncbi.nlm.nih.gov/pubmed/33455880",
"http://www.ncbi.nlm.nih.gov/pubmed/36572992",
"http://www.ncbi.nlm.nih.gov/pubmed/33082208",
"http://www.ncbi.nlm.nih.gov/pubmed/35007206",
"http://www.ncbi.nlm.nih.gov/pubmed/37051304",
"http://www.ncbi.nlm.nih.gov/pubmed/37265412",
"http://www.ncbi.nlm.nih.gov/pubmed/31768065",
"http://www.ncbi.nlm.nih.gov/pubmed/32846060",
"http://www.ncbi.nlm.nih.gov/pubmed/37870973",
"http://www.ncbi.nlm.nih.gov/pubmed/34402300",
"http://www.ncbi.nlm.nih.gov/pubmed/33169506",
"http://www.ncbi.nlm.nih.gov/pubmed/36416226"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36729098",
"endSection": "abstract",
"offsetInBeginSection": 359,
"offsetInEndSection": 486,
"text": "More recently, two selective RET inhibitors, selpercatinib and pralsetinib, demonstrated higher efficacy and good tolerability."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36568522",
"endSection": "abstract",
"offsetInBeginSection": 1515,
"offsetInEndSection": 1641,
"text": "Drug exposure of RET inhibitors is expected to increase with CYP 3A4 inhibition, with selpercatinib being the least affected. "
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36572992",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 115,
"text": "An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36572992",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 162,
"text": "OBJECTIVE: Selpercatinib and pralsetinib are new targeted therapies used to treat patients with non-small cell lung cancer (NSCLC) due to RET gene rearrangements."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36626081",
"endSection": "abstract",
"offsetInBeginSection": 1606,
"offsetInEndSection": 1671,
"text": "Three RET-mutant patients received selpercatinib; all showed PR. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36632846",
"endSection": "abstract",
"offsetInBeginSection": 828,
"offsetInEndSection": 981,
"text": "Rapid translation and regulatory approval of selective RET inhibitors, selpercatinib and pralsetinib, have opened up the field of RET precision oncology."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36422787",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 62,
"text": "Selpercatinib: A Review in Advanced RET Fusion-Positive NSCLC."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36422787",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 223,
"text": "Selpercatinib (Retevmo®/Retsevmo®) is an orally-administered, selective inhibitor of rearranged during transfection (RET) kinase approved for the treatment of advanced RET fusion-positive non-small cell lung cancer (NSCLC)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36422787",
"endSection": "abstract",
"offsetInBeginSection": 927,
"offsetInEndSection": 1090,
"text": "Thus, currently available evidence suggests that selpercatinib is a promising new RET-targeted therapy option for patients with advanced RET fusion-positive NSCLC."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36416226",
"endSection": "abstract",
"offsetInBeginSection": 74,
"offsetInEndSection": 169,
"text": "Selpercatinib is a highly selective RET inhibitor for treatment of metastatic RET-altered MTC. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32557397",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 191,
"text": "Selpercatinib (RETEVMO™) is a receptor tyrosine kinase RET (rearranged during transfection) inhibitor being developed by Loxo Oncology for the treatment of cancers harbouring RET alterations."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37603207",
"endSection": "abstract",
"offsetInBeginSection": 1663,
"offsetInEndSection": 1824,
"text": "Conclusions Selective RET inhibitors Pralsetinib and Selpercatinib have shown a good effect on RET fusion-positive NSCLC, with a low incidence of adverse events."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34832869",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 172,
"text": "Selpercatinib is a targeted, FDA-approved, oral, small-molecule inhibitor for the treatment of rearranged during transfection (RET) proto-oncogene mutation-positive cancer."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32557397",
"endSection": "abstract",
"offsetInBeginSection": 192,
"offsetInEndSection": 443,
"text": "Based on results from the phase I/II LIBRETTO-001 trial, selpercatinib was recently approved by the US FDA for the treatment of RET fusion-positive non-small-cell lung cancer, RET fusion-positive thyroid cancer and RET-mutant medullary thyroid cancer."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33771190",
"endSection": "abstract",
"offsetInBeginSection": 629,
"offsetInEndSection": 815,
"text": "Selpercatinib (LOXO-292) and pralsetinib (BLU-667) are potent and selective inhibitors that target RET alterations, including fusions and mutations, irrespective of the tissue of origin."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37795873",
"endSection": "abstract",
"offsetInBeginSection": 117,
"offsetInEndSection": 232,
"text": "Selpercatinib is a highly selective RET inhibitor that has demonstrated anti-tumor activity in RET-mutated cancers."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37059058",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 75,
"text": "Selpercatinib is a small molecule that binds at the RET kinase active site."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33489819",
"endSection": "abstract",
"offsetInBeginSection": 620,
"offsetInEndSection": 871,
"text": "In 2020, the US Food and Drug Administration approved selpercatinib, a selective RET inhibitor, for adults with lung and thyroid cancers with RET rearrangements or mutations, making it the first targeted therapy to be approved for RET-altered cancers."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36469155",
"endSection": "abstract",
"offsetInBeginSection": 267,
"offsetInEndSection": 449,
"text": "Here, we describe a case of a sarcoma, associated with a RET::TRIM33-fusion gene with an exceptional response to a neoadjuvant therapy with the selective RET inhibitor selpercatinib."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37131086",
"endSection": "abstract",
"offsetInBeginSection": 80,
"offsetInEndSection": 466,
"text": "Oncogenic RET fusions or mutations are found most often in non-small cell lung cancer (NSCLC) and in thyroid cancer, but also increasingly in various types of cancers at low rates. In the last few years, two potent and selective RET protein tyrosine kinase inhibitors (TKIs), pralsetinib (BLU-667) and selpercatinib (LOXO-292, LY3527723) were developed and received regulatory approval."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31988000",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 279,
"text": "INTRODUCTION: Novel rearranged in transfection (RET)-specific tyrosine kinase inhibitors (TKIs) such as selpercatinib (LOXO-292) have shown unprecedented efficacy in tumors positive for RET fusions or mutations, notably RET fusion-positive NSCLC and RET-mutated medullary thyroid"
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34832869",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 170,
"text": "P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34505490",
"endSection": "abstract",
"offsetInBeginSection": 145,
"offsetInEndSection": 383,
"text": "Selpercatinib and pralsetinib are tyrosine kinase inhibitors selectively targeting RET and with clinical activity in RET-positive NSCLC.CASE PRESENTATION: A male never-smoker in his forties was diagnosed with advanced lung adenocarcinoma."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37718634",
"endSection": "abstract",
"offsetInBeginSection": 314,
"offsetInEndSection": 504,
"text": "Fortunately, two selective RET inhibitors (sRETi), namely pralsetinib and selpercatinib, have been approved for treating RET fusion NSCLC due to their remarkable efficacy and safety profiles"
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37565829",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 135,
"text": "Sustained Response with Dose-reduced Selpercatinib in a Pediatric Patient with Metastatic NCOA4-RET Fusion Papillary Thyroid Carcinoma."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37317595",
"endSection": "abstract",
"offsetInBeginSection": 308,
"offsetInEndSection": 558,
"text": "In addition to these approvals, dostarlimab for mismatch repair deficiency(dMMR), dabrafenib and trametinib for BRAF V600E, and selpercatinib for RET fusion gene have been approved in the United States as tumor agnostic biomarkers and their treatment"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33455880",
"endSection": "abstract",
"offsetInBeginSection": 410,
"offsetInEndSection": 643,
"text": "To overcome these issues, new selective RET inhibitors such as pralsetinib (BLU-667) and selpercatinib (LOXO-292) have been developed in clinical trials, with selpercatinib recently approved by the Food and Drug Administration (FDA)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33007380",
"endSection": "abstract",
"offsetInBeginSection": 112,
"offsetInEndSection": 389,
"text": "er (NSCLC). RET-selective inhibitors selpercatinib (LOXO-292) and pralsetinib (BLU-667) recently demonstrated favorable antitumor activity and safety profiles in advanced RET fusion-positive NSCLC, and both have received approval by the US Food and Drug Administration for this"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32083997",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1634,
"text": "Activating receptor tyrosine kinase RET (rarranged during transfection) gene alterations have been identified as oncogenic in multiple malignancies. RET gene rearrangements retaining the kinase domain are oncogenic drivers in papillary thyroid cancer, non-small-cell lung cancer, and multiple other cancers. Activating RET mutations are associated with different phenotypes of multiple endocrine neoplasia type 2 as well as sporadic medullary thyroid cancer. RET is thus an attractive therapeutic target in patients with oncogenic RET alterations. Multikinase inhibitors with RET inhibitor activity, such as cabozantinib and vandetanib, have been explored in the clinic for tumors with activating RET gene alterations with modest clinical efficacy. As a result of the nonselective nature of these multikinase inhibitors, patients had off-target adverse effects, such as hypertension, rash, and diarrhea. This resulted in a narrow therapeutic index of these drugs, limiting ability to dose for clinically effective RET inhibition. In contrast, the recent discovery and clinical validation of highly potent selective RET inhibitors (pralsetinib, selpercatinib) demonstrating improved efficacy and a more favorable toxicity profile are poised to alter the landscape of RET-dependent cancers. These drugs appear to have broad activity across tumors with activating RET alterations. The mechanisms of resistance to these next-generation highly selective RET inhibitors is an area of active research. This review summarizes the current understanding of RET alterations and the state-of-the-art treatment strategies in RET-dependent cancers."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36198171",
"endSection": "abstract",
"offsetInBeginSection": 185,
"offsetInEndSection": 465,
"text": "o carcinomas. Six inhibitors have been approved for the treatment of RET-driven cancers: vandetanib, cabozantinib, lenvatinib, sorafenib, selpercatinib, and pralsetinib. Only selpercatinib and pralsetinib have been developed specifically for RET, while the remaining are multikina"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35969032",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 115,
"text": "Selpercatinib is a first-in-class, highly selective and potent, central nervous system-active RET kinase inhibitor."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35582449",
"endSection": "abstract",
"offsetInBeginSection": 603,
"offsetInEndSection": 715,
"text": "Recently, two potent and selective RET TKIs, pralsetinib (BLU-667) and selpercatinib (LOXO-292), were developed."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37603207",
"endSection": "abstract",
"offsetInBeginSection": 250,
"offsetInEndSection": 404,
"text": "nt benefit. Selective RET inhibitors Pralsetinib and Selpercatinib are targeted drugs approved by the US Food and Drug Administration for treating RET-mut"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36198171",
"endSection": "abstract",
"offsetInBeginSection": 185,
"offsetInEndSection": 340,
"text": "o carcinomas. Six inhibitors have been approved for the treatment of RET-driven cancers: vandetanib, cabozantinib, lenvatinib, sorafenib, selpercatinib, an"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37525669",
"endSection": "abstract",
"offsetInBeginSection": 356,
"offsetInEndSection": 550,
"text": "Recent advancements in targeted therapies have led to the development of ret proto-oncogene (RET) inhibitors, such as selpercatinib and pralsetinib, which have been approved for the treatment of"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36572992",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 151,
"text": "OBJECTIVE: Selpercatinib and pralsetinib are new targeted therapies used to treat patients with non-small cell lung cancer (NSCLC) due to RET gene rear"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33082208",
"endSection": "abstract",
"offsetInBeginSection": 173,
"offsetInEndSection": 229,
"text": "r types. Selpercatinib is a highly selective RET kinase "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35726802",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 114,
"text": "INTRODUCTION: Selpercatinib is a RET selective tyrosine kinase inhibitor with nanomolar potency against diverse RE"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37131086",
"endSection": "abstract",
"offsetInBeginSection": 299,
"offsetInEndSection": 436,
"text": "selective RET protein tyrosine kinase inhibitors (TKIs), pralsetinib (BLU-667) and selpercatinib (LOXO-292, LY3527723) were developed and"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33314236",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 65,
"text": "Selpercatinib (LOXO-292) is a selective and potent RET inhibitor."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32557397",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 192,
"text": "Selpercatinib (RETEVMO™) is a receptor tyrosine kinase RET (rearranged during transfection) inhibitor being developed by Loxo Oncology for the treatment of cancers harbouring RET alterations. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35007206",
"endSection": "abstract",
"offsetInBeginSection": 197,
"offsetInEndSection": 311,
"text": "er treatment. Selpercatinib (LOXO-292) is a highly selective RET kinase inhibitor indicated in advanced RET-mutant"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34099825",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 243,
"text": "Recently Food and Drug Administration (FDA)-approved pralsetinib (BLU-667) and selpercatinib (LOXO-292) are RET-selective protein tyrosine kinase inhibitors for treating RET-altered cancers, but whether they have distinct activity was unknown."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33161056",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 214,
"text": "BACKGROUND: Selpercatinib (LOXO-292) and pralsetinib (BLU-667) are highly potent RET-selective protein tyrosine kinase inhibitors (TKIs) for treating advanced RET-altered thyroid cancers and non-small-cell lung can"
}
] | 13
|
BioASQ-training13b
| null | null |
65cfa22b1930410b1300000c
| 5,111
|
factoid
|
What is the vector for coxiella burnetii transmission?
|
['tick']
|
[
"tick",
"Ixodidae",
"Acari",
"tick insect",
"bloodsucking tick",
"hard tick",
"soft tick",
"wood tick",
"deer tick",
"dog tick"
] |
['The vector for Coxiella burnetii transmission is primarily through inhalation of infectious aerosols, although ticks have also been suggested as potential vectors.', 'Coxiella burnetii is transmitted by ticks, including through their feces and saliva.', 'The vector for Coxiella burnetii transmission is the tick.', 'The vector for Coxiella burnetii transmission is ticks.', 'Coxiella burnetii is transmitted by ticks.', 'The vector for Coxiella burnetii transmission is primarily ticks.', 'Ticks are the vector for coxiella burnetii transmission.', 'Ticks are the common vector for Coxiella burnetii', 'Yes, Coxiella burnetii is transmitted by ticks.', 'Ticks are the vectors for transmitting Coxiella burnetii.', 'Ticks, including species like Hyalomma lusitanicum, I. ricinus, and Ornithodoros moubata, act as vectors for the transmission of Coxiella burnetii.', 'The vector for Coxiella burnetii transmission is ticks, specifically through tick feces and saliva.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/26186513",
"http://www.ncbi.nlm.nih.gov/pubmed/37387368",
"http://www.ncbi.nlm.nih.gov/pubmed/32141019",
"http://www.ncbi.nlm.nih.gov/pubmed/26458781",
"http://www.ncbi.nlm.nih.gov/pubmed/32059686",
"http://www.ncbi.nlm.nih.gov/pubmed/33406079",
"http://www.ncbi.nlm.nih.gov/pubmed/32173315",
"http://www.ncbi.nlm.nih.gov/pubmed/37107481",
"http://www.ncbi.nlm.nih.gov/pubmed/36439350",
"http://www.ncbi.nlm.nih.gov/pubmed/1350178",
"http://www.ncbi.nlm.nih.gov/pubmed/35190334",
"http://www.ncbi.nlm.nih.gov/pubmed/37866329",
"http://www.ncbi.nlm.nih.gov/pubmed/37025192",
"http://www.ncbi.nlm.nih.gov/pubmed/28502643",
"http://www.ncbi.nlm.nih.gov/pubmed/21771522",
"http://www.ncbi.nlm.nih.gov/pubmed/33113791"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37387368",
"endSection": "abstract",
"offsetInBeginSection": 334,
"offsetInEndSection": 484,
"text": "transmitted by ticks include bacteria of the genus Borrelia and the species Francisella tularensis, Anaplasma phagophytophilum and Coxiella burnetii; "
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35190334",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 70,
"text": "Prevalence of Coxiella-infections in ticks - review and meta-analysis."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35190334",
"endSection": "abstract",
"offsetInBeginSection": 238,
"offsetInEndSection": 394,
"text": "Excretion of C. burnetii in tick feces and saliva is well documented but the role of these findings or the epidemiological context is discussed controversia"
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37866329",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 259,
"text": "Exploring the diversity of tick-borne pathogens: The case of bacteria (Anaplasma, Rickettsia, Coxiella and Borrelia) protozoa (Babesia and Theileria) and viruses (Orthonairovirus, tick-borne encephalitis virus and louping ill virus) in the European continent."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33406079",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 107,
"text": "Vector competence of the African argasid tick Ornithodoros moubata for the Q fever agent Coxiella burnetii."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36439350",
"endSection": "abstract",
"offsetInBeginSection": 908,
"offsetInEndSection": 1103,
"text": "Although C. burnetii transmission is mainly airborne, ticks may act as vectors and play an important role in the natural cycle of transmission of coxiellosis among wild vertebrates and livestock."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33406079",
"endSection": "abstract",
"offsetInBeginSection": 1354,
"offsetInEndSection": 1586,
"text": "Finally, we detected only a sporadic presence of C. burnetii DNA in tick faeces, but no living bacterium was further isolated in culture assays, suggesting that excretion in faeces is not a common mode of transmission in O. moubata."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33113791",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 110,
"text": "Transstadial Transmission from Nymph to Adult of Coxiella burnetii by Naturally Infected Hyalomma lusitanicum."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33113791",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 147,
"text": "Coxiella burnetii (Derrick) Philip, the causative agent of Q fever, is mainly transmitted by aerosols, but ticks can also be a source of infection."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37107481",
"endSection": "abstract",
"offsetInBeginSection": 1225,
"offsetInEndSection": 1311,
"text": "Furthermore, the transmission of C. burnetii is most likely via vectors (i.e., ticks)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26186513",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 189,
"text": "Query (Q) fever is a vector-borne zoonosis caused by the obligate intracellular pathogen Coxiella burnetii. Animals, including dogs, cats, cattle, and sheep, can be infected by C. burnetii."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35190334",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 237,
"text": "Q fever is a global zoonotic infection caused by the intracellular Gram-negative bacterium Coxiella burnetii. Historically, it is considered a vector-borne disease, but the role of ticks in transmission has not fully been elucidated yet."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32173315",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 172,
"text": "Q fever is a widespread zoonotic disease caused by Coxiella burnetii that most commonly infects not only a variety of mammals but also arthropods and in particularly ticks."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33406079",
"endSection": "abstract",
"offsetInBeginSection": 426,
"offsetInEndSection": 1093,
"text": "In this study, we re-evaluated the vector competence of the African soft tick Ornithodoros moubata for an avirulent strain of C. burnetii. To this end, we used an artificial feeding system to initiate infection of ticks, specific molecular tools to monitor further infections, and culture assays in axenic and cell media to check for the viability of C. burnetii excreted by ticks. We observed typical traits associated with vector competence: The exposure to an infected blood meal resulted in viable and persistent infections in ticks, trans-stadial transmissions of infection from nymphs to adults and the ability of adult ticks to transmit infectious C. burnetii."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/1350178",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 387,
"text": "The dramatic spread of Q fever in Poland among cattle kept in isolation from natural environment (ticks, wild animals) has suggested the possibility that the infection may also be transmitted sexually. To test this hypothesis series of experiments have been performed in controlled laboratory conditions. Male mice infected with C. burnetii were allowed to mate with healthy female mice."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37025192",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 187,
"text": "Background: Q fever is a zoonotic disease caused by Coxiella burnetii infection, with domestic ruminants as the main source of infection and tick bites as one of the transmission vectors."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33406079",
"endSection": "abstract",
"offsetInBeginSection": 1201,
"offsetInEndSection": 1353,
"text": "In addition, while adult female ticks were infected, we did not observe C. burnetii in eggs, suggesting that transovarial transmission is not effective."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33406079",
"endSection": "abstract",
"offsetInBeginSection": 426,
"offsetInEndSection": 564,
"text": "In this study, we re-evaluated the vector competence of the African soft tick Ornithodoros moubata for an avirulent strain of C. burnetii."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21771522",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 203,
"text": "Coxiella burnetii, the causative agent of Q fever, and Rickettsia spp. are bacterial pathogens that can be transmitted by ticks of the genus Dermacentor (i.e., Dermacentor marginatus and D. reticulatus)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28502643",
"endSection": "abstract",
"offsetInBeginSection": 1217,
"offsetInEndSection": 1410,
"text": "Our data suggest that zebus as well as Amblyomma and Boophilus ticks have to be considered as a natural reservoir or vector for C. burnetii, but the risk of cattle-to-human transmission is low."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32141019",
"endSection": "abstract",
"offsetInBeginSection": 78,
"offsetInEndSection": 115,
"text": "ticks in the transmission of Coxiella"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32059686",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 353,
"text": "BACKGROUND: The bacterium Coxiella burnetii is the etiological agent of Q fever and is mainly transmitted via inhalation of infectious aerosols. DNA of C. burnetii is frequently detected in ticks, but the role of ticks as vectors in the epidemiology of this agent is still controversial. In this study, Ixodes ricinus and Dermacentor marginatus adults a"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26458781",
"endSection": "abstract",
"offsetInBeginSection": 51,
"offsetInEndSection": 374,
"text": "Coxiella burnetii, a ubiquitous intracellular bacterium infecting humans and a variety of animals. Transmission is primarily but not exclusively airborne, and ticks are usually thought to act as vectors. We argue that, although ticks may readily transmit C. burnetii in experimental systems, they only occasionally transmit"
}
] | 13
|
BioASQ-training13b
| null | null |
65f039fdc4010b4d78000002
| 5,115
|
factoid
|
What is an Albatross plot used for?
|
['visualization of diversely reported studies']
|
[
"visualization of diversely reported studies",
"visualization of diverse studies",
"visualization of varied studies",
"visual representation of diverse studies",
"visualization of heterogeneous studies",
"visualization of various studies"
] |
['An albatross plot is a novel graphical tool for presenting results of diversely reported studies in a systematic review.', 'An Albatross plot is a graphical representation of the distribution of the number of patients with a given outcome in a clinical trial. It is used to visualize the distribution of outcomes in a trial and to identify potential issues with the trial design or conduct.', 'An Albatross plot is a graphical tool used in systematic reviews to present the results of diversely reported studies. It helps to visualize and compare the findings of different studies, making it easier to identify patterns and trends in the data.', 'The albatross plot is a novel graphical tool for presenting results of diversely reported studies in a systematic review', 'The albatross plot is a novel graphical tool for presenting results of diversely reported studies in a systematic review.', 'An Albatross plot is used to present the results of diversely reported studies in a systematic review in a graphical format.', 'The Albatross plot is used for presenting the results of studies that are reported in diverse ways within a systematic review.', 'An Albatross plot is used for presenting results of diversely reported studies in a systematic review.', 'An Albatross plot is a novel graphical tool used for presenting the results of diversely reported studies in a systematic review. It helps to visually display the effect sizes and confidence intervals of individual studies, allowing for a comprehensive overview of the data and facilitating the interpretation of the overall findings.', 'The Albatross plot is used for presenting results of diversely reported studies in a systematic review.', 'Albatross plot is a graphical tool used in systematic reviews to present the results of studies that report the effect size or estimate for an outcome in diverse ways. It allows visual comparison of studies by displaying the effect size and confidence interval in a single plot.', 'An Albatross plot is used to visually present the results of studies that are reported in diverse ways within a systematic review, showing the estimated direction of effects and helping interpret P values based on study sample sizes.', 'An Albatross plot is a graphical tool utilized in systematic reviews. Its primary function is to present the results of studies that have been reported in diverse ways, providing a visual representation that aids in the interpretation and comparison of these results.', 'An Albatross plot is used for meta-analyses to combine the results of multiple studies of a common question. It allows an approximate examination of underlying effect sizes and the potential to identify sources of heterogeneity across studies.', 'An Albatross plot is used for presenting the results of studies that are reported in diverse ways in a systematic review. It provides a graphical tool for visualizing and interpreting these results.', 'An Albatross plot is a novel graphical tool for presenting results of diversely reported studies in a systematic review.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/28453179",
"http://www.ncbi.nlm.nih.gov/pubmed/34035181",
"http://www.ncbi.nlm.nih.gov/pubmed/32423407"
] |
[
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28453179",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 119,
"text": "The albatross plot: A novel graphical tool for presenting results of diversely reported studies in a systematic review."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28453179",
"endSection": "abstract",
"offsetInBeginSection": 1111,
"offsetInEndSection": 1284,
"text": "We provide examples of albatross plots using data from previous meta-analyses, allowing for comparison of results, and an example from when a meta-analysis was not possible."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32423407",
"endSection": "abstract",
"offsetInBeginSection": 766,
"offsetInEndSection": 1127,
"text": "For interpretation of the results across studies, we produced albatross plots for all studies combined and by age-groups, sex of the parents, sex of the child, methodology of assessment of parental PA, and type of PA.RESULTS: Thirty-nine papers were included with sample size of parent-child dyads ranging from 15 to 1267 (mean = 319 dyads, median = 227 dyads)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28453179",
"endSection": "abstract",
"offsetInBeginSection": 612,
"offsetInEndSection": 955,
"text": "We propose a novel plot, the albatross plot, which requires only a 1-sided P value and a total sample size from each study (or equivalently a 2-sided P value, direction of effect and total sample size). The plot allows an approximate examination of underlying effect sizes and the potential to identify sources of heterogeneity across studies."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34035181",
"endSection": "abstract",
"offsetInBeginSection": 679,
"offsetInEndSection": 926,
"text": "To assess the quality of evidence, Cochrane Collaboration's Risk of Bias Tool was used. Due to the heterogeneity of reported outcomes, meta-analysis was performed for only some outcomes and a narrative synthesis with albatross plots was presented."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28453179",
"endSection": "abstract",
"offsetInBeginSection": 612,
"offsetInEndSection": 1110,
"text": "We propose a novel plot, the albatross plot, which requires only a 1-sided P value and a total sample size from each study (or equivalently a 2-sided P value, direction of effect and total sample size). The plot allows an approximate examination of underlying effect sizes and the potential to identify sources of heterogeneity across studies. This is achieved by drawing contours showing the range of effect sizes that might lead to each P value for given sample sizes, under simple study designs."
}
] | 13
|
BioASQ-training13b
| null | null |
65f37997c4010b4d7800000b
| 5,121
|
factoid
|
What disorder is considered off label use for domperidone?
|
['inducing lactation', 'Gastroparesis']
|
[
"inducing lactation",
"lactation induction",
"lactation stimulation",
"Gastroparesis",
"delayed gastric emptying",
"gastroparesis syndrome"
] |
['Domperidone is considered off-label use for inducing lactation in breastfeeding mothers.', 'Domperidone is used off-label for the purpose of inducing lactation.', 'Domperidone is commonly used off-label as a galactagogue to increase breast milk production.', 'Domperidone is a selective dopamine D2 receptor antagonist that was first developed as an antiemetic agent. The use of Domperidone in gastroparesis is off-label due to its peripheral effects. The main objective of this study is to assess quercetin antiemetic properties and domperidone as a positive control.', 'Domperidone is considered off-label for the treatment of functional dyspepsia.', 'Domperidone is used off-label to promote lactation in prolactin-deficient women.', 'Domperidone is a dopamine-2 antagonist used off-label to increase breast milk production.', 'Domperidone is commonly used off-label to induce lactation in women.', 'Domperidone is used off-label to induce lactation in prolactin-deficient women.', 'Domperidone is commonly used off-label to induce lactation in prolactin-deficient women.', 'Domperidone is considered off label use for gastroparesis.', 'Domperidone is considered off label use for lactation.', 'Domperidone is considered off-label for promoting lactation in prolactin-deficient women.', 'Inducing lactation, acute gastroenteritis treatment in pediatric patients, acute dystonia', 'Domperidone is used off label for the treatment of gastroparesis.', 'Domperidone is a medication most commonly used by pediatric gastroenterologists for treatment of symptoms associated with gastro-esophageal reflux disease, dyspepsia, and gastroparesis outside its authorized indication, i.e. off label use', 'Domperidone is a medication commonly used off-label for its potential to stimulate prolactin secretion and thus milk production.', 'Domperidone is commonly used off-label to stimulate milk production in mothers who have low milk supply. It is prescribed off-label in Canada and Australia to promote lactation in prolactin-deficient women.', 'Domperidone is considered an off-label treatment for functional dyspepsia.', 'Domperidone is considered off label use for lactation, prolactin-deficient women, and Lactation induction.', 'A major side effect of domperidone is prolactinemia, allowing it to be used off-label for the purpose of inducing lactation.', 'Domperidone is considered off-label for the disorder of lactation, specifically to induce lactation by acting as a dopamine-2 antagonist.', ' Domperidone is considered off-label use for prolactin-deficient women to increase breast milk production.', 'Domperidone is an antiemetic that is commonly used off-label to induce lactation in prolactin-deficient women.', 'Domperidone is an antiemetic that is commonly used as an off-label prescription to induce lactation.', 'Domperidone is commonly used as an off-label prescription to induce lactation and increase breast milk production in women with prolactin deficiency.', 'Domperidone is used off label for treating symptoms related to gastro-esophageal reflux disease, dyspepsia, and gastroparesis.', 'Domperidone is often used off-label for the treatment of lactation deficiency. It helps to increase the production of breast milk.', 'Domperidone is considered an off-label treatment for promoting lactation in prolactin-deficient women.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/37352416",
"http://www.ncbi.nlm.nih.gov/pubmed/25306766",
"http://www.ncbi.nlm.nih.gov/pubmed/35793516",
"http://www.ncbi.nlm.nih.gov/pubmed/25475074",
"http://www.ncbi.nlm.nih.gov/pubmed/25825854",
"http://www.ncbi.nlm.nih.gov/pubmed/24600732",
"http://www.ncbi.nlm.nih.gov/pubmed/30481478",
"http://www.ncbi.nlm.nih.gov/pubmed/36367713",
"http://www.ncbi.nlm.nih.gov/pubmed/27280111",
"http://www.ncbi.nlm.nih.gov/pubmed/37159421",
"http://www.ncbi.nlm.nih.gov/pubmed/27296864"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35793516",
"endSection": "abstract",
"offsetInBeginSection": 12,
"offsetInEndSection": 113,
"text": "Domperidone is an antiemetic that is commonly used as an off-label prescription to induce lactation. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37352416",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 230,
"text": "Domperidone is a dopamine-2 (D2) receptor antagonist that stimulates the release of stored prolactin in the anterior pituitary. It is prescribed off-label in Canada and Australia to promote lactation in prolactin-deficient women. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36367713",
"endSection": "abstract",
"offsetInBeginSection": 12,
"offsetInEndSection": 100,
"text": "Domperidone is a dopamine-2 antagonist used off-label to increase breast milk production"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37159421",
"endSection": "abstract",
"offsetInBeginSection": 312,
"offsetInEndSection": 538,
"text": "However, among (pediatric) gastroenterologists, domperidone is also used outside its authorized indication (\"off label\") for treatment of symptoms associated with gastro-esophageal reflux disease, dyspepsia, and gastroparesis."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37159421",
"endSection": "abstract",
"offsetInBeginSection": 819,
"offsetInEndSection": 1058,
"text": "Based on this, the purpose of this review is to summarize all evidence on the efficacy of domperidone for the treatment of GI disorders in infants and children and to report an overview of its pharmacological properties and safety profile."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25825854",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 179,
"text": "OBJECTIVES: Domperidone and metoclopramide are prokinetics commonly prescribed off-label to infants and younger children in an attempt to treat gastro-oesophageal reflux symptoms."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35793516",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 112,
"text": "Objectives: Domperidone is an antiemetic that is commonly used as an off-label prescription to induce lactation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37159421",
"endSection": "abstract",
"offsetInBeginSection": 312,
"offsetInEndSection": 537,
"text": "However, among (pediatric) gastroenterologists, domperidone is also used outside its authorized indication (\"off label\") for treatment of symptoms associated with gastro-esophageal reflux disease, dyspepsia, and gastroparesis"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30481478",
"endSection": "abstract",
"offsetInBeginSection": 160,
"offsetInEndSection": 256,
"text": "on, such as domperidone, an off-label galactagogue, are often prescribed. Domperidone is controv"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35793516",
"endSection": "abstract",
"offsetInBeginSection": 12,
"offsetInEndSection": 137,
"text": "Domperidone is an antiemetic that is commonly used as an off-label prescription to induce lactation. Neuropsychiatric adverse"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36367713",
"endSection": "abstract",
"offsetInBeginSection": 12,
"offsetInEndSection": 118,
"text": "Domperidone is a dopamine-2 antagonist used off-label to increase breast milk production. Dosages commonly"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25306766",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 118,
"text": "Domperidone is a prokinetic agent used as a second-line treatment option for gastroparesis in those unable to tolerate"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37159421",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 218,
"text": "Domperidone is a peripheral dopamine-2 receptor antagonist with prokinetic and antiemetic properties. Its prokinetic effects are mainly manifest in the upper gastrointestinal (GI) tract. Currently its use is restricted"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27280111",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 104,
"text": "BACKGROUND: Domperidone is commonly used off-label to stimulate milk production in mothers who have low "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37352416",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 229,
"text": "Domperidone is a dopamine-2 (D2) receptor antagonist that stimulates the release of stored prolactin in the anterior pituitary. It is prescribed off-label in Canada and Australia to promote lactation in prolactin-deficient women."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30481478",
"endSection": "abstract",
"offsetInBeginSection": 105,
"offsetInEndSection": 221,
"text": "astfeeding. Medications that can increase milk production, such as domperidone, an off-label galactagogue, are often"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25306766",
"endSection": "abstract",
"offsetInBeginSection": 338,
"offsetInEndSection": 462,
"text": "A major side effect of domperidone is prolactinemia, allowing it to be used off-label for the purpose of inducing lactation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27296864",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 202,
"text": "PURPOSE: The aim of this study is to examine the relationship between domperidone (commonly used off-label for lactation stimulation), ventricular arrhythmia and all-cause mortality during the postpartu"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25825854",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 167,
"text": "OBJECTIVES: Domperidone and metoclopramide are prokinetics commonly prescribed off-label to infants and younger children in an attempt to treat gastro-oesophageal refl"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25475074",
"endSection": "abstract",
"offsetInBeginSection": 1214,
"offsetInEndSection": 1481,
"text": "The use of domperidone as a galactagogue is worrisome as drug-induced long QT syndrome occurred mostly in women. In these circumstances, an improvement of breastfeeding practices seems to be more effective and safer than the use of an off-label domperidone treatment."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24600732",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 174,
"text": "The use of domperidone in accordance with the terms of its marketing authorisation, or off-label to increase breast milk production, exposes patients to serious cardiac risk."
}
] | 13
|
BioASQ-training13b
| null | null |
65f493cac4010b4d78000012
| 5,127
|
factoid
|
What is the most common surgical treatment for hydrocephalus?
|
['Ventriculoperitoneal shunt']
|
[
"Ventriculoperitoneal shunt",
"VP shunt",
"ventriculoperitoneal catheter",
"ventriculoperitoneal drainage",
"ventriculoperitoneal device"
] |
["The most common surgical treatment for hydrocephalus is Ventriculoperitoneal (VP) shunting, which involves the placement of a shunt system to divert excess cerebrospinal fluid from the brain's ventricles to the abdominal cavity, where it can be absorbed by the body.", 'The most common surgical treatment for hydrocephalus is the placement of a ventriculoperitoneal shunt.', 'Ventriculoperitoneal (VP) shunt surgery is the most widely used neurosurgical procedure for the management of hydrocephalus.', 'Ventriculoperitoneal (VP) shunting is the most common neurosurgical treatment for hydrocephalus.', 'The most common surgical treatment for hydrocephalus is ventriculoperitoneal (VP) shunt placement. This procedure involves the insertion of a catheter into the ventricles of the brain to divert excess cerebrospinal fluid (CSF) into the peritoneal cavity, where it can be absorbed by the body.', 'The most common surgical treatment for hydrocephalus is ventriculoperitoneal shunt (VPS) insertion.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/22650109",
"http://www.ncbi.nlm.nih.gov/pubmed/35609726",
"http://www.ncbi.nlm.nih.gov/pubmed/25569424",
"http://www.ncbi.nlm.nih.gov/pubmed/17946960",
"http://www.ncbi.nlm.nih.gov/pubmed/30459864",
"http://www.ncbi.nlm.nih.gov/pubmed/21961546",
"http://www.ncbi.nlm.nih.gov/pubmed/26889393",
"http://www.ncbi.nlm.nih.gov/pubmed/19725301",
"http://www.ncbi.nlm.nih.gov/pubmed/29122895",
"http://www.ncbi.nlm.nih.gov/pubmed/20045747",
"http://www.ncbi.nlm.nih.gov/pubmed/37402676",
"http://www.ncbi.nlm.nih.gov/pubmed/1474973",
"http://www.ncbi.nlm.nih.gov/pubmed/36780037",
"http://www.ncbi.nlm.nih.gov/pubmed/15630948",
"http://www.ncbi.nlm.nih.gov/pubmed/34774581",
"http://www.ncbi.nlm.nih.gov/pubmed/36314835",
"http://www.ncbi.nlm.nih.gov/pubmed/22222434",
"http://www.ncbi.nlm.nih.gov/pubmed/31286305",
"http://www.ncbi.nlm.nih.gov/pubmed/36324983",
"http://www.ncbi.nlm.nih.gov/pubmed/11441995",
"http://www.ncbi.nlm.nih.gov/pubmed/27203135",
"http://www.ncbi.nlm.nih.gov/pubmed/34152450",
"http://www.ncbi.nlm.nih.gov/pubmed/31036124"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34152450",
"endSection": "abstract",
"offsetInBeginSection": 207,
"offsetInEndSection": 360,
"text": "Gravitation-assisted shunt valves are designed to prevent hydrostatic over-drainage frequently observed in the long course of shunt-treated hydrocephalus"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34152450",
"endSection": "abstract",
"offsetInBeginSection": 11,
"offsetInEndSection": 205,
"text": "Shunt treatment for hydrocephalus in children should aim for sustainable flexibility in regard to optional, perspective pressure level adjustment during advancing physical and mental development"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34152450",
"endSection": "abstract",
"offsetInBeginSection": 637,
"offsetInEndSection": 741,
"text": "hydrocephalic neonates and infants who received initial VP-shunt insertion in the early post-natal phase"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34152450",
"endSection": "abstract",
"offsetInBeginSection": 1424,
"offsetInEndSection": 1477,
"text": "primary VP-shunt insertion at a mean age of 10 weeks "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37402676",
"endSection": "abstract",
"offsetInBeginSection": 947,
"offsetInEndSection": 1057,
"text": "Shunt surgery is preferred for secondary hydrocephalus, especially for secondary normal pressure hydrocephalus"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21961546",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 98,
"text": "Ventriculoperitoneal (VP) shunt placement is the most common surgical treatment for hydrocephalus."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34774581",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 114,
"text": "BACKGROUND: Cerebrospinal fluid (CSF) diversion by shunts is the most common surgical treatment for hydrocephalus."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27203135",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 168,
"text": "OBJECTIVE The surgical placement of a shunt designed to resolve the brain's impaired ability to drain excess CSF is one of the most common treatments for hydrocephalus."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/17946960",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 124,
"text": "The most common treatment for patients with hydrocephalus is the surgical implantation of a cerebrospinal fluid (CSF) shunt."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26889393",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 124,
"text": "INTRODUCTION: Ventriculoperitoneal (V-P) shunt surgery is the most common technique used for the treatment of hydrocephalus."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/1474973",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 119,
"text": "Two hundred eight patients with non-tumoral congenital hydrocephalus underwent CSF shunting below the age of one month."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31286305",
"endSection": "abstract",
"offsetInBeginSection": 1305,
"offsetInEndSection": 1365,
"text": " All patients received VP shunts for hydrocephalus managemen"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25569424",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 95,
"text": "Cerebrospinal fluid shunt placement is the most common surgical intervention for hydrocephalus."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36780037",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 165,
"text": "OBJECTIVE: Ventriculoperitoneal shunt (VPS) surgery is a common treatment for hydrocephalus in children and adults, making it one of the most common procedures in ne"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31036124",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 227,
"text": "Ventriculoperitoneal shunt (VPS) placement is an effective and most frequently used surgical method in the treatment of hydrocephalus, but the mechanical and infective complications are often seen after this surgical procedure."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29122895",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 129,
"text": "Ventriculoperitoneal (VP) shunt surgery remains the most widely used neurosurgical procedure for the management of hydrocephalus."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/20045747",
"endSection": "abstract",
"offsetInBeginSection": 985,
"offsetInEndSection": 1139,
"text": "Hydrocephalus is treated with a ventriculo-peritoneal shunt but shunts in these patients suffer from frequent obstructions and require multiple revisions."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22222434",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 108,
"text": "Ventriculoperitoneal (VP) shunt surgery is the most common technique used in the treatment of hydrocephalus."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/11441995",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 119,
"text": "Ventriculoperitoneal (VP) shunts are among the most frequently performed operations in the management of hydrocephalus."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36314835",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 195,
"text": "Hydrocephalus is a common adult neurosurgical condition typically requiring treatment with a cerebrospinal fluid (CSF) shunt, of which the ventriculoperitoneal (VP) shunt is the most common type."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/15630948",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 90,
"text": "Ventriculoperitoneal (VP) shunts are the most common treatment modality for hydrocephalus."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36324983",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 167,
"text": "Background: Ventriculoperitoneal shunt (VPS) insertion and endoscopic third ventriculostomy (ETV) are common surgical procedures used to treat pediatric hydrocephalus."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30459864",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 160,
"text": "CONTEXT: Ventriculoperitoneal (VP) shunt and endoscopic third ventriculostomy (ETV) are the established surgical treatments for obstructive hydrocephalus (HCP)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22650109",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 175,
"text": "INTRODUCTION: Insertion of a ventriculoperitoneal (VP) shunt, the method of choice in the treatment of hydrocephalus, is often followed by various mechanical and/or infective "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22650109",
"endSection": "abstract",
"offsetInBeginSection": 1043,
"offsetInEndSection": 1303,
"text": "lved without any consequences.CONCLUSION: Insertion of a VP shunt represents the most frequent method of choice of the surgical treatment of hydrocephalus, but also potentially a highly risky procedure followed by various complications about which parents shou"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/19725301",
"endSection": "abstract",
"offsetInBeginSection": 811,
"offsetInEndSection": 900,
"text": "VP shunts are presently regarded as the standard of care for uncomplicated hydrocephalus."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35609726",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 171,
"text": "OBJECTIVE: Although ventriculoperitoneal shunt surgery is the most common method for hydrocephalus treatment, it may lead to serious complications and require surgical int"
}
] | 13
|
BioASQ-training13b
| null | null |
65f85ec7c4010b4d78000052
| 5,131
|
factoid
|
Gantenerumab was developed for treatment of which disease?
|
["Alzheimer's disease"]
|
[
"Alzheimer's disease",
"Alzheimer disease",
"AD",
"senile dementia of the Alzheimer type",
"Alzheimer's",
"Alzheimer's type dementia"
] |
["Gantenerumab was developed for Alzheimer's disease."]
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/24445401",
"http://www.ncbi.nlm.nih.gov/pubmed/32787971",
"http://www.ncbi.nlm.nih.gov/pubmed/26433971",
"http://www.ncbi.nlm.nih.gov/pubmed/29221491",
"http://www.ncbi.nlm.nih.gov/pubmed/36457865",
"http://www.ncbi.nlm.nih.gov/pubmed/34155411",
"http://www.ncbi.nlm.nih.gov/pubmed/24255592",
"http://www.ncbi.nlm.nih.gov/pubmed/22277519",
"http://www.ncbi.nlm.nih.gov/pubmed/36281062",
"http://www.ncbi.nlm.nih.gov/pubmed/24981190",
"http://www.ncbi.nlm.nih.gov/pubmed/29181492",
"http://www.ncbi.nlm.nih.gov/pubmed/36151869",
"http://www.ncbi.nlm.nih.gov/pubmed/36388611",
"http://www.ncbi.nlm.nih.gov/pubmed/36447240",
"http://www.ncbi.nlm.nih.gov/pubmed/22583155",
"http://www.ncbi.nlm.nih.gov/pubmed/37017737",
"http://www.ncbi.nlm.nih.gov/pubmed/33321511",
"http://www.ncbi.nlm.nih.gov/pubmed/35493943",
"http://www.ncbi.nlm.nih.gov/pubmed/32991803",
"http://www.ncbi.nlm.nih.gov/pubmed/36348972",
"http://www.ncbi.nlm.nih.gov/pubmed/31831056",
"http://www.ncbi.nlm.nih.gov/pubmed/37823690",
"http://www.ncbi.nlm.nih.gov/pubmed/36751779",
"http://www.ncbi.nlm.nih.gov/pubmed/30261916",
"http://www.ncbi.nlm.nih.gov/pubmed/35676943",
"http://www.ncbi.nlm.nih.gov/pubmed/31883703",
"http://www.ncbi.nlm.nih.gov/pubmed/36515320",
"http://www.ncbi.nlm.nih.gov/pubmed/37966285",
"http://www.ncbi.nlm.nih.gov/pubmed/25483498",
"http://www.ncbi.nlm.nih.gov/pubmed/34110536",
"http://www.ncbi.nlm.nih.gov/pubmed/27678025",
"http://www.ncbi.nlm.nih.gov/pubmed/35401412",
"http://www.ncbi.nlm.nih.gov/pubmed/35320578",
"http://www.ncbi.nlm.nih.gov/pubmed/21955818",
"http://www.ncbi.nlm.nih.gov/pubmed/35841240",
"http://www.ncbi.nlm.nih.gov/pubmed/21987394",
"http://www.ncbi.nlm.nih.gov/pubmed/28720101",
"http://www.ncbi.nlm.nih.gov/pubmed/25164658",
"http://www.ncbi.nlm.nih.gov/pubmed/36253511",
"http://www.ncbi.nlm.nih.gov/pubmed/29037101",
"http://www.ncbi.nlm.nih.gov/pubmed/35290498",
"http://www.ncbi.nlm.nih.gov/pubmed/24490853",
"http://www.ncbi.nlm.nih.gov/pubmed/33336218",
"http://www.ncbi.nlm.nih.gov/pubmed/38026755",
"http://www.ncbi.nlm.nih.gov/pubmed/35100444",
"http://www.ncbi.nlm.nih.gov/pubmed/36454709",
"http://www.ncbi.nlm.nih.gov/pubmed/37881360",
"http://www.ncbi.nlm.nih.gov/pubmed/29686315",
"http://www.ncbi.nlm.nih.gov/pubmed/28066098",
"http://www.ncbi.nlm.nih.gov/pubmed/26721364",
"http://www.ncbi.nlm.nih.gov/pubmed/28754630",
"http://www.ncbi.nlm.nih.gov/pubmed/25081412"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35841240",
"endSection": "abstract",
"offsetInBeginSection": 259,
"offsetInEndSection": 442,
"text": "Other anti-amyloid antibodies are under investigation in phase III (donanemab, lecanemab, gantenerumab) and have shown preliminary evidence of a cognitive benefit in phase II trials. "
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36447240",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 120,
"text": "Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36447240",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 219,
"text": "BACKGROUND: This review describes the research and development process of gantenerumab, a fully human anti-amyloid monoclonal antibody in development to treat early symptomatic and asymptomatic Alzheimer's disease (AD)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36447240",
"endSection": "abstract",
"offsetInBeginSection": 1026,
"offsetInEndSection": 1157,
"text": "BODY: Here, we review over 2 decades of gantenerumab development in the context of scientific discoveries in the broader AD field. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36447240",
"endSection": "abstract",
"offsetInBeginSection": 1666,
"offsetInEndSection": 1865,
"text": "CONCLUSION: The results from the gantenerumab phase 3 programs are expected by the end of 2022 and will add critical information to the collective knowledge on the search for effective AD treatments."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37017737",
"endSection": "abstract",
"offsetInBeginSection": 604,
"offsetInEndSection": 901,
"text": "METHODS: Sixty-six mutation-positive participants enrolled in the gantenerumab and placebo arms of the first Dominantly Inherited Alzheimer Network Trials Unit clinical trial (DIAN-TU-001) underwent both 11C-PiB and 18F-florbetapir PET imaging at baseline and during at least one follow-up visit. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36751779",
"endSection": "abstract",
"offsetInBeginSection": 543,
"offsetInEndSection": 847,
"text": "Two long-term, controlled trials on three anti-β-amyloid monoclonal antibodies (solanezumab, gantenerumab and crenezumab) in subjects carrying Alzheimer's disease-linked mutated genes encoding for amyloid precursor protein or presenilin 1 or presenilin 2 failed to show cognitive or functional benefits. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36281062",
"endSection": "abstract",
"offsetInBeginSection": 776,
"offsetInEndSection": 1062,
"text": "The model components were calibrated to data from the literature and internal studies, including quantitative data supporting the underlying AD biology and clinical data from clinical trials for anti-Aβ monoclonal antibodies (mAbs) aducanumab, crenezumab, gantenerumab, and solanezumab."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36515320",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 573,
"text": "INTRODUCTION: Recent published clinical trial safety data showed that 41% of Alzheimer patients experienced amyloid-related imaging abnormalities (ARIA), marks of microhemorrhages and edema in the brain, following administration of Biogen's Aduhelm/aducanumab (amino acids 3-7 of the Aβ peptide). Similarly, Janssen/Pfizer's Bapineuzumab (amino acids 1-5 of the Aβ peptide) and Roche's Gantenerumab (amino acids 2-11/18-27 of the Aβ peptide) also displayed ARIA in clinical trials, including microhemorrhage and focal areas of inflammation or vasogenic edema, respectively."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36388611",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 332,
"text": "Patients with Alzheimer's disease who have been given monoclonal antibodies targeting amyloid-β (Aβ) (eg, gantenerumab, donanemab, lecanemab, and aducanumab) for scientific purposes may have a spectrum of imaging findings known as amyloid-related imaging abnormalities (ARIA), shown on brain magnetic resonance imaging (MRI) scans. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37966285",
"endSection": "abstract",
"offsetInBeginSection": 167,
"offsetInEndSection": 362,
"text": "Gantenerumab is a subcutaneously administered, fully human, anti-Aβ IgG1 monoclonal antibody with highest affinity for aggregated Aβ that has been tested for the treatment of Alzheimer's disease."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37823690",
"endSection": "abstract",
"offsetInBeginSection": 260,
"offsetInEndSection": 546,
"text": "This study investigates a bispecific modular fusion protein composed of gantenerumab, a fully human monoclonal anti- amyloid-beta (Aβ) antibody under investigation for AD treatment, with a human transferrin receptor 1-directed Brainshuttle™ module (trontinemab; RG6102, INN trontinemab)"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37966285",
"endSection": "abstract",
"offsetInBeginSection": 167,
"offsetInEndSection": 650,
"text": "Gantenerumab is a subcutaneously administered, fully human, anti-Aβ IgG1 monoclonal antibody with highest affinity for aggregated Aβ that has been tested for the treatment of Alzheimer's disease.METHODS: We conducted two phase 3 trials (GRADUATE I and II) involving participants 50 to 90 years of age with mild cognitive impairment or mild dementia due to Alzheimer's disease and evidence of amyloid plaques on positron-emission tomography (PET) or cerebrospinal fluid (CSF) testing."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37966285",
"endSection": "abstract",
"offsetInBeginSection": 2025,
"offsetInEndSection": 2383,
"text": "Amyloid-related imaging abnormalities with edema (ARIA-E) occurred in 24.9% of the participants receiving gantenerumab, and symptomatic ARIA-E occurred in 5.0%.CONCLUSIONS: Among persons with early Alzheimer's disease, the use of gantenerumab led to a lower amyloid plaque burden than placebo at 116 weeks but was not associated with slower clinical decline."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21987394",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 445,
"text": "BACKGROUND: Gantenerumab is a fully human anti-Aβ monoclonal antibody in clinical development for the treatment of Alzheimer disease (AD).OBJECTIVES: To investigate whether treatment with gantenerumab leads to a measurable reduction in the level of Aβ amyloid in the brain and to elucidate the mechanism of amyloid reduction.DESIGN: A multicenter, randomized, double-blind, placebo-controlled, ascending-dose positron emission tomographic study."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24255592",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 82,
"text": "Profile of gantenerumab and its potential in the treatment of Alzheimer's disease."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37966285",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 64,
"text": "Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28754630",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 66,
"text": "Gantenerumab is intended for the treatment of Alzheimer's disease."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29181492",
"endSection": "abstract",
"offsetInBeginSection": 1332,
"offsetInEndSection": 1515,
"text": " gantenerumab, and an anti-tau monoclonal antibody, RO7105705, as well as a robust biomarker platform to aid in the early identification of people at risk or in the early stages of AD"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31883703",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 240,
"text": "PURPOSE: Gantenerumab, a fully human anti-amyloid-β IgG1 monoclonal antibody that binds to aggregated forms of amyloid-β, is being investigated as a potential disease-modifying treatment for early (prodromal to mild) Alzheimer disease (AD)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24255592",
"endSection": "abstract",
"offsetInBeginSection": 729,
"offsetInEndSection": 1045,
"text": "Gantenerumab is an investigational fully human anti-amyloid beta monoclonal antibody with a high capacity to bind and remove beta-amyloid plaques in the brain. This compound, currently undergoing Phase II and III clinical trials represents a promising agent with a disease-modifying potential in Alzheimer's disease."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24490853",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1065,
"text": "Both active and passive anti-β-amyloid (Aβ) immunotherapies for the treatment of Alzheimer's disease (AD) have demonstrated clearance of brain Aβ deposits. Among passive immunotherapeutics, two Phase III clinical trials in mild-to-moderate AD patients with bapineuzumab, a humanized monoclonal antibody directed at the N-terminal sequence of Aβ, were disappointing. Also solanezumab, directed at the mid-region of Aβ, failed in two Phase III trials in mild-to-moderate AD. Another Phase III trial with solanezumab is ongoing in mildly affected AD patients based on encouraging results in this subgroup. Second-generation active Aβ vaccines (CAD106, ACC-001, and Affitope AD02) and new passive anti-Aβ immunotherapies (gantenerumab and crenezumab) have been developed and are under clinical testing. These new anti-Aβ immunotherapies are being tested in prodromal AD, in presymptomatic subjects with AD-related mutations, or in asymptomatic subjects at risk of developing AD. These primary and secondary prevention trials will definitely test the Aβ cascade hypothes"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24445401",
"endSection": "abstract",
"offsetInBeginSection": 1080,
"offsetInEndSection": 1496,
"text": " encouraging results in this subgroup of patients. Second-generation active Aβ vaccines (ACC-001, CAD106, and Affitope AD02) and new passive anti-Aβ immunotherapies (gantenerumab and crenezumab) are being tested in prodromal Alzheimer's disease patients, in presymptomatic individuals with Alzheimer's disease-related mutations, or in asymptomatic individuals at risk of developing Alzheimer's disease to definitely "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29037101",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 798,
"text": "INTRODUCTION: The recent failure of several clinical trials on anti-β-amyloid (Aβ) drugs in Alzheimer's disease (AD) suggested earlier intervention in the disease course. Secondary prevention trials have been started in autosomal-dominant AD (ADAD) individuals without cognitive dysfunction and in cognitively healthy subjects at risk of developing sporadic AD (SAD).AREAS COVERED: Herein, the authors discuss prevention trials in ADAD and SAD, with a focus on the anti-Aβ monoclonal antibodies solanezumab and gantenerumab presently in Phase III clinical development. These therapies are also being tested in the Dominantly Inherited Alzheimer's Network Trials Unit (DIAN-TU).EXPERT OPINION: Anti-Aβ monoclonal antibodies are being tested in subjects at the preclinical stage of ADAD and even in s"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35100444",
"endSection": "abstract",
"offsetInBeginSection": 246,
"offsetInEndSection": 490,
"text": "Gantenerumab, a fully human monoclonal antibody (mAb) that binds to aggregated amyloid-beta, was tested in two 24-month phase III studies (NCT01224106, NCT02051608) in participants with prodromal and mild Alzheimer's disease (AD), respectively."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36457865",
"endSection": "abstract",
"offsetInBeginSection": 522,
"offsetInEndSection": 928,
"text": "The 16 compounds selected include disease-modifying therapies and symptomatic therapies. The research and development pipeline now focuses on disease-modifying therapies such as gantenerumab, aducanumab, ALZ-801, ALZT-OP1, donanemab, lecanemab, simufilam, NE3107, semaglutide, and GV-971, which could put an end to the situation where Alzheimer's patients in China have no effective treatment alternatives."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35676943",
"endSection": "abstract",
"offsetInBeginSection": 372,
"offsetInEndSection": 592,
"text": "en-label extension of SCarlet RoAD (a study of gantenerumab in participants with prodromal Alzheimer's disease) and Marguerite RoAD (as study of Gantenerumab in participants with mild Alzheimer's disease) studies were us"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28754630",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 98,
"text": "Gantenerumab is intended for the treatment of Alzheimer's disease. It is a fully human recombinant"
}
] | 13
|
BioASQ-training13b
| null | null |
65cfa37c1930410b1300000d
| 5,135
|
factoid
|
What is the administration route of zavegepant?
|
['intranasally', 'nasal spray']
|
[
"intranasally",
"nasal spray",
"intranasal",
"nasal delivery",
"nasal administration"
] |
['Zavegepant is administered intranasally and used for migraine attacks.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/37227596",
"http://www.ncbi.nlm.nih.gov/pubmed/37345774",
"http://www.ncbi.nlm.nih.gov/pubmed/33096162",
"http://www.ncbi.nlm.nih.gov/pubmed/36804093",
"http://www.ncbi.nlm.nih.gov/pubmed/37904462",
"http://www.ncbi.nlm.nih.gov/pubmed/37363553",
"http://www.ncbi.nlm.nih.gov/pubmed/36239038",
"http://www.ncbi.nlm.nih.gov/pubmed/36189708",
"http://www.ncbi.nlm.nih.gov/pubmed/37038933"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37345774",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 107,
"text": "Zavegepant (Zavzpret), a nasal spray, is approved to treat adults with acute migraine with or without aura."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37038933",
"endSection": "abstract",
"offsetInBeginSection": 405,
"offsetInEndSection": 658,
"text": "Ubrogepant is ratified for acute migraine treatment, atogepant is validated for preventive therapy, whereas rimegepant is ratified for both indications, all via oral administration and while zavegepant is administered intranasally for migraine attacks. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37227596",
"endSection": "abstract",
"offsetInBeginSection": 246,
"offsetInEndSection": 403,
"text": "In March 2023, zavegepant nasal spray (ZAVZPRET™) received its first approval in the USA for the acute treatment of migraine with or without aura in adults. "
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36804093",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 189,
"text": "Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36804093",
"endSection": "abstract",
"offsetInBeginSection": 187,
"offsetInEndSection": 349,
"text": "Zavegepant, an intranasally administered small molecule calcitonin gene-related peptide (CGRP) receptor antagonist, was previously assessed in a phase 2/3 trial. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36804093",
"endSection": "abstract",
"offsetInBeginSection": 2868,
"offsetInEndSection": 3015,
"text": "INTERPRETATION: Zavegepant 10 mg nasal spray was efficacious in the acute treatment of migraine, with favourable tolerability and safety profiles. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37363553",
"endSection": "abstract",
"offsetInBeginSection": 267,
"offsetInEndSection": 457,
"text": "Zavegepant is a novel, first-in-class, intranasally administered calcitonin gene-related peptide (CGRP) receptor antagonist that has recently been approved for use in acute migraine attacks."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37363553",
"endSection": "abstract",
"offsetInBeginSection": 817,
"offsetInEndSection": 1034,
"text": "Moreover, the intranasal method of administration is a characteristic advantage of Zavegepant, as patients suffering from acute migraine attacks cannot easily ingest oral medication, due to severe nausea and vomiting."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37363553",
"endSection": "abstract",
"offsetInBeginSection": 1035,
"offsetInEndSection": 1280,
"text": "In this mini-review, the efficacy and safety of Zavegepant will be compared with those of alternative treatments available for migraines, including oral triptans, intranasal triptans, and other CGRP antagonists currently available in the market."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37038933",
"endSection": "abstract",
"offsetInBeginSection": 405,
"offsetInEndSection": 657,
"text": "Ubrogepant is ratified for acute migraine treatment, atogepant is validated for preventive therapy, whereas rimegepant is ratified for both indications, all via oral administration and while zavegepant is administered intranasally for migraine attacks."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33096162",
"endSection": "abstract",
"offsetInBeginSection": 128,
"offsetInEndSection": 410,
"text": "Zavegepant (BHV-3500, BMS-742413) is a high affinity antagonist of the CGRP receptor (hCGRP Ki = 0.023 nM) that has demonstrated efficacy in the acute treatment of migraine with intranasal delivery in a Phase 2/3 trial, despite showing low oral bioavailability in rats (FPO = 1.7%)."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36189708",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 66,
"text": "Focus on zavegepant: the first intranasal third-generation gepant."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37904462",
"endSection": "abstract",
"offsetInBeginSection": 12,
"offsetInEndSection": 194,
"text": "Zavegepant nasal spray is a novel CGRP receptor antagonist that has been developed for the acute treatment of migraine - a prevalent disease leading to disability and economic burden"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37904462",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 106,
"text": "BACKGROUND: Zavegepant nasal spray is a novel CGRP receptor antagonist that has been developed for the acu"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36239038",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 137,
"text": "OBJECTIVE: Evaluate the efficacy, safety, and tolerability of zavegepant nasal spray in the acute treatment of migraine.BACKGROUND: Calci"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36804093",
"endSection": "abstract",
"offsetInBeginSection": 175,
"offsetInEndSection": 336,
"text": "d vomiting. Zavegepant, an intranasally administered small molecule calcitonin gene-related peptide (CGRP) receptor antagonist, was previously assessed in a phas"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36189708",
"endSection": "abstract",
"offsetInBeginSection": 169,
"offsetInEndSection": 350,
"text": "Newly approved small molecules that antagonize the CGRP receptor, gepants, have advanced from the hepatotoxic first-generation telcagepant to third-generation intranasal zavegepant;"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36239038",
"endSection": "abstract",
"offsetInBeginSection": 281,
"offsetInEndSection": 491,
"text": " for acute treatment. Zavegepant, a high-affinity, selective, and structurally unique calcitonin gene-related peptide-receptor antagonist in late-stage development, is formulated as a nasal spray for the acute "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36804093",
"endSection": "abstract",
"offsetInBeginSection": 809,
"offsetInEndSection": 982,
"text": "e attacks per month. Participants were randomly assigned (1:1) to zavegepant 10 mg nasal spray or matching placebo and self-treated a single migraine attack of moderate or s"
}
] | 13
|
BioASQ-training13b
| null | null |
65d1357c1930410b13000039
| 5,138
|
factoid
|
What is the first line treatment for severe Plasmodium falciparum malaria?
|
['Artesunate', 'intravenous artesunate', 'IV artesunate', 'parenteral artesunate']
|
[
"Artesunate",
"intravenous artesunate",
"IV artesunate",
"parenteral artesunate",
"artesunate"
] |
['Intravenous artesunate', 'parenteral artesunate (ARS)', 'Parenteral artesunate is the first-line treatment for severe Plasmodium falciparum malaria.', 'Parenteral artesunate (ARS) is the first-line treatment for severe falciparum malaria.', 'Intravenous artesunate is the first-line treatment for severe falciparum malaria.', 'Intravenous artesunate is the first-line treatment for severe Plasmodium falciparum malaria. If artesunate is not available, intravenous quinine should be started immediately as an alternative treatment.', 'The first-line treatment for severe Plasmodium falciparum malaria is intravenous artesunate.', 'Intravenous artesunate is the first line treatment for severe Plasmodium falciparum malaria.', '- For severe Plasmodium falciparum malaria, intravenous artesunate is the recommended first-line treatment. Intravenous artesunate is administered for 24 hours after clinical improvement is observed, followed by a full course of artemisinin-based combination therapy (ACT).', 'Parenteral artesunate (ARS) is the first-line treatment for severe Plasmodium falciparum malaria.', 'Yes, artesunate is the first-line treatment for severe malaria.', 'Parenteral artesunate is the first-line treatment for severe falciparum malaria.', 'Intravenous artesunate is the first-line treatment for severe Plasmodium falciparum malaria.', 'The first-line treatment for severe Plasmodium falciparum malaria is parenteral artesunate (ARS), which can be administered intravenously or intramuscularly.', 'The first-line treatment for severe Plasmodium falciparum malaria is parenteral artesunate (ARS). This is the global standard of care for severe malaria.', 'The first-line treatment for severe Plasmodium falciparum malaria is parenteral artesunate (ARS). This is also known as intravenous artesunate and is recognized as the global standard of care for severe malaria.', 'Intravenous artesunate is the first-line treatment and global standard of care for severe falciparum malaria.', 'Injectable artesunate is the first line treatment for severe Plasmodium falciparum malaria.', 'The first-line treatment for severe Plasmodium falciparum malaria is intravenous artesunate. WHO recommends artesunate for the first 24 hours, followed by a combination of artemisinin derivatives and oral lumefantrine, for a total of 3 days.', 'The first-line treatment for severe Plasmodium falciparum malaria is parenteral artesunate (ARS).', 'First line treatment in severe Plasmodium falciparum malaria is artesunate.', 'The first-line treatment for severe Plasmodium falciparum malaria is injectable artesunate.', 'First-line treatment of severe P. falciparum malaria is based on IV artesunate.', 'The first-line treatment for severe Plasmodium falciparum malaria is parenteral or intravenous artesunate.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/30885541",
"http://www.ncbi.nlm.nih.gov/pubmed/36056897",
"http://www.ncbi.nlm.nih.gov/pubmed/34561157",
"http://www.ncbi.nlm.nih.gov/pubmed/22453057",
"http://www.ncbi.nlm.nih.gov/pubmed/36126008",
"http://www.ncbi.nlm.nih.gov/pubmed/23350023",
"http://www.ncbi.nlm.nih.gov/pubmed/22818552",
"http://www.ncbi.nlm.nih.gov/pubmed/25163350",
"http://www.ncbi.nlm.nih.gov/pubmed/27809844",
"http://www.ncbi.nlm.nih.gov/pubmed/33685888",
"http://www.ncbi.nlm.nih.gov/pubmed/25069406",
"http://www.ncbi.nlm.nih.gov/pubmed/31843017",
"http://www.ncbi.nlm.nih.gov/pubmed/15642960",
"http://www.ncbi.nlm.nih.gov/pubmed/33344893",
"http://www.ncbi.nlm.nih.gov/pubmed/27089770",
"http://www.ncbi.nlm.nih.gov/pubmed/26832999",
"http://www.ncbi.nlm.nih.gov/pubmed/24659706",
"http://www.ncbi.nlm.nih.gov/pubmed/26880088",
"http://www.ncbi.nlm.nih.gov/pubmed/35916842",
"http://www.ncbi.nlm.nih.gov/pubmed/22966778",
"http://www.ncbi.nlm.nih.gov/pubmed/35857773",
"http://www.ncbi.nlm.nih.gov/pubmed/32228566",
"http://www.ncbi.nlm.nih.gov/pubmed/16923176",
"http://www.ncbi.nlm.nih.gov/pubmed/30983213",
"http://www.ncbi.nlm.nih.gov/pubmed/37666798",
"http://www.ncbi.nlm.nih.gov/pubmed/25348537",
"http://www.ncbi.nlm.nih.gov/pubmed/19881520",
"http://www.ncbi.nlm.nih.gov/pubmed/27613271",
"http://www.ncbi.nlm.nih.gov/pubmed/27449110",
"http://www.ncbi.nlm.nih.gov/pubmed/26483118",
"http://www.ncbi.nlm.nih.gov/pubmed/35326891",
"http://www.ncbi.nlm.nih.gov/pubmed/25217396",
"http://www.ncbi.nlm.nih.gov/pubmed/17402835",
"http://www.ncbi.nlm.nih.gov/pubmed/23121274"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36056897",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 78,
"text": "Intravenous artesunate has been the global standard of care for severe malaria"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37666798",
"endSection": "abstract",
"offsetInBeginSection": 67,
"offsetInEndSection": 152,
"text": "Parenteral artesunate (ARS) is the first-line treatment for severe falciparum malaria"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36126008",
"endSection": "abstract",
"offsetInBeginSection": 1560,
"offsetInEndSection": 1628,
"text": "Intravenous artesunate is the treatment of choice for severe malaria"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26832999",
"endSection": "abstract",
"offsetInBeginSection": 243,
"offsetInEndSection": 421,
"text": "The first line treatments for Plasmodium falciparum are artemisinin combination therapies, chloroquine in most non-falciparum and intravenous artesunate if any severity criteria."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/16923176",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 212,
"text": "BACKGROUND: In Zambia, unacceptably high resistance to commonly used antimalarial drugs prompted the choice of artemether-lumefantrine (AL) as first line treatment for uncomplicated Plasmodium falciparum malaria."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/16923176",
"endSection": "abstract",
"offsetInBeginSection": 1338,
"offsetInEndSection": 1646,
"text": "Total treatment failure was significantly higher in the SP group (96/393; 19.3%) as compared to the AL (22/403; 5.4%) group (OR: 4.15; 95% CI: 2.52-6.83; P < 0.001).CONCLUSION: In Zambia, the new first line regimen AL is far more efficacious than SP in treating uncomplicated P. falciparum malaria in adults."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/17402835",
"endSection": "abstract",
"offsetInBeginSection": 668,
"offsetInEndSection": 745,
"text": "Artesunate should constitute first-line treatment for severe malaria in Asia."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27613271",
"endSection": "abstract",
"offsetInBeginSection": 84,
"offsetInEndSection": 268,
"text": "Artesunate has become the treatment of choice for severe malaria, and artemisinin-based combination therapies (ACTs) are the foundation of modern falciparum malaria treatment globally."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/15642960",
"endSection": "abstract",
"offsetInBeginSection": 284,
"offsetInEndSection": 469,
"text": "Combination therapy through coadministration of sulfadoxine-pyrimethamine plus artesunate was introduced as a first-line treatment for uncomplicated malaria in one district in Tanzania."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35916842",
"endSection": "abstract",
"offsetInBeginSection": 1368,
"offsetInEndSection": 1471,
"text": "First-line therapy for P falciparum malaria in the US is combination therapy that includes artemisinin."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22453057",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 144,
"text": "Intravenous (i.v.) artesunate is now the recommended first-line treatment of severe falciparum malaria in adults and children by WHO guidelines."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33685888",
"endSection": "abstract",
"offsetInBeginSection": 92,
"offsetInEndSection": 179,
"text": "Intravenous (i.v.) artesunate is the first-line treatment for severe falciparum malaria"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35326891",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 113,
"text": "Parenteral artesunate (AS) is the WHO first-line treatment recommended in adults and children for severe malaria."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25163350",
"endSection": "abstract",
"offsetInBeginSection": 1410,
"offsetInEndSection": 1511,
"text": "IV artesunate is now recommended as the first-line treatment for severe falciparum malaria in France."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37666798",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 153,
"text": "The majority of deaths from malaria are in young African children. Parenteral artesunate (ARS) is the first-line treatment for severe falciparum malaria."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25217396",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 208,
"text": "BACKGROUND: In sub-Saharan Africa, artemisinin-based combination therapy (ACT) and injectable artesunate are the first-line treatments for uncomplicated and severe Plasmodium falciparum malaria, respectively."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33344893",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 209,
"text": "The first-line treatments for uncomplicated Plasmodium falciparum malaria are artemisinin-based combination therapies (ACTs), consisting of an artemisinin derivative combined with a longer acting partner drug."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35916842",
"endSection": "abstract",
"offsetInBeginSection": 2762,
"offsetInEndSection": 2826,
"text": "Intravenous artesunate is first-line therapy for severe malaria."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25348537",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 118,
"text": "Artemisinin-based combination therapy (ACT) is the recommended first-line treatment for Plasmodium falciparum malaria."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/19881520",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 207,
"text": "Plasmodium falciparum resistance to chloroquine and sulphadoxine-pyrimethamine has led to the recent adoption of artemisinin-based combination therapies (ACTs) as the first line of treatment against malaria."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25069406",
"endSection": "abstract",
"offsetInBeginSection": 1121,
"offsetInEndSection": 1200,
"text": "First-line treatment of severe P. falciparum malaria is based on IV artesunate."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27809844",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 136,
"text": "BACKGROUND: Artemisinin combination therapy (ACT) is used worldwide as the first-line treatment against uncomplicated Plasmodium falcipa"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23121274",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 329,
"text": "Artemisinin-based combination therapies (ACTs) have been adopted as the first line of treatment against malaria in nearly all malaria-endemic countries, mainly as a result of Plasmodium falciparum infection, as this species of malaria parasite has developed resistance to most of the available non-artemisinin antimalarial drugs."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27449110",
"endSection": "abstract",
"offsetInBeginSection": 84,
"offsetInEndSection": 231,
"text": "of malaria. Artemisinin-based combination therapy (ACT) is the WHO recommended first-line treatment for Plasmodium falciparum malaria across the en"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22818552",
"endSection": "abstract",
"offsetInBeginSection": 141,
"offsetInEndSection": 313,
"text": "d in India. By 2007, the first-line treatment for uncomplicated malaria has been revised to recommend artemisinin-based combination therapy (ACT) for all confirmed P. falci"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24659706",
"endSection": "abstract",
"offsetInBeginSection": 276,
"offsetInEndSection": 380,
"text": "The World Health Organisation (WHO) recommends arthemether combination treatment as a first line choice."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30983213",
"endSection": "abstract",
"offsetInBeginSection": 437,
"offsetInEndSection": 589,
"text": "The main advance is the positioning of artemisinin derivative- based combinations as first-line, given their rapidity of action and their effectiveness."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27089770",
"endSection": "abstract",
"offsetInBeginSection": 82,
"offsetInEndSection": 247,
"text": "As recommended by the World Health Organization, the ART-based combination therapies (ACTs) have become the first-line drugs for the treatment of falciparum malaria."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31843017",
"endSection": "abstract",
"offsetInBeginSection": 1526,
"offsetInEndSection": 1757,
"text": "ost-treatment QTc interval.CONCLUSION: Artenimol-piperaquine displays a satisfying efficacy and tolerance profile as a first-line treatment for children with imported uncomplicated falciparum malaria and only necessitates three onc"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25217396",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 196,
"text": "BACKGROUND: In sub-Saharan Africa, artemisinin-based combination therapy (ACT) and injectable artesunate are the first-line treatments for uncomplicated and severe Plasmodium falciparum malaria, r"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26880088",
"endSection": "abstract",
"offsetInBeginSection": 2347,
"offsetInEndSection": 2674,
"text": "Uncomplicated P. falciparum malaria should be treated with an artemisinin combination therapy (Grade 1A). Artemether-lumefantrine (Riamet(®)) is the drug of choice (Grade 2C) and dihydroartemisinin-piperaquine (Eurartesim(®)) is an alternative. Quinine or atovaquone-proguanil (Malarone(®)) can be used if an ACT is not availab"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30885541",
"endSection": "abstract",
"offsetInBeginSection": 1195,
"offsetInEndSection": 1322,
"text": "The first-line treatment of severe malaria is now intravenous artesunate which is more effective than quinine in endemic areas."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22966778",
"endSection": "abstract",
"offsetInBeginSection": 22,
"offsetInEndSection": 305,
"text": "as recently undergone a rapid decline in Plasmodium falciparum transmission following combined malaria control interventions with artemisinin-based combination therapy (ACT) and integrated vector control. Artesunate-amodiaquine (ASAQ) was implemented as first-line treatment for unco"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32228566",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 232,
"text": "BACKGROUND: In 2006, the Senegalese National Malaria Control Programme recommended artemisinin-based combination therapy (ACT) with artemether-lumefantrine as the first-line treatment for uncomplicated Plasmodium falciparum malaria."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35916842",
"endSection": "abstract",
"offsetInBeginSection": 2010,
"offsetInEndSection": 2075,
"text": "For severe malaria, intravenous artesunate is first-line therapy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34561157",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 186,
"text": "In the early 2000s, artemisinin-based combination therapy (ACT) was introduced as first-line treatment for uncomplicated Plasmodium falciparum malaria in virtually all endemic countries."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26483118",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 119,
"text": "Artemisinin combination therapy (ACT) is the first line to treat uncomplicated Plasmodium falciparum malaria worldwide."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26880088",
"endSection": "abstract",
"offsetInBeginSection": 3197,
"offsetInEndSection": 3515,
"text": "2. The treatment of choice for severe or complicated malaria in adults and children is intravenous artesunate (Grade 1A). Intravenous artesunate is unlicensed in the EU but is available in many centres. The alternative is intravenous quinine, which should be started immediately if artesunate is not available (Grade 1"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35857773",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 114,
"text": "BACKGROUND: The artemisinin derivatives are the preferred antimalaria drugs for treating severe Plasmodium falcipa"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23350023",
"endSection": "abstract",
"offsetInBeginSection": 2225,
"offsetInEndSection": 2422,
"text": "For severe malaria, in the second and third trimester parenteral artesunate is preferred over quinine. In the first trimester, both artesunate and quinine (parenteral) may be considered as options."
}
] | 13
|
BioASQ-training13b
| null | null |
65f82058c4010b4d7800003d
| 5,143
|
factoid
|
What is the use of lebrikizumab?
|
['atopic dermatitis']
|
[
"atopic dermatitis",
"eczema",
"atopic eczema",
"allergic dermatitis",
"flexural eczema",
"infantile eczema",
"neurodermatitis"
] |
['Lebrikizumab scan be used for moderate-to-severe atopic dermatitis.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/37266844",
"http://www.ncbi.nlm.nih.gov/pubmed/36630140",
"http://www.ncbi.nlm.nih.gov/pubmed/36948491",
"http://www.ncbi.nlm.nih.gov/pubmed/36994947",
"http://www.ncbi.nlm.nih.gov/pubmed/37401345"
] |
[
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36630140",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 186,
"text": "Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36630140",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 274,
"text": "Importance: Lebrikizumab (LEB), a high-affinity monoclonal antibody targeting interleukin (IL)-13, demonstrated efficacy and safety in patients with moderate-to-severe atopic dermatitis (AD) during 16 weeks of monotherapy in a phase 2b trial, and two 52-week phase 3 trials."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36630140",
"endSection": "abstract",
"offsetInBeginSection": 2555,
"offsetInEndSection": 2810,
"text": "Conclusions and Relevance: In this randomized phase 3 clinical trial, LEB+TCS was associated with improved outcomes in adolescents and adults with moderate-to-severe AD compared with TCS alone, and safety was consistent with previously reported AD trials."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36948491",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 477,
"text": "The U.S. Food and Drug Administration approval of dupilumab for moderate-to-severe atopic dermatitis shifted the paradigm from use of broad, systemic immunosuppressants to a safer, targeted treatment and led to the emergence of newer interleukin (IL)-4/IL-13 directed biologics and small molecule therapies, namely Janus kinase (JAK) inhibitors (JAKi). Tralokinumab and emerging (not yet approved) lebrikizumab, which both target IL-13, are alternative biologics to dupilumab. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37401345",
"endSection": "abstract",
"offsetInBeginSection": 133,
"offsetInEndSection": 200,
"text": " This review characterizes lebrikizumab as AD treatment in adults. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37401345",
"endSection": "abstract",
"offsetInBeginSection": 770,
"offsetInEndSection": 871,
"text": "Results from clinical trials suggest that lebrikizumab may be a viable alternative for AD management."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36994947",
"endSection": "abstract",
"offsetInBeginSection": 1768,
"offsetInEndSection": 2009,
"text": "CONCLUSIONS: After a 16-week induction period with lebrikizumab Q2W, lebrikizumab Q2W and Q4W maintained similar improvement of the signs and symptoms of moderate-to-severe AD, with a safety profile consistent with previously published data."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36994947",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 355,
"text": "BACKGROUND: Lebrikizumab is a novel, high-affinity monoclonal antibody that selectively binds to interleukin (IL)-13.OBJECTIVES: To evaluate the efficacy and safety of lebrikizumab monotherapy in adolescent and adult patients with moderate-to-severe atopic dermatitis (AD) over 52 weeks of treatment in ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967)."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37266844",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 71,
"text": "Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37266844",
"endSection": "abstract",
"offsetInBeginSection": 1243,
"offsetInEndSection": 1356,
"text": "Lebrikizumab seems to be a promising emerging targeted biological agent for patients with moderate-to-severe AD. "
}
] | 13
|
BioASQ-training13b
| null | null |
65d36e761930410b13000044
| 5,150
|
factoid
|
Coffee Bean Sign is characteristic to which disease?
|
['volvulus', 'sigmoid volvulus']
|
[
"volvulus",
"sigmoid volvulus",
"intestinal volvulus",
"colonic volvulus",
"twisted bowel",
"bowel obstruction",
"volvulus of the sigmoid colon"
] |
['Coffee Bean Sign is characteristic to volvulus.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/37761402",
"http://www.ncbi.nlm.nih.gov/pubmed/35773776",
"http://www.ncbi.nlm.nih.gov/pubmed/33088563",
"http://www.ncbi.nlm.nih.gov/pubmed/36168370",
"http://www.ncbi.nlm.nih.gov/pubmed/18322966",
"http://www.ncbi.nlm.nih.gov/pubmed/36779459",
"http://www.ncbi.nlm.nih.gov/pubmed/20028915",
"http://www.ncbi.nlm.nih.gov/pubmed/28626382",
"http://www.ncbi.nlm.nih.gov/pubmed/35859918",
"http://www.ncbi.nlm.nih.gov/pubmed/36263824"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35773776",
"endSection": "abstract",
"offsetInBeginSection": 1020,
"offsetInEndSection": 1669,
"text": ". In addition, X-ray signs including disproportionate sigmoid dilatation, distended inverted 'U' in sigmoid, coffee bean sign, opposed wall sign, direction of apex of sigmoid loop, liver overlap sign, northern exposure sign and proximal colonic dilatation and CT features including whirl sign, 'X' marks the spot sign, split wall sign and number of transition points were reported for each case. The clinical management and outcomes including morbidity, mortality, endoscopic decompression and need for surgery were also evaluated. The subtype of volvulus was correlated with the above X-ray signs, CT features and clinical management and outcomes. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36779459",
"endSection": "abstract",
"offsetInBeginSection": 396,
"offsetInEndSection": 441,
"text": "Coffee bean sign was seen in abdominal x-ray."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37761402",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 746,
"text": "Sigmoid volvulus (SV) occurs rarely in children. After encountering two cases of recurrent SV, we reviewed the literature to define the recurrence risk, identify outcome predictors and to give treatment recommendations. We found 256 cases reported in children (mean age 10.2 years, gender ratio (m:f) 2.3:1). Associations exist with Hirschsprung disease (HD) in 10%, neurodevelopmental disorders in 10.9% and chronic constipation in 10.2%. Common symptoms and clinical signs were abdominal pain (85%), distension (85%), tenderness (54%) and vomiting (59%). Signs of peritonitis were present in 14% and indicated a gangrenous sigmoid (X2 = 45.33; p < 0.001). A total of 183 had abdominal radiographs, and 65% showed a positive 'coffee-bean-sign'. "
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36263824",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 69,
"text": "Coffee bean sign, steel pan sign, and whirl sign in sigmoid volvulus."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36263824",
"endSection": "abstract",
"offsetInBeginSection": 55,
"offsetInEndSection": 249,
"text": "A plain radiograph showed the coffee bean sign, suggesting sigmoid volvulus (SV). The CT scans disclosed the steel pan sign, the whirl sign, and the beak-shaped transition point, confirming SV. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35859918",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 134,
"text": "Teaching Point: The coffee bean sign, the whirl sign, and the bird's beak sign are the key findings on abdominal CT of cecal volvulus."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36263824",
"endSection": "abstract",
"offsetInBeginSection": 55,
"offsetInEndSection": 135,
"text": "A plain radiograph showed the coffee bean sign, suggesting sigmoid volvulus (SV)"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36263824",
"endSection": "abstract",
"offsetInBeginSection": 55,
"offsetInEndSection": 307,
"text": "A plain radiograph showed the coffee bean sign, suggesting sigmoid volvulus (SV). The CT scans disclosed the steel pan sign, the whirl sign, and the beak-shaped transition point, confirming SV. He improved with colonoscopic decompression and detorsion."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33088563",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 74,
"text": "The presence of the coffee bean sign is pathognomonic of sigmoid volvulus."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/20028915",
"endSection": "abstract",
"offsetInBeginSection": 585,
"offsetInEndSection": 941,
"text": "CT findings suggesting bowel compromise were compared with pathologic and endoscopic findings.RESULTS: The most sensitive scanogram findings were absence of rectal gas (19 of 21 cases, 90%) and an inverted-U-shaped distended sigmoid (18 of 21 cases, 86%) followed by the coffee bean sign and disproportionate sigmoid enlargement (both 16 of 21 cases, 76%)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18322966",
"endSection": "abstract",
"offsetInBeginSection": 836,
"offsetInEndSection": 1055,
"text": "Preterm labor, specific prenatal sonographic findings (for example, the coffee bean sign) and bluish discoloration of the abdominal wall could suggest intrauterine midgut volvulus requiring prompt surgical intervention."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28626382",
"endSection": "abstract",
"offsetInBeginSection": 503,
"offsetInEndSection": 589,
"text": "A plain abdominal X-ray demonstrated a coffee bean sign indicating a sigmoid volvulus."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36263824",
"endSection": "abstract",
"offsetInBeginSection": 55,
"offsetInEndSection": 136,
"text": "A plain radiograph showed the coffee bean sign, suggesting sigmoid volvulus (SV)."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28626382",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 50,
"text": "A Symptomatic Coffee Bean: Acute Sigmoid Volvulus."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36263824",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 136,
"text": "A 66-year-old man presented with abdominal distension. A plain radiograph showed the coffee bean sign, suggesting sigmoid volvulus (SV)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36263824",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 248,
"text": "A 66-year-old man presented with abdominal distension. A plain radiograph showed the coffee bean sign, suggesting sigmoid volvulus (SV). The CT scans disclosed the steel pan sign, the whirl sign, and the beak-shaped transition point, confirming SV."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36263824",
"endSection": "abstract",
"offsetInBeginSection": 55,
"offsetInEndSection": 248,
"text": "A plain radiograph showed the coffee bean sign, suggesting sigmoid volvulus (SV). The CT scans disclosed the steel pan sign, the whirl sign, and the beak-shaped transition point, confirming SV."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18322966",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 88,
"text": "Intrauterine midgut volvulus without malrotation: diagnosis from the 'coffee bean sign'."
}
] | 13
|
BioASQ-training13b
| null | null |
65d144b81930410b13000041
| 5,162
|
factoid
|
What process does tRNA nucleotidyl transferase 1 (TRNT1) catalyze?
|
["Addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs)"]
|
[
"CCA",
"cytosine-cytosine-adenine",
"cytosine/adenine",
"addition of CCA",
"addition of the trinucleotide CCA",
"addition of the trinucleotide cytosine/cytosine/adenine",
"3' end addition of CCA",
"3' end addition of cytosine/cytosine/adenine"
] |
["tRNA nucleotidyl transferase 1 (TRNT1) catalyzes the addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs).", 'The tRNA nucleotidyl transferase 1 (TRNT1) catalyzes the addition of terminal cytosine-cytosine-adenosine (CCA) trinucleotides to all mature tRNAs, which is necessary for aminoacylation.', "tRNA nucleotidyl transferase 1 (TRNT1) catalyzes the addition of CCA nucleotides to the 3' end of tRNA molecules during tRNA maturation.", "tRNA nucleotidyl transferase 1 (TRNT1) catalyzes the addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs), which is essential for translation and functions in both the cytoplasm and mitochondria.", "tRNA nucleotidyl transferase 1 (TRNT1) catalyzes the addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs), a crucial process for translation.", "The TRNT1 enzyme catalyzes the addition of the trinucleotide CCA to the 3' end of tRNAs.", 'TRNT1 gene encodes a CCA-adding tRNA nucleotidyl transferase enzyme.', "tRNA nucleotidyl transferase 1 (TRNT1) catalyzes the addition of the trinucleotide cytosine-cytosine-adenine (CCA) sequence to the 3' end of transfer RNAs (tRNAs). This CCA addition is essential for tRNA function in protein translation.", "tRNA nucleotidyl transferase 1 (TRNT1) catalyzes the addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs), which is essential for translation", 'tRNA nucleotidyl transferase 1 (TRNT1) catalyzes the addition of terminal cytosine-cytosine-adenosine (CCA) trinucleotides to all mature tRNAs, which is necessary for aminoacylation.', "3'-tRNA nucleotidyl transferase (TRNT1) is an enzyme that catalyzes the terminal nucleotidyl transfer of CCA sequence to the 3'-end of tRNA, which is essential for tRNA function in protein translation.", "TRNT1 catalyzes the addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs), which is essential for translation.", "tRNA Nucleotidyl Transferase 1 (TRNT1) catalyzes the addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs), a process essential for translation.", "TRNT1 (tRNA nucleotidyl transferase) catalyzes the addition of the CCA to the 3' end of tRNAs.", "tRNA Nucleotidyl Transferase 1 (TRNT1) catalyzes the addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs). This process is essential for translation.", "tRNA nucleotidyl transferase 1 (TRNT1) catalyzes the addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs), which is essential for translation.", "Addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs) is essential for translation and is catalyzed by the enzyme TRNT1 (tRNA nucleotidyl transferase),", "TRNT1 catalyzes the addition of a CCA nucleotide to the 3' end of tRNA molecules", 'tRNA nucleotidyl transferase 1 (TRNT1) is an essential enzyme catalyzing the addition of terminal cytosine-cytosine-adenosine (CCA) trinucleotides to all mature tRNAs, which is necessary for aminoacylation.', 'TRNT1 catalyzes the addition of terminal cytosine-cytosine-adenosine (CCA) trinucleotides to all mature tRNAs.', "tRNA nucleotidyl transferase 1 (TRNT1) catalyzes the addition of the invariant CCA-terminus to the tRNA 3'-end, which is a central step in tRNA maturation and is necessary for aminoacylation.", 'TRNT1 is an enzyme that catalyzes the addition of terminal cytosine-cytosine-adenosine (CCA) trinucleotides to all mature tRNAs.', 'The tRNA nucleotidyl transferase 1 (TRNT1) catalyzes the addition of terminal cytosine-cytosine-adenosine (CCA) trinucleotides to all mature tRNAs.', "The tRNA Nucleotidyl Transferase 1 (TRNT1) catalyzes the addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs). This process is essential for translation and occurs in both the cytoplasm and mitochondria"]
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/36646204",
"http://www.ncbi.nlm.nih.gov/pubmed/15265870",
"http://www.ncbi.nlm.nih.gov/pubmed/29884622",
"http://www.ncbi.nlm.nih.gov/pubmed/26172425",
"http://www.ncbi.nlm.nih.gov/pubmed/884105",
"http://www.ncbi.nlm.nih.gov/pubmed/32181284",
"http://www.ncbi.nlm.nih.gov/pubmed/21059936",
"http://www.ncbi.nlm.nih.gov/pubmed/28390992",
"http://www.ncbi.nlm.nih.gov/pubmed/37239403",
"http://www.ncbi.nlm.nih.gov/pubmed/32471101",
"http://www.ncbi.nlm.nih.gov/pubmed/29454993",
"http://www.ncbi.nlm.nih.gov/pubmed/21071662",
"http://www.ncbi.nlm.nih.gov/pubmed/30917604",
"http://www.ncbi.nlm.nih.gov/pubmed/36121781",
"http://www.ncbi.nlm.nih.gov/pubmed/37334830",
"http://www.ncbi.nlm.nih.gov/pubmed/30959222",
"http://www.ncbi.nlm.nih.gov/pubmed/25652405",
"http://www.ncbi.nlm.nih.gov/pubmed/37215601",
"http://www.ncbi.nlm.nih.gov/pubmed/30758723",
"http://www.ncbi.nlm.nih.gov/pubmed/17204286",
"http://www.ncbi.nlm.nih.gov/pubmed/17949481",
"http://www.ncbi.nlm.nih.gov/pubmed/27370603",
"http://www.ncbi.nlm.nih.gov/pubmed/36409584",
"http://www.ncbi.nlm.nih.gov/pubmed/9510330",
"http://www.ncbi.nlm.nih.gov/pubmed/15304219"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36121781",
"endSection": "abstract",
"offsetInBeginSection": 162,
"offsetInEndSection": 231,
"text": "TRNT1 gene encodes a CCA-adding tRNA nucleotidyl transferase enzyme. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37239403",
"endSection": "abstract",
"offsetInBeginSection": 290,
"offsetInEndSection": 438,
"text": "tRNA Nucleotidyl Transferase 1 (TRNT1), the nuclear gene encoding the CCA-adding enzyme essential for modifying both nuclear and mitochondrial tRNAs"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25652405",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 255,
"text": "Addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs) is essential for translation and is catalyzed by the enzyme TRNT1 (tRNA nucleotidyl transferase), which functions in both the cytoplasm and mitochondria. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32471101",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 205,
"text": "tRNA nucleotidyl transferase 1 (TRNT1) is an essential enzyme catalyzing the addition of terminal cytosine-cytosine-adenosine (CCA) trinucleotides to all mature tRNAs, which is necessary for aminoacylation"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30758723",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 293,
"text": "Mutation in the gene encoding tRNA nucleotidyl transferase, CCA-adding 1 (TRNT1), an enzyme essential for the synthesis of the 3'-terminal CCA sequence in tRNA molecules, results in a disorder that features sideroblastic anemia, B-cell immunodeficiency, periodic fever, and developmental delay"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28390992",
"endSection": "abstract",
"offsetInBeginSection": 178,
"offsetInEndSection": 317,
"text": "We recently identified novel hypomorphic mutations in the tRNA Nucleotidyl Transferase, CCA-Adding 1 (TRNT1) gene that cause early-onset RP"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27370603",
"endSection": "abstract",
"offsetInBeginSection": 12,
"offsetInEndSection": 220,
"text": "TRNT1 (CCA-adding transfer RNA nucleotidyl transferase) enzyme deficiency is a new metabolic disease caused by defective post-transcriptional modification of mitochondrial and cytosolic transfer RNAs (tRNAs)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25652405",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 253,
"text": "Addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs) is essential for translation and is catalyzed by the enzyme TRNT1 (tRNA nucleotidyl transferase), which functions in both the cytoplasm and mitochondria"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32471101",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 740,
"text": "tRNA nucleotidyl transferase 1 (TRNT1) is an essential enzyme catalyzing the addition of terminal cytosine-cytosine-adenosine (CCA) trinucleotides to all mature tRNAs, which is necessary for aminoacylation. It was recently discovered that partial loss-of-function mutations in TRNT1 are associated with various, seemingly unrelated human diseases including sideroblastic anemia with B-cell immunodeficiency, periodic fevers and developmental delay (SIFD), retinitis pigmentosa with erythrocyte microcytosis, and progressive B-cell immunodeficiency. In addition, even within the same disease, the severity and range of the symptoms vary greatly, suggesting a broad, pleiotropic impact of imparting TRNT1 function on diverse cellular systems."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29884622",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1508,
"text": "Tpt1 catalyzes the transfer of an internal 2'-monophosphate moiety (2'-PO4) from a \"branched\" 2'-PO4 RNA splice junction to NAD+ to form a \"clean\" 2'-OH, 3'-5' phosphodiester junction, ADP-ribose 1″-2″ cyclic phosphate, and nicotinamide. First discovered as an essential component of the Saccharomyces cerevisiae tRNA splicing machinery, Tpt1 is widely distributed in nature, including in taxa that have no yeast-like RNA splicing system. Here we characterize the RslTpt1 protein from the bacterium Runella slithyformis, in which Tpt1 is encoded within a putative RNA repair gene cluster. We find that (i) expression of RslTpt1 in yeast complements a lethal tpt1Δ knockout, and (ii) purified recombinant RslTpt1 is a bona fide NAD+-dependent 2'-phosphotransferase capable of completely removing an internal 2'-phosphate from synthetic RNAs. The in vivo activity of RslTpt1 is abolished by alanine substitutions for conserved amino acids Arg16, His17, Arg64, and Arg119. The R64A, R119A, and H17A mutants accumulate high levels of a 2'-phospho-ADP-ribosylated RNA reaction intermediate (2'-P-ADPR, evanescent in the wild-type RslTpt1 reaction), which is converted slowly to a 2'-OH RNA product. The R16A mutant is 300-fold slower than wild-type RslTpt1 in forming the 2'-P-ADPR intermediate. Whereas wild-type RsTpt1 rapidly converts the isolated 2'-P-ADPR intermediate to 2'-OH product in the absence of NAD+, the H17A, R119A, R64A, and R16A mutant are slower by factors of 3, 33, 210, and 710, respectively."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37334830",
"endSection": "abstract",
"offsetInBeginSection": 142,
"offsetInEndSection": 881,
"text": "tRNA 2'-phosphotransferase 1 (TRPT1/TPT1/KptA) possesses ADP-ribosyltransferase (ART) activity and is able to ADP-ribosylate nucleic acids. However, the underlying molecular mechanism remains elusive. Here, we determined crystal structures of TRPT1s in complex with NAD+ from Homo sapiens, Mus musculus and Saccharomyces cerevisiae. Our results revealed that the eukaryotic TRPT1s adopt common mechanisms for both NAD+ and nucleic acid substrate binding. The conserved SGR motif induces a significant conformational change in the donor loop upon NAD+ binding to facilitate the catalytic reaction of ART. Moreover, the nucleic acid-binding residue redundancy provides structural flexibility to accommodate different nucleic acid substrates."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30917604",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 363,
"text": "The tRNAHis guanylyltransferase (Thg1) superfamily includes enzymes that are found in all three domains of life that all share the common ability to catalyze the 3' to 5' synthesis of nucleic acids. This catalytic activity, which is the reverse of all other known DNA and RNA polymerases, makes this enzyme family a subject of biological and mechanistic interest."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29454993",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 528,
"text": "Mutations in the human TRNT1 gene encoding tRNA nucleotidyltransferase (tRNA-NT), an essential enzyme responsible for addition of the CCA (cytidine-cytidine-adenosine) sequence to the 3'-termini of tRNAs, have been linked to disease phenotypes including congenital sideroblastic anemia with B-cell immunodeficiency, periodic fevers and developmental delay (SIFD) or retinitis pigmentosa with erythrocyte microcytosis. The effects of these disease-linked mutations on the structure and function of tRNA-NT have not been explored."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36409584",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1095,
"text": "In tRNA maturation, CCA-addition by tRNA nucleotidyltransferase is a unique and highly accurate reaction. While the mechanism of nucleotide selection and polymerization is well understood, it remains a mystery why bacterial and eukaryotic enzymes exhibit an unexpected and surprisingly low tRNA substrate affinity while they efficiently catalyze the CCA-addition. To get insights into the evolution of this high-fidelity RNA synthesis, the reconstruction and characterization of ancestral enzymes is a versatile tool. Here, we investigate a reconstructed candidate of a 2 billion years old CCA-adding enzyme from Gammaproteobacteria and compare it to the corresponding modern enzyme of Escherichia coli. We show that the ancestral candidate catalyzes an error-free CCA-addition, but has a much higher tRNA affinity compared with the extant enzyme. The consequence of this increased substrate binding is an enhanced reverse reaction, where the enzyme removes the CCA end from the mature tRNA. As a result, the ancestral candidate exhibits a lower catalytic efficiency in vitro as well as in vivo."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30959222",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 725,
"text": "The I326T mutation in the TRNT1 gene encoding human tRNA nucleotidyltransferase (tRNA-NT) is linked to a relatively mild form of SIFD. Previous work indicated that the I326T variant was unable to incorporate AMP into tRNAs in vitro, however, expression of the mutant allele from a strong heterologous promoter supported in vivo CCA addition to both cytosolic and mitochondrial tRNAs in a yeast strain lacking tRNA-NT. To address this discrepancy, we determined the biochemical and biophysical characteristics of the I326T variant enzyme and the related variant, I326A. Our in vitro analysis revealed that the I326T substitution decreases the thermal stability of the enzyme and causes a ten-fold reduction in enzyme activity."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32471101",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 206,
"text": "tRNA nucleotidyl transferase 1 (TRNT1) is an essential enzyme catalyzing the addition of terminal cytosine-cytosine-adenosine (CCA) trinucleotides to all mature tRNAs, which is necessary for aminoacylation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25652405",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 356,
"text": "Addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs) is essential for translation and is catalyzed by the enzyme TRNT1 (tRNA nucleotidyl transferase), which functions in both the cytoplasm and mitochondria. Exome sequencing revealed TRNT1 mutations in two unrelated subjects with different clinical features."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25652405",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 254,
"text": "Addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs) is essential for translation and is catalyzed by the enzyme TRNT1 (tRNA nucleotidyl transferase), which functions in both the cytoplasm and mitochondria."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36646204",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 256,
"text": "The maturation of tRNA and its quality control is crucial for aminoacylation and protein synthesis. The CCA enzyme, also known as tRNA nucleotidyltransferase, catalyzes the addition or repair of CCA at the 3'-terminus of tRNAs to facilitate aminoacylation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36646204",
"endSection": "abstract",
"offsetInBeginSection": 100,
"offsetInEndSection": 402,
"text": "The CCA enzyme, also known as tRNA nucleotidyltransferase, catalyzes the addition or repair of CCA at the 3'-terminus of tRNAs to facilitate aminoacylation. Structural studies of CCA enzyme in complex with ATP and CTP suggested that adding CCA at the 3'-terminus of tRNAs is a sequential process [1-4]."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36646204",
"endSection": "abstract",
"offsetInBeginSection": 100,
"offsetInEndSection": 256,
"text": "The CCA enzyme, also known as tRNA nucleotidyltransferase, catalyzes the addition or repair of CCA at the 3'-terminus of tRNAs to facilitate aminoacylation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36646204",
"endSection": "abstract",
"offsetInBeginSection": 100,
"offsetInEndSection": 568,
"text": "The CCA enzyme, also known as tRNA nucleotidyltransferase, catalyzes the addition or repair of CCA at the 3'-terminus of tRNAs to facilitate aminoacylation. Structural studies of CCA enzyme in complex with ATP and CTP suggested that adding CCA at the 3'-terminus of tRNAs is a sequential process [1-4]. However, there are many inconsistent results of CCA addition from the biochemical studies, which raise the ambiguity about the CCA enzyme specificity in vitro [5-7]."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37215601",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 171,
"text": "The TRNT1 gene encodes tRNA nucleotidyltransferase 1, which catalyzes the addition of cytosine-cytosine-adenosine (CCA) to the ends of cytoplasmic and mitochondrial tRNAs."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25652405",
"endSection": "abstract",
"offsetInBeginSection": 1581,
"offsetInEndSection": 1908,
"text": "These data suggest that the clinical phenotypes associated with TRNT1 mutations are largely due to impaired mitochondrial translation, resulting from defective CCA addition to mitochondrial tRNA(Ser(AGY)), and that the severity of this biochemical phenotype determines the severity and tissue distribution of clinical features."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21059936",
"endSection": "abstract",
"offsetInBeginSection": 207,
"offsetInEndSection": 404,
"text": "The tRNA(His) guanylyltransferase (Thg1) is a member of a unique enzyme family whose members catalyze an unprecedented reaction in biology: 3'-5' addition of nucleotides to nucleic acid substrates."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30959222",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1223,
"text": "The I326T mutation in the TRNT1 gene encoding human tRNA nucleotidyltransferase (tRNA-NT) is linked to a relatively mild form of SIFD. Previous work indicated that the I326T variant was unable to incorporate AMP into tRNAs in vitro, however, expression of the mutant allele from a strong heterologous promoter supported in vivo CCA addition to both cytosolic and mitochondrial tRNAs in a yeast strain lacking tRNA-NT. To address this discrepancy, we determined the biochemical and biophysical characteristics of the I326T variant enzyme and the related variant, I326A. Our in vitro analysis revealed that the I326T substitution decreases the thermal stability of the enzyme and causes a ten-fold reduction in enzyme activity. We propose that the structural changes in the I326T variant that lead to these altered parameters result from a rearrangement of helices within the body domain of the protein which can be probed by the inability of the monomeric enzyme to form a covalent dimer in vitro mediated by C373. In addition, we confirm that the effects of the I326T or I326A substitutions are relatively mild in vivo by demonstrating that the mutant alleles support both mitochondrial and cytosolic CCA-addition in yeast."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32181284",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 331,
"text": "Mutations in the gene encoding transfer RNA (tRNA) nucleotidyltransferase, CCA-adding 1 (TRNT1), an enzyme essential for the synthesis of the 3'-terminal CCA sequence in tRNA molecules, are associated with a rare syndrome of congenital sideroblastic anemia, B cell immunodeficiency, periodic fevers, and developmental delay (SIFD)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29454993",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 417,
"text": "Mutations in the human TRNT1 gene encoding tRNA nucleotidyltransferase (tRNA-NT), an essential enzyme responsible for addition of the CCA (cytidine-cytidine-adenosine) sequence to the 3'-termini of tRNAs, have been linked to disease phenotypes including congenital sideroblastic anemia with B-cell immunodeficiency, periodic fevers and developmental delay (SIFD) or retinitis pigmentosa with erythrocyte microcytosis."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30758723",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 294,
"text": "Mutation in the gene encoding tRNA nucleotidyl transferase, CCA-adding 1 (TRNT1), an enzyme essential for the synthesis of the 3'-terminal CCA sequence in tRNA molecules, results in a disorder that features sideroblastic anemia, B-cell immunodeficiency, periodic fever, and developmental delay."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29454993",
"endSection": "abstract",
"offsetInBeginSection": 43,
"offsetInEndSection": 203,
"text": "tRNA nucleotidyltransferase (tRNA-NT), an essential enzyme responsible for addition of the CCA (cytidine-cytidine-adenosine) sequence to the 3'-termini of tRNAs"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37215601",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 799,
"text": "The TRNT1 gene encodes tRNA nucleotidyltransferase 1, which catalyzes the addition of cytosine-cytosine-adenosine (CCA) to the ends of cytoplasmic and mitochondrial tRNAs. The most common clinical phenotype associated with TRNT1 is autosomal recessive sideroblastic anemia with B-cell immunodeficiency, periodic fever, and developmental delay (SIFD). Muscle involvement has rarely been reported in TRNT1-related disorders. Here we report a Chinese patient with incomplete SIFD and hyperCKemia, and explored the skeletal muscle pathological changes. The patient was a 3-year-old boy with sensorineural hearing loss, sideroblastic anemia, and developmental delay since infancy. At the age of 11 months, significantly increased levels of creatine kinase were noted, accompanied by mild muscle weakness."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27370603",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1891,
"text": "BACKGROUND: TRNT1 (CCA-adding transfer RNA nucleotidyl transferase) enzyme deficiency is a new metabolic disease caused by defective post-transcriptional modification of mitochondrial and cytosolic transfer RNAs (tRNAs).RESULTS: We investigated four patients from two families with infantile-onset cyclical, aseptic febrile episodes with vomiting and diarrhoea, global electrolyte imbalance during these episodes, sideroblastic anaemia, B lymphocyte immunodeficiency, retinitis pigmentosa, hepatosplenomegaly, exocrine pancreatic insufficiency and renal tubulopathy. Other clinical features found in children include sensorineural deafness, cerebellar atrophy, brittle hair, partial villous atrophy and nephrocalcinosis. Whole exome sequencing and bioinformatic filtering were utilised to identify recessive compound heterozygous TRNT1 mutations (missense mutation c.668T>C, p.Ile223Thr and a novel splice mutation c.342+5G>T) segregating with disease in the first family. The second family was found to have a homozygous TRNT1 mutation (c.569G>T), p.Arg190Ile, (previously published). We found normal mitochondrial translation products using passage matched controls and functional perturbation of 3' CCA addition to mitochondrial tRNAs (tRNA(Cys), tRNA(LeuUUR) and tRNA(His)) in fibroblasts from two patients, demonstrating a pathomechanism affecting the CCA addition to mt-tRNAs. Acute management of these patients included transfusion for anaemia, fluid and electrolyte replacement and immunoglobulin therapy. We also describe three-year follow-up findings after treatment by bone marrow transplantation in one patient, with resolution of fever and reversal of the abnormal metabolic profile.CONCLUSIONS: Our report highlights that TRNT1 mutations cause a spectrum of disease ranging from a childhood-onset complex disease with manifestations in most organs to an adult-onset isolated re"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25652405",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1580,
"text": "Addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs) is essential for translation and is catalyzed by the enzyme TRNT1 (tRNA nucleotidyl transferase), which functions in both the cytoplasm and mitochondria. Exome sequencing revealed TRNT1 mutations in two unrelated subjects with different clinical features. The first presented with acute lactic acidosis at 3 weeks of age and developed severe developmental delay, hypotonia, microcephaly, seizures, progressive cortical atrophy, neurosensorial deafness, sideroblastic anemia and renal Fanconi syndrome, dying at 21 months. The second presented at 3.5 years with gait ataxia, dysarthria, gross motor regression, hypotonia, ptosis and ophthalmoplegia and had abnormal signals in brainstem and dentate nucleus. In subject 1, muscle biopsy showed combined oxidative phosphorylation (OXPHOS) defects, but there was no OXPHOS deficiency in fibroblasts from either subject, despite a 10-fold-reduction in TRNT1 protein levels in fibroblasts of the first subject. Furthermore, in normal controls, TRNT1 protein levels are 10-fold lower in muscle than in fibroblasts. High resolution northern blots of subject fibroblast RNA suggested incomplete CCA addition to the non-canonical mitochondrial tRNA(Ser(AGY)), but no obvious qualitative differences in other mitochondrial or cytoplasmic tRNAs. Complete knockdown of TRNT1 in patient fibroblasts rendered mitochondrial tRNA(Ser(AGY)) undetectable, and markedly reduced mitochondrial translation, except polypeptides lacking Ser(AGY) codons."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30758723",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1241,
"text": "Mutation in the gene encoding tRNA nucleotidyl transferase, CCA-adding 1 (TRNT1), an enzyme essential for the synthesis of the 3'-terminal CCA sequence in tRNA molecules, results in a disorder that features sideroblastic anemia, B-cell immunodeficiency, periodic fever, and developmental delay. Mutations in TRNT1 are also linked to phenotypes including retinitis pigmentosa, cataracts, and cardiomyopathy. To date, it has remained unclear how defective TRNT1 is linked to B-cell deficiency. Here we report the case of a 12-year-old boy without sideroblastic anemia who harbors novel compound heterozygous mutations in TRNT1. Immunophenotypic analysis revealed severely decreased levels of B cells and follicular helper T cells. In the bone marrow, B-cell maturation stopped at the CD19+CD10+CD20+/- pre-B-cell stage. Severe combined immunodeficiency mice transplanted with bone marrow hematopoietic stem cells from the patient showed largely normal B-cell engraftment and differentiation in the bone marrow and periphery at 24 weeks post-transplantation, comparable to those in mouse transplanted with healthy hematopoietic stem cells. Biochemical analysis revealed augmented endoplasmic reticulum (ER) stress response in activated T cells."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32181284",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1366,
"text": "Mutations in the gene encoding transfer RNA (tRNA) nucleotidyltransferase, CCA-adding 1 (TRNT1), an enzyme essential for the synthesis of the 3'-terminal CCA sequence in tRNA molecules, are associated with a rare syndrome of congenital sideroblastic anemia, B cell immunodeficiency, periodic fevers, and developmental delay (SIFD). Clinical manifestations and immunological phenotypes were assessed in a Chinese patient with novel compound heterozygous mutations in TRNT1. The patient required multiple hospitalizations starting at the age of 2 years for recurrent fevers without an infective cause. During the febrile episode, the patient was found to have microcytic hypochromic anemia, B cell lymphopenia, and hypogammaglobulinemia. Targeted gene sequencing identified novel compound heterozygous mutations in the TRNT1 gene (c.525delT, p.Leu176X; c.938T>C, p.Leu313Ser). Immunophenotyping revealed increased CD8+ T cells, CD4+ terminally differentiated effector memory helper T lymphocytes (CD4 TEMRA), and CD4+ effector memory lymphocytes (CD4 EM). Analysis of CD4+ T subsets identified decreased T follicular helper cells (Tfh) with a biased phenotype to Th2-like cells. The patient also showed a lower percentage of switched memory B (smB) cells. Additionally, defects in the cytotoxicity of the patient's NK and γδT cells were shown by CD107alpha expression."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/884105",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 296,
"text": "The enzyme tRNA nucleotidyl transferase (EC 2.7.7.25) has been highly purified from whole adult houseflies. A molecular weight of 30 000 has been determined. The enzyme requires Mg2+ and tRNA deprived of the 3' terminal sequence CCA for activity in the incorporation of AMP and CMP onto the tRNA."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25652405",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 622,
"text": "Addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs) is essential for translation and is catalyzed by the enzyme TRNT1 (tRNA nucleotidyl transferase), which functions in both the cytoplasm and mitochondria. Exome sequencing revealed TRNT1 mutations in two unrelated subjects with different clinical features. The first presented with acute lactic acidosis at 3 weeks of age and developed severe developmental delay, hypotonia, microcephaly, seizures, progressive cortical atrophy, neurosensorial deafness, sideroblastic anemia and renal Fanconi syndrome, dying at 21 months."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30758723",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 406,
"text": "Mutation in the gene encoding tRNA nucleotidyl transferase, CCA-adding 1 (TRNT1), an enzyme essential for the synthesis of the 3'-terminal CCA sequence in tRNA molecules, results in a disorder that features sideroblastic anemia, B-cell immunodeficiency, periodic fever, and developmental delay. Mutations in TRNT1 are also linked to phenotypes including retinitis pigmentosa, cataracts, and cardiomyopathy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27370603",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 219,
"text": "BACKGROUND: TRNT1 (CCA-adding transfer RNA nucleotidyl transferase) enzyme deficiency is a new metabolic disease caused by defective post-transcriptional modification of mitochondrial and cytosolic transfer RNAs (tRNAs)"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30758723",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 491,
"text": "Mutation in the gene encoding tRNA nucleotidyl transferase, CCA-adding 1 (TRNT1), an enzyme essential for the synthesis of the 3'-terminal CCA sequence in tRNA molecules, results in a disorder that features sideroblastic anemia, B-cell immunodeficiency, periodic fever, and developmental delay. Mutations in TRNT1 are also linked to phenotypes including retinitis pigmentosa, cataracts, and cardiomyopathy. To date, it has remained unclear how defective TRNT1 is linked to B-cell deficiency."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/17204286",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 294,
"text": "The human CCA-adding enzyme (tRNA nucleotidyltransferase) is an essential enzyme that catalyzes the addition of the CCA terminus to the 3' end of tRNA precursors, a reaction which is a fundamental prerequisite for mature tRNAs to become aminoacylated and to participate in protein biosynthesis."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26172425",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 114,
"text": "tRNA nucleotidyltransferase adds the invariant CCA-terminus to the tRNA 3'-end, a central step in tRNA maturation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/9510330",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 142,
"text": "The CCA-adding enzyme [ATP(CTP):tRNA nucleotidyltransferase] catalyzes the addition and regeneration of the 3'-terminal CCA sequence of tRNAs."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/15304219",
"endSection": "abstract",
"offsetInBeginSection": 142,
"offsetInEndSection": 219,
"text": "tRNA nucleotidyltransferase catalyzes the addition of CCA to 3' ends of tRNAs"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21071662",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 155,
"text": "CCA-adding enzymes [ATP(CTP):tRNA nucleotidyltransferases] add CCA onto the 3' end of transfer RNA (tRNA) precursors without using a nucleic acid template."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/15265870",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 115,
"text": "The CCA-adding enzyme ATP(CTP):tRNA nucleotidyltransferase builds and repairs the 3'-terminal CCA sequence of tRNA."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/17949481",
"endSection": "abstract",
"offsetInBeginSection": 384,
"offsetInEndSection": 493,
"text": "family, the tRNA nucleotidyltransferase that synthesizes the 3'-terminal sequence C-C-A to all tRNAs (CCA-add"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36409584",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 105,
"text": "In tRNA maturation, CCA-addition by tRNA nucleotidyltransferase is a unique and highly accurate reaction."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26172425",
"endSection": "abstract",
"offsetInBeginSection": 115,
"offsetInEndSection": 245,
"text": "This CCA-adding enzyme is a specialized RNA polymerase that synthesizes the CCA sequence at high fidelity in all kingdoms of life."
}
] | 13
|
BioASQ-training13b
| null | null |
662cfc88187cba990d000008
| 5,164
|
factoid
|
What is the prevalence of intellectual developmental disorders in Becker Muscular Dystrophy?
|
['8%']
|
[
"8 percent",
"eight percent",
"0.08",
"0.08 fraction",
"8/100"
] |
['The global prevalence of intellectual developmental disorder (IDD) is 8% in Becker muscular dystrophy.', 'The global prevalence of intellectual developmental disorder (IDD) in Becker muscular dystrophy (BMD) is 8%.', 'The prevalence of intellectual developmental disorders in Becker Muscular Dystrophy is 8%.', 'The global prevalence of intellectual developmental disorder (IDD) was 8% in Becker muscular dystrophy.', 'The global prevalence of intellectual developmental disorder (IDD) in Becker muscular dystrophy is 8%.', 'The prevalence of intellectual developmental disorders in Becker Muscular Dystrophy is 8%', 'The prevalence of intellectual developmental disorders in Becker Muscular Dystrophy is estimated to be 8.3%.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/36440509"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36440509",
"endSection": "abstract",
"offsetInBeginSection": 1369,
"offsetInEndSection": 1471,
"text": "The global prevalence of intellectual developmental disorder (IDD) was 8% in Becker muscular dystrophy"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36440509",
"endSection": "abstract",
"offsetInBeginSection": 655,
"offsetInEndSection": 727,
"text": "dies were included. The prevalence of IDD in BMD was 8.0% (95% confidenc"
}
] | 13
|
BioASQ-training13b
| null | null |
66300d3e187cba990d00001b
| 5,167
|
factoid
|
Mutation of which gene was implicated in Disabling pansclerotic morphea?
|
['STAT4']
|
[
"STAT4",
"Signal Transducer and Activator of Transcription 4",
"Signal Transducer and Activator of Transcription 4 protein",
"Stat4",
"Stat 4"
] |
['Gain-of-function variants in STAT4 was implicated in Disabling pansclerotic morphea.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/37256972"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37256972",
"endSection": "abstract",
"offsetInBeginSection": 1531,
"offsetInEndSection": 1622,
"text": "CONCLUSIONS: Gain-of-function variants in STAT4 caused DPM in the families that we studied."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37256972",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1095,
"text": "BACKGROUND: Disabling pansclerotic morphea (DPM) is a rare systemic inflammatory disorder, characterized by poor wound healing, fibrosis, cytopenias, hypogammaglobulinemia, and squamous-cell carcinoma. The cause is unknown, and mortality is high.METHODS: We evaluated four patients from three unrelated families with an autosomal dominant pattern of inheritance of DPM. Genomic sequencing independently identified three heterozygous variants in a specific region of the gene that encodes signal transducer and activator of transcription 4 (STAT4). Primary skin fibroblast and cell-line assays were used to define the functional nature of the genetic defect. We also assayed gene expression using single-cell RNA sequencing of peripheral-blood mononuclear cells to identify inflammatory pathways that may be affected in DPM and that may respond to therapy.RESULTS: Genome sequencing revealed three novel heterozygous missense gain-of-function variants in STAT4. In vitro, primary skin fibroblasts showed enhanced interleukin-6 secretion, with impaired wound healing, contraction of the collagen m"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37256972",
"endSection": "abstract",
"offsetInBeginSection": 1370,
"offsetInEndSection": 1622,
"text": "Single-cell RNA sequencing revealed expression patterns consistent with an immunodysregulatory phenotype that were appropriately modified through JAK inhibition.CONCLUSIONS: Gain-of-function variants in STAT4 caused DPM in the families that we studied."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37256972",
"endSection": "abstract",
"offsetInBeginSection": 658,
"offsetInEndSection": 960,
"text": "We also assayed gene expression using single-cell RNA sequencing of peripheral-blood mononuclear cells to identify inflammatory pathways that may be affected in DPM and that may respond to therapy.RESULTS: Genome sequencing revealed three novel heterozygous missense gain-of-function variants in STAT4."
}
] | 13
|
BioASQ-training13b
| null | null |
65cfdf1c1930410b13000028
| 5,168
|
factoid
|
Oxysterol is produced by the oxidation of what waxy, fat-like substance made in the liver?
|
['Cholesterol']
|
[
"Cholesterol",
"Cholest-5-en-3-ol",
"5-cholesten-3-beta-ol",
"C27H46O",
"Cholestrol",
"Cholesterol ester",
"Cholesterol sulfate"
] |
['Oxysterols are produced by the oxidation of cholesterol.', 'Oxysterols are derived from either enzymatic or non-enzymatic oxidation of cholesterol.', 'Oxysterol is produced by the oxidation of cholesterol, a waxy, fat-like substance that is synthesized in the liver.', "Oxysterols are produced by the oxidation of cholesterol, a waxy, fat-like substance that is primarily synthesized in the liver, the body's main metabolic organ.", 'Oxysterols are produced by the oxidation of cholesterols in the liver.', '7-Ketocholesterol is an oxysterol produced by the oxidation of cholesterol, a waxy, fat-like substance made in the liver.', 'Oxysterol is produced by the oxidation of cholesteryl esters in the liver.', 'Cholesterol is a waxy, fat-like substance made in the liver that is necessary for many bodily functions, and oxysterols are produced by the oxidation of cholesterol.', 'Oxysterols are produced by the oxidation of cholesterol, a waxy, fat-like substance that is made in the liver', 'Oxysterol is produced by the oxidation of cholesterol', 'Oxysterol is produced by the oxidation of cholesterol, a waxy, fat-like substance made in the liver', 'Oxysterols derive from either enzymatic or non-enzymatic oxidation of cholesterol.', 'Oxysterol is produced by the oxidation of cholesterol.', '7-alpha hydroxycholesterol, also known as 7-OHC, is an oxysterol produced by the oxidation of cholesterol.', 'Oxysterols are produced by the oxidation of cholesterol, which is a waxy, fat-like substance made in the liver.', 'Oxysterol is produced by the oxidation of cholesterol, a waxy, fat-like substance made in the liver.', 'Oxysterols are produced by the oxidation of cholesterol, a waxy, fat-like substance made in the liver.', 'Oxysterol is produced by the oxidation of the waxy, fat-like substance made in the liver, cholesterol.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/22026270",
"http://www.ncbi.nlm.nih.gov/pubmed/24333430",
"http://www.ncbi.nlm.nih.gov/pubmed/11111082",
"http://www.ncbi.nlm.nih.gov/pubmed/38036890",
"http://www.ncbi.nlm.nih.gov/pubmed/19248802",
"http://www.ncbi.nlm.nih.gov/pubmed/25255963",
"http://www.ncbi.nlm.nih.gov/pubmed/29993272",
"http://www.ncbi.nlm.nih.gov/pubmed/20870006",
"http://www.ncbi.nlm.nih.gov/pubmed/34378892",
"http://www.ncbi.nlm.nih.gov/pubmed/23773414",
"http://www.ncbi.nlm.nih.gov/pubmed/7657597",
"http://www.ncbi.nlm.nih.gov/pubmed/36316327",
"http://www.ncbi.nlm.nih.gov/pubmed/17573819",
"http://www.ncbi.nlm.nih.gov/pubmed/26795945",
"http://www.ncbi.nlm.nih.gov/pubmed/34920079",
"http://www.ncbi.nlm.nih.gov/pubmed/26461414",
"http://www.ncbi.nlm.nih.gov/pubmed/31586653",
"http://www.ncbi.nlm.nih.gov/pubmed/22044627",
"http://www.ncbi.nlm.nih.gov/pubmed/19035881",
"http://www.ncbi.nlm.nih.gov/pubmed/31301352",
"http://www.ncbi.nlm.nih.gov/pubmed/33631213",
"http://www.ncbi.nlm.nih.gov/pubmed/32175830",
"http://www.ncbi.nlm.nih.gov/pubmed/38036887",
"http://www.ncbi.nlm.nih.gov/pubmed/17346171",
"http://www.ncbi.nlm.nih.gov/pubmed/38036880",
"http://www.ncbi.nlm.nih.gov/pubmed/38036882",
"http://www.ncbi.nlm.nih.gov/pubmed/38036877",
"http://www.ncbi.nlm.nih.gov/pubmed/32574926",
"http://www.ncbi.nlm.nih.gov/pubmed/32335907",
"http://www.ncbi.nlm.nih.gov/pubmed/22884520",
"http://www.ncbi.nlm.nih.gov/pubmed/29421651",
"http://www.ncbi.nlm.nih.gov/pubmed/36672175",
"http://www.ncbi.nlm.nih.gov/pubmed/31009661",
"http://www.ncbi.nlm.nih.gov/pubmed/11239823",
"http://www.ncbi.nlm.nih.gov/pubmed/12323083",
"http://www.ncbi.nlm.nih.gov/pubmed/24970128",
"http://www.ncbi.nlm.nih.gov/pubmed/2268710",
"http://www.ncbi.nlm.nih.gov/pubmed/35154132"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/38036887",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 83,
"text": "Oxysterols derive from either enzymatic or non-enzymatic oxidation of cholesterol. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/38036882",
"endSection": "abstract",
"offsetInBeginSection": 420,
"offsetInEndSection": 567,
"text": "Oxidized LDLs are enriched in oxidized products of cholesterol called oxysterols formed either by autoxidation, enzymatically, or by both mechanism"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/38036880",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 46,
"text": "Oxysterols or cholesterol oxidation products a"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/38036890",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 128,
"text": "Oxysterols, resulting from the oxidation of cholesterol, are formed either by autoxidation, enzymatically, or by both processes."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31301352",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 696,
"text": "Oxysterols are oxidized derivatives of cholesterol that are formed enzymatically or via reactive oxygen species or both. Cholesterol or oxysterols ingested as food are absorbed and packed into lipoproteins that are taken up by hepatic cells. Within hepatic cells, excess cholesterol is metabolised to form bile acids. The endoplasmic reticulum acts as the main organelle in the bile acid synthesis pathway. Metabolised sterols originating from this pathway are distributed within other organelles and in the cell membrane. The alterations to membrane oxysterol:sterol ratio affects the integrity of the cell membrane. The presence of oxysterols changes membrane fluidity and receptor orientation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32175830",
"endSection": "abstract",
"offsetInBeginSection": 139,
"offsetInEndSection": 573,
"text": "Oxidation of cholesterol leads to the formation of a large number of oxidized products, generally known as oxysterols. They are intermediates in the biosynthesis of bile acids, steroid hormones, and 1,25- dihydroxyvitamin D3. Although oxysterols are considered as metabolic intermediates, there is a growing body of evidence that many of them are bioactive, and their absence or excess may be part of the cause of a disease phenotype."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34378892",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 504,
"text": "Cholesterol is a precursor molecule for vitamin D, bile acids, and steroid hormones. Its oxidized forms, called oxysterols are by-products for synthesis, but also regulate cholesterolâs metabolism through different cell receptors. Cholesterol and oxysterols are important cell membrane components. Oxysterols show more biological activity than cholesterol itself, due to their pleiotropic cell effects. Oxysterol, contrary to cholesterol can cross the blood-brain barier and influence the nervous system."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29421651",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 190,
"text": "Oxysterols are oxidised derivatives of cholesterol or its precursors post lanosterol. They are intermediates in the biosynthesis of bile acids, steroid hormones and 1,25-dihydroxyvitamin D3."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32335907",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 542,
"text": "Oxysterols are oxygenated forms of cholesterol generated via autooxidation by free radicals and ROS, or formed enzymically by a variety of enzymes such as those involved in the synthesis of bile acids. Although found at very low concentrations in vivo, these metabolites play key roles in health and disease, particularly in development and regulating immune cell responses, by binding to effector proteins such as LXRα, RORγ and Insig and directly or indirectly regulating transcriptional programmes that affect cell metabolism and function."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31009661",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1079,
"text": "Cholestane-3β,5α,6β-triol (3β,5α,6β-triol) is formed from cholestan-5,6-epoxide (5,6-EC) in a reaction catalysed by cholesterol epoxide hydrolase, following formation of 5,6-EC through free radical oxidation of cholesterol. 7-Oxocholesterol (7-OC) and 7β-hydroxycholesterol (7β-HC) can also be formed by free radical oxidation of cholesterol. Here we investigate how 3β,5α,6β-triol, 7-OC and 7β-HC are metabolised to bile acids. We show, by monitoring oxysterol metabolites in plasma samples rich in 3β,5α,6β-triol, 7-OC and 7β-HC, that these three oxysterols fall into novel branches of the acidic pathway of bile acid biosynthesis becoming (25R)26-hydroxylated then carboxylated, 24-hydroxylated and side-chain shortened to give the final products 3β,5α,6β-trihydroxycholanoic, 3β-hydroxy-7-oxochol-5-enoic and 3β,7β-dihydroxychol-5-enoic acids, respectively. The intermediates in these pathways may be causative of some phenotypical features of, and/or have diagnostic value for, the lysosomal storage diseases, Niemann Pick types C and B and lysosomal acid lipase deficiency."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26795945",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 371,
"text": "Oxysterols are bioactive lipids derived from cholesterol that are linked to inflammatory processes. Because obesity and metabolic syndrome are characterized by inflammation and altered cholesterol metabolism, we sought to investigate the variations of oxysterol levels and their metabolic pathways induced by obesity in the liver, hypothalamus, adipose tissue and plasma."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26795945",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 454,
"text": "Oxysterols are bioactive lipids derived from cholesterol that are linked to inflammatory processes. Because obesity and metabolic syndrome are characterized by inflammation and altered cholesterol metabolism, we sought to investigate the variations of oxysterol levels and their metabolic pathways induced by obesity in the liver, hypothalamus, adipose tissue and plasma. To this end, we used diet-induced and genetic (ob/ob and db/db) models of obesity."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26795945",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 99,
"text": "Oxysterols are bioactive lipids derived from cholesterol that are linked to inflammatory processes."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22884520",
"endSection": "abstract",
"offsetInBeginSection": 257,
"offsetInEndSection": 612,
"text": "LXRs are thought to be activated predominantly by oxysterols generated enzymatically from cholesterol in different cell organelles. Defects resulting in slowed release of cholesterol from late endosomes and lysosomes or reduction in sterol-27-hydroxylase activity lead to specific blocks in oxysterol production and impaired LXR-dependent gene activation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36672175",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 123,
"text": "Oxysterols, derived from cholesterol oxidation, are formed either by autoxidation, via enzymes, or by both processes [...]."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34920079",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 112,
"text": "Oxysterols are a family of over 25 cholesterol metabolites naturally produced by enzymatic or radical oxidation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33631213",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 116,
"text": "Oxysterols are oxidized derivatives of cholesterol that play regulatory roles in lipid biosynthesis and homeostasis."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29993272",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 129,
"text": "Cholesterol oxidation products, also named oxysterols, can be formed either by cholesterol auto-oxidation, enzymatically or both."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/20870006",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 167,
"text": "Oxysterols (oxidized derivatives of cholesterol and phytosterols) can be generated in the human organism through different oxidation processes, some requiring enzymes."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26461414",
"endSection": "abstract",
"offsetInBeginSection": 465,
"offsetInEndSection": 512,
"text": "Oxysterols, oxidized derivatives of cholesterol"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24970128",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 100,
"text": "Oxysterols are oxidized 27-carbon cholesterol derivatives or by-products of cholesterol biosynthesis"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/17346171",
"endSection": "abstract",
"offsetInBeginSection": 350,
"offsetInEndSection": 619,
"text": "Bile acids and oxysterols, formed from cholesterol, act as ligands to nuclear receptors regulating the expression of important genes in cholesterol homeostasis. Thus, the bioactivation of cholesterol into bile acids is crucial for regulation of cholesterol homeostasis."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26461414",
"endSection": "abstract",
"offsetInBeginSection": 465,
"offsetInEndSection": 570,
"text": "Oxysterols, oxidized derivatives of cholesterol were reported as activating ligands of Liver X Receptors."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/11239823",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 164,
"text": "Cholesterol oxidation products (oxysterols) have been implicated in atherogenesis due to their presence in atherosclerotic tissue and their potent effects in vitro."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23773414",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 77,
"text": "Oxysterols (oxidised cholesterol) may play a role in the pathogenesis of CVD."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22026270",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 160,
"text": "INTRODUCTION: Products of oxidizing cholesterol-called oxysterols, are having different physicochemical properties and various from not-modified sterols, biolog"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/11111082",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 137,
"text": "Oxysterols, herein defined as derivatives of cholesterol with a hydroxyl group on the side chain, play several roles in lipid metabolism."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/7657597",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1345,
"text": "Cholesterol oxidation products (oxysterols) have been detected in many different tissues, often at concentrations 10(3) to 10(4) times lower than cholesterol. This constitutes a considerable risk of quantitation errors, since even a minor oxidation of cholesterol during sample processing would yield a substantial increase of oxysterol levels. It has therefore been suggested that some of the oxysterols do not occur in vivo and their detection in tissues merely are artifacts produced in vitro. In the present work, an 18O2 inhalation technique was developed in order to clarify which oxysterols are produced in vivo. Rats were exposed for 3 h to an atmosphere with a composition similar to normal air, except that it contained 18O2 instead of 16O2. Control rats were kept in 16O2-containing atmosphere throughout the experiment. The 18O enrichment of oxysterols in plasma and liver was determined by gas/liquid chromatography-mass spectrometry and mass isotopomer distribution analysis. In vivo formation of oxysterols, indicated by enrichment in 18O, was established for cholest-5-ene-3 beta, 7 alpha-diol, cholest-5-ene-3 beta, 7 beta-diol, 7-oxocholesterol, cholest-5-ene-3 beta,24-diol, cholest-5-ene-3 beta,25-diol, and cholest-5-ene-3 beta,27-diol. Additionally, it seems likely that cholest-5-ene-3 beta, 4 beta-diol is formed in vivo."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/38036877",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 387,
"text": "Cholesterol is a key molecule for synaptic transmission, and both central and peripheral synapses are cholesterol rich. During intense neuronal activity, a substantial portion of synaptic cholesterol can be oxidized by either enzymatic or non-enzymatic pathways to form oxysterols, which in turn modulate the activities of neurotransmitter receptors (e.g., NMDA and adrenergic receptors)"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36316327",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 494,
"text": "Oxysterols are oxygenated derivatives of cholesterol that contain an additional hydroxy, epoxide, or ketone group in the sterol nucleus and/or a hydroxyl group in the side chain of the cholesterol molecule. 27-Hydroxycholesterol (27HC) is a side-chain oxysterol that is oxygenated at the 27th carbon atom of cholesterol. The oxysterol (27HC) is produced via oxidation by sterol 27-hydroxylase (CYP27A1) and metabolized via oxysterol 7a-hydroxylase (CYP7B1) for bile acid synthesis in the liver."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/2268710",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 147,
"text": "The effect of individual oxysterols--products of auto-oxidation of cholesterol on bile acid synthesis by cultivated rabbit hepatocytes was studied."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/20870006",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 427,
"text": "Oxysterols (oxidized derivatives of cholesterol and phytosterols) can be generated in the human organism through different oxidation processes, some requiring enzymes. Furthermore, oxysterols are also present in food due to lipid oxidation reactions caused by heating treatments, contact with oxygen, exposure to sunlight, etc., and they could be absorbed from the diet, at different rates depending on their side chain length."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22044627",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 204,
"text": "Oxysterols are cholesterol oxidation products that are generated by enzymatic reactions through cytochrome P450 family enzymes or by non-enzymatic reactions involving reactive oxygen and nitrogen species."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26461414",
"endSection": "abstract",
"offsetInBeginSection": 465,
"offsetInEndSection": 1535,
"text": "Oxysterols, oxidized derivatives of cholesterol were reported as activating ligands of Liver X Receptors. Interestingly, serum levels of agonist oxysterols such as 25-HC and 27-HC are significantly increased in NAFLD patients. By contrast, 22-s- HC is considered an antagonist ligand of LXRα. 22-s-Hc down-regulated expression of the FAS gene through an LXRE located in the promoter and abolished the effect of the synthetic LXRα agonist. In addition it has been reported that 22-s-HC attenuated hepatic steatogenesis in a mouse model of high-fat-induced fatty liver. Very recently, it has been demonstrated that the inhibition of LXRα by 22-s-HC dramatically represses steatosis and HIF-1 mediated activation of MCP-1 in ethanol-induced fatty liver injury in hepatocytes as well as in Kupferr cells. Our data demonstrated that High fat diet (HF) caused liver steatosis while an atherogenic diet (ATH) diet induced hepatocellular ballooning, but only the Ath+HF diet resulted in steatohepatitis with associated mitochondrial dysfunction and impaired mitochondriogenesis."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22026270",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1161,
"text": "INTRODUCTION: Products of oxidizing cholesterol-called oxysterols, are having different physicochemical properties and various from not-modified sterols, biological activity. Amongst characteristic effects of these connections are: stopping the activity of HMG-CoA reductase, antiproliferative action, apoptosis induction, changes in the structure and functioning of the cell membrane and influence on remodeling of the immunological system. Mechanisms of oxysterols influence on the cellular level include a broad spectrum of complicated biological activities and they haven't been examined to the end yet.MATERIAL AND METHODS: In order to experiment execution the rat livers have been collected and the microscope sections have been made by standard technics, staining by haematoxylin and eosin (H&E). In each preparation 222 hepatic cells surrounding 10 central veins have been analysed and 222 hepatic cells occuring around 10 triads. The total surface ofcell, nucleus and cytoplasm have been taken for analysis.RESULTS: In all researched cases the analysed parameters have been reduced in area liver traid and central vein. Decreasing of area value of cell"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/11111082",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 379,
"text": "Oxysterols, herein defined as derivatives of cholesterol with a hydroxyl group on the side chain, play several roles in lipid metabolism. Members of this class regulate the expression of genes that participate in both sterol and fat metabolism, serve as substrates for the synthesis of bile acids, and are intermediates in the transfer of sterols from the periphery to the liver."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/7657597",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 831,
"text": "Cholesterol oxidation products (oxysterols) have been detected in many different tissues, often at concentrations 10(3) to 10(4) times lower than cholesterol. This constitutes a considerable risk of quantitation errors, since even a minor oxidation of cholesterol during sample processing would yield a substantial increase of oxysterol levels. It has therefore been suggested that some of the oxysterols do not occur in vivo and their detection in tissues merely are artifacts produced in vitro. In the present work, an 18O2 inhalation technique was developed in order to clarify which oxysterols are produced in vivo. Rats were exposed for 3 h to an atmosphere with a composition similar to normal air, except that it contained 18O2 instead of 16O2. Control rats were kept in 16O2-containing atmosphere throughout the experiment."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/11239823",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1443,
"text": "Cholesterol oxidation products (oxysterols) have been implicated in atherogenesis due to their presence in atherosclerotic tissue and their potent effects in vitro. One of the major oxysterols currently of interest is 7-ketocholesterol (7K) and it has been suggested that the diet is an important source of this oxysterol. This investigation tested the hypothesis that 7K, delivered in a physiologically relevant vehicle, chylomicron remnant-like emulsion (CMR), would be metabolised and excreted by mice in a similar manner and to a similar extent as previously observed in rats when delivered in a chemically modified lipoprotein, acetylated low-density lipoprotein (acLDL). Indeed, the metabolism of 14C-7K delivered in CMR mirrored that of acLDL and was much more rapid than (3)H-cholesterol delivered simultaneously. The 7K-derived (14)C was cleared from the liver, appeared in the intestine and was excreted in the faeces. A substantial proportion of the 7K-derived (14)C in the intestine and faeces was aqueous-soluble, indicating metabolism to polar products, presumably bile acids. Moreover, while cholesterol-derived (3)H increased in the aorta, (14)C appeared transiently and there was no observable accumulation within 24 h. The data confirm our previous findings of rapid hepatic metabolism of 7K when delivered in acLDL and demonstrate that 7K delivered in a vehicle of dietary significance is similarly metabolised and excreted."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23773414",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1091,
"text": "Oxysterols (oxidised cholesterol) may play a role in the pathogenesis of CVD. Similar to cholesterol, plant sterols are susceptible to oxidation. However, less is known about the potential atherogenicity of oxidised plant sterols (oxyphytosterols). In the present study, the atherogenicity of a mixture of oxyphytosterols was examined by feeding female LDL receptor-deficient (LDLR+/ -) mice for 35 weeks a control diet (atherogenic high-fat diet; n 9), an oxysterol diet (control diet+0·025 % (w/w) oxysterols; n 12) or an oxyphytosterol diet (control diet+0·025 % (w/w) oxyphytosterols; n 12). In the LDLR+/ - mice, serum levels of cholesterol, lipoprotein profiles, cholesterol exposure and inflammatory markers at the end of the experiment were comparable between the three diet groups. Nevertheless, the proportion of severe atherosclerotic lesions was significantly higher after oxysterol (41 %; P= 0·004) and oxyphytosterol (34 %; P= 0·011) diet consumption than after control diet consumption (26 %). Oxyphytosterol levels in the lesions were the highest in the oxyphytosterol group."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31586653",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 587,
"text": "The research literature on atherosclerosis includes findings investigating the atherosclerotic effect of oxysterols, which are the oxidation products of cholesterol; and the literature on oxysterols refers to mechanisms by which oxysterols cause phospholipid packing defects in cell membranes. This review synthesizes these two bodies of research findings to describe how oxysterols cause phospholipid packing defects within the membranes of vascular endothelial cells, potentially increasing cell permeability of low-density lipoprotein cholesterol which may lead to atheroma formation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/12323083",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 418,
"text": "There are conflicting reports regarding the effect of dietary cholesterol-oxidation products (oxysterols) on the development of atherosclerosis in experimental animals. To address this issue, apolipoprotein (Apo) E-deficient mice were fed a purified diet (AIN-93) or the same purified diet containing 0.2 g cholesterol or 0.2 g oxysterols/kg. The dietary oxysterols had no significant effect on the serum lipid levels."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32335907",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 201,
"text": "Oxysterols are oxygenated forms of cholesterol generated via autooxidation by free radicals and ROS, or formed enzymically by a variety of enzymes such as those involved in the synthesis of bile acids."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31301352",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 120,
"text": "Oxysterols are oxidized derivatives of cholesterol that are formed enzymatically or via reactive oxygen species or both."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29421651",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 85,
"text": "Oxysterols are oxidised derivatives of cholesterol or its precursors post lanosterol."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32175830",
"endSection": "abstract",
"offsetInBeginSection": 139,
"offsetInEndSection": 257,
"text": "Oxidation of cholesterol leads to the formation of a large number of oxidized products, generally known as oxysterols."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32574926",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 222,
"text": "Oxysterols are critical regulators of inflammation and cholesterol metabolism in cells. They are oxidation products of cholesterol and may be differentially metabolised in subcellular compartments and in biological fluids."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32574926",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 428,
"text": "Oxysterols are critical regulators of inflammation and cholesterol metabolism in cells. They are oxidation products of cholesterol and may be differentially metabolised in subcellular compartments and in biological fluids. New analytical methods are needed to improve our understanding of oxysterol trafficking and the molecular interplay between the cellular compartments required to maintain cholesterol/oxysterol homeostasis."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/19248802",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 118,
"text": "Oxysterols are oxidized derivatives of cholesterol or by-products of cholesterol biosynthesis with multiple functions."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24970128",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 141,
"text": "Oxysterols are oxidized 27-carbon cholesterol derivatives or by-products of cholesterol biosynthesis, with a spectrum of biologic activities."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25255963",
"endSection": "abstract",
"offsetInBeginSection": 307,
"offsetInEndSection": 531,
"text": " cholesterol. Oxysterols are products of cholesterol oxidation that accumulate in conditions associated with increased cellular levels of reactive oxygen species, such as hypoxia and oxidative stress, activating LXR and inhi"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/17573819",
"endSection": "abstract",
"offsetInBeginSection": 112,
"offsetInEndSection": 302,
"text": "Oxysterols and other cholesterol oxidation products are effective ligands of liver X activated receptor (LXR) nuclear receptors, major regulators of genes subserving cholesterol homeostasis."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36316327",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 206,
"text": "Oxysterols are oxygenated derivatives of cholesterol that contain an additional hydroxy, epoxide, or ketone group in the sterol nucleus and/or a hydroxyl group in the side chain of the cholesterol molecule."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35154132",
"endSection": "abstract",
"offsetInBeginSection": 249,
"offsetInEndSection": 368,
"text": "Oxysterols are oxidized forms of cholesterol that regulate cellular cholesterol and alter immune responses to bacteria."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/19035881",
"endSection": "abstract",
"offsetInBeginSection": 443,
"offsetInEndSection": 816,
"text": "Oxysterols are formed in amounts proportional to cholesterol content in the cell and therefore LXR operate as cholesterol sensors which protect from cholesterol overload by inhibiting intestinal cholesterol absorption, stimulating cholesterol efflux from cells to high-density lipoproteins (HDL), its transport to the liver, conversion to bile acids, and biliary excretion."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/7657597",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 158,
"text": "Cholesterol oxidation products (oxysterols) have been detected in many different tissues, often at concentrations 10(3) to 10(4) times lower than cholesterol."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24333430",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 189,
"text": "Liver X receptors LXRα (NR1H3) and LXRβ (NR1H2) are transcription factors belonging to the nuclear receptor superfamily, activated by specific oxysterols, oxidized derivatives of cholestero"
}
] | 13
|
BioASQ-training13b
| null | null |
662a4b08b9f8b89d7e00000b
| 5,170
|
factoid
|
Which chromosome is most commonly affected by loss of heterozygosity in glioblastoma?
|
['Chromosome 10', '10']
|
[
"Chromosome 10",
"10",
"chr10",
"Chromosome X",
"Chromosome Ten"
] |
['Glioblastomas develop de novo (primary glioblastomas) or through progression from low-grade or anaplastic astrocytoma (secondary glioblastomas). There is increasing evidence that these glioblastoma subtypes develop through different genetic pathways. Loss of heterozygosity (LOH) on chromosome 10 is the most frequent genetic alteration in glioblastomas. In particular, LOH on 10q is a major factor in the evolution of glioblastoma multiform as the common phenotypic endpoint of both genetic pathways, whereas LOH on 10p is largely restricted to the primary glioblastoma.', 'The most common genetic alteration in glioblastomas is loss of heterozygosity (LOH) on chromosome 10. This chromosomal loss is a significant factor in the development of glioblastoma multiform, which can occur through two different genetic pathways: de novo (primary glioblastomas) or progression from low-grade or anaplastic astrocytoma (secondary glioblastomas). LOH on 10q is a major factor in the evolution of glioblastoma multiform for both genetic pathways, while LOH on 10p is predominantly restricted to the primary (de novo) glioblastoma. In summary, chromosome 10 is the chromosome most commonly affected by LOH in glioblastoma.', 'The most frequent genetic alteration in glioblastomas, a type of brain tumor, is the loss of heterozygosity (LOH) on chromosome 10. This occurs specifically on the long arm of chromosome 10, denoted as LOH 10q. This genetic change is common to both primary and secondary glioblastomas, suggesting it plays a significant role in the development and progression of these tumors. While LOH on 10p also occurs, it is mostly restricted to primary (de novo) glioblastomas. Therefore, chromosome 10, particularly 10q, is the most commonly affected chromosome by LOH in glioblastoma.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/17691218",
"http://www.ncbi.nlm.nih.gov/pubmed/10604735",
"http://www.ncbi.nlm.nih.gov/pubmed/28960585",
"http://www.ncbi.nlm.nih.gov/pubmed/8641967",
"http://www.ncbi.nlm.nih.gov/pubmed/34970477",
"http://www.ncbi.nlm.nih.gov/pubmed/9591629",
"http://www.ncbi.nlm.nih.gov/pubmed/15924253",
"http://www.ncbi.nlm.nih.gov/pubmed/1975510",
"https://pubmed.ncbi.nlm.nih.gov/19430887/",
"http://www.ncbi.nlm.nih.gov/pubmed/9690672",
"http://www.ncbi.nlm.nih.gov/pubmed/1415476",
"http://www.ncbi.nlm.nih.gov/pubmed/1346255",
"http://www.ncbi.nlm.nih.gov/pubmed/9285695",
"http://www.ncbi.nlm.nih.gov/pubmed/9393744",
"http://www.ncbi.nlm.nih.gov/pubmed/1384665",
"http://www.ncbi.nlm.nih.gov/pubmed/7621407",
"http://www.ncbi.nlm.nih.gov/pubmed/9885980",
"http://www.ncbi.nlm.nih.gov/pubmed/8098856",
"http://www.ncbi.nlm.nih.gov/pubmed/1357919",
"http://www.ncbi.nlm.nih.gov/pubmed/10433932",
"http://www.ncbi.nlm.nih.gov/pubmed/10653004",
"http://www.ncbi.nlm.nih.gov/pubmed/10560660",
"http://www.ncbi.nlm.nih.gov/pubmed/1320666",
"http://www.ncbi.nlm.nih.gov/pubmed/8651304",
"http://www.ncbi.nlm.nih.gov/pubmed/10850866",
"http://www.ncbi.nlm.nih.gov/pubmed/19430887",
"http://www.ncbi.nlm.nih.gov/pubmed/21483128",
"http://www.ncbi.nlm.nih.gov/pubmed/1975968",
"http://www.ncbi.nlm.nih.gov/pubmed/7687872",
"http://www.ncbi.nlm.nih.gov/pubmed/8370584",
"http://www.ncbi.nlm.nih.gov/pubmed/2544511",
"http://www.ncbi.nlm.nih.gov/pubmed/9499454"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/10653004",
"endSection": "abstract",
"offsetInBeginSection": 439,
"offsetInEndSection": 551,
"text": "Loss of heterozygosity (LOH) on chromosome 10 (LOH#10) is the most frequent genetic alteration in glioblastomas;"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/10653004",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 250,
"text": "Glioblastomas develop de novo (primary glioblastomas) or through progression from low-grade or anaplastic astrocytoma (secondary glioblastomas). There is increasing evidence that these glioblastoma subtypes develop through different genetic pathways."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/10653004",
"endSection": "abstract",
"offsetInBeginSection": 1090,
"offsetInEndSection": 1353,
"text": "These results are in accordance with the view that LOH on 10q is a major factor in the evolution of glioblastoma multiform as the common phenotypic end point of both genetic pathways, whereas LOH on 10p is largely restricted to the primary (de novo) glioblastoma."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34970477",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 74,
"text": "Loss of heterozygosity (LOH) on chromosome 10 frequently occurs in gliomas"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/10653004",
"endSection": "abstract",
"offsetInBeginSection": 439,
"offsetInEndSection": 631,
"text": "Loss of heterozygosity (LOH) on chromosome 10 (LOH#10) is the most frequent genetic alteration in glioblastomas; the involvement of tumor suppressor genes, other than PTEN, has been suggested."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28960585",
"endSection": "abstract",
"offsetInBeginSection": 86,
"offsetInEndSection": 253,
"text": "Loss of heterozygosity (LOH) at markers of the long arm of chromosome 10 is the most common genetic alteration in glioblastoma, being detectable in up to 80% of cases."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/8370584",
"endSection": "abstract",
"offsetInBeginSection": 342,
"offsetInEndSection": 519,
"text": "The most common genetic alteration detected involved allele losses of chromosome 10 loci; these losses were observed in all glioblastomas and in three of the anaplastic gliomas."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/10433932",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 143,
"text": "Loss of heterozygosity on chromosome 10 (LOH#10) is the most frequent genetic alteration in glioblastomas and occurs in more than 80% of cases."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/10653004",
"endSection": "abstract",
"offsetInBeginSection": 831,
"offsetInEndSection": 970,
"text": "The majority (88%) of primary glioblastomas with LOH#10 showed LOH at all informative markers, suggesting loss of the entire chromosome 10."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/10604735",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 119,
"text": "Loss of heterozygosity (LOH) for chromosome 10 is the most frequent genetic abnormality observed in high-grade gliomas."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34970477",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 75,
"text": "Loss of heterozygosity (LOH) on chromosome 10 frequently occurs in gliomas."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/15924253",
"endSection": "abstract",
"offsetInBeginSection": 100,
"offsetInEndSection": 236,
"text": "Loss of heterozygosity of chromosome 10 and mutations in the tumor suppressor gene PTEN on 10q are molecular hallmarks of glioblastomas."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/9393744",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 124,
"text": "Loss of heterozygosity (LOH) from chromosome 10 is a hallmark of glioblastoma, the most malignant (grade IV) form of glioma."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/10850866",
"endSection": "abstract",
"offsetInBeginSection": 263,
"offsetInEndSection": 535,
"text": "Primary glioblastomas are characterized by EGFR amplification/overexpression, PTEN mutation, homozygous p16 deletion, and loss of heterozygosity (LOH) on entire chromosome 10, whereas secondary glioblastomas frequently contain p53 mutations and show LOH on chromosome 10q."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/9690672",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 179,
"text": "Loss of heterozygosity (LOH) on chromosome 10 is the most frequent genetic alteration associated with the evolution of malignant astrocytic tumors and it may involve several loci."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/10653004",
"endSection": "abstract",
"offsetInBeginSection": 439,
"offsetInEndSection": 550,
"text": "Loss of heterozygosity (LOH) on chromosome 10 (LOH#10) is the most frequent genetic alteration in glioblastomas"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/8651304",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 317,
"text": "The loss of genetic material on chromosome 10q is frequent in different tumors and particularly in malignant gliomas. We analyzed 90 of these tumors and found loss of heterozygosity (LOH) in >90% of the informative loci in glioblastoma multiforme (GBM). Initial studies restricted the common LOH region to 10q24-qter."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/1346255",
"endSection": "abstract",
"offsetInBeginSection": 1267,
"offsetInEndSection": 1394,
"text": "LOH on chromosome 10 was found in 61% of glioblastomas, in 23% of anaplastic astrocytomas, but in 0% of low-grade astrocytomas."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/10560660",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 104,
"text": "The genetic abnormality most frequently identified in glioblastomas is loss of alleles on chromosome 10."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/9591629",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 86,
"text": "Deletions of chromosome 10 are the most frequent genetic abnormality in glioblastomas."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28960585",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 253,
"text": "Glioblastoma is the most frequent and aggressive brain tumor in the adult population. Loss of heterozygosity (LOH) at markers of the long arm of chromosome 10 is the most common genetic alteration in glioblastoma, being detectable in up to 80% of cases."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/9499454",
"endSection": "abstract",
"offsetInBeginSection": 75,
"offsetInEndSection": 258,
"text": "Allelic deletions encompassing all or part of chromosome 10q occur frequently in GBMs, indicating that loss of one or more tumor suppressor genes on 10q plays a role in GBM formation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/7687872",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 230,
"text": "Cytogenetic and restriction fragment length polymorphism (RFLP) studies have shown that loss of one entire copy of chromosome 10 is a common genetic event in glioblastoma multiforme, the most malignant glial brain tumor in humans."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/1975510",
"endSection": "abstract",
"offsetInBeginSection": 1070,
"offsetInEndSection": 1286,
"text": "A high-resolution restriction fragment length polymorphism study of chromosome 10 loci in these patients showed that loss of broad regions of chromosome 10 was a common event, particularly in glioblastoma multiforme."
}
] | 13
|
BioASQ-training13b
| null | null |
6630154c187cba990d000021
| 5,172
|
factoid
|
Which genetic alteration is most commonly associated with the classical subtype of glioblastoma?
|
['Epidermal growth factor receptor (EGFR) amplification', 'EGFR amplification', 'EGFR gene amplification', 'Amplification of the epidermal growth factor receptor (EGFR)', 'EGFR overexpression', 'high EGFR expression']
|
[
"Epidermal growth factor receptor (EGFR) amplification",
"EGFR amplification",
"EGFR gene amplification",
"Amplification of the epidermal growth factor receptor (EGFR)",
"EGFR overexpression",
"high EGFR expression",
"EGFR",
"epidermal growth factor receptor",
"ErbB-1",
"HER1"
] |
['The classical subtype of glioblastoma is most commonly associated with epidermal growth factor receptor (EGFR) gene amplification, occurring in 40-60% of cases. Despite EGFR overexpression contributing to the aggressive nature of GBM and numerous clinical trials for targeted therapies, no significant benefits have been reported due to resistance factors such as tumor heterogeneity, alternative pathways, and blood-brain barrier. Further understanding of these mechanisms is crucial for effective treatment strategies.', 'Despite all of the progress in understanding its molecular biology and pathogenesis, glioblastoma (GBM) is one of the most aggressive types of cancer, and without an efficient treatment modality at the moment, it remains largely incurable. Nowadays, it is known that epidermal growth factor receptor (EGFR) amplification is one of the most commonly associated genetic alterations of the classical subtype of glioblastoma. However, targeted therapies against this type of receptor have not yet shown a clear clinical benefit.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/37446288",
"http://www.ncbi.nlm.nih.gov/pubmed/22539962",
"http://www.ncbi.nlm.nih.gov/pubmed/24410805",
"http://www.ncbi.nlm.nih.gov/pubmed/26757882",
"http://www.ncbi.nlm.nih.gov/pubmed/34608482",
"http://www.ncbi.nlm.nih.gov/pubmed/33053208",
"http://www.ncbi.nlm.nih.gov/pubmed/24457079",
"http://www.ncbi.nlm.nih.gov/pubmed/30680510",
"http://www.ncbi.nlm.nih.gov/pubmed/20129251",
"http://www.ncbi.nlm.nih.gov/pubmed/32998960",
"http://www.ncbi.nlm.nih.gov/pubmed/33435537",
"http://www.ncbi.nlm.nih.gov/pubmed/31733287"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37446288",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 598,
"text": "Despite all of the progress in understanding its molecular biology and pathogenesis, glioblastoma (GBM) is one of the most aggressive types of cancers, and without an efficient treatment modality at the moment, it remains largely incurable. Nowadays, one of the most frequently studied molecules with important implications in the pathogenesis of the classical subtype of GBM is the epidermal growth factor receptor (EGFR). Although many clinical trials aiming to study EGFR targeted therapies have been performed, none of them have reported promising clinical results when used in glioma patients."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33435537",
"endSection": "abstract",
"offsetInBeginSection": 463,
"offsetInEndSection": 692,
"text": "It is known that epidermal growth factor receptor (EGFR) amplification is a characteristic of the classical subtype of glioma. However, targeted therapies against this type of receptor have not yet shown a clear clinical benefit."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31733287",
"endSection": "abstract",
"offsetInBeginSection": 370,
"offsetInEndSection": 836,
"text": "We tested this assumption by a multilevel analysis ranging from a detailed histopathological analysis to a genome-wide expression profiling by microarray and RNA-seq on gliomas induced by two distinct molecular alterations: the overstimulation of the PDGF- and the EGF- pathways. These alterations are landmarks of proneural and classical glioblastoma subtypes respectively. However, our results consistently showed a strong similarity between the two glioma models."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30680510",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 118,
"text": "EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33053208",
"endSection": "abstract",
"offsetInBeginSection": 587,
"offsetInEndSection": 713,
"text": "FHL1 is highly expressed and positively correlated with EGFR levels in human GBM, particularly those of the classical subtype."
}
] | 13
|
BioASQ-training13b
| null | null |
663016bb187cba990d000023
| 5,178
|
factoid
|
What is PUL-2 in Duchenne Muscular Dystrophy?
|
['Performance of Upper Limb', 'assessement measure of upper limb function']
|
[
"Performance of Upper Limb",
"assessement measure of upper limb function",
"Upper Limb Performance",
"Upper Limb Function Assessment",
"Upper Extremity Performance",
"Upper Extremity Function Assessment",
"Assessment of Upper Limb Performance",
"Upper Limb Assessment Measure"
] |
['PUL 2.0 is the performance of upper limb 2.0 (PUL) and is widely used to assess upper limb function in DMD patients.', 'PUL-2, or Performance of the Upper Limb 2.0, is a measure used to assess upper limb function in patients with Duchenne Muscular Dystrophy.', 'The Performance of Upper Limb version 2.0 (PUL 2.0) is a widely used tool to assess upper limb function in Duchenne Muscular Dystrophy patients.', 'PUL 2.0 or Performance of Upper Limb 2.0 is a tool used to assess the function of the upper limbs in patients with Duchenne Muscular Dystrophy (DMD).', 'PUL-2, or Performance of Upper Limb 2.0, is a standardized assessment tool used to evaluate upper limb function in Duchenne Muscular Dystrophy (DMD) patients', 'PUL (Performance of Upper Limb) 2.0 is a widely used assessment tool to evaluate upper limb function in patients with Duchenne Muscular Dystrophy (DMD).', 'The performance of upper limb 2.0 in Duchenne Muscular Dystrophy is an assessment tool used to evaluate upper limb function in DMD patients.', 'The performance of upper limb 2.0 (PUL) is a widely used assessment tool to evaluate upper limb function in Duchenne Muscular Dystrophy (DMD) patients.', 'The performance of upper limb 2.0 (PUL) is widely used to assess upper limb function in DMD patients', 'The performance of upper limb 2.0 (PUL) is widely used to assess upper limb function in Duchenne Muscular Dystrophy.', 'PUL-2, or Performance of Upper Limb 2.0, is a tool used to assess upper limb function in patients with Duchenne Muscular Dystrophy (DMD).', 'The Performance of Upper Limb 2.0 (PUL-2) in Duchenne Muscular Dystrophy is a widely used assessment tool for evaluating upper limb function in patients with this condition.', 'PUL 2.0 (Performance of Upper Limb 2.0) is a functional assessment tool used to evaluate upper limb function in patients with Duchenne muscular dystrophy (DMD). It measures the ability to perform various upper limb tasks and helps track disease progression and treatment effects in DMD.', 'PUL-2 is a clinical scale for assessing the performance of the upper limb in patients with Duchenne muscular dystrophy.', 'The performance of upper limb 2.0 (PUL) is widely used to assess upper limb function in DMD patients.', 'PUL-2 is a component of the Performance of Upper Limb 2.0 (PUL) assessment tool, which is used to evaluate upper limb function in patients with Duchenne Muscular Dystrophy (DMD).', 'The Performance of Upper Limb version 2.0 (PUL 2.0) is increasingly used in Duchenne Muscular Dystrophy (DMD) to study longitudinal functional changes of motor upper limb function in ambulant and non-ambulant patients.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/37066919"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37066919",
"endSection": "abstract",
"offsetInBeginSection": 12,
"offsetInEndSection": 113,
"text": "The performance of upper limb 2.0 (PUL) is widely used to assess upper limb function in DMD patients."
}
] | 13
|
BioASQ-training13b
| null | null |
66302487187cba990d000031
| 5,179
|
factoid
|
What is the average median survival for advanced colorectal cancer patients?
|
['32.4 months', '32 months', '24-30 months']
|
[
"32.4 months",
"32 months",
"24-30 months",
"two years and eight months",
"two years and six months",
"two years",
"two and a half years",
"two years and four months"
] |
['In summary, based on the provided data, the average median overall survival (OS) of advanced colorectal cancer patients has improved over time from approximately 22.6 months between 2004 and 2012 to around 32.4 months for those diagnosed between 2016 and 2019. The weighted average median survival for the entire period is about 28.0 months.', 'According to the abstracts provided, the average median survival for advanced colorectal cancer patients varies depending on the specific study and population. However, based on the information presented, it can be concluded that: * The median overall survival for metastatic colorectal cancer is nearly 2 years (Abstract 1). * Median survival in advanced colorectal cancer patients treated with 5-fluorouracil (5FU) and leucovorin (LV) is between 12 and 18 months, with a specific study reporting a median survival of 18 months (Abstract 3). * The median survival for advanced CRC reported in clinical trials now approaches 2 years (Abstract 4). * In untreated advanced colorectal cancer patients, the median survival was found to be 24 months (range 16-42) (Abstract 5). , Overall, the average median survival for advanced colorectal cancer patients appears to be around 18-24 months.', 'The average median survival for advanced colorectal cancer patients is 20 months.The addition of ramicurumab to second line therapy significantly improved median overall survival.KRAS gene mutation in colorectal cancer patients is closely associated with poor prognosis.Obesity is a risk factor for poor overall survival in patients with colorectal cancer.EGFR, primary tumor site, and multiple metastases of tumor are independent risk factors for poor overall survival in patients with colorectal cancer.Fluorouracil has been the mainstay of chemotherapy for advanced colorectal cancer for over 40 years and is effective in prolonging time to disease progression and survival.', 'Median OS was roughly stable for patients diagnosed between 2004 and 2012 (22.6 months) but since has steadily improved for those diagnosed in 2013 to 2015 (28.8 months), and 2016 to 2019 (32.4 months.', 'The average median survival for advanced colorectal cancer patients is 25 months.', 'The average median survival for advanced colorectal cancer patients has been roughly stable for those diagnosed between 2004 and 2012 at 22.6 months, but has shown a steady improvement for those diagnosed in 2013 to 2015 (28.8 months) and 2016 to 2019 (32.4 months).', 'Median OS was roughly stable for patients diagnosed between 2004 and 2012 (22.6 months) but since has steadily improved for those diagnosed in 2013 to 2015 (28.8 months), and 2016 to 2019 (32.4 months)', '32.4 months\n\nContext: The median OS was 22.6 months for patients diagnosed between 2004 and 2012, 28.8 months for those diagnosed in 2013 to 2015, and 32.4 months for those diagnosed in 2016 to 2019.\nQuestion: What is the average median survival for advanced colorectal cancer patients?\nAnswer: 32.4 months\n\nContext: The median OS was 22.6 months for patients diagnosed between 2004 and 2012, 28.8 months for those diagnosed in 2013 to 2015, and 32.4 months for those diagnosed in 2016 to 2019.\nQuestion: What is the average median survival for advanced colorectal cancer patients?\nAnswer: 32.4 months\n\nContext: The median OS was 22.6 months for patients diagnosed between 2004 and 2012, 28.8 months for those diagnosed in 2013 to 2015, and 32.4 months for those diagnosed in 2016 to 2019.\nQuestion: What is the average median survival for advanced colorectal cancer patients?\nAnswer: 32.4 months\n\nContext:', 'The average median survival for advanced colorectal cancer patients has steadily improved over time, with the median OS being 22.6 months for those diagnosed between 2004 and 2012, 28.8 months for those diagnosed in 2013 to 2015, and 32.4 months for those diagnosed in 2016 to 2019.', 'The average median survival for advanced colorectal cancer patients is approximately 20-24 months based on various studies; however, the median overall survival has increased over time due to advancements in treatment strategies.', 'The average median survival for advanced colorectal cancer patients has improved over time. For patients diagnosed between 2004 and 2012, the median OS was 22.6 months, while for those diagnosed in 2013 to 2015, it was 28.8 months, and for those diagnosed in 2016 to 2019, it was 32.4 months.', 'The average median survival time for advanced colorectal cancer patients is approximately 15 months. This is based on the data from several studies that report median survival times ranging from 6 to 25 months. It is important to note that the survival time can vary depending on the stage of the disease, the treatment regimen, and other patient-specific factors.', 'Based on the provided information, the median survival time for patients with advanced or metastatic colorectal cancer ranges from approximately 6 to 25 months, depending on factors such as extent of metastases and treatment received.\n\nWithout treatment, median survival is around 7.5 to 11 months. Systemic chemotherapy modestly improves median survival to about 12 months. More aggressive treatments like regional chemotherapy or combined chemotherapy regimens (e.g. FOLFOX, FOLFIRI) can extend median survival further to 15-17 months or even up to 23-25 months in some cases.\n\nHowever, even with treatment, 5-year survival rates remain low, ranging from under 5% to 31%. Advanced colorectal cancer is rarely curable, although treatments can prolong survival. Median survival is highly variable based on individual patient and cancer characteristics.', "The average median survival for advanced colorectal cancer patients, based on the abstracts provided, appears to be around 7 months. This estimate comes from a review of the natural history of disseminated colorectal cancer, which states that the overall median survival rate of patients with hepatic metastases from colorectal primary cancer is approximately 7 months. However, it's important to note that many patients survive for three years and some even live for more than ten years without any specific treatment. This variability in survival times underscores the complex nature of colorectal cancer and the importance of personalized medical approaches.", 'The median overall survival (OS) for patients diagnosed with advanced colorectal cancer has been improving over the years. For those diagnosed between 2004 and 2012, it was roughly 22.6 months. It improved to 28.8 months for those diagnosed between 2013 and 2015, and further improved to 32.4 months for those diagnosed between 2016 and 2019.', 'The average median survival for advanced colorectal cancer patients is 32.4 months.', "22.6 months for patients diagnosed between 2004 and 2012, 28.8 months for those diagnosed in 2013 to 2015, and 32.4 months for those diagnosed in 2016 to 2019. \n\nPlease go ahead and ask your question. I'll do my best to provide a concise answer. \n\n(Note: Please keep your question related to the context provided.)", "The average median survival for advanced colorectal cancer patients is not explicitly stated in the provided Wikipedia articles. However, the articles mention that the five-year survival rate in the United States was around 65% in 2014, and the individual likelihood of survival depends on factors such as the stage of the cancer, the ability to remove the cancer surgically, and the person's overall health. The articles also discuss various treatment options for colorectal cancer, including surgery, radiation therapy, chemotherapy, and targeted therapy, as well as the importance of early detection and prevention through lifestyle changes and regular screenings.\n\nBased on the provided articles, the median survival time for patients with inoperable liver metastases from colorectal cancer is 7.4 to 11 months. Systemic chemotherapy produces a modest improvement to 12 months, while regional chemotherapy produces a further improvement to 15 to 17 months. The median survival time after diagnosis of metastases is almost comparable with 17 months. The median survival time was 6 months in the entire cohort, 16 months, 7.5 months, 8.5 months for all patients, 11 months for patients with solitary hepatic tumour, and 7.5 months for those with multiple tumours. Combined with regimens such as FOLFOX or FOLFIRI, median survival rates have been increased to an average of 23 months. The 1Y-PFS was 28.5% (median survival time (MST): 7.4 months), 1Y-OS was 76.6% (MST not reached), 3Y-PFS was 5.5% (MST: 7.4 months), and 3Y-OS was 26.4% (MST: 25.2 months).", 'The average median overall survival (OS) of advanced colorectal cancer patients has improved over time: 22.6 months for diagnoses between 2004 and 2012, 28.8 months for those diagnosed between 2013 and 2015, and 32.4 months for those diagnosed between 2016 and 2019. The average median survival across these periods is approximately 28.0 months.', 'The average median survival for advanced colorectal cancer patients is 32.4 months, 28.8 months, and 22.6 months for the years 2016 to 2019, 2013 to 2015, and 2004 to 2012 respectively.', 'The median overall survival (OS) for advanced colorectal cancer patients has improved over time:\n\n- For those diagnosed between 2004 and 2012, median OS was roughly stable at 22.6 months\n- For those diagnosed from 2013 to 2015, median OS improved to 28.8 months \n- Most recently, for patients diagnosed between 2016 to 2019, the median OS further increased to 32.4 months\n\nIn summary, the average median survival for advanced colorectal cancer patients diagnosed in recent years is around 32 months, representing a substantial improvement compared to earlier time periods.', 'The average median survival for advanced colorectal cancer (CRC) patients cannot be precisely determined from the provided text, as it presents data on overall survival (OS) improvements over time at a single institution, the University of Texas M.D. Anderson Cancer Center (UTMDACC). However, some key points can help approximate an answer: , 1. Median OS for de novo metastatic CRC patients at UTMDACC was 22.6 months for those diagnosed between 2004 and 2012., 2. For patients diagnosed from 2013 to 2015, the median OS improved to 28.8 months, and further increased to 32.4 months for those diagnosed from 2016 to 2019. , Considering these figures, a rough estimate of the average median survival for advanced CRC patients may fall between 22.6 and 32.4 months, with an understanding', 'The average median survival for advanced colorectal cancer patients has been improving over the years. It was roughly stable at 22.6 months for patients diagnosed between 2004 and 2012, improved to 28.8 months for those diagnosed in 2013 to 2015, and further improved to 32.4 months for those diagnosed in 2016 to 2019.', 'The average median survival for advanced colorectal cancer patients is between 12-20 months, however, this can vary based on many factors such as patient demographics, disease presentation, treatment response, and comorbidities.', 'The average median survival for advanced colorectal cancer patients has been improving over the years. For patients diagnosed between 2004 and 2012, the median overall survival (OS) was about 22.6 months. This improved to 28.8 months for those diagnosed between 2013 and 2015, and further increased to 32.4 months for those diagnosed between 2016 and 2019', 'The median time to worsening of the ECOG performance-status score from 0 or 1 to 2 or more was 9.3 months in the combination group and 6.3 months in the FTD-TPI group (hazard ratio, 0.54; 95% CI, 0.43 to 0.67).', 'The average median survival for patients with advanced colorectal cancer has slightly improved over the years. For those diagnosed between 2004 and 2012, the median overall survival (OS) was 22.6 months. However, there has been a steady increase in survival for more recently diagnosed patients. Those diagnosed between 2013 and 2015 had a median OS of 28.8 months, while those diagnosed between 2016 and 2019 experienced a further improvement in survival, with a median OS of 32.4 months. Therefore, on average, the median survival for advanced colorectal cancer patients is around 27-32 months, based on the most recent data.', "The average median survival for advanced colorectal cancer patients is around 65% in the United States, according to 2014 data. However, survival rates can vary significantly and depend on various factors, including the stage of the cancer, the effectiveness of treatment, and the patient's overall health. Median survival time for patients with inoperable liver metastases from colorectal cancer is 7.4 to 17 months. When combined with regimens such as FOLFOX or FOLFIRI, median survival rates have been increased to an average of 23 months.", 'The average median survival for advanced colorectal cancer patients has been improving, with it being 22.6 months for those diagnosed between 2004 and 2012, 28.8 months for those diagnosed between 2013 and 2015, and 32.4 months for those diagnosed between 2016 and 2019.', 'The average median survival for advanced colorectal cancer patients is 25 months, with hepatic metastases showing a median survival of 7 months and current patients having an expected median survival of 20 months.', 'Advanced or metastatic colorectal cancer is a deadly disease with poor prognosis. Median survival for such patients is around 22-24 months, however, with novel therapeutic interventions, its been improved slightly.', 'Based on the provided information, the median overall survival for patients with advanced colorectal cancer has been improving in recent years:\n\nFor patients diagnosed between 2004 and 2012, median overall survival was around 22.6 months. \n\nFor those diagnosed from 2013 to 2015, median overall survival increased to 28.8 months.\n\nMost recently, for patients diagnosed between 2016 and 2019, the median overall survival further improved to 32.4 months.\n\nSo in summary, while advanced colorectal cancer remains difficult to cure, treatment advances have extended median survival from under 2 years to nearly 3 years over the past 15 years. However, individual prognosis still depends on factors like extent of disease, treatment options, and overall health.', 'The average median survival for advanced colorectal cancer patients has improved from 22.6 months between 2004 and 2012 to 28.8 months for those diagnosed in 2013 to 2015, and further improved to 32.4 months for those diagnosed in 2016 to 2019', 'The average median survival for advanced colorectal cancer patients has steadily improved over the years. For patients diagnosed between 2004 and 2012, the median overall survival (OS) was roughly stable at 22.6 months. However, for those diagnosed in 2013 to 2015, the median OS improved to 28.8 months, and for those diagnosed in 2016 to 2019, the median OS further improved to 32.4 months.', 'The average median survival for advanced colorectal cancer patients is around 65% in the United States, according to 2014 data. However, the median overall survival for patients diagnosed between 2004 and 2012 was 22.6 months, but it has steadily improved for those diagnosed in 2013 to 2015 (28.8 months) and 2016 to 2019 (32.4 months).', 'The average median survival for advanced colorectal cancer patients is 20 months. The addition of ramicurumab to second-line therapy significantly improved median overall survival. Immunotherapy has shown promise in GI malignancies, with the combination of pembrolizumab and chemotherapy extending median survival in patients with advanced colorectal cancer to 21 months. KRAS gene mutation is a poor prognostic factor in colorectal cancer patients, and advanced age and high TNM stage are independent risk factors for postoperative outcome in early-stage colorectal cancer patients. Class II and III obesity is associated with a modestly increased risk of disease recurrence and death in colorectal cancer patients. Fluorouracil has been the mainstay of chemotherapy for advanced colorectal cancer for over 40 years, and its use has been shown to prolong time to disease progression and survival in these patients.', 'Based on the information provided, the median survival time for patients with advanced colorectal cancer, specifically those with liver metastases, ranges from approximately 6 to 17 months without treatment or with systemic chemotherapy alone. Some key findings:\n\n- Without treatment, median survival is around 7.4 to 11 months\n- With systemic chemotherapy, median survival improves modestly to around 12 months \n- Regional chemotherapy can further improve median survival to 15-17 months\n- More recent combination regimens like FOLFOX or FOLFIRI have increased median survival to around 23 months on average\n\nSo in summary, median survival for advanced colorectal cancer with liver metastases is quite poor, typically under 1.5 years, but modern chemotherapy regimens have improved this to almost 2 years. The exact median survival depends on the specific treatment approach.', " In summary, advanced colorectal cancer patients have varied survival outcomes depending on the extent and location of the disease, the patient's age, overall health status, and the effectiveness of available treatment options. Improvements in early detection and prompt initiation of appropriate chemoradiation regimens can help improve patient outcomes and reduce the need for extensive surgery and associated morbidity. ", '30 months is the average median survival for advanced colorectal cancer patients, however it can vary based on several factors such as patient age, general health status, treatment response and presence of metastatic disease.', 'The average median survival is close to 15 months and in best-case scenario approximately 40 months.', 'According to the abstracts, the average median survival for advanced colorectal cancer patients varies from study to study. In one study, the median overall survival was reported to be nearly 2 years (20 months). Another study found a median survival of 18 months with a range of 12-18 months. A third study reported a median survival of 24 months in untreated advanced colorectal cancer patients. Overall, the median survival for advanced colorectal cancer patients appears to range from approximately 18-24 months, with some studies reporting longer or shorter median survivals depending on the specific patient population and treatment regimens used.', 'The median survival for advanced colorectal cancer patients is 12-18 months.', 'Based on the provided snippets, it appears that the question refers to the median overall survival (OS) of advanced colorectal cancer patients. The snippets suggest a steady improvement in median OS over time. , The median OS was roughly stable at 22.6 months for patients diagnosed between 2004 and 2012. However, for those diagnosed between 2013 and 2015, the median OS improved to 28.8 months, and further increased to 32.4 months for patients diagnosed between 2016 and 2019. , To calculate the average median survival, we can take a weighted average of these values based on the number of years in each period. Assuming equal weights, the average median OS would be approximately (22.6 + 28.8 + 32.4) / 3 = 28.0 months. , Therefore, the average median survival for advanced colorectal cancer patients is roughly 28.0 months.', 'The average median survival for advanced colorectal cancer patients is approximately 20-24 months, but has shown improvement over time due to advancements in treatment strategies. However, exact values can vary between studies and patient groups.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/36781990",
"http://www.ncbi.nlm.nih.gov/pubmed/1588370",
"http://www.ncbi.nlm.nih.gov/pubmed/22763194",
"http://www.ncbi.nlm.nih.gov/pubmed/7008761",
"http://www.ncbi.nlm.nih.gov/pubmed/15547753",
"http://www.ncbi.nlm.nih.gov/pubmed/10826427",
"http://www.ncbi.nlm.nih.gov/pubmed/3435011",
"http://www.ncbi.nlm.nih.gov/pubmed/32148114",
"http://www.ncbi.nlm.nih.gov/pubmed/12482332",
"http://www.ncbi.nlm.nih.gov/pubmed/34380826",
"http://www.ncbi.nlm.nih.gov/pubmed/22848257",
"http://www.ncbi.nlm.nih.gov/pubmed/30003196",
"http://www.ncbi.nlm.nih.gov/pubmed/36013160",
"http://www.ncbi.nlm.nih.gov/pubmed/33206858",
"http://www.ncbi.nlm.nih.gov/pubmed/31933846",
"http://www.ncbi.nlm.nih.gov/pubmed/29516930",
"http://www.ncbi.nlm.nih.gov/pubmed/36630020",
"http://www.ncbi.nlm.nih.gov/pubmed/37699362",
"http://www.ncbi.nlm.nih.gov/pubmed/11596040",
"http://www.ncbi.nlm.nih.gov/pubmed/30973370",
"http://www.ncbi.nlm.nih.gov/pubmed/32638384",
"http://www.ncbi.nlm.nih.gov/pubmed/29755763",
"http://www.ncbi.nlm.nih.gov/pubmed/16334762",
"http://www.ncbi.nlm.nih.gov/pubmed/38091773",
"http://www.ncbi.nlm.nih.gov/pubmed/14975808"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36781990",
"endSection": "abstract",
"offsetInBeginSection": 513,
"offsetInEndSection": 713,
"text": "Median OS was roughly stable for patients diagnosed between 2004 and 2012 (22.6 months) but since has steadily improved for those diagnosed in 2013 to 2015 (28.8 months), and 2016 to 2019 (32.4 months"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30973370",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1331,
"text": "OBJECTIVES: The survival of patients with metastatic colorectal cancer (CRC) has been increasing over recent decades due to improvements in chemotherapy and surgery. There is a need to refine prognostic information to more accurately predict survival as patients survive for any given length of time to assist multidisciplinary cancer management teams in treatment decisions.MATERIALS AND METHODS: We performed a single center retrospective analysis of patients treated with metastatic CRC (unresectable and resectable) who survived >24 months between 2005 and 2015 (N=155). Patient tumor and treatment related variables were collected. Overall survival (OS) estimates conditional on surviving >24 months were compared with actuarial survival estimates of a cohort of patients (33,104 resected, 39,382 unresected) from the National Cancer Database (NCDB).RESULTS: With a median follow-up of 44.2 months, the median OS of resected patients (n=86) was not reached. The median OS of unresected patients was 75.9 months. The conditional survival probabilities of living 1, 2, or 3 years longer after 24 months of survival are 92%, 72%, and 52%, respectively, in unresectable patients and 98%, 92%, and 89% in patients who were resected. The corresponding NCDB 1, 2, and 3 year actuarial survival was 38%, 20%, and 11% for unresected pa"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29516930",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1227,
"text": "CONTEXT: Colorectal cancers are frequent among cancers of gastrointestinal system. Whether there are any differences between survival in rectum and colon cancer patients is controversial.AIMS: In this study, we aimed to compare survival in surgically treated rectum and colon cancers and determine the factors affecting survival.SUBJECTS AND METHODS: The patients with colon and rectum cancer operated between 2009 and 2013 were examined retrospectively using prospective database. Patients were categorized as colon and rectum according to the tumor's location. Survival was identified as the primary outcome. Kaplan-Meier survival analysis and log-rank tests in survival assessment were used.RESULTS: One hundred and sixty-one patients with a mean age of 62.8 ± 12.7 years were included in the study. Male/female ratio was 1.6. Colon and rectum patients were counted as 92 (%57.1) and 69 (%42.9), respectively. Both groups were similar in demographic data (P > 0.05). It was observed that in 46 months (mean) of follow-up, 39.7% (n: 64) died, and 60.3% (n: 97) survived. Median survival time was 79 months, and 5-year cumulative survival rate was 60.8%. Five-year cumulative survival rates in stages for 1, 2, 3 and 4 were 88"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32638384",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1223,
"text": "Reported median overall survival (mOS) in metastatic colorectal cancer (mCRC) patients participating in systemic therapy trials has increased to over 30 months. It is uncertain whether trial results translate to real-life populations. Moreover, patients prefer presentation of multiple survival scenarios. Population-based data of all stage IV CRC patients diagnosed between 2008 and 2016 were obtained from the Netherlands Cancer Registry, which has a case ascertainment completeness surpassing 95%. We calculated the following percentiles (scenarios) of OS per year of diagnosis for the total population, and for treatment subgroups: 10th (best-case), 25th (upper-typical), 50th (median), 75th (lower-typical) and 90th (worst-case). Twenty-five percent of patients did not receive any antitumor treatment. From 2008 to 2016, mOS of the total population (n = 27275) remained unchanged at approximately 12 months. OS improved only for the upper-typical and best-case patients; by 4.2 to 29.1 months (P < .001), and by 6 to 62 months (P < .001), respectively. No clinically relevant change was observed among patients who received systemic therapy, with mOS close to 15 months and best-case scenario approximately 40 months."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34380826",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1019,
"text": "BACKGROUND: In this real-life practice study, we aimed to find whether elderly colorectal cancer (CRC) patients in our center were treated optimally and also if this has an effect on overall survival (OS) or not.METHODS: We have retrospectively screened 150 CRC patients older than 65 years, diagnosed in our institution between 2010 and 2018. As study variables, patient characteristics, tumor location, tumor, nodes, metastases stage, Eastern Cooperative Oncology Group performance status (ECOG PS), comorbidities, adjuvant or metastatic chemotherapy regimens, and treatment toxicity were recorded, and the OS rate of patients was assessed.RESULTS: The median age was 72 (range 65 - 89) years and 48 (32%) patients had metastatic disease at the time of diagnosis. The median OS (mOS) in the suboptimal adjuvant treatment group was 31.5 (range 20.7-42.3) months, whereas mOS was not reached during the median follow-up time in the optimal treatment group (P = 0.036). The addition of oxaliplatin to chemotherapy had no"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32148114",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 863,
"text": "Background: The study aimed to assess the overall and stage-specific colorectal cancer (CRC) survival and to identify the prognostic factors for survival among Thai patients.Research design and methods: The retrospective data of CRC patients from a university hospital-based cancer registry from 2001 to 2014 were used to estimate five-year overall survival (OS). Kaplan-Meier method and log-rank tests were used to assess the differences in five-year OS by age at diagnosis, diagnostic period, tumor site, stage at diagnosis and treatment modalities. A multivariate Cox's proportional hazard model was used to identify independent prognostic factors for the OS.Results: A total of 1,507 (48%) colon and 1,648 (52%) rectal cancer patients were included. Five-year OS for CRC patients was 44%. It differed significantly by stage, age group, and treatment received."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33206858",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 758,
"text": "BACKGROUND: Hospital-based studies recently have shown increases in colorectal cancer survival, and better survival for women, young people, and patients diagnosed at an early disease stage.OBJECTIVE: To describe the overall survival and analyze the prognostic factors of patients treated for colorectal cancer at an oncology center.METHODS: The analysis included patients diagnosed with colon and rectal adenocarcinoma between 2000 and 2013 and identified in the Hospital Cancer Registry at A.C.Camargo Cancer Center. Overall 5-year survival was estimated using the Kaplan-Meier method, and prognostic factors were evaluated in a Cox regression model. Hazard ratios (HR) are reported with 95% confidence intervals (CI).RESULTS: Of 2,279 colorectal cancer ca"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29755763",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 942,
"text": "BACKGROUND: An aging population and a high incidence of colorectal cancer (CRC) in patients over the age of 80 make it important to understand survival times, hazard ratios and prognostic factors in this group. A better understanding of these factors will help clinicians determine appropriate therapeutic strategies for such patients, including when more aggressive treatment strategies may be preferred to palliative treatment.METHODS: A retrospective analysis of 619 CRC patients of ≥80 years of age from 1991-2010 at Baylor Scott & White Hospital in Temple, Texas. Twelve variables were analyzed through statistical analysis as potential prognostic factors for survival. Univariate and multivariate Cox proportional hazard models were used to determine hazard ratios. The elderly population was further stratified by age subgroup (80-84, 85-89, ≥90).RESULTS: Median survival time was 53.6, 30.0, and 11.3 months for age groups of 80-84, 8"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37699362",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1245,
"text": "Introduction Survival of patients suffering from metastatic colorectal cancer (mCRC) has increased over the last decades. These benefits appear to be restricted to patients aged 50 and above. However, among the population aged < 50, CRC incidence and mortality rates are significantly rising. The clinical benefit of treatment in this population still is a matter of debate. We aim to compare the clinical outcome between patients aged 50 and younger. Methods In this retrospective, observational study, we analyzed data from 1077 patients treated for mCRC at three cancer centers in Austria from January 2005 to December 2019. Patients were divided into two groups based on age at diagnosis: <50 years (eo-CRC) and >50 years (regular-onset CRC, ro-CRC). Propensity score matching was used to control for potential biases, and survival outcomes were compared between the two groups. Results The differences in tumor characteristics between eo-CRC and ro-CRC in the overall population were primarily related to tumor sidedness and disease-free survival following intended curative resection. Our data show that eo-CRC patients underwent metastases resection more often and received significantly more lines of treatment in the palliative setting."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36630020",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 855,
"text": "PURPOSE: The purpose of this study was to evaluate clinical outcomes of standard therapies in previously treated, advanced colorectal cancer (CRC) patients.METHODS: A systematic literature review was conducted in Embase, MEDLINE, and CENTRAL databases (January 2000-July 2021), annual oncology conferences (2019-2021), and clinicaltrials.gov to identify studies evaluating the use of licensed interventions in second-line or later settings. The primary outcome of interest was objective response rate (ORR) and secondary outcomes included progression-free survival (PFS) and overall survival (OS). ORR was pooled using the Freeman-Tukey double arcsine transformation. For survival outcomes, published Kaplan-Meier curves for OS and PFS were digitized to re-construct individual patient-level data and pooled following the methodology described by Combescu"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22848257",
"endSection": "abstract",
"offsetInBeginSection": 1018,
"offsetInEndSection": 1099,
"text": "The results showed the median survival of patients to be 24 months (range 16-42)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22848257",
"endSection": "abstract",
"offsetInBeginSection": 1018,
"offsetInEndSection": 1184,
"text": "The results showed the median survival of patients to be 24 months (range 16-42). One-year survival was found to be 65% while the 2-year survival was found to be 25%."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/16334762",
"endSection": "abstract",
"offsetInBeginSection": 748,
"offsetInEndSection": 834,
"text": " median survival from the diagnosis of advanced/metastatic disease was 34.3 months. On"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22848257",
"endSection": "abstract",
"offsetInBeginSection": 1100,
"offsetInEndSection": 1395,
"text": "One-year survival was found to be 65% while the 2-year survival was found to be 25%. A satisfactory quality of life was also observed. In conclusion, colorectal cancer is a slow-going malignancy, as indicated by the long-term survival of patients and the biological characteristics of the tumor."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22848257",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 58,
"text": "Survival of untreated advanced colorectal cancer patients."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/12482332",
"endSection": "abstract",
"offsetInBeginSection": 797,
"offsetInEndSection": 998,
"text": "Recent randomized trials of first-line chemotherapy for metastatic colorectal cancer in which patients were likely to have access to all 3 effective drugs demonstrated median survivals of 18-20 months."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/15547753",
"endSection": "abstract",
"offsetInBeginSection": 1112,
"offsetInEndSection": 1195,
"text": "Survival of all patients was as follows: median 25 months (range 16.1-33.9 months)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/38091773",
"endSection": "abstract",
"offsetInBeginSection": 928,
"offsetInEndSection": 1032,
"text": "Median follow-up was 33 months (range 5-61) with a response rate of 63.6% and stable disease rate of 75%"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/15547753",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1350,
"text": "Our primary objective was to determine the median and overall survival and secondarily the response rate to first- and second-line chemotherapy of patients with advanced colorectal metastatic disease. Three-hundred and seventy-nine patients (median age 60 years, range 30-87 years) were enrolled from April 1993 to March 2000. Median follow-up was 6 years (range 3-10 years), until July 2003. All patients were evaluable for survival and 342 were evaluable for response and toxicity. Thirty-seven patients did not undergo chemotherapy. All patients had confirmed histology as well as metastatic disease based on radiological tests. First-line treatment was administered to 342 patients: leucovorin (LV) 30 mg/m2 and 5-fluorouracil (5-FU) 425 mg/m2. Three different combinations were given as second-line treatment during different chronological periods: i) 5-FU, mitomycin-C and doxorubicin (FAM); ii) 5-FU and cisplatin (CDDP) and iii) 5-FU, LV and irinotecan (CPT-II). Responses were observed as follows: first-line treatment 16.37%, after FAM 25%, following 5-FU-CDDP 26.83% and after 5-FU-LV-CPT-II, 30.61%. Survival of all patients was as follows: median 25 months (range 16.1-33.9 months). The longest survival was of patients on 5-FU-LV-CPT-II. Median survival of patients with stable disease was 19 months and of untreated patients 12 months."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/14975808",
"endSection": "abstract",
"offsetInBeginSection": 171,
"offsetInEndSection": 1589,
"text": "The last ten years allowed a rapid evolution for colon chemotherapy with a switch from 5-FU modulated by leucovorin to poly-chemotherapy (fluoropyrimidines with oxaliplatin or irinotecan) integrated into therapeutic strategies, where surgery had a place more and more important in metastatic patients. In correlation with these advances, median survival of patient with metastatic colorectal cancer is between 17 and 22 months. Targeted therapeutics with monoclonal antibody such as EGF inhibitors (cetuximab) or VEGF inhibitors (bevacizumab) had for the first time demonstrated efficacy with encouraging results in randomised trials. In adjuvant situation, LV5FU2 is less toxic than monthly FUFOL and no statistically significant difference could be detected in disease-free or overall survival between the two schedules. Oxaliplatin combined with 5 fluorouracil and leucovorin (FOLFOX4) is the first combination to demonstrate significant superiority over 5 fluorouracil and leucovorin in adjuvant treatment of colorectal cancer. Fluorouracil-based adjuvant chemotherapy benefited to patients with stage II or III colon cancer with microsatellite-stable tumours or tumour exhibiting low-frequency microsatellite instability but may be not those with tumours exhibiting high-frequency microsatellite instability (MSI). These data need to be confirmed by prospective studies before changing our therapeutic references."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/1588370",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1653,
"text": "PURPOSE: The advantage of chemotherapy in asymptomatic patients with advanced colorectal cancer is debatable. Whether early chemotherapy improves survival and the length of the symptom-free period versus no therapy until symptoms appear was studied in a randomized trial.PATIENTS AND METHODS: A total of 183 patients with advanced, but asymptomatic colorectal cancer were randomly allocated to receive either initial treatment with sequential methotrexate 250 mg/m2 during the first 2 hours, and fluorouracil (5-FU) 500 mg/m2 at hours 3 and 23 followed by leucovorin rescue initiated at hour 24 (MFL) for 12 courses or to primary expectancy with chemotherapy not considered until symptoms appeared. One patient was ineligible and excluded from analysis. Nine patients did not fulfill the inclusion criteria and five patients refused treatment allocation; these patients were not excluded from the study population so as not to introduce bias. So far, 51 of 90 (60%) patients in the expectancy group have received chemotherapy.RESULTS: Overall survival was better in the MFL group than in the expectancy group (Breslow-Gehan, P less than .02; log-rank, P = .13) with a difference in median survival of approximately 5 months. Also the symptom-free period and the time to disease progression were longer in the MFL group (P less than .001), with median differences of 8 and 4 months, respectively. Toxicity to MFL treatment was low; however, three patients died because of toxicity--none of them should have received therapy because of poor performance or S-creatinine elevation. The patients maintained an excellent performance throughout the MFL treatme"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/11596040",
"endSection": "abstract",
"offsetInBeginSection": 1208,
"offsetInEndSection": 1555,
"text": " trend was most pronounced for patients with colorectal carcinoma. At 5 years after the initial diagnosis, the remaining median survival was longest for patients with colorectal carcinoma, almost 6 years (71.5 months), followed by patients with lung carcinoma (52.5 months), breast carcinoma (42.5 months), and prostate carcinoma (34.5 months). Al"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/11596040",
"endSection": "abstract",
"offsetInBeginSection": 1278,
"offsetInEndSection": 1669,
"text": "5 years after the initial diagnosis, the remaining median survival was longest for patients with colorectal carcinoma, almost 6 years (71.5 months), followed by patients with lung carcinoma (52.5 months), breast carcinoma (42.5 months), and prostate carcinoma (34.5 months). Although race was a correlate with initial survival, gender and age had more impact on late conditional survival.CON"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/11596040",
"endSection": "abstract",
"offsetInBeginSection": 1208,
"offsetInEndSection": 1669,
"text": " trend was most pronounced for patients with colorectal carcinoma. At 5 years after the initial diagnosis, the remaining median survival was longest for patients with colorectal carcinoma, almost 6 years (71.5 months), followed by patients with lung carcinoma (52.5 months), breast carcinoma (42.5 months), and prostate carcinoma (34.5 months). Although race was a correlate with initial survival, gender and age had more impact on late conditional survival.CON"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/11596040",
"endSection": "abstract",
"offsetInBeginSection": 1278,
"offsetInEndSection": 1863,
"text": "5 years after the initial diagnosis, the remaining median survival was longest for patients with colorectal carcinoma, almost 6 years (71.5 months), followed by patients with lung carcinoma (52.5 months), breast carcinoma (42.5 months), and prostate carcinoma (34.5 months). Although race was a correlate with initial survival, gender and age had more impact on late conditional survival.CONCLUSIONS: The conditional median survival provides useful and encouraging information for patients who survive with advanced disease and for healthcare professionals who treat these patients. Ho"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/10826427",
"endSection": "abstract",
"offsetInBeginSection": 216,
"offsetInEndSection": 321,
"text": "ctively. Systemic chemotherapy produces a modest improvement to 48, 21, and 3 percent and 12 months, resp"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/10826427",
"endSection": "abstract",
"offsetInBeginSection": 322,
"offsetInEndSection": 434,
"text": "ctively. Regional chemotherapy produces a further improvement to 64, 25, and 5 percent and 15 to 17 months, resp"
}
] | 13
|
BioASQ-training13b
| null | null |
66099907fdcbea915f000015
| 5,181
|
factoid
|
Where in the body would the globus pallidus be found?
|
['brain', 'basal ganglia']
|
[
"brain",
"cerebrum",
"encephalon",
"basal ganglia",
"striatum",
"nucleus accumbens",
"putamen",
"globus pallidus",
"caudate nucleus"
] |
['The globus pallidus is a structure found in the brain.', 'The globus pallidus would be found in the brain.', 'The globus pallidus can be found in the basal ganglia, thalamus, and putamen.', 'The globus pallidus would be found in the basal ganglia.', 'The globus pallidus is a part of the basal ganglia, which is a group of nuclei located deep within the cerebral hemispheres of the brain.', 'The globus pallidus is found in the brain.', 'The globus pallidus is found in the brain. It is part of the basal ganglia, which is involved in the control of voluntary motor movements.', 'The globus pallidus is located in the brain.', 'The globus pallidus is a structure in the brain', 'The globus pallidus is located in the brain, specifically in regions such as the substantia nigra and nucleus accumbens.', 'The globus pallidus is found in the basal ganglia.', 'Globus pallidus is one of the components of the basal ganglia, located deep within the brain. It is responsible for the regulation of motor control and movement.', 'The globus pallidus is found in the basal ganglia of the brain.', 'The globus pallidus is found deep within the brain', 'The globus pallidus is located in the basal ganglia.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/36418626",
"http://www.ncbi.nlm.nih.gov/pubmed/26917269",
"http://www.ncbi.nlm.nih.gov/pubmed/31927758",
"http://www.ncbi.nlm.nih.gov/pubmed/7133405",
"http://www.ncbi.nlm.nih.gov/pubmed/14614896",
"http://www.ncbi.nlm.nih.gov/pubmed/2428943",
"http://www.ncbi.nlm.nih.gov/pubmed/32906651",
"http://www.ncbi.nlm.nih.gov/pubmed/30262639",
"http://www.ncbi.nlm.nih.gov/pubmed/33409084",
"http://www.ncbi.nlm.nih.gov/pubmed/15169693",
"http://www.ncbi.nlm.nih.gov/pubmed/2579980",
"http://www.ncbi.nlm.nih.gov/pubmed/36309960",
"http://www.ncbi.nlm.nih.gov/pubmed/34129267",
"http://www.ncbi.nlm.nih.gov/pubmed/36895960",
"http://www.ncbi.nlm.nih.gov/pubmed/36378365",
"http://www.ncbi.nlm.nih.gov/pubmed/36719479",
"http://www.ncbi.nlm.nih.gov/pubmed/31778724",
"http://www.ncbi.nlm.nih.gov/pubmed/37403078",
"http://www.ncbi.nlm.nih.gov/pubmed/37660542",
"http://www.ncbi.nlm.nih.gov/pubmed/1380517",
"http://www.ncbi.nlm.nih.gov/pubmed/18688722",
"http://www.ncbi.nlm.nih.gov/pubmed/3469674",
"http://www.ncbi.nlm.nih.gov/pubmed/30822586",
"http://www.ncbi.nlm.nih.gov/pubmed/12764086",
"http://www.ncbi.nlm.nih.gov/pubmed/30077619",
"http://www.ncbi.nlm.nih.gov/pubmed/37336974",
"http://www.ncbi.nlm.nih.gov/pubmed/36724759",
"http://www.ncbi.nlm.nih.gov/pubmed/4063830",
"http://www.ncbi.nlm.nih.gov/pubmed/15322674",
"http://www.ncbi.nlm.nih.gov/pubmed/1401259",
"http://www.ncbi.nlm.nih.gov/pubmed/37492559",
"http://www.ncbi.nlm.nih.gov/pubmed/2153714",
"http://www.ncbi.nlm.nih.gov/pubmed/26706479",
"http://www.ncbi.nlm.nih.gov/pubmed/37532091",
"http://www.ncbi.nlm.nih.gov/pubmed/20107133"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36724759",
"endSection": "abstract",
"offsetInBeginSection": 277,
"offsetInEndSection": 522,
"text": "This pilot study was conducted in 4 patients with Parkinson's disease (PD) who underwent MRI-guided deep brain stimulation of the globus pallidus internus (GPi). CSF was obtained via lumbar puncture after general anesthesia and prior to incision"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36719479",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 160,
"text": "We and others have observed reduced volumes of brain regions, including the nucleus accumbens, globus pallidus, hypothalamus, and habenula in opioid addiction. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36418626",
"endSection": "abstract",
"offsetInBeginSection": 355,
"offsetInEndSection": 731,
"text": "Quantitative susceptibility mapping (QSM) was performed, and magnetic susceptibility was measured using three-dimensional volumes of interest (VOIs) for the caudate nucleus (CN), globus pallidus (GP), putamen (PT), and ventrolateral thalamic nucleus (VL). Cross-sectional analysis was performed for 99 patients with normal development and 39 patients with delayed development."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36378365",
"endSection": "abstract",
"offsetInBeginSection": 169,
"offsetInEndSection": 298,
"text": " Several reports have shown that deep brain stimulation (DBS) of the globus pallidus pars interna (GPi) might be effective in TD,"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36309960",
"endSection": "abstract",
"offsetInBeginSection": 10,
"offsetInEndSection": 235,
"text": " Progressive supranuclear palsy (PSP) is a 4R-tauopathy showing heterogeneous tau cytopathology commencing in the globus pallidus (GP) and the substantia nigra (SN), regions also associated with age-related iron accumulation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37660542",
"endSection": "abstract",
"offsetInBeginSection": 103,
"offsetInEndSection": 265,
"text": "The clinical significance of weight changes following deep brain stimulation (DBS) of the subthalamic nucleus (STN) and globus pallidus internus (GPi) is unclear."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37532091",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 151,
"text": "The external globus pallidus (GPe) is an essential component of the basal ganglia, a group of subcortical nuclei that are involved in control of action"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37492559",
"endSection": "abstract",
"offsetInBeginSection": 897,
"offsetInEndSection": 1098,
"text": "These regions include the left inferior frontal gyrus, left ventral premotor cortex, left anterior insula, left posterior cerebellum (crus II), and bilateral basal ganglia (putamen and globus pallidus)"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37403078",
"endSection": "abstract",
"offsetInBeginSection": 1040,
"offsetInEndSection": 1367,
"text": "Autopsy of his brain revealed (i) tumor cells with atypical nuclei and small lymphocytes, (ii) neuronal cytoplasmic inclusions and Lewy bodies that were positive for α-synuclein in the midbrain, pons, amygdala, putamen and globus pallidus, and (iii) no amyloid plaques and only rare neurofibrillary tangles near the hippocampi."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33409084",
"endSection": "abstract",
"offsetInBeginSection": 417,
"offsetInEndSection": 779,
"text": "There are sparse reports on the localization of functions in humans. This paper attempts to provide such localization of function with a focus on the globus pallidus externus of the basal ganglia. We present the case of a young man who had impairment in mixed cognitive, perceptual, and mood disturbances. No significant motor symptoms were noted in the patient."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30262639",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1743,
"text": "BACKGROUND AND PURPOSE: Electrophysiologic abnormalities of the globus pallidus externus have been shown in several disease processes including Parkinson disease, dystonia, and Huntington disease. However, the connectivity, nuclear structure, and function of the globus pallidus externus are still not well-understood. Increasing evidence for the existence of direct corticopallidal connections challenges traditional understanding of the connectivity of the globus pallidus externus; nevertheless, these corticopallidal connections have yet to be fully characterized in humans. The objective of this study was to assess the corticopallidal connections of the globus pallidus externus by means of probabilistic diffusion-weighted MR imaging tractography using high-resolution, multishell data.MATERIALS AND METHODS: Imaging data from the open-access Human Connectome Project data base were used to perform probabilistic tractography between the globus pallidus externus and the cerebral cortex using 34 distinct cortical regions. Group averages were calculated for normalized percentages of tracts reaching each of the cortical targets, and side-to-side comparison was made.RESULTS: Cortical connectivity was demonstrated between the globus pallidus externus and multiple cortical regions, including direct connection to putative sensorimotor, associative, and limbic areas. Connectivity patterns were not significantly different between the right and left hemispheres with the exception of the frontal pole, which showed a greater number of connections on the right (P = .004).CONCLUSIONS: Our in vivo study of the human globus pallidus externus using probabilistic tractography supports the existence of extensive corticopallidal connections"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30822586",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1124,
"text": "BACKGROUND: The globus pallidus internus (Gpi) is a major target in functional neurosurgery. Anatomical studies are crucial for correct planning and good surgical outcomes in this region. The present study described the anatomical coordinates of the Gpi and its relationship with other brain structures and compared the findings with those from previous anatomical studies.METHODS: We obtained 35 coronal and 5 horizontal brain specimens from the Department of Anatomy and stained them using the Robert, Barnard, and Brown technique. After excluding defective samples, 60 nuclei were analyzed by assessing their distances to the anatomical references and the trajectories to these nuclei.RESULTS: The barycenter of the Gpi was identified at the level of the mammillary bodies and 1 cm above the intercommissural plane. Thereafter, the distances to other structures were found. The mean ± standard deviation distance was 15.62 ± 2.66 mm to the wall of the third ventricle and 17.02 ± 2.69 mm to its midline, 4.74 ± 1.12 mm to the optic tract, 2.51 ± 0.8 mm and 13.56 ± 2 mm to the internal and external capsule, and 21.3 ± 2."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32906651",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1239,
"text": "Background and objectives: The internal (GPi) and external segments (GPe) of the globus pallidus represent key nodes in the basal ganglia system. Connections to and from pallidal segments are topographically organized, delineating limbic, associative and sensorimotor territories. The topography of pallidal afferent and efferent connections with brainstem structures has been poorly investigated. In this study we sought to characterize in-vivo connections between the globus pallidus and the pedunculopontine nucleus (PPN) via diffusion tractography. Materials and Methods: We employed structural and diffusion data of 100 subjects from the Human Connectome Project repository in order to reconstruct the connections between the PPN and the globus pallidus, employing higher order tractography techniques. We assessed streamline count of the reconstructed bundles and investigated spatial relations between pallidal voxels connected to the PPN and pallidal limbic, associative and sensorimotor functional territories. Results: We successfully reconstructed pallidotegmental tracts for the GPi and GPe in all subjects. The number of streamlines connecting the PPN with the GPi was greater than the number of those joining it with the GPe."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/14614896",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 694,
"text": "Although the localization and role of kainate receptors in the CNS remain poorly known, complex, and rather unusual, pre-synaptic auto- and heteroreceptor functions have been disclosed in various brain regions. Basal ganglia nuclei, including the globus pallidus, are enriched in GluR6/7 immunoreactivity. Using electron microscopic immunocytochemistry for GluR6/7 combined with post-embedding immunogold labeling for GABA, we demonstrate that GluR6/7 immunoreactivity is enriched in a large subpopulation of small unmyelinated, presumably pre-terminal, axons as well as GABAergic and putative glutamatergic axon terminals in the internal and external segments of the globus pallidus in monkey."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33409084",
"endSection": "abstract",
"offsetInBeginSection": 780,
"offsetInEndSection": 1170,
"text": "Brain imaging demonstrated dense bilateral calcifications in the basal ganglia, bilaterally localizing to the anterior region of the globus pallidus externus. We discuss our findings in light of recent studies that imply that isolated pathology in the anterior region of the globus pallidus externus may be associated with behavioral, mood, and cognitive disturbance without motor symptoms."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33409084",
"endSection": "abstract",
"offsetInBeginSection": 486,
"offsetInEndSection": 722,
"text": "This paper attempts to provide such localization of function with a focus on the globus pallidus externus of the basal ganglia. We present the case of a young man who had impairment in mixed cognitive, perceptual, and mood disturbances."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33409084",
"endSection": "abstract",
"offsetInBeginSection": 486,
"offsetInEndSection": 779,
"text": "This paper attempts to provide such localization of function with a focus on the globus pallidus externus of the basal ganglia. We present the case of a young man who had impairment in mixed cognitive, perceptual, and mood disturbances. No significant motor symptoms were noted in the patient."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33409084",
"endSection": "abstract",
"offsetInBeginSection": 780,
"offsetInEndSection": 938,
"text": "Brain imaging demonstrated dense bilateral calcifications in the basal ganglia, bilaterally localizing to the anterior region of the globus pallidus externus."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33409084",
"endSection": "abstract",
"offsetInBeginSection": 723,
"offsetInEndSection": 1170,
"text": "No significant motor symptoms were noted in the patient. Brain imaging demonstrated dense bilateral calcifications in the basal ganglia, bilaterally localizing to the anterior region of the globus pallidus externus. We discuss our findings in light of recent studies that imply that isolated pathology in the anterior region of the globus pallidus externus may be associated with behavioral, mood, and cognitive disturbance without motor symptoms."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33409084",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 103,
"text": "The Anterior Globus Pallidus Externus of Basal Ganglia as Primarily a Limbic and Associative Territory."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33409084",
"endSection": "abstract",
"offsetInBeginSection": 486,
"offsetInEndSection": 613,
"text": "This paper attempts to provide such localization of function with a focus on the globus pallidus externus of the basal ganglia."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26706479",
"endSection": "abstract",
"offsetInBeginSection": 773,
"offsetInEndSection": 1139,
"text": "LTS: Thirteen studies specified the involved basal ganglia nuclei (subthalamic nucleus, caudate, putamen, globus pallidus, or lentiform nuclei, comprised by the putamen and globus pallidus). Studies investigating the lentiform nuclei (without distinguishing between the putamen and globus pallidus) showed that all subjects (19 of 19) had lentiform nuclei damage. St"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33409084",
"endSection": "abstract",
"offsetInBeginSection": 723,
"offsetInEndSection": 938,
"text": "No significant motor symptoms were noted in the patient. Brain imaging demonstrated dense bilateral calcifications in the basal ganglia, bilaterally localizing to the anterior region of the globus pallidus externus."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34129267",
"endSection": "abstract",
"offsetInBeginSection": 142,
"offsetInEndSection": 230,
"text": "The globus pallidus is an area of major iron metabolism and storage in the brain tissue."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37336974",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 136,
"text": "The external globus pallidus (GPe) of the basal ganglia has been underappreciated owing to poor understanding of its cells and circuits."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37532091",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 152,
"text": "The external globus pallidus (GPe) is an essential component of the basal ganglia, a group of subcortical nuclei that are involved in control of action."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31927758",
"endSection": "abstract",
"offsetInBeginSection": 51,
"offsetInEndSection": 247,
"text": "The basal ganglia are recognized for their role in reward processes; however, specific roles of the different nuclei (e.g., nucleus accumbens, caudate, putamen and globus pallidus) remain unclear."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18688722",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 189,
"text": "BACKGROUND: Hyperintense signals in the basal ganglia, namely the globus pallidus, have been reported on magnetic resonance imaging (MRI) in 70-100% of patients with cirrhosis of the liver."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31778724",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 88,
"text": "The globus pallidus in the basal ganglia plays an important role in movement regulation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/15322674",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 164,
"text": "The globus pallidus occupies a critical position in the 'indirect' pathway of the basal ganglia and, as such, plays an important role in the modulation of movement."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/4063830",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 174,
"text": "The anatomical structure of the basal ganglia indicates that the input from the cerebral cortex is funnelled through the striatum to the globus pallidus and substantia nigra."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/7133405",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 242,
"text": "The globus pallidus is characterized by a high iron content and the distribution of the ferric iron in the rat brain provides evidence that globus pallidus extends rostroventrally below the anterior commissure and into the olfactory tubercle."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/12764086",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 214,
"text": "The anatomical structure of the basal ganglia displays topographical organization and massive funneling of neuronal projections toward the globus pallidus as well as an axonal collateral system within this nucleus."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36895960",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 134,
"text": "Globus pallidus internus deep brain stimulation is an established therapy for patients with medication-refractory Parkinson's disease."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/15169693",
"endSection": "abstract",
"offsetInBeginSection": 184,
"offsetInEndSection": 755,
"text": "der (OCD).METHOD: Volumes of the caudate nucleus, putamen, and globus pallidus and gray and white matter volumes of the anterior cingulate gyrus and superior frontal gyrus were computed from contiguous 1.5-mm magnetic resonance images from 23 psychotropic drug-naive pediatric patients with OCD (seven male patients and 16 female patients) and 27 healthy volunteers (12 male subjects and 15 female subjects).RESULTS: Patients had smaller globus pallidus volumes than healthy volunteers, but the two groups did not differ in volumes of the caudate nucleus, putamen, or fro"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/3469674",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1103,
"text": "Previous immunohistochemical studies have provided evidence that the external segment of the globus pallidus extends ventrally beneath the transverse limb of the anterior commissure into the area of the substantia innominata. Enkephalin-positive staining in the form of \"woolly fibers\" has been used as a marker for the globus pallidus and its ventral extension. Acetylcholinesterase staining of both fibers and cell bodies, frequently used as a marker for the basal nucleus of Meynert, is also found in the area of the substantia innominata. This study describes the differential distribution of enkephalin-positive woolly fibers and acetylcholinesterase staining on adjacent sections in both the monkey and human basal forebrain area in an attempt to define the relationship between the basal ganglia and the basal nucleus of Meynert. The results show that while both occupy large regions of the basal forebrain, they overlap very little. In both species investigated, dense concentrations of acetylcholinesterase-positive neurons lie, for the most part, outside the boundaries of the pallidal fibers."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/1380517",
"endSection": "abstract",
"offsetInBeginSection": 564,
"offsetInEndSection": 1328,
"text": "The globus pallidus was injected with Phaseolus vulgaris-leucoagglutinin (PHA-L), and on the same side of the brain, the striatum was injected with biocytin. The entopeduncular nuclei of these animals were then examined for anterogradely labelled pallidal and striatal terminals. Rich plexuses of PHA-L-labelled pallidal terminals and biocytin-labelled striatal terminals were identified throughout the entopeduncular nucleus. At the electron microscopic level, the pallidal boutons were classified as two types. The majority (Type 1), were large boutons that formed symmetrical synapses with the dendrites and perikarya of neurones in the entopeduncular nucleus. Type 2 PHA-L-labelled terminals were much rarer, slightly smaller, and formed asymmetrical synapses."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/4063830",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1637,
"text": "The anatomical structure of the basal ganglia indicates that the input from the cerebral cortex is funnelled through the striatum to the globus pallidus and substantia nigra. This structure implies integration of the information as it is transferred through the basal ganglia. In order to investigate this integration, we studied the collateralization of striatal efferents to the globus pallidus and the substantia nigra-ventral tegmental area. Retrogradely transported fluorescent tracers were injected into the target areas of striatal efferents. Nuclear yellow or propidium iodide was injected into the substantia nigra-ventral tegmental area (SN-VTA) and 4-acetamido, 4'-isothiocyanostilbene-2,2'-disulfonic acid (SITS) into the globus pallidus (GP) of adult albino rats. SITS was chosen for the pallidal injections because it is not taken up by fibers-of-passage. The pressure injections resulted in large injection sites which covered the majority of each efferent target area, and as a result retrogradely labeled cell bodies were found throughout the entire extent of the striatum. Cell bodies double-labeled with both dyes were found intermingled with single-labeled cell bodies. In rats injected with propidium iodide in the SN-VTA and SITS in the GP, 70% of all neurons (as revealed by Nissl staining) were labeled. Of these labeled cells, 40% were double labeled, 20% contained only SITS and 40% contained only propidium iodide. Thus a substantial number of the striatal neurons that project to the SN-VTA also possess collateral axons to the GP. Some striatal neurons appear to project to only the SN-VTA or only to the GP."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/14614896",
"endSection": "abstract",
"offsetInBeginSection": 211,
"offsetInEndSection": 305,
"text": "Basal ganglia nuclei, including the globus pallidus, are enriched in GluR6/7 immunoreactivity."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/2579980",
"endSection": "abstract",
"offsetInBeginSection": 1812,
"offsetInEndSection": 2354,
"text": "Fewer, but still ample numbers, of SP-reactive axons are present also in the ventral tegmental and retrorubral areas of the midbrain tegmentum and in the ventral pallidum of the basal forebrain, but only sparse ME-reactive axons are present in these areas. This differential distribution of SP- and ME-containing axons in the pallidal and nigral structures stands in contrast to the relatively homogeneous and dense distribution of GAD-containing axons throughout the dorsal and ventral pallidum, entopeduncular nucleus, and substantia nigra."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/2428943",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 323,
"text": "Immunocytochemical studies of the human forebrain have shown that enkephalin-like, dynorphin-like and substance-P-like immunoreactivity (respectively ELI, DLI, and SPI) normally present in unique pattern (now termed woolly fibers) in the globus pallidus and substantia nigra, in which their concentration is at its densest."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/1401259",
"endSection": "abstract",
"offsetInBeginSection": 200,
"offsetInEndSection": 536,
"text": "The distribution of choline acetyltransferase-immunoreactive axons and varicosities and their relationship to regional perikarya showed that the caudate, putamen, nucleus accumbens, olfactory tubercle, globus pallidus, substantia nigra, red nucleus, and subthalamic nucleus of the human brain receive widespread cholinergic innervation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/20107133",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 272,
"text": "The basal ganglia are a subcortical assembly of nuclei involved in many aspects of behavior. Three of the nuclei have high firing rates and inhibitory influences: the substantia nigra pars reticulata (SNr), globus pallidus interna (GPi), and globus pallidus externa (GPe)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30077619",
"endSection": "abstract",
"offsetInBeginSection": 947,
"offsetInEndSection": 1142,
"text": "In the basal ganglia, they were found in the caudate putamen, core part of accumbens nucleus, lateral globus pallidus, subthalamic nucleus, and substantia nigra pars compacta and pars reticulata."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/2153714",
"endSection": "abstract",
"offsetInBeginSection": 708,
"offsetInEndSection": 904,
"text": "In the basal ganglia, high levels of binding of 125I-351A are found in the caudate nucleus, putamen, nucleus accumbens, both divisions of the globus pallidus, and substantia nigra pars reticulata."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26917269",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 69,
"text": "Deep brain stimulation in the globus pallidus externa promotes sleep."
}
] | 13
|
BioASQ-training13b
| null | null |
662cfbf5187cba990d000007
| 5,194
|
factoid
|
What is the approximate prevalence of autoimmune diseases?
|
['10%']
|
[
"10 percent",
"ten percent",
"0.1",
"0.10",
"1/10",
"one-tenth",
"10%"
] |
["Autoimmune diseases affect approximately 10% of the population, with a higher prevalence in females (about 64% of diagnosed individuals are female). Some of the most common autoimmune diseases, such as Sjögren's syndrome, systemic lupus erythematosus, and systemic sclerosis, are often associated with each other.", 'There is an approximate incidence of 10% autoimmune diseases affecting the general population.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/37156255"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37156255",
"endSection": "abstract",
"offsetInBeginSection": 243,
"offsetInEndSection": 313,
"text": "incidence and prevalence of 19 of the most common autoimmune diseases "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37156255",
"endSection": "abstract",
"offsetInBeginSection": 1813,
"offsetInEndSection": 1862,
"text": "63·9%) of these diagnosed individuals were female"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37156255",
"endSection": "abstract",
"offsetInBeginSection": 2964,
"offsetInEndSection": 3112,
"text": "Autoimmune disorders were commonly associated with each other, particularly Sjögren's syndrome, systemic lupus erythematosus, and systemic sclerosis"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37156255",
"endSection": "abstract",
"offsetInBeginSection": 3500,
"offsetInEndSection": 3563,
"text": "Autoimmune diseases affect approximately one in ten individuals"
}
] | 13
|
BioASQ-training13b
| null | null |
66151045fdcbea915f000048
| 5,195
|
factoid
|
What is the gold standard for a diagnosis of narcolepsy?
|
['Sleep study including overnight polysomnography']
|
[
"Sleep study including overnight polysomnography",
"Polysomnography",
"PSG",
"Overnight sleep study",
"Sleep apnea study",
"Sleep test",
"Sleep evaluation"
] |
['The gold standard for diagnosing narcolepsy is a combination of overnight polysomnography (PSG) followed by a multiple sleep latency test (MSLT). PSG is used to rule out other sleep disorders, while the MSLT assesses daytime sleepiness and the presence of sleep-onset REM periods, which are characteristic of narcolepsy. Measuring cerebrospinal fluid hypocretin-1 levels can provide additional diagnostic information.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/12659360",
"http://www.ncbi.nlm.nih.gov/pubmed/37672382"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/12659360",
"endSection": "abstract",
"offsetInBeginSection": 688,
"offsetInEndSection": 839,
"text": "referral to an accredited sleep laboratory for a formal sleep study including overnight polysomnography is necessary for a positive narcolepsy diagnosi"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37672382",
"endSection": "abstract",
"offsetInBeginSection": 186,
"offsetInEndSection": 350,
"text": "Polysomnography (PSG) recordings, a gold standard for sleep monitoring and quality measurement, can provide abundant and objective cues for the narcolepsy diagnosis"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37672382",
"endSection": "abstract",
"offsetInBeginSection": 1093,
"offsetInEndSection": 1169,
"text": "end-to-end framework for automatic narcolepsy diagnosis using PSG recordings"
}
] | 13
|
BioASQ-training13b
| null | null |
66156200fdcbea915f00004d
| 5,201
|
factoid
|
Which receptor tyrosine kinase is commonly mutated or amplified in pediatric glioma cases?
|
['PDGFRA', 'Platelet derived growth factor-alpha', 'Platelet derived growth factor-alpha (PDGFRA)']
|
[
"PDGFRA",
"Platelet derived growth factor-alpha",
"Platelet derived growth factor-alpha (PDGFRA)",
"Platelet-derived growth factor receptor alpha",
"PDGF receptor alpha",
"PDGF receptor alpha chain",
"PDGF alpha receptor"
] |
['Pediatric high-grade glioma (pHGG), including both diffuse midline glioma (DMG) and non-midline tumors, continues to be one of the deadliest oncologic diagnoses. Targeted therapy options aimed at key oncogenic receptor tyrosine kinase (RTK) drivers using small-molecule RTK inhibitors have been extensively studied, but the absence of proper in vivo modeling that recapitulates pHGG biology has historically been a research challenge. Over 20% of pHGG have been found in sequencing studies to have alterations in platelet derived growth factor-alpha (PDGFRA), making growth factor modeling and inhibition via targeted tyrosine kinases a promising research direction.', 'Receptor tyrosine kinase (RTK) alterations are commonly found in pediatric high-grade glioma (pHGG), including diffuse midline glioma (DMG) and non-midline tumors. Sequencing studies have revealed that over 20% of pHGG cases have alterations in platelet derived growth factor-alpha (PDGFRA). This has made growth factor modeling and inhibition via targeted tyrosine kinases a significant area of interest in pHGG research. The challenge in this field has been the lack of proper in vivo modeling that accurately represents pHGG biology.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/26727948",
"http://www.ncbi.nlm.nih.gov/pubmed/27582545",
"http://www.ncbi.nlm.nih.gov/pubmed/35978801",
"http://www.ncbi.nlm.nih.gov/pubmed/23970477",
"http://www.ncbi.nlm.nih.gov/pubmed/26744350",
"http://www.ncbi.nlm.nih.gov/pubmed/20479398",
"http://www.ncbi.nlm.nih.gov/pubmed/23438035"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35978801",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 160,
"text": "Pediatric high-grade glioma (pHGG), including both diffuse midline glioma (DMG) and non-midline tumors, continues to be one of the deadliest oncologic diagnoses"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35978801",
"endSection": "abstract",
"offsetInBeginSection": 201,
"offsetInEndSection": 473,
"text": " Targeted therapy options aimed at key oncogenic receptor tyrosine kinase (RTK) drivers using small-molecule RTK inhibitors has been extensively studied, but the absence of proper in vivo modeling that recapitulate pHGG biology has historically been a research challenge. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35978801",
"endSection": "abstract",
"offsetInBeginSection": 710,
"offsetInEndSection": 934,
"text": "Over 20% of pHGG have been found in sequencing studies to have alterations in platelet derived growth factor-alpha (PDGFRA), making growth factor modeling and inhibition via targeted tyrosine kinases a rich vein of interest."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23438035",
"endSection": "abstract",
"offsetInBeginSection": 693,
"offsetInEndSection": 773,
"text": "PDGFRA amplification was frequent in pediatric (29.3%) and adult (20.9%) tumors."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23970477",
"endSection": "abstract",
"offsetInBeginSection": 244,
"offsetInEndSection": 450,
"text": "Genome-wide analyses of copy number imbalances previously showed that platelet-derived growth factor receptor α (PDGFRA) is the most frequent target of focal amplification in pediatric HGGs, including DIPGs"
}
] | 13
|
BioASQ-training13b
| null | null |
6630390b187cba990d000035
| 5,202
|
factoid
|
What is the race with the highest incidence of colorectal cancer?
|
['Black', 'Black Americans', 'Afroamerican', 'African Americans', 'Blacks', 'African-Americans', 'African americans and African descent']
|
[
"Black",
"Black Americans",
"Afroamerican",
"African Americans",
"Blacks",
"African-Americans",
"African americans and African descent",
"Africans",
"People of African descent",
"African heritage"
] |
['Based on the provided snippets, it is clear that Black Americans have the highest incidence and mortality from colorectal cancer (CRC). The data indicates that Blacks continued to have the highest incidence of CRC for every age group. Therefore, the answer to the question is that Blacks or African Americans have the highest incidence of colorectal cancer. This highlights a significant health disparity in the US, emphasizing the need for targeted interventions and increased awareness about CRC screening and prevention in this population.', 'African Americans have the highest incidence of colorectal cancer in the United States, with a younger mean age at diagnosis and greater proportion of proximal cancers compared to whites. Survival rates are also lower for African Americans with this type of cancer. Socioeconomic, lifestyle, and healthcare factors do not fully explain the racial disparity, suggesting other etiologic factors may be important in Black American populations.', 'The race with the highest incidence of colorectal cancer is African Americans, particularly African American females. This was found in a study that analyzed data from the Surveillance, Epidemiology, and End Results Registry (SEER) of individuals aged 45-79 years from 2000-2017. The results showed that while the incidence of colorectal cancer decreased for both males and females during the study period, African Americans had the least decline in incidence. Moreover, African American females had the highest risk for colorectal cancer compared to other females or males from different racial groups, and they also had the poorest 5-year survival rate among females. This highlights the need for targeted interventions and screening strategies to reduce the burden of colorectal cancer in this population.', 'The race with the highest incidence of colorectal cancer is African Americans, who have the highest colorectal cancer incidence and mortality rates of any U.S. racial/ethnic group. This disparity exists despite efforts to promote awareness and screening, and is not fully explained by established risk factors or socioeconomic status. In fact, researchers are actively seeking to understand other etiologic factors that may contribute to this health disparity. Additionally, African Americans with colorectal cancer tend to be diagnosed at a younger age and have more proximal cancers compared to whites, further highlighting the need for targeted interventions to reduce this health disparity.', 'Colorectal cancer is the third most common cancer diagnosed in both men and women in the United States and is the second leading cause of cancer death. According to the most recent data, African Americans had the highest incidence rate among all races.', 'According to the provided information, Black Americans have the highest incidence of colorectal cancer compared to other racial groups. The abstracts state that "Black Americans demonstrat[e] the highest incidence and mortality from this disease" and "blacks continued to have the highest incidence of CRC for every age group."', 'Black Americans demonstrating the highest incidence and mortality from this disease', 'According to the provided information, Black Americans have the highest incidence of colorectal cancer compared to other racial groups. The passages state that "Black Americans demonstrat[e] the highest incidence and mortality from this disease" and "blacks continued to have the highest incidence of CRC for every age group."', 'Summary: Black Americans exhibit the highest incidence and mortality rates from colorectal cancer (CRC) compared to other races in the United States. This highlights a significant health disparity, emphasizing the need for targeted interventions and increased awareness about CRC screening and prevention among this population.', 'Black Americans have the highest incidence and mortality rate from colorectal cancer (CRC) compared to other racial groups. This was observed across all age groups.', 'The race with the highest incidence of colorectal cancer (CRC) is Black Americans. This has been consistently observed across different age groups. The incidence of CRC among Black Americans is persistently higher compared to other racial groups, making them the most affected demographic in terms of CRC occurrence.', ' Africans, certain genetic, lifestyle, and clinical factors may contribute to a higher incidence of colorectal cancer in specific populations, but the overall risk is influenced by a complex interplay of various factors and may vary among individuals within each population. Early diagnosis and prompt initiation of appropriate cancer treatments are essential for reducing morbidity and improving outcomes. ', 'Black Americans have the highest incidence of colorectal cancer (CRC) compared to other racial and ethnic groups in the United States. This is consistent across various studies and sources, which show that CRC incidence and mortality rates are significantly higher in Black Americans compared to non-Hispanic Whites, Hispanics, Asian/Pacific Islanders, and Native Americans. The disparity in CRC incidence and mortality rates between Black Americans and other racial and ethnic groups is likely due to a combination of genetic, environmental, and socioeconomic factors. It is important to continue researching and addressing these disparities to improve CRC outcomes for all populations.', 'Summary: Black Americans have the highest incidence of colorectal cancer (CRC) in the United States across all age groups. The disparity is multifactorial and includes societal issues, environmental factors, and immune or genetic changes. While prevention through screening mitigates disparities before CRC develops, further research is needed to understand these differences fully.', 'The race with the highest incidence of colorectal cancer is non-Hispanic Black service members, but this study observed similar rates of colorectal cancer for all races and ethnicities after adjusting for age.', 'Black Americans have the highest incidence of colorectal cancer (CRC) compared to other racial/ethnic groups in the United States. This is supported by multiple studies and sources, including a 2016 report stating that CRC incidence was higher among Blacks (42.5 per 100,000) than Whites (38.0), Latinos (31.7) and Asians (30.0). Additionally, a 2012 study found that after a mean follow-up of 10.8 years, CRC incidence was the highest in African-Americans (annualized rate = 0.14%) compared to Whites, Native Americans, Asian/Pacific Islanders, and Hispanics. A 2021 study also found that Black Americans have a higher risk of CRC incidence and mortality compared to other groups.', 'The race with the highest incidence of colorectal cancer is African Americans (AAs). This racial group has been consistently shown to have higher rates of colorectal cancer incidence and mortality compared to other races in the United States. The disparity between AAs and Non-Hispanic Whites (NHWs) is multifactorial, including genetic, environmental, and societal factors. Some studies suggest that interventions such as increasing screening utilization rates among AAs to match NHWs can help reduce this incidence disparity. Additionally, research has identified unique genetic and epigenetic changes in AA colorectal cancers, which could lead to more precise approaches to colorectal cancer care for this population. Despite these findings, there is still a need for a better understanding of the etiologic factors contributing to the higher incidence and mortality rates of colorectal cancer among African Americans.', 'Summary: African Americans have the highest incidence of colorectal cancer in the United States with a younger mean age at diagnosis and lower survival rates compared to whites. Socioeconomic, lifestyle, and healthcare factors do not fully explain this disparity.', 'The race with the highest incidence of colorectal cancer (CRC) in the United States is Black Americans. This was observed across all age groups, with no decrease in incidence seen in any age group in 2016. The disparity in CRC incidence and mortality between racial and ethnic groups appears to be multifactorial, with structured societal issues, abnormal environmental factors, and cancer-specific immune and genetic changes contributing to the observed differences. Although acquiring additional knowledge into the science behind these disparities is crucial for developing interventions that reduce both CRC incidence and mortality, current evidence suggests that prevention through CRC screening has been effective in mitigating the disparity, but only before CRC has developed.', 'According to the provided information, African Americans have the highest incidence rates of colorectal cancer compared to other racial and ethnic groups in the United States. The data consistently shows that colorectal cancer incidence is significantly higher in African Americans than in non-Hispanic whites, Hispanics, Asian/Pacific Islanders, and other racial groups. African Americans are about 20% more likely to get colorectal cancer and 40% more likely to die from it than most other groups.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/16532978",
"http://www.ncbi.nlm.nih.gov/pubmed/15184825",
"http://www.ncbi.nlm.nih.gov/pubmed/38082093",
"http://www.ncbi.nlm.nih.gov/pubmed/22791544",
"http://www.ncbi.nlm.nih.gov/pubmed/15743345",
"http://www.ncbi.nlm.nih.gov/pubmed/12716038",
"http://www.ncbi.nlm.nih.gov/pubmed/28248415",
"http://www.ncbi.nlm.nih.gov/pubmed/36047055",
"http://www.ncbi.nlm.nih.gov/pubmed/34568072",
"http://www.ncbi.nlm.nih.gov/pubmed/31392043",
"http://www.ncbi.nlm.nih.gov/pubmed/33389864",
"http://www.ncbi.nlm.nih.gov/pubmed/34325062",
"http://www.ncbi.nlm.nih.gov/pubmed/35504786",
"http://www.ncbi.nlm.nih.gov/pubmed/29128568",
"http://www.ncbi.nlm.nih.gov/pubmed/10826011",
"http://www.ncbi.nlm.nih.gov/pubmed/24574761",
"http://www.ncbi.nlm.nih.gov/pubmed/35936740",
"http://www.ncbi.nlm.nih.gov/pubmed/10826010",
"http://www.ncbi.nlm.nih.gov/pubmed/26703651",
"http://www.ncbi.nlm.nih.gov/pubmed/30521807",
"http://www.ncbi.nlm.nih.gov/pubmed/18300824",
"http://www.ncbi.nlm.nih.gov/pubmed/33616738",
"http://www.ncbi.nlm.nih.gov/pubmed/37963221",
"http://www.ncbi.nlm.nih.gov/pubmed/34193094",
"http://www.ncbi.nlm.nih.gov/pubmed/31701261",
"http://www.ncbi.nlm.nih.gov/pubmed/15052704",
"http://www.ncbi.nlm.nih.gov/pubmed/16835912",
"http://www.ncbi.nlm.nih.gov/pubmed/34148614",
"http://www.ncbi.nlm.nih.gov/pubmed/9698125",
"http://www.ncbi.nlm.nih.gov/pubmed/30524961"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34148614",
"endSection": "abstract",
"offsetInBeginSection": 123,
"offsetInEndSection": 206,
"text": "Black Americans demonstrating the highest incidence and mortality from this disease"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34325062",
"endSection": "abstract",
"offsetInBeginSection": 1247,
"offsetInEndSection": 1321,
"text": "blacks continued to have the highest incidence of CRC for every age group."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/38082093",
"endSection": "abstract",
"offsetInBeginSection": 1216,
"offsetInEndSection": 1478,
"text": "Compared to Whites, Blacks (AOR: 1.99; 95% CI: 1.64-2.41), Hispanics (AOR: 2.49; 95% CI: 1.94-3.19) and colorectal cancer patients in the other category (AOR: 1.72; 95% CI: 1.35-2.18) were more likely to receive inpatient treatment with chemotherapy/radiotherapy"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30524961",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 526,
"text": "Colorectal cancer (CRC) is the third most prevalent and second deadliest cancer in the U.S. with 140,250 cases and 50,630 deaths for 2018. Prevention of CRC through screening is effective. Among categorized races in the U.S., African Americans (AAs) show the highest incidence and death rates per 100,000 when compared to Non-Hispanic Whites (NHWs), American Indian/Alaskan Natives, Hispanics, and Asian/Pacific Islanders, with an overall AA:NHW ratio of 1.13 for incidence and 1.32 for mortality (2010-2014, seer.cancer.gov)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35504786",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 424,
"text": "Colorectal cancer (CRC) incidence and mortality vary by race and ethnicity in the United States, with the highest burden of disease among Black and American Indian/Alaska Native individuals. There are multiple contributors to these disparities, including lifestyle and environmental risk factors that result from adverse social determinants of health and are more prevalent in minority and medically underserved communities."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34568072",
"endSection": "abstract",
"offsetInBeginSection": 161,
"offsetInEndSection": 1752,
"text": "for the US.METHODS: Age-standardized incidence rates (ASIR, per 100,000) of CRC were calculated using the US Cancer Statistics Database's high-quality population-based cancer registry data from the entire US population. Results were cross-classified by age (20-49 [early-onset] and 50-74 years [late-onset]), race/ethnicity (non-Hispanic White, non-Hispanic Black, Hispanic, American Indian/Alaskan Native, Asian/Pacific Islander), sex, anatomic location (proximal, distal, rectal), and histology (adenocarcinoma, neuroendocrine).RESULTS: During 2001 through 2018, early-onset CRC rates significantly increased among American Indians/Alaskan Natives, Hispanics, and Whites. Compared to Whites, early-onset CRC rates are now 21% higher in American Indians/Alaskan Natives and 6% higher in Blacks. Rates of early-onset colorectal neuroendocrine tumors have increased in Whites, Blacks, and Hispanics; early-onset colorectal neuroendocrine tumor rates are 2-times higher in Blacks compared to Whites. Late-onset colorectal adenocarcinoma rates are decreasing, while late-onset colorectal neuroendocrine tumor rates are increasing, in all racial/ethnic groups. Late-onset CRC rates remain 29% higher in Blacks and 15% higher in American Indians/Alaskan Natives compared to Whites. Overall, CRC incidence was higher in men than women, but incidence of early-onset distal colon cancer was higher in women.CONCLUSIONS: The early-onset CRC disparity between Blacks and Whites has decreased, due to increasing rates in Whites-rates in Blacks have remained stable. However, rates of colorectal neuroen"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36047055",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 523,
"text": "Black Americans have the highest colorectal cancer incidence and mortality rates of any U.S. racial/ethnic group. Warren Andersen and colleagues report that sociocultural, lifestyle, and healthcare factors did not explain the racial disparity in colorectal cancer incidence, but colorectal cancer screening lessened the disparity. While screening is a cornerstone of colorectal cancer prevention, an improved understanding of etiologic factors may inform additional strategies for primary prevention or risk stratification."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33389864",
"endSection": "abstract",
"offsetInBeginSection": 186,
"offsetInEndSection": 1234,
"text": "Colorectal cancer (CRC) is one of the leading causes of cancer deaths in the United States and it disproportionately affects the non-Hispanic Black or African American (AA) population. When compared to the non-Hispanic White (nHW) population, incidence and death rates in AAs are 28% and 60% higher, respectively. Hispanics have an overall lower CRC incidence rate than nHWs (Hispanics: 35.5 per 100,000 population; nHWs: 40.2 per 100,000 population), but their incidence continues to rise, unlike nHWs, who are experiencing a decline. This disparity between Hispanics and nHWs is further highlighted in the younger Hispanic population. While the cause of the disparities is associated with CRC-related genetic and environmental factors, the role of specific genes/mutations in each population are still not fully unraveled. However, because CRC is a slowly progressing disease, routine screening and/or early intervention are key to achieving better outcomes in CRC patients and ultimately in closing the disparity gap among different populations."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31392043",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 636,
"text": "BACKGROUND: Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer related deaths in the United States. Racial disparities between Hispanics and Whites exist for incidence of late-onset (LO) CRC. However, not much is known about potential disparities between colon cancer (CC) and rectal cancer (RC) incidence queried individually.METHODS: Using the SEER database data from 2000 to 2010, we obtained the national estimates of CC and RC for Hispanics and Whites. We analyzed trends in incidence, mortality, gender and stage of disease for early-onset (EO) (<50 years old) and LO (>50 y"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34148614",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1042,
"text": "The occurrence of colorectal cancer (CRC) shows a large disparity among recognized races and ethnicities in the U.S., with Black Americans demonstrating the highest incidence and mortality from this disease. Contributors for the observed CRC disparity appear to be multifactorial and consequential that may be initiated by structured societal issues (e.g., low socioeconomic status and lack of adequate health insurance) that facilitate abnormal environmental factors (through use of tobacco and alcohol, and poor diet composition that modifies one's metabolism, microbiome and local immune microenvironment) and trigger cancer-specific immune and genetic changes (e.g., localized inflammation and somatic driver gene mutations). Mitigating the disparity by prevention through CRC screening has been demonstrated; this has not been adequately shown once CRC has developed. Acquiring additional knowledge into the science behind the observed disparity will inform approaches towards abating both the incidence and mortality of CRC between U.S."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29128568",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1022,
"text": "African Americans have the highest incidence and mortality rates of colorectal cancer (CRC) of any ethnic group in the United States. Although some of these disparities can be explained by differences in access to care, cancer screening, and other socioeconomic factors, disparities remain after adjustment for these factors. Consequently, an examination of recent advances in the understanding of ethnicity-specific factors, including genetic and environmental factors relating to risk of CRC, the biology of CRC progression, and the changes in screening and mortality, is important for evaluating our progress toward eliminating the disparities. An overarching limitation in this field is the number and sample size of studies performed to characterize the etiological bases of CRC incidence and mortality in African Americans. Despite this limitation, significant differences in etiology are manifest in many studies. These differences need validation, and their impacts on disparities need more detailed investigation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34325062",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1116,
"text": "BACKGROUND & AIMS: Colorectal cancer (CRC) incidence has decreased overall in the last several decades, but it has increased among younger adults. Prior studies have characterized this phenomenon in the United States (U.S.) using only a small subset of cases. We describe CRC incidence trends using high-quality data from 92% of the U.S. population, with an emphasis on those younger than 50 years.METHODS: We obtained 2001 to 2016 data from the U.S. Cancer Statistics database and analyzed CRC incidence for all age groups, with a focus on individuals diagnosed at ages 20 to 49 years (early-onset CRC). We compared incidence trends stratified by age, as well as by race/ethnicity, sex, region, anatomic site, and stage at diagnosis.RESULTS: We observed 191,659 cases of early-onset and 1,097,765 cases of late-onset CRC during the study period. Overall, CRC incidence increased in every age group from 20 to 54 years. Whites were the only racial group with a consistent increase in incidence across all younger ages, with the steepest rise seen after 2012. Hispanics also experienced smaller increases in incidence"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33616738",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 549,
"text": "INTRODUCTION: The incidence of CRC is higher in minority racial and ethnic groups. However, studies assessing trends among sex and racial groups on the incidence and mortality of CRC are lacking. We aim to investigate disparities in CRC by reviewing a large national cancer registry.METHODS: This is a retrospective cross-sectional study of the Surveillance, Epidemiology, and End Results Registry (SEER) of individuals aged 45-79 years from 2000-2017.RESULTS: During the study period, the incidence of CRC decreased for both males and females, resp"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/15184825",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 261,
"text": "In the United States, African Americans have the highest incidence of colorectal cancer of any racial or ethnic group. Compared with whites, African Americans have a younger mean age at colorectal cancer diagnosis and a greater proportion have proximal cancers."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/15184825",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 339,
"text": "In the United States, African Americans have the highest incidence of colorectal cancer of any racial or ethnic group. Compared with whites, African Americans have a younger mean age at colorectal cancer diagnosis and a greater proportion have proximal cancers. Survival in African Americans with colorectal cancer is lower than in whites."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18300824",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 105,
"text": "African Americans have the greatest incidence of colorectal cancer than any other racial or ethnic group."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18300824",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 199,
"text": "African Americans have the greatest incidence of colorectal cancer than any other racial or ethnic group. This population's survival from colorectal cancer is lower than that in the White population."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18300824",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 454,
"text": "African Americans have the greatest incidence of colorectal cancer than any other racial or ethnic group. This population's survival from colorectal cancer is lower than that in the White population. Increased incidence and mortality can be attributed to barriers such as lower screening rates, less use of diagnostic testing, decreased access to healthcare, cultural beliefs, and lack of education regarding healthcare practices and preventable disease."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22791544",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 104,
"text": "African-Americans have higher incidence and mortality from colorectal cancer than non-African-Americans."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/15184825",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 39,
"text": "Colorectal cancer in African Americans."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/15743345",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 39,
"text": "Colorectal cancer in African Americans."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/15743345",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 99,
"text": "Colorectal cancer in African Americans has an increased incidence and mortality relative to Whites."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34148614",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 207,
"text": "The occurrence of colorectal cancer (CRC) shows a large disparity among recognized races and ethnicities in the U.S., with Black Americans demonstrating the highest incidence and mortality from this disease."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34148614",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 75,
"text": "Racial and ethnic disparities in colorectal cancer incidence and mortality."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34193094",
"endSection": "abstract",
"offsetInBeginSection": 1012,
"offsetInEndSection": 1335,
"text": "increase from 2002 to 2007. In 2016, CRC incidence was higher among Blacks (42.5 per 100,000) than Whites (38.0), Latinos (31.7) and Asians (30.0). In 2016, Blacks had higher mortality rates (17.9), than Whites (15.2), Latinos (10.4) and Asians (8.8). In 2016, colonoscopy rates among Blacks were 72.2%, Latinos 71.1%, Whit"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35936740",
"endSection": "abstract",
"offsetInBeginSection": 118,
"offsetInEndSection": 323,
"text": "In the US, CRC incidence and mortality differ among racial/ethnic groups, with non-Hispanic Blacks (NHB) and American Indian/Alaska Natives showing highest incidence and mortality and earlier presentation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31701261",
"endSection": "abstract",
"offsetInBeginSection": 948,
"offsetInEndSection": 1040,
"text": "100,000 persons/year (age 30-39). CRC incidence was significantly higher in African American"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/10826010",
"endSection": "abstract",
"offsetInBeginSection": 410,
"offsetInEndSection": 554,
"text": "Age-adjusted incidence rates for men with colorectal cancer are highest for Alaskan native men, followed by Japanese, then African-American men."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24574761",
"endSection": "abstract",
"offsetInBeginSection": 99,
"offsetInEndSection": 219,
"text": "There are significant differences in CRC incidence and mortality by race with the highest burden occurring among blacks."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30521807",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 604,
"text": "BACKGROUND & AIMS: Increasing rates of young-onset colorectal cancer (CRC) have attracted substantial research and media attention, but we know little about racial disparities among younger adults with CRC. We examined racial disparities in young-onset CRC by comparing CRC incidence and relative survival among younger (<50-year-old) adults in 2 time periods.METHODS: Using data from the Surveillance, Epidemiology, and End Results program of cancer registries, we estimated CRC incidence rates (per 100,000 persons 20-49 years old) from 1992 through 2014 for different periods (1992-1996 vs 2010-2014) "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/10826010",
"endSection": "abstract",
"offsetInBeginSection": 165,
"offsetInEndSection": 867,
"text": "Racial and ethnic disparities in incidence, mortality and survival rates, and trends exist for this disease. Differences in colorectal cancer screening, early detection, and treatment in minority communities are related to therapeutic outcomes. Age-adjusted incidence rates for men with colorectal cancer are highest for Alaskan native men, followed by Japanese, then African-American men. For women, the incidence is highest for Alaskan native women, followed by African-American, then Japanese women. Mortality rates in men are highest for African Americans, followed by Alaskan natives and then Hawaiians. In women, mortality rates are highest for Alaskan natives, then African Americans and whites."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/12716038",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 886,
"text": "Worldwide, colorectal carcinoma (CRC) varies by race-ethnicity. The highest incidence occurs in whites of European descent. Rates in blacks of South Africa are much lower, but rise with migration to westernized countries, i.e. African Americans (blacks) in the US. In the US, CRC age-specific incidence rates increased dramatically with biologic aging for black and white men and women. For all ages, rates were slightly higher for black than for whites. Among whites, overall annual rates peaked in the 1980s then declined. Stage- and subsite-specific rate shifts suggested earlier detection of cancers through screening, particularly in the distal colon. Blacks have not experienced the same stage- and subsite temporal shifts, which were observed in whites. CRC racial differences have been attributed to biologic and/or non-biologic factors as well as to routine screening patterns."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28248415",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1346,
"text": "Colorectal cancer (CRC) is one of the most common malignancies in the United States. Every 3 years, the American Cancer Society provides an update of CRC incidence, survival, and mortality rates and trends. Incidence data through 2013 were provided by the Surveillance, Epidemiology, and End Results program, the National Program of Cancer Registries, and the North American Association of Central Cancer Registries. Mortality data through 2014 were provided by the National Center for Health Statistics. CRC incidence rates are highest in Alaska Natives and blacks and lowest in Asian/Pacific Islanders, and they are 30% to 40% higher in men than in women. Recent temporal patterns are generally similar by race and sex, but differ by age. Between 2000 and 2013, incidence rates in adults aged ≥50 years declined by 32%, with the drop largest for distal tumors in people aged ≥65 years (incidence rate ratio [IRR], 0.50; 95% confidence interval [95% CI], 0.48-0.52) and smallest for rectal tumors in ages 50 to 64 years (male IRR, 0.91; 95% CI, 0.85-0.96; female IRR, 1.00; 95% CI, 0.93-1.08). Overall CRC incidence in individuals ages ≥50 years declined from 2009 to 2013 in every state except Arkansas, with the decrease exceeding 5% annually in 7 states; however, rectal tumor incidence in those ages 50 to 64 years was stable in most states."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/9698125",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1850,
"text": "BACKGROUND: Although colorectal cancer rates are low among most groups of Native Americans in North America, rates for Alaska Natives have been substantially elevated compared with US rates for all races combined.METHODS: To better describe the epidemiology of colorectal cancer incidence and survival among Alaska Natives, stratified by gender and tribal/ethnic affiliation, we examined data collected by the Alaska Native Cancer Registry 1969-1993. We calculated age-adjusted and age-specific incidence as well as actuarial survival rates, and examined histological type, site, stage at diagnosis, and treatment. We compared these data to colorectal cancer data from whites living in western Washington.RESULTS: In all, 587 colorectal cancer cases were identified among Alaska Natives over the 25-year period, for an age-adjusted annual incidence rate of 71.4/100000 in women, and 69.3/100000 in men. Compared to Alaska Indians, colon cancer rates were significantly higher in Aleuts (relative risk [RR] = 1.6, 95% CI: 1.2-2.2) and in Eskimos (RR = 1.5, 95% CI: 1.2-1.8), while rectal cancer rates did not differ by race/ethnicity. Alaska Natives experienced a 50% higher incidence rate of colorectal cancer overall compared to western Washington whites (RR = 1.5, 95% CI: 1.3-1.6), although rectal cancer rates were similar in the two populations. The highest RR were seen among Alaska Native women; Aleuts and Eskimos had colon cancer rates more than twice that of western Washington white women. No unusual qualitative features were found in the cancers occurring in Alaska Natives. Actuarial colorectal cancer survival rates for Alaska Natives overall were 74% at one year and 42% at 5 years; these rates were very similar to those observed for the western Washington population. Both one and 5-year survival rates showed a significant trend to"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/15052704",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1918,
"text": "OBJECTIVE: National and state data document racial differences in colorectal cancer (CRC) mortality and incidence. Screening for CRC reduces cancer incidence and deaths. Racial differences in colorectal cancer screening behavior may contribute to the racial disparity in incidence and mortality. The purpose of this study was to determine if colorectal cancer screening rates are different between blacks and whites while controlling for potential confounders.STUDY DESIGN: Cross-sectional survey. DATA SOURCE(S)/STUDY SETTING: We used data from the North Carolina Colon Cancer Study, a population-based case-control study conducted in 33 counties of North Carolina. We analyzed data from 598 control subjects who were eligible for colorectal cancer screening.METHODS: Trained nurses conducted face-to-face interviews from October 1996 through October 2000.RESULTS: Overall, 50% of the respondents were compliant with CRC screening guidelines. In the multivariable logistic regression model having a regular doctor and participation in a general medical exam were significantly associated with current screening status with odds ratios (OR) (95% confidence interval (CI)) of 3.8 (1.7-8.3) and 3.7 (2.1-6.7), respectively. Older age was a significant predictor of current screening status with an OR (95% CI) of 2.9 (1.7-4.8) for those 60-69 compared to respondents 50-59 and OR 3.2 (1.9-5.5) for those 70 and older compared to respondents 50-59. After adjusting for age, having a regular doctor and participation in general medical exams, race was not significantly associated with current CRC screening status, with an OR of 1.1 (95% CI 0.7-1.6).CONCLUSION: CRC screening rates in North Carolina were low. Race was not a significant determinant of screening behavior and therefore does not explain the racial disparity in incidence or survival. Older age, having a regular doctor and participating in general medical "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/16532978",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 737,
"text": "BACKGROUND AND AIMS: Colorectal cancer screening beginning at age 50 is recommended for all Americans considered at average risk for the development of colorectal cancer regardless of gender or race/ethnicity. We determined the influence of gender and race/ethnicity on the cost-effectiveness of recommended colorectal cancer screening regimens.METHODS: We determined age-specific colorectal cancer incidence rates; the proportion of left-sided cancers; and the proportion of localized cancers in Asian, black, Latino and white men and women using the California Cancer Registry. We incorporated these data and available data for life expectancy and colorectal cancer survival to model the cost-effectiveness of two 35-year colorectal ca"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29128568",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 133,
"text": "African Americans have the highest incidence and mortality rates of colorectal cancer (CRC) of any ethnic group in the United States."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36047055",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 92,
"text": "Black Americans have the highest colorectal cancer incidence and mortality rates of any U.S."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37963221",
"endSection": "abstract",
"offsetInBeginSection": 1069,
"offsetInEndSection": 1313,
"text": "Although non-Hispanic Black service members have historically had the highest incidence of colorectal cancer within the U.S. military, this study observed similar rates of colorectal cancer for all races and ethnicities after adjusting for age."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37963221",
"endSection": "abstract",
"offsetInBeginSection": 713,
"offsetInEndSection": 1313,
"text": "Age-adjusted colorectal cancer rates were similar for males and females (4.46 and 4.33 cases per 100,000 person-years, respectively) and rates were relatively similar by service as well as race and ethnicity. This finding could be attributed to the small number of cases in this study due to better screening practices in the Military Health System (MHS). Although non-Hispanic Black service members have historically had the highest incidence of colorectal cancer within the U.S. military, this study observed similar rates of colorectal cancer for all races and ethnicities after adjusting for age."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/16835912",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 514,
"text": "BACKGROUND: Cancers of the colon and rectum are the third most common malignancy among males and females in the United States, although incidence and mortality have declined in recent years. We evaluated recent trends in colorectal cancer incidence in the United States by subsite and stage at diagnosis.METHODS: Data for this analysis included all cases of colorectal cancer diagnosed between 1992 and 2001 and reported to the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37963221",
"endSection": "abstract",
"offsetInBeginSection": 922,
"offsetInEndSection": 1555,
"text": "This finding could be attributed to the small number of cases in this study due to better screening practices in the Military Health System (MHS). Although non-Hispanic Black service members have historically had the highest incidence of colorectal cancer within the U.S. military, this study observed similar rates of colorectal cancer for all races and ethnicities after adjusting for age. Incident rates of colorectal cancer within the U.S. military increase monotonically with age, with service members over the age of 45 with the highest incidence, re-enforcing the need to promote wellness screening among military populations."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37963221",
"endSection": "abstract",
"offsetInBeginSection": 1069,
"offsetInEndSection": 1668,
"text": "Although non-Hispanic Black service members have historically had the highest incidence of colorectal cancer within the U.S. military, this study observed similar rates of colorectal cancer for all races and ethnicities after adjusting for age. Incident rates of colorectal cancer within the U.S. military increase monotonically with age, with service members over the age of 45 with the highest incidence, re-enforcing the need to promote wellness screening among military populations. The importance of the DHA guideline changes that decreased colorectal screenings to age 45 years is significant."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/16532978",
"endSection": "abstract",
"offsetInBeginSection": 770,
"offsetInEndSection": 1169,
"text": "LTS: Age-specific colorectal cancer incidence rates were highest in black men and lowest in Latino women. Screening beginning at age 50 was most cost-effective in black men and least cost-effective in Latino women (measured as dollars spent per year of life saved) using annual fecal occult blood testing combined with flexible sigmoidoscopy every five years and using colonoscopy every 10 years. Th"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/16532978",
"endSection": "abstract",
"offsetInBeginSection": 347,
"offsetInEndSection": 876,
"text": "THODS: We determined age-specific colorectal cancer incidence rates; the proportion of left-sided cancers; and the proportion of localized cancers in Asian, black, Latino and white men and women using the California Cancer Registry. We incorporated these data and available data for life expectancy and colorectal cancer survival to model the cost-effectiveness of two 35-year colorectal cancer-screening interventions.RESULTS: Age-specific colorectal cancer incidence rates were highest in black men and lowest in Latino women. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26703651",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 253,
"text": "Colorectal cancer (CRC) is the second most common cancer among African American women and the third most common cancer for African American men. The mortality rate from CRC is highest among African Americans compared to any other racial or ethnic group."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/10826011",
"endSection": "abstract",
"offsetInBeginSection": 522,
"offsetInEndSection": 824,
"text": "In American blacks, there is evidence for a higher prevalence of right-sided colonic tumors and an earlier age of onset of colorectal cancer. In addition, blacks have the highest colon cancer incidence in the United States among ethnic groups and have poorer 5-year survival rates compared with whites."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34193094",
"endSection": "abstract",
"offsetInBeginSection": 1012,
"offsetInEndSection": 1131,
"text": "increase from 2002 to 2007. In 2016, CRC incidence was higher among Blacks (42.5 per 100,000) than Whites (38.0), Latin"
}
] | 13
|
BioASQ-training13b
| null | null |
66214c5db9f8b89d7e000002
| 5,204
|
factoid
|
LRP6 is a member of what superfamily of cell-surface receptors?
|
['Low Density lipoprotein receptors']
|
[
"Low Density lipoprotein receptors",
"LDL receptors",
"Low-Density Lipoprotein Receptors",
"LDL-R",
"LDL receptor",
"Low-density lipoprotein receptor"
] |
['LRP6 is a member of the low-density lipoprotein receptor superfamily of cell-surface receptors.', 'LRP6 is a member of the low-density lipoprotein receptor (LDLR) superfamily of cell-surface receptors.', 'LRP6 is a member of the low-density lipoprotein (LDL) receptor superfamily of cell-surface receptors.', 'LRP6 (low-density lipoprotein receptor-related protein 6) is a member of the LDL receptor superfamily that plays an important role in regulating the Wnt/β-catenin signaling pathway.', 'LRP6 is a member of the low-density lipoprotein receptor superfamily of cell-surface receptors', 'LRP6 is a member of the low-density lipoprotein receptor superfamily.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/35052459",
"http://www.ncbi.nlm.nih.gov/pubmed/26046396",
"http://www.ncbi.nlm.nih.gov/pubmed/16263759",
"http://www.ncbi.nlm.nih.gov/pubmed/16390319",
"http://www.ncbi.nlm.nih.gov/pubmed/28966723",
"http://www.ncbi.nlm.nih.gov/pubmed/9704021",
"http://www.ncbi.nlm.nih.gov/pubmed/30038821",
"http://www.ncbi.nlm.nih.gov/pubmed/15064719",
"http://www.ncbi.nlm.nih.gov/pubmed/31679626",
"http://www.ncbi.nlm.nih.gov/pubmed/22615920",
"http://www.ncbi.nlm.nih.gov/pubmed/17326769",
"http://www.ncbi.nlm.nih.gov/pubmed/34026761",
"http://www.ncbi.nlm.nih.gov/pubmed/20543981",
"http://www.ncbi.nlm.nih.gov/pubmed/15516984",
"http://www.ncbi.nlm.nih.gov/pubmed/34490514",
"http://www.ncbi.nlm.nih.gov/pubmed/29312635",
"http://www.ncbi.nlm.nih.gov/pubmed/32661084"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35052459",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 96,
"text": "LRP6 is a member of the low-density lipoprotein receptor superfamily of cell-surface receptors. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/16390319",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 119,
"text": "LRP5, along with LRP6 and their Drosophila homolog, Arrow, constitute a novel subclass of the LDL receptor superfamily."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35052459",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 94,
"text": "LRP6 is a member of the low-density lipoprotein receptor superfamily of cell-surface receptors"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22615920",
"endSection": "abstract",
"offsetInBeginSection": 12,
"offsetInEndSection": 204,
"text": "LGR6 (leucine-rich repeat containing, G protein-coupled receptor 6) is a member of the rhodopsin-like seven transmembrane domain receptor superfamily with the highest homology to LGR4 and LGR5"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35052459",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 623,
"text": "LRP6 is a member of the low-density lipoprotein receptor superfamily of cell-surface receptors. It is required for the activation of the Wnt/β-catenin signalling pathway. LRP6 is detected in different tissue types and is involved in numerous biological activities such as cell proliferation, specification, metastatic cancer, and embryonic development. LRP6 is essential for the proper development of different organs in vertebrates, such as Xenopus laevis, chickens, and mice. In human, LRP6 overexpression and mutations have been reported in multiple complex diseases including hypertension, atherosclerosis, and cancers."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34490514",
"endSection": "abstract",
"offsetInBeginSection": 760,
"offsetInEndSection": 1392,
"text": "Although the low-density-lipoprotein-receptor-related-protein (LRP) family is best known for its role in binding and endocytosis of lipoproteins, specific members appear to have additional roles in cellular communication. Indeed, for WNT/β-catenin signalling one apparently universal requirement is the presence of either LRP5 or LRP6 in combination with one of the ten Frizzled (FZD) WNT receptors (FZD1-10). In the 20 years since their discovery as WNT/FZD co-receptors, research on the LRP family has contributed greatly to our understanding of WNT signalling and LRPs have emerged as central players in WNT/β-catenin signalling."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28966723",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 817,
"text": "The LOW-density lipoprotein related protein 6 (LRP6) receptor is an important effector of canonical Wnt signaling, a developmental pathway, whose dysregulation has been implicated in various diseases including cancer. The membrane proximal low-density lipoprotein (LDL) receptor repeats in LRP6 exhibit homology to ligand binding repeats in the LDL receptor (LDLR), but lack known function. We generated single amino acid substitutions of LRP6-LDLR repeat residues, which are highly conserved in the human LDLR and mutated in patients with Familial Hypercholesteremia (FH). These substitutions negatively impacted LRP6 internalization and activation of Wnt signaling. By mass spectrometry, we observed that the Itch E3 ubiquitin ligase associated with and ubiquitinated wild type LRP6 but not the LDLR repeat mutants."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34026761",
"endSection": "abstract",
"offsetInBeginSection": 154,
"offsetInEndSection": 840,
"text": "In vertebrates, low density lipoprotein receptor-related proteins 5 and 6 (LRP5 and LRP6), the single-pass transmembrane proteins, act as coreceptors of Wnt ligands and are indispensable for Wnt signal transduction. LRP5 and LRP6 are highly homologous and widely co-expressed in embryonic and adult tissues, and they share similar function in mediating Wnt signaling. However, they also exhibit distinct characteristics by interacting with different protein partners. As such, each of them possesses its own unique functions. In this review, we systematically discuss the similarity and divergence of LRP5 and LRP6 in mediating Wnt and other signaling in the context of kidney diseases."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29312635",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 744,
"text": "Low density lipoprotein (LDL) receptor-related protein-6 (LRP6) is an important co-receptor of Wnt pathway, which plays a predominant role in development and progression of colorectal cancer. Recently, dysregulation of LRP6 has proved to be involved in the progression of cancers, but its biological role and clinical significance in colorectal cancer remain unclear. In present study, we revealed that phosphorylation of LRP6 was aberrantly upregulated in colorectal carcinoma correlating with TNM or Dukes staging and worse prognosis. In addition, phosphorylated LRP6 was positively correlated with nuclear accumulation of β-catenin. Overexpression or activation of LRP6 could activate Wnt signaling and promote tumor cell migration in vitro."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32661084",
"endSection": "abstract",
"offsetInBeginSection": 72,
"offsetInEndSection": 983,
"text": "Internalization of the low-density lipoprotein receptor-related protein 6 (LRP6) receptor complex can either promote or attenuate canonical WNT signaling, depending on the employed internalization pathway. Detailed analysis of the mechanism of LRP6 internalization and its temporal regulation is crucial for understanding the different cellular responses to WNT stimulation under varying conditions and in various cell types. Here, we elucidate the mechanisms involved in the internalization of LRP6 and re-evaluate existing, partly contradicting, theories on the regulation of LRP6 receptor internalization. We utilize a computational approach that aims at finding a set of mechanisms that accounts for the temporal dynamics of LRP6 receptor internalization upon WNT stimulation. Starting with a simple simulation model, we successively extend and probe the model's behavior based on quantitative measurements."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35052459",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 95,
"text": "LRP6 is a member of the low-density lipoprotein receptor superfamily of cell-surface receptors."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35052459",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 170,
"text": "LRP6 is a member of the low-density lipoprotein receptor superfamily of cell-surface receptors. It is required for the activation of the Wnt/β-catenin signalling pathway."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35052459",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 352,
"text": "LRP6 is a member of the low-density lipoprotein receptor superfamily of cell-surface receptors. It is required for the activation of the Wnt/β-catenin signalling pathway. LRP6 is detected in different tissue types and is involved in numerous biological activities such as cell proliferation, specification, metastatic cancer, and embryonic development."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31679626",
"endSection": "abstract",
"offsetInBeginSection": 137,
"offsetInEndSection": 415,
"text": "Lipoprotein receptor-related protein 6 (LRP6) is a member of the low-density lipoprotein receptor (LDLR) family composed of structurally related cell surface receptors and acts, in consort with Frizzled receptors, as a coreceptor to mediate the Wnt/β-catenin signalling pathway."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31679626",
"endSection": "abstract",
"offsetInBeginSection": 137,
"offsetInEndSection": 575,
"text": "Lipoprotein receptor-related protein 6 (LRP6) is a member of the low-density lipoprotein receptor (LDLR) family composed of structurally related cell surface receptors and acts, in consort with Frizzled receptors, as a coreceptor to mediate the Wnt/β-catenin signalling pathway. Impaired LRP6 signalling in humans has been associated with multiple cardiovascular risk factors such as elevated serum LDL, triglycerides, and glucose levels."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31679626",
"endSection": "abstract",
"offsetInBeginSection": 137,
"offsetInEndSection": 829,
"text": "Lipoprotein receptor-related protein 6 (LRP6) is a member of the low-density lipoprotein receptor (LDLR) family composed of structurally related cell surface receptors and acts, in consort with Frizzled receptors, as a coreceptor to mediate the Wnt/β-catenin signalling pathway. Impaired LRP6 signalling in humans has been associated with multiple cardiovascular risk factors such as elevated serum LDL, triglycerides, and glucose levels. Considerable efforts have been deployed to better understand the underlying mechanisms of LRP6-associated disorders, and the therapeutic targeting of LRP6 has been demonstrated to have positive effects in various animal models of cardiovascular disease."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/20543981",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 129,
"text": "BACKGROUND: The low density lipoprotein receptor-related protein-6 (LRP6) is an essential co-receptor for canonical Wnt signaling"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/20543981",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 298,
"text": "BACKGROUND: The low density lipoprotein receptor-related protein-6 (LRP6) is an essential co-receptor for canonical Wnt signaling. Dickkopf 1 (Dkk1), a major secreted Wnt signaling antagonist, binds to LRP6 with high affinity and prevents the Frizzled-Wnt-LRP6 complex formation in response to Wnts"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/20543981",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 460,
"text": "BACKGROUND: The low density lipoprotein receptor-related protein-6 (LRP6) is an essential co-receptor for canonical Wnt signaling. Dickkopf 1 (Dkk1), a major secreted Wnt signaling antagonist, binds to LRP6 with high affinity and prevents the Frizzled-Wnt-LRP6 complex formation in response to Wnts. Previous studies have demonstrated that Dkk1 promotes LRP6 internalization and degradation when it forms a ternary complex with the cell surface receptor Kremen"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/9704021",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 406,
"text": "A novel member of the low density lipoprotein receptor (LDLR) gene family has been identified and characterized. This gene, termed LDL receptor-related protein 6 (LRP6), encodes a transmembrane protein which has 71% identity and is structurally similar to the protein encoded by LRP5, a proposed candidate gene for type 1 diabetes located on human chromosome 11q13. LRP6 maps to human chromosome 12p11-p13."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/15516984",
"endSection": "abstract",
"offsetInBeginSection": 83,
"offsetInEndSection": 277,
"text": "The low-density lipoprotein (LDL) receptor-related protein-6 (LRP6), a novel member of the expanding LDL receptor family, functions as an indispensable co-receptor for the Wnt signaling pathway."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/17326769",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 199,
"text": "Low-density lipoprotein receptor-related protein 6 (LRP6) is a member of low-density lipoprotein receptor (LDLR) family which cooperates with Frizzled receptors to transduce the canonical Wnt signal."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/16263759",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 94,
"text": "Wnt co-receptors LRP5 and LRP6 are two members of the low-density lipoprotein receptor family."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35052459",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 74,
"text": "LRP6 Receptor Plays Essential Functions in Development and Human Diseases."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35052459",
"endSection": "abstract",
"offsetInBeginSection": 171,
"offsetInEndSection": 352,
"text": "LRP6 is detected in different tissue types and is involved in numerous biological activities such as cell proliferation, specification, metastatic cancer, and embryonic development."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/9704021",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 107,
"text": "Isolation and characterization of LRP6, a novel member of the low density lipoprotein receptor gene family."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22615920",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 193,
"text": "BACKGROUND: LGR6 (leucine-rich repeat containing, G protein-coupled receptor 6) is a member of the rhodopsin-like seven transmembrane domain receptor superfamily with the highest homology to LG"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26046396",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 116,
"text": "Low-density lipoprotein receptor-related protein 6 (LRP6) is a member of the low-density lipoprotein receptor family"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/16263759",
"endSection": "abstract",
"offsetInBeginSection": 17,
"offsetInEndSection": 94,
"text": "LRP5 and LRP6 are two members of the low-density lipoprotein receptor family."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31679626",
"endSection": "abstract",
"offsetInBeginSection": 137,
"offsetInEndSection": 908,
"text": "Lipoprotein receptor-related protein 6 (LRP6) is a member of the low-density lipoprotein receptor (LDLR) family composed of structurally related cell surface receptors and acts, in consort with Frizzled receptors, as a coreceptor to mediate the Wnt/β-catenin signalling pathway. Impaired LRP6 signalling in humans has been associated with multiple cardiovascular risk factors such as elevated serum LDL, triglycerides, and glucose levels. Considerable efforts have been deployed to better understand the underlying mechanisms of LRP6-associated disorders, and the therapeutic targeting of LRP6 has been demonstrated to have positive effects in various animal models of cardiovascular disease. This review presents a synthetic summary highlighting the major roles of LRP6."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/16263759",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 873,
"text": "Wnt co-receptors LRP5 and LRP6 are two members of the low-density lipoprotein receptor family. Receptor-associated protein is not only a specialized chaperone but also a universal antagonist for members of the low-density lipoprotein receptor family. Here we test whether Mesd, a newly identified chaperone for members of the low-density lipoprotein receptor family, also binds to mature receptors at the cell surface and antagonizes ligand binding. We found that Mesd binds to cell surface LRP5 and LRP6, but not to other members of the low-density lipoprotein receptor family. Scatchard analysis revealed that Mesd binds cell surface LRP6 with high affinity (K(d) approximately 3.3 nM). Interestingly, the C-terminal region of Mesd, which is absent in sequences from invertebrates, is necessary and sufficient for binding to mature LRP6, and is required for LRP6 folding."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/16390319",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 521,
"text": "LRP5, along with LRP6 and their Drosophila homolog, Arrow, constitute a novel subclass of the LDL receptor superfamily. The arrangement of structural motifs in these receptors is different from the other members of the superfamily, and only recently have we begun to understand the functional importance of human LRP5 (and LRP6). Whole genome positional cloning studies have identified a number of mutations in LRP5 that underlie inherited human diseases/phenotypes, particularly those involving the skeleton and the eye."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/15516984",
"endSection": "abstract",
"offsetInBeginSection": 83,
"offsetInEndSection": 520,
"text": "The low-density lipoprotein (LDL) receptor-related protein-6 (LRP6), a novel member of the expanding LDL receptor family, functions as an indispensable co-receptor for the Wnt signaling pathway. Although the role of LRP6 in embryonic development is now well established, its role in tumorigenesis is unclear. We report that LRP6 is readily expressed at the transcript level in several human cancer cell lines and human malignant tissues."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22615920",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1489,
"text": "BACKGROUND: LGR6 (leucine-rich repeat containing, G protein-coupled receptor 6) is a member of the rhodopsin-like seven transmembrane domain receptor superfamily with the highest homology to LGR4 and LGR5. LGR6 was found as one of the novel genes mutated in colon cancer through total exon sequencing and its promoter region is hypermethylated in 20-50% of colon cancer cases. In the skin, LGR6 marks a population of stem cells that can give rise to all cell lineages. Recently, we and others demonstrated that LGR4 and LGR5 function as receptors of R-spondins to potentiate Wnt/β-catenin signaling. However, the binding affinity and functional response of LGR6 to R-spondins, and the activity of colon cancer mutants of LGR6 have not been determined.PRINCIPAL FINDINGS: We found that LGR6 also binds and responds to R-spondins 1-3 with high affinity to enhance Wnt/β-catenin signaling through increased LRP6 phosphorylation. Similar to LGR4 and LGR5, LGR6 is not coupled to heterotrimeric G proteins or to β-arrestin following R-spondin stimulation. Functional and expression analysis of three somatic mutations identified in colon cancer samples indicates that one mutant fails to bind and respond to R-spondin (loss-of-function), but the other two have no significant effect on receptor function. Overexpression of wild-type LGR6 in HeLa cells leads to increased cell migration following co-treatment with R-spondin1 and Wnt3a when compared to vector control cells or cells overexpressi"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/15064719",
"endSection": "abstract",
"offsetInBeginSection": 196,
"offsetInEndSection": 1078,
"text": "The identification of both Frizzled and LRP5/6 (LRP: low-density lipoprotein receptor-related protein) proteins as components of cell-surface receptors for Wnt proteins has raised questions about their individual functions. We have investigated this issue through a structure-function analysis of Frizzled and LRP proteins that have been implicated in Wnt1 signaling. Consistent with other reports, we find that LRP6/Arrow proteins deleted for their extracellular domain are able to activate the Wnt/beta-catenin signaling pathway. Importantly, our results demonstrate that this signaling from LRP6/Arrow derivatives can occur in a Frizzled- and ligand-independent manner. Furthermore, we show that the PPSP motifs within the intracellular domain of LRP6 are required for signaling. In contrast to results with LRP6, overexpression of Frizzled proteins did not activate the pathway."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28966723",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 217,
"text": "The LOW-density lipoprotein related protein 6 (LRP6) receptor is an important effector of canonical Wnt signaling, a developmental pathway, whose dysregulation has been implicated in various diseases including cancer."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34026761",
"endSection": "abstract",
"offsetInBeginSection": 154,
"offsetInEndSection": 369,
"text": "In vertebrates, low density lipoprotein receptor-related proteins 5 and 6 (LRP5 and LRP6), the single-pass transmembrane proteins, act as coreceptors of Wnt ligands and are indispensable for Wnt signal transduction."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29312635",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 191,
"text": "Low density lipoprotein (LDL) receptor-related protein-6 (LRP6) is an important co-receptor of Wnt pathway, which plays a predominant role in development and progression of colorectal cancer."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31679626",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 415,
"text": "Coronary artery disease (CAD), often related to dyslipidemia, is a major cause of death worldwide, highlighting unmet therapeutic needs. Lipoprotein receptor-related protein 6 (LRP6) is a member of the low-density lipoprotein receptor (LDLR) family composed of structurally related cell surface receptors and acts, in consort with Frizzled receptors, as a coreceptor to mediate the Wnt/β-catenin signalling pathway."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30038821",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 282,
"text": "Low-density lipoprotein receptor-related protein 6 (LRP6) is a co-receptor for Wnt signaling and can be recruited by multiple growth factors/hormones to their receptors facilitating intracellular signaling activation. The ligands that bind directly to LRP6 have not been identified."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30038821",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 217,
"text": "Low-density lipoprotein receptor-related protein 6 (LRP6) is a co-receptor for Wnt signaling and can be recruited by multiple growth factors/hormones to their receptors facilitating intracellular signaling activation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30038821",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 406,
"text": "Low-density lipoprotein receptor-related protein 6 (LRP6) is a co-receptor for Wnt signaling and can be recruited by multiple growth factors/hormones to their receptors facilitating intracellular signaling activation. The ligands that bind directly to LRP6 have not been identified. Here, we report that bioactive oxidized phospholipids (oxPLs) are native ligands of LRP6, but not the closely related LRP5."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22615920",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 205,
"text": "BACKGROUND: LGR6 (leucine-rich repeat containing, G protein-coupled receptor 6) is a member of the rhodopsin-like seven transmembrane domain receptor superfamily with the highest homology to LGR4 and LGR5."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31679626",
"endSection": "abstract",
"offsetInBeginSection": 137,
"offsetInEndSection": 304,
"text": "Lipoprotein receptor-related protein 6 (LRP6) is a member of the low-density lipoprotein receptor (LDLR) family composed of structurally related cell surface receptors"
}
] | 13
|
BioASQ-training13b
| null | null |
662cfd21187cba990d000009
| 5,205
|
factoid
|
What are episignatures?
|
['unique genomic DNA methylation patterns']
|
[
"unique genomic DNA methylation patterns",
"distinct genomic DNA methylation patterns",
"specific genomic DNA methylation patterns",
"individual genomic DNA methylation patterns",
"characteristic genomic DNA methylation patterns"
] |
['Episignatures are genomic DNA methylation patterns that are associated with specific diseases, such as Duchenne Muscular Dystrophy. These patterns can be used for diagnostic testing and as disease biomarkers.', 'Episignatures are unique genomic DNA methylation patterns that can be used for diagnostic testing and as disease biomarkers', 'Episignatures are a type of epigenetic signature that refers to specific patterns of DNA methylation and histone modifications that are associated with certain genetic disorders.', 'Episignatures are distinct, highly sensitive, and specific biomarkers that have recently been applied in clinical diagnosis of genetic syndromes.', 'Episignatures are unique genomic DNA methylation patterns associated with certain genetic syndromes. They can be used for diagnostic testing and as disease biomarkers.', 'Episignatures are unique genomic DNA methylation patterns that can be used for diagnostic testing and as disease biomarkers.', 'Episignatures are unique genomic DNA methylation patterns that are associated with genetic syndromes and can be used for diagnostic testing and as disease biomarkers', 'Episignatures are unique genomic DNA methylation patterns that have been associated with a growing number of genetic syndromes. These DNA methylation patterns can be used for diagnostic testing and as disease biomarkers.', 'Episignatures refer to unique genomic DNA methylation patterns that have been associated with a growing number of genetic syndromes. These episignatures can be used for diagnostic testing and as disease biomarkers.', 'Episignatures are unique genomic DNA methylation patterns that can be used for diagnostic testing and as disease biomarkers in genetic syndromes.', 'Episignatures are unique genomic DNA methylation patterns.', 'Episignatures are unique genomic DNA methylation patterns. They are associated with various genetic syndromes and can be used for diagnostic testing and as disease biomarkers', 'Episignatures are distinct, highly sensitive, and specific biomarkers that represent unique genomic DNA methylation patterns.', 'Episignatures are unique genomic DNA methylation patterns that have been associated with a growing number of genetic syndromes. They can be used for diagnostic testing and as disease biomarkers.', 'Episignatures refer to unique genomic DNA methylation patterns that have been associated with certain genetic syndromes. These episignatures can be used for diagnostic testing and as disease biomarkers.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/36572586"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36572586",
"endSection": "abstract",
"offsetInBeginSection": 548,
"offsetInEndSection": 744,
"text": "A growing number of genetic syndromes have been associated with unique genomic DNA methylation patterns (called \"episignatures\") that can be used for diagnostic testing and as disease biomarkers. "
}
] | 13
|
BioASQ-training13b
| null | null |
66301e04187cba990d000027
| 5,207
|
factoid
|
What are the clinical indication for Transarterial Chemoembolization (TACE) in liver metastasis for colorectal cancer?
|
['Unresectable chemotherapy refractory liver metastasis when conventional therapies fail', 'Liver dominant metastasis', 'liver metastases not amenable to curative surgical resection']
|
[
"Unresectable chemotherapy refractory liver metastasis when conventional therapies fail",
"Liver dominant metastasis",
"liver metastases not amenable to curative surgical resection",
"unresectable liver metastasis",
"chemotherapy-resistant liver metastasis",
"liver metastasis",
"non-resectable liver metastasis",
"liver cancer metastasis",
"advanced liver metastasis",
"liver secondary tumors"
] |
["Transarterial chemoembolization (TACE) is a locoregional therapy used in the palliative treatment of primary and secondary hepatic malignancies, including colorectal cancer liver metastases (CRLM). TACE involves the injection of a chemotherapeutic agent and embolic material into the hepatic artery, which supplies blood to the liver tumors. This results in a high concentration of the chemotherapeutic agent within the tumor, while minimizing systemic exposure and associated side effects. TACE can be used as a bridge to surgery, downstaging of unresectable tumors, or as a palliative treatment for patients with unresectable or recurrent CRLM. The use of TACE in CRLM has been shown to improve overall survival and progression-free survival in some studies, but its role in the management of CRLM remains controversial. The decision to use TACE in CRLM should be individualized and based on the patient's clinical presentation, tumor burden, and liver function.", "TACE is a treatment option for liver metastasis in colorectal cancer, especially when surgical resection is not possible. It is typically used when both lobes of the liver are involved, making surgical resection impossible. In selected cases, chemotherapy may be given systemically or via the hepatic artery. The effectiveness and safety of percutaneous ethanol injection, another treatment option, are not well established. The prognosis for colorectal cancer depends on various factors, including the stage of the cancer, the person's overall health, and the success of treatment.", 'Transarterial Chemoembolization (TACE) is indicated for liver metastasis in colorectal cancer when conventional therapies fail, metastases recurrence occurs, or the cancer is unresectable and refractory to chemotherapy. It is particularly effective for larger, intermediate (3-5 cm) lesions.', 'Transarterial Chemoembolization (TACE) in liver metastasis for colorectal cancer is clinically indicated for colorectal liver metastases, unresectable chemotherapy refractory CRCLM, and liver-dominant colorectal liver metastases.', 'Transarterial Chemoembolization (TACE) is a treatment option for liver metastasis from colorectal cancer when conventional therapies fail or metastases recurrence occurs. It is well tolerated and effective in patients with unresectable chemotherapy refractory liver metastases', 'Transarterial chemoembolization (TACE) is an interventional radiologic procedure in which chemotherapeutic agents and embolic materials are injected through the hepatic artery for the treatment of liver malignancies, including metastatic colorectal cancer (mCRC). TACE is considered when surgical resection is not possible or if the metastases are limited to the liver and confined to one lobe.', "Transarterial Chemoembolization (TACE) is not specifically mentioned as a clinical indication for liver metastasis of colorectal cancer in the provided articles. The general treatment for colorectal cancer with liver metastasis includes surgery, radiation therapy, chemotherapy, and targeted therapy. The choice of treatment depends on the stage and location of the cancer, as well as the patient's overall health. Chemotherapy is often used in stages III and IV of colon cancer, and it can include capecitabine, fluorouracil, irinotecan, oxaliplatin, and UFT. For rectal cancer, chemoradiotherapy is often used in conjunction with chemotherapy in a neoadjuvant fashion to enable surgical resection. Immunotherapy with immune checkpoint inhibitors has been found to be useful for a type of colorectal cancer with mismatch repair deficiency and microsatellite instability. Palliative care is recommended for any person who has advanced colon cancer or who has significant symptoms.\n\nTACE is a procedure that is well tolerated and effective in patients with unresectable chemotherapy refractory liver tumors, but it is not specifically mentioned as a clinical indication for liver metastasis of colorectal cancer.", 'TACE is a treatment option for liver metastasis in colorectal cancer, typically used when both lobes of the liver are involved, making surgical resection impossible. It is a minimally invasive procedure that involves injecting chemotherapy drugs directly into the artery that supplies blood to the tumor, followed by embolization to block the blood flow to the tumor. The aim is to shrink the tumor and improve symptoms. In selected cases, chemotherapy may be given systemically or via the hepatic artery. The effectiveness and safety of percutaneous ethanol injection, another treatment option, are not well established.', 'The main clinical indications for using Transarterial Chemoembolization (TACE) in liver metastases from colorectal cancer are:\n\n1. When the liver metastases are unresectable or not amenable to curative surgical resection\n2. As a palliative treatment for chemotherapy-refractory liver metastases to reduce tumor burden, slow progression, and improve quality of life\n3. When conventional therapies fail or metastatic recurrence occurs\n\nTACE is generally well tolerated but may be less effective for larger metastatic lesions (3-5 cm). It allows delivery of high-dose chemotherapy directly to liver tumors while sparing normal liver tissue.', 'Transarterial chemoembolization (TACE) is increasingly used for patients with liver-dominant colorectal metastases after failure of surgery or systemic chemotherapy. It can potentially be used for pre- and post-operative downsizing, minimizing time-to-surgery, and prolongation of overall survival after surgery in patients with colorectal liver only metastases. However, it is not currently recommended as a standard treatment for colorectal liver metastases.', 'Transarterial Chemoembolization (TACE) is indicated for liver metastasis in colorectal cancer patients when conventional therapies fail, or metastases recurrence occurs. It is particularly effective and well-tolerated in patients with unresectable chemotherapy refractory.', 'The clinical indications for Transarterial Chemoembolization (TACE) in liver metastasis for colorectal cancer are unresectable and chemorefractory liver metastases. TACE is considered when systemic therapy has failed, and surgical resection is not possible. The goal of TACE is to prolong survival and palliate symptoms. It can be used as a standalone treatment or in combination with other local or systemic therapies. Conventional TACE (cTACE) and DEBIRI-TACE are two types of chemoembolization that have shown comparable results in different clinical settings, although the evidence is not yet definitive due to variations in study populations and prior therapies. A multidisciplinary approach is recommended to offer patients the best possible care.', 'TACE clinical indications for liver metastases from colorectal cancer include unresectable lesions, chemo-refractory disease, post-conventional therapy recurrence, and intermediate-sized (3-5 cm) tumors with poor local control rates and overall survival. TACE is a well-tolerated alternative to systemic chemotherapy for these patient populations.', 'Transarterial Chemoembolization (TACE) is a minimally invasive treatment for liver metastasis of colorectal cancer. TACE is a combination of chemotherapy and embolization of the hepatic artery, which is the main blood supply of the liver. The clinical indication for TACE in liver metastasis of colorectal cancer is the presence of unresectable liver metastasis, which is defined as liver metastasis that cannot be removed by surgery. TACE is used to treat liver metastasis that is unresectable or has failed to respond to previous treatments. The treatment is usually performed in patients with advanced colorectal cancer that has spread to the liver, and it can be used as a palliative treatment to relieve symptoms such as pain and bleeding. TACE can also be used as a neoadjuvant treatment before surgery to reduce the size of liver metastasis and improve the chances of successful surgical resection.', 'Transarterial Chemoembolization (TACE) is a minimally invasive treatment option for liver metastasis from colorectal cancer when conventional therapies fail or metastases recurrence occurs. It involves the delivery of chemotherapy drugs directly to the tumor through a catheter inserted into the hepatic artery, while simultaneously blocking the blood supply to the tumor. This combination of chemotherapy and embolization can help to reduce the size of the tumor and improve patient outcomes', 'Transarterial Chemoembolization (TACE) is indicated for liver metastases from colorectal cancer that are unresectable and refractory to chemotherapy, especially when lesions are larger (3-5 cm) and conventional therapies have failed or metastases recur.', "TACE is indicated for colorectal cancer liver metastases when the disease is unresectable, refractory to chemotherapy, or recurrent after conventional treatments. It's also considered for intermediate-sized lesions with poor local control and overall survival rates, providing an alternative treatment option to systemic chemotherapy.", 'Based on the provided abstracts, Transarterial Chemoembolization (TACE) is a treatment option for unresectable colorectal cancer with liver metastasis (CRCLM). The clinical indications for TACE in liver metastasis for colorectal cancer are: , 1. Unresectable liver metastases: TACE can be used to treat patients who are not eligible for surgical resection of their liver metastases., 2. Failure of systemic therapy: TACE can be considered as an additional treatment option after the failure of first-line, second-line, third-line, or fourth-line systemic chemotherapy and targeted therapy. , In these situations, TACE with drug-eluting beads (DEB-TACE) combined with systemic chemotherapy and targeted therapy may lead to a favorable disease control rate and survival outcomes in patients with CRCLM.', 'Transarterial Chemoembolization (TACE) is a minimally invasive treatment for liver metastasis of colorectal cancer. TACE is a combination of chemotherapy and embolization of the hepatic artery, which is the main blood supply of the liver. The clinical indication for TACE in liver metastasis of colorectal cancer is the presence of unresectable liver metastasis, which is defined as liver metastasis that cannot be removed by surgery. TACE is used to treat liver metastasis that is unresectable or has progressed after previous treatment with surgery or chemotherapy. TACE is also used to relieve symptoms such as pain and bleeding in patients with liver metastasis. The response to TACE is evaluated by imaging studies such as CT or MRI, and the response is usually evaluated after 2-3 months of treatment. The minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice are the presence of unresectable liver metastasis, the absence of metastasis in other organs, and the presence of a KRAS mutation. The role of epiregulin and amphiregulin in the use of EGFR inhibitors for colorectal cancer is to promote the progression of colorectal cancer by activating the EGFR signaling pathway. The clinical management and outcomes of patients with liver metastasis of colorectal cancer treated with TACE are affected by the subtype of volvulus, which is classified into three subtypes based on the X-ray signs and CT features. The subtype of volvulus is correlated with the clinical management and outcomes of patients with liver metastasis of colorectal cancer.', 'Transarterial chemoembolization (TACE) is a therapeutic option for patients with colorectal cancer liver metastasis who are not candidates for curative treatments. It has been shown to improve the prognosis of these patients.', 'Dummy', 'TACE is an option for unresectable colorectal cancer liver metastases when conventional therapies fail or recurrence occurs, indicated by: 1) Unresectable liver-only mets, 2) failure of systemic chemo (progression on at least two lines), 3) presence of predominantly liver disease, and 4) absence of significant extrahepatic spread. It can be used alone or with other therapies in a multidisciplinary approach for individual patient strategies.', 'Transarterial Chemoembolization (TACE) is typically indicated for patients with unresectable liver metastasis from colorectal cancer that is refractory to chemotherapy. This means that the cancer has not responded to conventional chemotherapy treatments. TACE is often considered when other therapies fail or when metastases recurrence occurs', "The key clinical indications for using transarterial chemoembolization (TACE) in colorectal cancer liver metastases are:\n\n1) When the liver metastases are not amenable to curative surgical resection \n2) As a palliative treatment to reduce tumor burden and symptoms\n3) To deliver high-dose chemotherapy directly to liver tumors while sparing normal liver tissue\n\nTACE is used as a minimally invasive, palliative treatment for colorectal liver metastases that cannot be surgically removed. It works by blocking the tumor's blood supply and delivering chemotherapy locally to the tumor, resulting in higher drug concentrations in the tumor for a longer time compared to the rest of the liver. However, TACE is not a curative treatment for metastatic colorectal cancer.", '1. Symptom palliation in unresectable cases.\n2. Tumor downsizing prior to surgery.\n3. Bridge to surgery.\n4. Control of tumor growth.', 'Transarterial chemoembolization (TACE) is a treatment modality for liver metastasis for colorectal cancer. It is used for patients with unresectable liver metastasis, and it is a palliative treatment for patients with liver metastasis that is not amenable to surgical resection. TACE is a minimally invasive procedure that involves the delivery of chemotherapy directly to the liver through the hepatic artery. It has been shown to be effective in improving survival and quality of life in patients with liver metastasis from colorectal cancer.', "Transarterial Chemoembolization (TACE) is an alternative treatment for unresectable colorectal cancer liver metastasis (CRCLM). Clinical indications include: 1) Unresectable liver metastases, where TACE can be used when surgery isn't possible; and 2) Failure of systemic therapy, making it a potential option after chemotherapy or targeted treatment. In these cases, using DEB-TACE with other treatments may improve disease control and survival rates in CRCLM patients.", 'Transarterial chemoembolization (TACE) is a treatment modality for liver metastasis of colorectal cancer. It is used for patients with unresectable liver metastasis, and it is effective in improving survival time and quality of life.', "The main indications for TACE are:\n* Unresectable or transiently resectable colorectal liver metastases\n* Achieving stable disease after initial chemotherapy\n* Improvement of the patient's performance status\n* To obtain a tumor response or to downstage the tumor burden before a planned curative surgery\n* To treat lesions that do not respond to systemic chemotherapy\n* To treat tumor recurrence after liver resection", 'Transarterial Chemoembolization (TACE) in liver metastasis for colorectal cancer is well-tolerated and effective in patients with unresectable chemotherapy refefractory (larger intermediate (3-5 cm), when conventional therapies fail, or metastases recurrence occurs..', 'Transarterial Chemoembolization (TACE) is a well-tolerated and effective treatment option for patients with unresectable, chemotherapy-refractory liver metastases from colorectal cancer. It is particularly beneficial for larger, intermediate (3-5 cm) lesions, where local control rates and overall survival are relatively worse.', '1. Symptomatic control of intrahepatic tumor burden, particularly in patients with unresectable, or progressive disease 2. Liver-dominant metastases, in the absence of extrahepatic disease 3. Improving patient survival 4. Bridge to transplant in selected patients 5. Downsizing of liver lesion in preparation for resection in selected patients.', 'The clinical indications for Transarterial Chemoembolization (TACE) in liver metastasis for colorectal cancer include: * Unresectable liver metastases * Chemotherapy refractory disease * Recurrence of metastases after conventional therapies * Intermediate-sized lesions (3-5 cm) with poor local control rates and overall survival , TACE is a well-tolerated and effective treatment option in these patient populations, offering an alternative to systemic chemotherapy.', 'TACE is indicated for patients with unresectable, chemotherapy-refractory liver metastases from colorectal cancer. \n\nPlease provide your answer in a concise and clear manner. \nPlease note that you should not provide any additional information beyond what is provided in the context. \nPlease also note that you should not provide any information that is not supported by the context. \nPlease be accurate and precise in your answer. \nPlease be polite and respectful in your tone. \nPlease be patient and understanding in your response. \nPlease be aware that you are a biomedical question answering assistant, and you should provide answers based on the context provided. \nPlease be aware that you should not provide any personal opinions or biases in your answer. \nPlease be aware that you should not provide any information that is not supported by the context. \nPlease be aware that you should not provide any information that is not accurate or precise. \nPlease be aware that you should be polite, respectful, patient, and understanding in your response. \nPlease be aware that you are a biomedical question answering assistant, and you should provide answers based on the context provided. \nPlease be aware that you should not provide any personal opinions or biases in your answer. \nPlease be aware that you', 'Transarterial Chemoembolization (TACE) in liver metastasis for colorectal cancer is indicated for the treatment of CRLM using irinotecan-loaded microspheres in patients with colorectal cancer.', 'Based on the provided abstracts, Transarterial Chemoembolization (TACE) is a viable option for patients with unresectable liver metastases from colorectal cancer who have failed or are refractory to systemic chemotherapy. The clinical indications for TACE in liver metastasis for colorectal cancer include: * Unresectable liver metastases * Failure or refractoriness to systemic chemotherapy * Palliation of symptoms related to liver metastases , TACE can be used as a salvage therapy to control local metastases and improve survival time. The procedure involves the local injection of a combination of chemotherapeutic and embolic agents, which can be tailored to individual patients based on their clinical setting and prior therapies.', 'The clinical indication for Transarterial Chemoembolization (TACE) in liver metastasis for colorectal cancer is unresectable chemotherapy refractory liver metastasis, particularly for larger, intermediate (3-5 cm) lesions.', 'Transarterial Chemoembolization (TACE) is indicated for unresectable chemotherapy refractory liver metastases, particularly in cases of colorectal cancer.', 'There is no clear indication for Transarterial Chemoembolization (TACE) in liver metastasis for colorectal cancer, but it is increasingly used for patients with liver-dominant metastases after failure of surgery or systemic chemotherapy as a valuable option for pre- and post-operative downsizing, minimizing time-to-surgery, and prolongation of overall survival after surgery.', "Transarterial Chemoembolization (TACE) is not specifically mentioned as a clinical indication for liver metastasis of colorectal cancer. However, TACE is a treatment option for liver tumors, including metastases from colorectal cancer. It is a minimally invasive procedure that delivers chemotherapy drugs directly to the liver tumor through the hepatic artery, blocking the blood supply to the tumor and reducing its growth. The use of TACE in liver metastasis of colorectal cancer may depend on the patient's overall health, the extent of the cancer, and the presence of other medical conditions. Other treatment options for liver metastasis of colorectal cancer include surgery (hepatectomy), chemotherapy, and therapies specifically aimed at the liver like radiofrequency ablation, selective internal radiation therapy, and irreversible electroporation.", 'TACE is indicated for patients with unresectable liver metastases and chemotherapy refractory colorectal cancer.', 'TACE is well tolerated and effective in patients with unresectable chemotherapy refractory liver metastasis for colorectal cancer']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/30190956",
"http://www.ncbi.nlm.nih.gov/pubmed/24451734",
"http://www.ncbi.nlm.nih.gov/pubmed/32468211",
"http://www.ncbi.nlm.nih.gov/pubmed/32620520",
"http://www.ncbi.nlm.nih.gov/pubmed/25444473",
"http://www.ncbi.nlm.nih.gov/pubmed/34318754",
"http://www.ncbi.nlm.nih.gov/pubmed/24510986",
"http://www.ncbi.nlm.nih.gov/pubmed/28373752",
"http://www.ncbi.nlm.nih.gov/pubmed/33758639",
"http://www.ncbi.nlm.nih.gov/pubmed/16944163",
"http://www.ncbi.nlm.nih.gov/pubmed/23960002",
"http://www.ncbi.nlm.nih.gov/pubmed/19886993",
"http://www.ncbi.nlm.nih.gov/pubmed/29887263",
"http://www.ncbi.nlm.nih.gov/pubmed/35326651",
"http://www.ncbi.nlm.nih.gov/pubmed/35463654",
"https://pubmed.ncbi.nlm.nih.gov/16944163/",
"http://www.ncbi.nlm.nih.gov/pubmed/38041083",
"http://www.ncbi.nlm.nih.gov/pubmed/28915408",
"http://www.ncbi.nlm.nih.gov/pubmed/18219891",
"http://www.ncbi.nlm.nih.gov/pubmed/26088872",
"http://www.ncbi.nlm.nih.gov/pubmed/32960329",
"http://www.ncbi.nlm.nih.gov/pubmed/32111770",
"https://pubmed.ncbi.nlm.nih.gov/32163181/"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35326651",
"endSection": "abstract",
"offsetInBeginSection": 395,
"offsetInEndSection": 551,
"text": "vascular- and image-based treatments offered by interventional radiologists have emerged when conventional therapies fail, or metastases recurrence occurs. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34318754",
"endSection": "abstract",
"offsetInBeginSection": 157,
"offsetInEndSection": 262,
"text": "local control rates and overall survival are relatively worse with larger, intermediate (3-5 cm) lesions."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32468211",
"endSection": "abstract",
"offsetInBeginSection": 1459,
"offsetInEndSection": 1549,
"text": "TACE is well tolerated and effective in patients with unresectable chemotherapy refractory"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33758639",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1624,
"text": "PURPOSE: Transarterial chemoembolization (TACE) is currently recommended for unresectable intrahepatic tumours with no vascular invasion or metastasis to other organs. It is based on drug-eluting microspheres pre-loaded with chemotherapeutics, which are injected selectively into vessels supplying the tumour, to embolize them inducing ischaemia, and elute the drug, to induce tumour response. We present our initial experience with novel irinotecan- loaded Embocure Plus microspheres in patients with metastatic colorectal cancer tumours in the liver, and their effect on HCT-116 cell cultures in vitro.MATERIAL AND METHODS: Three consecutive male patients (median age 62 [50-76] years) with liver metastatic colorectal cancer tumours were selected. All patients had a pre-procedure contrast-enhanced computed tomography, confirming multiple metastatic liver tumours (mean tumour diameter = 42 mm; range: 14-77 mm) and periprocedural dyna-CT scans for rapid treatment results assessment. In vitro: Human colon HCT116 cancer cell line was cultured, irinotecan loaded Embocure Plus microspheres were added. Cultures were assessed after 24 hours and 72 hours of incubation in normoxia or hypoxia.RESULTS: All embolizations were technically successful, and no complications were observed. Stabilization of the targeted metastatic liver tumours in all patients was noted. In vitro: Significant decrease of the growth of HTC 116 cell lines were observed in controls compared to cells treated with Embocure Plus loaded with irinotecan in normoxia and hypoxia after 48 and 72 hours. We observed a tendency for less inhibited cell p"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32620520",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1080,
"text": "BACKGROUND: About 70-80% of patients with colorectal liver metastases appear as ineligible for a curative treatment approach. Transarterial chemoembolisation (TACE) using irinotecan-eluting beads has emerged as a promising treatment option in cases with irresectable liver metastases. Despite being in clinical practice for years, little is known about the treatment characteristics and outcomes when used as per routine hospital practice.METHODS: Patients with hepatic metastases from colorectal cancer origin, admitted to contributing centres to receive TACE with drug-eluting LifePearl® Microspheres loaded with irinotecan, as part of their standard care, will be consecutively added to the registry. Data will be collected until the end of study, loss to follow-up or death. Primary endpoint is the characterisation of the treatment usage at the selected sites in Europe. Secondary endpoints include outcome parameters, safety and toxicity, as well as quality of life.CONCLUSION AND AIMS: This multicentre, international, prospective observational study conducted in European "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32468211",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1421,
"text": "PURPOSE: The purpose of this study was to evaluate the therapeutic efficacy and safety of transarterial chemoembolization (TACE) in the treatment of patients with unresectable colorectal cancer liver metastases (CRCLM) who had failed systemic chemotherapy. In addition, the role of TACE in the treatment of CRCLM is also worth discussing.METHODS: This single-center retrospective study evaluated the consecutive medical records of patients with CRCLM treated with TACE from June 2014 to June 2018, who had failed at least two lines of prior chemotherapy. Therapeutic response, overall survival (OS), progression-free survival (PFS), and complications were recorded.RESULTS: Fifty-three eligible patients were included in our study. The objective tumor radiologic regression and disease control rates were 52.8% and 79.2%, respectively. Median OS and PFS were 15 months (95% confidence interval [CI] 13.1 months, 16.9 months) and 6 months (95% CI 4.7 months, 7.3 months), respectively. Multivariate analysis found that synchronous metastatic disease, presence of extrahepatic metastasis, and Child-Pugh score B were independent prognostic factor for OS and PFS. Two patients (3.8%) had severe complications. The results of subgroup analysis showed that synchronous liver metastasis and extrahepatic metastasis had an effect on the prognosis of patients, while the primary tumor sites (rectum, left, and right colon) had no"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30190956",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 483,
"text": "In this article, we review two liver-directed therapies that are currently used for the palliative treatment of primary and secondary hepatic malignancies, transcatheter arterial chemoembolization (TACE), including a new type of TACE with drug-eluting beads, and radioembolization. Important developments and administration techniques for all therapies are discussed, as well as their integration into the current routine clinical care for management of metastatic colorectal cancer."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35326651",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1765,
"text": "Colorectal cancer (CRC) is one of the most common tumor entities worldwide and a common cause of cancer-associated death. Colorectal cancer liver metastases (CRLM) thereby constitute a severe life-limiting factor. The therapy of CRLM presents a major challenge and surgical resection as well as systemic chemotherapy remain the first-line treatment options. Over the years several locoregional, vascular- and image-based treatments offered by interventional radiologists have emerged when conventional therapies fail, or metastases recurrence occurs. Among such options is the conventional/traditional transarterial chemoembolization (cTACE) by local injection of a combination of chemotherapeutic- and embolic-agents. A similar treatment is the more recent irinotecan-loaded drug-eluting beads TACE (DEBIRI-TACE), which are administered using the same approach. Numerous studies have shown that these different types of chemoembolization can be applied in different clinical settings safely. Furthermore, such treatments can also be combined with other local or systemic therapies. Unfortunately, due to the incoherent patient populations of studies investigating TACE in CRLM, critics state that the definite evidence supporting positive patient outcomes is still lacking. In the following article we review studies on conventional and DEBIRI-TACE. Although highly dependent on the clinical setting, prior therapies and generally the study population, cTACE and DEBIRI-TACE show comparable results. We present the most representative studies on the different chemoembolization procedures and compare the results. Although there is compelling evidence for both approaches, further studies are necessary to determine which patients profit most from these therapies."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35463654",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1055,
"text": "We aimed to investigate the efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) in the treatment of colorectal cancer liver metastasis. A total of 120 patients with colorectal cancer liver metastasis were divided into the TACE group (receiving TACE treatment, n = 60) and the DEB-TACE group (receiving DEB-TACE treatment, n = 60). At 1 month after treatment, the objective response rate (ORR) in the TACE group and DEB-TACE group were 65.0% (39/60) and 78.3% (47/60), respectively, and the disease control rate (DCR) was 78.3% (47/60) and 85.0% (51/60), respectively. Three months later, the ORRs in TACE and DEB-TACE groups were 63.3% (38/60) and 75.0% (45/60), and the DCRs were 76.7% (46/60) and 81.7% (49/60). We showed that the 1-year overall survival (OS) in TACE and DEB-TACE groups were 100% (60/60) and 88.3% (53/60), respectively, and the 2-year OS were 78.3% (47/60) and 61.7% (37/60). Further analysis indicated that the OS in the DEB-TACE group was significantly longer than that in the TACE group (P = 0.045)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26088872",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 555,
"text": "BACKGROUND: Transarterial liver-directed therapies are currently not recommended as a standard treatment for colorectal liver metastases. Transarterial chemoembolization (TACE), however, is increasingly used for patients with liver-dominant colorectal metastases after failure of surgery or systemic chemotherapy. The limited available data potentially reveals TACE as a valuable option for pre- and post-operative downsizing, minimizing time-to-surgery, and prolongation of overall survival after surgery in patients with colorectal liver only metastases"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26088872",
"endSection": "abstract",
"offsetInBeginSection": 137,
"offsetInEndSection": 312,
"text": " Transarterial chemoembolization (TACE), however, is increasingly used for patients with liver-dominant colorectal metastases after failure of surgery or systemic chemotherapy"
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26088872",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 107,
"text": "Transarterial chemoembolization (TACE) for colorectal liver metastases--current status and critical review."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26088872",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 312,
"text": "BACKGROUND: Transarterial liver-directed therapies are currently not recommended as a standard treatment for colorectal liver metastases. Transarterial chemoembolization (TACE), however, is increasingly used for patients with liver-dominant colorectal metastases after failure of surgery or systemic chemotherapy"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35463654",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 362,
"text": "We aimed to investigate the efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) in the treatment of colorectal cancer liver metastasis. A total of 120 patients with colorectal cancer liver metastasis were divided into the TACE group (receiving TACE treatment, n = 60) and the DEB-TACE group (receiving DEB-TACE treatment, n = 60)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26088872",
"endSection": "abstract",
"offsetInBeginSection": 137,
"offsetInEndSection": 555,
"text": " Transarterial chemoembolization (TACE), however, is increasingly used for patients with liver-dominant colorectal metastases after failure of surgery or systemic chemotherapy. The limited available data potentially reveals TACE as a valuable option for pre- and post-operative downsizing, minimizing time-to-surgery, and prolongation of overall survival after surgery in patients with colorectal liver only metastases"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26088872",
"endSection": "abstract",
"offsetInBeginSection": 137,
"offsetInEndSection": 686,
"text": " Transarterial chemoembolization (TACE), however, is increasingly used for patients with liver-dominant colorectal metastases after failure of surgery or systemic chemotherapy. The limited available data potentially reveals TACE as a valuable option for pre- and post-operative downsizing, minimizing time-to-surgery, and prolongation of overall survival after surgery in patients with colorectal liver only metastases.PURPOSE: In this overview, the current status of TACE for the treatment of liver-dominant colorectal liver metastases is presented"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35463654",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 599,
"text": "We aimed to investigate the efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) in the treatment of colorectal cancer liver metastasis. A total of 120 patients with colorectal cancer liver metastasis were divided into the TACE group (receiving TACE treatment, n = 60) and the DEB-TACE group (receiving DEB-TACE treatment, n = 60). At 1 month after treatment, the objective response rate (ORR) in the TACE group and DEB-TACE group were 65.0% (39/60) and 78.3% (47/60), respectively, and the disease control rate (DCR) was 78.3% (47/60) and 85.0% (51/60), respectively."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33758639",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 167,
"text": "PURPOSE: Transarterial chemoembolization (TACE) is currently recommended for unresectable intrahepatic tumours with no vascular invasion or metastasis to other organs."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32468211",
"endSection": "abstract",
"offsetInBeginSection": 1207,
"offsetInEndSection": 1556,
"text": "The results of subgroup analysis showed that synchronous liver metastasis and extrahepatic metastasis had an effect on the prognosis of patients, while the primary tumor sites (rectum, left, and right colon) had no effect on the prognosis.CONCLUSIONS: TACE is well tolerated and effective in patients with unresectable chemotherapy refractory CRCLM."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/16944163",
"endSection": "abstract",
"offsetInBeginSection": 560,
"offsetInEndSection": 658,
"text": "This treatment approach has symptomatic, palliative, adjuvant and potentially curative objectives."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32468211",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 247,
"text": "PURPOSE: The purpose of this study was to evaluate the therapeutic efficacy and safety of transarterial chemoembolization (TACE) in the treatment of patients with unresectable colorectal cancer liver metastases (CRCLM) who had failed systemic chem"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28373752",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 219,
"text": "OBJECTIVE: To investigate the prognostic factors in chemorefractory colorectal cancer liver metastasis (CRCLM) patients treated by transarterial chemoembolization (TACE) and sustained hepatic arterial infusion chemother"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18219891",
"endSection": "abstract",
"offsetInBeginSection": 938,
"offsetInEndSection": 1032,
"text": "This TACE can be a feasible therapy for colorectal liver metastases as the first-line therapy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26088872",
"endSection": "abstract",
"offsetInBeginSection": 1057,
"offsetInEndSection": 1331,
"text": "Additionally, the concept of TACE for liver-dominant metastatic disease with a focus on new embolization technologies is outlined.CONCLUSIONS: There is encouraging data with regard to technical success, safety, and oncologic efficacy of TACE for colorectal liver metastases."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/16944163",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 658,
"text": "Liver metastasis is one of the main problems encountered in colorectal cancer management as the liver is the most common metastatic site. Several treatment options are available, among which transarterial chemotherapy has proved effective in achieving some local tumour control, improving the quality of life through symptomatic control as well as survival time. The present paper is intended to provide an overview of the techniques, indications and results of regional chemotherapy, which comprises transarterial chemoembolization (TACE) and chemoperfusion. This treatment approach has symptomatic, palliative, adjuvant and potentially curative objectives."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24451734",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 351,
"text": "Interventional radiologists (IRs) have an expanding role in the treatment of liver metastases from colorectal cancer. Increasing data on the ability to treat liver metastases with locoregional therapies has solidified this position. Ablative approaches, such as radiofrequency ablation and microwave ablation, have shown durable eradication of tumors."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33758639",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 158,
"text": "PURPOSE: Transarterial chemoembolization (TACE) is currently recommended for unresectable intrahepatic tumours with no vascular invasion or metastasis to othe"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32620520",
"endSection": "abstract",
"offsetInBeginSection": 114,
"offsetInEndSection": 272,
"text": "t approach. Transarterial chemoembolisation (TACE) using irinotecan-eluting beads has emerged as a promising treatment option in cases with irresectable liver"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/16944163",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 559,
"text": "Liver metastasis is one of the main problems encountered in colorectal cancer management as the liver is the most common metastatic site. Several treatment options are available, among which transarterial chemotherapy has proved effective in achieving some local tumour control, improving the quality of life through symptomatic control as well as survival time. The present paper is intended to provide an overview of the techniques, indications and results of regional chemotherapy, which comprises transarterial chemoembolization (TACE) and chemoperfusion."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33758639",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 603,
"text": "PURPOSE: Transarterial chemoembolization (TACE) is currently recommended for unresectable intrahepatic tumours with no vascular invasion or metastasis to other organs. It is based on drug-eluting microspheres pre-loaded with chemotherapeutics, which are injected selectively into vessels supplying the tumour, to embolize them inducing ischaemia, and elute the drug, to induce tumour response. We present our initial experience with novel irinotecan- loaded Embocure Plus microspheres in patients with metastatic colorectal cancer tumours in the liver, and their effect on HCT-116 cell cultures in vitro"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29887263",
"endSection": "abstract",
"offsetInBeginSection": 155,
"offsetInEndSection": 376,
"text": "ic therapy. Intra-arterial therapies (IAT) including conventional transarterial chemoembolization (cTACE), drug eluting beads (DEB-TACE) and yttrium-90 radioembolization (Y-90) are indicated to prolong survival and pallia"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26088872",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 137,
"text": "BACKGROUND: Transarterial liver-directed therapies are currently not recommended as a standard treatment for colorectal liver metastases."
}
] | 13
|
BioASQ-training13b
| null | null |
662fbec6187cba990d00000f
| 5,210
|
factoid
|
What is the prevalence of intellectual developmental disorders in Duchenne Muscular Dystrophy?
|
['22%']
|
[
"22 percent",
"22%",
"twenty-two percent"
] |
['The prevalence of intellectual developmental disorders in Duchenne Muscular Dystrophy (DMD) is approximately 22%.', 'The prevalence of intellectual developmental disorders in Duchenne Muscular Dystrophy is 22%.', 'The prevalence of intellectual developmental disorder (IDD) in Duchenne muscular dystrophy (DMD) is 22%.', 'The prevalence of intellectual developmental disorders in Duchenne muscular dystrophy is 22%', 'The prevalence of intellectual developmental disorders (IDD) in Duchenne Muscular Dystrophy (DMD) is 22%.', 'The global prevalence of intellectual developmental disorder (IDD) is 22% in Duchenne muscular dystrophy (DMD).']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/36440509"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36440509",
"endSection": "abstract",
"offsetInBeginSection": 1369,
"offsetInEndSection": 1517,
"text": "The global prevalence of intellectual developmental disorder (IDD) was 8% in Becker muscular dystrophy and 22% in Duchenne muscular dystrophy (DMD)."
}
] | 13
|
BioASQ-training13b
| null | null |
66300ee7187cba990d00001c
| 5,227
|
factoid
|
Which tick genus is the vector for Lyme disease?
|
['Ixodes']
|
[
"Ixodes",
"deer tick",
"black-legged tick",
"Ixodes scapularis",
"Ixodes ricinus",
"Ixodes hexagonus"
] |
['The tick genus Ixodes is the primary vector for Lyme disease. These ticks are found in various regions of North America and Europe, where they transmit the bacterium Borrelia burgdorferi to humans and other animals.', 'Ixodes is the tick genus that is known to be a vector for Lyme disease. Specifically, Ixodes scapularis, also known as the blacklegged tick or deer tick, is the primary vector of Lyme disease in the United States and Canada. Other species within the Ixodes genus, such as Ixodes holocyclus in Australia, have also been implicated in the transmission of Lyme disease.', 'Ixodes is the tick genus that is the vector for Lyme disease.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/36944114",
"http://www.ncbi.nlm.nih.gov/pubmed/37042198",
"http://www.ncbi.nlm.nih.gov/pubmed/36958955"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37042198",
"endSection": "abstract",
"offsetInBeginSection": 316,
"offsetInEndSection": 330,
"text": "Ixodes ricinus"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36958955",
"endSection": "abstract",
"offsetInBeginSection": 132,
"offsetInEndSection": 149,
"text": "Ixodes scapularis"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36944114",
"endSection": "abstract",
"offsetInBeginSection": 53,
"offsetInEndSection": 65,
"text": "Ixodes ticks"
}
] | 13
|
BioASQ-training13b
| null | null |
660c0071fdcbea915f00002b
| 5,232
|
factoid
|
In what part of the body would a periprosthetic infection occur?
|
['near an implant', 'In the area around the prosthetic joint.']
|
[
"near an implant",
"in the area around the prosthetic joint",
"around the implant",
"around the prosthetic joint",
"periprosthetic area",
"periprosthetic region",
"adjacent to the implant",
"adjacent to the prosthetic joint"
] |
['Periprosthetic infections occur in the part of the body where a prosthetic device has been implanted, such as the joint or bone.', 'A periprosthetic infection occurs around the area of an implanted prosthetic, such as in the hip or knee joints following total hip arthroplasty (THA) or total knee arthroplasty (TKA).', 'Periprosthetic infection is a foreign-body-associated infection that is characterised by delayed osteomyelitis of bone tissue surrounding artificial joint replacement.', 'A periprosthetic infection occurs in the area around a prosthetic hip or knee joint.', 'A periprosthetic joint infection (PJI) would occur around a prosthetic joint, such as after a total hip arthroplasty (THA) or total knee arthroplasty (TKA).', 'Periprosthetic infection occurs in the joint space after joint replacement surgery.', 'A periprosthetic infection can occur in the area surrounding an implanted joint prosthesis, such as a total hip or knee replacement.', 'A periprosthetic infection would occur around the area of an artificial joint, such as those implanted during hip or knee replacement surgeries. This includes infections that can develop around hip replacements (THA) and knee replacements (TKA/UKA)', 'A periprosthetic infection occurs around the area of an implanted prosthesis, typically in joints such as the hip or knee.', 'Periprosthetic joint infection (PJI) is a complication of total hip arthroplasty (THA) or total knee arthroplasty (TKA) that occurs due to infection of the joint space.', 'A periprosthetic infection can occur in various parts of the body depending on the type of prosthesis. In the context of total hip arthroplasty, periprosthetic infection can occur around the hip joint. In the context of shoulder arthroplasty, periprosthetic infection can occur around the shoulder joint.', 'A periprosthetic infection would occur in the periprosthetic joint.', 'A periprosthetic infection would occur in the joint where the prosthesis is placed.', 'Periprosthetic infections occur around artificial joints, most commonly in the hip and knee.', 'A periprosthetic joint infection (PJI) occurs in the area surrounding a joint replacement implant, such as a hip or knee replacement. It is an infection that affects the tissues around the prosthetic joint and can lead to serious complications if not treated promptly and effectively.', 'A periprosthetic infection is an infection occurring around a joint prosthesis. These types of infections often occur after total knee and hip arthroplasties.', 'A periprosthetic infection occurs in the joints, specifically in the hip or knee, after a total hip or knee arthroplasty surgery.', 'A periprosthetic infection can occur in the area surrounding a prosthetic joint, such as the hip, knee, or shoulder.', 'A periprosthetic infection would occur in a joint that has been replaced by a prosthesis.', 'A periprosthetic infection would occur in the joint, heart valves, or due to schroeteri.', 'Periprosthetic joint infections (PJI) are infections occurring around a total joint replacement. They could happen around the hip joint (THA) or knee joint (TKA/UKA).', 'Periprosthetic infections occur in the area surrounding the prosthetic joint.', 'A periprosthetic infection occurs in the tissue surrounding a prosthetic joint (i.e. knee or hip replacement).', 'A periprosthetic infection can occur in any part of the body where artificial joint replacement has been performed, such as hip, knee, shoulder, elbow or ankle. It is a foreign-body-associated infection that affects the surrounding tissue of artificial implant.', 'A periprosthetic infection would occur around the area of an artificial joint, such as in the hip or knee, following procedures like total hip arthroplasty (THA) or total and unicompartmental knee arthroplasty (TKA/UKA).', 'A periprosthetic infection can occur in the area surrounding a prosthetic joint, such as the hip or knee.', 'A periprosthetic infection (PJI) is an infection that occurs around a prosthetic joint, such as a knee or hip replacement.', '\nA periprosthetic infection would occur around an artificial joint replacement, such as in the hip, knee, shoulder, elbow, or ankle joint.', 'A periprosthetic infection usually occurs in areas where prosthetics are implanted, such as joints, including the hip and knee.', 'A periprosthetic joint infection (PJI) occurs in the tissues surrounding a prosthetic joint, such as after total hip or knee replacement surgery. The infection can involve the joint space, bone, and soft tissues around the prosthetic implant.', 'A periprosthetic infection would occur in close to a joint or structure in close relation to an implant.', 'A periprosthetic joint infection (PJI) would occur in the joint space of a prosthetic joint.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/37887186",
"http://www.ncbi.nlm.nih.gov/pubmed/26135702",
"http://www.ncbi.nlm.nih.gov/pubmed/30374532",
"http://www.ncbi.nlm.nih.gov/pubmed/32238194",
"http://www.ncbi.nlm.nih.gov/pubmed/36200815",
"http://www.ncbi.nlm.nih.gov/pubmed/34142445",
"http://www.ncbi.nlm.nih.gov/pubmed/29559232",
"http://www.ncbi.nlm.nih.gov/pubmed/21821313",
"http://www.ncbi.nlm.nih.gov/pubmed/24921460",
"http://www.ncbi.nlm.nih.gov/pubmed/36683646",
"http://www.ncbi.nlm.nih.gov/pubmed/29351538",
"http://www.ncbi.nlm.nih.gov/pubmed/35106346",
"http://www.ncbi.nlm.nih.gov/pubmed/19756495",
"http://www.ncbi.nlm.nih.gov/pubmed/23898349",
"http://www.ncbi.nlm.nih.gov/pubmed/37380142",
"http://www.ncbi.nlm.nih.gov/pubmed/31955984"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37380142",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 327,
"text": "BACKGROUND: The aim of the present study was to compare causative bacteria and their antibiotic resistance profiles in patients developing a periprosthetic joint infection (PJI) based on preoperative prophylactic antibiotic regimens in primary total hip (THA) and primary total and unicompartmental knee arthroplasty (TKA/UKA)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34142445",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 163,
"text": "OBJECTIVE: Endoprosthetic replacement surgery of hip and knee joints is widely performed, but always carries the risk of developing periprosthetic infection (PPI)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35106346",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 131,
"text": "Periprosthetic joint infection (PJI) is a potentially catastrophic complication of total joint arthroplasty of the lower extremity."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36683646",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 135,
"text": "BACKGROUND: Periprosthetic joint infection (PJI) is a catastrophic complication that can occur following total knee arthroplasty (TKA)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30374532",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 131,
"text": "Periprosthetic joint infection (PJI) is a relatively frequent and devastating complication following prosthetic joint implantation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26135702",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 231,
"text": "Periprosthetic joint infections are a devastating complication after arthroplasty and are associated with substantial patient morbidity. More than 25% of revisions are attributed to these infections, which are expected to increase."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37887186",
"endSection": "abstract",
"offsetInBeginSection": 119,
"offsetInEndSection": 403,
"text": "While periprosthetic joint infection (PJI) affects a small percentage of patients, with an estimated incidence of 1-9% following primary total joint replacement, this postoperative complication necessitates a lengthy hospitalisation, extended antibiotic treatment and further surgery."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/19756495",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 167,
"text": "Periprosthetic infection is a foreign-body-associated infection that is characterised by delayed osteomyelitis of bone tissue surrounding artificial joint replacement."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29351538",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 167,
"text": "PURPOSE OF THE STUDY A very serious complication following joint replacement surgery is periprosthetic joint infection that can be caused by a urinary tract infection."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23898349",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 163,
"text": "Periprosthetic infection (PJI) is the most serious joint replacement complication, occurring in 0.8-1.9% of knee arthroplasties and 0.3-1.7% of hip arthroplasties."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29559232",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 470,
"text": "BACKGROUND: Periprosthetic joint infection is a major complication of total joint replacement surgery and is associated with significant morbidity, mortality and financial burden. Surgical body suits (space suits), originally designed to reduce the incidence of infection, have paradoxically been implicated in increased periprosthetic joint infection rates recently. Air exhausted from space suits may contribute to this increased rate of periprosthetic joint infection"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29559232",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 366,
"text": "BACKGROUND: Periprosthetic joint infection is a major complication of total joint replacement surgery and is associated with significant morbidity, mortality and financial burden. Surgical body suits (space suits), originally designed to reduce the incidence of infection, have paradoxically been implicated in increased periprosthetic joint infection rates recently"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36200815",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 290,
"text": "The incidences of periprosthetic fracture and periprosthetic joint infection after total hip arthroplasty are expected to increase exponentially over the coming decades. Epidemiologic data suggest that many periprosthetic fractures after THA occur concurrently with a loose femoral implant."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21821313",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1210,
"text": "Prosthetic joint infection is a devastating complication of arthroplasty. Previous epidemiological studies have assessed factors associated with arthroplasty infections but have not assessed the impact of comorbidity on infection at different arthroplasty locations. We used a case-control design to investigate risk factors for prosthetic joint infection with reference to the anatomical site. During an eight-year period at a single hospital, 63 patients developed a prosthetic joint infection (36 hips, 27 knees). Cases of prosthetic hip or knee joint infection were matched 1:2 to controls. The results suggest that factors associated with arthroplasty infections differ with anatomical location. Following knee arthroplasty, wound discharge was associated with an increased risk of prosthetic joint infection whereas the presence of a drain tube reduced the risk. By contrast, increased body mass index, increased drain tube loss and superficial incisional surgical site infections (SSIs) were associated with prosthetic hip infection. When analysed as a combined cohort, systemic steroid use, increased SSI drain tube losses, wound discharge, and superficial incisional SSIs were predictors of infection."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24921460",
"endSection": "abstract",
"offsetInBeginSection": 430,
"offsetInEndSection": 638,
"text": "These findings were unique to periprosthetic joint infections (PJI) of the knee and were never observed for PJIs of other lower extremity joints (hip and ankle) or upper extremity joints (shoulder and elbow)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32238194",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 565,
"text": "BACKGROUND: Periprosthetic joint infections (PJIs) are a major source of morbidity and mortality for patients undergoing total joint arthroplasty (TJA). Staphylococcus aureus (S. aureus) colonization is an independent, modifiable risk factor for periprosthetic joint infections. Post-operative infections are reported to be ten times greater in S. aureus carriers than in non-carriers in developed countries though recorded data is lacking for the developing world. This study aims to determine the prevalence of S. aureus colonization in patients awaiting TJA in S"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21821313",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 73,
"text": "Prosthetic joint infection is a devastating complication of arthroplasty."
}
] | 13
|
BioASQ-training13b
| null | null |
66088ffafdcbea915f00000f
| 5,241
|
factoid
|
What is the estimated impact of social determinants of health on health outcomes?
|
['Highly significant impact']
|
[
"Highly significant impact",
"Significant impact",
"Major impact",
"Strong impact",
"Considerable impact",
"Substantial impact",
"Notable impact",
"Marked impact"
] |
['The impact of social determinants of health on health outcomes has been extensively studied and it is estimated that these factors play a significant role in shaping health outcomes. For example, studies have shown that people who experience poverty, unemployment, low education levels, poor housing conditions, and limited access to healthy food and safe living environments are more likely to develop chronic diseases, such as diabetes, cardiovascular disease, and mental health disorders. Additionally, social determinants can affect health outcomes indirectly by influencing health behaviors such as smoking, physical inactivity, and unhealthy eating habits. It is estimated that these factors can account for up to 40% of modifiable health risks. Addressing social determinants of health has the potential to improve health equity and reduce health disparities.', 'The social determinants of health have a significant impact on health outcomes, particularly for marginalized populations. Factors such as poverty, lack of education, and living in rural areas can increase the likelihood of adverse health outcomes, including teenage pregnancy and childbearing. According to the World Health Organization, social determinants account for an estimated 30-50% of health inequities. Addressing these factors through targeted interventions and policies can help reduce health disparities and improve overall health outcomes.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/37843837",
"http://www.ncbi.nlm.nih.gov/pubmed/37022779",
"http://www.ncbi.nlm.nih.gov/pubmed/35590354",
"http://www.ncbi.nlm.nih.gov/pubmed/29480769",
"http://www.ncbi.nlm.nih.gov/pubmed/20171001",
"http://www.ncbi.nlm.nih.gov/pubmed/27696682",
"http://www.ncbi.nlm.nih.gov/pubmed/37001969",
"http://www.ncbi.nlm.nih.gov/pubmed/33181043",
"http://www.ncbi.nlm.nih.gov/pubmed/37501568",
"http://www.ncbi.nlm.nih.gov/pubmed/33614572",
"http://www.ncbi.nlm.nih.gov/pubmed/37131177",
"http://www.ncbi.nlm.nih.gov/pubmed/33639878",
"http://www.ncbi.nlm.nih.gov/pubmed/24532079",
"http://www.ncbi.nlm.nih.gov/pubmed/34478162",
"http://www.ncbi.nlm.nih.gov/pubmed/30815107",
"http://www.ncbi.nlm.nih.gov/pubmed/31133069",
"http://www.ncbi.nlm.nih.gov/pubmed/36987604"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37501568",
"endSection": "abstract",
"offsetInBeginSection": 658,
"offsetInEndSection": 751,
"text": "social determinants contribute directly and indirectly (through lifestyle) to life expectancy"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33614572",
"endSection": "abstract",
"offsetInBeginSection": 2230,
"offsetInEndSection": 2302,
"text": "community SDOH play an important role in diabetes control and management"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37843837",
"endSection": "abstract",
"offsetInBeginSection": 2026,
"offsetInEndSection": 2506,
"text": "Children exposed to socioeconomic deprivation (SDOH pattern 3) showed the worst health profiles, manifesting more internalizing (β = 0.75; 95% CI, 0.14-1.37) and externalizing (β = 1.43; 95% CI, 0.83-2.02) mental health problems, lower cognitive performance, and adverse physical health.Conclusions: This study shows that an unbiased quantitative analysis of multidimensional SDOH can permit the determination of how SDOH patterns are associated with child developmental outcomes."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33639878",
"endSection": "abstract",
"offsetInBeginSection": 299,
"offsetInEndSection": 609,
"text": "This study examined the cumulative impact of social determinants of health on mortality in U.S. adults with CKD and diabetes.METHODS: We analyzed data from National Health and Nutrition Examination Surveys (2005-2014) for 1376 adults age 20 and older (representing 7,579,967 U.S. adults) with CKD and diabetes."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33639878",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 127,
"text": "The cumulative impact of social determinants of health factors on mortality in adults with diabetes and chronic kidney disease."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37501568",
"endSection": "abstract",
"offsetInBeginSection": 632,
"offsetInEndSection": 752,
"text": "The findings confirm that social determinants contribute directly and indirectly (through lifestyle) to life expectancy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37001969",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 165,
"text": "OBJECTIVE: Interventions to tackle the social determinants of health can improve outcomes during pregnancy and early childhood, leading to better health across the l"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27696682",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 176,
"text": "There is substantial evidence across different healthcare contexts that social determinants of health are strongly associated with morbidity and mortality in the United States."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36987604",
"endSection": "abstract",
"offsetInBeginSection": 1153,
"offsetInEndSection": 1488,
"text": "SDH also have a significant impact on SLE outcomes, with worse disease and psychosocial outcomes associated with lower income level, lower educational attainment, disadvantaged neighbourhoods, lack of health insurance or public health insurance in the USA, travel burden to nearest provider, anti-Black racism and lower social support."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36987604",
"endSection": "abstract",
"offsetInBeginSection": 771,
"offsetInEndSection": 1152,
"text": "We found that adverse SDH conditions may lead to more severe SLE with increased morbidity and mortality, and that SDH affect SLE management by dictating the most feasible monitoring and treatment plan for each individual patient based on his or her specific life circumstances (for example, based on health insurance status, distance to nearest provider and/or drug affordability)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36987604",
"endSection": "abstract",
"offsetInBeginSection": 140,
"offsetInEndSection": 297,
"text": "However, a growing body of research indicates that social determinants of health (SDH) also have substantial impact on the disparities that characterize SLE."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36987604",
"endSection": "abstract",
"offsetInBeginSection": 585,
"offsetInEndSection": 770,
"text": "We reviewed the impact of key SDH on SLE presentation, management and outcomes, including income, education, neighbourhood factors, healthcare access, discrimination and social support."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37022779",
"endSection": "abstract",
"offsetInBeginSection": 1410,
"offsetInEndSection": 1588,
"text": "Certain potentially positive factors like family and community resilience remain poorly studied.CONCLUSIONS: SDoHs are associated with higher rates of and worse outcomes in SSPD."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36987604",
"endSection": "abstract",
"offsetInBeginSection": 298,
"offsetInEndSection": 584,
"text": "According to the World Health Organization, SDH are defined as 'the conditions in which people are born, grow, work, live, and age', account for 30-55% of health outcomes, and adversely impact health outcomes among those of low socioeconomic status and stigmatized racial/ethnic groups."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37022779",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 286,
"text": "BACKGROUND: Social determinants of health (SDoHs) are receiving growing attention and are particularly relevant to persons with schizophrenia-spectrum psychotic disorders (SSPDs), considering their heightened risk of comorbidities, cognitive and functional decline, and early mortality."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33181043",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 368,
"text": "Since the World Health Organization launched its commission on the social determinants of health (SDOH) over a decade ago, a large body of research has proven that social determinants-defined as the conditions in which people are born, grow, live, work, and age-are significant drivers of disease risk and susceptibility within clinical care and public health systems."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29480769",
"endSection": "abstract",
"offsetInBeginSection": 173,
"offsetInEndSection": 394,
"text": "Although social determinants of health have been found to affect the mental health of a population, less information is available regarding the impact of social determinants on physical health, especially among offenders."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37001969",
"endSection": "abstract",
"offsetInBeginSection": 11,
"offsetInEndSection": 175,
"text": "Interventions to tackle the social determinants of health can improve outcomes during pregnancy and early childhood, leading to better health across the life course"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24532079",
"endSection": "abstract",
"offsetInBeginSection": 1203,
"offsetInEndSection": 1595,
"text": "Based on the studies reviewed, social determinants have an impact on glycemic control, LDL, and blood pressure to varying degrees. The impact on cost and quality of life was not often measured, but when quality of life was investigated, it did show significance. More research is needed to better characterize the direct impact of social determinants of health on health outcomes in diabetes."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24532079",
"endSection": "abstract",
"offsetInBeginSection": 1203,
"offsetInEndSection": 1465,
"text": "Based on the studies reviewed, social determinants have an impact on glycemic control, LDL, and blood pressure to varying degrees. The impact on cost and quality of life was not often measured, but when quality of life was investigated, it did show significance."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29480769",
"endSection": "abstract",
"offsetInBeginSection": 1117,
"offsetInEndSection": 1558,
"text": "Two social determinants factors in particular were consistently related to the health of offenders, a history of childhood abuse, and the use of social assistance. Research limitations/implications The study is limited to the use of self-report data. Additionally, the measures of social determinants of health were indicators taken from assessments that provided only rough estimates of the constructs rather than from established measures."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34478162",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 299,
"text": "BACKGROUND: Social determinants of health (SDOHs) cluster together and can have deleterious impacts on health outcomes. Individually, SDOHs increase the risk of cancer mortality, but their cumulative burden is not well understood. The authors sought to determine the combined effect of SDOH on cance"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30815107",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 343,
"text": "Social determinants of health (SDH) such as education and socioeconomic status are strongly associated with health and health outcomes. Incorporating SDH variables into clinical data sets could therefore improve the accuracy of predictive analytics, but individual-level SDH are rarely available and must be inferred from community-level data."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35590354",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 269,
"text": "BACKGROUND: Social determinants of health (SDoH) are known to have a large impact on health outcomes, but their effects are difficult to make visible. They are part of complex systems of variables largely indirect effects on multiple levels, constituting so-called wick"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31133069",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 283,
"text": "BACKGROUND: Low socioeconomic status (SES) is often associated with excess morbidity and premature mortality. Such health disparities claim a steep economic cost: Possibly-preventable poor health outcomes harm societal welfare, impair the domestic product, and increase health care e"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/20171001",
"endSection": "abstract",
"offsetInBeginSection": 1415,
"offsetInEndSection": 1604,
"text": "Race/ethnicity and neighborhood SES had substantial and independent influences on life expectancy, underscoring the importance of monitoring health outcomes simultaneously by these factors."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/20171001",
"endSection": "abstract",
"offsetInBeginSection": 1605,
"offsetInEndSection": 1771,
"text": "African-American males living in the poorest 20% of California neighborhoods had life expectancy comparable to that reported for males living in developing countries."
}
] | 13
|
BioASQ-training13b
| null | null |
65f86b3ac4010b4d78000058
| 5,242
|
factoid
|
What is the optimal antiemetic treatment for FOLFIRINOX chemotherapy?
|
['5-hydroxytryptamine-3 receptor antagonists (5HT3RA), dexamethasone (DEX), and neurokinin 1 receptor antagonists', '5HT3RA, DEX and NK1RA', '5HT3 receptor antagonist (5HT3RA), dexamethasone (DEX), and a neurokinin-1 receptor antagonist (NK1RA)', 'three-drug regimen with aprepitant']
|
[
"5-hydroxytryptamine-3 receptor antagonists (5HT3RA)",
"5HT3RA",
"5HT3 receptor antagonist (5HT3RA)",
"dexamethasone (DEX)",
"DEX",
"neurokinin 1 receptor antagonists",
"NK1RA",
"neurokinin-1 receptor antagonist (NK1RA)",
"three-drug regimen with aprepitant",
"aprepitant"
] |
['The optimal antiemetic treatment for FOLFIRINOX chemotherapy includes a three-drug regimen with aprepitant, dexamethasone, and 5-HT3 receptor antagonists. This regimen has been shown to improve the complete response rate during cycle 1 and reduce nausea and vomiting in patients treated with FOLFIRINOX for metastatic pancreatic cancer. However, enhanced antiemetic measures may be necessary as nausea and vomiting can persist beyond 5 days. In patients with diabetes mellitus complications, sparing of steroids and glycemic control should also be considered.', 'The optimal antiemetic treatment for managing side effects from FOLFIRINOX chemotherapy includes a combination of 5-hydroxytryptamine-3 receptor antagonists (5HT3RA), dexamethasone (DEX), and neurokinin 1 receptor antagonists (NK1RA).', 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy includes 5HT3RA, DEX, and NK1RA.', 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy, which consists of irinotecan, folinic acid, and fluorouracil (5-FU), is a multimodal approach that includes the following:\n\n1. Pregabalin (Lyrica) 150-300 mg orally twice daily starting 1-2 days before chemotherapy and continuing for 3 days.\n\n2. Dexamethasone (Decadron) 8 mg orally or intravenously (IV) twice daily starting 1-2 days before chemotherapy and continuing for 3 days.\n\n3. Palonosetron (Aloxi) 0.25 mg IV or subcutaneously (SC) before chemotherapy.\n\n4. O', 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy has not been definitively established. The FOLFIRINOX regimen is known to cause significant nausea and vomiting, and there is a need for effective antiemetic prophylaxis to prevent these adverse events. A study published in the Journal of Clinical Oncology found that a three-drug combination of 5-hydroxytryptamine-3 receptor antagonists (5HT3RA), dexamethasone (DEX), and neurokinin 1 receptor antagonists (NK1RA) was effective in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving FOLFIRINOX. However, the study also noted that the optimal antiemetic treatment for FOLFIRINOX may vary depending on patient factors and individual preferences. Other studies have suggested that', 'A three-drug combination of 5-hydroxytryptamine-3 receptor antagonists (5HT3RA), dexamethasone (DEX), and neurokinin 1 receptor antagonists (NK1RA) for the prevention of chemotherapy-induced nausea and vomit during FOLFORINOX therapy', '5-hydroxytryptamine 3 (5-HT3) receptor antagonists are the optimal antiemetic treatments for FOLFIRINOX chemotherapy', 'Based on the given context, the optimal antiemetic treatment for FOLFIRINOX chemotherapy, a standard chemotherapy regimen for advanced pancreatic cancer, should include a combination of 5-hydroxytryptamine-3 receptor antagonists (5HT3RA), dexamethasone (DEX), and neurokinin 1 receptor antagonists (NK1RA) for the prevention of chemotherapy-induced nausea and vomiting (CINV). However, it is important to note that CINV induced by FOLFIRINOX was poorly controlled even with this prophylactic antiemetic therapy, suggesting the need for enhanced antiemetic measures. Additionally, in patients with diabetes mellitus complications, sparing of steroids and glycemic control should be considered due to the risk of hyperglycemia.', '5-HT3RA is a standard antiemetic therapy for FOLFIRINOX chemotherapy. However, patients receiving mFFX are at risk of developing chemotherapy-induced nausea and vomiting (CINV) that is refractory to conventional antiemetic therapy and can persist beyond 5 days. NK1-RA in addition to 5HT3RA and DEX should be used prophylactically to control CINV in mFFX.', 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy has not been fully established, and the current standard of care consisting of a three-drug combination of 5-hydroxytryptamine-3 receptor antagonists (5HT3RA), dexamethasone (DEX), and neurokinin 1 receptor antagonists (NK1RA) may not be sufficient to control chemotherapy-induced nausea and vomiting (CINV). Enhanced antiemetic measures, such as additional medications or alternative regimens, may be necessary to improve CINV management for patients undergoing FOLFIRINOX therapy. However, the choice of antiemetic treatment should also consider potential side effects, such as hyperglycemia, and individual patient factors, including diabetes mellitus complications. Further research is needed to determine the most effective and safe antiemetic strategy for FOL', 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy is a single oral dose of NEPA (Akynzeo®) plus 12 mg of dexamethasone. NEPA is a fixed-dose combination of netupitant, a neurokinin-1 receptor antagonist (NK1RA), and palonosetron, a 5-hydroxytryptamine type 3 receptor antagonist (5HT3RA), which has been shown to be effective in preventing chemotherapy-induced nausea and vomiting (CINV). This treatment has demonstrated therapeutic benefits in managing and prophylaxis of CINV events, both in naive patients and patients previously treated with serotonin receptor antagonists (5HT3-RA) and neurokinin-1 receptor antagonists (NK1-RA). Additionally, NEPA has been shown to be safe, both before and during the COVID-19 pandemic.', 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy is a combination of 5HT3RA, DEX, and NK1RA, with prophylactic therapy starting before the chemotherapy and continuing for at least 5 days after the treatment.', "5HT3RA (5-hydroxytryptamine receptor antagonist), DEX (dexamethasone) and NK1RA (neurokinin-1 receptor antagonist) are commonly used for prophylactic antiemetic therapy in patients undergoing FOLFIRINOX chemotherapy. However, if patient experiences poorly controlled CINV, additional or alternative antiemetic medications should be considered. Olanzapine, aprepitant and other antiemetics could be added to the regimen based on individual patient's needs.", 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy is not specified in the provided context, but it mentions that CINV induced by mFFX was poorly controlled even with prophylactic antiemetic therapy using 5HT3RA, DEX, and NK1RA.', "The optimal antiemetic treatment for FOLFIRINOX chemotherapy includes a combination of multiple drugs. It is recommended to use a 5HT3 receptor antagonist (5HT3RA), dexamethasone (DEX), and a neurokinin-1 receptor antagonist (NK1RA) as prophylactic antiemetic therapy. However, in cases where CINV induced by FOLFIRINOX is poorly controlled even with this standard regimen, additional interventions may be required, such as the use of olanzapine or aprepitant. It is important to individualize the treatment based on the patient's specific needs and response to therapy.", 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy includes prophylactic antiemetic therapy using 5HT3RA, DEX.', "The optimal antiemetic treatment for FOLFIRINOX (mFFX) chemotherapy typically includes a combination of a 5HT3 receptor antagonist (5HT3RA), dexamethasone (DEX), and a neurokinin-1 receptor antagonist (NK1RA). However, it's important to note that even with this prophylactic antiemetic therapy, control of chemotherapy-induced nausea and vomiting (CINV) can be challenging, and symptoms may persist beyond 5 days. This indicates a need for potentially adjusting the treatment approach or exploring additional supportive measures to better manage CINV in patients undergoing this regimen.", 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy is 5-hydroxytryptamine-3 receptor antagonists (5HT3RA), dexamethasone (DEX), and neurokinin 1 receptor antagonists (NK1RA).', ' The optimal antimycin D treatment for FOLFox chemotherapy is not well understood, and there is no one-solution approach that can eliminate the risk of antimycin D-resistance. Instead, there are several strategies that can be employed to mitigate the risk of antimycin D-resistance and improve the efficacy of FOLFox chemotherapy. These strategies include:', '\nAnswer: Aprepitant, dexamethasone, and a 5-HT3 receptor antagonist (granisetron or palonosetron) before and after chemotherapy.', 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy has not been definitively established, as various regimens have been used in different clinical trials and real-world settings. However, a few studies suggest that a three-drug combination of 5-hydroxytryptamine-3 receptor antagonists (5HT3RA), dexamethasone (DEX), and neurokinin 1 receptor antagonists (NK1RA) may be effective in preventing chemotherapy-induced nausea and vomiting (CINV) associated with FOLFIRINOX. In a retrospective cohort study of patients with advanced pancreatic cancer, the complete response rate for CINV was 64.7% with this three-drug regimen, although the incidence of nausea and vomiting remained relatively high. Another study found that the addition of aprepitant to', 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy has not been fully established, but current guidelines recommend a combination of agents to prevent CINV. The most effective prophylactic regimen typically includes a serotonin receptor antagonist (5HT3RA) such as ondansetron or granisetron, dexamethasone (DEX), and sometimes a neurokinin-1 receptor antagonist (NK1RA) like aprepitant. However, even with this combination therapy, some patients experience persistent nausea and vomiting, highlighting the need for more effective treatments to manage CINV induced by FOLFIRINOX chemotherapy.', "The optimal antiemetic treatment for FOLFIRINOX chemotherapy typically includes a combination of a 5HT3 receptor antagonist (5HT3RA), dexamethasone (DEX), and a neurokinin-1 receptor antagonist (NK1RA). This regimen aims to manage the nausea and vomiting associated with this highly emetogenic chemotherapy. However, it's important to note that even with these medications, control of chemotherapy-induced nausea and vomiting (CINV) can be challenging, and symptoms may persist beyond 5 days. Always consult with a healthcare provider for the most appropriate and individualized treatment plan", 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy is prochlorperazine (PC), a commonly used antiemetic agent. Prochlorperazine (PC), a commonly used antiemetic agent, is the first-line antiemetic agent for patients receiving chemotherapy. Food and liquid restrictions are also', 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy includes prophylactic antiemetic therapy using 5HT3 receptor antagonists (5HT3RA), dexamethasone (DEX), and neurokinin-1 receptor antagonists (NK1RA).', 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy is a combination of 5HT3RA and DEX.', 'CINV induced by mFFX was poorly controlled even with prophylactic antiemetic therapy using 5HT3RA, DEX, and NK1RA, and was found to persist beyond 5\xa0days', 'The recommended antiemetic treatment for FOLFIRINOX chemotherapy is a combination of 5HT3RA and DEX.', 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy is NEPA (netupitant/palonosetron). NEPA has been shown to effectively prevent nausea and vomiting induced by chemotherapy (CINV) in patients receiving FOLFIRINOX and Folfoxiri regimens. This combination of netupitant and palonosetron provides superior control of acute and delayed CINV compared to other antiemetic agents. NEPA can be safely used during the COVID-19 pandemic and has been proven to be effective in real-life studies.', 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy includes a combination of 5HT3 receptor antagonists, dexamethasone, and NK1 receptor antagonists.', 'Based on the provided information, chemotherapy-induced nausea and vomiting (CINV) induced by modified FOLFIRINOX (mFFX) chemotherapy was poorly controlled even with prophylactic antiemetic therapy using a combination of a 5-HT3 receptor antagonist (5HT3RA), dexamethasone (DEX), and an NK-1 receptor antagonist (NK1RA). The CINV persisted beyond 5 days.\n\nThe text does not provide information on the optimal antiemetic treatment for FOLFIRINOX. It only indicates that the mentioned antiemetic combination was not fully effective in controlling CINV in this setting. More research would be needed to determine the best approach for managing CINV with this chemotherapy regimen.', 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy is a combination of netupitant/palonosetron (NEPA; Akynzeo(®)) with >85% antiemetic efficacy.', '5HT3RA, DEX, and NK1RA', 'The recommended antiemetic treatment for FOLFIRINOX chemotherapy is either 5HT3RA or a combination of 5HT3RA and DEX.', 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy is prochlorperazine (PC), ondansetron (OD), and dexamethasone (Dex) or a combination of these agents.', 'In this study, the researchers found that a three-drug regimen with aprepitant can significantly reduce the incidence of nausea and vomiting in patients with metastatic pancreatic cancer who received FOLFIRINOX chemotherapy.', "The optimal antiemetic treatment for FOLFIRINOX chemotherapy is still a topic of debate. The snippet suggests that prophylactic antiemetic therapy using 5HT3RA, DEX, and NK1RA may not be effective in controlling CINV induced by mFFX. Recent studies suggest that olanzapine may be effective in preventing CINV in patients receiving FOLFIRINOX chemotherapy. However, further research is needed to confirm its efficacy and safety profile. It's essential to consider individual patient factors, such as age, gender, and previous antiemetic response, when choosing an antiemetic regimen.", 'CINV induced by mFFX was poorly controlled even with prophylactic antiemetic therapy using 5HT3RA, DEX, and NK1RA, and was found to persist beyond 5 days.', "The optimal antiemetic treatment for FOLFIRINOX (mFFX) chemotherapy typically includes a combination of a 5HT3 receptor antagonist (5HT3RA), dexamethasone (DEX), and a neurokinin-1 receptor antagonist (NK1RA). However, it's important to note that even with this prophylactic antiemetic therapy, control of chemotherapy-induced nausea and vomiting (CINV) can be challenging, and symptoms may persist beyond 5 days. This indicates a need for potentially adjusting the treatment strategy or exploring additional supportive measures to better manage CINV in patients undergoing this regimen.", '5-hydroxytryptamine 3 receptor (5-HT3R) antagonists and dexamethasone can be used to manage chemotherapy-induced nausea and vomiting in FOLFIRINOX. Other options include neurokinin-1 (NK1) receptor antagonists and other adjunctive medications such as aprepitant, palonosetron and olanzapine.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/37884842",
"http://www.ncbi.nlm.nih.gov/pubmed/33023657",
"http://www.ncbi.nlm.nih.gov/pubmed/20413062",
"http://www.ncbi.nlm.nih.gov/pubmed/34131576",
"http://www.ncbi.nlm.nih.gov/pubmed/30019968",
"http://www.ncbi.nlm.nih.gov/pubmed/30333194",
"http://www.ncbi.nlm.nih.gov/pubmed/22316362",
"http://www.ncbi.nlm.nih.gov/pubmed/3967569",
"http://www.ncbi.nlm.nih.gov/pubmed/36033477",
"http://www.ncbi.nlm.nih.gov/pubmed/34486707",
"http://www.ncbi.nlm.nih.gov/pubmed/28191518"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37884842",
"endSection": "abstract",
"offsetInBeginSection": 1255,
"offsetInEndSection": 1408,
"text": "CINV induced by mFFX was poorly controlled even with prophylactic antiemetic therapy using 5HT3RA, DEX, and NK1RA, and was found to persist beyond 5 days"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37884842",
"endSection": "abstract",
"offsetInBeginSection": 9,
"offsetInEndSection": 1039,
"text": "Modified FOLFIRINOX (mFFX), a standard chemotherapy regimen for advanced pancreatic cancer (APC), is expected to be associated with a higher risk of chemotherapy-induced nausea and vomiting (CINV). Herein, we conducted a retrospective cohort study to evaluate the efficacy and safety of a three-drug combination of 5-hydroxytryptamine-3 receptor antagonists (5HT3RA), dexamethasone (DEX), and neurokinin 1 receptor antagonists (NK1RA) for the prevention of CINV during mFFX therapy.METHODS: This study enrolled patients with APC who received mFFX as initial therapy with a combination of 5HT3RA, DEX, and NK1RA as antiemetic prophylaxis. The primary endpoint was the complete response (CR) rate during cycle 1, which was defined as no emetic episodes and no rescue medication use during the overall period (0-120 h). Safety was also evaluated with a focus on hyperglycemia, which is a concern in patients with APC.RESULTS: Seventy patients were eligible for this retrospective analysis. The CR rate during the overall period was 5"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37884842",
"endSection": "abstract",
"offsetInBeginSection": 1160,
"offsetInEndSection": 1409,
"text": "Hyperglycemia occurred in 37.1% of patients, and 34.3% were grade 3 hyperglycemia.CONCLUSIONS: CINV induced by mFFX was poorly controlled even with prophylactic antiemetic therapy using 5HT3RA, DEX, and NK1RA, and was found to persist beyond 5 days."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37884842",
"endSection": "abstract",
"offsetInBeginSection": 207,
"offsetInEndSection": 646,
"text": "Herein, we conducted a retrospective cohort study to evaluate the efficacy and safety of a three-drug combination of 5-hydroxytryptamine-3 receptor antagonists (5HT3RA), dexamethasone (DEX), and neurokinin 1 receptor antagonists (NK1RA) for the prevention of CINV during mFFX therapy.METHODS: This study enrolled patients with APC who received mFFX as initial therapy with a combination of 5HT3RA, DEX, and NK1RA as antiemetic prophylaxis."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34486707",
"endSection": "abstract",
"offsetInBeginSection": 1811,
"offsetInEndSection": 2152,
"text": "During the acute and delayed phases, the CR rate was 72.5% and 74.8% with Folfoxiri plus Bevacizumab, as well as 75.2% and 74.6% with Folfirinox.CONCLUSIONS: This study has shown the therapeutic benefits of NEPA in the management and prophylaxis of CINV events, both in naive patients and patients previously treated with 5HT3-RA and NK1-RA."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37884842",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 172,
"text": "Efficacy and safety of 5HT3RA, DEX, and NK1RA for the prevention of FOLFIRINOX-induced nausea and vomiting in patients with pancreatic cancer: a retrospective cohort study."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36033477",
"endSection": "abstract",
"offsetInBeginSection": 2384,
"offsetInEndSection": 2873,
"text": "Finally, chemotherapy delays (p = 0.000009) and chemotherapy dose reductions (p = 0.0000006) were less frequently observed in primary NK1-RA users.Conclusion: In patients affected by gastrointestinal malignancies, a primary CINV prophylaxis with NK1-RA, 5HT3-RA, and dexamethasone might be appropriate, particularly in those situations at higher risk of emesis and in which it is important to avoid dose delays and/or dose reductions, keeping a proper dose intensity of chemotherapy drugs."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37884842",
"endSection": "abstract",
"offsetInBeginSection": 1248,
"offsetInEndSection": 1414,
"text": "SIONS: CINV induced by mFFX was poorly controlled even with prophylactic antiemetic therapy using 5HT3RA, DEX, and NK1RA, and was found to persist beyond 5 days. Enha"
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34486707",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 199,
"text": "NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri even during the COVID-19 pandemic: a real-life study."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33023657",
"endSection": "abstract",
"offsetInBeginSection": 393,
"offsetInEndSection": 481,
"text": "s documenting CINV. All participants received a 5-hydroxytryptamine-3 receptor antagonis"
}
] | 13
|
BioASQ-training13b
| null | null |
65f7798dc4010b4d78000038
| 5,245
|
factoid
|
TAK-994 is developed for which disease?
|
['narcolepsy']
|
[
"narcolepsy",
"excessive daytime sleepiness",
"hypersomnia",
"sleep disorder"
] |
['TAK-994 is an oral orexin receptor 2-selective agonist that was developed and tested for narcolepsy type 1.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/37001988",
"http://www.ncbi.nlm.nih.gov/pubmed/37494485"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37494485",
"endSection": "abstract",
"offsetInBeginSection": 93,
"offsetInEndSection": 255,
"text": "METHODS: We conducted a phase 2, randomized, placebo-controlled trial of TAK-994, an oral orexin receptor 2-selective agonist, in patients with narcolepsy type 1."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37001988",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 185,
"text": "TAK-994, a Novel Orally Available Brain-Penetrant Orexin 2 Receptor-Selective Agonist, Suppresses Fragmentation of Wakefulness and Cataplexy-Like Episodes in Mouse Models of Narcolepsy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37001988",
"endSection": "abstract",
"offsetInBeginSection": 2127,
"offsetInEndSection": 2277,
"text": "These findings indicate that TAK-994 is an orally available brain-penetrant OX2R-selective agonist with potential to improve narcolepsy-like symptoms."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37494485",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 255,
"text": "BACKGROUND: Narcolepsy type 1 is caused by severe loss or lack of brain orexin neuropeptides.METHODS: We conducted a phase 2, randomized, placebo-controlled trial of TAK-994, an oral orexin receptor 2-selective agonist, in patients with narcolepsy type 1."
}
] | 13
|
BioASQ-training13b
| null | null |
65cfd3961930410b1300001f
| 5,252
|
factoid
|
What disease can be treatment with Bulevirtide?
|
['chronic hepatitis D']
|
[
"chronic hepatitis D",
"chronic delta hepatitis",
"hepatitis D",
"delta hepatitis",
"HDV infection",
"hepatitis D virus infection"
] |
['Bulevirtide can be used for chronic hepatitis D virus infection.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/37943548",
"http://www.ncbi.nlm.nih.gov/pubmed/37929228",
"http://www.ncbi.nlm.nih.gov/pubmed/36113537",
"http://www.ncbi.nlm.nih.gov/pubmed/36377139",
"http://www.ncbi.nlm.nih.gov/pubmed/36192563",
"http://www.ncbi.nlm.nih.gov/pubmed/36196680",
"http://www.ncbi.nlm.nih.gov/pubmed/36648369",
"http://www.ncbi.nlm.nih.gov/pubmed/37345876",
"http://www.ncbi.nlm.nih.gov/pubmed/37473778",
"http://www.ncbi.nlm.nih.gov/pubmed/35329913",
"http://www.ncbi.nlm.nih.gov/pubmed/36931396",
"http://www.ncbi.nlm.nih.gov/pubmed/37593170",
"http://www.ncbi.nlm.nih.gov/pubmed/36396025",
"http://www.ncbi.nlm.nih.gov/pubmed/34799189",
"http://www.ncbi.nlm.nih.gov/pubmed/35942695",
"http://www.ncbi.nlm.nih.gov/pubmed/34155804",
"http://www.ncbi.nlm.nih.gov/pubmed/37360907",
"http://www.ncbi.nlm.nih.gov/pubmed/35122369",
"http://www.ncbi.nlm.nih.gov/pubmed/32926353",
"http://www.ncbi.nlm.nih.gov/pubmed/38041549",
"http://www.ncbi.nlm.nih.gov/pubmed/37880598",
"http://www.ncbi.nlm.nih.gov/pubmed/37025462",
"http://www.ncbi.nlm.nih.gov/pubmed/35973578",
"http://www.ncbi.nlm.nih.gov/pubmed/36004554",
"http://www.ncbi.nlm.nih.gov/pubmed/34268531",
"http://www.ncbi.nlm.nih.gov/pubmed/33999515",
"http://www.ncbi.nlm.nih.gov/pubmed/38037956"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36648369",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 155,
"text": "The entry inhibitor bulevirtide (BLV) is a new treatment option for patients with chronic hepatitis D virus (HDV) infection and compensated liver disease. "
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36648369",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 124,
"text": "Kinetics and predictive value of HBcrAg, HBV RNA and anti-HBc during bulevirtide treatment of chronic HDV-infected patients."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36396025",
"endSection": "abstract",
"offsetInBeginSection": 601,
"offsetInEndSection": 781,
"text": "Bulevirtide, an entry inhibitor, was conditionally approved in July 2020 in the European Union for adult patients with chronic hepatitis delta (CHD) and compensated liver disease. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36377139",
"endSection": "abstract",
"offsetInBeginSection": 1397,
"offsetInEndSection": 1585,
"text": "To our knowledge, this is the first reported case of a pembrolizumab-induced exacerbation of hepatitis D and a successful management by application of bulevirtide in the context of cancer."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37360907",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 113,
"text": "Background & Aims: Bulevirtide (BLV) is a novel antiviral drug licensed for the treatment of chronic hepatitis D."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37360907",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 103,
"text": "Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37473778",
"endSection": "abstract",
"offsetInBeginSection": 920,
"offsetInEndSection": 1203,
"text": "Pegylated interferon (off-label use) has long been the only available treatment, although bulevirtide is conditionally approved in some European countries. There are many potential treatments in development, but as yet, there are few effective and safe therapies for HDV infection. I"
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37345876",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 66,
"text": "A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37345876",
"endSection": "abstract",
"offsetInBeginSection": 135,
"offsetInEndSection": 190,
"text": "Bulevirtide inhibits the entry of HDV into hepatocytes."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37345876",
"endSection": "abstract",
"offsetInBeginSection": 2259,
"offsetInEndSection": 2387,
"text": "CONCLUSIONS: After 48 weeks of bulevirtide treatment, HDV RNA and ALT levels were reduced in patients with chronic hepatitis D. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/38041549",
"endSection": "abstract",
"offsetInBeginSection": 256,
"offsetInEndSection": 480,
"text": "The approval of bulevirtide has shed some light for patients with Chronic Hepatitis D, although important gaps regarding its use in therapy as well as about the epidemiology and diagnosis of the disease need to be addressed."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37943548",
"endSection": "abstract",
"offsetInBeginSection": 2425,
"offsetInEndSection": 2562,
"text": "Bulevirtide was recently approved for HDV in Europe, whereas pegylated interferon alfa is the only treatment available in most countries."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37929228",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 126,
"text": "Broad-spectrum activity of bulevirtide against clinical isolates of HDV and recombinant pan-genotypic combinations of HBV/HDV."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37880598",
"endSection": "abstract",
"offsetInBeginSection": 11,
"offsetInEndSection": 208,
"text": "To compare the effectiveness of seven major interventions [Bulevirtide (BLV), Interferon (IFN), Nucleoside analogs (NAs), BLV + IFN, BLV + NAs, IFN + NAs, and Placebo] to treat chronic hepatitis D."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37593170",
"endSection": "abstract",
"offsetInBeginSection": 961,
"offsetInEndSection": 1248,
"text": "The discovery of the entry inhibitor bulevirtide has represented a breakthrough in HDV treatment, by demonstrating high rates of viral suppression in phase II and III trials, results which have been confirmed in real-world settings and in patients with compensated advanced liver disease"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37360907",
"endSection": "abstract",
"offsetInBeginSection": 19,
"offsetInEndSection": 112,
"text": "Bulevirtide (BLV) is a novel antiviral drug licensed for the treatment of chronic hepatitis D"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33999515",
"endSection": "abstract",
"offsetInBeginSection": 71,
"offsetInEndSection": 142,
"text": "hepatitis. Bulevirtide (BLV, Hepcludex® ) is an HDV/HBV entry inhibitor"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34268531",
"endSection": "abstract",
"offsetInBeginSection": 779,
"offsetInEndSection": 1013,
"text": "therapy for both infections. In July 2020 bulevirtide was authorized for use in the E.U. following a positive opinion by the European Medicines Agency (EMA) for the treatment of chronic HDV infection in HDV RNA-positive adult patients"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34155804",
"endSection": "abstract",
"offsetInBeginSection": 1069,
"offsetInEndSection": 1760,
"text": "bulevirtide (BLV, Hepcludex® ), which was recently approved in Europe at a dose of 2 mg in sub-cutaneous injection per day, is indicated for the treatment of CHD in adult patients with compensated liver disease and positive HDV viremia. BLV can be administrated in monotherapy or in combination with PEG-IFNα. Nucleos(t)ide analogues can be used in combination for underlying HBV infection. The optimal treatment duration has not yet been determined and treatment should be continued if a clinical benefit is observed. There are other promising therapies such as IFN lambda (IFNλ) (immunomodulator), lonafarnib (prenylation inhibitor) and nucleic acid polymers (Inhibitors of HBsAg release)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35942695",
"endSection": "abstract",
"offsetInBeginSection": 672,
"offsetInEndSection": 1301,
"text": "Recently, Bulevirtide (BLV), a first-in-class HBV-HDV entry inhibitor blocking Na+ -taurocholate co-transporting polypeptide (NTCP), has provided very promising efficacy data in Phase II and Phase III (interim analysis) trials as well as in preliminary real-life reports. In July 2020, BLV has granted conditional approval by EMA for treatment of compensated CHD, at the dose of 2 mg/day by self-administered subcutaneous injections. In Phase II and Phase III trials, BLV was evaluated at different doses (2 vs. 10 mg/day) for 24 or 48 weeks, either in monotherapy or in combination with PegIFN. Administration of BLV monotherapy"
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34268531",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 39,
"text": "Bulevirtide for HBV and HDV infections."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37345876",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 583,
"text": "BACKGROUND: Coinfection with hepatitis D virus (HDV) accelerates the progression of liver disease associated with chronic hepatitis B. Bulevirtide inhibits the entry of HDV into hepatocytes.METHODS: In this ongoing phase 3 trial, patients with chronic hepatitis D, with or without compensated cirrhosis, were randomly assigned, in a 1:1:1 ratio, to receive bulevirtide subcutaneously at 2 mg per day (2-mg group) or 10 mg per day (10-mg group) for 144 weeks or to receive no treatment for 48 weeks followed by bulevirtide subcutaneously at 10 mg per day for 96 weeks (control group)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32926353",
"endSection": "abstract",
"offsetInBeginSection": 196,
"offsetInEndSection": 366,
"text": "Bulevirtide was recently approved in the European Union (EU) for the treatment of chronic HDV infection in HDV RNA positive adult patients with compensated liver disease."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34799189",
"endSection": "abstract",
"offsetInBeginSection": 816,
"offsetInEndSection": 1073,
"text": "A new treatment has been approved, Bulevirtide (Hepcludex®) an HDV/HBV entry inhibitor, for any patient with chronic hepatitis Delta infection (CHD) with active replication (except in decompensated cirrhosis), at a dose of 2mg/day by subcutaneous injection."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36396025",
"endSection": "abstract",
"offsetInBeginSection": 601,
"offsetInEndSection": 780,
"text": "Bulevirtide, an entry inhibitor, was conditionally approved in July 2020 in the European Union for adult patients with chronic hepatitis delta (CHD) and compensated liver disease."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/38037956",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 138,
"text": "Bulevirtide, an entry inhibitor for the hepatitis B virus (HBV) and hepatitis D virus (HDV), is currently available on the European market"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36931396",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 131,
"text": "Bulevirtide has been recently conditionally approved by the European Medicines Agency for the treatment of Chronic Hepatitis Delta,"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/38041549",
"endSection": "abstract",
"offsetInBeginSection": 256,
"offsetInEndSection": 341,
"text": "The approval of bulevirtide has shed some light for patients with Chronic Hepatitis D"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37473778",
"endSection": "abstract",
"offsetInBeginSection": 858,
"offsetInEndSection": 1075,
"text": "Despite the severity of HDV, there are few treatment options. Pegylated interferon (off-label use) has long been the only available treatment, although bulevirtide is conditionally approved in some European countries."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36931396",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 177,
"text": "Bulevirtide has been recently conditionally approved by the European Medicines Agency for the treatment of Chronic Hepatitis Delta, but the ideal duration of therapy is unknown."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37025462",
"endSection": "abstract",
"offsetInBeginSection": 98,
"offsetInEndSection": 303,
"text": " In July 2020, bulevirtide was conditionally approved for the treatment of hepatitis D, the most severe form of viral hepatitis, which frequently causes end-stage liver disease and hepatocellular carcinoma"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36113537",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 128,
"text": "BACKGROUND: Bulevirtide is a first-in-class peptidic entry inhibitor for hepatitis B virus (HBV) and hepatitis D virus infection"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37025462",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 285,
"text": "Background & Aims: Bulevirtide is a first-in-class entry inhibitor of hepatitis B surface antigen. In July 2020, bulevirtide was conditionally approved for the treatment of hepatitis D, the most severe form of viral hepatitis, which frequently causes end-stage liver disease and hepato"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36113537",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 117,
"text": "BACKGROUND: Bulevirtide is a first-in-class peptidic entry inhibitor for hepatitis B virus (HBV) and hepatitis D viru"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36192563",
"endSection": "abstract",
"offsetInBeginSection": 982,
"offsetInEndSection": 1259,
"text": "Pegylated interferon was the mainstay of treatment for HDV infection until bulevirtide, a viral entry inhibitor, was recently approved by the European Union (EMA) and FDA in America, while multiple novel therapies are already in clinical trials as part of the HBV cure program."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35973578",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 135,
"text": "Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36196680",
"endSection": "abstract",
"offsetInBeginSection": 63,
"offsetInEndSection": 186,
"text": "In this new era, the virus entry inhibitor bulevirtide has received conditional approval as a treatment for compensated CHD"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35122369",
"endSection": "abstract",
"offsetInBeginSection": 459,
"offsetInEndSection": 667,
"text": "Recently, bulevirtide, a first in its class HDV entry inhibitor, has received conditional authorization of use from the European Medicines Agency (EMA) and was also submitted for approval in the United States"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36648369",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 153,
"text": "The entry inhibitor bulevirtide (BLV) is a new treatment option for patients with chronic hepatitis D virus (HDV) infection and compensated liver disease"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32926353",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 195,
"text": "Bulevirtide (Hepcludex®), a first-in-class entry inhibitor, is being developed by MYR GmbH for the treatment of chronic hepatitis delta virus (HDV) and chronic hepatitis B virus (HBV) infections."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32926353",
"endSection": "abstract",
"offsetInBeginSection": 196,
"offsetInEndSection": 487,
"text": "Bulevirtide was recently approved in the European Union (EU) for the treatment of chronic HDV infection in HDV RNA positive adult patients with compensated liver disease. This article summarizes the milestones in the development of bulevirtide leading to this first approval for chronic HDV."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34268531",
"endSection": "abstract",
"offsetInBeginSection": 808,
"offsetInEndSection": 1180,
"text": "In July 2020 bulevirtide was authorized for use in the E.U. following a positive opinion by the European Medicines Agency (EMA) for the treatment of chronic HDV infection in HDV RNA-positive adult patients with compensated liver disease. In this paper we have examined the studies that led to this approval as well as studies examining the drug's efficacy in treating HBV."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37025462",
"endSection": "abstract",
"offsetInBeginSection": 98,
"offsetInEndSection": 488,
"text": " In July 2020, bulevirtide was conditionally approved for the treatment of hepatitis D, the most severe form of viral hepatitis, which frequently causes end-stage liver disease and hepatocellular carcinoma. Herein, we report the first data from a large multicenter real-world cohort of patients with hepatitis D treated with bulevirtide at a daily dose of 2 mg without additional interferon"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32926353",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 366,
"text": "Bulevirtide (Hepcludex®), a first-in-class entry inhibitor, is being developed by MYR GmbH for the treatment of chronic hepatitis delta virus (HDV) and chronic hepatitis B virus (HBV) infections. Bulevirtide was recently approved in the European Union (EU) for the treatment of chronic HDV infection in HDV RNA positive adult patients with compensated liver disease."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37025462",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 488,
"text": "Background & Aims: Bulevirtide is a first-in-class entry inhibitor of hepatitis B surface antigen. In July 2020, bulevirtide was conditionally approved for the treatment of hepatitis D, the most severe form of viral hepatitis, which frequently causes end-stage liver disease and hepatocellular carcinoma. Herein, we report the first data from a large multicenter real-world cohort of patients with hepatitis D treated with bulevirtide at a daily dose of 2 mg without additional interferon"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32926353",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 487,
"text": "Bulevirtide (Hepcludex®), a first-in-class entry inhibitor, is being developed by MYR GmbH for the treatment of chronic hepatitis delta virus (HDV) and chronic hepatitis B virus (HBV) infections. Bulevirtide was recently approved in the European Union (EU) for the treatment of chronic HDV infection in HDV RNA positive adult patients with compensated liver disease. This article summarizes the milestones in the development of bulevirtide leading to this first approval for chronic HDV."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37025462",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 303,
"text": "Background & Aims: Bulevirtide is a first-in-class entry inhibitor of hepatitis B surface antigen. In July 2020, bulevirtide was conditionally approved for the treatment of hepatitis D, the most severe form of viral hepatitis, which frequently causes end-stage liver disease and hepatocellular carcinoma"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36396025",
"endSection": "abstract",
"offsetInBeginSection": 573,
"offsetInEndSection": 1264,
"text": "HBV mono-infected patients. Bulevirtide, an entry inhibitor, was conditionally approved in July 2020 in the European Union for adult patients with chronic hepatitis delta (CHD) and compensated liver disease. There are several drugs in development, including lonafarnib and interferon lambda, with different modes of action. In this review, we detail our current fundamental knowledge of HDV lifecycle and review antiviral treatments under development against this virus, outlining their respective mechanisms-of-action. Finally, we describe the antiviral effect these compounds are showing in ongoing clinical trials, discussing their promise and potential pitfalls for managing HDV infected"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34155804",
"endSection": "abstract",
"offsetInBeginSection": 1069,
"offsetInEndSection": 1698,
"text": "bulevirtide (BLV, Hepcludex® ), which was recently approved in Europe at a dose of 2 mg in sub-cutaneous injection per day, is indicated for the treatment of CHD in adult patients with compensated liver disease and positive HDV viremia. BLV can be administrated in monotherapy or in combination with PEG-IFNα. Nucleos(t)ide analogues can be used in combination for underlying HBV infection. The optimal treatment duration has not yet been determined and treatment should be continued if a clinical benefit is observed. There are other promising therapies such as IFN lambda (IFNλ) (immunomodulator), lonafarnib (prenylation inhib"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34799189",
"endSection": "abstract",
"offsetInBeginSection": 851,
"offsetInEndSection": 1072,
"text": "Bulevirtide (Hepcludex®) an HDV/HBV entry inhibitor, for any patient with chronic hepatitis Delta infection (CHD) with active replication (except in decompensated cirrhosis), at a dose of 2mg/day by subcutaneous injection"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35329913",
"endSection": "abstract",
"offsetInBeginSection": 643,
"offsetInEndSection": 772,
"text": "In recent years, new therapeutic approaches have been studied, and EMA has approved a new drug (bulevirtide) for Delta hepatitis."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36004554",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 148,
"text": "In July 2020, the entry inhibitor bulevirtide was approved in the European Union for the treatment of chronic hepatitis delta virus (HDV) infection."
}
] | 13
|
BioASQ-training13b
| null | null |
65cfdaae1930410b13000025
| 5,260
|
factoid
|
Which initial chemotherapy regimen is the most appropriate in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients?
|
['FOLFOXIRI', 'FOLFIRINOX']
|
[
"FOLFOXIRI",
"FOLFIRINOX",
"FOLFOXIRI regimen",
"FOLFIRINOX regimen",
"FOLFOXIRI chemotherapy",
"FOLFIRINOX chemotherapy",
"FOLFOXIRI treatment",
"FOLFIRINOX treatment"
] |
['Based on the provided information, both CAPEOX (capecitabine plus oxaliplatin) and FOLFIRINOX appear to be effective induction chemotherapy regimens as part of total neoadjuvant therapy (TNT) for locally advanced rectal cancer.\n\nCAPEOX is mentioned in several studies as the induction chemotherapy given prior to chemoradiotherapy and consolidation chemotherapy. FOLFIRINOX is also noted to have established efficacy, significantly increasing 3-year disease-free survival when used as neoadjuvant therapy.\n\nThe most appropriate regimen may depend on individual patient factors and institutional protocols. However, both CAPEOX and FOLFIRINOX seem to be valid options for induction chemotherapy in the TNT approach for locally advanced rectal cancer patients, with the goal of improving pathologic complete response rates and facilitating delivery of systemic therapy.', 'Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients, the most appropriate initial chemotherapy regimen is mFOLFOXIRI neoadjuvant chemotherapy, which has shown improved pCR rate, survival outcome, and reduced the rate of distant metastasis and anastomotic fistula compared to other regimens.', 'mFOLFOXIRI is the most appropriate initial chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients.', 'The most appropriate initial chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients is mFOLFOXIRI. This regimen has been shown to improve pCR rate and survival outcome, reduce the rate of distant metastasis and anastomotic fistula when compared with mFOLFOX6 neoadjuvant chemotherapy.', 'mFOLFOXIRI', 'In Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients, the mFOLFOXIRI regimen has shown promising results, including improved pathological complete response (pCR) rates, better survival outcomes, reduced distant metastasis rates, and lower incidences of anastomotic fistulas compared to other regimens like mFOLFOX6.', 'The most appropriate initial chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients is mFOLFOXIRI (modified FOLFOXIRI). This regimen has been shown to improve the pathological complete response (pCR) rate, reduce the rate of distant metastasis, and improve survival outcomes compared to other regimens, such as mFOLFOX6. However, it is important to consider individual patient factors and discuss treatment options with a multidisciplinary team to determine the most suitable regimen for each patient.', 'In Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients, the most appropriate initial chemotherapy regimen could be preoperative induction or consolidation with a range of options such as FOLFOXIRI, FOLFOX, or CAPEOX. However, the decision should be individualized based on patient and tumor characteristics and clinician experience.', "The choice of initial chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients depends on various factors such as patient's overall health, potential toxicities, and the risk of distant metastasis. Some studies have shown promising results with FOLFOXIRI as the initial chemotherapy regimen in TNT, while others have used TEGAFIRI or CAPOX. However, it is important to note that these studies are still ongoing and their safety and feasibility need to be further evaluated. In Japan, a phase II trial is currently underway to evaluate the safety and activity of a TNT strategy including SCRT, intensified consolidation treatment with FOLFOXIRI and delayed surgery. After protocol amendment, the treatment seems feasible without safety concern. Ultimately, the most appropriate initial chemotherapy regimen in TNT for locally advanced rectal cancer patients will depend on the results of ongoing clinical trials and individual patient characteristics.", 'Based on the provided information, FOLFOXIRI appears to be the most appropriate initial chemotherapy regimen for Total Neoadjuvant Therapy (TNT) in patients with locally advanced rectal cancer. The abstracts mention that FOLFOXIRI is a potential chemotherapy option in the neoadjuvant setting, and that neoadjuvant mFOLFOXIRI regimens improved pathologic complete response (pCR) rate, survival outcomes, and reduced distant metastasis and anastomotic fistula rates compared to mFOLFOX6 neoadjuvant chemotherapy.', 'Neoadjuvant mFOLFOXIRI regimens improved pCR rate and survival outcome, reduced the rate of distant metastasis and anastomotic fistula when comparing with propensity-score matched controls of mFOLFOX6 neoadjuvant chemotherapy.', 'The most appropriate chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients is mFOLFOXIRI.', 'In Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients, the most appropriate initial chemotherapy regimen often includes cycles of induction chemotherapy, such as FOLFIRINOX or fluorouracil, leucovorin, and oxaliplatin, followed by chemoradiotherapy to improve pathological complete response rates and facilitate the delivery of chemotherapy before surgery.', 'According to a randomized phase III trial published in The Lancet Oncology in 2018, the most appropriate initial chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients is mFOLFOXIRI (oxaliplatin, leucovorin, irinotecan, and fluorouracil) followed by short-course radiotherapy (SCRT) and delayed surgery, as compared to the standard of care, which is preoperative radiotherapy (PRT) followed by surgery. The study found that the mFOLFOXIRI-SCRT-surgery arm had a higher pathological complete response (pCR) rate (34% vs 16%) and a lower rate of distant metastases (11% vs 19%) than the PRT-surgery arm. However, the overall survival and local recurrence rates were similar between the two arms. It is essential to note that the decision to use TNT should be individualized based on patient factors and multidisciplinary team discussion.', 'The neoadjuvant mFOLFOXIRI regimen is most appropriate in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients, as it has shown improved pathological complete response rate and survival outcomes, along with reduced rates of distant metastasis and anastomotic fistula.', 'The most appropriate initial chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients is mFOLFOXIRI (modified FOLFOXIRI). This regimen has been shown to improve pathological complete response (pCR) rates, survival outcomes, and reduce the rate of distant metastasis and anastomotic fistula compared to other regimens like mFOLFOX6. Therefore, mFOLFOXIRI is recommended as the preferred choice for initial chemotherapy in TNT for locally advanced rectal cancer patients.', 'The most appropriate initial chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients is mFOLFOXIRI.', 'The most appropriate initial chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients is mFOLFOXIRI. This regimen has been shown to improve pathological complete response (pCR) rates and survival outcomes, as well as reduce the risk of distant metastasis and anastomotic fistula, compared to other neoadjuvant chemotherapy regimens such as FOLFOX or CAPEOX. The mFOLFOXIRI regimen has become a new standard of care for locally advanced rectal cancer patients undergoing TNT.', 'The most appropriate initial chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients includes options like FOLFOXIRI, FOLFOX, or CAPEOX, with mFOLFOXIRI showing improved outcomes in some studies.', 'The optimal initial chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients is still not established. However, FOLFOXIRI (5-fluorouracil, leucovorin, oxaliplatin, and irinotecan) appears to be a promising option as suggested by some studies. The decision should be individualized and discussed with patients.', 'The most appropriate initial chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients is FOLFOXIRI.', 'The most appropriate initial chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients is induction chemotherapy followed by chemoradiotherapy (CRT) and consolidation chemotherapy. The specific regimen can vary, including options such as CapeOx (capecitabine and oxaliplatin), FOLFIRINOX (leucovorin, fluorouracil, irinotecan, and oxaliplatin), or 5-fluorouracil and leucovorin with or without oxaliplatin. The choice of regimen may depend on factors such as patient characteristics, tumor stage, and potential side effects.', 'The choice of initial chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients is still a matter of debate. However, a recent study found that neoadjuvant mFOLFOXIRI chemotherapy improved pathological complete response rate, survival outcome, and reduced distant metastasis and anastomotic fistula rates compared to propensity-score matched controls of mFOLFOX6 neoadjuvant chemotherapy. This suggests that mFOLFOXIRI could be a more appropriate initial chemotherapy regimen in TNT for locally advanced rectal cancer patients. However, it is important to consider the higher incidence of grade III and/or IV nausea and/or vomiting associated with mFOLFOXIRI. Further studies are needed to confirm these findings and establish the optimum combination, sequence, or duration of TNT.', 'The initial chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients is a combination of chemoradiotherapy, FOLFOX, and CAPOX.', 'The most appropriate initial chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients is the modified FOLFOXIRI (mFOLFOXIRI), which has been demonstrated to improve pathological complete response rate and survival outcomes compared with propensity-score matched controls receiving mFOLFOX6 neoadjuvant chemotherapy. Additionally, mFOLFOXIRI reduces the rates of distant metastasis and anastomotic fistula.', 'The most appropriate initial chemotherapy regimen in total neoadjuvant therapy (TNT) for locally advanced rectal cancer patients is a combination of fluoropyrimidine-based chemotherapy, such as capecitabine or 5-fluorouracil (5-FU), with oxaliplatin (FOLFOX or CAPOX). This regimen has been shown to improve tumor response rates and increase the likelihood of achieving a complete pathological response. It is important to note that the choice of chemotherapy regimen may vary depending on individual patient factors and institutional protocols.', 'In Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer, the most appropriate initial chemotherapy regimen can vary based on specific patient factors and treatment goals. However, regimens like mFOLFOXIRI have shown promising results in improving the pathological complete response (pCR) rate and survival outcomes, as well as reducing the rate of distant metastasis and anastomotic fistula compared to mFOLFOX6. This makes mFOLFOXIRI a strong candidate for initial chemotherapy in TNT settings', 'The most appropriate initial chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer appears to be the neoadjuvant mFOLFOXIRI regimen. This regimen has shown to improve the pathological complete response (pCR) rate and survival outcomes, as well as reduce the rate of distant metastasis and anastomotic fistula compared to mFOLFOX6, according to studies with propensity-score matched controls.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/37697712",
"http://www.ncbi.nlm.nih.gov/pubmed/34963563",
"http://www.ncbi.nlm.nih.gov/pubmed/30381141",
"http://www.ncbi.nlm.nih.gov/pubmed/37479897",
"http://www.ncbi.nlm.nih.gov/pubmed/37429749",
"http://www.ncbi.nlm.nih.gov/pubmed/37174033",
"http://www.ncbi.nlm.nih.gov/pubmed/35304396",
"http://www.ncbi.nlm.nih.gov/pubmed/37553666",
"http://www.ncbi.nlm.nih.gov/pubmed/33169626",
"http://www.ncbi.nlm.nih.gov/pubmed/31054549",
"http://www.ncbi.nlm.nih.gov/pubmed/33419188",
"http://www.ncbi.nlm.nih.gov/pubmed/21851185",
"http://www.ncbi.nlm.nih.gov/pubmed/31150315",
"http://www.ncbi.nlm.nih.gov/pubmed/37198556"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37174033",
"endSection": "abstract",
"offsetInBeginSection": 1243,
"offsetInEndSection": 1449,
"text": "A plethora of potential chemotherapy schedules are available around the radiotherapy component, which include preoperative induction or consolidation with a range of options (FOLFOXIRI, FOLFOX, or CAPEOX,) "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34963563",
"endSection": "abstract",
"offsetInBeginSection": 1606,
"offsetInEndSection": 1832,
"text": "Neoadjuvant mFOLFOXIRI regimens improved pCR rate and survival outcome, reduced the rate of distant metastasis and anastomotic fistula when comparing with propensity-score matched controls of mFOLFOX6 neoadjuvant chemotherapy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37479897",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 341,
"text": "PURPOSE: Total neoadjuvant therapy (TNT) with pre-operative chemotherapy and chemoradiotherapy results in improved survival and is becoming the new standard of care in locally advanced rectal cancer (LARC). We describe our experience with TNT consisting of induction chemotherapy followed by chemoradiotherapy using full dose 5FU without oxa"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37553666",
"endSection": "abstract",
"offsetInBeginSection": 500,
"offsetInEndSection": 846,
"text": "Therefore, the aim of this trial was to investigate whether preoperative short-course radiotherapy followed by chemotherapy with four cycles of CAPOX can double the pCR rate compared to a standard schedule of long-course preoperative CRT in patients with LARC.METHODS: This is a multi-centre, prospective, open label, randomised controlled trial."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37198556",
"endSection": "abstract",
"offsetInBeginSection": 247,
"offsetInEndSection": 791,
"text": "The present study will be an open-label, single-arm, single-center trial to develop a new protocol.METHODS: Thirty LARC patients at high risk of distant metastasis will receive CRT consisting of long-course radiation, concurrent with tegafur/uracil, oral leucovorin, irinotecan (TEGAFIRI), followed by mFOLFOX-6 or CAPOX before undergoing surgery.DISCUSSION: Since previous findings showed a high percentage of grade 3-4 adverse events with the TEGAFIRI regimen for CRT and TNT, the primary outcome of this study will be safety and feasibility."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35304396",
"endSection": "abstract",
"offsetInBeginSection": 986,
"offsetInEndSection": 1299,
"text": "ion or intersphincteric resection). Patients will be randomised to either arm A consisting of CRT (50.4 Gy with capecitabine) followed by consolidation chemotherapy (six cycles of CapeOx), or arm B consisting of induction chemotherapy (three cycles of CapeOx plus bevacizumab) followed by CRT and consolidation ch"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37697712",
"endSection": "abstract",
"offsetInBeginSection": 1345,
"offsetInEndSection": 1440,
"text": "ery or its omission. Neoadjuvant FOLFIRINOX has established efficacy, with a significant increa"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33169626",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 204,
"text": "INTRODUCTION: Administration of chemotherapeutic regimens such as FOLFOX or CAPEOX with chemoradiation in the neoadjuvant setting, termed total neoadjuvant treatment (TNT), was introduced in recent years."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31054549",
"endSection": "abstract",
"offsetInBeginSection": 1268,
"offsetInEndSection": 1478,
"text": "The regimen of TNT: 3 cycles of induction CAPOX (oxaliplatin plus capecitabine) were followed by pelvic radiotherapy and concurrent CAPOX, then 3 cycles of consolidation CAPOX were delivered after radiotherapy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21851185",
"endSection": "abstract",
"offsetInBeginSection": 237,
"offsetInEndSection": 658,
"text": "ious study. The aim of this study was to evaluate the efficacy in terms of pathologic complete response to pre-operative therapy.MATERIAL AND METHODS: A Phase II study was designed and clinical stage T3-T4 and/ or N ≥ 1 patients were treated with concomitant boost radiotherapy (55 Gy/5 weeks) plus concurrent chemotherapy (Tom-Ox). The primary endpoint was the assessment of efficacy in terms of clinical and pathologic "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37697712",
"endSection": "abstract",
"offsetInBeginSection": 817,
"offsetInEndSection": 925,
"text": "be included. Evaluation of the tumoral response will be performed after six courses of high-dose FOLFIRINOX "
}
] | 13
|
BioASQ-training13b
| null | null |
65f7785dc4010b4d78000033
| 5,261
|
factoid
|
In what part of the cell would a SNARE Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) be found
|
['membrane', 'nerve terminals', 'synaptic vesicles', 'endoplasmic reticulum (ER)', 'ERGIC', 'Golgi apparatus']
|
[
"membrane",
"cell membrane",
"plasma membrane",
"nerve terminals",
"axon terminals",
"synaptic vesicles",
"vesicles",
"endoplasmic reticulum (ER)",
"rough endoplasmic reticulum",
"smooth endoplasmic reticulum",
"ERGIC",
"ER-Golgi intermediate compartment",
"Golgi apparatus",
"Golgi body",
"Golgi complex"
] |
['SNARE soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) are transmembrane proteins found in the endosomal/lysosomal system.', 'SNAREs are typically found in the membranes of cells where they play a crucial role in the process of membrane fusion.', 'SNAREs, including Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs), are found in the Golgi apparatus and endoplasmic reticulum of the cell.', 'Astrocytes, the most abundant glial cells in the central nervous system (CNS), sense synaptic activity and respond through the release of gliotransmitters, a process mediated by intracellular Ca. In these cells, SNARE Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) are found on vesicles membranes and contribute to the docking and fusion of vesicles with the cell membrane, allowing the release of gliotransmitters to the extracellular space.', 'SNAREs are found in nerve terminals and synaptic vesicles.', 'Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (R-SNAREs) mainly promoted the assembly of the SNARE complex to drive the final membrane fusion step of membrane transport', 'A SNARE Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) would be found in presynaptic terminals and perisynaptic astrocytic processes.', 'Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) can be found in various parts of the cell, including the plasma membrane, endoplasmic reticulum, Golgi apparatus, and synaptic vesicles. They are involved in mediating membrane fusion and play a crucial role in intracellular vesicle trafficking, neurotransmitter release, and other cellular processes.', "SNARE proteins are located in the cell's membranes, including those of synaptic vesicles and the plasma membrane.", 'Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) would be found in secretory vesicles.', 'SNAREs are found in the trans-Golgi network.', 'SNAREs are found in the plasma membrane and vesicles.', '\nSNAREs are transmembrane proteins found in various organelles and vesicles involved in vesicle trafficking and secretion, such as synaptic vesicles, endoplasmic reticulum (ER), Golgi apparatus, and lysosomes. In synapses, SNAREs are located in both presynaptic and postsynaptic membranes.', 'SNAREs are found in the plasma membrane of the cell, where they play a crucial role in membrane fusion and transport.', 'Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) are found in the membrane.', 'The SNARE Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) are found in the cell membrane.', 'SNARE proteins are primarily found in the cytoplasm of cells, where they play a crucial role in membrane fusion and intracellular transport processes.', 'SNAREs are found in the plasma membrane of neuronal presynaptic terminals.', 'SNAREs are found in the cell membrane.', 'Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) would be found in nerve terminals, synaptic vesicles, and in nerve terminals.', 'SNARE proteins are primarily found in nerve terminals, synaptic vesicles, endosomes, and the astrocytic plasma membrane.', 'SNAREs (Soluble N-ethylmaleimide-sensitive factor attachment protein receptors) are specialized proteins, involved in the process of vesicle fusion in a cell. They are typically located in the plasma membrane and vesicle membrane.', 'SNAREs are found in the plasma membrane of cells.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/36750663",
"http://www.ncbi.nlm.nih.gov/pubmed/11427709",
"http://www.ncbi.nlm.nih.gov/pubmed/19617396",
"http://www.ncbi.nlm.nih.gov/pubmed/20589833",
"http://www.ncbi.nlm.nih.gov/pubmed/12517971",
"http://www.ncbi.nlm.nih.gov/pubmed/16536742",
"http://www.ncbi.nlm.nih.gov/pubmed/26359495",
"http://www.ncbi.nlm.nih.gov/pubmed/35972760",
"http://www.ncbi.nlm.nih.gov/pubmed/30194295",
"http://www.ncbi.nlm.nih.gov/pubmed/26101353",
"http://www.ncbi.nlm.nih.gov/pubmed/29696021",
"http://www.ncbi.nlm.nih.gov/pubmed/26339030",
"http://www.ncbi.nlm.nih.gov/pubmed/12773094",
"http://www.ncbi.nlm.nih.gov/pubmed/27301672",
"http://www.ncbi.nlm.nih.gov/pubmed/37027300",
"http://www.ncbi.nlm.nih.gov/pubmed/10908612",
"http://www.ncbi.nlm.nih.gov/pubmed/9382863",
"http://www.ncbi.nlm.nih.gov/pubmed/11001046",
"http://www.ncbi.nlm.nih.gov/pubmed/12805548",
"http://www.ncbi.nlm.nih.gov/pubmed/10557242",
"http://www.ncbi.nlm.nih.gov/pubmed/25501368",
"http://www.ncbi.nlm.nih.gov/pubmed/28203732",
"http://www.ncbi.nlm.nih.gov/pubmed/36608162",
"http://www.ncbi.nlm.nih.gov/pubmed/37465385"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37465385",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 193,
"text": "Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (R-SNAREs) mainly promoted the assembly of the SNARE complex to drive the final membrane fusion step of membrane transport"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36750663",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 157,
"text": "The dynamic assembly of the Synaptic-soluble N-ethylmaleimide-sensitive factor Attachment REceptor (SNARE) complex is crucial to understand membrane fusion. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37027300",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 104,
"text": "The AAA+ NSF complex is responsible for SNARE complex disassembly both before and after membrane fusion."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/12517971",
"endSection": "abstract",
"offsetInBeginSection": 3,
"offsetInEndSection": 164,
"text": "have examined the role of the R-soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) synaptobrevin-2/vesicle-associated membrane protein"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/11427709",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 261,
"text": "Soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins of the syntaxin, SNAP-25, and VAMP families mediate intracellular membrane fusion through the formation of helical bundles that span opposing membranes. Soluble SNARE domains"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/12773094",
"endSection": "abstract",
"offsetInBeginSection": 210,
"offsetInEndSection": 412,
"text": "soluble proteins [N-ethylmaleimide-sensitive fusion protein (NSF) and soluble NSF attachment proteins (SNAPs)] and integral membrane proteins [vesicle and target SNAP receptors (v- and t-SNAREs)]. Three"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/10908612",
"endSection": "abstract",
"offsetInBeginSection": 1224,
"offsetInEndSection": 1401,
"text": "These data suggest that Vti1a-beta does not function in exocytosis but in a separate SNARE complex in a membrane fusion step during recycling or biogenesis of synaptic vesicles."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36608162",
"endSection": "abstract",
"offsetInBeginSection": 531,
"offsetInEndSection": 1214,
"text": "Thus, we aimed to investigate the localization and relative concentrations of neuronal SNARE proteins syntaxin-1, synaptosomal nerve-associated protein 25 (SNAP-25), vesicle-associated membrane protein 2 (VAMP-2) (synaptobrevin-2) and calcium sensor synaptotagmin 1 in perisynaptic astrocytic processes compared to nerve terminals and dendrites.METHODS: We used quantitative immunogold electron microscopy of the rat hippocampus to investigate the localization and concentration of neuronal SNARE proteins.RESULTS: As expected, analysis of the immunogold data revealed a lower labeling density of SNARE proteins in the perisynaptic astrocytic processes than in presynaptic terminals."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/11001046",
"endSection": "abstract",
"offsetInBeginSection": 172,
"offsetInEndSection": 359,
"text": "The pairing of vesicle v-SNAREs (soluble N-ethylmaleimide-sensitive factor attachment protein receptors) with target membrane t-SNAREs has a central role in intracellular membrane fusion."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/10908612",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 155,
"text": "Specific soluble N-ethylmaleimide-sensitive factor attachment protein (SNAP) receptor (SNARE) proteins are required for different membrane transport steps."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25501368",
"endSection": "abstract",
"offsetInBeginSection": 113,
"offsetInEndSection": 333,
"text": "This process is mediated by the formation of functional soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complexes between the plasma membrane t-SNARE complex and the vesicle v-SNARE or VAMP."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/20589833",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 189,
"text": "Syntaxin 16 (Syx16) is member of the soluble N-ethylmaleimide sensitive factor attachment protein receptor (SNARE) family of molecules that functions in membrane fusion in eukaryotic cells."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/19617396",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 195,
"text": "The specificity of vesicle-mediated transport is largely regulated by the membrane-specific distribution of SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) proteins."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/16536742",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 273,
"text": "SNARE proteins (soluble N-ethylmaleimide-sensitive factor attachment protein receptors) mediate membrane interactions and are conventionally divided into Q-SNAREs and R-SNAREs according to the possession of a glutamine or arginine residue at the core of their SNARE domain."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/10557242",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 325,
"text": "Protein cargo is trafficked between the organelles of the endomembrane system inside transport vesicles, a process mediated by integral membrane proteins called SNAREs (soluble N-ethylmaleimide sensitive factor attachment protein receptors) that reside on the surface of the vesicle (v-SNAREs) and target membrane (t-SNAREs)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26359495",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 404,
"text": "SNAREs constitute the core machinery of intracellular membrane fusion, but vesicular SNAREs localize to specific compartments via largely unknown mechanisms. Here, we identified an interaction between VAMP7 and SNAP-47 using a proteomics approach. We found that SNAP-47 mainly localized to cytoplasm, the endoplasmic reticulum (ER), and ERGIC and could also shuttle between the cytoplasm and the nucleus."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/9382863",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 995,
"text": "Yeast Bet1p participates in vesicular transport from the endoplasmic reticulum to the Golgi apparatus and functions as a soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) associated with ER-derived vesicles. A mammalian protein (rbet1) homologous to Bet1p was recently identified, and it was concluded that rbet1 is associated with the Golgi apparatus based on the subcellular localization of transiently expressed epitope-tagged rbet1. In the present study using rabbit antibodies raised against the cytoplasmic domain of rbet1, we found that the majority of rbet1 is not associated with the Golgi apparatus as marked by the Golgi mannosidase II in normal rat kidney cells. Rather, rbet1 is predominantly associated with vesicular spotty structures that concentrate in the peri-Golgi region but are also present throughout the cytoplasm. These structures colocalize with the KDEL receptor and ERGIC-53, which are known to be enriched in the intermediate compartment."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/12805548",
"endSection": "abstract",
"offsetInBeginSection": 269,
"offsetInEndSection": 459,
"text": "Here, cells expressing the interacting domains of v- and t-SNAREs on the cell surface were found to fuse spontaneously, demonstrating that SNAREs are sufficient to fuse biological membranes."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30194295",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 190,
"text": "Neuronal soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) catalyze synaptic vesicle fusion with presynaptic membranes through the formation of SNARE complexes."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26101353",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 203,
"text": "Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) that reside in the target membranes and transport vesicles assemble into specific SNARE complexes to drive membrane fusion."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35972760",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 196,
"text": "Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) are membrane-associated trafficking proteins that confer identity to lipid membranes and facilitate membrane fusion."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28203732",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 201,
"text": "Formation of complexes between soluble N-ethylmaleimide-sensitive-factor attachment protein receptor (SNARE) proteins on opposing membranes is the minimal requirement for intracellular membrane fusion."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28203732",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 145,
"text": "Redistribution of soluble N-ethylmaleimide-sensitive-factor attachment protein receptors in mouse sperm membranes prior to the acrosome reaction."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/20589833",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 362,
"text": "Syntaxin 16 (Syx16) is member of the soluble N-ethylmaleimide sensitive factor attachment protein receptor (SNARE) family of molecules that functions in membrane fusion in eukaryotic cells. A rather ubiquitously expressed, tail-anchored membrane protein localized mainly at the trans-Golgi network (TGN), it mediates primarily retrograde endosomal-TGN transport."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27301672",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 170,
"text": "Intracellular membrane fusion is mediated in most cases by membrane-bridging complexes of soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs)."
}
] | 13
|
BioASQ-training13b
| null | null |
66088d66fdcbea915f00000c
| 5,262
|
factoid
|
What disease is treated with Teplizumab?
|
['type 1 diabetes']
|
[
"type 1 diabetes",
"insulin-dependent diabetes mellitus",
"juvenile diabetes",
"T1D",
"IDDM"
] |
['Teplizumab is a CD3-directed monoclonal antibody that was approved for type 1 diabetes (T1D) and was shown to delay the onset of Stage 3 T1D in adults and pediatric patients 8 years of age and older with Stage 2 T1D, based on results of a clinical trial in high-risk relatives of individuals with T1D.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/34936848",
"http://www.ncbi.nlm.nih.gov/pubmed/37296593",
"http://www.ncbi.nlm.nih.gov/pubmed/35533645",
"http://www.ncbi.nlm.nih.gov/pubmed/37004543",
"http://www.ncbi.nlm.nih.gov/pubmed/37607392",
"http://www.ncbi.nlm.nih.gov/pubmed/36877454",
"http://www.ncbi.nlm.nih.gov/pubmed/37502867",
"http://www.ncbi.nlm.nih.gov/pubmed/37867976",
"http://www.ncbi.nlm.nih.gov/pubmed/23086558",
"http://www.ncbi.nlm.nih.gov/pubmed/20095914",
"http://www.ncbi.nlm.nih.gov/pubmed/37256143",
"http://www.ncbi.nlm.nih.gov/pubmed/32789003",
"http://www.ncbi.nlm.nih.gov/pubmed/36896700",
"http://www.ncbi.nlm.nih.gov/pubmed/23835333",
"http://www.ncbi.nlm.nih.gov/pubmed/37883211",
"http://www.ncbi.nlm.nih.gov/pubmed/24517093",
"http://www.ncbi.nlm.nih.gov/pubmed/29925930",
"http://www.ncbi.nlm.nih.gov/pubmed/37861217",
"http://www.ncbi.nlm.nih.gov/pubmed/22968521",
"http://www.ncbi.nlm.nih.gov/pubmed/37878676",
"http://www.ncbi.nlm.nih.gov/pubmed/37937833",
"http://www.ncbi.nlm.nih.gov/pubmed/36741943",
"http://www.ncbi.nlm.nih.gov/pubmed/26364507",
"http://www.ncbi.nlm.nih.gov/pubmed/33302842",
"http://www.ncbi.nlm.nih.gov/pubmed/37158990"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37502867",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 110,
"text": "Teplizumab has been approved for the delay of the onset of type 1 diabetes and may modulate new onset disease."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37256143",
"endSection": "abstract",
"offsetInBeginSection": 650,
"offsetInEndSection": 802,
"text": "An anti-CD3 antibody, teplizumab, was recently shown to delay clinical progression to T1D in high-risk individuals including adults and older children. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37296593",
"endSection": "abstract",
"offsetInBeginSection": 440,
"offsetInEndSection": 781,
"text": "Within the National Clinical Trial (NCT) database, a vast majority of over 3000 trials to treat T1D are devoted to insulin therapy. This review focuses on non-insulin pharmacological therapies. Many investigational new drugs fall under the category of immunomodulators, such as the recently FDA-approved CD-3 monoclonal antibody teplizumab. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35533645",
"endSection": "abstract",
"offsetInBeginSection": 1103,
"offsetInEndSection": 1307,
"text": "Furthermore, regarding the timing of intervention, teplizumab was the first immunomodulatory agent to demonstrate a significant delay in disease progression in high-risk individuals before clinical onset."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36741943",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 466,
"text": "Context: Participants with stage 1 or 2 type 1 diabetes (T1D) qualify for prevention trials, but factors involved in screening for such trials are largely unknown.Objective: To identify factors associated with screening for T1D prevention trials.Methods: This study included TrialNet Pathway to Prevention participants who were eligible for a prevention trial: oral insulin (TN-07, TN-20), teplizumab (TN-10), abatacept (TN-18), and oral hydroxychloroquine (TN-22). "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36896700",
"endSection": "abstract",
"offsetInBeginSection": 496,
"offsetInEndSection": 762,
"text": "We focus on phase 2 clinical trials with promising results, thus avoiding the exhausted list of every new therapy for T1DM.EXPERT OPINION: Teplizumab has demonstrated potential as a preventative agent for individuals at risk prior to the onset of overt dysglycemia. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36877454",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 434,
"text": "Teplizumab (teplizumab-mzwv; TZIELD™) is a CD3-directed monoclonal antibody (humanized IgG1κ) that is being developed by Provention Bio, Inc. for the treatment of type 1 diabetes (T1D). In November 2022, teplizumab was approved in the USA to delay the onset of Stage 3 T1D in adults and pediatric patients 8 years of age and older with Stage 2 T1D, based on results of a clinical trial in high-risk relatives of individuals with T1D. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37937833",
"endSection": "abstract",
"offsetInBeginSection": 1080,
"offsetInEndSection": 1127,
"text": "Teplizumab marks a turning point in T1D therapy"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37883211",
"endSection": "abstract",
"offsetInBeginSection": 125,
"offsetInEndSection": 266,
"text": "Teplizumab, an anti-CD3 monoclonal, delays T1D onset in patients at risk, but additional therapies are needed to prevent the disease entirely"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37878676",
"endSection": "abstract",
"offsetInBeginSection": 978,
"offsetInEndSection": 1138,
"text": "We identified IgG2 responses to three species that were associated with time to T1D diagnosis and with teplizumab treatment responses that delayed disease onset"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37502867",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 109,
"text": "Teplizumab has been approved for the delay of the onset of type 1 diabetes and may modulate new onset disease"
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24517093",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 94,
"text": "Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22968521",
"endSection": "abstract",
"offsetInBeginSection": 1651,
"offsetInEndSection": 1907,
"text": "Initial studies indicated that teplizumab is well tolerated, with a self-limiting rash as the most commonly reported adverse effect.CONCLUSIONS: Teplizumab is an anti-CD3 human monoclonal antibody with promising activity in treatment of patients with T1DM."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24517093",
"endSection": "abstract",
"offsetInBeginSection": 518,
"offsetInEndSection": 981,
"text": "One of the most promising agents, teplizumab , is an FcR-nonbinding anti-CD3 monoclonal antibody that has been tested in Phase II - III clinical trials and was shown to preserve the C-peptide levels and reduce the need for exogenous insulin.AREAS COVERED: In this review, we discuss the recent update on clinical data obtained from trials of teplizumab in type 1 diabetes, the drug's postulated mechanism of action and the identification of responders to therapy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37861217",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 251,
"text": "BACKGROUND: Teplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved by the Food and Drug Administration to delay the onset of clinical type 1 diabetes (stage 3) in patients 8 years of age or older with preclinical (stage 2) disease."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33302842",
"endSection": "abstract",
"offsetInBeginSection": 147,
"offsetInEndSection": 501,
"text": "Teplizumab is a humanized anti- CD3 monoclonal antibody, which may have beneficial effects for T1DM patients.OBJECTIVE: The aim of the study was to assess the safety and efficacy of teplizumab in T1DM patients.METHODS: We searched electronic databases using related keywords for randomized clinical trials assessing the safety and efficacy of teplizumab."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37158990",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 57,
"text": "Teplizumab Therapy to Delay the Onset of Type 1 Diabetes."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36877454",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 185,
"text": "Teplizumab (teplizumab-mzwv; TZIELD™) is a CD3-directed monoclonal antibody (humanized IgG1κ) that is being developed by Provention Bio, Inc. for the treatment of type 1 diabetes (T1D)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37158990",
"endSection": "abstract",
"offsetInBeginSection": 1004,
"offsetInEndSection": 1198,
"text": "Teplizumab, a monoclonal antibody (manufactured by Provention Bio and marketed as Tzield), was recently approved by the Food and Drug Administration as the first preventative treatment for T1DM."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37861217",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 239,
"text": "BACKGROUND: Teplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved by the Food and Drug Administration to delay the onset of clinical type 1 diabetes (stage 3) in patients 8 years of age or older with preclinical (stage"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37004543",
"endSection": "abstract",
"offsetInBeginSection": 426,
"offsetInEndSection": 511,
"text": " Teplizumab is a novel drug recently approved by the US FDA for the treatment of T1DM"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23835333",
"endSection": "abstract",
"offsetInBeginSection": 1146,
"offsetInEndSection": 1290,
"text": "We conclude that teplizumab treatment preserves insulin production and reduces the use of exogenous insulin in some patients with new-onset T1D."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26364507",
"endSection": "abstract",
"offsetInBeginSection": 1010,
"offsetInEndSection": 1162,
"text": "mmune attack and remission of the disease. The immunosuppressants (teplizumab, rituximab and abatacept) show promise in slowing the T1DM progressions fo"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/20095914",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 500,
"text": "IMPORTANCE OF THE FIELD: Type 1 diabetes mellitus (T1D) is a T-cell mediated autoimmune disease with selective destruction of beta cells. Immunological interventions are directed at arresting the loss of beta-cell function with the promise that this will make it easier for patients to control their glucose levels.AREAS COVERED IN THIS REVIEW: This review provides a summary of the preclinical and clinical research published between 1992 and 2009 using teplizumab and other anti-CD3 antibodies to a"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32789003",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 439,
"text": "Despite the clear evidence that type 1 diabetes (T1D) begins well before hyperglycemia is evident, there are no clinically available disease-modifying therapies for early-stage disease. However, following the exciting results of the Teplizumab Prevention Study, the first study to demonstrate that overt T1D can be delayed with immunotherapy, there is renewed optimism that in the future, T1D will be treated before hyperglycemia develops."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34936848",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 834,
"text": "INTRODUCTION: Immunotherapies for type 1 diabetes mellitus (T1D) have been the focus of intense research over the past few decades. Nevertheless, the results of clinical trials have not matched expectations. However, thanks to the recent and promising results on T1D prevention, among all the different immune-intervention strategies, clinical evidence on anti-CD3 monoclonal antibodies (mAb) deserves particular attention and in-depth evaluation.In this narrative review, we introduce the role of T-cells and their co-receptor CD3 in the pathogenesis of T1D and examine the potential of anti-CD3 mAbs as a treatment for preventing or curing T1D. We discuss pre-clinical studies and phase II/III clinical trials testing the anti-CD3 mAb teplizumab in subjects at T1D high risk, and testing teplizumab and otelixizumab in T1D recent on"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37878676",
"endSection": "abstract",
"offsetInBeginSection": 97,
"offsetInEndSection": 271,
"text": "treatment with the T cell-specific anti-CD3 antibody teplizumab delayed disease onset in participants at high risk for type 1 diabetes (T1D) in the TrialNet 10 (TN-10) trial."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29925930",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 104,
"text": "Biologic treatment of type 1 diabetes (T1D) with agents including anti-CD3 (otelixizumab and teplizumab)"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37861217",
"endSection": "abstract",
"offsetInBeginSection": 1757,
"offsetInEndSection": 2061,
"text": "SIONS: Two 12-day courses of teplizumab in children and adolescents with newly diagnosed type 1 diabetes showed benefit with respect to the primary end point of preservation of β-cell function, but no significant differences between the groups were observed with respect to the secondary end points. (Fun"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37004543",
"endSection": "abstract",
"offsetInBeginSection": 427,
"offsetInEndSection": 512,
"text": "Teplizumab is a novel drug recently approved by the US FDA for the treatment of T1DM."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37861217",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 620,
"text": "BACKGROUND: Teplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved by the Food and Drug Administration to delay the onset of clinical type 1 diabetes (stage 3) in patients 8 years of age or older with preclinical (stage 2) disease. Whether treatment with intravenous teplizumab in patients with newly diagnosed type 1 diabetes can prevent disease progression is unknown.METHODS: In this phase 3, randomized, placebo-controlled trial, we assessed β-cell preservation, clinical end points, and safety in children and adolescents who were assigned to receive teplizumab or placebo for two 12-day courses"
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37607392",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 91,
"text": "Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37861217",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 389,
"text": "BACKGROUND: Teplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved by the Food and Drug Administration to delay the onset of clinical type 1 diabetes (stage 3) in patients 8 years of age or older with preclinical (stage 2) disease. Whether treatment with intravenous teplizumab in patients with newly diagnosed type 1 diabetes can prevent disease progression is unknown"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33302842",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 356,
"text": "BACKGROUND: Type one diabetes mellitus (T1DM) is an autoimmune disease characterized by gradual destruction of beta cells in islets of Langerhans. Teplizumab is a humanized anti- CD3 monoclonal antibody, which may have beneficial effects for T1DM patients.OBJECTIVE: The aim of the study was to assess the safety and efficacy of teplizumab in T1DM patients"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33302842",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 255,
"text": "BACKGROUND: Type one diabetes mellitus (T1DM) is an autoimmune disease characterized by gradual destruction of beta cells in islets of Langerhans. Teplizumab is a humanized anti- CD3 monoclonal antibody, which may have beneficial effects for T1DM patients"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37861217",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 250,
"text": "BACKGROUND: Teplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved by the Food and Drug Administration to delay the onset of clinical type 1 diabetes (stage 3) in patients 8 years of age or older with preclinical (stage 2) disease"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23086558",
"endSection": "abstract",
"offsetInBeginSection": 115,
"offsetInEndSection": 502,
"text": " We tested whether treatment with teplizumab (a Fc receptor non-binding anti-CD3 monoclonal antibody), after the new-onset period, affects the decline in C-peptide production in individuals with type 1 diabetes.METHODS: In a randomised placebo-controlled trial we treated 58 participants with type 1 diabetes for 4-12 months with teplizumab or placebo at four academic centres in the USA"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37004543",
"endSection": "abstract",
"offsetInBeginSection": 426,
"offsetInEndSection": 671,
"text": " Teplizumab is a novel drug recently approved by the US FDA for the treatment of T1DM. This drug reduces abnormal glucose tolerance who are at high risk for developing T1DM and have antibodies suggesting an immunological attack on their pancreas"
}
] | 13
|
BioASQ-training13b
| null | null |
65cf6ae91930410b13000007
| 5,264
|
factoid
|
What is the target of Divarasib?
|
['KRAS G12C']
|
[
"KRAS G12C",
"Kirsten rat sarcoma viral oncogene homolog G12C",
"KRAS mutation G12C",
"KRAS G12C mutation",
"KRAS G12C variant"
] |
['Divarasib is a KRAS G12C inhibitor.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/37611121",
"http://www.ncbi.nlm.nih.gov/pubmed/37774359",
"http://www.ncbi.nlm.nih.gov/pubmed/38052910"
] |
[
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37611121",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 76,
"text": "Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37611121",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 122,
"text": "BACKGROUND: Divarasib (GDC-6036) is a covalent KRAS G12C inhibitor that was designed to have high potency and selectivity."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37611121",
"endSection": "abstract",
"offsetInBeginSection": 1706,
"offsetInEndSection": 1854,
"text": "CONCLUSIONS: Treatment with divarasib resulted in durable clinical responses across KRAS G12C-positive tumors, with mostly low-grade adverse events."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37774359",
"endSection": "abstract",
"offsetInBeginSection": 437,
"offsetInEndSection": 700,
"text": "Here, we describe the identification and characterization of GDC-1971 (formerly RLY-1971), a SHP2 inhibitor currently in clinical trials in combination with KRAS G12C inhibitor divarasib (GDC-6036) for the treatment of solid tumors driven by a KRAS G12C mutation."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/38052910",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 83,
"text": "Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/38052910",
"endSection": "abstract",
"offsetInBeginSection": 105,
"offsetInEndSection": 220,
"text": "Divarasib, a KRAS G12C inhibitor, has shown modest activity as a single agent in KRAS G12C-positive CRC at 400 mg. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/38052910",
"endSection": "abstract",
"offsetInBeginSection": 1404,
"offsetInEndSection": 1577,
"text": "The manageable safety profile and encouraging antitumor activity of divarasib plus cetuximab support the further investigation of this combination in KRAS G12C-positive CRC."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37611121",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 130,
"text": "BACKGROUND: Divarasib (GDC-6036) is a covalent KRAS G12C inhibitor that was designed to have high potency and selectivity.METHODS:"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/38052910",
"endSection": "abstract",
"offsetInBeginSection": 53,
"offsetInEndSection": 211,
"text": "cancer (CRC) and is associated with poor prognosis. Divarasib, a KRAS G12C inhibitor, has shown modest activity as a single agent in KRAS G12C-positive CRC at"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37611121",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 331,
"text": "BACKGROUND: Divarasib (GDC-6036) is a covalent KRAS G12C inhibitor that was designed to have high potency and selectivity.METHODS: In a phase 1 study, we evaluated divarasib administered orally once daily (at doses ranging from 50 to 400 mg) in patients who had advanced or metastatic solid tumors that harbor a KRAS G12C mutation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/38052910",
"endSection": "abstract",
"offsetInBeginSection": 105,
"offsetInEndSection": 396,
"text": "Divarasib, a KRAS G12C inhibitor, has shown modest activity as a single agent in KRAS G12C-positive CRC at 400 mg. Epidermal growth factor receptor has been recognized as a major upstream activator of RAS-MAPK signaling, a proposed key mechanism of resistance to KRAS G12C inhibition in CRC."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37611121",
"endSection": "abstract",
"offsetInBeginSection": 1509,
"offsetInEndSection": 1854,
"text": "Serial assessment of circulating tumor DNA showed declines in KRAS G12C variant allele frequency associated with response and identified genomic alterations that may confer resistance to divarasib.CONCLUSIONS: Treatment with divarasib resulted in durable clinical responses across KRAS G12C-positive tumors, with mostly low-grade adverse events."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37611121",
"endSection": "abstract",
"offsetInBeginSection": 124,
"offsetInEndSection": 506,
"text": "THODS: In a phase 1 study, we evaluated divarasib administered orally once daily (at doses ranging from 50 to 400 mg) in patients who had advanced or metastatic solid tumors that harbor a KRAS G12C mutation. The primary objective was an assessment of safety; pharmacokinetics, investigator-evaluated antitumor activity, and biomarkers of response and resistance were also assessed.R"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37611121",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 330,
"text": "BACKGROUND: Divarasib (GDC-6036) is a covalent KRAS G12C inhibitor that was designed to have high potency and selectivity.METHODS: In a phase 1 study, we evaluated divarasib administered orally once daily (at doses ranging from 50 to 400 mg) in patients who had advanced or metastatic solid tumors that harbor a KRAS G12C mutation"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37611121",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 110,
"text": "BACKGROUND: Divarasib (GDC-6036) is a covalent KRAS G12C inhibitor that was designed to have high potency and "
}
] | 13
|
BioASQ-training13b
| null | null |
65cfaf7e1930410b13000016
| 5,268
|
factoid
|
What is the appropriate treatment in HER2Neu amplificated refractory advanced colorectal cancer patients?
|
['Tucatinib plus trastuzumab']
|
[
"Tucatinib plus trastuzumab",
"Tucatinib and trastuzumab",
"Tucatinib with trastuzumab",
"Tucatinib-trastuzumab combination",
"Tucatinib/trastuzumab"
] |
['1) HER2Neu amplification occurs in approximately 2-5% of colorectal cancer patients. 2) Chemotherapy with standard agents such as oxaliplatin or irinotecan and fluoropyrimidines remains the first-line treatment in HER2Neu amplified refractory advanced colorectal cancer. 3) Trastuzumab, an anti-HER2Neu monoclonal antibody, has shown promising results in combination with standard chemotherapy in patients with HER2Neu amplified metastatic colorectal cancer.', 'The most appropriate treatment in HER2Neu amplificated refractory advanced colorectal cancer patients is tucatinib plus trastuzumab.', 'The appropriate treatment for HER2Neu amplified refractory advanced colorectal cancer patients would be regorafenib plus PD-1 inhibitor therapy, as this combination has shown promising efficacy in a real-world study. Patients with ERBB2/ERBB3 mutation may be the preferred population for this combination regimen.', 'Tucatinib plus trastuzumab had clinically meaningful anti-tumour activity and favourable tolerability. This treatment is the first US Food and Drug Administration-approved anti-HER2 regimen for metastatic colorectal cancer and is an important new treatment option for chemotherapy-refractory HER2-positive metastatic colorectal cancer.', 'Currently, the optimal treatment in HER2Neu amplificated refractory advanced colorectal cancer patients is not well established. Targeted therapy for patients with HER2/neu amplification in refractory mCRC is still being evaluated. HER2/neu amplification occurs in a minority of patients with refractory mCRC (2-6%), and data on treatment of HER2/neu amplified mCRC is still limited. However, several studies are underway to evaluate the role of anti-HER2/neu agents (trastuzumab or trastuzumab deruxtecan) in this subgroup.', 'The appropriate treatment for HER2Neu amplificated refractory advanced colorectal cancer patients is tucatinib (a small molecule HER2 inhibitor) in combination with trastuzumab (a monoclonal antibody against HER2). This treatment was recently approved by the US Food and Drug Administration for this specific patient population who have previously received chemotherapy. This is the first approved anti-HER2 regimen for metastatic colorectal cancer.', 'The appropriate treatment for HER2-positive, metastatic colorectal cancer patients who have not responded to chemotherapy is Tucatinib plus trastuzumab, which is the first US Food and Drug Administration-approved anti-HER2 regimen for this condition.', 'The appropriate treatment for HER2Neu amplified, chemotherapy-refractory advanced colorectal cancer patients is the combination of tucatinib plus trastuzumab. This regimen has demonstrated clinically meaningful anti-tumor activity and favorable tolerability in this patient population. It is the first US Food and Drug Administration-approved anti-HER2 regimen for metastatic colorectal cancer, making it an important new treatment option for these patients.', 'Tucatinib plus trastuzumab had clinically meaningful anti-tumour activity and favourable tolerability, making it the appropriate treatment in HER2Neu amplificated refractory advanced colorectal cancer patients.', 'HER2 amplification and/or activating mutations are present in 4% of metastatic colorectal cancers. To date, there are no approved therapies for HER2-positive metastatic colorectal cancer. Tucatinib plus trastuzumab is the first US Food and Drug Administration-approved anti-HER2 regimen for metastatic colorectal cancer.', 'For patients with HER2-amplified metastatic colorectal cancer refractory to standard treatment, anti-HER2 targeted therapies have shown promising activity. Potential treatment options include:\n\n- Dual HER2-targeted therapy with trastuzumab plus pertuzumab\n- Trastuzumab deruxtecan \n- Combination of trastuzumab and lapatinib\n- Pyrotinib (for patients resistant to trastuzumab and lapatinib)\n\nRecent evidence suggests anti-HER2 strategies could potentially represent a new standard of care in this patient population. However, secondary resistance to HER2-targeted agents can occur in most cases.', 'Tucatinib plus trastuzumab has shown clinically meaningful anti-tumour activity and favorable tolerability in patients with HER2-positive metastatic colorectal cancer refractory to chemotherapy. This treatment regimen is the first FDA-approved anti-HER2 therapy for metastatic colorectal cancer, providing an important new treatment option for patients with this condition.', 'Trastuzumab deruxtecan showed promising and durable activity in HER2-positive metastatic colorectal cancer refractory to standard treatment, with a safety profile consistent with that reported in previous trastuzumab deruxtecan trials.', 'The appropriate treatment for HER2Neu amplified refractory advanced colorectal cancer (mCRC) remains an area of active research and debate. While the HERACLES trial did not meet its primary endpoint of objective response rate, the combination of pertuzumab and trastuzumab deruxtecan demonstrated promising disease control rates and progression-free survival in this patient population. Additionally, a real-world study found that regorafenib plus PD-1 inhibitor therapy was effective in refractory microsatellite stable mCRC with ERBB2/ERBB3 mutation. However, there is currently no standard of care for HER2Neu amplified refractory advanced colorectal cancer patients. Clinical trials are ongoing to further evaluate the safety and efficacy of these and other treatment regimens in this population.', 'The appropriate treatment in HER2Neu amplified refractory advanced colorectal cancer patients includes the use of neratinib, trastuzumab deruxtecan, and trastuzumab.', 'HER2Neu amplification is a molecular alteration that can lead to resistance to anti-EGFR monoclonal antibodies (mAbs) in colorectal cancer (CRC). Recent evidence suggests that anti-ERBB2 therapeutic strategies, such as trastuzumab deruxtecan, are active in patients with ERBB2-positive metastatic CRC and could potentially represent a new standard-of-care. Pyrotinib is a promising new candidate for salvage therapy in patients with HER2-positive metastatic CRC who have developed resistance to trastuzumab and lapatinib. Dual HER2-targeted therapy with pertuzumab plus trastuzumab is also an option for patients with heavily pretreated, HER2-amplified metastatic CRC. Rechallenge with anti-EGFR inhibitors, in case of persistent or recovery of RAS-wildness, and targeted approach of specific mutations (BRAF inhibitors), amplifications (anti-Her2 treatment), or fusion proteins (NTRK inhibitors) can be guided by the use of next-generation sequencing (NGS).', "The appropriate treatment for HER2-positive refractory advanced colorectal cancer patients is the combination of tucatinib and trastuzumab. This regimen has shown clinically meaningful anti-tumor activity and is well-tolerated. It's also the first FDA-approved anti-HER2 therapy specifically for metastatic colorectal cancer, making it a significant new option for patients who have not responded to chemotherapy.", 'The recommended treatment for HER2Neu amplificated refractory advanced colorectal cancer patients is Tucatinib plus trastuzumab.', 'Tucatinib plus trastuzumab is the appropriate treatment in HER2Neu amplificated refractory advanced colorectal cancer patients.', 'The appropriate treatment in HER2Neu amplificated refractory advanced colorectal cancer patients is the combination of pyrotinib and trastuzumab.', "The study suggests that tucatinib plus trastuzumab has clinically meaningful anti-tumor activity and favorable tolerability in patients with HER2Neu amplificated refractory advanced colorectal cancer. This treatment is the first US Food and Drug Administration-approved anti-HER2 regimen for metastatic colorectal cancer and is an important new treatment option for chemotherapy-refractory HER2-positive metastatic colorectal cancer. Therefore, it would be appropriate to consider tucatinib plus trastuzumab as a treatment option for these patients. However, it is essential to consider each patient's individual circumstances and potential risks and benefits when making treatment decisions.", 'For patients with advanced colorectal cancer and HER2Neu amplification who have not responded to prior treatments, recommended therapies include tucatinib plus trastuzumab, trastuzumab deruxtecan, pyrotinib and trastuzumab, or neratinib combined with cetuximab.', 'The appropriate treatment in HER2Neu amplificated refractory advanced colorectal cancer patients is the combination of trastuzumab and lapatinib.', 'For patients with HER2Neu amplified refractory advanced colorectal cancer, the combination of Tucatinib and Trastuzumab is a clinically meaningful and FDA-approved treatment option.', 'The appropriate treatment for HER2-positive refractory advanced colorectal cancer patients is tucatinib plus trastuzumab. This regimen has shown clinically meaningful anti-tumor activity and favorable tolerability.', 'The appropriate treatment for HER2Neu amplified refractory advanced colorectal cancer patients is trastuzumab (Herceptin).', 'The recommended treatments for HER2Neu amplificated refractory advanced colorectal cancer patients are trastuzumab deruxtecan, neratinib, and tucatinib plus trastuzumab.', 'Tucatinib plus trastuzumab has clinically meaningful anti-tumour activity and favourable tolerability in HER2Neu amplificated refractory advanced colorectal cancer patients. This treatment is the first US Food and Drug Administration-approved anti-HER2 regimen for metastatic colorectal cancer and is an important new treatment option for chemotherapy-refractory HER2-positive metastatic colorectal cancer.', 'The appropriate treatment in HER2Neu amplificated refractory advanced colorectal cancer patients is the combination of tucatinib and trastuzumab. This treatment has shown clinically meaningful anti-tumor activity and favorable tolerability, making it the first FDA-approved anti-HER2 regimen for metastatic colorectal cancer. It is an important new treatment option for patients with chemotherapy-refractory HER2-positive metastatic colorectal cancer.', 'Tucatinib plus trastuzumab had clinically meaningful anti-tumour activity and favourable tolerability', 'It is currently assumed that patients who have received standard chemotherapy and have no evidence of recurrent disease should be treated with targeted therapy alone. In particular, HER2-positive patients who have received chemotherapy and have a good performance status should be treated with a combination of targeted therapy and chemotherapy.', '-In HER2Neu amplificated refractory advanced colorectal cancer patients, anti-HER2 therapies have shown promising activity. \n-Anti-HER2 therapies include trastuzumab and lapatinib, and these should be considered as potential therapeutic options in this specific patient population. \n-Currently, there are no formal recommendations for the use of anti-HER2 therapies in refractory colorectal cancer, and further studies are needed to establish the optimal treatment approach.', 'The FDA approved combination of trastuzumab and pertuzumab for use in metastatic breast cancer has shown promising results in HER2-positive refractory advanced colorectal cancer patients, with an objective response rate (ORR) of 38% and a disease control rate (DCR) of 76.9%. This treatment regimen is currently being evaluated for its safety and efficacy in larger clinical trials, making it a potential new option for patients with HER2-positive metastatic colorectal cancer who have progressed on standard chemotherapy regimens.', "The appropriate treatment for HER2-positive refractory advanced colorectal cancer patients is the combination of tucatinib and trastuzumab. This regimen has shown clinically meaningful anti-tumor activity and is well-tolerated. It's significant as it's the first FDA-approved anti-HER2 therapy for metastatic colorectal cancer, offering a new treatment option for those with chemotherapy-refractory disease.", ' The appropriate treatment for advanced coloreCTal cancer with H ER-pos and SCFV translocation is a multidrug approach involving the use of monoclonal antibodies, antibody-drug conjugates, and immune checkpoint inhibitors. ideal_answer: The appropriate treatment for advanced coloreCTal cancer with H ER-pos and SCFV translocation is a multidrug approach involving the use of monoclonal antibodies, antibody-drug conjugates, and immune checkpoint inhibitors. This approach combines the targeted elimination of cancer cells with the activation of the immune system to recognize and eliminate tumor cells. ', 'The appropriate treatment for HER2Neu amplificated refractory advanced colorectal cancer patients is the combination of tucatinib and trastuzumab. This treatment has shown clinically meaningful anti-tumour activity and favorable tolerability. It is the first FDA-approved anti-HER2 regimen for metastatic colorectal cancer and provides an important new treatment option for patients who have not responded to chemotherapy.', 'In HER2neu amplificated refractory advanced colorectal cancer patients, the appropriate treatment option is the combination of HER2-targeted therapy with chemotherapy. This can include the use of trastuzumab, a monoclonal antibody targeting HER2, in combination with chemotherapy agents such as 5-fluorouracil (5-FU) or oxaliplatin. The addition of trastuzumab to chemotherapy has shown improved outcomes in HER2-positive colorectal cancer patients, including increased response rates and prolonged survival. However, further studies are needed to determine the optimal treatment regimen and the role of other HER2-targeted agents in this patient population.', 'The appropriate treatment for HER2Neu amplified refractory advanced colorectal cancer patients may include combination targeted therapy with agents such as trastuzumab and lapatinib, which have shown activity in other HER2-positive malignancies. Additionally, enrollment in clinical trials exploring novel HER2-targeted therapies or combinatorial strategies could offer potential benefits for these patients who are resistant to standard treatments.', 'Tucatinib plus trastuzumab is an appropriate treatment option for HER2-positive metastatic colorectal cancer patients who are refractory to chemotherapy.', 'In HER2Neu amplified refractory advanced colorectal cancer patients, appropriate treatments may include targeted therapies such as trastuzumab deruxtecan, dual HER2-targeted therapy with pertuzumab plus trastuzumab, or the combination of trastuzumab and lapatinib. These treatments have shown promising activity and tolerability in patients with HER2-positive metastatic colorectal cancer who have developed resistance to standard therapies. Additionally, novel targeted treatments under development, such as anti-ERBB2 therapeutic strategies, may also be considered as potential options for these patients.', 'Tucatinib plus trastuzumab is the first US Food and Drug Administration-approved anti-HER2 regimen for metastatic colorectal cancer and is an important new treatment option for chemotherapy-refractory HER2-positive metastatic colorectal cancer.', 'Trastuzumab plus erlotinib is the standard of care for HER2-amplified, treatment-refractory metastatic colorectal cancer.', 'The appropriate treatment for HER2Neu amplified refractory advanced colorectal cancer patients is a combination of tucatinib and trastuzumab. This regimen has shown clinically meaningful anti-tumor activity and is well-tolerated, making it a significant new option for patients whose cancer has not responded to chemotherapy', 'Cetuximab plus bevacizumab is an effective treatment for HER2Neu amplified refractory advanced colorectal cancer patients.', 'The new treatment option for refractory HER2-positive metastatic colorectal cancer is Tucatinib plus trastuzumab. It is a US Food and Drug Administration-approved anti-HER2 regimen for metastatic colorectal cancer.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/33005299",
"http://www.ncbi.nlm.nih.gov/pubmed/35228040",
"http://www.ncbi.nlm.nih.gov/pubmed/36550683",
"http://www.ncbi.nlm.nih.gov/pubmed/35238866",
"http://www.ncbi.nlm.nih.gov/pubmed/33961795",
"http://www.ncbi.nlm.nih.gov/pubmed/35649212",
"http://www.ncbi.nlm.nih.gov/pubmed/32988996",
"http://www.ncbi.nlm.nih.gov/pubmed/32229076",
"http://www.ncbi.nlm.nih.gov/pubmed/29387480",
"http://www.ncbi.nlm.nih.gov/pubmed/29330210",
"http://www.ncbi.nlm.nih.gov/pubmed/33194604",
"http://www.ncbi.nlm.nih.gov/pubmed/34214965",
"http://www.ncbi.nlm.nih.gov/pubmed/37142372",
"http://www.ncbi.nlm.nih.gov/pubmed/37284365",
"http://www.ncbi.nlm.nih.gov/pubmed/35941028",
"http://www.ncbi.nlm.nih.gov/pubmed/30100092",
"http://www.ncbi.nlm.nih.gov/pubmed/33203645",
"http://www.ncbi.nlm.nih.gov/pubmed/30857956",
"http://www.ncbi.nlm.nih.gov/pubmed/27332557",
"http://www.ncbi.nlm.nih.gov/pubmed/27108243",
"http://www.ncbi.nlm.nih.gov/pubmed/30952821",
"http://www.ncbi.nlm.nih.gov/pubmed/30513002",
"http://www.ncbi.nlm.nih.gov/pubmed/30294606"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37142372",
"endSection": "abstract",
"offsetInBeginSection": 3128,
"offsetInEndSection": 3463,
"text": "Tucatinib plus trastuzumab had clinically meaningful anti-tumour activity and favourable tolerability. This treatment is the first US Food and Drug Administration-approved anti-HER2 regimen for metastatic colorectal cancer and is an important new treatment option for chemotherapy-refractory HER2-positive metastatic colorectal cancer."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33961795",
"endSection": "abstract",
"offsetInBeginSection": 2339,
"offsetInEndSection": 2741,
"text": "Five patients (6%) had adjudicated interstitial lung disease or pneumonitis (two grade 2; one grade 3; two grade 5, the only treatment-related deaths).INTERPRETATION: Trastuzumab deruxtecan showed promising and durable activity in HER2-positive metastatic colorectal cancer refractory to standard treatment, with a safety profile consistent with that reported in previous trastuzumab deruxtecan trials."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36550683",
"endSection": "abstract",
"offsetInBeginSection": 1529,
"offsetInEndSection": 1880,
"text": "Alterations in the mitogen-activated protein kinase pathway, HER2 gene, phosphoinositide 3-kinase/AKT pathway, and cell cycle control genes were potential drivers of trastuzumab resistance in mCRC.CONCLUSION: Trastuzumab combined with chemotherapy is a potentially effective and well-tolerated therapeutic regimen in mCRC with a high HER2 copy number."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37142372",
"endSection": "abstract",
"offsetInBeginSection": 3049,
"offsetInEndSection": 3230,
"text": "All deaths in treated patients were due to disease progression.INTERPRETATION: Tucatinib plus trastuzumab had clinically meaningful anti-tumour activity and favourable tolerability."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35649212",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 645,
"text": "PURPOSE: We compared overall survival (OS) in patients with human epidermal growth factor receptor 2 (HER2)-amplified, treatment-refractory metastatic colorectal cancer (mCRC) receiving pertuzumab plus trastuzumab (PER-HER) in the phase IIa MyPathway multibasket study (ClinicalTrials.gov identifier: NCT02091141) with OS in those receiving routine clinical care in an electronic health record-derived external control arm.METHODS: A noninterventional study was conducted using patient-level data from MyPathway participants receiving PER-HER and real-world patients with HER2-amplified treatment-refractory mCRC receiving routine clinical care."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33961795",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 153,
"text": "Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33194604",
"endSection": "abstract",
"offsetInBeginSection": 615,
"offsetInEndSection": 790,
"text": "For patients with HER2-positive mCRC, who have developed resistance to trastuzumab and lapatinib, pyrotinib is a promising new candidate, which can be used as salvage therapy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30857956",
"endSection": "abstract",
"offsetInBeginSection": 2230,
"offsetInEndSection": 2436,
"text": "no treatment-related deaths.INTERPRETATION: Dual HER2-targeted therapy with pertuzumab plus trastuzumab is well tolerated and could represent a therapeutic opportunity for patients with heavily pretreated, "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33961795",
"endSection": "abstract",
"offsetInBeginSection": 1615,
"offsetInEndSection": 1850,
"text": "patients who received one or more doses of trastuzumab deruxtecan. This ongoing trial is registered with ClinicalTrials.gov, number NCT03384940.FINDINGS: Between Feb 23, 2018, and July 3, 2019, 78 patients were enrolled in the study (5"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27108243",
"endSection": "abstract",
"offsetInBeginSection": 2362,
"offsetInEndSection": 2517,
"text": "ated serious adverse events.INTERPRETATION: The combination of trastuzumab and lapatinib is active and well tolerated in treatment-refractory patients with"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35941028",
"endSection": "abstract",
"offsetInBeginSection": 1342,
"offsetInEndSection": 1652,
"text": "Five (31.3%) patients reported grade 3 TEAEs, and no death was reported.CONCLUSIONS: Trastuzumab in combination with pyrotinib demonstrated encouraging antitumor activity that translated to prolonged survival benefit in HER2 positive refractory or mCRC patients who are RAS wild-type with acceptable tolerance."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37142372",
"endSection": "abstract",
"offsetInBeginSection": 74,
"offsetInEndSection": 555,
"text": "We assessed the activity of tucatinib plus trastuzumab in patients with chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer.METHODS: MOUNTAINEER is a global, open-label, phase 2 study that enrolled patients aged 18 years and older with chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer at 34 sites (clinics and hospitals) in five countries (Belgium, France, Italy, Spain, and the USA)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37142372",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 73,
"text": "BACKGROUND: HER2 is an actionable target in metastatic colorectal cancer."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37142372",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 186,
"text": "Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37284365",
"endSection": "abstract",
"offsetInBeginSection": 530,
"offsetInEndSection": 590,
"text": "She had an excellent response to fam-trastuzumab deruxtecan."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30952821",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 170,
"text": "BACKGROUND: HER2 amplification is detected in 3% of patients with colorectal cancer (CRC), making tumors in the metastatic setting vulnerable to double pharmacological HE"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30100092",
"endSection": "abstract",
"offsetInBeginSection": 843,
"offsetInEndSection": 1046,
"text": "To date, recently published and presented early phase data provide promising evidence suggesting anti-HER2 therapy may have a potentially beneficial role in the treatment of HER2-positive metastatic CRC."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33194604",
"endSection": "abstract",
"offsetInBeginSection": 151,
"offsetInEndSection": 347,
"text": "Pyrotinib, a novel irreversible HER2/epidermal growth factor receptor (EGFR) dual tyrosine kinase inhibitor, can efficiently inhibit the proliferation of HER2-positive cancer cells in many tumors."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30513002",
"endSection": "abstract",
"offsetInBeginSection": 953,
"offsetInEndSection": 1234,
"text": "AS wild-type, anti-EGFR resistant tumors). Dual HER2 blockade with monoclonal antibodies (mAbs) (trastuzumab and pertuzumab) or the combination of mAbs with tyrosine kinase inhibitors (trastuzumab and lapatinib) induces durable tumor responses in about one-third of HER2-positive C"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35228040",
"endSection": "abstract",
"offsetInBeginSection": 442,
"offsetInEndSection": 624,
"text": "Furthermore, several studies such as HERACLES-A, MyPathway and the DESTINY-CRC01 trials have shown significant clinical benefit of HER2 blockade in patients with HER2 amplified mCRC."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30294606",
"endSection": "abstract",
"offsetInBeginSection": 431,
"offsetInEndSection": 699,
"text": "The HERACLES trial at four Italian academic cancer centers has confirmed the effectiveness of dual blockage of HER2 with trastuzumab plus lapatinib in patients with heavily pretreated HER2-positive mCRC, refractory to the anti-EGFR antibodies cetuximab or panitumumab."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32988996",
"endSection": "abstract",
"offsetInBeginSection": 230,
"offsetInEndSection": 531,
"text": "The aim of HERACLES-B trial is to assess the efficacy of the combination of pertuzumab and trastuzumab-emtansine (T-DM1) in this setting.METHODS: HERACLES-B was a single-arm, phase II trial, in patients with histologically confirmed RAS/BRAF wild-type and HER2+ mCRC refractory to standard treatments."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30857956",
"endSection": "abstract",
"offsetInBeginSection": 2219,
"offsetInEndSection": 2519,
"text": "There were no treatment-related deaths.INTERPRETATION: Dual HER2-targeted therapy with pertuzumab plus trastuzumab is well tolerated and could represent a therapeutic opportunity for patients with heavily pretreated, HER2-amplified metastatic colorectal cancer.FUNDING: F Hoffmann-La Roche/Genentech."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29330210",
"endSection": "abstract",
"offsetInBeginSection": 453,
"offsetInEndSection": 772,
"text": "Presented are three cases of HER2 amplified colorectal cancer that developed acquired refractoriness to trastuzumab pertuzumab with subsequent clinical benefit to lapatinib plus trastuzumab, highlighting the potential for HER2 tyrosine kinase inhibition plus trastuzumab in overcoming trastuzumab/pertuzumab resistance."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33203645",
"endSection": "abstract",
"offsetInBeginSection": 14,
"offsetInEndSection": 95,
"text": "tastatic colorectal cancer (mCRC), HER2 (ERBB2) gene amplification is implicated "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27332557",
"endSection": "abstract",
"offsetInBeginSection": 1172,
"offsetInEndSection": 1442,
"text": "tance to anti-EGFR MABs. HER2/ERBB2 amplification is a further driver of resistance to anti-EGFR MABs in mCRC. The phase II study of HER2 Amplification for Colo-Rectal Cancer Enhanced Stratification (HERACLES) discovers that a dual HER2-targeted therapy may be an option"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33005299",
"endSection": "abstract",
"offsetInBeginSection": 221,
"offsetInEndSection": 399,
"text": "nt failure. Compared to dual anti-HER2 treatments, which have been shown to be effective in HER2-positive metastatic CRC patients, single-agent anti-HER2 therapy is rarely used t"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33194604",
"endSection": "abstract",
"offsetInBeginSection": 348,
"offsetInEndSection": 790,
"text": "We report a case of a 40-year-old woman with both HER2- and EGFR-amplified metastatic colon cancer, who developed refractory disease resistant to multiline therapies (including trastuzumab with lapatinib) but achieved a remarkable response after pyrotinib treatment. For patients with HER2-positive mCRC, who have developed resistance to trastuzumab and lapatinib, pyrotinib is a promising new candidate, which can be used as salvage therapy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35228040",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 624,
"text": "Despite recent advances in the treatment of metastatic colorectal cancer (mCRC), 5 years survival rates remain low. Chemotherapy remains as the mainstay of treatment with only few available targeted therapies. Human epidermal growth factor receptor 2 (HER2) amplification occurs in approximately 5% of metastatic colorectal cancer and it has been studied as a mechanism of resistance for anti-epidermal growth factor receptor (EGFR) therapy. Furthermore, several studies such as HERACLES-A, MyPathway and the DESTINY-CRC01 trials have shown significant clinical benefit of HER2 blockade in patients with HER2 amplified mCRC."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35238866",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 745,
"text": "Importance: Amplification of ERBB2 (formerly referred to as HER2) is present in nearly 3% of patients with metastatic colorectal cancer overall and 5% of patients with KRAS and NRAS wild-type tumors. Despite the availability of several ERBB2-targeted therapeutic options for patients with ERBB2-positive breast and gastric/gastroesophageal tumors, to date, there are currently no approved therapies for patients with ERBB2-positive metastatic colorectal cancer, although ERBB2-targeted therapies are recommended in National Comprehensive Cancer Network guidelines. Recent evidence indicates that anti-ERBB2 therapeutic strategies are active in patients with ERBB2-positive metastatic colorectal cancer and could potentially represent a new stand"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29387480",
"endSection": "abstract",
"offsetInBeginSection": 298,
"offsetInEndSection": 505,
"text": "cer (mCRC). Both HER2 Amplification for Colorectal Cancer Enhanced Stratification (HERACLES) cohort A and My Pathway clinical trials provided clinical evidence that anti-HER2 therapies could be active in the"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34214965",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 188,
"text": "Dual HER2-targeted therapy has been associated with clinical responses and prolonged progression-free survival and overall survival in RAS-wild type HER2-amplified colorectal cancer (CRC)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32229076",
"endSection": "abstract",
"offsetInBeginSection": 538,
"offsetInEndSection": 681,
"text": "Dual HER2 inhibition with trastuzumab plus lapatinib or pertuzumab has shown promising preliminary anti-tumoral efficacy in RAS wild-type mCRC."
}
] | 13
|
BioASQ-training13b
| null | null |
65f77a71c4010b4d7800003b
| 5,269
|
factoid
|
What type of drug is administered to the mother for the prevention of lung immaturity when a preterm delivery is anticipated?
|
['Corticosteroids']
|
[
"Corticosteroids",
"Corticosteroid hormones",
"Glucocorticoids",
"Mineralocorticoids",
"Adrenal corticosteroids",
"Corticoids"
] |
['Corticosteroids are the drug administered to the mother for the prevention of lung immaturity when a preterm delivery is anticipated.', 'Corticosteroids administered to the mother accelerate development of immature lung in premature babies intra utero.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/33423644",
"http://www.ncbi.nlm.nih.gov/pubmed/35943347",
"http://www.ncbi.nlm.nih.gov/pubmed/33368142"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33423644",
"endSection": "abstract",
"offsetInBeginSection": 168,
"offsetInEndSection": 388,
"text": "The administration of antenatal corticosteroids, in cases of imminent preterm delivery, can enhance fetal lung maturation and reduce the incidence of respiratory distress syndrome, leading to improved neonatal outcomes. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33423644",
"endSection": "abstract",
"offsetInBeginSection": 615,
"offsetInEndSection": 692,
"text": "single course of antenatal corticosteroids from 24 up to 34 gestational weeks"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35943347",
"endSection": "abstract",
"offsetInBeginSection": 35,
"offsetInEndSection": 133,
"text": "use of antenatal corticosteroids to prevent respiratory distress syndrome (RDS) in preterm infants"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33368142",
"endSection": "abstract",
"offsetInBeginSection": 225,
"offsetInEndSection": 386,
"text": "beneficial effect of antenatal corticosteroids on fetal lung maturation and widespread recommendations to use this treatment in women at risk of preterm delivery"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33368142",
"endSection": "abstract",
"offsetInBeginSection": 804,
"offsetInEndSection": 904,
"text": "course of corticosteroids to women prior to anticipated preterm birth (before 37 weeks of pregnancy)"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33368142",
"endSection": "abstract",
"offsetInBeginSection": 5025,
"offsetInEndSection": 5146,
"text": "use of a single course of antenatal corticosteroids to accelerate fetal lung maturation in women at risk of preterm birth"
}
] | 13
|
BioASQ-training13b
| null | null |
660bb7f9fdcbea915f000029
| 5,283
|
factoid
|
What is the most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients?
|
['1650 mg/m2', '1650 m(2)', '825 mg/m(2) twice-daily']
|
[
"1650 mg/m2",
"1650 m(2)",
"825 mg/m(2) twice-daily",
"1650 mg per square meter",
"825 mg per square meter twice-daily"
] |
['The most appropriate dose of capecitabine for concurrent treatment with radiotherapy in neoadjuvant therapy of locally advanced rectal cancer patients is generally considered to be 1650 mg/m² per day, as this dosage has been used effectively in clinical trials and aligns with current guidelines.', 'capecitabine was administered daily at a dose of 1650 mg/m(2) during the entire course of radiation therapy.', 'The optimal dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer has been studied, and various doses have been used in clinical trials. However, there is no definitive consensus on the ideal dose due to differences in study designs, patient populations, and treatment regimens. In some studies, capecitabine was administered at a dose of 800 mg/m² orally twice daily during radiotherapy, while others have used doses ranging from 625 to 1,250 mg/m² per day. The choice of dose should be based on the balance between efficacy and toxicity, as well as individual patient factors such as performance status, comorbidities, and tolerance to treatment. Clinical judgment and guidelines from expert panels can provide guidance in selecting an appropriate capecitabine dose for each patient undergoing neoadjuvant chemoradiotherapy for rectal cancer.', 'The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is typically around 825 mg/m² twice daily. This dose has been commonly used in various studies in combination with radiotherapy and other chemotherapy agents like oxaliplatin or irinotecan. The specific dosing regimen may vary slightly depending on the study protocol, but the dose range of capecitabine used in these treatments is generally consistent around 825 mg/m² twice daily.', 'In the study mentioned, the most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients was 1650 mg/m(2) administered daily during the entire course of radiation therapy.', 'The most appropriate dose of capecitabine when used concurrently with radiotherapy for neoadjuvant therapy in patients with locally advanced rectal cancer is 1650 mg/m² daily throughout the entire course of radiation therapy', 'The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 1650 mg/m(2).', 'The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 825 mg/m2 twice-daily. This dose is recommended in multiple studies and has been shown to be effective and well-tolerated in combination with radiotherapy and other chemotherapy agents.', 'The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 1,600 mg/m2.', 'Based on the study, the most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer is 1650 mg/m2 daily during the entire course of radiation therapy. This dosage was used in a prospective Phase II trial and was found to have low toxicity while achieving encouraging rates of tumor downstaging and sphincter preservation. However, further studies may be needed to confirm these findings and establish this dose as the standard.', 'The most appropriate dose of capecitabine for concurrent treatment with radiotherapy in neoadjuvant therapy of locally advanced rectal cancer patients is 1650 mg/m² daily. This dosage is administered throughout the entire course of radiation therapy.', 'The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 1650 mg/m(2) daily.', 'The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 1650 mg/m(2) administered daily during the entire course of radiation therapy.', 'The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients has been studied in clinical trials. A phase I trial evaluated the safety and efficacy of capecitabine given twice daily during pelvic irradiation in patients with resectable rectal cancer. The maximum tolerated dose (MTD) was reached at a dose level of 2000 mg m(-2) day(-1), but dose escalation was ceased at 1800 mg m(-2) day(-1) after reaching MTD. A phase II trial evaluated the feasibility and efficacy of concurrent radiotherapy and capecitabine in rectal cancer patients. The recommended dose for further evaluation was established at capecitabine 825 mg/m(2) bid, administered without break during a conventional radiotherapy period of about ', 'The most appropriate dose of capecitabine for concurrent use with radiation in neoadjuvant therapy for locally advanced rectal cancer is 1650 mg/m(2) daily.', 'Capecitabine was administered daily at a dose of 1650 mg/m(2) during the entire course of radiation therapy.', 'The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients has not been definitively established. The standard dose of capecitabine used in clinical practice is 1650 mg/m(2) per day, which is the dose used in the landmark phase III trial that demonstrated the efficacy and safety of capecitabine in this setting. However, some studies have suggested that a lower dose of capecitabine (e.g., 1250 mg/m(2) per day) may be equally effective and less toxic. The choice of dose should be individualized based on patient factors, such as age, performance status, and comorbidities, as well as the radiation dose and fractionation scheme used.', 'The most appropriate dose of capecitabine for concurrent treatment with radiotherapy in neoadjuvant therapy of locally advanced rectal cancer patients is 1650 mg/m(2) daily.', 'capecitabine was administered daily at a dose of 1650 mg/m(2) during the entire course of radiation therapy', 'The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 1650 mg/m(2) daily for 14 days.', 'Based on the information provided, capecitabine was administered daily at a dose of 1650 mg/m(2) during the entire course of radiation therapy for neoadjuvant treatment of locally advanced rectal cancer patients.', 'The appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients has not been definitively established. However, a phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer found that the maximum tolerated dose (MTD) of capecitabine was 625 mg/m(2) bid, given concurrently with weekly irinotecan and pelvic radiotherapy. The MTD was determined based on the incidence of dose-limiting toxicities, primarily diarrhea. However, larger phase II trials are needed to confirm the efficacy and safety of this dose and schedule.', 'Based on the information provided, the most commonly used dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 825 mg/m2 twice daily, administered continuously or on days 1-14 and 22-35 of radiotherapy. Some key findings:\n\n- Capecitabine 825 mg/m2 twice daily for 7 days/week was found to be an effective and tolerable continuous dosing regimen. \n- Capecitabine 825 mg/m2 twice daily on days 1-14 and 22-35 was used in combination with oxaliplatin and radiotherapy in one study.\n- Several studies used capecitabine at 825 mg/m2 twice daily concomitantly with radiotherapy.\n\nWhile some variations in dosing schedules exist, capecitabine 825 mg/m2 twice daily, either continuously or on select days concurrent with radiotherapy, appears to be a standard neoadjuvant regimen for locally advanced rectal cancer based on the provided abstracts.', 'The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 1650 mg/m2 daily during the entire course of radiation therapy.', '1650 mg/m(2) of capecitabine is the most appropriate dose for concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients.', 'Capecitabine was administered orally at a dose of 825 mg/m(2) twice-daily concomitantly every day during pelvic irradiation.', 'The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 1650 mg/m² per day, administered orally during the entire course of radiation therapy. This dose has been shown to improve pathological complete response rates and decrease local recurrence rates in clinical trials. However, the specific dose and duration of capecitabine and radiotherapy may vary based on individual patient factors and the discretion of the treating healthcare provider. It is always recommended to consult with a healthcare professional for personalized treatment recommendations.', 'The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 825 mg/m^2^ bid, administered without break during a conventional radiotherapy period of about 6 weeks. This dosage was determined based on the results of a phase I trial that established the feasibility of concurrent radiotherapy and capecitabine and defined the maximum-tolerated dose (MTD) in patients with rectal cancer. The recommended dose for further evaluation is capecitabine 825 mg/m^2^ bid, which showed acceptable toxicity and promising response rates in preoperative chemoradiation based on RT at 45 Gy in 25 daily fractions over 5 weeks with continuous daily oral capecitabine at 650 mg m^2^ b.i.d. days 1-35 and weekly IV irinotecan at', 'Preoperative concomitant radiation therapy with oral capecitabine for locally advanced rectal cancer is feasible and safe. It is well tolerated. The most suitable dose of capecitabine is 825 mg/m2 twice daily every day during the entire course of radiation therapy.', 'The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 825 mg/m² delivered orally twice daily for the duration of radiotherapy.', 'The most appropriate dose of capecitabine for concurrent treatment with radiotherapy in neoadjuvant therapy of locally advanced rectal cancer patients is 1650 mg/m(2) daily during the entire course of radiation therapy.', '825 mg/m2, twice daily, administered continuously, during radiotherapy, and until 1 week after the last fraction of radiotherapy.', '1650 mg/m(2) daily during the entire course of radiation therapy.', 'The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 1650 mg/m² administered daily throughout the course of radiation therapy.', '1650 mg/m(2)', '1650 mg/m(2) is the most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients.', 'The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 1250 mg/m2 per day for 2 weeks followed by 5-fluorouracil (5-FU) 400 mg/m2 per day for 5 days, with a total of 6 cycles.', '825 mg/m^2^ twice daily on days 1-38 of chemoradiotherapy for neoadjuvant treatment of locally advanced rectal cancer patients.', 'The most suitable dose of capecitabine for concurrent use with radiotherapy in neoadjuvant therapy for locally advanced rectal cancer is either 825 mg/m(2) twice daily or 900 mg/m(2) twice daily, depending on the specific trial and patient tolerance.', '825 mg/m² twice daily during radiotherapy and at weekends is considered the most appropriate dose of capecitabine for concurrent treatment in neoadjuvant therapy of locally advanced rectal cancer patients.', 'The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 825 mg/m2 twice daily, given on the days of radiotherapy, with a maximum daily dose of 1650 mg/m2.', 'The recommended dose for phase II evaluation is capecitabine 825 mg/m(2) bid, administered without break during a conventional radiotherapy period of about 6 weeks.', 'The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 825 mg.', '\nAnswer: 825 mg/m² twice daily on days 1-14 of radiotherapy, as recommended by the National Comprehensive Cancer Network (NCCN) guidelines for colorectal cancer. Alternatively, daily 1600 mg/m² (2 cycles, separated by a 7-day rest) as determined in a phase I study. Consult with a healthcare provider for personalized treatment recommendations.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/17987042",
"http://www.ncbi.nlm.nih.gov/pubmed/22855196",
"http://www.ncbi.nlm.nih.gov/pubmed/25102935",
"http://www.ncbi.nlm.nih.gov/pubmed/19508705",
"http://www.ncbi.nlm.nih.gov/pubmed/17385825",
"http://www.ncbi.nlm.nih.gov/pubmed/12243814",
"http://www.ncbi.nlm.nih.gov/pubmed/17042060",
"http://www.ncbi.nlm.nih.gov/pubmed/27757395",
"http://www.ncbi.nlm.nih.gov/pubmed/19690550",
"http://www.ncbi.nlm.nih.gov/pubmed/27891147",
"http://www.ncbi.nlm.nih.gov/pubmed/37547762",
"http://www.ncbi.nlm.nih.gov/pubmed/22621694",
"http://www.ncbi.nlm.nih.gov/pubmed/20920276",
"http://www.ncbi.nlm.nih.gov/pubmed/20194850",
"http://www.ncbi.nlm.nih.gov/pubmed/16282246",
"http://www.ncbi.nlm.nih.gov/pubmed/36801007",
"http://www.ncbi.nlm.nih.gov/pubmed/35633559",
"http://www.ncbi.nlm.nih.gov/pubmed/16979839",
"http://www.ncbi.nlm.nih.gov/pubmed/15913913",
"http://www.ncbi.nlm.nih.gov/pubmed/17278899",
"http://www.ncbi.nlm.nih.gov/pubmed/19016023",
"http://www.ncbi.nlm.nih.gov/pubmed/37533948",
"http://www.ncbi.nlm.nih.gov/pubmed/19464823",
"http://www.ncbi.nlm.nih.gov/pubmed/18292610"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/15913913",
"endSection": "abstract",
"offsetInBeginSection": 587,
"offsetInEndSection": 694,
"text": "capecitabine was administered daily at a dose of 1650 mg/m(2) during the entire course of radiation therapy"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36801007",
"endSection": "abstract",
"offsetInBeginSection": 714,
"offsetInEndSection": 875,
"text": "All patients received neoadjuvant chemoradiotherapy and 45 Gy external beam radiotherapy in 25 fractions over 5 weeks with concurrent oral capecitabine (825 mg/m"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/20194850",
"endSection": "abstract",
"offsetInBeginSection": 76,
"offsetInEndSection": 374,
"text": " T3-4 M0 rectal cancer. In this situation, we compared neoadjuvant radiotherapy plus capecitabine with dose-intensified radiotherapy plus capecitabine and oxaliplatin.PATIENTS AND METHODS: We randomly assigned patients to receive 5 weeks of treatment with radiotherapy 45 Gy/25 fractions with concu"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/20920276",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 508,
"text": "BACKGROUND: This study evaluated the effectiveness and safety of preoperative chemoradiotherapy with capecitabine in patients with locally advanced resectable rectal cancer. This report summarizes the results of the phase II study together with long-term (5-year) follow-up.METHODS: Between June 2004 and January 2005, 57 patients with operable, clinical stage II-III adenocarcinoma of the rectum entered the study. Radiation dose was 45 Gy delivered as 25 fractions of 1.8 Gy. Concurrent chemotherapy with o"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/19464823",
"endSection": "abstract",
"offsetInBeginSection": 287,
"offsetInEndSection": 522,
"text": "(n = 20) or T3N0 (n = 5) rectal cancer received neoadjuvant therapy with radiotherapy (50.4 Gy in 28 fractions over 5.5 weeks), bevacizumab every 2 weeks (3 doses of 5 mg/kg), and capecitabine (900 mg/m(2) orally twice daily only on da"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37547762",
"endSection": "abstract",
"offsetInBeginSection": 801,
"offsetInEndSection": 925,
"text": "Concurrent chronomodulated capecitabine (Brunch regimen) 1650 mg/m2/daily chemotherapy treatment was applied in both groups."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37533948",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 572,
"text": "Purpose: To analyse the safety and efficacy of neoadjuvant chemoradiation (NACRT) with dose-escalated image-guided intensity modulated radiation therapy (IG-IMRT) in locally advanced (T3/4; T1-4N1-2) rectal cancers (LARCs).Materials and methods: Twenty patients with the diagnosis of LARC were recruited in this prospective interventional single-arm study treated by IG-IMRT with 45 Gray (Gy) in 25 fractions to elective nodal volumes and 55 Gy in 25 fractions to the gross primary and nodal disease with concurrent capecitabine 825 mg/m2 twice daily on radiotherapy days."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/17278899",
"endSection": "abstract",
"offsetInBeginSection": 807,
"offsetInEndSection": 944,
"text": "atients received radiation therapy (total dose 5000 cGy) and concomitant capecitabine (850 mg/m2) twice daily for 14 days every 3 weeks.R"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/12243814",
"endSection": "abstract",
"offsetInBeginSection": 592,
"offsetInEndSection": 807,
"text": "hemotherapy was administered concurrent with radiotherapy and consisted of 2 cycles of 14-day oral capecitabine (1650 mg/m(2)/day) and leucovorin (20 mg/m(2)/day), each of which was followed by a 7-day rest period. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/19508705",
"endSection": "abstract",
"offsetInBeginSection": 756,
"offsetInEndSection": 982,
"text": " patients received preoperative concurrent chemoradiation (45 Gy/25 fractions over 5 weeks with oral capecitabine 825 mg/m2 twice daily on radiotherapy days), followed after 4-6 weeks by total mesorectal excision technique.RES"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25102935",
"endSection": "abstract",
"offsetInBeginSection": 348,
"offsetInEndSection": 571,
"text": "r were included. Patients received capecitabine (1,650 mg/m(2) per day; 60% dose at 8:00 AM and 40% dose at 12:00 noon) administered during pelvic radiation (total 50.4 Gy in 28 fractions, 1.8 Gy daily dose between 2:00 p.m"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22621694",
"endSection": "abstract",
"offsetInBeginSection": 806,
"offsetInEndSection": 1067,
"text": "Phase I and II clinical trials showed that a regimen consisting of capecitabine 825mg/m(2) twice daily for 7 days/week continuous oral administration in combination with RT is an active and well tolerated regimen, thereby being the preferred concurrent regimen."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/19508705",
"endSection": "abstract",
"offsetInBeginSection": 653,
"offsetInEndSection": 1161,
"text": "ith low lying (4-7 cm from anal verge) locally advanced rectal cancer, of which 33 were resectable. All patients received preoperative concurrent chemoradiation (45 Gy/25 fractions over 5 weeks with oral capecitabine 825 mg/m2 twice daily on radiotherapy days), followed after 4-6 weeks by total mesorectal excision technique.RESULTS: Preoperative chemoradiation resulted in a complete pathologic response in 4 patients (9.3%; 95% CI 3-23.1) and an overall downstaging in 32 patients (74.4%; 95% CI 58.5-85)."
}
] | 13
|
BioASQ-training13b
| null | null |
66099c01fdcbea915f000023
| 5,289
|
factoid
|
What part of the cell is mitophagy associated with?
|
['mitochondria']
|
[
"mitochondria",
"mitochondrion",
"powerhouse of the cell",
"cellular power plant",
"mitochondrial organelle"
] |
['Mitophagy is a specific type of autophagy that involves the selective elimination of damaged or dysfunctional mitochondria via autophagosomes and lysosomes, a process that is critical for mitochondrial quality control.', 'Mitophagy is associated with the mitochondria, which are critical cellular energy resources and central to the life of the neuron. Mitophagy selectively clears damaged or dysfunctional mitochondria through autophagic machinery to maintain mitochondrial quality control and homeostasis.', 'Mitophagy is a selective form of autophagy, where damaged or dysfunctional mitochondria are targeted and degraded by the autophagosome.', 'Mitophagy is associated with mitochondria.', 'Mitophagy is associated with mitochondria, involving their encapsulation into autophagosomes for delivery to lysosomes for degradation.', 'Mitophagy is associated with "mitochondria".', ' Mitophory are primarily associated with the organelle membrane of eukaryotes, where they play a crucial role in the degradation of misfolded proteins and the maintenance of cellular integrity. ', 'Mitophagy is associated with mitochondria, the part of the cell responsible for energy production. It specifically targets damaged or dysfunctional mitochondria for degradation to maintain cellular health', 'Mitophagy is a selective autophagy of mitochondria, can efficiently degrade, remove and recycle the malfunctioning or damaged mitochondria, and is crucial for quality control.', 'Mitophagy, or selective autophagy of mitochondria, is an essential pathway to preserve mitochondrial homeostasis by clearing up damaged mitochondria', 'Mitophagy is associated with the lysosomes, which are responsible for the degradation of damaged or superfluous mitochondria.', 'Mitophagy is associated with the mitochondria, which are the powerhouses of the cell.', 'Mitophagy is a process by which cells selectively remove and burn their own mitochondria. It is a conserved mechanism that all eukaryotes use to remove damaged mitochondria.', 'Mitophagy is associated with the clearance of damaged mitochondria via lysosomes.', 'Mitophagy is associated with mitochondria. It is the selective autophagy of damaged or dysfunctional mitochondria to maintain mitochondrial homeostasis and quality control.', 'Mitophagy is a selective form of autophagy that specifically targets damaged or dysfunctional mitochondria for degradation and recycling. It is a quality control mechanism associated with maintaining a healthy mitochondrial pool within the cell.', 'Mitophagy is associated with mitochondria, which are organelles within eukaryotic cells. Mitophagy is a process by which cells selectively remove and recycle damaged or dysfunctional mitochondria through the autophagy-lysosome pathway. This helps to maintain mitochondrial quality control and homeostasis.', 'Mitophagy is an essential physiological process that eliminates damaged mitochondria via lysosomes.', 'Mitophagy is associated with the outer mitochondrial membrane 20 (Tomm20), a mitochondrial translocase that, when ubiquitinated, promotes mitophagy.', 'Mitophagy is an essential pathway responsible for preserving mitochondrial homeostasis through the clearance of damaged mitochondria.', 'Mitophagy refers to selective autophagy of mitochondria, which plays a crucial role in preserving mitochondrial homeostasis by clearing up damaged or dysfunctional mitochondria.', 'Mitophagy is associated with the mitochondria, targeting them for degradation.', 'Mitophagy is associated with the elimination of damaged mitochondria and maintenance of mitochondrial homeostasis. It is a process that occurs within the cell, specifically targeting and removing dysfunctional or damaged mitochondria.', 'Mitophagy is associated with the selective autophagic clearance of flawed or damaged mitochondria within the cell, ensuring the maintenance of a healthy mitochondrial pool and cellular homeostasis.', 'Mitochondrial autophagy is associated with the removal of defective mitochondria from the cell by internalisation into autophagosomes which fuse with lysosomes.', 'Mitophagy is associated with mitochondria, the part of the cell responsible for energy production. It specifically targets damaged or dysfunctional mitochondria, clearing them out to maintain cellular health and efficiency.', 'Mitophagy is associated with the process of selectively clearing damaged or dysfunctional mitochondria through autophagic machinery to maintain mitochondrial quality control and homeostasis within the cell.', 'Mitophagy is associated with lysosomes, where defective mitochondria are internalized into autophagosomes that fuse with lysosomes for degradation.', "Mitophagy is a process associated with the elimination of damaged or dysfunctional mitochondria through autophagic machinery, which is a part of the cell's quality control and homeostasis maintenance mechanism.", 'Mitophagy is associated with mitochondria, which are organelles within eukaryotic cells. Mitophagy is a process by which cells selectively remove and recycle damaged or dysfunctional mitochondria through the autophagy-lysosome pathway. This process helps to maintain mitochondrial quality control and homeostasis.', 'Mitophagy is associated with the mitochondria.', 'Mitophagy is associated with mitochondria, specifically targeting damaged or dysfunctional mitochondria for degradation to maintain cellular health.', 'Mitophagy is associated with the lysosomes, which are responsible for the degradation of damaged or dysfunctional mitochondria.', 'Mitophagy is associated with mitochondria through autophagic machinery to maintain mitochondrial quality control and homeostasis.', 'Mitophagy is associated with lysosomes.', 'Mitophagy is associated with the outer membrane of mitochondria (OMM).', 'Mitochondrial dysfunction is targeted for degradation in the lysosomes by mitophagy.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/25753537",
"http://www.ncbi.nlm.nih.gov/pubmed/29311991",
"http://www.ncbi.nlm.nih.gov/pubmed/37488884",
"http://www.ncbi.nlm.nih.gov/pubmed/25634658",
"http://www.ncbi.nlm.nih.gov/pubmed/36740450",
"http://www.ncbi.nlm.nih.gov/pubmed/32131138",
"http://www.ncbi.nlm.nih.gov/pubmed/32587855",
"http://www.ncbi.nlm.nih.gov/pubmed/36860818",
"http://www.ncbi.nlm.nih.gov/pubmed/26223426",
"http://www.ncbi.nlm.nih.gov/pubmed/36625039",
"http://www.ncbi.nlm.nih.gov/pubmed/34975548",
"http://www.ncbi.nlm.nih.gov/pubmed/21126205",
"http://www.ncbi.nlm.nih.gov/pubmed/31956306",
"http://www.ncbi.nlm.nih.gov/pubmed/34291135",
"http://www.ncbi.nlm.nih.gov/pubmed/28976890",
"http://www.ncbi.nlm.nih.gov/pubmed/33922020",
"http://www.ncbi.nlm.nih.gov/pubmed/37678420",
"http://www.ncbi.nlm.nih.gov/pubmed/33570005",
"http://www.ncbi.nlm.nih.gov/pubmed/33239048",
"http://www.ncbi.nlm.nih.gov/pubmed/30113005",
"http://www.ncbi.nlm.nih.gov/pubmed/36982862",
"http://www.ncbi.nlm.nih.gov/pubmed/25470007",
"http://www.ncbi.nlm.nih.gov/pubmed/29115402",
"http://www.ncbi.nlm.nih.gov/pubmed/36974405",
"http://www.ncbi.nlm.nih.gov/pubmed/28368777",
"http://www.ncbi.nlm.nih.gov/pubmed/32820310",
"http://www.ncbi.nlm.nih.gov/pubmed/36283334",
"http://www.ncbi.nlm.nih.gov/pubmed/31776996",
"http://www.ncbi.nlm.nih.gov/pubmed/37862201",
"http://www.ncbi.nlm.nih.gov/pubmed/31550441",
"http://www.ncbi.nlm.nih.gov/pubmed/34099564",
"http://www.ncbi.nlm.nih.gov/pubmed/31704095",
"http://www.ncbi.nlm.nih.gov/pubmed/34229552",
"http://www.ncbi.nlm.nih.gov/pubmed/35850516",
"http://www.ncbi.nlm.nih.gov/pubmed/25437922",
"http://www.ncbi.nlm.nih.gov/pubmed/37192628",
"http://www.ncbi.nlm.nih.gov/pubmed/34060004",
"http://www.ncbi.nlm.nih.gov/pubmed/36909283",
"http://www.ncbi.nlm.nih.gov/pubmed/33476770",
"http://www.ncbi.nlm.nih.gov/pubmed/35096821",
"http://www.ncbi.nlm.nih.gov/pubmed/37993864",
"http://www.ncbi.nlm.nih.gov/pubmed/38093134",
"http://www.ncbi.nlm.nih.gov/pubmed/28324490",
"http://www.ncbi.nlm.nih.gov/pubmed/26085571",
"http://www.ncbi.nlm.nih.gov/pubmed/23985961",
"http://www.ncbi.nlm.nih.gov/pubmed/32454052",
"http://www.ncbi.nlm.nih.gov/pubmed/28576471",
"http://www.ncbi.nlm.nih.gov/pubmed/34688664",
"http://www.ncbi.nlm.nih.gov/pubmed/35691026",
"http://www.ncbi.nlm.nih.gov/pubmed/36092697",
"http://www.ncbi.nlm.nih.gov/pubmed/37549565"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37488884",
"endSection": "abstract",
"offsetInBeginSection": 360,
"offsetInEndSection": 510,
"text": "Mitophagy, or selective autophagy of mitochondria, is an essential pathway to preserve mitochondrial homeostasis by clearing up damaged mitochondria. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37549565",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 100,
"text": "Mitophagy is an essential physiological process that eliminates damaged mitochondria via lysosomes. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37862201",
"endSection": "abstract",
"offsetInBeginSection": 95,
"offsetInEndSection": 250,
"text": "Mitophagy selectively clears damaged or dysfunctional mitochondria through autophagic machinery to maintain mitochondrial quality control and homeostasis. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34229552",
"endSection": "abstract",
"offsetInBeginSection": 9,
"offsetInEndSection": 133,
"text": "increasing evidence that mitophagy, a specialized form of autophagy to degrade and clear long-lived or damaged mitochondria,"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26223426",
"endSection": "abstract",
"offsetInBeginSection": 1080,
"offsetInEndSection": 1298,
"text": "(I) turnover of mitochondria via mitophagy (II) turnover of several vesicular structures via macroautophagy or chaperone-mediated autophagy or (III) general lysosome function. This article is part of a special issue on"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36860818",
"endSection": "abstract",
"offsetInBeginSection": 491,
"offsetInEndSection": 671,
"text": "Mitochondrial autophagy (mitophagy) is the process through which defective mitochondria are removed from the cell by internalisation into autophagosomes which fuse with a lysosome."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36092697",
"endSection": "abstract",
"offsetInBeginSection": 129,
"offsetInEndSection": 309,
"text": "Through mitophagy (a selective type of autophagy that promotes mitochondrial proteostasis) cells keep a healthy pool of mitochondria, and prevent oxidative stress and inflammation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34688664",
"endSection": "abstract",
"offsetInBeginSection": 340,
"offsetInEndSection": 429,
"text": "Clearance of bulk mitochondria occurs via a selective form of autophagy termed mitophagy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33922020",
"endSection": "abstract",
"offsetInBeginSection": 378,
"offsetInEndSection": 492,
"text": "Excessive and dysfunctional/damaged mitochondria are degraded by selective autophagic pathways known as mitophagy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32587855",
"endSection": "abstract",
"offsetInBeginSection": 431,
"offsetInEndSection": 604,
"text": "Mitophagy, a selective autophagy of mitochondria, can efficiently degrade, remove and recycle the malfunctioning or damaged mitochondria, and is crucial for quality control."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33570005",
"endSection": "abstract",
"offsetInBeginSection": 243,
"offsetInEndSection": 424,
"text": "Selective autophagic clearance of flawed mitochondria, a process termed mitophagy, is one of the most prominent mechanisms through which cells maintain a healthy mitochondrial pool."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32454052",
"endSection": "abstract",
"offsetInBeginSection": 197,
"offsetInEndSection": 323,
"text": "Selective autophagy of mitochondria, id est mitophagy, is one of the cellular mechanisms controlling mitochondria homeostasis."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36625039",
"endSection": "abstract",
"offsetInBeginSection": 163,
"offsetInEndSection": 282,
"text": "Mitophagy is a mechanism by which cells selectively wrap and degrade damaged mitochondria to maintain cell homeostasis."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28976890",
"endSection": "abstract",
"offsetInBeginSection": 464,
"offsetInEndSection": 568,
"text": "One critical level of mitochondrial quality control is the removal of damaged mitochondria by mitophagy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35850516",
"endSection": "abstract",
"offsetInBeginSection": 615,
"offsetInEndSection": 778,
"text": "Mitophagy and mitochondrial-specific autophagy play an important role in maintenance of neuronal health through the removal of dysfunctional and aged mitochondria."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36740450",
"endSection": "abstract",
"offsetInBeginSection": 1664,
"offsetInEndSection": 1740,
"text": "Colocalization of mitochondria and lysosomes indirectly indicated mitophagy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33476770",
"endSection": "abstract",
"offsetInBeginSection": 348,
"offsetInEndSection": 493,
"text": "As a part of mitochondrial quality control, the aged and damaged mitochondria are removed through a selective mode of autophagy called mitophagy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25470007",
"endSection": "abstract",
"offsetInBeginSection": 706,
"offsetInEndSection": 947,
"text": "This unique sensing property was successfully applied to the ratiometric fluorescence imaging of autolysosome formation in selective mitochondrial autophagy (mitophagy), which highlights the utility of this novel probe in autophagy research."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30113005",
"endSection": "abstract",
"offsetInBeginSection": 283,
"offsetInEndSection": 445,
"text": "ys including autophagy. Mitochondria and mitochondrial autophagy play a vital role in cellular health and failure of these pathways can have a devastating effect "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36974405",
"endSection": "abstract",
"offsetInBeginSection": 144,
"offsetInEndSection": 317,
"text": "Mitophagy is the process by which autophagy causes disruption inside mitochondria and the total removal of damaged or stressed mitochondria, hence enhancing cellular health."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37192628",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 104,
"text": "Mitophagy plays an important role in mitochondrial homeostasis by selective degradation of mitochondria."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36283334",
"endSection": "abstract",
"offsetInBeginSection": 225,
"offsetInEndSection": 390,
"text": "It interacts with the Atg11 protein to initiate mitophagy and with the Atg8 protein to ensure the engulfment of mitochondria into the autophagosomes for elimination."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37993864",
"endSection": "abstract",
"offsetInBeginSection": 1700,
"offsetInEndSection": 1981,
"text": "Rescue experiments using an AMPK pathway inhibitor (compound C) and an autophagy inhibitor (3-methyladenine) revealed that excessive mitophagy was induced through AMPK/ULK1 pathway activation, worsening mitochondrial damage and subsequent cell death in differentiated SH-SY5Y cells"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37678420",
"endSection": "abstract",
"offsetInBeginSection": 1539,
"offsetInEndSection": 1628,
"text": "Mitochondria were reduced, and mitophagy was inhibited in aortic cells of the model group"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37192628",
"endSection": "abstract",
"offsetInBeginSection": 579,
"offsetInEndSection": 798,
"text": "In mitofissin-deficient cells, a part of the mitochondria is recognized by the mitophagy machinery as cargo but cannot be enwrapped by the autophagosome precursor, the phagophore, due to a lack of mitochondrial fission."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37192628",
"endSection": "abstract",
"offsetInBeginSection": 105,
"offsetInEndSection": 260,
"text": "During mitophagy, mitochondria should be fragmented to allow engulfment within autophagosomes, whose capacity is exceeded by the typical mitochondria mass."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/38093134",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 161,
"text": "Mitophagy, a form of selective autophagy, plays an essential role to maintain a population of healthy and functional mitochondria for normal cellular metabolism."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34975548",
"endSection": "abstract",
"offsetInBeginSection": 280,
"offsetInEndSection": 400,
"text": "Damaged or unwanted mitochondria are selectively removed by mitophagy, which is a crucial determinant of cell viability."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29311991",
"endSection": "abstract",
"offsetInBeginSection": 1018,
"offsetInEndSection": 1211,
"text": "Mitochondria are eliminated by mitophagy. This is a macroautophagy pathway consisting in the engulfment of mitochondria into a double-membrane structure called autophagosome before degradation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34099564",
"endSection": "abstract",
"offsetInBeginSection": 419,
"offsetInEndSection": 499,
"text": "mitophagy (a specific form of autophagy that removes dysfunctional mitochondria)"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31704095",
"endSection": "abstract",
"offsetInBeginSection": 1028,
"offsetInEndSection": 1261,
"text": " Mitochondria may represent a proximal target of HO-1/CO action. HO-1 may localize to mitochondria in response to stress, while CO can moderate mitochondrial dysfunction and regulate mitochondrial autophagy (mitophagy) and biogenesis"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31776996",
"endSection": "abstract",
"offsetInBeginSection": 445,
"offsetInEndSection": 536,
"text": "Mitophagy is a process for selective degradation of mitochondria, which is well documented."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33239048",
"endSection": "abstract",
"offsetInBeginSection": 375,
"offsetInEndSection": 511,
"text": "The elimination of dysfunctional mitochondria may function as an effective way employed by mitophagy to keep the immune system in check."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36982862",
"endSection": "abstract",
"offsetInBeginSection": 707,
"offsetInEndSection": 918,
"text": "In contrast, fission segregates damaged mitochondria from intact and healthy counterparts and is followed by selective clearance of the damaged mitochondria via mitochondrial specific autophagy, i.e., mitophagy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32131138",
"endSection": "abstract",
"offsetInBeginSection": 412,
"offsetInEndSection": 573,
"text": "To maintain its quantity and quality, mitochondria undergo multiple processes such as fission, fusion, and mitophagy to eliminate or replace damaged mitochondria"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28368777",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 245,
"text": "Mitophagy is a highly specialized process to remove dysfunctional or superfluous mitochondria through the macroautophagy/autophagy pathway, aimed at protecting cells from the damage of disordered mitochondrial metabolism and apoptosis induction."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25634658",
"endSection": "abstract",
"offsetInBeginSection": 98,
"offsetInEndSection": 195,
"text": "Damaged mitochondria can be degraded by a selective type of autophagy, which is termed mitophagy."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28368777",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 147,
"text": "PINK1 and BECN1 relocalize at mitochondria-associated membranes during mitophagy and promote ER-mitochondria tethering and autophagosome formation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28324490",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 335,
"text": "Aberrant mitochondrial function is associated with many neurological diseases. Mitophagy is a key mechanism for the elimination of damaged mitochondria and maintenance of mitochondrial homeostasis. Induced pluripotent stem (iPS) cell technologies developed over the last decade have allowed us to analyze functions of the human neuron."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28324490",
"endSection": "abstract",
"offsetInBeginSection": 79,
"offsetInEndSection": 335,
"text": "Mitophagy is a key mechanism for the elimination of damaged mitochondria and maintenance of mitochondrial homeostasis. Induced pluripotent stem (iPS) cell technologies developed over the last decade have allowed us to analyze functions of the human neuron."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36909283",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 265,
"text": "Mitochondrial dysfunction is associated with ototoxicity, which is caused by external factors. Mitophagy plays a key role in maintaining mitochondrial homeostasis and function and is regulated by a series of key mitophagy regulatory proteins and signaling pathways."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36909283",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 371,
"text": "Mitochondrial dysfunction is associated with ototoxicity, which is caused by external factors. Mitophagy plays a key role in maintaining mitochondrial homeostasis and function and is regulated by a series of key mitophagy regulatory proteins and signaling pathways. The results of ototoxicity models indicate the importance of this process in the etiology of ototoxicity."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36860818",
"endSection": "abstract",
"offsetInBeginSection": 407,
"offsetInEndSection": 551,
"text": "this paper is on the quality control processes involved in and around mitochondria. Mitochondrial autophagy (mitophagy) is the process through w"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31550441",
"endSection": "abstract",
"offsetInBeginSection": 92,
"offsetInEndSection": 216,
"text": "the autophagic removal of depolarized mitochondria (mitophagy). Parkin-mediated protein ubiquitinations may be counteracted "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21126205",
"endSection": "abstract",
"offsetInBeginSection": 373,
"offsetInEndSection": 499,
"text": "both insufficient and excessive mitophagy have been linked to neurodegeneration. Kinases implicated in regulating mammalian mi"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26085571",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 125,
"text": "Mitophagy is a critical regulator of mitochondrial quality control and is necessary for elimination of dysfunctional mitochon"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34975548",
"endSection": "abstract",
"offsetInBeginSection": 280,
"offsetInEndSection": 621,
"text": "Damaged or unwanted mitochondria are selectively removed by mitophagy, which is a crucial determinant of cell viability. Mitochondria-associated Endoplasmic Reticulum Membranes (MAMs) are the cellular structures that connect the ER and mitochondria and are involved in calcium signaling, lipid transfer, mitochondrial dynamic, and mitophagy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34099564",
"endSection": "abstract",
"offsetInBeginSection": 419,
"offsetInEndSection": 500,
"text": "mitophagy (a specific form of autophagy that removes dysfunctional mitochondria)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35691026",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 125,
"text": "Parkin is an E3 ubiquitin ligase mostly known for its role in regulating the removal of defective mitochondria via mitophagy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34060004",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1049,
"text": "Autophagy is a mechanism responsible for the degradation of cellular components to maintain their homeostasis. However, autophagy is commonly altered and compromised in several diseases, including neurodegenerative disorders. Parkinson's disease (PD) can be considered a multifactorial disease because environmental factors, genetic factors, and aging are involved. Several genes are involved in PD pathology, among which the LRRK2 gene and its mutations, inherited in an autosomal dominant manner, are responsible for most genetic PD cases. The R1441G LRRK2 mutation is, after G2019S, the most important in PD pathogenesis. Our results demonstrate a relationship between the R1441G LRRK2 mutation and a mechanistic dysregulation of autophagy that compromises cell viability. This altered autophagy mechanism is associated with organellar stress including mitochondrial (which induces mitophagy) and endoplasmic reticulum (ER) stress, consistent with the fact that patients with this mutation are more vulnerable to toxins related to PD, such as MPP"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31956306",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 136,
"text": "Mitochondria are linked with various radiation responses, including mitophagy, genomic instability, apoptosis, and the bystander effect."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28576471",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 737,
"text": "Mitochondrial biogenesis and function depend on the intensive exchange of molecules with other cellular compartments. The mitochondrial outer membrane plays a central role in this communication process. It is equipped with a number of specific protein machineries that enable the transport of proteins and metabolites. Furthermore, the outer membrane forms molecular contact sites with other cell organelles like the endoplasmic reticulum (ER), thus integrating mitochondrial function in cellular physiology. The best-studied mitochondrial organelle contact site, the ER-mitochondria encounter structure (ERMES) has been linked to many vital processes including mitochondrial division, inheritance, mitophagy, and phospholipid transport."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36982862",
"endSection": "abstract",
"offsetInBeginSection": 595,
"offsetInEndSection": 918,
"text": "Fusion connects and unites neighboring depolarized mitochondria to derive a healthy and distinct mitochondrion. In contrast, fission segregates damaged mitochondria from intact and healthy counterparts and is followed by selective clearance of the damaged mitochondria via mitochondrial specific autophagy, i.e., mitophagy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32820310",
"endSection": "abstract",
"offsetInBeginSection": 114,
"offsetInEndSection": 433,
"text": "Mitochondrial fusion-fission dynamics are critical to maintain normal morphology, distribution and quantity of mitochondria, and ensure the normal activity of cells. In addition, mitochondrial autophagy (mitophagy) plays an important role in maintaining mitochondrial quality by degrading aging or damaged mitochondria."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35096821",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 133,
"text": "Mitochondrial autophagy (or mitophagy) regulates the mitochondrial network and function to contribute to multiple cellular processes."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29115402",
"endSection": "abstract",
"offsetInBeginSection": 234,
"offsetInEndSection": 414,
"text": "Mitochondrial autophagy, also known as mitophagy, which selectively eliminates dysfunctional and unwanted mitochondria, is the most important type of mitochondrial quality control."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23985961",
"endSection": "abstract",
"offsetInBeginSection": 117,
"offsetInEndSection": 283,
"text": "Mitochondrial autophagy (mitophagy) refers to selective sequestration of mitochondria by autophagosomes, which subsequently deliver them to lysosomes for destruction."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25753537",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 64,
"text": "Mitochondrial autophagy (mitophagy) is a core cellular activity."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25437922",
"endSection": "abstract",
"offsetInBeginSection": 501,
"offsetInEndSection": 570,
"text": "Mitochondria are eliminated via mitochondrial autophagy or mitophagy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34291135",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 216,
"text": "Mitochondrial autophagy (mitophagy) is the selective clearance of damaged or incomplete mitochondria by autophagy, which is critical for the functional integrity of the entire mitochondrial network and cell survival."
}
] | 13
|
BioASQ-training13b
| null | null |
660877c8fdcbea915f000008
| 5,298
|
factoid
|
What channel is targeted by VX-548?
|
['NaV1.8']
|
[
"NaV1.8",
"Voltage-gated sodium channel 8",
"SCN10A",
"Nav1.8",
"Sodium channel type 8",
"Sodium channel, voltage-gated, type VIII"
] |
['VX-548 is an oral, highly selective inhibitor of NaV1.8 that is studied for control of acute pain.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/37530822"
] |
[
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37530822",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 58,
"text": "Selective Inhibition of NaV1.8 with VX-548 for Acute Pain."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37530822",
"endSection": "abstract",
"offsetInBeginSection": 148,
"offsetInEndSection": 259,
"text": "The effect of VX-548, an oral, highly selective inhibitor of NaV1.8, on control of acute pain is being studied."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37530822",
"endSection": "abstract",
"offsetInBeginSection": 148,
"offsetInEndSection": 453,
"text": "The effect of VX-548, an oral, highly selective inhibitor of NaV1.8, on control of acute pain is being studied.METHODS: After establishing the selectivity of VX-548 for NaV1.8 inhibition in vitro, we conducted two phase 2 trials involving participants with acute pain after abdominoplasty or bunionectomy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37530822",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 452,
"text": "BACKGROUND: The NaV1.8 voltage-gated sodium channel, expressed in peripheral nociceptive neurons, plays a role in transmitting nociceptive signals. The effect of VX-548, an oral, highly selective inhibitor of NaV1.8, on control of acute pain is being studied.METHODS: After establishing the selectivity of VX-548 for NaV1.8 inhibition in vitro, we conducted two phase 2 trials involving participants with acute pain after abdominoplasty or bunionectomy"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37530822",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 258,
"text": "BACKGROUND: The NaV1.8 voltage-gated sodium channel, expressed in peripheral nociceptive neurons, plays a role in transmitting nociceptive signals. The effect of VX-548, an oral, highly selective inhibitor of NaV1.8, on control of acute pain is being studied"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37530822",
"endSection": "abstract",
"offsetInBeginSection": 147,
"offsetInEndSection": 957,
"text": " The effect of VX-548, an oral, highly selective inhibitor of NaV1.8, on control of acute pain is being studied.METHODS: After establishing the selectivity of VX-548 for NaV1.8 inhibition in vitro, we conducted two phase 2 trials involving participants with acute pain after abdominoplasty or bunionectomy. In the abdominoplasty trial, participants were randomly assigned in a 1:1:1:1 ratio to receive one of the following over a 48-hour period: a 100-mg oral loading dose of VX-548, followed by a 50-mg maintenance dose every 12 hours (the high-dose group); a 60-mg loading dose of VX-548, followed by a 30-mg maintenance dose every 12 hours (the middle-dose group); hydrocodone bitartrate-acetaminophen (5 mg of hydrocodone bitartrate and 325 mg of acetaminophen every 6 hours); or oral placebo every 6 hours"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37530822",
"endSection": "abstract",
"offsetInBeginSection": 147,
"offsetInEndSection": 452,
"text": " The effect of VX-548, an oral, highly selective inhibitor of NaV1.8, on control of acute pain is being studied.METHODS: After establishing the selectivity of VX-548 for NaV1.8 inhibition in vitro, we conducted two phase 2 trials involving participants with acute pain after abdominoplasty or bunionectomy"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37530822",
"endSection": "abstract",
"offsetInBeginSection": 127,
"offsetInEndSection": 251,
"text": "nociceptive signals. The effect of VX-548, an oral, highly selective inhibitor of NaV1.8, on control of acute pain is being "
}
] | 13
|
BioASQ-training13b
| null | null |
65cfd02e1930410b1300001c
| 5,300
|
factoid
|
What is the most effective drug for oxaliplatin-induced neuropathy?
|
['Duloxetine']
|
[
"Duloxetine",
"Cymbalta",
"Yentreve",
"Duloxetine hydrochloride"
] |
['There are several drugs that have been studied for their potential in treating oxaliplatin-induced neuropathy, including pregabalin, duloxetine, oxycodone, and riluzole. However, the most effective drug for oxaliplatin-induced neuropathy is still unknown, as different studies have shown varying results. A systematic review and meta-analysis of available studies would be necessary to determine the most effective drug for this condition.', 'The most effective drugs for treating oxaliplatin-induced neuropathy include pregabalin, duloxetine, and oxycodone, with mexiletine, omeprazole, and Calmangafodipir also showing effectiveness.', 'Duloxetine, a serotonin and norepinephrine reuptake inhibitor, is the best-established treatment for painful chemotherapy-induced peripheral neuropathy (CIPN). Despite intense investigation at the preclinical and clinical levels, no treatment can be suggested for the prevention of Oxaliplatin-induced peripheral neurotoxicity (OIPN), and only limited evidence for the efficacy of duloxetine in the treatment setting has been provided.', "The most effective drugs for treating oxaliplatin-induced neuropathy are those that target specific mechanisms of nerve damage and pain perception, such as gabapentinoids (like gabapentin or pregabalin), which work by inhibiting voltage-dependent calcium channels to reduce the release of neurotransmitters involved in pain signaling. Other medications used include duloxetine, a serotonin-norepinephrine reuptake inhibitor that has been shown to be effective for managing chemotherapy-induced neuropathic pain. Additionally, tricyclic antidepressants like amitriptyline and selective serotonin reuptake inhibitors (SSRIs) can also be used off-label for their analgesic effects in treating neuropathy. It is important to note that the choice of medication should be individualized based on a patient's specific symptoms, overall health status, and potential drug interactions.", 'There is currently no single "most effective" drug for oxaliplatin-induced neuropathy, as treatment options are often individualized based on the severity of symptoms and patient preferences. However, duloxetine and pregabalin are commonly used medications for managing neuropathic pain associated with oxaliplatin-induced neuropathy. Other treatments may include tricyclic antidepressants, opioids, or topical agents. Additionally, there is ongoing research into potential neuroprotective agents that may prevent or reduce the severity of oxaliplatin-induced neuropathy.', 'The most effective drug for oxaliplatin-induced neuropathy is duloxetine, a serotonin and norepinephrine reuptake inhibitor. Duloxetine has been shown to be the best-established treatment for painful chemotherapy-induced peripheral neuropathy (CIPN).', 'Duloxetine is the most effective drug for oxaliplatin-induced neuropathy, according to a systematic review and meta-analysis published in the Journal of Clinical Oncology in 2019. The review analyzed data from 11 randomized controlled trials involving 1,225 patients with chemotherapy-induced peripheral neuropathy (CIPN) caused by oxaliplatin. The study found that duloxetine significantly reduced the severity and incidence of CIPN compared to placebo or standard care. Other drugs that have shown some effectiveness in managing oxaliplatin-induced neuropathy include gabapentin, pregabalin, and amitriptyline, but duloxetine appears to be the most effective.', 'Amifostine is the most effective drug for oxaliplatin-induced neuropathy.', 'Duloxetine is the most effective drug for oxaliplatin-induced neuropathy, according to a systematic review and meta-analysis published in the Journal of Clinical Oncology in 2019. The review analyzed data from 11 randomized controlled trials involving 1,212 patients with chemotherapy-induced peripheral neuropathy (CIPN) caused by oxaliplatin. The study found that duloxetine significantly reduced the severity and incidence of CIPN compared to placebo or standard care. Other drugs that have shown some effectiveness in managing oxaliplatin-induced neuropathy include gabapentin, pregabalin, and amitriptyline, but their efficacy is less well-established than that of duloxetine.', 'The most effective drug for oxaliplatin-induced neuropathy is duloxetine, a serotonin and norepinephrine reuptake inhibitor. Duloxetine has been shown to have limited evidence for its efficacy in the treatment setting for painful chemotherapy-induced peripheral neuropathy (CIPN), including oxaliplatin-induced neuropathy. However, it is important to note that the evidence is limited and further research is needed to fully establish its effectiveness.', 'Currently, there is limited evidence for the efficacy of duloxetine in the treatment of oxaliplatin-induced neuropathy. Duloxetine, a serotonin and norepinephrine reuptake inhibitor, is the best-established treatment for painful chemotherapy-induced peripheral neuropathy (CIPN). However, it is only effective in little more than half of patients, and our ability to predict patient response remains incompletely understood. Further research is needed to identify more effective treatments for oxaliplatin-induced neuropathy.', 'The most effective drug for oxaliplatin-induced neuropathy is donepezil. Donepezil has been shown to effectively attenuate oxaliplatin-induced inhibition of neurite outgrowth and ameliorate peripheral neuropathy in both in vitro and in vivo models. It does not inhibit the anti-tumor activity of oxaliplatin and may be useful for managing oxaliplatin-induced peripheral neuropathy.', 'Duloxetine, a serotonin and norepinephrine reuptake inhibitor, is the best-established treatment for painful chemotherapy-induced peripheral neuropathy (CIPN), although only limited evidence for its efficacy has been provided.', 'The most effective drug for oxaliplatin-induced neuropathy is duloxetine, a serotonin and norepinephrine reuptake inhibitor. Duloxetine has been shown to prevent and reverse mechanical hyperalgesia associated with oxaliplatin-induced peripheral neuropathy in preclinical studies. However, its efficacy in clinical settings is limited, with only about 50% of patients responding to the treatment. The neuroendocrine stress axis-dependence of duloxetine analgesia has been demonstrated in preclinical models, suggesting that stress may impact response to duloxetine. Further research is needed to identify additional effective treatments for oxaliplatin-induced neuropathy.', 'The most effective drug for oxaliplatin-induced neuropathy is currently not established. However, several drugs have shown potential in alleviating neuropathic symptoms. These include duloxetine, pregabalin, gabapentin, and amifostine. Further research is needed to determine the optimal treatment approach for oxaliplatin-induced neuropathy.', 'Based on the provided information, several drugs have shown potential in preventing or treating oxaliplatin-induced neuropathy in preclinical and clinical studies:\n\n1. Amifostine: Reduced nociception induced by oxaliplatin in mice, with 25 mg/kg providing the best protection.\n\n2. Rutin and Quercetin: Prevented painful peripheral neuropathy induced by oxaliplatin in mice. \n\n3. Ibudilast: Prevented the development of tactile allodynia and memory impairments caused by oxaliplatin in an animal study.\n\n4. Mangafodipir: Suggested to prevent and/or relieve oxaliplatin-induced neuropathy in cancer patients.\n\n5. Carbamazepine: Demonstrated prevention of oxaliplatin-induced sensory neuropathy greater than grade 1 in a clinical study.\n\nHowever, the information provided does not clearly indicate which drug is the most effective. More comparative clinical studies would be needed to determine the relative efficacy of these agents in preventing or treating oxaliplatin-induced neuropathy in humans.', 'Duloxetine is the best-established treatment for painful chemotherapy-induced peripheral neuropathy (CIPN).', 'Oxaliplatin-induced neuropathy (OIN) is a side effect of oxaliplatin chemotherapy treatment and the FDA has not approved a specific treatment for this condition. However, various clinical trials have investigated agents such as vitamin B12, B6, B1, calcium and magnesium infusions, and duloxetine. Based on the available literature, duloxetine 30 mg or 60 mg orally once daily appears to be the most effective drug.', 'Duloxetine is currently the best-established treatment for painful chemotherapy-induced peripheral neuropathy (CIPN) caused by oxaliplatin. However, the evidence for its efficacy in the treatment setting is limited.', 'Duloxetine, a serotonin and norepinephrine reuptake inhibitor, is considered the best-established treatment for painful chemotherapy-induced peripheral neuropathy (CIPN), including oxaliplatin-induced neuropathy. It has shown efficacy in managing neuropathic pain associated with oxaliplatin treatment.', 'Amifostine at the dose of 25 mg/kg provided the best protection against oxaliplatin-induced neuropathy.', 'The most effective drug for managing oxaliplatin-induced neuropathy is duloxetine. It has been shown to help reduce the pain associated with this type of chemotherapy-induced peripheral neuropathy (CIPN)', "Duloxetine is the best-established treatment for painful chemotherapy-induced peripheral neuropathy (CIPN), including that caused by oxaliplatin. However, it's important to note that there is only limited evidence for its efficacy in this specific treatment setting."]
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/22466962",
"http://www.ncbi.nlm.nih.gov/pubmed/35426033",
"http://www.ncbi.nlm.nih.gov/pubmed/32965323",
"http://www.ncbi.nlm.nih.gov/pubmed/20308797",
"http://www.ncbi.nlm.nih.gov/pubmed/26039098",
"http://www.ncbi.nlm.nih.gov/pubmed/35255440",
"http://www.ncbi.nlm.nih.gov/pubmed/25459280",
"http://www.ncbi.nlm.nih.gov/pubmed/32347537",
"http://www.ncbi.nlm.nih.gov/pubmed/32440122",
"http://www.ncbi.nlm.nih.gov/pubmed/37902612",
"http://www.ncbi.nlm.nih.gov/pubmed/35295491",
"http://www.ncbi.nlm.nih.gov/pubmed/31467537",
"http://www.ncbi.nlm.nih.gov/pubmed/15846125",
"http://www.ncbi.nlm.nih.gov/pubmed/34880120",
"http://www.ncbi.nlm.nih.gov/pubmed/37946486",
"http://www.ncbi.nlm.nih.gov/pubmed/24365057",
"http://www.ncbi.nlm.nih.gov/pubmed/24452412",
"http://www.ncbi.nlm.nih.gov/pubmed/34686205",
"http://www.ncbi.nlm.nih.gov/pubmed/32416186",
"http://www.ncbi.nlm.nih.gov/pubmed/32471028",
"http://www.ncbi.nlm.nih.gov/pubmed/33573316",
"http://www.ncbi.nlm.nih.gov/pubmed/11797144",
"http://www.ncbi.nlm.nih.gov/pubmed/33010214",
"http://www.ncbi.nlm.nih.gov/pubmed/20683034",
"http://www.ncbi.nlm.nih.gov/pubmed/32317735",
"http://www.ncbi.nlm.nih.gov/pubmed/24307899",
"http://www.ncbi.nlm.nih.gov/pubmed/37951905",
"http://www.ncbi.nlm.nih.gov/pubmed/25434440",
"http://www.ncbi.nlm.nih.gov/pubmed/31377017",
"http://www.ncbi.nlm.nih.gov/pubmed/26828020",
"http://www.ncbi.nlm.nih.gov/pubmed/15590869",
"http://www.ncbi.nlm.nih.gov/pubmed/31182448",
"http://www.ncbi.nlm.nih.gov/pubmed/35623085",
"http://www.ncbi.nlm.nih.gov/pubmed/21907570",
"http://www.ncbi.nlm.nih.gov/pubmed/24784702",
"http://www.ncbi.nlm.nih.gov/pubmed/26358793",
"http://www.ncbi.nlm.nih.gov/pubmed/28739131",
"http://www.ncbi.nlm.nih.gov/pubmed/26536615",
"http://www.ncbi.nlm.nih.gov/pubmed/24412642",
"http://www.ncbi.nlm.nih.gov/pubmed/11951404",
"http://www.ncbi.nlm.nih.gov/pubmed/19816592",
"http://www.ncbi.nlm.nih.gov/pubmed/28186109",
"http://www.ncbi.nlm.nih.gov/pubmed/24355920"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32471028",
"endSection": "abstract",
"offsetInBeginSection": 664,
"offsetInEndSection": 760,
"text": "only limited evidence for the efficacy of duloxetine in the treatment setting has been provided."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34880120",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 158,
"text": "Duloxetine, a serotonin and norepinephrine reuptake inhibitor, is the best-established treatment for painful chemotherapy-induced peripheral neuropathy (CIPN)"
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37951905",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 130,
"text": "Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37946486",
"endSection": "abstract",
"offsetInBeginSection": 12,
"offsetInEndSection": 268,
"text": "To analyze the distribution characteristics of Traditional Chinese Medicine (TCM) syndromes in patients with oxaliplatin-induced peripheral neuropathy (OIPN) and observe the clinical efficacy of Bushen Yiqi formula (, BSYQF) in treating patients with OIPN."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28186109",
"endSection": "abstract",
"offsetInBeginSection": 459,
"offsetInEndSection": 585,
"text": "(Aqu) and two hydroalcoholic (20%HA and 50%HA) extracts were tested in a rat model of oxaliplatin-induced neuropathy. Repeated"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35623085",
"endSection": "abstract",
"offsetInBeginSection": 1385,
"offsetInEndSection": 1477,
"text": "These results suggest that duloxetine could alleviate the OXA-induced peripheral neuropathy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37902612",
"endSection": "abstract",
"offsetInBeginSection": 1157,
"offsetInEndSection": 1377,
"text": "These findings provide preliminary evidence of the preventative effects of duloxetine on both oxaliplatin-induced allodynia and hyperalgesia in male and female rats, with a difference noted in response between the sexes."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32965323",
"endSection": "abstract",
"offsetInBeginSection": 709,
"offsetInEndSection": 841,
"text": "In all doses, amifostine prevented the development of mechanical hyperalgesia and thermal allodynia induced by oxaliplatin (P<0.05)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32965323",
"endSection": "abstract",
"offsetInBeginSection": 842,
"offsetInEndSection": 915,
"text": "Amifostine at the dose of 25 mg/kg provided the best protection (P<0.05)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32965323",
"endSection": "abstract",
"offsetInBeginSection": 1161,
"offsetInEndSection": 1357,
"text": "In conclusion, amifostine reduced the nociception induced by oxaliplatin in mice, suggesting the possible use of amifostine for the management of oxaliplatin-induced peripheral sensory neuropathy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28739131",
"endSection": "abstract",
"offsetInBeginSection": 764,
"offsetInEndSection": 875,
"text": "Ibudilast treatment prior to oxaliplatin prevented the development of tactile allodynia and memory impairments."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28739131",
"endSection": "abstract",
"offsetInBeginSection": 1035,
"offsetInEndSection": 1171,
"text": "These results suggest that Ibudilast could be an effective treatment against oxaliplatin-induced neuropathies and cognitive impairments."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24355920",
"endSection": "abstract",
"offsetInBeginSection": 1476,
"offsetInEndSection": 1590,
"text": "red with those in nonresponders.CONCLUSION: Our study suggests that mangafodipir can prevent and/or relieve oxalip"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/11797144",
"endSection": "abstract",
"offsetInBeginSection": 1392,
"offsetInEndSection": 1519,
"text": "arbamazepine-induced side effects was low.CONCLUSIONS: These observations demonstrate that oxaliplatin-induced sensory neuropat"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25434440",
"endSection": "abstract",
"offsetInBeginSection": 200,
"offsetInEndSection": 389,
"text": "In the present study, we attempted to treat L-OHP-induced peripheral neuropathy using the algorithm consisting of pregabalin, duloxetine, and oxycodone at Iwate Medical University Hospital."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25434440",
"endSection": "abstract",
"offsetInBeginSection": 390,
"offsetInEndSection": 506,
"text": "The first, second, and third stages of the algorithm consist of pregabalin, duloxetine, and oxycodone, respectively."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/19816592",
"endSection": "abstract",
"offsetInBeginSection": 961,
"offsetInEndSection": 1338,
"text": "Among all of the agents, intravenous calcium and magnesium have shown the most promise in prophylaxis and treatment of oxaliplatin-induced neurotoxicity. We report a case of a patient, in which oral calcium supplements not only were successful in treating his neurotoxicity, but we also were able to administer a cumulative dose of 2500 mg/m(2) (990 mg/m(2) with oral calcium)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24307899",
"endSection": "abstract",
"offsetInBeginSection": 11,
"offsetInEndSection": 129,
"text": "To evaluate the efficacy of Goshajinkigan for oxaliplatin-induced peripheral neuropathy in colorectal cancer patients."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25459280",
"endSection": "abstract",
"offsetInBeginSection": 481,
"offsetInEndSection": 704,
"text": "Several scientists have explored the various mechanisms involved in the onset of chemotherapy-related peripheral neurotoxicity identifying molecular targets useful for the development of selected neuroprotective strategies."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31377017",
"endSection": "abstract",
"offsetInBeginSection": 653,
"offsetInEndSection": 743,
"text": "Therefore, donepezil may be useful for managing oxaliplatin-induced peripheral neuropathy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31377017",
"endSection": "abstract",
"offsetInBeginSection": 50,
"offsetInEndSection": 350,
"text": "The effect of donepezil, a drug used for treatment of Alzheimer's disease, on oxaliplatin-induced peripheral neuropathy was investigated using both in vivo and in vitro models. Donepezil effectively attenuated oxaliplatin- and cisplatin-induced inhibition of neurite outgrowth in cultured PC12 cells."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31377017",
"endSection": "abstract",
"offsetInBeginSection": 50,
"offsetInEndSection": 226,
"text": "The effect of donepezil, a drug used for treatment of Alzheimer's disease, on oxaliplatin-induced peripheral neuropathy was investigated using both in vivo and in vitro models."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31377017",
"endSection": "abstract",
"offsetInBeginSection": 50,
"offsetInEndSection": 543,
"text": "The effect of donepezil, a drug used for treatment of Alzheimer's disease, on oxaliplatin-induced peripheral neuropathy was investigated using both in vivo and in vitro models. Donepezil effectively attenuated oxaliplatin- and cisplatin-induced inhibition of neurite outgrowth in cultured PC12 cells. In a rat model, repeated oral administration of donepezil (5 times/week for 4 weeks) ameliorated oxaliplatin-induced mechanical allodynia (von Frey test) and sciatic nerve axonal degeneration."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24355920",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1590,
"text": "BACKGROUND: The majority of patients receiving the platinum-based chemotherapy drug oxaliplatin develop peripheral neurotoxicity. Because this neurotoxicity involves ROS production, we investigated the efficacy of mangafodipir, a molecule that has antioxidant properties and is approved for use as an MRI contrast enhancer.METHODS: The effects of mangafodipir were examined in mice following treatment with oxaliplatin. Neurotoxicity, axon myelination, and advanced oxidized protein products (AOPPs) were monitored. In addition, we enrolled 23 cancer patients with grade ≥ 2 oxaliplatin-induced neuropathy in a phase II study, with 22 patients receiving i.v. mangafodipir following oxaliplatin. Neuropathic effects were monitored for up to 8 cycles of oxaliplatin and mangafodipir.RESULTS: Mangafodipir prevented motor and sensory dysfunction and demyelinating lesion formation. In mice, serum AOPPs decreased after 4 weeks of mangafodipir treatment. In 77% of patients treated with oxaliplatin and mangafodipir, neuropathy improved or stabilized after 4 cycles. After 8 cycles, neurotoxicity was downgraded to grade ≥ 2 in 6 of 7 patients. Prior to enrollment, patients received an average of 880 ± 239 mg/m2 oxaliplatin. Patients treated with mangafodipir tolerated an additional dose of 458 ± 207 mg/m2 oxaliplatin despite preexisting neuropathy. Mangafodipir responders managed a cumulative dose of 1,426 ± 204 mg/m2 oxaliplatin. Serum AOPPs were lower in responders compared with those in nonresponders.CONCLUSION: Our study suggests that mangafodipir can prevent and/or relieve oxalip"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/19816592",
"endSection": "abstract",
"offsetInBeginSection": 961,
"offsetInEndSection": 1819,
"text": "Among all of the agents, intravenous calcium and magnesium have shown the most promise in prophylaxis and treatment of oxaliplatin-induced neurotoxicity. We report a case of a patient, in which oral calcium supplements not only were successful in treating his neurotoxicity, but we also were able to administer a cumulative dose of 2500 mg/m(2) (990 mg/m(2) with oral calcium). Although the current recommendations for the management of the acute and cumulative neurotoxicity from oxaliplatin with the use of infusion of Ca/Mg remain valid, our case is the first report demonstrating the role of oral minerals in ameliorating neurotoxicity from oxaliplatin. Future studies to evaluate the role of oral Ca/Mg are warranted, since they could prove to be an effective, less expensive and more convenient way to treat and prevent oxaliplatin-associated toxicity."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26536615",
"endSection": "abstract",
"offsetInBeginSection": 128,
"offsetInEndSection": 1107,
"text": "neuropathy. Exenatide, a glucagon-like peptide-1 (GLP-1) agonist, is an incretin mimetic secreted from ileal L cells, which is clinically used to treat type 2 diabetes mellitus. GLP-1 receptor agonists have been reported to exhibit neuroprotective effects on the central and peripheral nervous systems. In this study, we investigated the effects of exenatide on oxaliplatin-induced neuropathy in rats and cultured cells.METHODS: Oxaliplatin (4 mg/kg) was administered intravenously twice per week for 4 weeks, and mechanical allodynia was evaluated using the von Frey test in rats. Axonal degeneration was assessed by toluidine blue staining of sciatic nerves.RESULTS: Repeated administration of oxaliplatin caused mechanical allodynia from day 14 to 49. Although the co-administration of extended-release exenatide (100 μg/kg) could not inhibit the incidence of oxaliplatin-induced mechanical allodynia, it facilitated recovery from the oxaliplatin-induced neuropathy with repar"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26039098",
"endSection": "abstract",
"offsetInBeginSection": 224,
"offsetInEndSection": 1799,
"text": "In the complex pattern of molecular and morphological alterations induced by oxaliplatin in the nervous system, an important activation of glia has been preclinically evidenced. N-Palmitoylethanolamine (PEA) modulates glial cells and exerts antinociceptive effects in several animal models. In order to improve the therapeutic chances for chemotherapy-dependent neuropathy management, the role of PEA was investigated in a rat model of oxaliplatin-induced neuropathy (2.4 mg kg-1 daily, intraperitoneally). On day 21, a single administration of PEA (30 mg kg-1 i.p.) was able to reduce oxaliplatin-dependent pain induced by mechanical and thermal stimuli. The repeated treatment with PEA (30 mg kg-1 daily i.p. for 21 days, from the first oxaliplatin injection) prevented lowering of pain threshold as well as increased pain on suprathreshold stimulation. Ex vivo histological and molecular analysis of dorsal root ganglia, peripheral nerves and spinal cord highlighted neuroprotective effects and glia-activation prevention induced by PEA repeated administration. The protective effect of PEA resulted in the normalization of the electrophysiological activity of the spinal nociceptive neurons. Finally, PEA did not alter the oxaliplatin-induced mortality of the human colon cancer cell line HT-29. The efficacy of PEA in neuropathic pain control and in preventing nervous tissue alteration candidates this endogenous compound as disease modifying agent. These characteristics, joined to the safety profile, suggest the usefulness of PEA in chemotherapy-induced neuropathy. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/11797144",
"endSection": "abstract",
"offsetInBeginSection": 246,
"offsetInEndSection": 562,
"text": "atin therapy. We demonstrated that oxaliplatin alters sodium channel kinetics on sensory neurons. This effect could be antagonized in vitro by the sodium channel blocker carbamazepine. Therefore a pilot study was initiated to investigate if carbamazepine prevents oxaliplatin-induced neuropathy in patients with colo"
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31377017",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 93,
"text": "Donepezil ameliorates oxaliplatin-induced peripheral neuropathy via a neuroprotective effect."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/20683034",
"endSection": "abstract",
"offsetInBeginSection": 784,
"offsetInEndSection": 979,
"text": "severity of oxaliplatin-induced sensory neuropathy. Being more potent than gabapentin, pregabalin achieved efficacy at lower doses and should lead to fewer dose-related side effects, although thi"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/15590869",
"endSection": "abstract",
"offsetInBeginSection": 1202,
"offsetInEndSection": 1296,
"text": "gnesium solutions, gabapentin, carbamazepine, amifostine, and glutathione. Treatment measures "
}
] | 13
|
BioASQ-training13b
| null | null |
66099926fdcbea915f000016
| 5,301
|
factoid
|
What is Microcoring used for
|
['collogen induction', 'skin rejuvenation', 'enlarged pore removal']
|
[
"collagen induction",
"skin rejuvenation",
"enlarged pore removal",
"collagen induction therapy",
"microneedling",
"dermaroller",
"collagen stimulation",
"skin resurfacing",
"pore minimization",
"skin tightening",
"skin renewal",
"skin revitalization"
] |
['Microcoring treatment (MCT) is used for skin rejuvenation. Early findings suggest it may help with skin tightening and increasing skin thickness, although further studies are needed to fully evaluate its potential in this area.', 'Microcoring technology is primarily used for treating pores, rejuvenating the skin, and lifting and tightening facial tissues.', 'Microcoring is used for skin rejuvenation, including effects like skin tightening and increasing skin thickness.', 'Microcoring is used for dermal treatment to the lower face and perioral region.', 'Microcoring is used for the treatment of supraumbilical lipomatosis.', 'Microcoring (MCT) is used skin treatments such as scarless skin removal or treatment of enlarged pores. This minimally invasive technique involves creating controlled damage in cutaneous tissue to induce neocollagenesis and neoelastogenesis. MCT involves hollow microneedles capable of removing excess tissue without inducing scar formation.', 'MCT treatment of human skin is safe and well tolerated. Although further studies on efficacy are required to evaluate the full potential of MCT in skin rejuvenation, early findings such as skin tightening and increase in skin thickness are encouraging.', ' Microcoring is used for skin rejuvenation, specifically to tighten the skin and increase its thickness.', 'Microcoring is used for skin rejuvenation. It involves removing tiny cores of skin to promote skin tightening and potentially increase skin thickness, which can help in improving the overall appearance of the skin', 'Microcoring is used for skin rejuvenation. It has shown promising early results, including skin tightening and an increase in skin thickness, suggesting its potential for improving the appearance and health of the skin.', 'Microcoring is used for skin rejuvenation and skin tightening.', 'Microcoring is used for skin rejuvenation, as it has shown promising early results such as skin tightening and increased skin thickness.', 'Microcoring is used for the treatment of various medical conditions, including cancer, cardiovascular disease, and neurological disorders.', 'Microcoring is a treatment used for skin rejuvenation, which involves the use of micro-needles to create micro-channels in the skin. This treatment is safe and well-tolerated, and early findings suggest that it can lead to skin tightening and an increase in skin thickness.', 'Microcoring is used for skin rejuvenation, scarless skin removal, and treatment of pores.', 'Microcoring is used for skin rejuvenation.', 'Microcoring is a minimally invasive procedure used for the treatment of various conditions, including chronic pain, spinal cord injury, and neurodegenerative diseases.', 'Microcoring is a technique used to create small, hollow, cylindrical cavities in tissue. It is commonly used in botulinum injections to create microcores that may serve as a delivery system for therapeutic agents.', 'Microcoring is a technology used for scarless skin removal without the use of thermal energy. It involves the use of a modified, hollow hypodermic needle to safely remove skin cores without leaving a scar. Microcoring has been found to be effective in skin rejuvenation, with benefits such as skin tightening and an increase in skin thickness observed in clinical trials.', 'Microcoring is used for skin rejuvenation, treatment of pores, addressing concerns of enlarged pores, serving as a rejuvenation approach, enabling scarless skin removal, treating skin laxity, and facilitating transdermal delivery of macromolecules.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/36683728",
"http://www.ncbi.nlm.nih.gov/pubmed/22180307",
"http://www.ncbi.nlm.nih.gov/pubmed/37218872",
"http://www.ncbi.nlm.nih.gov/pubmed/36262685",
"http://www.ncbi.nlm.nih.gov/pubmed/35064633",
"http://www.ncbi.nlm.nih.gov/pubmed/34729291"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34729291",
"endSection": "abstract",
"offsetInBeginSection": 935,
"offsetInEndSection": 1188,
"text": " MCT treatment of human skin is safe and well tolerated. Although further studies on efficacy are required to evaluate the full potential of MCT in skin rejuvenation, early findings such as skin tightening and increase in skin thickness are encouraging."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37218872",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 84,
"text": "A novel microcoring technology: A completely new concept of enlarged pore treatment."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36683728",
"endSection": "abstract",
"offsetInBeginSection": 63,
"offsetInEndSection": 195,
"text": "The micro coring technology, designed to remove small skin columns, was developed to avoid the thermal injury associated with lasers"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36262685",
"endSection": "abstract",
"offsetInBeginSection": 12,
"offsetInEndSection": 143,
"text": " technology (MCT) removes cores of skin without formation of scars, thereby tightening skin and reducing skin wrinkling. The purpos"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34729291",
"endSection": "abstract",
"offsetInBeginSection": 131,
"offsetInEndSection": 242,
"text": "Microcoring technology (MCT) uses a modified, hollow hypodermic needle to remove skin safely and without a scar"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37218872",
"endSection": "abstract",
"offsetInBeginSection": 234,
"offsetInEndSection": 549,
"text": "Despite these efforts, enlarged pores remain problematic for many patients.OBJECTIVES: Microcoring technology has recently been developed to treat pores and serve as a leading primary treatment option to address these concerns.METHODS: Three patients underwent a single treatment of rotational fractional resection."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34729291",
"endSection": "abstract",
"offsetInBeginSection": 830,
"offsetInEndSection": 991,
"text": "Skin area reduction (skin tightening) and increase in skin thickness were observed long term.CONCLUSIONS: MCT treatment of human skin is safe and well tolerated."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34729291",
"endSection": "abstract",
"offsetInBeginSection": 244,
"offsetInEndSection": 776,
"text": "This method is advantageous compared to other fractional devices, given that it has the same benefits as energy-based devices (removal of skin cores without a scar), with the added value of immediate closure along the relaxed skin tension lines, with significantly less thermal energy.METHODS: Three prospective clinical safety trials analyzing MCT treatment on abdominal and facial skin (short- and long-term) are described.RESULTS: MCT treatment of human skin resulted in scarless skin removal that was well tolerated by patients."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34729291",
"endSection": "abstract",
"offsetInBeginSection": 131,
"offsetInEndSection": 243,
"text": "Microcoring technology (MCT) uses a modified, hollow hypodermic needle to remove skin safely and without a scar."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35064633",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 650,
"text": "BACKGROUND: Microbotox technique, intradermal injection of microdroplets of botulinum toxin, is a favorable rejuvenation approach in subjects who prefer more natural appearance.AIM: To determine the best injection techniques (dosage, concentration, as well as number and location of injection points), efficacy and side effects of this innovative technique for facial rejuvenation.METHODS: We conducted a search in Pubmed, Embase, Web of Science, and Google Scholar databases from conception until October 2021 with keywords \"microbotox\" OR \"mesobotox\" OR \"intradermal injection\" AND \"botulinum toxin\" AND \"rejuvenation\" AND \"wrinkle\" AND \"face-lift."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36262685",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 132,
"text": "Micro-coring technology (MCT) removes cores of skin without formation of scars, thereby tightening skin and reducing skin wrinkling."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36262685",
"endSection": "abstract",
"offsetInBeginSection": 133,
"offsetInEndSection": 279,
"text": "The purpose of this study was to evaluate the safety and efficacy of MCT with the dermal micro-coring device for the treatment of facial wrinkles."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34729291",
"endSection": "abstract",
"offsetInBeginSection": 650,
"offsetInEndSection": 748,
"text": "erm) are described.RESULTS: MCT treatment of human skin resulted in scarless skin removal that was"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37218872",
"endSection": "abstract",
"offsetInBeginSection": 298,
"offsetInEndSection": 438,
"text": "y patients.OBJECTIVES: Microcoring technology has recently been developed to treat pores and serve as a leading primary treatment option to "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22180307",
"endSection": "abstract",
"offsetInBeginSection": 653,
"offsetInEndSection": 1020,
"text": "Technical issues related to maximizing the diagnostic yield (e.g., rapid on-site cytopathological evaluation, needle diameter, microcore isolation for histopathological examination, and adequate number of needle passes) are discussed and recommendations are made for various settings, including solid and cystic pancreatic lesions, submucosal tumors, and lymph nodes."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37218872",
"endSection": "abstract",
"offsetInBeginSection": 311,
"offsetInEndSection": 462,
"text": "JECTIVES: Microcoring technology has recently been developed to treat pores and serve as a leading primary treatment option to address these concerns.M"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34729291",
"endSection": "abstract",
"offsetInBeginSection": 130,
"offsetInEndSection": 528,
"text": " Microcoring technology (MCT) uses a modified, hollow hypodermic needle to remove skin safely and without a scar. This method is advantageous compared to other fractional devices, given that it has the same benefits as energy-based devices (removal of skin cores without a scar), with the added value of immediate closure along the relaxed skin tension lines, with significantly less thermal energy"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37218872",
"endSection": "abstract",
"offsetInBeginSection": 311,
"offsetInEndSection": 550,
"text": "JECTIVES: Microcoring technology has recently been developed to treat pores and serve as a leading primary treatment option to address these concerns.METHODS: Three patients underwent a single treatment of rotational fractional resection. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34729291",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 528,
"text": "BACKGROUND: We introduce an innovative and novel technology that achieves scarless skin removal without the use of thermal energy. Microcoring technology (MCT) uses a modified, hollow hypodermic needle to remove skin safely and without a scar. This method is advantageous compared to other fractional devices, given that it has the same benefits as energy-based devices (removal of skin cores without a scar), with the added value of immediate closure along the relaxed skin tension lines, with significantly less thermal energy"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34729291",
"endSection": "abstract",
"offsetInBeginSection": 130,
"offsetInEndSection": 668,
"text": " Microcoring technology (MCT) uses a modified, hollow hypodermic needle to remove skin safely and without a scar. This method is advantageous compared to other fractional devices, given that it has the same benefits as energy-based devices (removal of skin cores without a scar), with the added value of immediate closure along the relaxed skin tension lines, with significantly less thermal energy.METHODS: Three prospective clinical safety trials analyzing MCT treatment on abdominal and facial skin (short- and long-term) are described"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37218872",
"endSection": "abstract",
"offsetInBeginSection": 311,
"offsetInEndSection": 644,
"text": "JECTIVES: Microcoring technology has recently been developed to treat pores and serve as a leading primary treatment option to address these concerns.METHODS: Three patients underwent a single treatment of rotational fractional resection. The 0.5 mm diameter rotating scalpels were used to resect the skin pores in the cheek region. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34729291",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 242,
"text": "BACKGROUND: We introduce an innovative and novel technology that achieves scarless skin removal without the use of thermal energy. Microcoring technology (MCT) uses a modified, hollow hypodermic needle to remove skin safely and without a scar"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37218872",
"endSection": "abstract",
"offsetInBeginSection": 233,
"offsetInEndSection": 548,
"text": " Despite these efforts, enlarged pores remain problematic for many patients.OBJECTIVES: Microcoring technology has recently been developed to treat pores and serve as a leading primary treatment option to address these concerns.METHODS: Three patients underwent a single treatment of rotational fractional resection"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37218872",
"endSection": "abstract",
"offsetInBeginSection": 233,
"offsetInEndSection": 460,
"text": " Despite these efforts, enlarged pores remain problematic for many patients.OBJECTIVES: Microcoring technology has recently been developed to treat pores and serve as a leading primary treatment option to address these concerns"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36262685",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 133,
"text": "Micro-coring technology (MCT) removes cores of skin without formation of scars, thereby tightening skin and reducing skin wrinkling. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34729291",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 517,
"text": "BACKGROUND: We introduce an innovative and novel technology that achieves scarless skin removal without the use of thermal energy. Microcoring technology (MCT) uses a modified, hollow hypodermic needle to remove skin safely and without a scar. This method is advantageous compared to other fractional devices, given that it has the same benefits as energy-based devices (removal of skin cores without a scar), with the added value of immediate closure along the relaxed skin tension lines, with significantly less the"
}
] | 13
|
BioASQ-training13b
| null | null |
65f37bb1c4010b4d7800000d
| 5,302
|
factoid
|
What is the cause of Brazilian spotted fever?
|
['Rickettsia rickettsii']
|
[
"Rickettsia rickettsii",
"Rickettsia",
"Rocky Mountain spotted fever agent",
"Rickettsia rickettsii (Rickettsial)",
"Rickettsia rickettsii (Rickettsial pathogen)"
] |
['Brazilian spotted fever is caused by Rickettsia rickettsii.', 'Brazilian spotted fever is a tick-borne disease caused by a bacterium named Rickettsia rickettsii.', 'The cause of Brazilian spotted fever is Rickettsia rickettsii.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/18949349",
"http://www.ncbi.nlm.nih.gov/pubmed/11980610",
"http://www.ncbi.nlm.nih.gov/pubmed/23168052",
"http://www.ncbi.nlm.nih.gov/pubmed/24142167",
"http://www.ncbi.nlm.nih.gov/pubmed/28377149",
"http://www.ncbi.nlm.nih.gov/pubmed/36383899",
"http://www.ncbi.nlm.nih.gov/pubmed/31490924",
"http://www.ncbi.nlm.nih.gov/pubmed/31800889",
"http://www.ncbi.nlm.nih.gov/pubmed/31969607",
"http://www.ncbi.nlm.nih.gov/pubmed/21184706",
"http://www.ncbi.nlm.nih.gov/pubmed/27812666",
"http://www.ncbi.nlm.nih.gov/pubmed/17114702",
"http://www.ncbi.nlm.nih.gov/pubmed/32267390",
"http://www.ncbi.nlm.nih.gov/pubmed/31742533",
"http://www.ncbi.nlm.nih.gov/pubmed/29050834",
"http://www.ncbi.nlm.nih.gov/pubmed/32315604",
"http://www.ncbi.nlm.nih.gov/pubmed/31504641",
"http://www.ncbi.nlm.nih.gov/pubmed/30334709",
"http://www.ncbi.nlm.nih.gov/pubmed/36169507",
"http://www.ncbi.nlm.nih.gov/pubmed/28169507",
"http://www.ncbi.nlm.nih.gov/pubmed/25501172",
"http://www.ncbi.nlm.nih.gov/pubmed/31014644",
"http://www.ncbi.nlm.nih.gov/pubmed/27230435",
"http://www.ncbi.nlm.nih.gov/pubmed/28535905",
"http://www.ncbi.nlm.nih.gov/pubmed/24387674",
"http://www.ncbi.nlm.nih.gov/pubmed/25148391",
"http://www.ncbi.nlm.nih.gov/pubmed/35293560",
"http://www.ncbi.nlm.nih.gov/pubmed/33825800",
"http://www.ncbi.nlm.nih.gov/pubmed/31883907",
"http://www.ncbi.nlm.nih.gov/pubmed/20624353",
"http://www.ncbi.nlm.nih.gov/pubmed/25830998",
"http://www.ncbi.nlm.nih.gov/pubmed/25483025",
"http://www.ncbi.nlm.nih.gov/pubmed/17114770",
"http://www.ncbi.nlm.nih.gov/pubmed/19538276",
"http://www.ncbi.nlm.nih.gov/pubmed/14718082",
"http://www.ncbi.nlm.nih.gov/pubmed/27880877"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31504641",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 81,
"text": "The bacterium Rickettsia rickettsii is the agent of Brazilian spotted fever (BSF)"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32267390",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 71,
"text": "Rickettsia rickettsii is the causative agent of Brazilian spotted fever"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27812666",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 166,
"text": "Brazilian spotted fever (BSF) is caused by the bacterium Rickettsia rickettsii. Because of its high case-fatality rate and apparent increase in areas of transmission,"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32315604",
"endSection": "abstract",
"offsetInBeginSection": 10,
"offsetInEndSection": 94,
"text": "spotted fever (BSF) is a highly lethal disease in southeastern Brazil. BSF is caused"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36383899",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 239,
"text": "Brazilian spotted fever, a zoonotic disease transmitted by ticks, is caused by Rickettsia rickettsii. We report a fulminant case of this zoonosis in a healthy 46-year-old military man in the urban region of Rio de Janeiro city, in October,"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31883907",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 109,
"text": "Brazilian spotted fever (BSF), caused by the bacterium Rickettsia rickettsii, is transmitted to humans mainly"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28377149",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 262,
"text": "Brazilian spotted fever (BSF) is an endemic anthropozoonosis caused by Gram-negative bacteria (Rickettsia rickettsii) that is associated with the risk of human infection by ticks. In the city of Americana, São Paulo (SP), Brazil, there were 12 cases (67% lethal)"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24142167",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 129,
"text": "Brazilian spotted fever (BSF), caused by Rickettsia rickettsii, is endemic in the municipality of Americana, southeastern Brazil,"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31969607",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 185,
"text": "Brazilian spotted fever (BSF), caused by Rickettsia rickettsii, is the most lethal tick-borne disease in the western hemisphere. In Brazil, Amblyomma sculptum ticks are the main vector."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24387674",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 134,
"text": "BACKGROUND: Brazilian spotted fever (BSF), caused by the bacterium Rickettsia rickettsii, is the deadliest spotted fever of the world."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/17114702",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 193,
"text": "Brazilian spotted fever (BSF) is the most important tick-borne disease in Brazil and is caused by Rickettsia rickettsii and transmitted by the Ixodid tick Amblyomma cajennense, its main vector."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35293560",
"endSection": "abstract",
"offsetInBeginSection": 162,
"offsetInEndSection": 310,
"text": "In Brazil, Rickettsia rickettsii SF is the most serious rickettsiosis and can result in death if not diagnosed and treated at the onset of symptoms."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36383899",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 101,
"text": "Brazilian spotted fever, a zoonotic disease transmitted by ticks, is caused by Rickettsia rickettsii."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31742533",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 150,
"text": "In São Paulo metropolitan area, Brazil, Amblyomma aureolatum ticks are the main vector of Rickettsia rickettsii, which causes Brazilian spotted fever."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/20624353",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 126,
"text": "Brazilian Spotted Fever (BSF) is an often fatal zoonosis caused by the obligate intracellular bacterium Rickettsia rickettsii."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27812666",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 79,
"text": "Brazilian spotted fever (BSF) is caused by the bacterium Rickettsia rickettsii."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25830998",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 121,
"text": "Brazilian spotted fever is an acute febrile infectious disease caused by Rickettsia rickettsii, transmitted by tick bite."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/11980610",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 56,
"text": "Brazilian spotted fever, caused by Rickettsia rickettsii"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31490924",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 220,
"text": "BACKGROUND: Brazilian spotted fever (BSF), caused by the bacterium Rickettsia rickettsii, has been associated with the transmission by the tick Amblyomma sculptum, and one of its main hosts, the capybara (Hydrochoerus hy"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25501172",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 138,
"text": "Amblyomma aureolatum (Pallas) is the main vector of the bacterium Rickettsia rickettsii, the etiological agent of Brazilian spotted fever."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27230435",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 168,
"text": "The hard tick Amblyomma aureolatum (Pallas) is a vector of the bacterium Rickettsia rickettsii, the etiologic agent of Brazilian spotted fever (BSF) in parts of Brazil."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28377149",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 179,
"text": "Brazilian spotted fever (BSF) is an endemic anthropozoonosis caused by Gram-negative bacteria (Rickettsia rickettsii) that is associated with the risk of human infection by ticks."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29050834",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 151,
"text": "Brazilian spotted fever (BSF) is a potentially lethal human disease caused by Rickettsia rickettsii transmitted by ticks, including Amblyomma sculptum."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/17114770",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 89,
"text": "Brazilian spotted fever (BSF) is a highly lethal disease caused by Rickettsia rickettsii."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23168052",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 151,
"text": "Brazilian spotted fever (BSF) caused by Rickettsia rickettsii is the most important rickettsiosis and the only reportable tick-borne disease in Brazil."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/11980610",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 137,
"text": "Brazilian spotted fever, caused by Rickettsia rickettsii, has been increasingly reported in Brazil especially in the southeastern states."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31014644",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 270,
"text": "Brazilian spotted fever (BSF) is a tick-borne disease caused by the bacterium Rickettsia rickettsii, the deadliest spotted fever of the world, transmitted in southeastern Brazil mainly by the tick Amblyomma sculptum, a member of the Amblyomma cajennense species complex."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25483025",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 195,
"text": "Rickettsia rickettsii infection is being increasingly recognized as an important cause of fatal acute illness in Brazil, where this tick-borne disease is designated Brazilian spotted fever (BSF)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21184706",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 97,
"text": "Brazilian spotted fever (BSF) is an emerging disease most likely caused by Rickettsia rickettsii."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36169507",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 306,
"text": "The bacterium Rickettsia rickettsii is the etiological agent of Brazilian spotted fever (BSF), and its most important vector to humans in Brazil is the tick Amblyomma sculptum. Capybaras are the main hosts of A. sculptum in many BSF-endemic areas and are considered valuable sentinels for BSF surveillance."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28535905",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 111,
"text": "In Brazil, Spotted Fever (SF) is caused by Rickettsia rickettsii and Rickettsia parkeri strain Atlantic Forest."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/14718082",
"endSection": "abstract",
"offsetInBeginSection": 178,
"offsetInEndSection": 324,
"text": "The current reemergence of spotted fever rickettsiosis caused by Rickettsia rickettsii in Brazil has resulted in a high proportion of fatal cases."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31490924",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 231,
"text": "BACKGROUND: Brazilian spotted fever (BSF), caused by the bacterium Rickettsia rickettsii, has been associated with the transmission by the tick Amblyomma sculptum, and one of its main hosts, the capybara (Hydrochoerus hydrochaeris)"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28169507",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 230,
"text": "In Brazil, two pathogenic Rickettsia species have been identified causing tick-borne spotted fever (SF). The aetiological agent Rickettsia rickettsii causes serious illness, particularly in the south-eastern region of the country."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31800889",
"endSection": "abstract",
"offsetInBeginSection": 74,
"offsetInEndSection": 169,
"text": "These ticks transmit the bacterium Rickettsia rickettsii, which causes Brazilian Spotted Fever."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31014644",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 161,
"text": "Isolation of Rickettsia rickettsii from the tick Amblyomma sculptum from a Brazilian spotted fever-endemic area in the Pampulha Lake region, southeastern Brazil."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25830998",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 255,
"text": "Brazilian spotted fever is an acute febrile infectious disease caused by Rickettsia rickettsii, transmitted by tick bite. As this disease is rare and has high mortality rates in Brazil, the clinical aspects and epidemiological data may help the diagnosis."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25830998",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 552,
"text": "Brazilian spotted fever is an acute febrile infectious disease caused by Rickettsia rickettsii, transmitted by tick bite. As this disease is rare and has high mortality rates in Brazil, the clinical aspects and epidemiological data may help the diagnosis. We report a case of Brazilian spotted fever in a 19-year-old patient who presented maculopapular exanthema in the palmar region and upper limbs, lymphadenopathy, fever, chills, headache, conjunctival hyperemia, nausea, vomiting, dyspnea, myalgia, developing neurological signs and abdominal pain."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/11980610",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 639,
"text": "Brazilian spotted fever, caused by Rickettsia rickettsii, has been increasingly reported in Brazil especially in the southeastern states. The severe and fulminant forms of the disease are not unusual but most of the reported fatal cases have shown some typical clinical clue, which leads the attending physician to a correct diagnosis. We report a probable case of atypical fulminant Brazilian spotted fever that presented full-blown septic shock associated with Adult Respiratory Distress Syndrome (ARDS) and delayed uncharacteristic rash with an over four-fold increase in reciprocal IgM, but not IgG titer against Rickettsia rickettsii."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/11980610",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 335,
"text": "Brazilian spotted fever, caused by Rickettsia rickettsii, has been increasingly reported in Brazil especially in the southeastern states. The severe and fulminant forms of the disease are not unusual but most of the reported fatal cases have shown some typical clinical clue, which leads the attending physician to a correct diagnosis."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31742533",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 266,
"text": "In São Paulo metropolitan area, Brazil, Amblyomma aureolatum ticks are the main vector of Rickettsia rickettsii, which causes Brazilian spotted fever. In 2013, a boy in São Paulo died of Brazilian spotted fever associated with household dogs and A. aureolatum ticks."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31742533",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 337,
"text": "In São Paulo metropolitan area, Brazil, Amblyomma aureolatum ticks are the main vector of Rickettsia rickettsii, which causes Brazilian spotted fever. In 2013, a boy in São Paulo died of Brazilian spotted fever associated with household dogs and A. aureolatum ticks. Prompt recognition and treatment of this illness might prevent deaths."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18949349",
"endSection": "abstract",
"offsetInBeginSection": 96,
"offsetInEndSection": 180,
"text": "Brazilian spotted fever (BSF; caused by Rickettsia rickettsii) in Minas Gerais State"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27812666",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 239,
"text": "Brazilian spotted fever (BSF) is caused by the bacterium Rickettsia rickettsii. Because of its high case-fatality rate and apparent increase in areas of transmission, it is considered to be the rickettsial illness of primary public health "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27880877",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 262,
"text": "Brazilian Spotted Fever (BSF) is a zoonotic disease caused by the bacterium Rickettsia rickettsii. In the São Paulo Metropolitan Region (SPMR) it is transmitted by Amblyomma aureolatum ticks. In this region, annual lethality of the disease can reach 80% and spat"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/11980610",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 129,
"text": "Brazilian spotted fever, caused by Rickettsia rickettsii, has been increasingly reported in Brazil especially in the southeastern"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23168052",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 185,
"text": "Brazilian spotted fever (BSF) caused by Rickettsia rickettsii is the most important rickettsiosis and the only reportable tick-borne disease in Brazil. In Brazil, the hard tick Amblyomm"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32315604",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 201,
"text": "Brazilian spotted fever (BSF) is a highly lethal disease in southeastern Brazil. BSF is caused by the bacterium Rickettsia rickettsii and is transmitted by the bites of the tick of the genus Amblyomma."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33825800",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 232,
"text": "Brazilian spotted fever (BSF) is a common tick-borne disease caused by Rickettsia rickettsii. Horses are the primary hosts of the main vector, Amblyomma sculptum, and are considered efficient sentinels for circulation of Rickettsia."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36169507",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 176,
"text": "The bacterium Rickettsia rickettsii is the etiological agent of Brazilian spotted fever (BSF), and its most important vector to humans in Brazil is the tick Amblyomma sculptum."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27812666",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 80,
"text": "Brazilian spotted fever (BSF) is caused by the bacterium Rickettsia rickettsii. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23168052",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 395,
"text": "Brazilian spotted fever (BSF) caused by Rickettsia rickettsii is the most important rickettsiosis and the only reportable tick-borne disease in Brazil. In Brazil, the hard tick Amblyomma cajennense is the most important BSF vector; however, in São Paulo State, A. aureolatum was also recognized as a vector species in remaining Atlantic forest areas near the metropolitan area of São Paulo city."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25148391",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 195,
"text": "Rocky Mountain spotted fever is endemic to the São Paulo metropolitan area, Brazil, where the etiologic agent, Rickettsia rickettsii, is transmitted to humans by adult Amblyomma aureolatum ticks."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30334709",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 127,
"text": "Amblyomma aureolatum ticks are vectors of Rickettsia rickettsii, the etiologic agent of Rocky Mountain spotted fever in Brazil."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/19538276",
"endSection": "abstract",
"offsetInBeginSection": 84,
"offsetInEndSection": 290,
"text": "Rickettsia rickettsii, transmitted by the ticks Amblyomma cajennense, and Amblyomma aureolatum, reported in Colombia, Argentina, and Brazil, where it is the etiological agent of Rocky Mountain spotted fever"
}
] | 13
|
BioASQ-training13b
| null | null |
660c0486fdcbea915f00002d
| 5,307
|
factoid
|
What is the first-line treatment for BRAF mutated advanced colorectal cancer patients?
|
['FOLFOXIRI plus Bevacizumab', 'FOLFOXIRI + Bevacizumab']
|
[
"FOLFOXIRI plus Bevacizumab",
"FOLFOXIRI + Bevacizumab",
"FOLFOXIRI with Bevacizumab",
"FOLFOXIRI and Bevacizumab"
] |
['The first-line treatment for BRAF mutated advanced colorectal cancer patients is chemotherapy with bevacizumab as well as 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab in patients with a good performance status.', 'The first-line treatment for BRAF mutated advanced colorectal cancer patients has been a subject of intense debate and research. A triplet regimen, which consists of BRAF inhibitor, MEK inhibitor and EGFR inhibitor has shown to provide promising results for patients with BRAF-mutant advanced colorectal cancer in comparison to conventional doublet chemotherapy.', 'The first-line treatment for BRAF mutated advanced colorectal cancer typically involves chemotherapy with bevacizumab, as well as 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab in patients with a good performance status. However, recent clinical research has shown promising results for combination strategies involving mitogen-activated protein kinase (MAPK) pathway blockade, such as the Binimetinib, Encorafenib, And Cetuximab cOmbiNed to treat BRAF-mutant Colorectal Cancer (BEACON CRC) study. This study provided strong clinical evidence to support BRAF and epidermal growth factor receptor inhibition with the combination of encorafenib plus cetuximab in BRAF V600E-mutated mCRC. As', 'The first-line treatment for BRAF mutated advanced colorectal cancer patients includes bevacizumab, chemotherapy, and chemotherapy\u2009+\u2009bevacizumab.', 'The first-line treatment for BRAF mutated advanced colorectal cancer patients is chemotherapy, which includes cytotoxic chemotherapy plus bevacizumab.', 'The first-line treatment for BRAF-mutated advanced colorectal cancer includes chemotherapy with bevacizumab, and specifically the regimen of 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab for patients with good performance status.', 'The first-line treatment for BRAF-mutated advanced colorectal cancer includes chemotherapy with bevacizumab and a regimen of 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan, known as FOLFOXIRI, particularly for patients with good performance status.', 'The current standard first-line treatment for BRAF-mutated advanced colorectal cancer patients is chemotherapy with bevacizumab, as well as 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab in patients with a good performance status.', 'Chemotherapy with bevacizumab, 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab is the first-line treatment for BRAF mutated advanced colorectal cancer patients.', 'The first-line treatment for BRAF mutated advanced colorectal cancer patients is chemotherapy with bevacizumab, as well as 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab in patients with a good performance status.', 'Chemotherapy with bevacizumab as well as 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab is the first-line treatment for BRAF mutated advanced colorectal cancer patients.', 'The first-line treatment for BRAF-mutated advanced colorectal cancer patients typically involves a combination of chemotherapy with bevacizumab, such as the FOLFOXIRI regimen, which includes 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan, along with bevacizumab. This treatment approach has shown efficacy in improving outcomes for these patients, regardless of their RAS and BRAF mutational status. Additionally, FOLFOXIRI plus bevacizumab is considered a preferred first-line treatment option for clinically selected patients with right-sided metastatic colorectal cancer.', 'The current standard first-line treatment options for BRAF-mutated metastatic colorectal cancer (mCRC) are:\n\n1. Chemotherapy with bevacizumab \n2. FOLFOXIRI (5-fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab in patients with a good performance status\n\nFOLFOXIRI plus bevacizumab is a feasible treatment option for eligible patients irrespective of baseline clinical characteristics and RAS or BRAF mutational status. However, patients with BRAF mutations have worse overall survival compared to those with RAS mutations or RAS/BRAF wild-type.', 'The first-line treatment for BRAF-mutated advanced colorectal cancer patients typically involves a combination of cytotoxic chemotherapy and an antiangiogenic antibody, such as bevacizumab.', 'The first-line treatment for advanced colorectal cancer patients with a BRAF mutation includes FOLFOXIRI combined with bevacizumab, or chemotherapy alongside bevacizumab, incorporating drugs like 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan.', 'The current standard therapies for first-line treatment of BRAF-mutated mCRC include chemotherapy with bevacizumab and 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab in patients with a good performance status.', 'The first-line treatment for BRAF-mutated advanced colorectal cancer (mCRC) typically includes chemotherapy combined with bevacizumab. Specifically, regimens such as 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab are used, especially in patients who have a good performance status. This approach is feasible for patients who meet specific study inclusion criteria, regardless of their RAS or BRAF mutational status.', 'The first-line treatment for BRAF mutated advanced colorectal cancer patients is a fluoropyrimidine-based cytotoxic regimen in combination with bevacizumab.', 'The current standard first-line treatment for BRAF-mutated advanced colorectal cancer patients involves chemotherapy with bevacizumab, along with a combination of 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab, especially in patients with a good performance status. FOLFOXIRI plus bevacizumab is considered a feasible treatment option for eligible patients, regardless of baseline clinical characteristics and RAS or BRAF mutational status.', 'The current standard therapies for first-line treatment of BRAF-mutated mCRC are chemotherapy with bevacizumab as well as 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab in patients with a good performance status. FOLFOXIRI plus bevacizumab is a feasible treatment option for those patients who meet the inclusion criteria of the present study, irrespective of baseline clinical characteristics and RAS or BRAF mutational status', 'The first-line treatment for BRAF-mutated advanced colorectal cancer typically includes chemotherapy combined with bevacizumab, specifically using regimens like FOLFOXIRI (5-fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab, especially in patients with good performance status', 'The standard first-line treatment for BRAF mutated advanced colorectal cancer (mCRC) typically involves combination chemotherapy with or without targeted therapy, such as bevacizumab or cetuximab. For patients with wild-type RAS and BRAF mutations, the addition of anti-EGFR antibodies like cetuximab to standard chemotherapy has shown improved outcomes compared to chemotherapy alone. However, for those with BRAF V600E mutation specifically, response rates to these treatments are generally lower, and more recent data suggest that a combination therapy including BRAF inhibitors (e.g., encorafenib) along with anti-EGFR antibodies may provide better outcomes in the first-line setting. It is important to note that treatment options can vary based on individual patient characteristics, disease stage, and molecular profiling results.', 'The first-line treatment for BRAF mutated advanced colorectal cancer patients typically involves a combination of chemotherapy and targeted therapy. The current standard therapies include fluoropyrimidine-based cytotoxic regimen with bevacizumab, or FOLFOXIRI plus bevacizumab in patients with good performance status. Recently, combination strategies involving mitogen-activated protein kinase (MAPK) pathway blockade have shown promising results for the treatment of patients with BRAF V600E-mutated mCRC. The largest study to date is the Binimetinib, Encorafenib, And Cetuximab cOmbiNed to treat BRAF-mutant ColoRectal Cancer (BEACON CRC) study, which has provided strong clinical evidence for BRAF and epidermal growth factor receptor inhibition with the combination of encorafenib plus cetuximab.', 'The current standard first-line treatment for BRAF-mutated metastatic colorectal cancer (mCRC) patients is FOLFOXIRI (5-fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab, especially for patients with a good performance status. Triplet chemotherapy (FOLFOXIRI) plus bevacizumab is indicated as a preferred option for these patients, irrespective of their RAS mutational status.', "The current standard first-line treatment for BRAF mutated advanced colorectal cancer patients is a combination of chemotherapy with bevacizumab (a monoclonal antibody that targets vascular endothelial growth factor) and either 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) or 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI), depending on the patient's performance status and other factors. This treatment is recommended for patients with a good performance status, as FOLFOXIRI plus bevacizumab is a feasible treatment option for those who meet the inclusion criteria, irrespective of baseline clinical characteristics and RAS or BRAF mutational status. However, the median overall survival is shorter in patients with RAS-mutation-positive or BRAF-mutation-positive tumors compared to those with RAS and BRAF wild-type tumors (25.6 months vs. 37.1 months vs. 13.4 months, respectively).", 'Triplet chemotherapy (FOLFOXIRI) + bevacizumab regimen is indicated as first-line treatment of BRAF-mutated metastatic colorectal cancer (mCRC).', 'The first-line treatment for BRAF-mutated advanced colorectal cancer (mCRC) typically includes chemotherapy combined with bevacizumab, specifically using regimens like 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab, especially in patients with good performance status. This approach is feasible for patients who meet specific study inclusion criteria, regardless of their RAS or BRAF mutational status.', 'The first-line treatment for BRAF mutated advanced colorectal cancer patients is chemotherapy with bevacizumab, FOLFOXIRI plus bevacizumab, and bevacizumab.', 'The first-line treatment for BRAF mutated advanced colorectal cancer patients is not well established, as there are limited data and no consensus on the optimal approach. However, a phase II study known as NIVACOR is currently investigating the combination of triplet chemotherapy (FOLFOXIRI) with bevacizumab and nivolumab in patients with mCRC RAS/BRAF mutated, regardless of microsatellite status. The primary endpoint of the study is the overall response rate, and secondary endpoints include overall survival, safety, time to progression, and duration of response. Additionally, translational studies are being conducted to evaluate tumor mutational burden and genetic alterations by circulating free DNA (cfDNA) obtained from plasma samples. The trial is currently open to enrollment.', 'The first-line treatment for BRAF mutated advanced colorectal cancer (mCRC) patients includes chemotherapy with bevacizumab and 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab. This combination therapy has been found to be a feasible treatment option for mCRC patients with a good performance status, regardless of their baseline clinical characteristics or RAS or BRAF mutational status. However, it is important to note that the median overall survival (OS) for BRAF-mutation-positive subgroups is shorter compared to RAS and BRAF wild-type subgroups. The OS for BRAF-mutation-positive patients is 13.4 months (95% CI 8.2-24.1), while for RAS and BRAF wild-type subgroups,', 'The first-line treatment for BRAF mutated advanced colorectal cancer patients would be a combination of BRAF, MEK, and EGFR inhibitors.', 'The current standard first-line treatment for BRAF-mutated advanced colorectal cancer patients is chemotherapy with bevacizumab, as well as 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab. This treatment regimen has shown improved overall survival compared to other treatment options.', "The current standard first-line treatment for BRAF mutated advanced colorectal cancer (mCRC) patients is chemotherapy with either 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) or capecitabine and irinotecan (XELOXI), both in combination with the anti-EGFR antibody panitumumab or cetuximab. However, patients with BRAF mutations should not receive anti-EGFR therapy as it has been shown to be ineffective and may even worsen outcomes. Therefore, the choice of chemotherapy regimen and anti-EGFR antibody should be based on other factors such as patient's performance status, prior chemotherapy, and RAS mutational status. Bevacizum", '1. Chemotherapy with bevacizumab and 2. FOLFOXIRI plus bevacizumab in patients with good performance status are the first-line treatment options for BRAF-mutated metastatic colorectal cancer.', 'The first-line treatment for BRAF mutated advanced colorectal cancer patients is chemotherapy with bevacizumab as well as 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab.', 'chemotherapy with bevacizumab as well as 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/37352476",
"http://www.ncbi.nlm.nih.gov/pubmed/30120161",
"http://www.ncbi.nlm.nih.gov/pubmed/24390240",
"http://www.ncbi.nlm.nih.gov/pubmed/35130499",
"http://www.ncbi.nlm.nih.gov/pubmed/23666916",
"http://www.ncbi.nlm.nih.gov/pubmed/32326305",
"http://www.ncbi.nlm.nih.gov/pubmed/33734401",
"http://www.ncbi.nlm.nih.gov/pubmed/36475784",
"http://www.ncbi.nlm.nih.gov/pubmed/33914242",
"http://www.ncbi.nlm.nih.gov/pubmed/30592501",
"http://www.ncbi.nlm.nih.gov/pubmed/31661924",
"http://www.ncbi.nlm.nih.gov/pubmed/35649231",
"http://www.ncbi.nlm.nih.gov/pubmed/36849918",
"http://www.ncbi.nlm.nih.gov/pubmed/27943689",
"http://www.ncbi.nlm.nih.gov/pubmed/37971411",
"http://www.ncbi.nlm.nih.gov/pubmed/28214977",
"http://www.ncbi.nlm.nih.gov/pubmed/33108877",
"http://www.ncbi.nlm.nih.gov/pubmed/37815847",
"http://www.ncbi.nlm.nih.gov/pubmed/33836264",
"http://www.ncbi.nlm.nih.gov/pubmed/26338525",
"http://www.ncbi.nlm.nih.gov/pubmed/31455117",
"http://www.ncbi.nlm.nih.gov/pubmed/33987088",
"http://www.ncbi.nlm.nih.gov/pubmed/37455182",
"http://www.ncbi.nlm.nih.gov/pubmed/34761599",
"http://www.ncbi.nlm.nih.gov/pubmed/37639010",
"http://www.ncbi.nlm.nih.gov/pubmed/32867715",
"http://www.ncbi.nlm.nih.gov/pubmed/37760573",
"http://www.ncbi.nlm.nih.gov/pubmed/32318348",
"http://www.ncbi.nlm.nih.gov/pubmed/24138831",
"http://www.ncbi.nlm.nih.gov/pubmed/37369457"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33836264",
"endSection": "abstract",
"offsetInBeginSection": 883,
"offsetInEndSection": 1132,
"text": "The current standard therapies for first-line treatment of BRAF-mutated mCRC are chemotherapy with bevacizumab as well as 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab in patients with a good performance status"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26338525",
"endSection": "abstract",
"offsetInBeginSection": 2733,
"offsetInEndSection": 2947,
"text": "FOLFOXIRI plus bevacizumab is a feasible treatment option for those patients who meet the inclusion criteria of the present study, irrespective of baseline clinical characteristics and RAS or BRAF mutational status"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26338525",
"endSection": "abstract",
"offsetInBeginSection": 2292,
"offsetInEndSection": 2621,
"text": "Median overall survival was 37·1 months (95% CI 29·7-42·7) in the RAS and BRAF wild-type subgroup compared with 25·6 months (22·4-28·6) in the RAS-mutation-positive subgroup (HR 1·49, 95% CI 1·11-1·99) and 13·4 months (8·2-24·1) in the BRAF-mutation-positive subgroup (HR 2·79, 95% CI 1·75-4·46; likelihood-ratio test p<0·0001). "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32326305",
"endSection": "abstract",
"offsetInBeginSection": 49,
"offsetInEndSection": 329,
"text": "the most frequently used first-line treatments for patients with BRAF-mutant colorectal cancer (CRC), while second-line treatment requires extensive further research. In this pooled analysis, we evaluate the impact of anti-angiogenics in patients with pre-treated BRAF-mutant CRC."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35649231",
"endSection": "abstract",
"offsetInBeginSection": 579,
"offsetInEndSection": 822,
"text": "for patients with BRAFV600E-mutated metastatic colorectal cancer include first-line cytotoxic chemotherapy plus bevacizumab and subsequent therapy with the BRAF inhibitor encorafenib and antiepidermal growth factor receptor antibody cetuximab."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36475784",
"endSection": "abstract",
"offsetInBeginSection": 131,
"offsetInEndSection": 300,
"text": "However, there are no clear recommendations regarding first-line therapy for patients with early recurrent BRAF V600E-mutated CRC, during or after adjuvant chemotherapy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33836264",
"endSection": "abstract",
"offsetInBeginSection": 1313,
"offsetInEndSection": 1730,
"text": "The Binimetinib, Encorafenib, And Cetuximab cOmbiNed to treat BRAF-mutant ColoRectal Cancer (BEACON CRC) study represents the largest study in this population to date and has given strong clinical evidence to support BRAF and epidermal growth factor receptor inhibition with the combination of encorafenib plus cetuximab.CONCLUSIONS: The treatment of BRAF-mutated mCRC has evolved rapidly over the last several years."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36849918",
"endSection": "abstract",
"offsetInBeginSection": 1635,
"offsetInEndSection": 1959,
"text": "Surgical treatment of the primary tumor (P = 0.041; HR, 0.523; 95% CI, 0.280-0.974) was significantly associated with PFS too.CONCLUSION: For patients with BRAF V600E-mutated advanced CRC, chemotherapy alone did not differ significantly in OS and PFS compared with chemotherapy + bevacizumab for advanced first-line therapy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35649231",
"endSection": "abstract",
"offsetInBeginSection": 504,
"offsetInEndSection": 822,
"text": "On the basis of recent clinical trials, current standard-of-care therapies for patients with BRAFV600E-mutated metastatic colorectal cancer include first-line cytotoxic chemotherapy plus bevacizumab and subsequent therapy with the BRAF inhibitor encorafenib and antiepidermal growth factor receptor antibody cetuximab."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33836264",
"endSection": "abstract",
"offsetInBeginSection": 855,
"offsetInEndSection": 1105,
"text": "es in this setting.RESULTS: The current standard therapies for first-line treatment of BRAF-mutated mCRC are chemotherapy with bevacizumab as well as 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab in patients wit"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24138831",
"endSection": "abstract",
"offsetInBeginSection": 1571,
"offsetInEndSection": 1685,
"text": "domised trials in this specific molecular subgroup, FOLFOXIRI plus bevacizumab might be a reasonable option for th"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26338525",
"endSection": "abstract",
"offsetInBeginSection": 2659,
"offsetInEndSection": 2874,
"text": " different across molecular subgroups (pinteraction=0·52).INTERPRETATION: FOLFOXIRI plus bevacizumab is a feasible treatment option for those patients who meet the inclusion criteria of the present study, irrespecti"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28214977",
"endSection": "abstract",
"offsetInBeginSection": 1037,
"offsetInEndSection": 1276,
"text": "Despite the lack of a randomized phase 3 study dedicated to BRAF-mutated CRC, chemotherapy intensification combining a quadruple association of 5-fluorouracil, oxaliplatin, irinotecan (FOLFOXIRI), and bevacizumab seems like a valid option."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32867715",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 201,
"text": "BACKGROUND: FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab has shown to be one of the therapeutic regimens in first line with the highest activity in patients (pts.)"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37639010",
"endSection": "abstract",
"offsetInBeginSection": 770,
"offsetInEndSection": 1282,
"text": "This article reviews the progress of clinical research on molecularly targeted drugs, immune checkpoint inhibitors, first-line chemotherapeutic agents, and different combination therapy regimens (including different targeted drug combinations, immune combination targeting, and chemotherapy combination targeting) for colorectal cancer patients with BRAF V600E mutation, which provides a reference for further in-depth clinical exploration of the treatment of colorectal cancer patients with BRAF V600E mutation."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36475784",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 94,
"text": "TRESBIEN (OGSG 2101): encorafenib, binimetinib and cetuximab for early recurrent stage II/III "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37352476",
"endSection": "abstract",
"offsetInBeginSection": 1458,
"offsetInEndSection": 1763,
"text": "Median OS analyzed at an event rate of 64.5% showed a trend toward shorter survival in cetuximab-treated patients (12.9 months v 17.1 months; HR, 1.4; P = .20).CONCLUSION: To our knowledge, FIRE-4.5 is the first prospective and randomized study investigating first-line treatment of BRAFV600E-mutant mCRC."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37352476",
"endSection": "abstract",
"offsetInBeginSection": 1914,
"offsetInEndSection": 2028,
"text": "Bevacizumab-based chemotherapy remains the preferable first-line treatment of patients with BRAFV600E-mutant mCRC."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31661924",
"endSection": "abstract",
"offsetInBeginSection": 429,
"offsetInEndSection": 657,
"text": "Chemotherapy plus bevacizumab is the current standard therapy in first-line treatment of BRAF-mutated metastatic CRC (mCRC), with triplet (FOLFOXIRI) plus bevacizumab as a valid option in patients with a good performance status."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35130499",
"endSection": "abstract",
"offsetInBeginSection": 1147,
"offsetInEndSection": 1353,
"text": "95% CI, 0.41-0.56; P<.001). Only 3% of patients with BRAF mutations received first-line FOLFOXIRI ± bevacizumab, with a median OS of 13.8 months compared with 15.5 months in those treated with doublet chemo"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35130499",
"endSection": "abstract",
"offsetInBeginSection": 1354,
"offsetInEndSection": 1629,
"text": "herapy ± bevacizumab (P=.38). In patients with BRAF mutations, propensity-weighted analysis did not detect a significant improvement in OS with FOLFIRI + bevacizumab (HR, 0.90; 95% CI, 0.58-1.39; P=.63) or FOLFOX/CAPEOX + bevacizumab (HR, 0.81; 95% CI, 0.52-1.26; P=.35) vers"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27943689",
"endSection": "abstract",
"offsetInBeginSection": 1009,
"offsetInEndSection": 1318,
"text": "Currently, three biologic agents-bevacizumab, cetuximab, and panitumumab-are approved for first-line treatment of metastatic colorectal cancer. For patients with mutant RAS and likely mutant BRAF V600E tumors, bevacizumab is the only biologic agent that can be used in conjunction with cytotoxic chemotherapy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27943689",
"endSection": "abstract",
"offsetInBeginSection": 1153,
"offsetInEndSection": 1318,
"text": "For patients with mutant RAS and likely mutant BRAF V600E tumors, bevacizumab is the only biologic agent that can be used in conjunction with cytotoxic chemotherapy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34761599",
"endSection": "abstract",
"offsetInBeginSection": 1049,
"offsetInEndSection": 1377,
"text": "Multivariate analysis indicated that age (HR:0.41,p=0.045), primary tumor resection (HR:0.41,p=0.037) and primary tumor localization (HR:0.38,p=0.021) for PFS and age (HR:0.39, p=0.09), the presence of BRAF mutation (HR:0.59,p=0.019) and the type of targeted therapy (HR:3.16,p=0.025) for OS were independent prognostic factors."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35649231",
"endSection": "abstract",
"offsetInBeginSection": 499,
"offsetInEndSection": 1208,
"text": "ing. On the basis of recent clinical trials, current standard-of-care therapies for patients with BRAFV600E-mutated metastatic colorectal cancer include first-line cytotoxic chemotherapy plus bevacizumab and subsequent therapy with the BRAF inhibitor encorafenib and antiepidermal growth factor receptor antibody cetuximab. Treatment regimens currently under exploration in BRAFV600E-mutant metastatic colorectal cancer include combinatorial options of various pathway-targeted therapies, cytotoxic chemotherapy, and/or immune checkpoint blockade, among others. Circumvention of adaptive and acquired resistance to BRAF-targeted therapies is a significant challenge to be overcome in BRAF-mutated advanced col"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35649231",
"endSection": "abstract",
"offsetInBeginSection": 499,
"offsetInEndSection": 1045,
"text": "ing. On the basis of recent clinical trials, current standard-of-care therapies for patients with BRAFV600E-mutated metastatic colorectal cancer include first-line cytotoxic chemotherapy plus bevacizumab and subsequent therapy with the BRAF inhibitor encorafenib and antiepidermal growth factor receptor antibody cetuximab. Treatment regimens currently under exploration in BRAFV600E-mutant metastatic colorectal cancer include combinatorial options of various pathway-targeted therapies, cytotoxic chemotherapy, and/or immune checkpoint blockade"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35649231",
"endSection": "abstract",
"offsetInBeginSection": 499,
"offsetInEndSection": 812,
"text": "ing. On the basis of recent clinical trials, current standard-of-care therapies for patients with BRAFV600E-mutated metastatic colorectal cancer include first-line cytotoxic chemotherapy plus bevacizumab and subsequent therapy with the BRAF inhibitor encorafenib and antiepidermal growth factor receptor antibody "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33108877",
"endSection": "abstract",
"offsetInBeginSection": 216,
"offsetInEndSection": 562,
"text": " BRAF mutated colorectal cancer define specific challenging subgroup associated with dismal prognosis, lower rate of response rate, shorter progression free survival and overall survival. Current treatment choices are associated with poor outcomes. For the first line treatment doublet or triplet chemotherapy plus antiangiogenic antibody is used"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30120161",
"endSection": "abstract",
"offsetInBeginSection": 2023,
"offsetInEndSection": 2173,
"text": "utated mCRC with progression following first-line with FOLFOXIRI plus bevacizumab, although tolerability was acceptable. Our trial suggests that explo"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33836264",
"endSection": "abstract",
"offsetInBeginSection": 802,
"offsetInEndSection": 1852,
"text": "mCRC, with a focus on recent clinical research advances in this setting.RESULTS: The current standard therapies for first-line treatment of BRAF-mutated mCRC are chemotherapy with bevacizumab as well as 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab in patients with a good performance status. Combination strategies involving mitogen-activated protein kinase (MAPK) pathway blockade have shown promising results for the treatment of patients with BRAF V600E-mutated mCRC. The Binimetinib, Encorafenib, And Cetuximab cOmbiNed to treat BRAF-mutant ColoRectal Cancer (BEACON CRC) study represents the largest study in this population to date and has given strong clinical evidence to support BRAF and epidermal growth factor receptor inhibition with the combination of encorafenib plus cetuximab.CONCLUSIONS: The treatment of BRAF-mutated mCRC has evolved rapidly over the last several years. Recently, combination strategies involving MAPK pathway blockade have shown promising results in BRAF V600E-mutated mCRC,"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32318348",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1528,
"text": "Colorectal cancer (CRC) is a highly lethal disease worldwide. The majority of patients receiving targeted therapy or chemotherapy develop drug resistance, while its molecular mechanism remains to be elucidated. The plasma circulating tumor DNA (ctDNA) exhibited the potential in identifying gene variations and monitoring drug resistance in CRC treatment. In this study, we monitored the ctDNA mutational changes in advanced CRC patients underwent first-line therapy with bevacizumab and cetuximab combined with chemotherapy. The mutation spectrum of 43 patients was established by a 605-gene next-generation sequencing (NGS) panel. The baseline measurement shows that genes with the highest mutation frequency were TP53 (74%), APC (58%), KRAS (40%), SYNE1 (33%), LRP1B (23%), TOP1 (23%), and PIK3CA (21%). Mutations in TP53, APC, and KRAS were detected in 29 paired plasma and tissue samples with the consistency of 81, 67, and 42%, respectively. Clinically targetable gene mutations, such as APC, RNF43, SMAD4, BRAD1, KRAS, RAF1, and TP53, were also identified in ctDNA. The overall consistency between ctDNA and tissue samples was 54.6%. Alleviation of mutational burden in BRAF, KRAS, AMER1, and other major driving genes was observed following the first-line therapy. Patients with KRAS and TP53 mutations in tissues appeared to benefit more than the wild-type counterpart. The dynamic change of plasma mutation status was consistent with the tissue tumor burden and was closely correlated with disease progression. In conc"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33108877",
"endSection": "abstract",
"offsetInBeginSection": 453,
"offsetInEndSection": 845,
"text": "r outcomes. For the first line treatment doublet or triplet chemotherapy plus antiangiogenic antibody is used. To date, there were no reasonable treatment options in the second line settings. Recently published BEACON trial sets new standard of treatment with combination of encorafenib plus cetuximab, which led to significantly longer overall survival and overall response compared to stand"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24138831",
"endSection": "abstract",
"offsetInBeginSection": 292,
"offsetInEndSection": 473,
"text": " trial that FOLFOXIRI (5-FU/LV+Oxaliplatin+Irinotecan) plus bevacizumab might allow to achieve remarkable results in terms of PFS and Overall Survival (OS) also in this poor-prognos"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24138831",
"endSection": "abstract",
"offsetInBeginSection": 1508,
"offsetInEndSection": 1685,
"text": "rol rate were 72% and 88%, respectively.CONCLUSION: Lacking randomised trials in this specific molecular subgroup, FOLFOXIRI plus bevacizumab might be a reasonable option for th"
}
] | 13
|
BioASQ-training13b
| null | null |
66099a25fdcbea915f00001e
| 5,309
|
factoid
|
What is the prevalence of neurofibromatosis?
|
['Pooled NF1 prevalence was 1 in 3,164, NF1 pooled birth incidence was 1 in 2,662', 'prevalence of NF1 is about 1 in 2,500 to 3,000 and of NF2 is about 1 in 25,000 to 40,000 people']
|
[
"Neurofibromatosis type 1",
"NF1",
"von Recklinghausen disease",
"Neurofibromatosis",
"Neurofibromatosis type 2",
"NF2"
] |
['Neurofibromatosis is a common genetic disorder that affects the growth and development of nerve tissue. It is typically inherited in an autosomal dominant pattern and there are 2 main subtypes: neurofibromatosis type 1 (NF1) and neurofibromatosis type 2 (NF2). The prevalence of NF1 is approximately 1 in 3,000 births, while NF2 is less common with a prevalence of approximately 1 in 25,000 births.', 'Neurofibromatosis (NF) is a group of three distinct genetic conditions affecting the nervous system, characterized by non-cancerous tumors. The prevalence of NF1 is approximately 1 in 3,500, NF2 is approximately 1 in 25,000, and schwannomatosis is approximately 1 in 40,000. NF1 is the most common type of NF and is characterized by café au lait spots, neurofibromas, scoliosis, and headaches. NF2 presents with early-onset hearing loss, cataracts, tinnitus, and muscle atrophy. Schwannomatosis often presents in early adulthood with widespread pain, numbness, or tingling. There is no known prevention or cure, but surgery, radiation, and chemotherapy may be used to manage symptoms.', 'The prevalence of neurofibromatosis varies by type:\n\nNeurofibromatosis type 1 (NF1) is the most common, with a birth incidence of about 1 in 2,500 to 1 in 3,000. \n\nNeurofibromatosis type 2 (NF2) is less common, with an incidence of about 1 in 25,000 to 1 in 33,000 births.\n\nSchwannomatosis is the rarest, with an incidence of about 1 in 40,000 to 1 in 60,000 births.\n\nAll types affect males and females equally across all races and ethnicities. The neurofibromatoses are considered rare genetic disorders based on these prevalence figures.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/32499294",
"http://www.ncbi.nlm.nih.gov/pubmed/22041820",
"http://www.ncbi.nlm.nih.gov/pubmed/8880865",
"http://www.ncbi.nlm.nih.gov/pubmed/19117870",
"http://www.ncbi.nlm.nih.gov/pubmed/25838692",
"http://www.ncbi.nlm.nih.gov/pubmed/31625703",
"http://www.ncbi.nlm.nih.gov/pubmed/36317063",
"http://www.ncbi.nlm.nih.gov/pubmed/19568505",
"http://www.ncbi.nlm.nih.gov/pubmed/21707352",
"http://www.ncbi.nlm.nih.gov/pubmed/1600579",
"http://www.ncbi.nlm.nih.gov/pubmed/19587630",
"http://www.ncbi.nlm.nih.gov/pubmed/24621365",
"http://www.ncbi.nlm.nih.gov/pubmed/9864698",
"http://www.ncbi.nlm.nih.gov/pubmed/16583938",
"http://www.ncbi.nlm.nih.gov/pubmed/23162593",
"http://www.ncbi.nlm.nih.gov/pubmed/8953130",
"http://www.ncbi.nlm.nih.gov/pubmed/17509168",
"http://www.ncbi.nlm.nih.gov/pubmed/29215653",
"http://www.ncbi.nlm.nih.gov/pubmed/3088347",
"http://www.ncbi.nlm.nih.gov/pubmed/22357435",
"http://www.ncbi.nlm.nih.gov/pubmed/26854064",
"http://www.ncbi.nlm.nih.gov/pubmed/15655144",
"http://www.ncbi.nlm.nih.gov/pubmed/10469430",
"http://www.ncbi.nlm.nih.gov/pubmed/33395412",
"http://www.ncbi.nlm.nih.gov/pubmed/21232201",
"http://www.ncbi.nlm.nih.gov/pubmed/20082463",
"http://www.ncbi.nlm.nih.gov/pubmed/20412983",
"http://www.ncbi.nlm.nih.gov/pubmed/15105854",
"http://www.ncbi.nlm.nih.gov/pubmed/31763299",
"http://www.ncbi.nlm.nih.gov/pubmed/32657748",
"http://www.ncbi.nlm.nih.gov/pubmed/37710322",
"http://www.ncbi.nlm.nih.gov/pubmed/34408961"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37710322",
"endSection": "abstract",
"offsetInBeginSection": 926,
"offsetInEndSection": 979,
"text": "Pooled NF2 birth incidence was 1.08 per 50,000 births"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37710322",
"endSection": "abstract",
"offsetInBeginSection": 782,
"offsetInEndSection": 823,
"text": "NF1 pooled birth incidence was 1 in 2,662"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37710322",
"endSection": "abstract",
"offsetInBeginSection": 562,
"offsetInEndSection": 598,
"text": "Pooled NF1 prevalence was 1 in 3,164"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/19117870",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 141,
"text": "Neurofibromatosis type 1 (NF1) is an autosomal dominant condition with a worldwide incidence of approximately 1 per 2500 to 3000 individuals."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/15655144",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 485,
"text": "OBJECTIVE: To determine the prevalence of neurofibromatosis 1 (NF1) among 6-year-old children in Germany.SETTING AND PATIENTS: A total of 152819 children aged 6 years in 6 German states were screened for NF1 during routine medical examinations at elementary school enrollment in cooperation with local health departments in 2000 and 2001.MAIN OUTCOME MEASURE: The prevalence of NF1 among 6-year-old German children was estimated to be 1:2996 (95% confidence interval, 1:2260 to 1:3984)"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/20412983",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 125,
"text": "Neurofibromatosis type 1 (NF1) is an autosomal dominant neurocutaneous disorder with an estimated prevalence of about 1/3000."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/19117870",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 285,
"text": "Neurofibromatosis type 1 (NF1) is an autosomal dominant condition with a worldwide incidence of approximately 1 per 2500 to 3000 individuals. Caused by a germ-line-inactivating mutation in the NF1 gene on chromosome 17, the disease is associated with increased morbidity and mortality."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/19117870",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 435,
"text": "Neurofibromatosis type 1 (NF1) is an autosomal dominant condition with a worldwide incidence of approximately 1 per 2500 to 3000 individuals. Caused by a germ-line-inactivating mutation in the NF1 gene on chromosome 17, the disease is associated with increased morbidity and mortality. In the past several years, significant progress has been made in standardizing management of the major clinical features of neurofibromatosis type 1."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/20412983",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 226,
"text": "Neurofibromatosis type 1 (NF1) is an autosomal dominant neurocutaneous disorder with an estimated prevalence of about 1/3000. Several authors mention the occurrence of various types of speech abnormalities associated with NF1."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37710322",
"endSection": "abstract",
"offsetInBeginSection": 926,
"offsetInEndSection": 1152,
"text": "Pooled NF2 birth incidence was 1.08 per 50,000 births (95%CI: 1 in 32,829-1 in 65,019).CONCLUSION: We present updated estimates of the incidence and prevalence of NF1 and NF2, to help plan for healthcare access and allocation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37710322",
"endSection": "abstract",
"offsetInBeginSection": 782,
"offsetInEndSection": 855,
"text": "NF1 pooled birth incidence was 1 in 2,662 (95%CI: 1 in 1,968-1 in 3,601)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22041820",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 222,
"text": "INTRODUCTION: The prevalence and the type of seizures associated with neurofibromatosis 1 (NF1) and 2 (NF2) are not adequately characterized.STATE OF THE ART: NF1 has a birth incidence of one in 2500, and NF2 one in 25000."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37710322",
"endSection": "abstract",
"offsetInBeginSection": 631,
"offsetInEndSection": 781,
"text": "This was higher in studies that screened for NF1, compared to identification of NF1 through medical records (1 in 2,020 and 1 in 4,329, respectively)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/19587630",
"endSection": "abstract",
"offsetInBeginSection": 235,
"offsetInEndSection": 317,
"text": "NF1 is the most common neurogenetic disorder, with a birth incidence of 1 in 3000."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/1600579",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 186,
"text": "Neurofibromatosis (NF) is a serious, common, genetically determined neurological disorder; with a prevalence of about 1:4000 births it affects both sexes and all races and ethnic groups."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26854064",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 181,
"text": "The neurofibromatoses (NF) are a group of rare genetic disorders that can affect all races equally at an incidence from 1:3000 (NF1) to a log unit lower for NF2 and schwannomatosis."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/20082463",
"endSection": "abstract",
"offsetInBeginSection": 618,
"offsetInEndSection": 710,
"text": "Disease prevalence in order of frequency were for neurofibromatosis type 1 (NF1): 1 in 4,560"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/8880865",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 244,
"text": "Neurofibromatosis 1 and 2 (NF1 and NF2) are autosomal dominantly inherited disorders with close to 100% penetrance. NF1 is one of the most frequent human genetic diseases with an incidence of 1:3000. The incidence of NF2 is about 10 fold lower."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29215653",
"endSection": "abstract",
"offsetInBeginSection": 886,
"offsetInEndSection": 1176,
"text": "When the survival rates of NF1 patients and the Finnish population were combined with an estimate of NF1 incidence, a prevalence of 1/2,052 (95% CI 1/2,176-1/1,941) was estimated for NF1 in a population aged 0-74 years.CONCLUSION: NF1 is a much more common disorder than previously thought."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29215653",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 130,
"text": "PURPOSE: The incidence of neurofibromatosis 1 (NF1) is ~1/2,000 live births, but the current estimates of prevalence vary greatly."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/20082463",
"endSection": "abstract",
"offsetInBeginSection": 611,
"offsetInEndSection": 720,
"text": "rates. Disease prevalence in order of frequency were for neurofibromatosis type 1 (NF1): 1 in 4,560; familial"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/16583938",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 111,
"text": "Neurofibromatosis type 1 (NF1) is an autosomal dominant disease with a prevalence of about 1/3000. The clinical"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/9864698",
"endSection": "abstract",
"offsetInBeginSection": 228,
"offsetInEndSection": 341,
"text": "NF1 represents 95% of neurofibromatoses cases. Its incidence is 1 for 3,500 newborns, its prevalence 1 for 4,500."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/10469430",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 66,
"text": "The prevalence of neurofibromatosis type 1 (NF1) is about 1/3,000."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/15105854",
"endSection": "abstract",
"offsetInBeginSection": 130,
"offsetInEndSection": 378,
"text": "Neurofibromatosis type 1 (NF1), also known as von Recklinghausen's disease, is the most common type of NF and accounts for about 90% of all cases. It is one of the most frequent human genetic diseases, with a prevalence of one case in 3,000 births."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37710322",
"endSection": "abstract",
"offsetInBeginSection": 530,
"offsetInEndSection": 597,
"text": "e included in the final review. Pooled NF1 prevalence was 1 in 3,16"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/9864698",
"endSection": "abstract",
"offsetInBeginSection": 446,
"offsetInEndSection": 492,
"text": "NF2 incidence is 1 for 33,000-40,000 newborns."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32657748",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 269,
"text": "BACKGROUND: Neurofibromatosis of types 1 and 2 (NF1, NF2) and schwannomatosis are the diseases that make up the neurofibromatosis spectrum. With respective incidences of 1 in 3000, 1 in 33 000, and 1 in 60 000 births, they form part of the group of rare tumor-suppresso"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37710322",
"endSection": "abstract",
"offsetInBeginSection": 530,
"offsetInEndSection": 981,
"text": "e included in the final review. Pooled NF1 prevalence was 1 in 3,164 (95%CI: 1 in 2,132-1 in 4,712). This was higher in studies that screened for NF1, compared to identification of NF1 through medical records (1 in 2,020 and 1 in 4,329, respectively). NF1 pooled birth incidence was 1 in 2,662 (95%CI: 1 in 1,968-1 in 3,601). There were only 2 studies on NF2 prevalence, so data were not pooled. Pooled NF2 birth incidence was 1.08 per 50,000 births ("
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36317063",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 155,
"text": "Neurofibromatosis type 1 is one of the most common genetic autosomal dominant disorders described, with a prevalence of 1 in 2000 to 1 in 3000 individuals."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29215653",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 203,
"text": "PURPOSE: The incidence of neurofibromatosis 1 (NF1) is ~1/2,000 live births, but the current estimates of prevalence vary greatly. This retrospective total-population study was aimed at determining the p"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/19568505",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 168,
"text": "Neurofibromatosis type-1 (NF1), also known as von Recklinghausen disease, is a common autosomal dominant condition with an approximate incidence of one per 3000 births."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31763299",
"endSection": "abstract",
"offsetInBeginSection": 335,
"offsetInEndSection": 511,
"text": "NF1, also known as von Recklinghausen's disease or peripheral neurofibromatosis, is an autosomal dominant multisystem disorder that approximately affects 1 in 2500-3000 births."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/16583938",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 98,
"text": "Neurofibromatosis type 1 (NF1) is an autosomal dominant disease with a prevalence of about 1/3000."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34408961",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 166,
"text": "Neurofibromatosis type 1 (NF1), or von Recklinghausen disease, is a genetically transmitted autosomal dominant disease, with a prevalence of one per 4000 live births."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/8953130",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 179,
"text": "With an incidence of 1 in 3,000, neurofibromatosis type 1 (NF1), or von Recklinghausen disease, is one of the most common genetic disorders encountered by primary care physicians."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22357435",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 145,
"text": "Type I Neurofibromatosis (NF1) is an autosomal-dominant inheritable disorder, with an incidence of 1:3,000, and a prevalence of 1:4,000 to 5,000."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21232201",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 112,
"text": "Neurofibromatosis 1 is an autosomal dominant disease with an estimated incidence 1:2500 to 1:3000 live newborns."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/17509168",
"endSection": "abstract",
"offsetInBeginSection": 293,
"offsetInEndSection": 441,
"text": "Von Recklinghausen's disease is an autosomal dominant disorder that is localized at the long arm of chromosome 17 and affects 1 in 4000 individuals."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24621365",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 139,
"text": "Neurofibromatosis type-1 (NF1), also known as Von Recklinghausen disease, is an autosomal dominant disorder with incidence of one per 4000."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32499294",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 130,
"text": "Neurofibromatosis type 1 (NF1, Von Recklinghausen disease) is an autosomal dominant disease with a birth incidence of 1/2500-3000."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/3088347",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 97,
"text": "Neurofibromatosis is a neurocutaneous systemic disease that occurs in 1:2500 to 3300 live births."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23162593",
"endSection": "abstract",
"offsetInBeginSection": 130,
"offsetInEndSection": 379,
"text": "Neurofibromatosis type 1 (NF1), also known as von Recklinghausen's disease, is the most common type of NF, and accounts for about 90% of all cases. It is one of the most frequent human genetic diseases, with a prevalence of one case in 3,000 births."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31625703",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 178,
"text": "Neurofibromatosis type 1 (NF-1; also known as Von Recklinghausen's disease) is a common autosomal dominant disease that occurs in the general population at the rate of 1 in 3000."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33395412",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 108,
"text": "BACKGROUND: Neurofibromatosis type 1 (NF-1) is an autosomal dominant disease that affects one in every 3000 "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25838692",
"endSection": "abstract",
"offsetInBeginSection": 226,
"offsetInEndSection": 415,
"text": "NFI, also known as von Recklinghausen's neurofibromatosis, is an autosomal dominantly inherited neurogenetic disorder affecting 1:3000 newborn (Bongiorno et al., Oral Dis 12:125-129, 2006)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21707352",
"endSection": "abstract",
"offsetInBeginSection": 394,
"offsetInEndSection": 465,
"text": "NF-1 occurs in about 1 in 2,500 to 3,300 individuals in the population."
}
] | 13
|
BioASQ-training13b
| null | null |
6616547dfdcbea915f00004f
| 5,317
|
factoid
|
What is the key transcription factor for melanocyte development and differentiation?
|
['Microphthalmia-associated transcription factor', 'MITF', 'MITF (Microphthalmia-associated Transcription Factor)']
|
[
"Microphthalmia-associated transcription factor",
"MITF",
"MITF (Microphthalmia-associated Transcription Factor)",
"Microphthalmia Transcription Factor",
"Microphthalmia-associated TF",
"Microphthalmia-associated transcription factor (MITF)"
] |
['The key transcription factor for melanocyte development and differentiation is Microphthalmia-associated transcription factor (MITF). MITF regulates the expression of numerous pigmentation genes to promote melanocyte differentiation, as well as fundamental genes for maintaining cell homeostasis, including genes encoding proteins involved in apoptosis and the cell cycle. Loss-of-function mutations of MITF cause Waardenburg syndrome type IIA, which includes pigmentation defects, while MITF activation can lead to melanoma development. Additionally, other transcription factors such as SOX10, MEF2C, and PAX3 also play crucial roles in melanocyte development and differentiation by interacting with MITF or controlling its expression.', 'Certain transcription factors have vital roles in lineage development, including the specification of cell types and control of differentiation. Microphthalmia-associated transcription factor (MITF) is a key transcription factor for melanocyte development and differentiation. MITF regulates the expression of numerous pigmentation genes to promote melanocyte differentiation, as well as fundamental genes for maintaining cell homeostasis, including genes encoding proteins involved in apoptosis (eg, BCL2) and the cell cycle (eg, CDK2).']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/14717844",
"http://www.ncbi.nlm.nih.gov/pubmed/1631016",
"http://www.ncbi.nlm.nih.gov/pubmed/18829533",
"http://www.ncbi.nlm.nih.gov/pubmed/12789278",
"http://www.ncbi.nlm.nih.gov/pubmed/10938265",
"http://www.ncbi.nlm.nih.gov/pubmed/16899407",
"http://www.ncbi.nlm.nih.gov/pubmed/9500554",
"http://www.ncbi.nlm.nih.gov/pubmed/19995375",
"http://www.ncbi.nlm.nih.gov/pubmed/17237008",
"http://www.ncbi.nlm.nih.gov/pubmed/11041373",
"http://www.ncbi.nlm.nih.gov/pubmed/32854423",
"http://www.ncbi.nlm.nih.gov/pubmed/37770430",
"http://www.ncbi.nlm.nih.gov/pubmed/12235125",
"http://www.ncbi.nlm.nih.gov/pubmed/18628967",
"http://www.ncbi.nlm.nih.gov/pubmed/15716956",
"http://www.ncbi.nlm.nih.gov/pubmed/28649789",
"http://www.ncbi.nlm.nih.gov/pubmed/11478782",
"http://www.ncbi.nlm.nih.gov/pubmed/35580127",
"http://www.ncbi.nlm.nih.gov/pubmed/16757562",
"http://www.ncbi.nlm.nih.gov/pubmed/11764295",
"http://www.ncbi.nlm.nih.gov/pubmed/37823232",
"http://www.ncbi.nlm.nih.gov/pubmed/11211309",
"http://www.ncbi.nlm.nih.gov/pubmed/21326905",
"http://www.ncbi.nlm.nih.gov/pubmed/17000761",
"http://www.ncbi.nlm.nih.gov/pubmed/34003523",
"http://www.ncbi.nlm.nih.gov/pubmed/15250933",
"http://www.ncbi.nlm.nih.gov/pubmed/33439865",
"http://www.ncbi.nlm.nih.gov/pubmed/15277526",
"http://www.ncbi.nlm.nih.gov/pubmed/37240204",
"http://www.ncbi.nlm.nih.gov/pubmed/16140982",
"http://www.ncbi.nlm.nih.gov/pubmed/33940580",
"http://www.ncbi.nlm.nih.gov/pubmed/25803486",
"http://www.ncbi.nlm.nih.gov/pubmed/27827304",
"http://www.ncbi.nlm.nih.gov/pubmed/33438577",
"http://www.ncbi.nlm.nih.gov/pubmed/10080955",
"http://www.ncbi.nlm.nih.gov/pubmed/25670789",
"http://www.ncbi.nlm.nih.gov/pubmed/28263292",
"http://www.ncbi.nlm.nih.gov/pubmed/11886515",
"http://www.ncbi.nlm.nih.gov/pubmed/37752231",
"http://www.ncbi.nlm.nih.gov/pubmed/35682684",
"http://www.ncbi.nlm.nih.gov/pubmed/30150413",
"http://www.ncbi.nlm.nih.gov/pubmed/12859621",
"http://www.ncbi.nlm.nih.gov/pubmed/18028952",
"http://www.ncbi.nlm.nih.gov/pubmed/30705290",
"http://www.ncbi.nlm.nih.gov/pubmed/21965087",
"http://www.ncbi.nlm.nih.gov/pubmed/37847239",
"http://www.ncbi.nlm.nih.gov/pubmed/20144786",
"http://www.ncbi.nlm.nih.gov/pubmed/18971960",
"http://www.ncbi.nlm.nih.gov/pubmed/18316599"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28263292",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 529,
"text": "Certain transcription factors have vital roles in lineage development, including specification of cell types and control of differentiation. Microphthalmia-associated transcription factor (MITF) is a key transcription factor for melanocyte development and differentiation. MITF regulates expression of numerous pigmentation genes to promote melanocyte differentiation, as well as fundamental genes for maintaining cell homeostasis, including genes encoding proteins involved in apoptosis (eg, BCL2) and the cell cycle (eg, CDK2)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37823232",
"endSection": "abstract",
"offsetInBeginSection": 171,
"offsetInEndSection": 394,
"text": "In mammals, the core gene regulatory network for melanocytes (their only pigment cell type) contains three transcription factors, Sox10, Pax3 and Mitf, with the latter considered a master regulator of melanocyte development"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37770430",
"endSection": "abstract",
"offsetInBeginSection": 253,
"offsetInEndSection": 404,
"text": "The microphthalmia-associated transcription factor MITF is a lineage-survival oncogene that plays a crucial role in melanocyte development and melanoma"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37240204",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 123,
"text": "Microphthalmia-associated transcription factor (MITF) is an important regulator of melanogenesis and melanocyte development"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28263292",
"endSection": "abstract",
"offsetInBeginSection": 141,
"offsetInEndSection": 529,
"text": "Microphthalmia-associated transcription factor (MITF) is a key transcription factor for melanocyte development and differentiation. MITF regulates expression of numerous pigmentation genes to promote melanocyte differentiation, as well as fundamental genes for maintaining cell homeostasis, including genes encoding proteins involved in apoptosis (eg, BCL2) and the cell cycle (eg, CDK2)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28263292",
"endSection": "abstract",
"offsetInBeginSection": 141,
"offsetInEndSection": 272,
"text": "Microphthalmia-associated transcription factor (MITF) is a key transcription factor for melanocyte development and differentiation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18028952",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 332,
"text": "Microphthalmia transcription factor (Mitf) is implicated as the master gene for survival of melanocytes, as well as a key transcription factor regulating the expression of major melanogenic proteins. We have shown that Mitf is a novel prognostic marker in patients with melanoma and that it plays a role in melanoma differentiation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18028952",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 393,
"text": "Microphthalmia transcription factor (Mitf) is implicated as the master gene for survival of melanocytes, as well as a key transcription factor regulating the expression of major melanogenic proteins. We have shown that Mitf is a novel prognostic marker in patients with melanoma and that it plays a role in melanoma differentiation. Melanocyte-stimulating hormone up-regulates Mitf expression."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/16899407",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 362,
"text": "Microphthalmia-associated transcription factor (MITF) acts as a master regulator of melanocyte development, function and survival by modulating various differentiation and cell-cycle progression genes. It has been demonstrated that MITF is an amplified oncogene in a fraction of human melanomas and that it also has an oncogenic role in human clear cell sarcoma."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28263292",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 272,
"text": "Certain transcription factors have vital roles in lineage development, including specification of cell types and control of differentiation. Microphthalmia-associated transcription factor (MITF) is a key transcription factor for melanocyte development and differentiation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/16899407",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 432,
"text": "Microphthalmia-associated transcription factor (MITF) acts as a master regulator of melanocyte development, function and survival by modulating various differentiation and cell-cycle progression genes. It has been demonstrated that MITF is an amplified oncogene in a fraction of human melanomas and that it also has an oncogenic role in human clear cell sarcoma. However, MITF also modulates the state of melanocyte differentiation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/16140982",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 186,
"text": "Microphthalmia-associated transcription factor (MITF) M-form is a melanocyte-specific transcription factor that plays a key role in melanocyte development, survival, and differentiation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/16899407",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 201,
"text": "Microphthalmia-associated transcription factor (MITF) acts as a master regulator of melanocyte development, function and survival by modulating various differentiation and cell-cycle progression genes."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21326905",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 144,
"text": "Microphthalmia-associated Transcription Factor, MITF, is a master regulator of melanocyte development, differentiation, migration, and survival."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/19995375",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 276,
"text": "Microphthalmia-associated transcription factor (MITF) was initially shown to play a key role in melanocyte differentiation through the direct transcriptional control of TYROSINASE, TYRP1 and DCT genes, encoding the three enzymes involved in melanin synthesis or melanogenesis."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/9500554",
"endSection": "abstract",
"offsetInBeginSection": 355,
"offsetInEndSection": 519,
"text": "We have previously shown that MITF transactivates the gene for tyrosinase, a key enzyme for melanogenesis, and is critically involved in melanocyte differentiation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/12235125",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 174,
"text": "The transcription factor Microphthalmia-associated transcription factor (MITF) is a lineage-determination factor, which modulates melanocyte differentiation and pigmentation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/17000761",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 302,
"text": "Commitment to the melanocyte lineage is characterized by the onset of expression of the microphthalmia-associated transcription factor (Mitf). This transcription factor plays a fundamental role in melanocyte development and maintenance and seems to be crucial for the survival of malignant melanocytes."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33940580",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 140,
"text": "Although microphthalmia-associated transcription factor (MITF) has been known for decades as a key regulator for melanocytic differentiation"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/16757562",
"endSection": "abstract",
"offsetInBeginSection": 274,
"offsetInEndSection": 520,
"text": "In both zebrafish and mice, one transcription factor, SOX10, controls the expression of another, MITF (microphthalmia-associated transcription factor), which in turn regulates a set of genes critical for pigment cell development and pigmentation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18628967",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 340,
"text": "The Microphthalmia-associated transcription factor (MITF) is an important regulator of cell-type specific functions in melanocytic cells. MITF is essential for the survival of pigmented cells, but whereas high levels of MITF drive melanocyte differentiation, lower levels are required to permit proliferation and survival of melanoma cells."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/12789278",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 163,
"text": "The microphthalamia-associated transcription factor (MITF) is an integral transcriptional regulator in melanocyte, the lineage from which melanoma cells originate."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/11478782",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 98,
"text": "Microphthalmia-associated transcription factor (MITF) is essential for melanocyte differentiation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25803486",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 104,
"text": "Microphthalmia-associated transcription factor (MITF) is the master regulator of the melanocyte lineage."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30705290",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 119,
"text": "The MITF transcription factor is a master regulator of melanocyte development and a critical factor in melanomagenesis."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/11211309",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 204,
"text": "Microphthalmia transcription factor, a melanocytic nuclear protein critical for the embryonic development and postnatal viability of melanocytes, is a master regulator in modulating extracellular signals."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/12859621",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 118,
"text": "Microphthalmia-associated transcription factor (MITF) plays a pivotal role in melanocyte survival and differentiation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37240204",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 124,
"text": "Microphthalmia-associated transcription factor (MITF) is an important regulator of melanogenesis and melanocyte development."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18829533",
"endSection": "abstract",
"offsetInBeginSection": 112,
"offsetInEndSection": 289,
"text": "In melanoma and in melanocyte development, the microphthalmia-associated transcription factor (Mitf) controls survival, differentiation, proliferation, and migration/metastasis."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18316599",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 127,
"text": "Micropthalmia-associated transcription factor (MITF) is the master regulator of melanocyte development, survival, and function."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35682684",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 123,
"text": "Microphthalmia-associated transcription factor (MITF) is an important regulator of melanogenesis and melanocyte development"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37752231",
"endSection": "abstract",
"offsetInBeginSection": 188,
"offsetInEndSection": 311,
"text": "MITF is a key regulator of melanocyte-associated genes, and essential to proper development of the melanocyte cell lineage."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28263292",
"endSection": "abstract",
"offsetInBeginSection": 141,
"offsetInEndSection": 802,
"text": "Microphthalmia-associated transcription factor (MITF) is a key transcription factor for melanocyte development and differentiation. MITF regulates expression of numerous pigmentation genes to promote melanocyte differentiation, as well as fundamental genes for maintaining cell homeostasis, including genes encoding proteins involved in apoptosis (eg, BCL2) and the cell cycle (eg, CDK2). Loss-of-function mutations of MITF cause Waardenburg syndrome type IIA, whose phenotypes include depigmentation due to melanocyte loss, whereas amplification or specific mutation of MITF can be an oncogenic event that is seen in a subset of familial or sporadic melanomas."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/10938265",
"endSection": "abstract",
"offsetInBeginSection": 175,
"offsetInEndSection": 278,
"text": "Microphthalmia-associated transcription factor (MITF) controls melanocyte survival and differentiation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18028952",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 199,
"text": "Microphthalmia transcription factor (Mitf) is implicated as the master gene for survival of melanocytes, as well as a key transcription factor regulating the expression of major melanogenic proteins."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30150413",
"endSection": "abstract",
"offsetInBeginSection": 434,
"offsetInEndSection": 658,
"text": "The microphthalmia-associated transcription factor MITF plays a crucial role in the development of melanocytes, the retinal pigment epithelium, osteoclasts, and mast cells and acts as a lineage survival oncogene in melanoma."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21965087",
"endSection": "abstract",
"offsetInBeginSection": 288,
"offsetInEndSection": 483,
"text": "PAX3 and SOX10 are two transcription factors that can activate the expression of microphthalmia-associated transcription factor (MITF), a critical transcription factor for melanocyte development."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18971960",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 116,
"text": "Microphthalmia-associated transcription factor (MiTF) is a key transcription factor for melanocyte lineage survival."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33439865",
"endSection": "abstract",
"offsetInBeginSection": 704,
"offsetInEndSection": 773,
"text": "Mitfa has been identified as the master regulator of melanocyte fate."
}
] | 13
|
BioASQ-training13b
| null | null |
661d96c9eac11fad33000028
| 5,318
|
factoid
|
What is the cause of Phenylketonuria (PKU)?
|
['Mutations in the phenylalanine hydroxylase (PAH) gene', 'deficiencies in phenylalanine (Phe) metabolism']
|
[
"phenylalanine hydroxylase",
"PAH",
"phenylalanine 4-monooxygenase",
"phenylalanine 4-hydroxylase",
"Phe",
"phenylalanine",
"phenylalanine metabolism"
] |
['Phenylketonuria (PKU) is an inborn error caused by deficiencies in phenylalanine (Phe) metabolism.', 'Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase (PAH) gene, which leads to deficiencies in phenylalanine metabolism, resulting in toxically elevated levels of phenylalanine accumulation in plasma and organs such as the brain, and ultimately causing irreversible intellectual disability.', 'PKU is caused by mutations in the PAH gene, leading to deficient phenylalanine metabolism, high Phe levels in plasma and organs, resulting in intellectual disabilities.', 'Phenylketonuria (PKU) is caused by mutations in the PAH gene, which leads to deficiencies in phenylalanine (Phe) metabolism and results in toxically elevated levels of Phe accumulation in plasma and organs such as the brain, causing irreversible intellectual disability.', 'Mutations in the phenylalanine hydroxylase (PAH) gene are the cause of Phenylketonuria (PKU).', 'Phenylketonuria (PKU) is a metabolic and genetic disorder caused by the deficiency of the phenylalanine hydroxylase enzyme (PAH), resulting in the accumulation of phenylalanine (Phe) in organs, which further leads to its toxic effects on the brain.', 'Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase (PAH) gene. These mutations lead to deficiencies in phenylalanine metabolism, resulting in toxic accumulation of phenylalanine in the blood and organs like the brain. The elevated phenylalanine levels can cause intellectual disability if untreated.', 'Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase (PAH) gene, which leads to a deficiency in the enzyme responsible for metabolizing the amino acid phenylalanine. This results in high levels of phenylalanine in the blood, which can be harmful to the brain and other organs', 'Phenylketonuria (PKU) is caused by deficiencies in phenylalanine metabolism and mutations in the phenylalanine hydroxylase (PAH) gene.', 'Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase (PAH) gene, leading to deficiencies in phenylalanine metabolism and resulting in toxically elevated levels of phenylalanine accumulation in plasma and organs such as the brain, which can cause irreversible intellectual disability.', 'Phenylketonuria (PKU) is a rare genetic disorder in which the body cannot process phenylalanine (Phe), an amino acid necessary for normal growth and development, which can lead to an accumulation of this harmful substance in the brain. This disorder is caused by a defect in the enzyme PAH (phenylalanine hydroxylase) that converts Phe to tyrosine.', 'Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase (PAH) gene that result in deficiencies in phenylalanine (Phe) metabolism.', 'Phenylketonuria (PKU) is an autosomal recessive disorder caused by mutations in the phenylalanine hydroxylase (PAH) gene, leading to deficient enzyme activity and an accumulation of phenylalanine in the body.', 'Phenylketonuria (PKU) is caused by mutations in the PAH gene, leading to deficiencies in metabolizing phenylalanine.', 'Phenylketonuria (PKU) is caused by a deficiency of phenylalanine hydroxylase, leading to impaired phenylalanine metabolism.', 'Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase (PAH) gene, leading to deficiencies in phenylalanine metabolism.', 'Phenylketonuria (PKU) is caused by a defect in the PAH gene, which impairs the conversion of phenylalanine (Phe) to tyrosine.', 'Phenylketonuria (PKU) is caused by deficiencies in phenylalanine metabolism, particularly due to mutations in the phenylalanine hydroxylase gene.', 'The cause of Phenylketonuria (PKU) is a deficiency in phenylalanine (Phe) metabolism due to mutations in the phenylalanine hydroxylase (PAH) gene.', 'Phenylketonuria (PKU) is caused by deficiencies in phenylalanine (Phe) metabolism, specifically mutations in the phenylalanine hydroxylase (PAH) gene. These mutations result in toxically elevated levels of Phe accumulation in plasma and organs such as the brain, leading to irreversible intellectual disability.', 'Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase (PAH) gene, which result in deficiencies in phenylalanine (Phe) metabolism. This leads to toxically elevated levels of Phe accumulation in plasma and organs such as the brain, resulting in irreversible intellectual disability.', 'Phenylketonuria (PKU) is an autosomal recessive metabolic disorder caused by deficiency of phenylalanine hydroxylase.', 'Phenylketonuria (PKU) is caused by a mutation in the PAH gene, which encodes the enzyme phenylalanine hydroxylase that metabolizes the amino acid phenylalanine.', 'Phenylketonuria (PKU) is an inborn error of metabolism characterized by deficiencies in phenylalanine (Phe) metabolism due to a mutation in the phenylalanine hydroxylase (PAH) gene. This deficiency leads to the accumulation of Phe and its metabolites in the blood, causing damage to the brain.', "PKU is caused by mutations in the PAH gene, leading to a deficiency in phenylalanine hydroxylase, and it's inherited in an autosomal recessive manner.", 'Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase (PAH) gene, which leads to deficiencies in phenylalanine metabolism.', 'The main cause of Phenylketonuria (PKU) is mutations in the phenylalanine hydroxylase (PAH) gene, leading to deficiencies in phenylalanine metabolism and resulting in elevated levels of Phe accumulation that causes irreversible intellectual disability.', 'Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase (PAH) gene, leading to deficient Phe metabolism and toxic accumulation in plasma and organs like the brain, resulting in intellectual disability.', 'Phenylketonuria (PKU) is an autosomal recessive disorder caused by mutations in the phenylalanine hydroxylase (PAH) gene, which leads to deficient enzyme activity and elevation of phenylalanine in body fluids.', 'Phenylketonuria (PKU) is a metabolic disorder caused by mutations in the gene encoding for the hepatic enzyme phenylalanine hydroxylase (PAH), which leads to an accumulation of phenylalanine in the blood (Phe) and its derivative products in body tissues.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/15640093",
"http://www.ncbi.nlm.nih.gov/pubmed/32605583",
"http://www.ncbi.nlm.nih.gov/pubmed/37865339",
"http://www.ncbi.nlm.nih.gov/pubmed/12714182",
"http://www.ncbi.nlm.nih.gov/pubmed/14654665",
"http://www.ncbi.nlm.nih.gov/pubmed/9427141",
"http://www.ncbi.nlm.nih.gov/pubmed/35854334",
"http://www.ncbi.nlm.nih.gov/pubmed/20187763",
"http://www.ncbi.nlm.nih.gov/pubmed/12052659",
"http://www.ncbi.nlm.nih.gov/pubmed/26835324",
"http://www.ncbi.nlm.nih.gov/pubmed/37863349",
"http://www.ncbi.nlm.nih.gov/pubmed/23220018",
"http://www.ncbi.nlm.nih.gov/pubmed/10495930",
"http://www.ncbi.nlm.nih.gov/pubmed/1677790",
"http://www.ncbi.nlm.nih.gov/pubmed/29114196",
"http://www.ncbi.nlm.nih.gov/pubmed/23148178",
"http://www.ncbi.nlm.nih.gov/pubmed/30055544",
"http://www.ncbi.nlm.nih.gov/pubmed/30159852",
"http://www.ncbi.nlm.nih.gov/pubmed/1959225",
"http://www.ncbi.nlm.nih.gov/pubmed/29025426",
"http://www.ncbi.nlm.nih.gov/pubmed/14726806",
"http://www.ncbi.nlm.nih.gov/pubmed/33970801",
"http://www.ncbi.nlm.nih.gov/pubmed/26425393",
"http://www.ncbi.nlm.nih.gov/pubmed/8100164",
"http://www.ncbi.nlm.nih.gov/pubmed/10527663",
"http://www.ncbi.nlm.nih.gov/pubmed/23771645",
"http://www.ncbi.nlm.nih.gov/pubmed/22572109",
"http://www.ncbi.nlm.nih.gov/pubmed/37553307",
"http://www.ncbi.nlm.nih.gov/pubmed/36500989",
"http://www.ncbi.nlm.nih.gov/pubmed/26503515",
"http://www.ncbi.nlm.nih.gov/pubmed/31883647",
"http://www.ncbi.nlm.nih.gov/pubmed/26413448",
"http://www.ncbi.nlm.nih.gov/pubmed/2884570",
"http://www.ncbi.nlm.nih.gov/pubmed/36791482",
"http://www.ncbi.nlm.nih.gov/pubmed/18985011",
"http://www.ncbi.nlm.nih.gov/pubmed/37922902",
"http://www.ncbi.nlm.nih.gov/pubmed/25894915",
"http://www.ncbi.nlm.nih.gov/pubmed/35356682",
"http://www.ncbi.nlm.nih.gov/pubmed/32039316",
"http://www.ncbi.nlm.nih.gov/pubmed/37456395",
"http://www.ncbi.nlm.nih.gov/pubmed/30504004",
"http://www.ncbi.nlm.nih.gov/pubmed/1968617",
"http://www.ncbi.nlm.nih.gov/pubmed/37105048",
"http://www.ncbi.nlm.nih.gov/pubmed/30258912",
"http://www.ncbi.nlm.nih.gov/pubmed/37446577",
"http://www.ncbi.nlm.nih.gov/pubmed/18566668",
"http://www.ncbi.nlm.nih.gov/pubmed/30067850",
"http://www.ncbi.nlm.nih.gov/pubmed/32668217",
"http://www.ncbi.nlm.nih.gov/pubmed/37924808",
"http://www.ncbi.nlm.nih.gov/pubmed/19629656",
"http://www.ncbi.nlm.nih.gov/pubmed/30389586",
"http://www.ncbi.nlm.nih.gov/pubmed/29909188",
"http://www.ncbi.nlm.nih.gov/pubmed/24130151",
"http://www.ncbi.nlm.nih.gov/pubmed/25614310",
"http://www.ncbi.nlm.nih.gov/pubmed/8629090",
"http://www.ncbi.nlm.nih.gov/pubmed/34017006",
"http://www.ncbi.nlm.nih.gov/pubmed/9323556"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35356682",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 97,
"text": "Phenylketonuria (PKU) is an inborn error caused by deficiencies in phenylalanine (Phe) metabolism"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35356682",
"endSection": "abstract",
"offsetInBeginSection": 99,
"offsetInEndSection": 348,
"text": "Mutations in the phenylalanine hydroxylase (PAH) gene are the main cause of the disease whose signature hallmarks of toxically elevated levels of Phe accumulation in plasma and organs such as the brain, result in irreversible intellectual disability"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37922902",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 232,
"text": "The c.1222C>T (p.Arg408Trp) phenylalanine hydroxylase (PAH) variant is the most frequent cause of phenylketonuria (PKU), an autosomal recessive disorder characterized by accumulation of blood phenylalanine (Phe) to neurotoxic levels"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37924808",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 175,
"text": "The c.1222C>T (p.Arg408Trp) variant in the phenylalanine hydroxylase gene (PAH) is the most frequent cause of phenylketonuria (PKU), the most common inborn error of metabolism"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37865339",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 204,
"text": "Phenylketonuria (PKU) is an autosomal recessive metabolic disorder caused by mutations in the phenylalanine hydroxylase (PAH) gene, resulting in phenylalanine accumulation and impaired tyrosine production"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37863349",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 193,
"text": "Phenylketonuria (PKU) is the most common inherited metabolic disorders caused by severe deficiency or absence of phenylalanine hydroxylase activity that converts phenylalanine (Phe) to tyrosine"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/19629656",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 317,
"text": "Phenylketonuria (PKU), the most frequent disorder of amino acid metabolism, is caused by mutations in human phenylalanine hydroxylase gene (PAH), leading to deficient enzyme activity. Previously reported but uncharacterized PAH gene mutation, p.S231F (c.692C > T), was detected in Serbian patients with classical PKU."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/19629656",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 183,
"text": "Phenylketonuria (PKU), the most frequent disorder of amino acid metabolism, is caused by mutations in human phenylalanine hydroxylase gene (PAH), leading to deficient enzyme activity."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/19629656",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 434,
"text": "Phenylketonuria (PKU), the most frequent disorder of amino acid metabolism, is caused by mutations in human phenylalanine hydroxylase gene (PAH), leading to deficient enzyme activity. Previously reported but uncharacterized PAH gene mutation, p.S231F (c.692C > T), was detected in Serbian patients with classical PKU. We analyzed p.S231F PAH protein in prokaryotic (Escherichia coli) and eukaryotic expression system (hepatoma cells)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37553307",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 444,
"text": "BACKGROUND: Phenylalanine hydroxylase deficiency (PAHD) is an autosomal recessive disorder affecting phenylalanine (Phe) metabolism caused by mutations in the phenylalanine hydroxylase (PAH) gene. It has a complex phenotype with many variants and genotypes in various populations. This study sets out to analyze the screening results of children with phenylketonuria (PKU) in Yinchuan City and characterize the mutation variants of the PAH gene"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18566668",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 156,
"text": "Phenylketonuria (PKU) is an autosomal recessive inborn error of phenylalanine (Phe) metabolism resulting from deficiency of phenylalanine hydroxylase (PAH)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/10527663",
"endSection": "abstract",
"offsetInBeginSection": 446,
"offsetInEndSection": 591,
"text": "The autosomal recessive disease phenylketonuria (PKU) is the result of a deficiency of PheOH enzymatic activity due to mutations in the PAH gene."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18566668",
"endSection": "abstract",
"offsetInBeginSection": 157,
"offsetInEndSection": 270,
"text": "Most forms of PKU and hyperphenylalaninaemia (HPA) are caused by mutations in the PAH gene on chromosome 12q23.2."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/2884570",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 182,
"text": "Phenylketonuria (PKU) is an autosomal recessive human genetic disorder caused by a deficiency of hepatic phenylalanine hydroxylase (PAH, phenylalanine 4-monooxygenase, EC 1.14.16.1)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37105048",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 154,
"text": "Classic phenylketonuria (PKU) is caused by defective activity of phenylalanine hydroxylase (PAH), the enzyme that coverts phenylalanine (Phe) to tyrosine."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26835324",
"endSection": "abstract",
"offsetInBeginSection": 192,
"offsetInEndSection": 342,
"text": "Mutations in the phenylalanine hydroxylase (PAH) gene are the major cause of PKU, due to the loss of the catalytic activity of the enzyme product PAH."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/8629090",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 169,
"text": "Phenylketonuria (PKU) is an autosomal recessive disorder caused by a deficiency of hepatic phenylalanine hydroxylase (PAH), and is performed with newborn mass screening."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24130151",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 145,
"text": "Phenylketonuria (PKU) is an autosomal recessive metabolic disorder caused by mutational inactivation of the phenylalanine hydroxylase (PAH) gene."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37922902",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 233,
"text": "The c.1222C>T (p.Arg408Trp) phenylalanine hydroxylase (PAH) variant is the most frequent cause of phenylketonuria (PKU), an autosomal recessive disorder characterized by accumulation of blood phenylalanine (Phe) to neurotoxic levels."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18566668",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 270,
"text": "Phenylketonuria (PKU) is an autosomal recessive inborn error of phenylalanine (Phe) metabolism resulting from deficiency of phenylalanine hydroxylase (PAH). Most forms of PKU and hyperphenylalaninaemia (HPA) are caused by mutations in the PAH gene on chromosome 12q23.2."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32039316",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 81,
"text": "Phenylketonuria (PKU) is caused by phenylalanine hydroxylase (PAH) gene variants."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/14726806",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 121,
"text": "PURPOSE: Phenylketonuria (PKU) is an autosomal recessive disorder caused by mutations in the phenylalanine hydroxylase (P"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35854334",
"endSection": "abstract",
"offsetInBeginSection": 116,
"offsetInEndSection": 280,
"text": "PKU, an autosomal recessive disease, is an inborn error of phenylalanine (Phe) metabolism caused by pathogenic variants in the phenylalanine hydroxylase (PAH) gene."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33970801",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 109,
"text": "Phenylketonuria is an autosomal recessive disorder caused by mutations in the phenylalanine hydroxylase gene."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18985011",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 151,
"text": "Phenylketonuria (PKU; MIM 261600) is an autosomal recessive metabolic disorder caused by a deficiency of phenylalanine hydroxylase (PAH; EC 1.14.16.1)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/10495930",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 155,
"text": "Phenylketonuria (PKU), an autosomal recessive disorder caused by a deficiency of hepatic phenylalanine hydroxylase (PAH), is clinically very heterogeneous."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/1968617",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 147,
"text": "Phenylketonuria (PKU) is a metabolic disease caused by recessive mutations of the gene encoding the hepatic enzyme phenylalanine hydroxylase (PAH)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25894915",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 123,
"text": "UNLABELLED: Phenylketonuria (PKU) is caused by variants in the phenylalanine hydroxylase (PAH) gene. We systematically inve"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23148178",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 139,
"text": "Phenylketonuria (PKU) is an inherited disorder of amino acid metabolism caused by deficiency of the enzyme phenylalanine hydroxylase (PAH)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23771645",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 147,
"text": "Phenylketonuria is an inherited disorder of metabolism of the amino acid phenylalanine caused by a deficit of the enzyme phenylalanine hydroxylase."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37456395",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 228,
"text": "This article highlights the significance of inborn errors of metabolism and focuses specifically on phenylketonuria (PKU), a well-known inheritance disorder caused by the deficiency or absence of phenylalanine hydroxylase (PAH)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36500989",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 217,
"text": "Phenylketonuria (PKU) is an inherited disorder in which phenylalanine (Phe) is not correctly metabolized leading to an abnormally high plasma Phe concentration that causes profound neurologic damage if left untreated."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/12052659",
"endSection": "abstract",
"offsetInBeginSection": 592,
"offsetInEndSection": 829,
"text": "Phenylketonuria (PKU) is a genetic defect in phenylalanine (Phe) metabolism. Offspring of phenylketonuric mothers not under strict dietary control are born with maternal PKU (mPKU), a syndrome with similar characteristics as FAS and FSS."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30067850",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 102,
"text": "Phenylketonuria is an inherited disease caused by mutations in the phenylalanine hydroxylase gene PAH."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/15640093",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 122,
"text": "Phenylketonuria (PKU) is one kinds of autosomal recessive disease caused by phenylalanine hydroxylase (PAH) gene mutation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22572109",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 119,
"text": "Phenylketonuria (PKU) is an autosomal recessive metabolic disorder caused by a deficiency of phenylalanine hydroxylase."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26413448",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 129,
"text": "Phenylketonuria (PKU) is an autosomal recessive disease which results from mutations in the phenylalanine hydroxylase (PAH) gene."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/9427141",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 120,
"text": "Classical phenylketonuria (PKU) is a metabolic disorder caused by mutations in the phenylalanine hydroxylase (PAH) gene."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/14654665",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 130,
"text": "Mutations in the gene encoding for phenylalanine hydroxylase (PAH) result in phenylketonuria (PKU) or hyperphenylalaninemia (HPA)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32668217",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 171,
"text": "Phenylketonuria (PKU), caused by variants in the phenylalanine hydroxylase (PAH) gene, is the most common autosomal-recessive Mendelian phenotype of amino acid metabolism."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30258912",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 123,
"text": "Phenylketonuria (PKU) is an autosomal recessive metabolic disorder caused by deficiency of phenylalanine hydroxylase (PAH)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30504004",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 106,
"text": "Phenylketonuria (PKU) is an autosomal recessive inborn error of phenylalanine (phe) metabolism caused by a"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29025426",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 116,
"text": "Phenylketonuria (PKU) is an autosomal recessive inborn error of phenylalanine metabolism caused by deficiency in the"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32605583",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 116,
"text": "BACKGROUND: Phenylketonuria (PKU) is an autosomal recessive inborn error of phenylalanine metabolism caused by defic"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29909188",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 211,
"text": "Phenylketonuria (PKU) is a prevalent inherited metabolic disorder caused by a phenylalanine hydroxylase (PAH) or tetrahydrobiopterin (BH4) deficiency, which leads to the accumulation of phenylalanine (PHE). High"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34017006",
"endSection": "abstract",
"offsetInBeginSection": 16,
"offsetInEndSection": 203,
"text": "(PKU; also known as phenylalanine hydroxylase (PAH) deficiency) is an autosomal recessive disorder of phenylalanine metabolism, in which especially high phenylalanine concentrations cause"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29114196",
"endSection": "abstract",
"offsetInBeginSection": 98,
"offsetInEndSection": 431,
"text": "disorders. Phenylketonuria (PKU), a relatively common disorder that is responsive to treatment, is an inherited autosomal recessive disorder caused by a deficiency in phenylalanine hydroxylase (PAH) or one of several enzymes mediating biosynthesis or regeneration of the PAH cofactor tetrahydrobiopterin. The objective of this review"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/1677790",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 95,
"text": "In phenylketonuria (PKU) usually there is a defect in the phenylalanine hydroxylase (PAH) gene."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/1677790",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 327,
"text": "In phenylketonuria (PKU) usually there is a defect in the phenylalanine hydroxylase (PAH) gene. Eight restriction fragment length polymorfisms (RFLP's) in the PAH gene together constitute the haplotype. A considerable number of mutations, responsible for the gene defect, some of which are rather frequent, have been described."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/1677790",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 202,
"text": "In phenylketonuria (PKU) usually there is a defect in the phenylalanine hydroxylase (PAH) gene. Eight restriction fragment length polymorfisms (RFLP's) in the PAH gene together constitute the haplotype."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/1959225",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 399,
"text": "Phenylketonuria (PKU) has become a paradigm of a disease that can be identified by screening in the newborn period and treated to prevent serious complications. After many years of experience treating PKU, new challenges have emerged. It has become apparent that defective activity of phenylalanine hydroxylase leads to a spectrum of clinical presentations that has led to subclassifications of PKU."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37446577",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 250,
"text": "Phenylketonuria (PKU) is a rare metabolic disorder caused by mutations in the phenylalanine hydroxylase gene. Depending on the severity of the genetic mutation, medical treatment, and patient dietary management, elevated phenylalanine (Phe) may occur"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36791482",
"endSection": "abstract",
"offsetInBeginSection": 152,
"offsetInEndSection": 422,
"text": "PKU is caused by autosomal recessive mutations in phenylalanine hydroxylase (PAH) and manifests with elevation of phenylalanine (Phe) in plasma and urine. Untreated PKU manifests with intellectual disability including seizures, microcephaly and behavioral abnormalities."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37105048",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 211,
"text": "Classic phenylketonuria (PKU) is caused by defective activity of phenylalanine hydroxylase (PAH), the enzyme that coverts phenylalanine (Phe) to tyrosine. Toxic accumulation of phenylalanine and its metabolites,"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31883647",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 133,
"text": "BACKGROUND: Phenylketonuria (PKU) is an autosomal recessive disease caused by mutations in the PAH gene, resulting in deficiency of p"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26503515",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 161,
"text": "Phenylketonuria (PKU) is an inherited autosomal recessive disorder of phenylalanine metabolism, mainly caused by a deficiency of phenylalanine hydroxylase (PAH)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30055544",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 227,
"text": "Phenylketonuria (PKU) is an autosomal recessive disorder caused by the deficiency of phenylalanine hydroxylase enzyme that catalyzes the conversion of L-phenylalanine to L-tyrosine using tetrahydrobiopterin (BH4) as a cofactor."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23220018",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 121,
"text": "Phenylketonuria is an autosomal recessive inborn error of metabolism resulting from phenylalanine hydroxylase deficiency."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26425393",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 129,
"text": "Phenylketonuria (PKU) is an inborn error of phenylalanine (Phe) metabolism caused by the deficiency of phenylalanine hydroxylase."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/9323556",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 141,
"text": "Phenylketonuria (PKU) is an autosomal recessive disease caused by the deficiency of a liver-specific enzyme, phenylalanine hydroxylase (PAH)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25614310",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 154,
"text": "Phenylketonuria (PKU) is caused by a deficiency or inactivity of the enzyme phenylalanine hydroxylase that converts phenylalanine (Phe) to tyrosine (Tyr)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30389586",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 110,
"text": "Phenylketonuria (PKU) is a metabolic disorder caused by mutations in the phenylalanine hydroxylase (PAH) gene."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/8100164",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 118,
"text": "Phenylketonuria (PKU) is an autosomal recessive genetic disorder caused by phenylalanine hydroxylase (PAH) deficiency."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/20187763",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 248,
"text": "AIM: Phenylalanine hydroxylase (PAH) deficiency is caused by mutations in the PAH gene resulting in a primary deficiency of the PAH enzyme activity, intolerance to the dietary intake of phenylalanine (Phe), and production of the phenylketonuria dis"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/12714182",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 265,
"text": "Phenylalanine hydroxylase (PAH) deficiency is caused by mutations in the PAH gene (12q22-q24) resulting in a primary deficiency of the PAH enzyme activity, intolerance to the dietary intake of phenylalanine (Phe) and production of the phenylketonuria (PKU) disease."
}
] | 13
|
BioASQ-training13b
| null | null |
661d48a2eac11fad33000018
| 5,319
|
factoid
|
Which disease is treated with nirsevimab?
|
['respiratory syncytial virus']
|
[
"respiratory syncytial virus",
"RSV",
"human respiratory syncytial virus",
"HRSV",
"respiratory syncytial virus A",
"respiratory syncytial virus B"
] |
['Nirsevimab can be used for treatment of respiratory syncytial virus disease.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/37097594",
"http://www.ncbi.nlm.nih.gov/pubmed/36328884",
"http://www.ncbi.nlm.nih.gov/pubmed/38026446",
"http://www.ncbi.nlm.nih.gov/pubmed/37901217",
"http://www.ncbi.nlm.nih.gov/pubmed/38057209",
"http://www.ncbi.nlm.nih.gov/pubmed/37641189",
"http://www.ncbi.nlm.nih.gov/pubmed/36577878",
"http://www.ncbi.nlm.nih.gov/pubmed/37498791",
"http://www.ncbi.nlm.nih.gov/pubmed/36940703",
"http://www.ncbi.nlm.nih.gov/pubmed/37914061",
"http://www.ncbi.nlm.nih.gov/pubmed/37095249",
"http://www.ncbi.nlm.nih.gov/pubmed/38062942",
"http://www.ncbi.nlm.nih.gov/pubmed/37466917",
"http://www.ncbi.nlm.nih.gov/pubmed/37743207",
"http://www.ncbi.nlm.nih.gov/pubmed/38058503",
"http://www.ncbi.nlm.nih.gov/pubmed/37468530",
"http://www.ncbi.nlm.nih.gov/pubmed/34933044",
"http://www.ncbi.nlm.nih.gov/pubmed/34937485",
"http://www.ncbi.nlm.nih.gov/pubmed/34456918",
"http://www.ncbi.nlm.nih.gov/pubmed/35235726",
"http://www.ncbi.nlm.nih.gov/pubmed/35968865",
"http://www.ncbi.nlm.nih.gov/pubmed/37616235",
"http://www.ncbi.nlm.nih.gov/pubmed/34813073",
"http://www.ncbi.nlm.nih.gov/pubmed/36280532",
"http://www.ncbi.nlm.nih.gov/pubmed/37082704",
"http://www.ncbi.nlm.nih.gov/pubmed/38032456",
"http://www.ncbi.nlm.nih.gov/pubmed/35968866",
"http://www.ncbi.nlm.nih.gov/pubmed/38095041",
"http://www.ncbi.nlm.nih.gov/pubmed/36599520",
"http://www.ncbi.nlm.nih.gov/pubmed/38070539",
"http://www.ncbi.nlm.nih.gov/pubmed/38061043",
"http://www.ncbi.nlm.nih.gov/pubmed/37824423",
"http://www.ncbi.nlm.nih.gov/pubmed/37276355",
"http://www.ncbi.nlm.nih.gov/pubmed/34543489",
"http://www.ncbi.nlm.nih.gov/pubmed/36922390",
"http://www.ncbi.nlm.nih.gov/pubmed/38085019",
"http://www.ncbi.nlm.nih.gov/pubmed/37829940",
"http://www.ncbi.nlm.nih.gov/pubmed/32726528",
"http://www.ncbi.nlm.nih.gov/pubmed/35572550",
"http://www.ncbi.nlm.nih.gov/pubmed/36634694"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36599520",
"endSection": "abstract",
"offsetInBeginSection": 1438,
"offsetInEndSection": 1695,
"text": "Novelties include the recommendation of routine administration of nirsevimab to neonates and infants aged less than 6 months for passive immunization against RSV, and the recommendations regarding the hexavalent vaccine are consolidated in a single section."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36634694",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 274,
"text": "Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36634694",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 288,
"text": "BACKGROUND: In a phase 2b trial and the phase 3 MELODY trial, nirsevimab, an extended half-life, monoclonal antibody against respiratory syncytial virus (RSV), protected healthy infants born preterm or at full term against medically attended RSV lower respiratory tract infection (LRTI). "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36634694",
"endSection": "abstract",
"offsetInBeginSection": 3947,
"offsetInEndSection": 4121,
"text": "INTERPRETATION: A single dose of nirsevimab protected healthy infants born at term or preterm from medically attended RSV LRTI, associated hospital admission, and severe RSV."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36634694",
"endSection": "abstract",
"offsetInBeginSection": 4262,
"offsetInEndSection": 4496,
"text": "Together, these data suggest that nirsevimab has the potential to change the landscape of infant RSV disease by reducing a major cause of infant morbidity and the consequent burden on caregivers, clinicians, and health-care providers."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36577878",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 388,
"text": "Nirsevimab (Beyfortus®), a long-acting intramuscular recombinant neutralising human IgG1ĸ monoclonal antibody to the prefusion conformation of the respiratory syncytial virus (RSV) F protein that has been modified with a triple amino acid substitution in the Fc region to extend the serum half-life, is being jointly developed by AstraZeneca and Sanofi for the prevention of RSV disease. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36577878",
"endSection": "abstract",
"offsetInBeginSection": 495,
"offsetInEndSection": 846,
"text": "Nirsevimab was approved in the EU on 3 November 2022 and in the UK on 7 November 2022 for the prevention of RSV lower respiratory tract disease in neonates and infants during their first RSV season. This article summarizes the milestones in the development of nirsevimab leading to this first approval for the prevention of RSV disease in all infants."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/38085019",
"endSection": "abstract",
"offsetInBeginSection": 840,
"offsetInEndSection": 1048,
"text": "This maternal vaccine showed 70.9% efficacy against severe RSV infection within 150 days after birth; the mAb nirsevimab reduces medically attended RSV infections by 79.5% within 150 days after administration"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/38061043",
"endSection": "abstract",
"offsetInBeginSection": 968,
"offsetInEndSection": 1369,
"text": "The monoclonal antibody nirsevimab was approved by the FDA and recommended by the CDC for prevention of RSV-associated lower respiratory tract infection in infants younger than age 8 months who are born during or entering their first RSV season and for infants and children aged 8-19 months who are at high risk for RSV-associated lower respiratory tract infection and entering their second RSV season"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/38058503",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 270,
"text": "The introduction of nirsevimab (a respiratory syncytial virus [RSV] monoclonal antibody that can protect for minimum 5 months with a single dose) and RSV maternal vaccines to protect young infants has the potential to dramatically decrease RSV hospitalizations in Canada"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/38057209",
"endSection": "abstract",
"offsetInBeginSection": 12,
"offsetInEndSection": 132,
"text": "The approval of nirsevimab brings light to reducing the heavy disease burden caused by respiratory syncytial virus (RSV)"
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34937485",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 156,
"text": "Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34813073",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 376,
"text": "INTRODUCTION: Respiratory syncytial virus (RSV) is associated with significant morbidity worldwide, especially among infants. We evaluated the potential impact of prophylactic nirsevimab, a monoclonal antibody, in infants experiencing their first RSV season, and the number of medically-attended lower respiratory tract infection episodes caused by RSV (RSV-MALRTI) in the USA"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34813073",
"endSection": "abstract",
"offsetInBeginSection": 125,
"offsetInEndSection": 376,
"text": " We evaluated the potential impact of prophylactic nirsevimab, a monoclonal antibody, in infants experiencing their first RSV season, and the number of medically-attended lower respiratory tract infection episodes caused by RSV (RSV-MALRTI) in the USA"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36328884",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 353,
"text": "INTRODUCTION: Respiratory Syncytial Virus (RSV) is a major cause of acute lower respiratory tract infections (ALRI) in infants. There are no licensed vaccines and only one monoclonal antibody available to protect infants from disease. A new and potentially longer-lasting monoclonal antibody, Nirsevimab, showed promising results in phase IIb/III trials"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34813073",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 562,
"text": "INTRODUCTION: Respiratory syncytial virus (RSV) is associated with significant morbidity worldwide, especially among infants. We evaluated the potential impact of prophylactic nirsevimab, a monoclonal antibody, in infants experiencing their first RSV season, and the number of medically-attended lower respiratory tract infection episodes caused by RSV (RSV-MALRTI) in the USA.METHODS: We developed an age-structured, dynamic, deterministic compartmental model reflecting RSV natural history, incorporating USA demographic data and an age-specific contact matrix"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34813073",
"endSection": "abstract",
"offsetInBeginSection": 125,
"offsetInEndSection": 562,
"text": " We evaluated the potential impact of prophylactic nirsevimab, a monoclonal antibody, in infants experiencing their first RSV season, and the number of medically-attended lower respiratory tract infection episodes caused by RSV (RSV-MALRTI) in the USA.METHODS: We developed an age-structured, dynamic, deterministic compartmental model reflecting RSV natural history, incorporating USA demographic data and an age-specific contact matrix"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34813073",
"endSection": "abstract",
"offsetInBeginSection": 125,
"offsetInEndSection": 684,
"text": " We evaluated the potential impact of prophylactic nirsevimab, a monoclonal antibody, in infants experiencing their first RSV season, and the number of medically-attended lower respiratory tract infection episodes caused by RSV (RSV-MALRTI) in the USA.METHODS: We developed an age-structured, dynamic, deterministic compartmental model reflecting RSV natural history, incorporating USA demographic data and an age-specific contact matrix. We assumed either no effect of nirsevimab on transmission (scenario 1) or a 50% reduction of viral shedding (scenario 2)"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37743207",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 435,
"text": "INTRODUCTION: Nirsevimab, a monoclonal antibody for the prevention of disease caused by respiratory syncytial virus (RSV), has recently been approved for use in Europe and Spain.OBJECTIVES: To provide recommendations for the administration of nirsevimab for prevention of RSV disease.METHODS: The approach chosen to develop these recommendations involved a critical review of the literature and the use of the Delphi and GRADE methods."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36577878",
"endSection": "abstract",
"offsetInBeginSection": 495,
"offsetInEndSection": 693,
"text": "Nirsevimab was approved in the EU on 3 November 2022 and in the UK on 7 November 2022 for the prevention of RSV lower respiratory tract disease in neonates and infants during their first RSV season."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36577878",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 387,
"text": "Nirsevimab (Beyfortus®), a long-acting intramuscular recombinant neutralising human IgG1ĸ monoclonal antibody to the prefusion conformation of the respiratory syncytial virus (RSV) F protein that has been modified with a triple amino acid substitution in the Fc region to extend the serum half-life, is being jointly developed by AstraZeneca and Sanofi for the prevention of RSV disease."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36577878",
"endSection": "abstract",
"offsetInBeginSection": 694,
"offsetInEndSection": 846,
"text": "This article summarizes the milestones in the development of nirsevimab leading to this first approval for the prevention of RSV disease in all infants."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36634694",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 287,
"text": "BACKGROUND: In a phase 2b trial and the phase 3 MELODY trial, nirsevimab, an extended half-life, monoclonal antibody against respiratory syncytial virus (RSV), protected healthy infants born preterm or at full term against medically attended RSV lower respiratory tract infection (LRTI)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37743207",
"endSection": "abstract",
"offsetInBeginSection": 1298,
"offsetInEndSection": 1720,
"text": "In patients in whom palivizumab is currently indicated, its substitution by nirsevimab is recommended to reduce the burden of bronchiolitis.CONCLUSIONS: Routine administration of nirsevimab to all infants aged less than 6 months born during the RSV season or aged less than 6 months at the start of the winter season is recommended to reduce the burden of disease and the frequency of hospitalization due to bronchiolitis."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37616235",
"endSection": "abstract",
"offsetInBeginSection": 94,
"offsetInEndSection": 315,
"text": "In July 2023, the Food and Drug Administration approved nirsevimab, a long-acting monoclonal antibody, for passive immunization to prevent RSV-associated lower respiratory tract infection among infants and young children."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36577878",
"endSection": "abstract",
"offsetInBeginSection": 388,
"offsetInEndSection": 494,
"text": "The extended serum half-life allows administration of nirsevimab as a single dose to cover the RSV season."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37276355",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 137,
"text": "Passive immunization with nirsevimab protects infants from severe RSV disease without impairing the immune response to natural infection."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34937485",
"endSection": "abstract",
"offsetInBeginSection": 357,
"offsetInEndSection": 504,
"text": " development. Nirsevimab (MEDI8897) is a monoclonal antibody with an extended half-life developed to protect infants for an entire RSV season with "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37616235",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 315,
"text": "Respiratory syncytial virus (RSV) is the leading cause of hospitalization among U.S. infants. In July 2023, the Food and Drug Administration approved nirsevimab, a long-acting monoclonal antibody, for passive immunization to prevent RSV-associated lower respiratory tract infection among infants and young children."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/38070539",
"endSection": "abstract",
"offsetInBeginSection": 376,
"offsetInEndSection": 536,
"text": "In July 2023, the U.S. Food and Drug Administration approved nirsevimab for the prevention of RSV-associated lower respiratory tract infections for all infants."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37743207",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 146,
"text": "INTRODUCTION: Nirsevimab, a monoclonal antibody for the prevention of disease caused by respiratory syncytial virus (RSV), has recently been appro"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36634694",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 223,
"text": "BACKGROUND: In a phase 2b trial and the phase 3 MELODY trial, nirsevimab, an extended half-life, monoclonal antibody against respiratory syncytial virus (RSV), protected healthy infants born preterm or at full term against "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36577878",
"endSection": "abstract",
"offsetInBeginSection": 379,
"offsetInEndSection": 641,
"text": "disease. The extended serum half-life allows administration of nirsevimab as a single dose to cover the RSV season. Nirsevimab was approved in the EU on 3 November 2022 and in the UK on 7 November 2022 for the prevention of RSV lower respiratory tract disease in"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37095249",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 136,
"text": "Nirsevimab is an extended half-life monoclonal antibody specific for the prefusion conformation of the respiratory syncytial virus (RSV)"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34937485",
"endSection": "abstract",
"offsetInBeginSection": 856,
"offsetInEndSection": 1244,
"text": "rom AstraZeneca and Sanofi.EXPERT OPINION: Nirsevimab (MEDI8897) is an RSV F protein monoclonal antibody and the next-generation RSV medicine having an extended half-life developed for the prevention of LRTI caused by RSV. Nirsevimab will supplant the current standard of care for RSV prevention. Importantly, nirsevimab requires a single dose to last the entire RSV season and may be giv"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37616235",
"endSection": "abstract",
"offsetInBeginSection": 958,
"offsetInEndSection": 1074,
"text": "Nirsevimab can prevent severe RSV disease among infants and young children at increased risk for severe RSV disease."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36922390",
"endSection": "abstract",
"offsetInBeginSection": 358,
"offsetInEndSection": 712,
"text": "Nirsevimab (formerly MEDI8897) is a highly potent, long-acting, human, recombinant mAb that received approval for the prevention of RSV infection in newborns and infants during their first RSV season from the EMA and the UK's Medicines and Healthcare products Regulatory Agency in November 2022 based on positive results in Phase 2b and 3 clinical trials"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32726528",
"endSection": "abstract",
"offsetInBeginSection": 180,
"offsetInEndSection": 344,
"text": "Nirsevimab is a monoclonal antibody with an extended half-life that is being developed to protect infants for an entire RSV season with a single intramuscular dose."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37641189",
"endSection": "abstract",
"offsetInBeginSection": 625,
"offsetInEndSection": 959,
"text": "Major updates for pediatric clinicians include a new recommendation for the monoclonal antibody nirsevimab for prevention of RSV disease in all infants, recommendations regarding use of 20-valent pneumococcal conjugate vaccine, and discussion of potential forthcoming changes to meningococcal and COVID-19 vaccination recommendations."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37743207",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 283,
"text": "INTRODUCTION: Nirsevimab, a monoclonal antibody for the prevention of disease caused by respiratory syncytial virus (RSV), has recently been approved for use in Europe and Spain.OBJECTIVES: To provide recommendations for the administration of nirsevimab for prevention of RSV disease"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37743207",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 434,
"text": "INTRODUCTION: Nirsevimab, a monoclonal antibody for the prevention of disease caused by respiratory syncytial virus (RSV), has recently been approved for use in Europe and Spain.OBJECTIVES: To provide recommendations for the administration of nirsevimab for prevention of RSV disease.METHODS: The approach chosen to develop these recommendations involved a critical review of the literature and the use of the Delphi and GRADE methods"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37743207",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 177,
"text": "INTRODUCTION: Nirsevimab, a monoclonal antibody for the prevention of disease caused by respiratory syncytial virus (RSV), has recently been approved for use in Europe and Spain"
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37616235",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 200,
"text": "Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37743207",
"endSection": "abstract",
"offsetInBeginSection": 647,
"offsetInEndSection": 858,
"text": "S: In the general neonatal population, routine administration of nirsevimab is recommended to reduce the frequency of illness and hospitalisation for bronchiolitis and RSV lower respiratory tract infection. Nirs"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37743207",
"endSection": "abstract",
"offsetInBeginSection": 180,
"offsetInEndSection": 436,
"text": "JECTIVES: To provide recommendations for the administration of nirsevimab for prevention of RSV disease.METHODS: The approach chosen to develop these recommendations involved a critical review of the literature and the use of the Delphi and GRADE methods. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37743207",
"endSection": "abstract",
"offsetInBeginSection": 180,
"offsetInEndSection": 464,
"text": "JECTIVES: To provide recommendations for the administration of nirsevimab for prevention of RSV disease.METHODS: The approach chosen to develop these recommendations involved a critical review of the literature and the use of the Delphi and GRADE methods. An expert group was formed. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37466917",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 361,
"text": "In children with congenital heart disease and/or chronic lung disease entering their second respiratory syncytial virus (RSV) season, 200 mg nirsevimab had a similar safety profile to that of palivizumab and resulted in nirsevimab serum exposures associated with efficacy in healthy infants, supporting efficacy in this population at risk of severe RSV disease."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35235726",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 318,
"text": "BACKGROUND: Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV fusion protein that has an extended half-life. The efficacy and safety of nirsevimab in healthy late-preterm and term infants are uncertain"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32726528",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 609,
"text": "BACKGROUND: Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in infants, and a need exists for prevention of RSV in healthy infants. Nirsevimab is a monoclonal antibody with an extended half-life that is being developed to protect infants for an entire RSV season with a single intramuscular dose.METHODS: In this trial conducted in both northern and southern hemispheres, we evaluated nirsevimab for the prevention of RSV-associated lower respiratory tract infection in healthy infants who had been born preterm (29 weeks 0 days to 34 weeks 6 days of gestation)"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32726528",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 343,
"text": "BACKGROUND: Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in infants, and a need exists for prevention of RSV in healthy infants. Nirsevimab is a monoclonal antibody with an extended half-life that is being developed to protect infants for an entire RSV season with a single intramuscular dose"
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37743207",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 155,
"text": "Nirsevimab for the prevention of respiratory syncytial virus disease in children. Statement of the Spanish Society of Paediatric Infectious Disease (SEIP)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/38070539",
"endSection": "abstract",
"offsetInBeginSection": 623,
"offsetInEndSection": 843,
"text": "virus in the body. Nirsevimab is expected to significantly reduce the health and economic burdens of RSV. This article provides an overview of nirsevimab, potential adverse effects, and implications for nursing practice."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34937485",
"endSection": "abstract",
"offsetInBeginSection": 848,
"offsetInEndSection": 1351,
"text": "leases from AstraZeneca and Sanofi.EXPERT OPINION: Nirsevimab (MEDI8897) is an RSV F protein monoclonal antibody and the next-generation RSV medicine having an extended half-life developed for the prevention of LRTI caused by RSV. Nirsevimab will supplant the current standard of care for RSV prevention. Importantly, nirsevimab requires a single dose to last the entire RSV season and may be given to term, preterm, and high-risk infants. However, even with nirsevimab approval there remains a need for"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37082704",
"endSection": "abstract",
"offsetInBeginSection": 312,
"offsetInEndSection": 546,
"text": "e measures. Recent evidence suggests the potential of nirsevimab in preventing RSV infection.Objective: This study aims to determine the efficacy and safety of nirsevimab in preventing RSV infection among infants using a review of rel"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37901217",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 320,
"text": "Introduction: Nirsevimab is an extended half-life (M252Y/S254T/T256E [YTE]-modified) monoclonal antibody to the pre-fusion conformation of the respiratory syncytial virus (RSV) Fusion protein, with established efficacy in preventing RSV-associated lower respiratory tract infection in infants for the duration of a typic"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35235726",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 213,
"text": "BACKGROUND: Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV fusion protein that has an extende"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35235726",
"endSection": "abstract",
"offsetInBeginSection": 1758,
"offsetInEndSection": 1947,
"text": "7.3%) who received placebo.CONCLUSIONS: A single injection of nirsevimab administered before the RSV season protected healthy late-preterm and term infants from medically attended RSV-assoc"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32726528",
"endSection": "abstract",
"offsetInBeginSection": 1944,
"offsetInEndSection": 2151,
"text": "hypersensitivity reactions.CONCLUSIONS: A single injection of nirsevimab resulted in fewer medically attended RSV-associated lower respiratory tract infections and hospitalizations than placebo throughout th"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34456918",
"endSection": "abstract",
"offsetInBeginSection": 478,
"offsetInEndSection": 611,
"text": "Nirsevimab is a human-derived, highly potent monoclonal antibody (mAb) with an extended half-life for RSV prophylaxis in all infants."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/38061043",
"endSection": "abstract",
"offsetInBeginSection": 968,
"offsetInEndSection": 1370,
"text": "The monoclonal antibody nirsevimab was approved by the FDA and recommended by the CDC for prevention of RSV-associated lower respiratory tract infection in infants younger than age 8 months who are born during or entering their first RSV season and for infants and children aged 8-19 months who are at high risk for RSV-associated lower respiratory tract infection and entering their second RSV season."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37824423",
"endSection": "abstract",
"offsetInBeginSection": 94,
"offsetInEndSection": 234,
"text": "Nirsevimab (Bevfortus, Sanofi and AstraZeneca) is recommended to prevent RSV-associated lower respiratory tract infection (LRTI) in infants."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37743207",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 164,
"text": "INTRODUCTION: Nirsevimab, a monoclonal antibody for the prevention of disease caused by respiratory syncytial virus (RSV), has recently been approved for use in Eur"
}
] | 13
|
BioASQ-training13b
| null | null |
65cebc0c1930410b13000003
| 5,320
|
factoid
|
Burrow Ink Test can be used to diagnose which disease?
|
['scabies']
|
[
"scabies",
"Sarcoptes scabiei",
"itch mite infestation",
"scabie",
"mange",
"human scabies"
] |
['Burrow Ink Test is used to diagnose scabies.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/8308357",
"http://www.ncbi.nlm.nih.gov/pubmed/23205026",
"http://www.ncbi.nlm.nih.gov/pubmed/37518420",
"http://www.ncbi.nlm.nih.gov/pubmed/21268539",
"http://www.ncbi.nlm.nih.gov/pubmed/23904181",
"http://www.ncbi.nlm.nih.gov/pubmed/26792847"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23904181",
"endSection": "abstract",
"offsetInBeginSection": 598,
"offsetInEndSection": 897,
"text": "Alternative diagnostic methods include the burrow ink test, video-dermatoscopy, newly serologic tests like PCR/ELISA, and specific IgE directed toward major mite components. Treatment of scabies consists of either topical permethrin or oral ivermectin, although the optimal regimen is still unclear."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23205026",
"endSection": "abstract",
"offsetInBeginSection": 1211,
"offsetInEndSection": 1722,
"text": " Two tests are used - the burrow ink test and handheld dermatoscopy. The burrow ink test is a simple, rapid, noninvasive test that can be used to screen a large number of patients. Handheld dermatoscopy is an accurate test, but requires special equipment and trained practitioners. Given the morbidity and costs of scabies infection, and that studies to date lack adequate internal and external validity, research to identify or develop accurate diagnostic tests for scabies infection is needed and justifiable."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21268539",
"endSection": "abstract",
"offsetInBeginSection": 134,
"offsetInEndSection": 408,
"text": "tudy was carried out on 200 patients referred to dermatology outpatient clinics in Sirte-Libya. Each was subjected to detailed questionnaire, dermatological skin examination, parasitological skin scraping test (SST), burrow ink test (BIT), drug administration and follow up."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/8308357",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 367,
"text": "This study is a parasitological and clinical study on human scabies. This study was carried out on 100 patients attending the Dermatology Outpatient Clinic at Ain Shams University Hospitals, including 54 males and 46 females. All patients were subjected to detailed history taking, complete dermatological examination including Skin Scraping Test and Burrow Ink Test."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37518420",
"endSection": "abstract",
"offsetInBeginSection": 116,
"offsetInEndSection": 267,
"text": "Nocturnal pruritus in 13 relatives, presence of burrows on clinical exam, and the positive scabies preparation led to the diagnosis of crusted scabies."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26792847",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 106,
"text": "The pruritic skin disease scabies is caused by the burrowing of the itch mite Sarcoptes scabiei (De Geer)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23205026",
"endSection": "abstract",
"offsetInBeginSection": 803,
"offsetInEndSection": 1397,
"text": "ies infection. Dermatoscopy by a trained practitioner has a positive likelihood ratio of 6.5 (95% CI 4.1 to 10.3) and a negative likelihood ratio of 0.1 (95% CI 0.06 to 0.2) for diagnosing scabies. The accuracy of other diagnostic tests could not be calculated from the data in the literature.CONCLUSIONS: In the face of such diagnostic inaccuracy, clinical judgment is still practical in diagnosing scabies. Two tests are used - the burrow ink test and handheld dermatoscopy. The burrow ink test is a simple, rapid, noninvasive test that can be used to screen a large number of patients. Handh"
}
] | 13
|
BioASQ-training13b
| null | null |
65cfcd541930410b13000019
| 5,326
|
factoid
|
What is the technique of choice to perform a caesarean section?
|
['Low transverse incision']
|
[
"Low transverse incision",
"Pfannenstiel incision",
"Bikini incision",
"Transverse abdominal incision",
"Low transverse abdominal incision"
] |
['Low transverse incision', 'Laparotomy followed by hysterotomy with a low transverse incision is the technique of choice to perform a caesarean section.', 'The technique of choice to perform a caesarean section is a low transverse incision, which is made horizontally in the lower part of the uterus.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/3497629",
"http://www.ncbi.nlm.nih.gov/pubmed/32760792"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32760792",
"endSection": "abstract",
"offsetInBeginSection": 146,
"offsetInEndSection": 233,
"text": "Usually laparotomy followed by hysterotomy with a low transverse incision is preferable"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/3497629",
"endSection": "abstract",
"offsetInBeginSection": 293,
"offsetInEndSection": 660,
"text": "There are indications when the preferred lower segment Caesarean section with a transverse incision should be avoided in the interest of the mother and baby. A low vertical incision has more advantages and less dangers than a classical fundal incision. It is prudent to defer the decision regarding the type of incision until the uterus is inspected intraoperatively."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/3497629",
"endSection": "abstract",
"offsetInBeginSection": 293,
"offsetInEndSection": 545,
"text": "There are indications when the preferred lower segment Caesarean section with a transverse incision should be avoided in the interest of the mother and baby. A low vertical incision has more advantages and less dangers than a classical fundal incision."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/3497629",
"endSection": "abstract",
"offsetInBeginSection": 293,
"offsetInEndSection": 450,
"text": "There are indications when the preferred lower segment Caesarean section with a transverse incision should be avoided in the interest of the mother and baby."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/3497629",
"endSection": "abstract",
"offsetInBeginSection": 160,
"offsetInEndSection": 545,
"text": "All the others were the standard transverse lower segment operation except for 1 which was a postmortem classical Caesarean section. There are indications when the preferred lower segment Caesarean section with a transverse incision should be avoided in the interest of the mother and baby. A low vertical incision has more advantages and less dangers than a classical fundal incision."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/3497629",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 450,
"text": "Eleven of the 3,420 Caesarean sections performed in Westmead Hospital, Sydney during a 6-year period from 1979 to 1985 were by a low vertical uterine incision. All the others were the standard transverse lower segment operation except for 1 which was a postmortem classical Caesarean section. There are indications when the preferred lower segment Caesarean section with a transverse incision should be avoided in the interest of the mother and baby."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/3497629",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 292,
"text": "Eleven of the 3,420 Caesarean sections performed in Westmead Hospital, Sydney during a 6-year period from 1979 to 1985 were by a low vertical uterine incision. All the others were the standard transverse lower segment operation except for 1 which was a postmortem classical Caesarean section."
}
] | 13
|
BioASQ-training13b
| null | null |
65f85fdbc4010b4d78000054
| 5,341
|
factoid
|
What is the faster length time for oxaliplatin infusion?
|
['1 mg/m(2)/min', '1 mg/m2/min']
|
[
"1 mg/m(2)/min",
"1 mg/m2/min"
] |
['The faster length time for oxaliplatin infusion is 30 minutes, which can be safely administered in patients with colorectal cancer without increasing neurotoxicity. This is in contrast to the standard infusion time of 120 minutes. Additionally, a recent study found that infusing oxaliplatin at a rate of 1 mg/m2/min (85 mg/m2 given over 85 min; 68 mg/m2 over 68 min, etc) did not increase the rate of hypersensitivity reactions (HSRs) and did not compromise patient safety.', 'The ideal and faster infusion time for oxaliplatin is 1 mg/m2/min. It was shown in a study that infusing oxaliplatin at this rate does not increase the rate of hypersensitivity reactions and does not compromise patient safety.', 'The faster length time for oxaliplatin infusion is 30 minutes as reported by a study on XELOX30 (capecitabine and oxaliplatin). This regimen was found to be convenient with an active second-line profile, similar safety to other schedules. However, the standard recommendation remains a 2-hour infusion time to reduce cold-induced neuropathy incidence.', 'Infusing oxaliplatin at a rate of 1 mg/m2/min is safe and does not increase the rate of hypersensitivity reactions (HSRs) compared to slower infusion rates. This faster 1 mg/m2/min infusion rate can be used in routine clinical practice without compromising patient safety.', 'The quickest infusion time for oxaliplatin is at a rate of 1 mg/m(2)/min.', '1 mg/m(2)/min is the faster length time for oxaliplatin infusion.', '3 hours is considered a faster length of time for oxaliplatin infusion, in contrast to the standard 6-hour infusion, as per the National Comprehensive Cancer Network (NCCN) guidelines.', 'Summary: The fastest oxaliplatin infusion time is 30 minutes, according to a phase II trial with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer resistant to irinotecan. This regimen shows similar activity and safety compared to other oxaliplatin schedules, but 2 hours is often recommended for reduced neurotoxicity risk. Infusion time should be individualized based on patient convenience, practical reasons, and potential risks for neuropathy.', 'The faster infusion time for oxaliplatin can be as short as 2 hours. This is considered safe and does not compromise patient safety, allowing for efficient treatment administration', 'The faster length time for oxaliplatin infusion is at a rate of 1 mg/m(2)/min, which has been found to not increase the rate of hypersensitivity reactions (HSRs) and does not compromise patient safety, making it safe for use in routine practice.', 'Infusing oxaliplatin at a rate of 1 mg/m2/min does not increase the rate of hypersensitivity reactions (HSRs) and does not compromise patient safety. This infusion rate is considered safe for use in routine practice.', 'The fastest length of time for oxaliplatin infusion that has been studied and found to be safe is a 30-minute infusion. This was observed in a phase II study of XELOX30 (capecitabine 1000 mg/m2 orally twice daily on days 1-14 and oxaliplatin 130 mg/m2 as a 30 min infusion on day 1) in patients with advanced colorectal cancer resistant to irinotecan. The study found that this infusion rate did not increase the rate of hypersensitivity reactions and did not compromise patient safety. This infusion rate is safe for use in routine practice.', 'Infusing oxaliplatin at a rate of 1 mg/m(2)/min does not increase the rate of hypersentitivity reactions and does not compromise patient safety. This infusion rate is safe for use in routine practice.', 'The fastest length of time for oxaliplatin infusion is 30 minutes. However, it is important to note that the incidence of side effects, such as peripheral sensory neuropathy, is claimed to be infusion rate-dependent and therefore a 2-hour infusion is often recommended. In some cases, a 120-minute infusion is recommended to avoid potential hypersensitivity reactions. However, a retrospective review of institutional experience has shown that infusing oxaliplatin at a rate of 1 mg/m(2)/min (85 mg/m(2) given over 85 min; 68 mg/m(2) over 68 min, etc) does not increase the rate of hypersensitivity reactions and does not compromise patient safety.', 'Oxaliplatin can be infused safely at a rate of 1 mg/m2/min.', '1 mg/m(2)/min\n\nContext: Infusing oxaliplatin at a rate of 1 mg/m(2)/min does not increase the rate of HSRs and does not compromise patient safety. This infusion rate is safe for use in routine practice. \nQuestion: What is the faster length time for oxaliplatin infusion?\nAnswer: 1 mg/m(2)/min\n\nContext: Infusing oxaliplatin at a rate of 1 mg/m(2)/min does not increase the rate of HSRs and does not compromise patient safety. This infusion rate is safe for use in routine practice. \nQuestion: What is the faster length time for oxaliplatin infusion?\nAnswer: 1 mg/m(2)/min\n\nContext: Infusing oxaliplatin at a rate of 1 mg/m(2)/min does not increase the rate of HSRs and does not compromise patient safety. This infusion rate is safe for use in routine practice. \nQuestion: What is the faster length time for oxaliplatin infusion?\nAnswer: 1 mg/m(2)/min\n\nContext: Infusing oxaliplatin at a rate of 1 mg/m', 'The fastest infusion time for oxaliplatin is 30 minutes, as mentioned in the articles. However, it is recommended to give oxaliplatin as a 120-minute infusion to prevent peripheral sensory neuropathy, which is a dose-limiting toxicity. In some cases, a 30-minute infusion can be safely administered without increasing neurotoxicity, but this may depend on the individual patient and their treatment plan. It is crucial to avoid extravasation during oxaliplatin infusion, as it may cause severe damage to connective tissues.', 'The fastest infusion rate for oxaliplatin (loxo), in routine practice, that decreases the rate of hypersensitivity reactions (HSRs) and does not compromise patient safety is 1 mg/m(2)/min.', "Based on the snippet provided, the recommended faster length time for oxaliplatin infusion is at a rate of 1 mg/m2/min. This infusion rate has been found to not increase the rate of hypersensitivity reactions (HSRs) and does not compromise patient safety. Therefore, this rate can be considered safe for use in routine practice. However, it's important to note that the infusion rate may vary depending on the specific clinical scenario and individual patient characteristics, so it's essential to consult with a healthcare provider or refer to the drug labeling for personalized recommendations.", 'The fastest length time for oxaliplating infusion is 30 minutes, as studied in a phase II clinical trial involving patients with advanced colorectal cancer resistant to irinotecan and 5-fluorouracil. The trial found that XELOX (capecitabine 1000 mg/m2 orally twice daily on days 1-14 and oxaliplatin 130 mg/m2 as a 30 min infusion on day 1) was an active and convenient second-line regimen with a safety profile similar to that of other oxaliplatin schedules. However, it is important to note that the incidence of neurotoxicity may be higher with shorter infusion times, and this should be carefully monitored and managed in clinical practice.', 'The faster length time for oxaliplatin infusion that does not increase the rate of Hypersensitivity Reactions (HSRs) and does not compromise patient safety is 1 mg/m2/min.', 'Based on the information provided, the faster infusion time for oxaliplatin appears to be 30 minutes. A few key points:\n\n- While a 2-hour infusion is often recommended to reduce the incidence of side effects, some studies used a 30-minute infusion time for oxaliplatin, especially when given as part of the XELOX/CAPOX regimen with capecitabine, for practical reasons and patient convenience.\n\n- One study found that infusing oxaliplatin at a fixed rate of 1 mg/m2/min (e.g. 85 mg/m2 over 85 minutes) did not increase hypersensitivity reaction rates compared to the standard 2-hour infusion. \n\n- Another study noted that a 30-minute infusion could be safely administered in colorectal cancer patients without increasing neurotoxicity compared to the 2-hour infusion.\n\nSo in summary, while 2 hours is the standard recommendation, oxaliplatin infusions of 30 minutes have been used safely and effectively in some treatment regimens and settings to improve convenience. The fastest reported infusion time that did not compromise safety was 1 mg/m2/min.', '1 mg/m(2)/min. \n\nPlease provide your answer. \n\n(Note: You can assume that the user has a basic understanding of medical terminology and concepts.) \n\n\n\n\n\nPlease provide your answer. \n\n(Note: You can assume that the user has a basic understanding of medical terminology and concepts.) \n\n\n\n\n\nPlease provide your answer. \n\n(Note: You can assume that the user has a basic understanding of medical terminology and concepts.) \n\n\n\n\n\nPlease provide your answer. \n\n(Note: You can assume that the user has a basic understanding of medical terminology and concepts.) \n\n\n\n\n\nPlease provide your answer. \n\n(Note: You can assume that the user has a basic understanding of medical terminology and concepts.) \n\n\n\n\n\nPlease provide your answer. \n\n(Note: You can assume that the user has a basic understanding of medical terminology and concepts.) \n\n\n\n\n\nPlease provide your answer. \n\n(Note: You can assume that the user has a basic understanding of medical terminology and concepts.) \n\n\n\n\n\nPlease provide your answer. \n\n(Note: You can assume that the user has a basic understanding of medical terminology and concepts.) \n\n\n\n\n\nPlease provide your answer. \n\n(Note: You can assume that the user has a basic understanding of medical terminology and concepts.) \n\n\n\n\n\nPlease provide your answer. \n\n(Note', 'The articles provided do not specify a faster length of time for oxaliplatin infusion. However, it is noted that infusing oxaliplatin at a rate of 1 mg/m2/min does not increase the rate of hypersensitivity reactions and is safe for use in routine practice.', 'The faster length of time for oxaliplatin infusion is 85 minutes, as evaluated in a retrospective cohort study comparing the safety outcomes of rapid administration of oxaliplatin to standard infusion. The study found that patients who received oxaliplatin plus LV5FU2 had significantly longer progression-free survival and better response rates compared to the control arm. However, the improvement in overall survival did not reach significance. The study also reported higher frequencies of National Cancer Institute common toxicity criteria grade 3/4 neutropenia in patients who received oxaliplatin plus LV5FU2.', 'The new policy of infusing oxaliplatin at a rate of 1 mg/m²/min allows for faster infusion times, reducing it to approximately 85 minutes or less depending on the dose administered (e.g., 85mg/m² in 85 min and 68mg/m² in 68 min). This revised rate is safe for routine practice without increasing hypersensitivity risk.', 'Infusing oxaliplatin at a rate of 1 mg/m(2)/min is the recommended infusion time for oxaliplatin.', 'The faster length time for oxaliplatin infusion is recommended at 1 mg/m2/min rate. This does not increase hypersensitivity reactions (HSRs) and maintains patient safety, but individual factors may influence this choice. Always consult a healthcare provider or refer to the drug labeling for personalized recommendations.', 'Oxaliplatin can be safely infused at a faster rate of 1 mg/m(2)/min, which means a dose of 85 mg/m(2) would be given over 85 minutes, a dose of 68 mg/m(2) over 68 minutes, and so on, without increasing the rate of hypersensitivity reactions or compromising patient safety.', 'Based on the abstract, the traditional infusion time for oxaliplatin was 120 minutes. However, with the new policy of infusing oxaliplatin at a rate of 1 mg/m²/min, the infusion time is significantly reduced. For example, an 85 mg/m² dose can be infused in 85 minutes, and a 68 mg/m² dose can be infused in 68 minutes. Therefore, the faster length of time for oxaliplatin infusion is approximately 85 minutes or less, depending on the dose administered. This revised infusion rate does not increase the risk of hypersensitivity reactions and is safe for routine practice.', 'Infusing oxaliplatin at a rate of 1 mg/m(2)/min is the faster length time for oxaliplatin infusion.', 'The fastest length of time for oxaliplatin infusion is 30 minutes, as studied in a phase II trial with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer resistant to irinotecan. This regimen showed similar activity and safety profile to other oxaliplatin schedules. However, it is important to note that the incidence of neurotoxicity may be infusion rate-dependent, and a 2-hour infusion is often recommended to reduce this side effect. The decision on the length of infusion time should be individualized based on patient convenience, practical reasons, and potential risks for neuropathy.', 'The faster infusion time for oxaliplatin can be as short as 2 hours. This is based on the information that infusing oxaliplatin at a rate of 1 mg/m²/min is considered safe and does not increase the rate of hypersensitivity reactions (HSRs), nor does it compromise patient safety. This infusion rate allows for a quicker administration while maintaining safety in routine practice.', 'The faster infusion time for oxaliplatin can be as short as 2 hours. This is based on the information that infusing oxaliplatin at a rate of 1 mg/m²/min is considered safe and does not increase hypersensitivity reactions (HSRs), nor does it compromise patient safety. This rate allows for a quicker administration while maintaining safety in routine practice.', 'The faster length time for oxaliplatin infusion is 1 mg/m(2)/min.', 'The faster length time for oxaliplatin infusion is a rate of 1 mg/m(2)/min.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/10668856",
"http://www.ncbi.nlm.nih.gov/pubmed/32451327",
"http://www.ncbi.nlm.nih.gov/pubmed/16088232",
"http://www.ncbi.nlm.nih.gov/pubmed/37525581",
"http://www.ncbi.nlm.nih.gov/pubmed/19238627",
"http://www.ncbi.nlm.nih.gov/pubmed/19622596",
"http://www.ncbi.nlm.nih.gov/pubmed/17450468",
"http://www.ncbi.nlm.nih.gov/pubmed/27072569",
"http://www.ncbi.nlm.nih.gov/pubmed/14755010"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27072569",
"endSection": "abstract",
"offsetInBeginSection": 1411,
"offsetInEndSection": 1590,
"text": " Infusing oxaliplatin at a rate of 1 mg/m(2)/min does not increase the rate of HSRs and does not compromise patient safety. This infusion rate is safe for use in routine practice."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27072569",
"endSection": "abstract",
"offsetInBeginSection": 694,
"offsetInEndSection": 864,
"text": "e then instituted a new policy to infuse all nonresearch doses of oxaliplatin at a set rate of 1 mg/m(2)/min (85 mg/m(2) given over 85 min; 68 mg/m(2) over 68 min, etc). "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27072569",
"endSection": "abstract",
"offsetInBeginSection": 694,
"offsetInEndSection": 937,
"text": "e then instituted a new policy to infuse all nonresearch doses of oxaliplatin at a set rate of 1 mg/m(2)/min (85 mg/m(2) given over 85 min; 68 mg/m(2) over 68 min, etc). The incidence of HSRs with the new infusion rate was actively monitored.R"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27072569",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 460,
"text": "PURPOSE: Oxaliplatin at a dose of 85 mg/m(2) traditionally has been administered over 120 min in the standard FOLFOX (infusional fluorouracil, leucovorin, and oxaliplatin) regimen. CapeOx (capecitabine plus oxaliplatin), in which the dose of oxaliplatin is 130 mg/m(2), has also been infused over 120 min. Maintenance of a prolonged infusion time has been largely based on the concern for a potential hypersensitivity reaction (HSR) if administered too quickly"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27072569",
"endSection": "abstract",
"offsetInBeginSection": 694,
"offsetInEndSection": 1098,
"text": "e then instituted a new policy to infuse all nonresearch doses of oxaliplatin at a set rate of 1 mg/m(2)/min (85 mg/m(2) given over 85 min; 68 mg/m(2) over 68 min, etc). The incidence of HSRs with the new infusion rate was actively monitored.RESULTS: Of 2,097 patients who previously received oxaliplatin over 120 min, 1,936 received a dose of 85 mg/m(2) (± 10%), and 161 received a dose of 130 mg/m(2). "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27072569",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 179,
"text": "PURPOSE: Oxaliplatin at a dose of 85 mg/m(2) traditionally has been administered over 120 min in the standard FOLFOX (infusional fluorouracil, leucovorin, and oxaliplatin) regimen"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27072569",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 180,
"text": "PURPOSE: Oxaliplatin at a dose of 85 mg/m(2) traditionally has been administered over 120 min in the standard FOLFOX (infusional fluorouracil, leucovorin, and oxaliplatin) regimen."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27072569",
"endSection": "abstract",
"offsetInBeginSection": 1323,
"offsetInEndSection": 1534,
"text": "The incidence of HSRs in patients treated at this fixed infusion rate was 8%.CONCLUSION: Infusing oxaliplatin at a rate of 1 mg/m(2)/min does not increase the rate of HSRs and does not compromise patient safety."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/16088232",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 648,
"text": "OBJECTIVES: The aim of the study was to define the feasibility and efficacy of Xelox (capecitabine and oxaliplatin) administered through a new and original schedule in advanced pretreated colorectal cancer (CRC) patients.METHODS: 36 metastatic CRC patients resistant at least to a previous 5-fluorouracil- and irinotecan-based chemotherapy line were included in the study.TREATMENT: Oxaliplatin 70 mg/m2 as continuous infusion for 12 h (8.00 a.m. to 8.00 p.m.) on days 1, 8 plus chronomodulated capecitabine 1,750 mg/m2/day per os (8.00 a.m. 25% of total dose; 6.00 p.m. 25% of total dose; 11.00 p.m. 50% of total dose), on days 1-14 every 21 days."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37525581",
"endSection": "abstract",
"offsetInBeginSection": 990,
"offsetInEndSection": 1315,
"text": "Rapid-rate oxaliplatin was not associated with increased HSR or difference in toxicity requiring dose reduction, delayed dose, or slowed infusion rate, but was associated with increased rate of permanent discontinuation of oxaliplatin, 7.8% and 1.1% in the rapid-rate group and standard-rate groups, respectively (p = 0.032)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37525581",
"endSection": "abstract",
"offsetInBeginSection": 239,
"offsetInEndSection": 409,
"text": "We evaluated the safety outcomes of rapid administration of oxaliplatin compared to standard infusion.METHODS: We performed a retrospective, cohort study by chart review."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27072569",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1553,
"text": "PURPOSE: Oxaliplatin at a dose of 85 mg/m(2) traditionally has been administered over 120 min in the standard FOLFOX (infusional fluorouracil, leucovorin, and oxaliplatin) regimen. CapeOx (capecitabine plus oxaliplatin), in which the dose of oxaliplatin is 130 mg/m(2), has also been infused over 120 min. Maintenance of a prolonged infusion time has been largely based on the concern for a potential hypersensitivity reaction (HSR) if administered too quickly.METHODS: We first performed a retrospective review of our institutional experience to assess whether HSR rates were similar in FOLFOX and CapeOx by using computerized pharmacy records between January 1, 2011, and December 31, 2013. We then instituted a new policy to infuse all nonresearch doses of oxaliplatin at a set rate of 1 mg/m(2)/min (85 mg/m(2) given over 85 min; 68 mg/m(2) over 68 min, etc). The incidence of HSRs with the new infusion rate was actively monitored.RESULTS: Of 2,097 patients who previously received oxaliplatin over 120 min, 1,936 received a dose of 85 mg/m(2) (± 10%), and 161 received a dose of 130 mg/m(2). The incidence of HSRs in the 85 mg/m(2) group was 11% versus 7% in the 130 mg/m(2) group (P = .13). Then between December 1, 2014, and June 4, 2015, 667 patients received oxaliplatin at a rate of 1 mg/m(2)/min for all doses. The incidence of HSRs in patients treated at this fixed infusion rate was 8%.CONCLUSION: Infusing oxaliplatin at a rate of 1 mg/m(2)/min does not increase the rate of HSRs and does not compromise patient safety. This infusion rate"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37525581",
"endSection": "abstract",
"offsetInBeginSection": 150,
"offsetInEndSection": 392,
"text": "mens may be infused over a rapid rate of 85 min instead of the standard time of 120 min. We evaluated the safety outcomes of rapid administration of oxaliplatin compared to standard infusion.METHODS: We performed a retrospective, cohort study"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32451327",
"endSection": "abstract",
"offsetInBeginSection": 113,
"offsetInEndSection": 414,
"text": " A known side effect of oxaliplatin administration via a peripheral vein is infusion-related pain. In this retrospective cohort study we compared the incidence of infusion-related pain in patients treated with oxaliplatin with or without simultaneous fluid infusion (FI) (800 mL glucose 5% in 2 hours)"
}
] | 13
|
BioASQ-training13b
| null | null |
66099967fdcbea915f000018
| 5,345
|
factoid
|
What disease is treated by Callosotomy
|
['epilepsy', 'Lennox-Gastaut syndrome (LGS), Ataxia, Epileptic spasms, Drop attacks']
|
[
"epilepsy",
"Lennox-Gastaut syndrome",
"LGS",
"Ataxia",
"epileptic spasms",
"drop attacks",
"Lennox-Gastaut syndrome (LGS)"
] |
["Callosotomy is a surgical procedure used to treat a variety of neurological conditions, including epilepsy, Parkinson's disease, and chronic pain.", 'The disease treated by Callosotomy is epilepsy.', 'Callosotomy is a palliative neurosurgical procedure for treating medically refractory epilepsy by reducing seizure burden in patients with various types of epilepsy, such as Lennox-Gastaut syndrome and Rett syndrome.', 'Corpus callosotomy (CC) is a palliative neurosurgical procedure for patients with intractable epilepsy.', 'The disease treated by Callosotomy is epilepsy, specifically intractable epilepsy and drug resistant epilepsy.', 'Corpus callosotomy is a surgical procedure used to treat drug-resistant epilepsy, specifically for patients who do not have resectable focal epileptogenic lesions.', 'Callosotomy is a surgical procedure that involves cutting the corpus callosum. This procedure is often used to treat epilepsy, particularly when a patient experiences debilitating drop attacks, but it is also used in the treatment of certain neuropsychiatric disorders.', 'The disease treated by Callosotomy is epilepsy, specifically medically resistant or drug-resistant epilepsy.', 'Callosotomy is a surgical procedure used to treat drug-resistant epilepsy (DRE) in patients who have not responded to medication.', 'Corpus callosotomy is a surgical procedure used to treat epilepsy, specifically generalized or multifocal drug-resistant epilepsy, medically refractory epilepsy, and generalized or unknown-onset seizures.', 'Corpus callosotomy is a surgical procedure used to treat epilepsy, specifically anterior callosotomy for medically resistant cases.', 'Corpus callosotomy is a surgical procedure used to treat patients with drug-resistant epilepsy, specifically to help reduce the severity and frequency of seizures.', 'Callosotomy, also known as Corpus Callosotomy (CC), is a palliative surgical procedure used to treat drug resistant epilepsy (DRE), specifically for patients with intractable epilepsy who do not have resectable focal epileptogenic lesions, and it is often employed to stop drop attacks.', 'Corpus callosotomy (CC) is a palliative surgical intervention for patients with medically refractory epilepsy.', 'Callosotomy is used to treat intractable epilepsy, specifically to help manage severe seizure types such as drop attacks in patients who do not respond to medication.', 'Callosotomy is primarily used to treat various forms of epilepsy, especially those that are resistant to medication.', 'Epilepsy is treated by Callosotomy.', 'Callosotomy is used to treat seizures.', 'Callosotomy is a neurosurgical procedure where the corpus callosum is sectioned. It is used to control intractable epilepsy by interrupting the spread of epileptic activity between the cerebral hemispheres.', 'Callosotomy is used to treat epilepsy.', 'Callosotomy is performed to manage epilepsy.', 'Corpus callosotomy is a surgical procedure used to treat intractable epilepsy and drug-resistant epilepsy.', 'Corpus callosotomy (CC) is a surgical procedure used to treat drug-resistant epilepsy (DRE), which is a disease characterized by recurrent seizures that do not respond to medication.', 'Corpus callosotomy (CC) is a surgical palliative procedure done for a selected group of patients with drug-resistant epilepsy (DRE) to stop drop attacks.', 'Corpus callosotomy is a surgical procedure used to treat patients with drug-resistant epilepsy, particularly those who experience severe and frequent drop attacks', 'Callosotomy is a surgical procedure used to treat epilepsy.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/35241305",
"http://www.ncbi.nlm.nih.gov/pubmed/36347391",
"http://www.ncbi.nlm.nih.gov/pubmed/35033693",
"http://www.ncbi.nlm.nih.gov/pubmed/27237542",
"http://www.ncbi.nlm.nih.gov/pubmed/17521926",
"http://www.ncbi.nlm.nih.gov/pubmed/32280261",
"http://www.ncbi.nlm.nih.gov/pubmed/2124757",
"http://www.ncbi.nlm.nih.gov/pubmed/36114075",
"http://www.ncbi.nlm.nih.gov/pubmed/7754863",
"http://www.ncbi.nlm.nih.gov/pubmed/30579267",
"http://www.ncbi.nlm.nih.gov/pubmed/30153937",
"http://www.ncbi.nlm.nih.gov/pubmed/25692412",
"http://www.ncbi.nlm.nih.gov/pubmed/37303192",
"http://www.ncbi.nlm.nih.gov/pubmed/36435385",
"http://www.ncbi.nlm.nih.gov/pubmed/36682756",
"http://www.ncbi.nlm.nih.gov/pubmed/37770691",
"http://www.ncbi.nlm.nih.gov/pubmed/20384766",
"http://www.ncbi.nlm.nih.gov/pubmed/32652281",
"http://www.ncbi.nlm.nih.gov/pubmed/16552568",
"http://www.ncbi.nlm.nih.gov/pubmed/31835250",
"http://www.ncbi.nlm.nih.gov/pubmed/22681320",
"http://www.ncbi.nlm.nih.gov/pubmed/35716888",
"http://www.ncbi.nlm.nih.gov/pubmed/8029136",
"http://www.ncbi.nlm.nih.gov/pubmed/36600777",
"http://www.ncbi.nlm.nih.gov/pubmed/31140570",
"http://www.ncbi.nlm.nih.gov/pubmed/31042603",
"http://www.ncbi.nlm.nih.gov/pubmed/18799327",
"http://www.ncbi.nlm.nih.gov/pubmed/10449075",
"http://www.ncbi.nlm.nih.gov/pubmed/19702730",
"http://www.ncbi.nlm.nih.gov/pubmed/11455228",
"http://www.ncbi.nlm.nih.gov/pubmed/35770757",
"http://www.ncbi.nlm.nih.gov/pubmed/32889189",
"http://www.ncbi.nlm.nih.gov/pubmed/35498367",
"http://www.ncbi.nlm.nih.gov/pubmed/18759631",
"http://www.ncbi.nlm.nih.gov/pubmed/35713776",
"http://www.ncbi.nlm.nih.gov/pubmed/27923529",
"http://www.ncbi.nlm.nih.gov/pubmed/18539083",
"http://www.ncbi.nlm.nih.gov/pubmed/27010176",
"http://www.ncbi.nlm.nih.gov/pubmed/23948796",
"http://www.ncbi.nlm.nih.gov/pubmed/14698693",
"http://www.ncbi.nlm.nih.gov/pubmed/7806786",
"http://www.ncbi.nlm.nih.gov/pubmed/25284034",
"http://www.ncbi.nlm.nih.gov/pubmed/10612336",
"http://www.ncbi.nlm.nih.gov/pubmed/32305273",
"http://www.ncbi.nlm.nih.gov/pubmed/37766507",
"http://www.ncbi.nlm.nih.gov/pubmed/35091359",
"http://www.ncbi.nlm.nih.gov/pubmed/36637309",
"http://www.ncbi.nlm.nih.gov/pubmed/21628134"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36435385",
"endSection": "abstract",
"offsetInBeginSection": 12,
"offsetInEndSection": 177,
"text": "Corpus callosotomy (CC) is a surgical palliative procedure done for a selected group of patients with drug resistant epilepsy (DRE) to stop drop attacks and prevent "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36637309",
"endSection": "abstract",
"offsetInBeginSection": 12,
"offsetInEndSection": 166,
"text": "Corpus callosotomy (CC) is a palliative neurosurgical procedure for patients with intractable epilepsy and without resectable focal epileptogenic lesions."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37303192",
"endSection": "abstract",
"offsetInBeginSection": 11,
"offsetInEndSection": 253,
"text": "Corpus callosotomy (CC) is a palliative surgical intervention for patients with medically refractory epilepsy that has evolved in recent years to include a less-invasive alternative with the use of laser interstitial thermal therapy (LITT). L"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36347391",
"endSection": "abstract",
"offsetInBeginSection": 504,
"offsetInEndSection": 779,
"text": "This review describes feline epilepsy syndrome and epilepsy-related pathology, and discusses the indications for and availability of neurosurgery, including lesionectomy, temporal lobectomy with hippocampectomy, and corpus callosotomy, for cats with different epilepsy types."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35716888",
"endSection": "abstract",
"offsetInBeginSection": 849,
"offsetInEndSection": 970,
"text": "In dogs with drug-resistant epilepsy, corpus callosotomy is available as a disconnection surgery for generalized epilepsy"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37770691",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 595,
"text": "Corpus callosotomy (CC) is an effective surgical treatment for medically resistant generalized or multifocal epilepsy (MRE). The premise of CC extrapolates from the observation that the corpus callosum is the predominant commissural pathway that allows spread and synchroneity of epileptogenic activity between the hemispheres. Candidacy for CC is typically reserved for patients seeking palliative epilepsy treatment with the goal of reducing the frequency of drop attacks, although reduction of other seizure semiologies (absence, complex partial seizures, and tonic-clonic) has been observed."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37770691",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 327,
"text": "Corpus callosotomy (CC) is an effective surgical treatment for medically resistant generalized or multifocal epilepsy (MRE). The premise of CC extrapolates from the observation that the corpus callosum is the predominant commissural pathway that allows spread and synchroneity of epileptogenic activity between the hemispheres."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18539083",
"endSection": "abstract",
"offsetInBeginSection": 167,
"offsetInEndSection": 658,
"text": "The rationale for this procedure is based on the hypothesis that the corpus callosum is a critical pathway for interhemispheric spread of epileptic activity. Efficacy and relatively low permanent morbidity in corpus callosotomy for medically intractable epilepsy have been demonstrated by more than six decades of experience. Callosotomy best ameliorates drop attacks (tonic and atonic seizures), though tonic-clonic, absence, and frontal lobe complex partial seizures often respond as well."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18539083",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 492,
"text": "Corpus callosotomy is a palliative surgical procedure that is suitable for some patients with intractable seizures who are not candidates for focal resective surgery. The rationale for this procedure is based on the hypothesis that the corpus callosum is a critical pathway for interhemispheric spread of epileptic activity. Efficacy and relatively low permanent morbidity in corpus callosotomy for medically intractable epilepsy have been demonstrated by more than six decades of experience."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18539083",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 324,
"text": "Corpus callosotomy is a palliative surgical procedure that is suitable for some patients with intractable seizures who are not candidates for focal resective surgery. The rationale for this procedure is based on the hypothesis that the corpus callosum is a critical pathway for interhemispheric spread of epileptic activity."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32889189",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 306,
"text": "Corpus callosotomy, first used in the management of epilepsy by William P. van Wagenen in 1940, was for years a contentious procedure. Two decades later, Nobel Laureate Roger W. Sperry's split-brain studies inspired surgeons to reexamine the role of corpus callosotomy in the control of epileptic seizures."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32889189",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 437,
"text": "Corpus callosotomy, first used in the management of epilepsy by William P. van Wagenen in 1940, was for years a contentious procedure. Two decades later, Nobel Laureate Roger W. Sperry's split-brain studies inspired surgeons to reexamine the role of corpus callosotomy in the control of epileptic seizures. In 1962, Joseph Bogen and Philip Vogel performed complete corpus callosotomies in patients with a history of generalized seizures."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18539083",
"endSection": "abstract",
"offsetInBeginSection": 325,
"offsetInEndSection": 734,
"text": "Efficacy and relatively low permanent morbidity in corpus callosotomy for medically intractable epilepsy have been demonstrated by more than six decades of experience. Callosotomy best ameliorates drop attacks (tonic and atonic seizures), though tonic-clonic, absence, and frontal lobe complex partial seizures often respond as well. In addition to seizure reduction, behavior and quality of life may improve."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18539083",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 166,
"text": "Corpus callosotomy is a palliative surgical procedure that is suitable for some patients with intractable seizures who are not candidates for focal resective surgery."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37770691",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 124,
"text": "Corpus callosotomy (CC) is an effective surgical treatment for medically resistant generalized or multifocal epilepsy (MRE)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37766507",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 154,
"text": "OBJECTIVE: Corpus callosotomy (CC) is an important treatment for atonic seizures in patients with generalized or multifocal drug-resistant epilepsy (DRE)."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37770691",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 86,
"text": "Corpus Callosotomy Is a Safe and Effective Procedure for Medically Resistant Epilepsy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35033693",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 87,
"text": "Corpus callosotomy is among the oldest surgeries performed for drug-resistant epilepsy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35770757",
"endSection": "abstract",
"offsetInBeginSection": 857,
"offsetInEndSection": 1268,
"text": "Two patients with epilepsy with myoclonic absences with atonia underwent corpus callosotomy; one patient was seizurefree eight months after surgery and the other had greater than 50% seizure reduction over a five-month period.SIGNIFICANCE: Phenotypic heterogeneity was evident based on seizure semiologies, comorbidities, seizure frequency and response to anti-seizure medications and non-medication treatments."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35498367",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 631,
"text": "Background: Whether epilepsy surgery, such as corpus callosotomy is effective in patients with pediatric intractable epilepsy with mitochondrial dysfunction is controversial, and there is a paucity of literature on this issue.Objective: This study aimed to assess and describe the effective application of corpus callosotomy for treating pediatric patients with intractable epilepsy with mitochondrial dysfunction in a single institution in Korea.Methods: This was a retrospective study of pediatric patients with intractable epilepsy and mitochondrial dysfunction who underwent corpus callosotomy in a single tertiary care center."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37770691",
"endSection": "abstract",
"offsetInBeginSection": 328,
"offsetInEndSection": 595,
"text": "Candidacy for CC is typically reserved for patients seeking palliative epilepsy treatment with the goal of reducing the frequency of drop attacks, although reduction of other seizure semiologies (absence, complex partial seizures, and tonic-clonic) has been observed."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35713776",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 318,
"text": "PURPOSE OF REVIEW: To summarize current evidence and recent developments in the surgical treatment of drug-resistant generalized epilepsy.RECENT FINDINGS: Current surgical treatments of drug-resistant generalized epilepsy include vagus nerve stimulation (VNS), deep brain stimulation (DBS) and corpus callosotomy (CC)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23948796",
"endSection": "abstract",
"offsetInBeginSection": 259,
"offsetInEndSection": 681,
"text": "Optimal treatment of seizures in AS remains undetermined.METHODS: We report a series of four patients with Aicardi syndrome who underwent surgical management of their epilepsy including two with corpus callosotomy (CC) of a partial corpus callosum and three with vagus nerve stimulator implantation.RESULTS: Seizure outcome was variable and ranged from near complete resolution of seizures to worsening of seizure profile."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/7806786",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 497,
"text": "Although corpus callosotomy has been used since 1940 to treat severe, medically intractable seizure disorders, controversy remains as to when, or even if, the surgery should be performed. Unlike other types of surgical therapy of epilepsy where the epileptic focus is identified and removed, corpus callosotomy is used to interrupt the propagation of epileptic discharges. The procedure is primarily used in patients with secondarily generalized seizures in whom focal resections are not possible."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31835250",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 137,
"text": "OBJECTIVE: Corpus callosotomy is a palliative procedure that is effective at reducing seizure burden in patients with medically refractor"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36600777",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 260,
"text": "Background: Medically refractory epilepsy constitutes up to one-third of the epilepsy pediatric patients. Corpus callosotomy (CC) has been used for the treatment of medically refractory epilepsy in children with atonic seizures and generalized tonic-clonic (GT"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27237542",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 157,
"text": "OBJECTIVE: Corpus callosotomy is a palliative neurosurgical treatment for patients with either generalized or multifocal refractory epilepsy and injurious dr"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/20384766",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 355,
"text": "Although many patients with medically refractory focal epilepsy are candidates for resective surgery, patients with multifocal epilepsy and symptomatic generalized epilepsy remain difficult to treat medically and surgically. Corpus callosotomy has been utilized since 1940 for the treatment of seizures, with reports of efficacy in multiple seizure types."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/10449075",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 112,
"text": "OBJECTIVE: Corpus callosotomy is a surgical option for medically uncontrolled generalized epilepsy in appropriat"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27923529",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 130,
"text": "Corpus callosotomy is a palliative therapy for refractory epilepsy, including West syndrome, without a resectable epileptic focus."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32280261",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 180,
"text": "INTRODUCTION: Corpus callosotomy (CCT) is a palliative procedure to treat injurious drop attacks or multifocal/generalized seizures in which resection of the epileptogenic focus is"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27010176",
"endSection": "abstract",
"offsetInBeginSection": 67,
"offsetInEndSection": 516,
"text": "This review focuses on the significance of CC for seizure disorders, the role of CC in seizure spread and the surgical disruption of callosal fibers (callosotomy) for treatment of patients with drug-resistant epilepsy.METHODS: Personal experience/extensive literature review.RESULTS: Structural CC pathologies comprise developmental abnormalities, callosal involvement in identified disorders, transient imaging findings and microstructural changes."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32652281",
"endSection": "abstract",
"offsetInBeginSection": 586,
"offsetInEndSection": 906,
"text": "In so doing, we also review the literature with regard to the neurosurgical management of these unique patients.CONCLUSIONS: For the subset of children who present with partial, rather than complete, agenesis of the corpus callosum, corpus callosotomy should be considered as a treatment option to reduce seizure burden."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31835250",
"endSection": "abstract",
"offsetInBeginSection": 7,
"offsetInEndSection": 127,
"text": "VE: Corpus callosotomy is a palliative procedure that is effective at reducing seizure burden in patients with medically"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/19702730",
"endSection": "abstract",
"offsetInBeginSection": 197,
"offsetInEndSection": 337,
"text": "low morbidity. Callosotomy is a more ambitious procedure, with a higher risk of complications but greater likelihood of seizure improvement."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32280261",
"endSection": "abstract",
"offsetInBeginSection": 7,
"offsetInEndSection": 324,
"text": "CTION: Corpus callosotomy (CCT) is a palliative procedure to treat injurious drop attacks or multifocal/generalized seizures in which resection of the epileptogenic focus is not feasible. We are presenting our experience in treating intractable epilepsy patients by CCT procedures.METHODS: We observed 16 patients who"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18759631",
"endSection": "abstract",
"offsetInBeginSection": 7,
"offsetInEndSection": 158,
"text": " Although corpus callosotomy has been used effectively since the late 1930s to treat severe, medically intractable seizure disorders, particularly aton"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22681320",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 222,
"text": "OBJECT: Corpus callosotomy is usually intended to alleviate-not to achieve total control of-epileptic seizures. A few patients experience complete seizure control after callosotomy, but the associated clinical factors are "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18759631",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 176,
"text": "OBJECT: Although corpus callosotomy has been used effectively since the late 1930s to treat severe, medically intractable seizure disorders, particularly atonic or drop-attack "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18539083",
"endSection": "abstract",
"offsetInBeginSection": 493,
"offsetInEndSection": 658,
"text": "Callosotomy best ameliorates drop attacks (tonic and atonic seizures), though tonic-clonic, absence, and frontal lobe complex partial seizures often respond as well."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25284034",
"endSection": "abstract",
"offsetInBeginSection": 944,
"offsetInEndSection": 1149,
"text": "Corpus callosotomy is a palliative surgical approach that aims at controlling potentially injurious seizures, for example, atonic or drop seizures, by preventing the bilateral spread of epileptic activity."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32305273",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 200,
"text": "Corpus callosotomy is a palliative surgical option for patients with refractory epilepsy and frequent drop attacks, decreasing seizure frequency and severity by disconnecting the cerebral hemispheres."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/2124757",
"endSection": "abstract",
"offsetInBeginSection": 822,
"offsetInEndSection": 909,
"text": "corpus callosotomies frequently reduce the number and severity of generalized seizures."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/17521926",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 89,
"text": "Corpus callosotomy has a long history as a palliative treatment for intractable epilepsy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31140570",
"endSection": "abstract",
"offsetInBeginSection": 7,
"offsetInEndSection": 157,
"text": "UND: Callosotomy represents a palliative procedure for intractable multifocal epilepsy. The extent of callosotomy and the benefits of adding anterior "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/10449075",
"endSection": "abstract",
"offsetInBeginSection": 12,
"offsetInEndSection": 162,
"text": "orpus callosotomy is a surgical option for medically uncontrolled generalized epilepsy in appropriate patients. Because numerous complications related"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21628134",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 263,
"text": "Gamma knife radiosurgery is a minimally invasive procedure which can be used for patients with intractable epilepsies as an alternative for surgical corpus callosotomy. We report a 13-year-old boy with intractable epilepsy who underwent radiosurgical callosotomy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/7806786",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 187,
"text": "Although corpus callosotomy has been used since 1940 to treat severe, medically intractable seizure disorders, controversy remains as to when, or even if, the surgery should be performed."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/20384766",
"endSection": "abstract",
"offsetInBeginSection": 225,
"offsetInEndSection": 355,
"text": "Corpus callosotomy has been utilized since 1940 for the treatment of seizures, with reports of efficacy in multiple seizure types."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35241305",
"endSection": "abstract",
"offsetInBeginSection": 823,
"offsetInEndSection": 989,
"text": "Because the seizures were intractable, a corpus callosotomy was performed at 16 years along with a concurrent brain biopsy from the bilateral lateral frontal cortices"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36682756",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 144,
"text": "Callosotomy is widely used today as a treatment option for medically refractory epilepsy in patients with generalized or unknown-onset seizures."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32280261",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 194,
"text": "INTRODUCTION: Corpus callosotomy (CCT) is a palliative procedure to treat injurious drop attacks or multifocal/generalized seizures in which resection of the epileptogenic focus is not feasible."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/16552568",
"endSection": "abstract",
"offsetInBeginSection": 479,
"offsetInEndSection": 959,
"text": "The aim of this study is to evaluate the outcome of corpus callosotomy for the treatment of childhood onset medically intractable epilepsy in a developing pediatric epilepsy surgery center.METHOD: We report 16 patients who underwent two thirds anterior corpus callosotomy for treatment of refractory seizures in childhood.RESULTS: All patients had drop attacks or multiple types of seizures, yet some showed focal onset with secondary generalization on electroencephalogram (EEG)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/16552568",
"endSection": "abstract",
"offsetInBeginSection": 1092,
"offsetInEndSection": 1338,
"text": "Overall 11/16 (69%) of our patients improved significantly after anterior callosotomy.CONCLUSION: Corpus callosotomy remains to be a fairly good choice of surgical treatment for childhood onset medically intractable epilepsy in selected patients."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36114075",
"endSection": "abstract",
"offsetInBeginSection": 375,
"offsetInEndSection": 658,
"text": "Here, we present a case of DEE with early childhood onset caused by anATP1A3variant that was effectively treated using corpus callosotomy (CC).CASE PRESENTATION: At the age of 3 years, the patient developed epileptic spasms, complicated by generalized and focal aware tonic seizures."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32280261",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 193,
"text": "INTRODUCTION: Corpus callosotomy (CCT) is a palliative procedure to treat injurious drop attacks or multifocal/generalized seizures in which resection of the epileptogenic focus is not feasible"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32889189",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 134,
"text": "Corpus callosotomy, first used in the management of epilepsy by William P. van Wagenen in 1940, was for years a contentious procedure."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/10449075",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 122,
"text": "OBJECTIVE: Corpus callosotomy is a surgical option for medically uncontrolled generalized epilepsy in appropriate patients"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/11455228",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 120,
"text": "Corpus callosotomy is an effective neurosurgical procedure for children with intractable atonic or drop attack seizures."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31835250",
"endSection": "abstract",
"offsetInBeginSection": 675,
"offsetInEndSection": 838,
"text": "THODS: The authors retrospectively reviewed all patients treated for medically refractory epilepsy by corpus callosotomy, either partial or completion, with LITT. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/8029136",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 150,
"text": "The authors present palliative therapy of severe epilepsy, i.e. callosotomy. Experimental studies and numerous clinical trials indicate possible use o"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/7754863",
"endSection": "abstract",
"offsetInBeginSection": 1328,
"offsetInEndSection": 1804,
"text": "From this paper the following conclusions can be drawn: a) epileptic patients with severe drug-resistant epilepsy due to bihemispheric cortical dysplasias are good candidates for callosotomy, b) one-stage extensive anterior callosotomy sparing the splenium is the procedure of choice, c) associated severe mental retardation seems to contra-indicate callosotomy, d) the neurophysiological study of the IHT can yield information on the functional status of the corpus callosum."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18799327",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 144,
"text": "PURPOSE: Corpus callosotomy can be an effective surgical treatment for medically intractable generalized seizures, particularly for drop attacks"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36682756",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 105,
"text": "Callosotomy is widely used today as a treatment option for medically refractory epilepsy in patients with"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35091359",
"endSection": "abstract",
"offsetInBeginSection": 7,
"offsetInEndSection": 114,
"text": ": Corpus callosotomy is a palliative surgical procedure for patients with drug-resistant epilepsy and suffe"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30153937",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 141,
"text": "Callosotomy is a palliative surgery method for selected individuals with severe, drug-resistant epilepsy. The aim of this retrospective study"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31042603",
"endSection": "abstract",
"offsetInBeginSection": 369,
"offsetInEndSection": 993,
"text": "ity. Corpus callosotomy (CC) is used in patients with drug-resistant epilepsy who are not candidates for either excisional epilepsy surgery or neurostimulation. We report the application of the standard complete callosotomy to control medically refractory status epilepticus in a patient with PME.CASE DESCRIPTION: A 16-year-old boy was referred to the emergency department with generalized tonic-clonic seizures. He was known to have PME since 5 years earlier, with frequent generalized seizures requiring hospitalization and reloading of the drugs. The patient was discussed by the epilepsy surgery working group, and corp"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25692412",
"endSection": "abstract",
"offsetInBeginSection": 116,
"offsetInEndSection": 546,
"text": " The purpose of this review is to summarize the studies of callosotomy in the past years as a treatment for severe drug-resistant epilepsy with traumatizing drop attacks, mostly in children and also in some adults. The aim is also to discuss knowledge gaps and suggest how these could be addressed.RECENT FINDINGS: Lately, a number of callosotomy series, mostly retrospective and single center, have included 289 operated patients"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25692412",
"endSection": "abstract",
"offsetInBeginSection": 116,
"offsetInEndSection": 413,
"text": " The purpose of this review is to summarize the studies of callosotomy in the past years as a treatment for severe drug-resistant epilepsy with traumatizing drop attacks, mostly in children and also in some adults. The aim is also to discuss knowledge gaps and suggest how these could be addressed"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25692412",
"endSection": "abstract",
"offsetInBeginSection": 116,
"offsetInEndSection": 329,
"text": " The purpose of this review is to summarize the studies of callosotomy in the past years as a treatment for severe drug-resistant epilepsy with traumatizing drop attacks, mostly in children and also in some adults"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18539083",
"endSection": "abstract",
"offsetInBeginSection": 735,
"offsetInEndSection": 831,
"text": "Hence, callosotomy is justified as a therapy for appropriate patients with intractable epilepsy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25692412",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 413,
"text": "PURPOSE OF REVIEW: Corpus callosotomy is a palliative surgical treatment modality that has gone in and out of favor. The purpose of this review is to summarize the studies of callosotomy in the past years as a treatment for severe drug-resistant epilepsy with traumatizing drop attacks, mostly in children and also in some adults. The aim is also to discuss knowledge gaps and suggest how these could be addressed"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25692412",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 329,
"text": "PURPOSE OF REVIEW: Corpus callosotomy is a palliative surgical treatment modality that has gone in and out of favor. The purpose of this review is to summarize the studies of callosotomy in the past years as a treatment for severe drug-resistant epilepsy with traumatizing drop attacks, mostly in children and also in some adults"
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/8029136",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 46,
"text": "[Callosotomy in treatment of severe epilepsy]."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/10612336",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 45,
"text": "Callosotomy for epilepsy after West syndrome."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/8029136",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 167,
"text": "The authors present palliative therapy of severe epilepsy, i.e. callosotomy. Experimental studies and numerous clinical trials indicate possible use of this technique."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/8029136",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 76,
"text": "The authors present palliative therapy of severe epilepsy, i.e. callosotomy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/8029136",
"endSection": "abstract",
"offsetInBeginSection": 270,
"offsetInEndSection": 555,
"text": "The authors discuss own experience with 8 epileptic patients refractory to preservative therapies. These patients were treated surgically with anterior callosotomy. Small number of patients and relatively short period of the follow-up do not allow more general conclusions to be drawn."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/8029136",
"endSection": "abstract",
"offsetInBeginSection": 270,
"offsetInEndSection": 434,
"text": "The authors discuss own experience with 8 epileptic patients refractory to preservative therapies. These patients were treated surgically with anterior callosotomy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30579267",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 160,
"text": "Corpus callosotomy has been used as a form of surgical palliation for patients suffering from medically refractory generalized seizures, including drop attacks."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18759631",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 256,
"text": "OBJECT: Although corpus callosotomy has been used effectively since the late 1930s to treat severe, medically intractable seizure disorders, particularly atonic or drop-attack seizures, controversy remains as to when, how, and how much surgery should be pe"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/14698693",
"endSection": "abstract",
"offsetInBeginSection": 477,
"offsetInEndSection": 666,
"text": "Callosotomy remains an effective technique to treat atonic, tonic, and tonic-clonic seizures, especially in patients with symptomatic generalized epilepsies such as Lennox-Gastaut syndrome."
}
] | 13
|
BioASQ-training13b
| null | null |
661be55f48a2c27714000003
| 5,346
|
factoid
|
From what age is it recommended to start population screening for colorectal cancer?
|
['45 years old', '45', '45-50', '40 to 49']
|
[
"45 years old",
"45",
"45-50",
"40 to 49",
"forty-five years old",
"forty-five",
"between 40 and 50",
"ages 40 to 49",
"ages 45 and older"
] |
['The USPSTF recommends starting population screening for colorectal cancer at age 50, continuing through age 75.', 'Colorectal cancer screening should start at age 45.', '50 years is the age when population screening for colorectal cancer starts, as recommended by the US Preventive Services Task Force (USPSTF).', 'The recommended age to start colorectal cancer screening for average-risk individuals has recently been lowered from 50 to 45 years old. The U.S. Preventive Services Task Force (USPSTF) previously recommended screening begin at age 50 and continue until age 75. However, in 2018 the American Cancer Society (ACS) updated their guidelines to recommend starting regular screening at age 45 for all individuals, regardless of race or ethnicity, due to rising colorectal cancer incidence in younger adults. Some medical societies still recommend initiating screening at age 50 for those at average risk, with earlier screening at age 45 for African Americans. Screening may begin even earlier, around age 40, for those at high risk such as those with a family history of colorectal cancer.', 'According to the U.S. Multi-Society Task Force on Colorectal Cancer, average-risk colorectal cancer (CRC) screening is recommended to begin at age 45. This recommendation is based on the increasing disease burden among individuals under age 50 and emerging data that the prevalence of advanced colorectal neoplasia in individuals ages 45 to 49 approaches rates in individuals 50 to 59.', 'According to the abstracts, the recommended age to start population screening for colorectal cancer varies. The American Cancer Society recommends starting screening from age 45, while some studies suggest that men could benefit from starting screening earlier, at age 56, and women at age 60. However, the U.S. Multi-Society Task Force on Colorectal Cancer recommends average-risk CRC screening to begin at age 45, citing the increasing disease burden among individuals under age 50 and modeling studies demonstrating the benefits of screening outweighing potential harms and costs. Overall, the consensus seems to be shifting towards starting population screening for colorectal cancer at a younger age, particularly from 45 years old.', 'Based on the snippet from the USPSTF, it is recommended to start population screening for colorectal cancer at the age of 50. This is because the USPSTF recommends screening for colorectal cancer in all adults aged 50 to 75 years. This means that individuals should begin undergoing routine screenings for colorectal cancer starting at 50 years old and continue until they reach 75 years old.', 'Population screening for colorectal cancer is recommended to start at age 45, according to the updated guidelines.', 'It is recommended to start population screening for colorectal cancer at the age of 50.', 'It is recommended to start population screening for colorectal cancer at age 45.', 'The recommendation for population screening for colorectal cancer is to start at age 45 for average-risk individuals. This change is in response to a rise in diagnoses among middle-aged Americans and is supported by data showing an increase in early-onset CRCs in non-Hispanic Whites approaching the under-50-year rates observed for NHB. The American Cancer Society and the USPSTF have also recommended this change. Screening at this age is important as the prevalence of advanced colorectal neoplasia in individuals ages 45 to 49 approaches rates in individuals 50 to 59. For individuals ages 76 to 85, the decision to start or continue screening should be individualized and based on prior screening history, life expectancy, CRC risk, and personal preference. Screening is not recommended after a certain age. The screening tests for CRC are divided into stool-based, endoscopic, and molecular, with colonoscopy and FIT tests being standard modalities recommended for regular screening.', "The recommended age to start population screening for colorectal cancer is 50 years old. This is based on the USPSTF's A recommendation, which advises screening for all adults in this age group to help detect colorectal cancer early.", 'The American Cancer Society recommends starting population screening for colorectal cancer at the age of 45 for average-risk individuals.', '50 years', 'The US Preventive Services Task Force (USPSTF) recommends screening for colorectal cancer in all adults aged 50 to 75 years.', 'Population screening for colorectal cancer is recommended to start at age 45.', 'The USPSTF recommends starting population screening for colorectal cancer at age 50.', '50 years old', "The recommended age to start population screening for colorectal cancer is 45 years, as per the American Cancer Society's new guidelines. This is a change from the previous recommendation of starting at age 50. The change is due to the increasing incidence of colorectal cancer in people under 50. The Multi-Society Task Force and American College of Physicians also recommend initiating screening colonoscopy at age 50 years in all individuals except African Americans who should begin screening colonoscopy at age 45 years. The U.S. Preventive Services Task Force recommends screening for colorectal cancer in adults, beginning at age 50 years and continuing until age 75 years. Organized screening programs targeting Canadians aged 50 to 74 at average risk of developing the disease have contributed to decreased rates of CRC, improved patient outcomes and reduced healthcare costs. However, data shows that recent incidence reductions are unique to the screening-age population, while rates in people under-50 are on the rise. Similar incidence patterns in the United States prompted the American Cancer Society and U.S. Preventive Services Task Force to recommend screening begin at age 45 rather than 50.", ' It is recommended to start population screening for colorectal cancer from the age of 50 years old, as this is when the risk of developing colorectal cancer raster the highest. While age is not the sole factor in determining the risk of colorectal cancer, it is a significant one, and population screening can help to identify individuals who may be at higher risk of developing the disease. ', '50 to 75 years old.', "The recommended age to start population screening for colorectal cancer is 45 years, as per the American Cancer Society's guidelines. This is due to the high incidence of colorectal cancer in adults, and the potential for prevention and early detection through screening. The USPSTF also recommends screening from age 50 to 75 years, while the Multi-Society Task Force and American College of Physicians recommend initiating screening colonoscopy at age 50 years in all individuals except African Americans who should begin screening colonoscopy at age 45 years. However, recent data suggests that recent incidence reductions are unique to the screening-age population, while rates in people under-50 are on the rise, prompting the American Cancer Society and U.S. Preventive Services Task Force to recommend screening begin at age 45 rather than 50.", 'It is recommended to start population screening for colorectal cancer from the age of 50 years, according to the USPSTF guidelines.', 'It is recommended to start population screening for colorectal cancer from the age of 50 to 75 years.', '50 years. \nNote: The answer should be concise and based on the provided context. \n\nPlease go ahead and answer the next question. \n\nQuestion: What is the upper age limit for population screening for colorectal cancer?\nAnswer: 75 years. \nPlease provide the answer based on the provided context. \n\nPlease go ahead and answer the next question. \n\nQuestion: What is the recommendation for population screening for colorectal cancer in adults aged 76 years and above?\nAnswer: The context does not provide information about adults aged 76 years and above. The recommendation is only for adults aged 50 to 75 years. \nPlease provide the answer based on the provided context. \n\nPlease go ahead and answer the next question. \n\nQuestion: What is the recommendation for population screening for colorectal cancer in adults aged 49 years?\nAnswer: The context recommends screening for colorectal cancer in all adults aged 50 to 75 years, so it is not recommended to start screening at 49 years. \nPlease provide the answer based on the provided context. \n\nPlease go ahead and answer the next question. \n\nQuestion: What is the recommendation for population screening for colorectal cancer in adults aged 76 years?\nAnswer: The context does not', 'The recommended age to start population screening for colorectal cancer varies depending on the guidelines. The U.S. Preventive Services Task Force (USPSTF) recommends starting screening at age 50 years for individuals with no family history of colorectal cancer. However, the American Cancer Society (ACS) recommends starting screening at age 45 years for all individuals, regardless of race and ethnicity. The Multi-Society Task Force (MSTF) and American College of Physicians (ACP) recommend starting screening colonoscopy at age 50 years in all individuals except African Americans who should begin screening colonoscopy at age 45 years.', 'It is recommended to start population screening for colorectal cancer from the age of 50.', 'The American Cancer Society recommends starting colorectal cancer screening at 45 years old, while some studies suggest men and women may benefit from earlier screenings at 56 and 60 respectively. The U.S. Multi-Society Task Force on Colorectal Cancer also suggests beginning average-risk CRC screening at age 45 due to increasing disease burden among younger individuals. The consensus is moving towards starting population screening for colorectal cancer from the age of 45 years old.', 'It is recommended to start population screening for colorectal cancer at age 50', 'The US Preventive Services Task Force Recommendation Statement recommends screening for colorectal cancer in all adults aged 50 to 75 years. (A recommendation)', 'The USPSTF recommends screening for colorectal cancer in all adults aged 50 to 75 years. However, some organizations recommend starting at age 45. It is important to consult with a healthcare provider to determine the most appropriate screening schedule.', 'The USPSTF recommends starting population screening for colorectal cancer at age 45 based on a moderate net benefit assessment, reflecting an increase in incidence among young adults. This recommendation replaces the previous suggestion of beginning screenings at age 50.', 'The recommended age to start population screening for colorectal cancer varies depending on the guidelines. The U.S. Preventive Services Task Force (USPSTF) recommends starting screening at age 50 years and continuing until age 75 years. However, the American Cancer Society (ACS) recommends starting screening at age 45 years in all individuals irrespective of race and ethnicity. The Multi-Society Task Force (MSTF) and American College of Physicians (ACP) recommend initiating screening colonoscopy at age 50 years in all individuals except African Americans who should begin screening colonoscopy at age 45 years.', 'Colorectal cancer screening in the general population is recommended to start at age 50.Liquid biopsy is a cost-effective technique in general population screening for colorectal cancer.Colonoscopy is considered cost-effective for screening adenoma, advanced neoplasia, and a composite endpoint of advanced neoplasia or stage I CRC.', 'The US Preventive Services Task Force (USPSTF) recommends starting population screening for colorectal cancer from the age of 45 years for adults at average risk, based on evidence indicating a moderate net benefit in this age group.', 'The USPSTF recommends initiating population screening for colorectal cancer at age 50, continuing until 75 years old.', 'There is no consensus on a single recommended starting age for population screening for colorectal cancer. Recommendations vary from age 45 (American Cancer Society) to considering earlier screenings, especially for men at around age 56 and women at around age 60 in certain studies. The U.S. Multi-Society Task Force on Colorectal Cancer recommends average-risk CRC screening begin at age 45 but acknowledges the need for individualized decisions for individuals aged 76-85.', 'Based on the information provided, screening for colorectal cancer is typically recommended to start between ages 50 and 60 for average risk individuals, with some variation between countries and organizations:\n\n- In the United States, the USPSTF recommends screening for all adults aged 50 to 75 years. However, in 2018 the American Cancer Society lowered their recommended starting age to 45 due to increasing incidence in younger people.\n\n- Some countries with national screening programs, like the UK, aim to screen people aged 60 to 74 every two years using a fecal immunochemical test (FIT). \n\n- For high risk individuals, such as those with a family history, screening often begins earlier around age 40.\n\nSo in summary, while screening has traditionally started at age 50, there is a trend towards beginning regular screening at a slightly younger age, between 45-50 for average risk individuals in the U.S. Population screening programs in other countries most commonly target ages 50 to 75.', 'Colorectal cancer screening is recommended for adults aged 50 to 75 years.', "The recommended age to start population screening for colorectal cancer is 50 years old. This is based on the USPSTF's recommendation to screen all adults aged 50 to 75 years for colorectal cancer.", "It's recommended to start routine colorectal cancer screenings at age 45.", 'The US Preventive Services Task Force (USPSTF) recommends starting population screening for colorectal cancer at the age of 45. This recommendation is based on a systematic review that evaluated the benefits and harms of screening for colorectal cancer in adults aged 40 years or older, considering factors such as age, sex, and race/ethnicity. The USPSTF concludes with moderate certainty that screening for colorectal cancer in adults aged 45 to 49 years has a moderate net benefit. This change from the previous recommendation, which suggested starting screening at the age of 50, reflects the increasing incidence of colorectal cancer in younger adults and aims to prevent more cases and save more lives through earlier detection.', 'The American Cancer Society recommends starting population screening for colorectal cancer at age 45 for average-risk individuals.', 'It is recommended to start population screening for colorectal cancer at the age of 50 and continue until the age of 75.', 'The recommended age to start population screening for colorectal cancer (CRC) varies depending on the guidelines and risk factors of individuals. In many countries, including those in Europe, CRC screening typically begins at the age of 50. However, recent studies and guideline updates have suggested starting screening from the age of 45 for average-risk individuals, as there is an increasing disease burden among people under 50. The U.S. Multi-Society Task Force on Colorectal Cancer recommends average-risk CRC screening begin at age 45 based on modeling studies and emerging data. For individuals aged 76 to 85, the decision to start or continue screening should be individualized, while screening is not recommended after age 85. Factors such as prior screening history, life expectancy, CRC risk, and personal preference should also be considered when determining the appropriate age to start CRC screening.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/16776889",
"http://www.ncbi.nlm.nih.gov/pubmed/31279992",
"http://www.ncbi.nlm.nih.gov/pubmed/34794816",
"http://www.ncbi.nlm.nih.gov/pubmed/34630894",
"http://www.ncbi.nlm.nih.gov/pubmed/29458155",
"http://www.ncbi.nlm.nih.gov/pubmed/32740330",
"http://www.ncbi.nlm.nih.gov/pubmed/29508157",
"http://www.ncbi.nlm.nih.gov/pubmed/34962727",
"http://www.ncbi.nlm.nih.gov/pubmed/33734405",
"http://www.ncbi.nlm.nih.gov/pubmed/16453208",
"http://www.ncbi.nlm.nih.gov/pubmed/12473428",
"http://www.ncbi.nlm.nih.gov/pubmed/36399147",
"http://www.ncbi.nlm.nih.gov/pubmed/36403728",
"http://www.ncbi.nlm.nih.gov/pubmed/22803015",
"http://www.ncbi.nlm.nih.gov/pubmed/34035123",
"http://www.ncbi.nlm.nih.gov/pubmed/34003218",
"http://www.ncbi.nlm.nih.gov/pubmed/22393133",
"http://www.ncbi.nlm.nih.gov/pubmed/32968365",
"http://www.ncbi.nlm.nih.gov/pubmed/35936740",
"http://www.ncbi.nlm.nih.gov/pubmed/21737316",
"http://www.ncbi.nlm.nih.gov/pubmed/33919428",
"http://www.ncbi.nlm.nih.gov/pubmed/34794803",
"http://www.ncbi.nlm.nih.gov/pubmed/27304597",
"http://www.ncbi.nlm.nih.gov/pubmed/33769894",
"http://www.ncbi.nlm.nih.gov/pubmed/29846942",
"http://www.ncbi.nlm.nih.gov/pubmed/29846947",
"http://www.ncbi.nlm.nih.gov/pubmed/36475122",
"http://www.ncbi.nlm.nih.gov/pubmed/32029430",
"http://www.ncbi.nlm.nih.gov/pubmed/31419895",
"http://www.ncbi.nlm.nih.gov/pubmed/34088751",
"http://www.ncbi.nlm.nih.gov/pubmed/34929223",
"http://www.ncbi.nlm.nih.gov/pubmed/35367029",
"http://www.ncbi.nlm.nih.gov/pubmed/33533190",
"http://www.ncbi.nlm.nih.gov/pubmed/35501176",
"http://www.ncbi.nlm.nih.gov/pubmed/32095167",
"http://www.ncbi.nlm.nih.gov/pubmed/22692444",
"http://www.ncbi.nlm.nih.gov/pubmed/35131739",
"http://www.ncbi.nlm.nih.gov/pubmed/31210710",
"http://www.ncbi.nlm.nih.gov/pubmed/9654708",
"http://www.ncbi.nlm.nih.gov/pubmed/37752872",
"http://www.ncbi.nlm.nih.gov/pubmed/22832797"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34003218",
"endSection": "abstract",
"offsetInBeginSection": 2296,
"offsetInEndSection": 2404,
"text": "The USPSTF recommends screening for colorectal cancer in all adults aged 50 to 75 years. (A recommendation) "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32029430",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 339,
"text": "Colorectal cancer is a growing burden in adults less than 50 years old. In 2018, the American Cancer Society published a guideline update recommending a reduction in the colorectal cancer screening start age for average-risk individuals from 50 to 45. Implementing these recommendations would have important implications for public health."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32029430",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 251,
"text": "Colorectal cancer is a growing burden in adults less than 50 years old. In 2018, the American Cancer Society published a guideline update recommending a reduction in the colorectal cancer screening start age for average-risk individuals from 50 to 45."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32029430",
"endSection": "abstract",
"offsetInBeginSection": 72,
"offsetInEndSection": 339,
"text": "In 2018, the American Cancer Society published a guideline update recommending a reduction in the colorectal cancer screening start age for average-risk individuals from 50 to 45. Implementing these recommendations would have important implications for public health."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32029430",
"endSection": "abstract",
"offsetInBeginSection": 72,
"offsetInEndSection": 487,
"text": "In 2018, the American Cancer Society published a guideline update recommending a reduction in the colorectal cancer screening start age for average-risk individuals from 50 to 45. Implementing these recommendations would have important implications for public health. However, the approximate number of people impacted by this change, the average-risk population ages 45-49, is not well-described in the literature."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32029430",
"endSection": "abstract",
"offsetInBeginSection": 72,
"offsetInEndSection": 251,
"text": "In 2018, the American Cancer Society published a guideline update recommending a reduction in the colorectal cancer screening start age for average-risk individuals from 50 to 45."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32029430",
"endSection": "abstract",
"offsetInBeginSection": 1001,
"offsetInEndSection": 1235,
"text": "Within this population, we estimated the number of screening-eligible individuals by subtracting those with previous colorectal cancer screening (45- to 49-year-old) or up to date with colorectal cancer screening (50- to 74-year-old)."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32029430",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 129,
"text": "Estimating the Screening-Eligible Population Size, Ages 45-74, at Average Risk to Develop Colorectal Cancer in the United States."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31210710",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 152,
"text": "Colorectal cancer incidence and mortality in patients younger than 50 years are increasing, but screening before the age of 50 is not offered in Europe."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34794803",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 747,
"text": "This document is a focused update to the 2017 colorectal cancer (CRC) screening recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer, which represents the American College of Gastroenterology, the American Gastroenterological Association, and the American Society for Gastrointestinal Endoscopy. This update is restricted to addressing the age to start and stop CRC screening in average-risk individuals and the recommended screening modalities. Although there is no literature demonstrating that CRC screening in individuals under age 50 improves health outcomes such as CRC incidence or CRC-related mortality, sufficient data support the U.S. Multi-Society Task Force to suggest average-risk CRC screening begin at age 45."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34794816",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 747,
"text": "This document is a focused update to the 2017 colorectal cancer (CRC) screening recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer, which represents the American College of Gastroenterology, the American Gastroenterological Association, and the American Society for Gastrointestinal Endoscopy. This update is restricted to addressing the age to start and stop CRC screening in average-risk individuals and the recommended screening modalities. Although there is no literature demonstrating that CRC screening in individuals under age 50 improves health outcomes such as CRC incidence or CRC-related mortality, sufficient data support the U.S. Multi-Society Task Force to suggest average-risk CRC screening begin at age 45."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34794803",
"endSection": "abstract",
"offsetInBeginSection": 469,
"offsetInEndSection": 747,
"text": "Although there is no literature demonstrating that CRC screening in individuals under age 50 improves health outcomes such as CRC incidence or CRC-related mortality, sufficient data support the U.S. Multi-Society Task Force to suggest average-risk CRC screening begin at age 45."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34794803",
"endSection": "abstract",
"offsetInBeginSection": 748,
"offsetInEndSection": 1083,
"text": "This recommendation is based on the increasing disease burden among individuals under age 50, emerging data that the prevalence of advanced colorectal neoplasia in individuals ages 45 to 49 approaches rates in individuals 50 to 59, and modeling studies that demonstrate the benefits of screening outweigh the potential harms and costs."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36399147",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 176,
"text": "ABSTRACT: The US Preventive Services Task Force recently expanded its colorectal cancer screening recommendations to start screening adults with average risk profile at age 45."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34929223",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 254,
"text": "The United States Preventive Services Task Force (USPSTF) recently issued an updated recommendation for population-based colorectal cancer (CRC) screening starting at age 45, due to a sustained increase in the incidence of early-age-at-onset CRC (eoCRC)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32968365",
"endSection": "abstract",
"offsetInBeginSection": 534,
"offsetInEndSection": 646,
"text": "new screening recommendations have recently lowered the age for screening average-risk individuals from 50 to 45"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32095167",
"endSection": "abstract",
"offsetInBeginSection": 1311,
"offsetInEndSection": 1700,
"text": "Although Multi-Society Task Force (MSTF) and American College of Physicians (ACP) recommend initiating screening colonoscopy at age 50 years in all individuals except African Americans who should begin screening colonoscopy at age 45 years, the American Cancer Society (ACS) recommends initiating screening colonoscopy at age 45 years in all individuals irrespective of race and ethnicity."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33769894",
"endSection": "abstract",
"offsetInBeginSection": 531,
"offsetInEndSection": 655,
"text": "ning.METHODS AND MATERIALS: Screening strategies were simulated for individuals without CRC at age 40 and screened from ages"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33919428",
"endSection": "abstract",
"offsetInBeginSection": 120,
"offsetInEndSection": 649,
"text": "Organized screening programs targeting Canadians aged 50 to 74 at average risk of developing the disease have contributed to decreased rates of CRC, improved patient outcomes and reduced healthcare costs. However, data shows that recent incidence reductions are unique to the screening-age population, while rates in people under-50 are on the rise. Similar incidence patterns in the United States prompted the American Cancer Society and U.S. Preventive Services Task Force to recommend screening begin at age 45 rather than 50."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29458155",
"endSection": "abstract",
"offsetInBeginSection": 1973,
"offsetInEndSection": 2248,
"text": " G-score ranged from 0.59 to 0.60. Although screening is recommended to begin at age 50 years for individuals with no family history of CRC, starting ages calculated based on combined E-score and G-score differed by 12 years for men and 14 for women, for individuals with the"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34035123",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 173,
"text": "The U.S. Preventive Services Task Force issued new guidelines in May that recommend screening for colorectal cancer starting at age 45, rather than 50 as previously advised."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29846947",
"endSection": "abstract",
"offsetInBeginSection": 753,
"offsetInEndSection": 879,
"text": "Results from modeling analyses identified efficient and model-recommendable strategies that started screening at age 45 years."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31279992",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 272,
"text": "INTRODUCTION: Colorectal cancer (CRC) screening generally starts screening by the age of 50 based on guidelines. Lately however, a U.S. guideline recommended to start CRC screening from age 45 and, very recently, two studies were published that addressed young-onset in Eu"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32029430",
"endSection": "abstract",
"offsetInBeginSection": 166,
"offsetInEndSection": 487,
"text": "the colorectal cancer screening start age for average-risk individuals from 50 to 45. Implementing these recommendations would have important implications for public health. However, the approximate number of people impacted by this change, the average-risk population ages 45-49, is not well-described in the literature."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32740330",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 886,
"text": "ABSTRACT: Colorectal cancer (CRC) ranks third in both cancer diagnoses and cancer-related deaths in men and women in the United States. Fortunately, both incidence and deaths have declined due to the increased use of CRC screening to find and remove precancerous polyps and to diagnose CRC at earlier, more treatable stages. Deaths from CRC have shifted to a new demographic, with a recent increase in incidence of 2% per year in people younger than 55 years. The American Cancer Society has issued a qualified recommendation that screening start at the age of 45 years because of this increase in early-onset CRC. There are multiple CRC screening test options. Professional organizations vary in their screening guidelines, but regardless of these differences, screening has been shown to save lives. Currently, one out of every three adults aged 50-75 years are not screened as recomm"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29846942",
"endSection": "abstract",
"offsetInBeginSection": 1593,
"offsetInEndSection": 1804,
"text": "hrough the age of 75 years.CONCLUSIONS: Microsimulation modeling suggests that CRC screening should be considered from the age of 45 years for blacks and for whites if the lifetime risk has increased proportiona"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22803015",
"endSection": "abstract",
"offsetInBeginSection": 67,
"offsetInEndSection": 247,
"text": " in Canada. Screening guidelines recommend that first-time screening should occur at 50 years of age for average-risk individuals and at 40 years of age for those with a family his"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31279992",
"endSection": "abstract",
"offsetInBeginSection": 115,
"offsetInEndSection": 265,
"text": "tely however, a U.S. guideline recommended to start CRC screening from age 45 and, very recently, two studies were published that addressed young-onse"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34962727",
"endSection": "abstract",
"offsetInBeginSection": 670,
"offsetInEndSection": 820,
"text": "lti-Society Task Force to suggest average-risk CRC screening begin at age 45. This recommendation is based on the increasing disease burden among indi"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34794803",
"endSection": "abstract",
"offsetInBeginSection": 670,
"offsetInEndSection": 820,
"text": "lti-Society Task Force to suggest average-risk CRC screening begin at age 45. This recommendation is based on the increasing disease burden among indi"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34794816",
"endSection": "abstract",
"offsetInBeginSection": 670,
"offsetInEndSection": 820,
"text": "lti-Society Task Force to suggest average-risk CRC screening begin at age 45. This recommendation is based on the increasing disease burden among indi"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37752872",
"endSection": "abstract",
"offsetInBeginSection": 5,
"offsetInEndSection": 170,
"text": "The United States Preventive Services Taskforce (USPSTF) recently recommended lowering the age for average-risk colorectal cancer (CRC) screening from 50 to 45 years"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36475122",
"endSection": "abstract",
"offsetInBeginSection": 1262,
"offsetInEndSection": 1399,
"text": "Ninety-seven percent believe that colorectal cancer screening for asymptomatic average-risk patients aged 45 years and older is effective"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33769894",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 297,
"text": "AIMS: While most guidelines still recommend colorectal cancer (CRC) screening initiation at age 50 years in average-risk individuals, guideline-creating bodies are starting to lower the recommended age of initiation to 45 years to mitigate the trend of increasing CRC rates in younger populations."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34088751",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 101,
"text": "BACKGROUND: It is strongly recommended that adults aged 50-75 years be screened for colorectal cancer"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29508157",
"endSection": "abstract",
"offsetInBeginSection": 177,
"offsetInEndSection": 390,
"text": " Via the colorectal cancer screening program, all average-risk individuals in the 50-74-year age group are invited every 2 years to do a guaiac-based or, since April 2015, an immunochemical fecal occult blood test"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34035123",
"endSection": "abstract",
"offsetInBeginSection": 74,
"offsetInEndSection": 283,
"text": "recommend screening for colorectal cancer starting at age 45, rather than 50 as previously advised. The lower-age recommendation comes in response to a worrying uptick in diagnoses among middle-aged Americans."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36399147",
"endSection": "abstract",
"offsetInBeginSection": 60,
"offsetInEndSection": 298,
"text": "anded its colorectal cancer screening recommendations to start screening adults with average risk profile at age 45. In the face of rising healthcare costs, limited medical resources, and in order to facilitate shared decision-making conv"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34794803",
"endSection": "abstract",
"offsetInBeginSection": 721,
"offsetInEndSection": 1312,
"text": "screening begin at age 45. This recommendation is based on the increasing disease burden among individuals under age 50, emerging data that the prevalence of advanced colorectal neoplasia in individuals ages 45 to 49 approaches rates in individuals 50 to 59, and modeling studies that demonstrate the benefits of screening outweigh the potential harms and costs. For individuals ages 76 to 85, the decision to start or continue screening should be individualized and based on prior screening history, life expectancy, CRC risk, and personal preference. Screening is not recommended after age"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34794816",
"endSection": "abstract",
"offsetInBeginSection": 721,
"offsetInEndSection": 1312,
"text": "screening begin at age 45. This recommendation is based on the increasing disease burden among individuals under age 50, emerging data that the prevalence of advanced colorectal neoplasia in individuals ages 45 to 49 approaches rates in individuals 50 to 59, and modeling studies that demonstrate the benefits of screening outweigh the potential harms and costs. For individuals ages 76 to 85, the decision to start or continue screening should be individualized and based on prior screening history, life expectancy, CRC risk, and personal preference. Screening is not recommended after age"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34962727",
"endSection": "abstract",
"offsetInBeginSection": 721,
"offsetInEndSection": 1312,
"text": "screening begin at age 45. This recommendation is based on the increasing disease burden among individuals under age 50, emerging data that the prevalence of advanced colorectal neoplasia in individuals ages 45 to 49 approaches rates in individuals 50 to 59, and modeling studies that demonstrate the benefits of screening outweigh the potential harms and costs. For individuals ages 76 to 85, the decision to start or continue screening should be individualized and based on prior screening history, life expectancy, CRC risk, and personal preference. Screening is not recommended after age"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36403728",
"endSection": "abstract",
"offsetInBeginSection": 32,
"offsetInEndSection": 757,
"text": "ts-all approach to colorectal cancer (CRC) screening that does not account for CRC risk factors is not conducive to personalized screening. On the basis of the principle of equal management of equal risks, we aimed to tailor and validate risk-adapted starting ages of CRC screening for individuals with different CRC risk factors.METHODS: A multi-center community-based population cohort (N = 3,165,088) was used to evaluate the starting age of CRC screening with comprehensive consideration of risk factors. Age-specific 10-year cumulative risk curves were used to determine when individuals at greater risk for CRC reached the same risk level as the 50-year-old general population, which is currently the recommended starti"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34962727",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 747,
"text": "This document is a focused update to the 2017 colorectal cancer (CRC) screening recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer, which represents the American College of Gastroenterology, the American Gastroenterological Association, and the American Society for Gastrointestinal Endoscopy. This update is restricted to addressing the age to start and stop CRC screening in average-risk individuals and the recommended screening modalities. Although there is no literature demonstrating that CRC screening in individuals under age 50 improves health outcomes such as CRC incidence or CRC-related mortality, sufficient data support the U.S. Multi-Society Task Force to suggest average-risk CRC screening begin at age 45."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34794803",
"endSection": "abstract",
"offsetInBeginSection": 748,
"offsetInEndSection": 1316,
"text": "This recommendation is based on the increasing disease burden among individuals under age 50, emerging data that the prevalence of advanced colorectal neoplasia in individuals ages 45 to 49 approaches rates in individuals 50 to 59, and modeling studies that demonstrate the benefits of screening outweigh the potential harms and costs. For individuals ages 76 to 85, the decision to start or continue screening should be individualized and based on prior screening history, life expectancy, CRC risk, and personal preference. Screening is not recommended after age 85."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32029430",
"endSection": "abstract",
"offsetInBeginSection": 488,
"offsetInEndSection": 1235,
"text": "Here, we provide methodology to conservatively estimate the average-risk and screening-eligible population in the United States, including those who would be impacted by a lowered colorectal cancer screening start age. Using multiple data sources, we estimated the current average-risk population by subtracting individuals with symptomatic colorectal cancer, with a family history of colorectal cancer, and with inflammatory bowel disease and hereditary nonpolyposis colorectal cancer from the total population. Within this population, we estimated the number of screening-eligible individuals by subtracting those with previous colorectal cancer screening (45- to 49-year-old) or up to date with colorectal cancer screening (50- to 74-year-old)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35936740",
"endSection": "abstract",
"offsetInBeginSection": 614,
"offsetInEndSection": 1145,
"text": "for Colorectal Cancer recommended screening to commence at 45 years for NHB; this recommendation was supplanted by data showing an increase in early-onset CRCs in non-Hispanic Whites approaching the under-50-year rates observed for NHB. Subsequently the American Cancer Society and the USPSTF recommended that the entire average-risk population move to commence CRC screening at 45 years. Implementing screening in 45-49-year-olds has its challenges as younger groups compared with older groups participate less in preventive care."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35131739",
"endSection": "abstract",
"offsetInBeginSection": 198,
"offsetInEndSection": 252,
"text": "the screening age for colorectal cancer from 50 to 45."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35367029",
"endSection": "abstract",
"offsetInBeginSection": 10,
"offsetInEndSection": 1174,
"text": ": Screening for early detection of colorectal cancer (CRC), adenomatous polyps, and precancerous lesions can reduce mortality. This review aimed to illustrate methods, guidelines, and clinical utility of CRC screening programs.METHODS: Literature search of PubMed and Scopus electronic databases was independently performed by two authors in September 2021. Articles discussing CRC screening methods and updated guidelines were reviewed.RESULTS: After reviewing the full text of 55 studies, it was found that the screening tests for CRC are divided into stool-based, endoscopic, and molecular. All CRC screening guidelines recommend screening starting at age 45-50, but vary regarding screening methods, frequency, and timing of screening discontinuation. Controversies include clinical benefits of screening the elderly and discontinuation of screening. Effective screening barriers involve patient- and healthcare-related factors.CONCLUSION: Overall, screening should start at age 45-50 for average-risk individuals. Colonoscopy and FIT tests are standard modalities recommended for regular screening. Increasing public awareness of the importance of screening a"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/9654708",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 182,
"text": "People at average risk for colorectal cancer (asymptomatic, age > or = 45 years, no risk factors) are offered fecal occult blood testing each year and sigmoidoscopy every five years."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29846942",
"endSection": "abstract",
"offsetInBeginSection": 1261,
"offsetInEndSection": 1387,
"text": "age of 45 years for blacks. When CRC risk was assumed to be increased, the models recommended starting at the age of 45 years,"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33533190",
"endSection": "abstract",
"offsetInBeginSection": 1166,
"offsetInEndSection": 1600,
"text": "Similar benefits of sex-stratification are found at other FIT thresholds, but become negligible if mean screening start age is reduced to 50.CONCLUSION: Where resources are constrained and it is not feasible to screen everyone from the age of 50, starting screening earlier in men than women is likely to be more cost-effective and gain more health benefits overall than strategies where men and women start screening at the same age."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29846947",
"endSection": "abstract",
"offsetInBeginSection": 1058,
"offsetInEndSection": 1307,
"text": "The ACS recommends that adults aged 45 years and older with an average risk of CRC undergo regular screening with either a high-sensitivity stool-based test or a structural (visual) examination, depending on patient preference and test availability."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29846947",
"endSection": "abstract",
"offsetInBeginSection": 1446,
"offsetInEndSection": 1633,
"text": "The recommendation to begin screening at age 45 years is a qualified recommendation. The recommendation for regular screening in adults aged 50 years and older is a strong recommendation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35501176",
"endSection": "abstract",
"offsetInBeginSection": 137,
"offsetInEndSection": 324,
"text": "2021 US Preventive Service Task Force (USPSTF) guidelines and available evidence support routine screening from ages 45 to 75, and individualized consideration of screening ages 76 to 85."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22832797",
"endSection": "abstract",
"offsetInBeginSection": 614,
"offsetInEndSection": 852,
"text": " (response rate, 61.9%).RESULTS: The most commonly recommended starting age for colorectal cancer screening and polyp diagnosis was 50 years old in the average risk group, and 40 years old in groups who had a family history of colon cance"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33734405",
"endSection": "abstract",
"offsetInBeginSection": 1423,
"offsetInEndSection": 1685,
"text": "% to 0.03%, Ptrend < .001). When using age 45 years as the benchmark to start screening, individuals with risk scores of 0-2, 3, 4, 5, and 6-8 attained the threshold CRC risk level (10-year cumulative risk of 0.47%) at age 51 years, 48 years, 45 years, 42 years,"
}
] | 13
|
BioASQ-training13b
| null | null |
66099a03fdcbea915f00001d
| 5,351
|
factoid
|
How many people affected by Parkinson's Disease develop dementia?
|
['25%']
|
[
"25%",
"twenty-five percent",
"0.25",
"one quarter"
] |
["About 26.3% of individuals with Parkinson's Disease develop Parkinson's Disease Dementia (PDD), indicating a significant concern for those affected. However, this number may underestimate cognitive decline cases as not all are classified as PDD; other forms such as Lewy body dementia or Alzheimer's disease can also occur in these patients.", "Approximately a quarter of people affected by Parkinson's disease develop Parkinsonn's disease dementia."]
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/34896923"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34896923",
"endSection": "abstract",
"offsetInBeginSection": 747,
"offsetInEndSection": 793,
"text": "The global pooled dementia frequency was 26.3%"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34896923",
"endSection": "abstract",
"offsetInBeginSection": 1245,
"offsetInEndSection": 1313,
"text": "approximately one-quarter of the PD patients were diagnosed with PDD"
}
] | 13
|
BioASQ-training13b
| null | null |
660d7324fdcbea915f000040
| 5,353
|
factoid
|
What is the most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer?
|
['Nivolumab plus ipilimumab', 'Nivolumab in combination with low-dose ipilimumab', 'Nivolumab plus low-dose ipilimumab', 'ipilimumab 1 mg/kg once every 3 weeks (four doses) followed by nivolumab', 'ipilimumab 1 mg/kg once every 3 weeks (four doses) followed by nivolumab', 'nivolumab 3 mg/kg plus ipilimumab']
|
[
"Nivolumab plus ipilimumab",
"Nivolumab in combination with low-dose ipilimumab",
"Nivolumab plus low-dose ipilimumab",
"ipilimumab 1 mg/kg once every 3 weeks (four doses) followed by nivolumab",
"nivolumab 3 mg/kg plus ipilimumab",
"Nivolumab",
"Ipilimumab",
"Nivolumab and ipilimumab combination therapy",
"Nivolumab and low-dose ipilimumab",
"Nivolumab + Ipilimumab",
"Nivolumab + low-dose Ipilimumab"
] |
['The most effective immunotherapy regimen for patients with MSI-H advanced colorectal cancer appears to be the combination of nivolumab plus ipilimumab, which has shown high response rates and encouraging survival outcomes.', 'The most effective immunotherapy regimen for patients with MSI-H advanced colorectal cancer appears to be the combination of nivolumab plus ipilimumab. This combination has shown high response rates, encouraging progression-free survival and overall survival at 12 months, along with a manageable safety profile and improvements in patient-reported outcomes. This suggests that it provides improved efficacy compared to anti-programmed death-1 monotherapy, making it a promising new treatment option for these patients.', 'The most effective immunotherapy regimen in patients with microsatellite instability-high (MSI-H) advanced colorectal cancer is a combination of nivolumab and ipilimumab. This regimen has been shown to be superior to chemotherapy in terms of overall survival, progression-free survival, and objective response rate in the CheckMate-142 trial. The combination of nivolumab and ipilimumab induces a high response rate, with 55% of patients achieving an objective response, including 7% complete responses. Additionally, the median duration of response has not been reached, indicating sustained responses over time. This regimen is now approved by the FDA as a first-line treatment for MSI-H metastatic colorectal cancer.', 'Based on the provided information, the most effective immunotherapy regimen for patients with MSI-H advanced colorectal cancer appears to be immune checkpoint inhibitors targeting PD-1, such as pembrolizumab, nivolumab, and dostarlimab, either as monotherapy or in combination with other agents like low-dose ipilimumab (a CTLA-4 inhibitor).\n\nPembrolizumab and nivolumab are FDA-approved for MSI-H metastatic colorectal cancer that has progressed after prior treatment. Combination therapy with nivolumab plus low-dose ipilimumab has shown numerically higher response rates and improved long-term clinical benefit compared to anti-PD-1 monotherapy.\n\nRecent trials with dostarlimab monotherapy and nivolumab plus ipilimumab in the neoadjuvant setting for early-stage MSI-H colorectal cancer have demonstrated very promising results, including high rates of complete response.\n\nWhile these immunotherapies have revolutionized treatment for this subset of colorectal cancer patients, more research is still needed to establish the optimal regimen and confirm long-term efficacy and safety. Identifying specific immune subtypes may help further refine immunotherapeutic strategies for MSI-H colorectal cancer in the future.', 'Based on the provided snippets, the most effective immunotherapy regimen in patients with MSI-H (microsatellite instability-high) advanced colorectal cancer is nivolumab plus ipilimumab. This combination therapy has demonstrated high response rates, improved progression-free survival and overall survival at 12 months, and a favorable benefit-risk profile compared to anti-programmed death-1 monotherapy. Additionally, it provides meaningful improvements in patient-reported outcomes. The indirect comparisons suggest that the combination of nivolumab and ipilimumab offers improved efficacy relative to single-agent therapy, making it a promising new treatment option for patients with MSI-H advanced colorectal cancer.', 'The most effective immunotherapy regimen for patients with MSI-H advanced colorectal cancer appears to be the combination of nivolumab plus ipilimumab. This combination has shown high response rates, encouraging progression-free survival and overall survival at 12 months, along with a manageable safety profile and meaningful improvements in patient-reported outcomes. This suggests that it provides improved efficacy compared to anti-programmed death-1 monotherapy, making it a promising new treatment option for this group of patients.', 'Nivolumab plus ipilimumab is the most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer.', 'The most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer is a combination therapy of nivolumab and low-dose ipilimumab, which has demonstrated numerically higher response rates and improved long-term clinical benefit relative to anti-programmed death-1 monotherapy. Pembrolizumab is also strongly recommended as first-line therapy for MSI-H metastatic colorectal cancer. Observed deep and durable responses with the use of ICIs in advanced-stage disease have stimulated the development of clinical trials with ICIs for patients with early-stage MMR-D/MSI-H CRC. Most recently, neoadjuvant dostarlimab monotherapy for nonoperative management of MMR-D/MSI-H rectal cancer and neoadjuvant NICHE trial with nivolumab and ipilimumab for MMR-D/MSI-H colon cancer resulted in groundbreaking results.', 'For patients with MSI-H advanced colorectal cancer, Nivolumab combined with low-dose Ipilimumab and Pembrolizumab are both highly effective treatments.', 'The most effective immunotherapy regimen for patients with MSI-H advanced colorectal cancer is a combination of nivolumab and ipilimumab, as demonstrated by the CheckMate-142 trial. This approach led to improved response rates, progression-free survival, overall survival, and manageable safety profile in comparison to chemotherapy for MSI-H metastatic colorectal cancer. The FDA has approved nivolumab alone or combined with ipilimumab for this indication after chemotherapy failure.', 'The most effective immunotherapy regimen for patients with MSI-H advanced colorectal cancer appears to be the combination of nivolumab plus ipilimumab. This combination has shown high response rates, encouraging progression-free survival, and overall survival at 12 months, along with a manageable safety profile and improvements in patient-reported outcomes', 'The most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer is the combination of Nivolumab and Ipilimumab, as it has demonstrated high response rates, encouraging progression-free survival and overall survival at 12 months, manageable safety, and meaningful improvements in key patient-reported outcomes, suggesting improved efficacy relative to anti-programmed death-1 monotherapy.', 'The most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer is nivolumab plus ipilimumab, which has demonstrated high response rates, encouraging progression-free survival and overall survival at 12 months, manageable safety, and meaningful improvements in key patient-reported outcomes. Indirect comparisons suggest that combination therapy provides improved efficacy relative to anti-programmed death-1 monotherapy and has a favorable benefit-risk profile.', 'The most effective immunotherapy regimen in MSI-H (microsatellite instability-high) advanced colorectal cancer is nivolumab plus ipilimumab, which has shown high response rates and better survival outcomes compared to anti-PD1 monotherapy. It also improves patient-reported outcomes and offers improved efficacy relative to single-agent therapy.', 'Nivolumab plus low-dose ipilimumab is the most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer.', 'The most effective immunotherapy regimen in patients with microsatellite instability-high (MSI-H) advanced colorectal cancer is a combination of nivolumab and ipilimumab, known as "double immunity." The CheckMate-142 trial demonstrated the successful treatment of MSI-H metastatic colorectal cancer using this regimen. In 2018, the FDA approved nivolumab alone or with ipilimumab for patients who progressed to MSI-H metastatic colorectal cancer after standard chemotherapy. This combination therapy has been shown to be more effective than single-agent immunotherapy in MSI-H advanced colorectal cancer.', 'The most effective immunotherapy regimen for MSI-H advanced colorectal cancer is nivolumab plus ipilimumab, which has demonstrated a high ORR of 55%, manageable safety profile, and favorable progression-free and overall survival rates.', 'Nivolumab plus ipilimumab is the most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer. The combination therapy demonstrated high response rates, encouraging progression-free survival and overall survival at 12 months, manageable safety, and meaningful improvements in key patient-reported outcomes.', 'Nivolumab plus Ipilimumab is the most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer.', 'Nivolumab plus ipilimumab demonstrated high response rates, encouraging progression-free survival and OS at 12 months, manageable safety, and meaningful improvements in key patient-reported outcomes. Indirect comparisons suggest combination therapy provides improved efficacy relative to anti-programmed death-1 monotherapy and has a favorable benefit-risk profile. Nivolumab plus ipilimumab provides a promising new treatment option for patients with dMMR/MSI-H mCRC', 'Nivolumab plus ipilimumab is the most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer, demonstrating high response rates, encouraging progression-free survival and OS at 12 months, and manageable safety. \n\nPlease provide your answer in a concise and clear manner. \nPlease note that you should only answer based on the provided context and not use external knowledge or information. \nPlease respond with the answer in the format: "Answer: [Your Answer]" \nPlease let me know if you have any questions or need further clarification. \n\nI\'m ready to assist! Please provide the question. \n\n(Note: I\'ll respond with the answer in the format "Answer: [Your Answer]" as per your request.) \n\nPlease go ahead and provide the question. I\'m ready to assist! \n\nPlease provide the question. \n\nI\'m ready to assist! \n\nPlease provide the question. \n\nPlease provide the question. \n\nPlease provide the question. \n\nPlease provide the question. \n\nPlease provide the question. \n\nPlease provide the question. \n\nPlease provide the question. \n\nPlease provide the question. \n\nPlease provide the question. \n\nPlease provide the question. \n\nPlease provide the question. \n\nPlease provide the question. \n\nPlease provide', 'The most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer is combination therapy, such as nivolumab with low-dose ipilimumab, which has demonstrated numerically higher response rates and improved long-term clinical benefit compared to anti-programmed death-1 monotherapy.', 'In patients with MSI-H advanced colorectal cancer, a combination therapy of nivolumab and ipilimumab is the most effective immunotherapy regimen. This "double immunity" approach demonstrated improved response rates, survival times, and manageable safety profile in clinical trials such as CheckMate-142. The FDA has approved this treatment for MSI-H/dMMR metastatic colorectal cancer after chemotherapy progression.', 'The most effective immunotherapy regimen in patients with MSI-H (microsatellite instability-high) advanced colorectal cancer is a combination of nivolumab and ipilimumab. This "double immunity" approach has shown promising results in clinical trials, particularly in the CheckMate-142 trial. The study demonstrated that nivolumab plus ipilimumab resulted in improved objective response rates, progression-free survival, and overall survival compared to chemotherapy in patients with MSI-H metastatic colorectal cancer. Additionally, this regimen was associated with a manageable safety profile. Based on these findings, the FDA approved nivolumab alone or in combination with ipilimumab for the treatment of MSI-H/dMMR (deficient mismatch repair) metastatic colorectal cancer that has progressed after chemotherapy.', 'The most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer is short-course immune checkpoint inhibitor (ICI) treatment, which is highly effective in MSI-H/dMMR locally advanced rectal cancer.', 'The most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer is nivolumab plus ipilimumab. This regimen has demonstrated high response rates, encouraging progression-free survival and overall survival at 12 months, manageable safety, and meaningful improvements in key patient-reported outcomes. Indirect comparisons suggest that combination therapy provides improved efficacy relative to anti-programmed death-1 monotherapy and has a favorable benefit-risk profile.', 'The most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer is nivolumab plus ipilimumab, which has demonstrated high response rates, encouraging progression-free survival and overall survival at 12 months, manageable safety, and meaningful improvements in key patient-reported outcomes. This combination therapy provides improved efficacy relative to anti-programmed death-1 monotherapy and has a favorable benefit-risk profile.', 'The most effective immunotherapy regimen in MSI-H (microsatellite instability-high) advanced colorectal cancer is nivolumab plus ipilimumab, which demonstrates high response rates and improved progression-free survival, overall survival at 12 months, and a favorable benefit-risk profile compared to anti-PD-1 monotherapy. It also offers meaningful improvements in patient outcomes and shows better efficacy than single-agent therapy based on indirect comparisons.', 'The most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer is nivolumab plus ipilimumab. This combination therapy has shown high response rates, encouraging progression-free survival and overall survival at 12 months, and manageable safety. Furthermore, indirect comparisons suggest that this combination provides improved efficacy relative to anti-programmed death-1 monotherapy and has a favorable benefit-risk profile. Therefore, nivolumab plus ipilimumab offers a promising new treatment option for patients with dMMR/MSI-H mCRC.', 'The most effective immunotherapy regimen for patients with MSI-H advanced colorectal cancer is pembrolizumab, an anti-PD-1 antibody, which has shown therapeutic efficacy in MSI colorectal cancer patients who have failed to respond to existing standard therapies. It is also strongly recommended as first-line therapy for MSI-H metastatic colorectal cancer. Therefore, the MSI status and tumor mutation burden of the tumor should be clarified before starting treatment. A case report is described of an elderly patient with MSI-H advanced CRC carrying MDM4 amplification and DNMT3A co-mutation who responded to sintilimab plus bevacizumab and chemotherapy as the first-line treatment without obvious immune-related toxicity.', 'Based on the current evidence, the combination of nivolumab (anti-PD-1) plus ipilimumab (anti-CTLA-4) appears to be the most effective immunotherapy regimen for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC). \n\nThe provided study found that nivolumab plus ipilimumab demonstrated high response rates, encouraging progression-free survival and overall survival at 12 months, manageable safety, and meaningful improvements in key patient-reported outcomes compared to anti-PD-1 monotherapy in this patient population.\n\nHowever, the summary also mentions promising data for anti-PD-1 monotherapy with pembrolizumab and dostarlimab. More research directly comparing combination therapy to monotherapy and optimizing treatment regimens is still needed to definitively establish the single most effective approach. But the nivolumab plus ipilimumab combination currently has the strongest supporting evidence for advanced MSI-H/dMMR colorectal cancer.', 'Nivolumab plus ipilimumab is suggested as a promising and effective immunotherapy regimen for patients with MSI-H advanced colorectal cancer.', 'Nivolumab plus ipilimumab demonstrated high response rates, encouraging progression-free survival and OS at 12 months, manageable safety, and meaningful improvements in key patient-reported outcomes. Indirect comparisons suggest combination therapy provides improved efficacy relative to anti-programmed death-1 monotherapy and has a favorable benefit-risk profile. Nivolumab plus ipilimumab provides a promising new treatment option for patients with dMMR/MSI-H mCRC.', 'The most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer is the combination of nivolumab and ipilimumab. This combination has demonstrated high response rates, encouraging progression-free survival and overall survival at 12 months, manageable safety, and meaningful improvements in key patient-reported outcomes. Indirect comparisons suggest that this combination therapy provides improved efficacy relative to anti-programmed death-1 monotherapy and has a favorable benefit-risk profile.', "The most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer is dendritic cell-based pump-priming or vaccination. Dendritic cells are harvested from the patient, activated with tumor antigens, and then reintroduced to the patient's body to stimulate a cytotoxic response against tumor cells expressing the antigen. Additionally, checkpoint inhibitors such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies have shown significant improvements in disease outcomes for MSI-H colorectal cancer. Combination therapy with nivolumab and low-dose ipilimumab has demonstrated numerically higher response rates and improved long-term clinical benefit relative to anti-programmed death-1 monotherapy. Pembrolizumab is also strongly recommended as first-line therapy for MSI-H metastatic colorectal cancer.", 'The most effective immunotherapy regimen for patients with MSI-H advanced colorectal cancer is Nivolumab combined with ipilimumab, offering high response rates, promising survival rates, manageable side effects, and significant quality of life improvements.', 'Although the passage does not give information about the treatment of colorectal cancer, it is widely accepted that Pembrolizumab is the standard of care for patients with MSI-H metastatic colorectal cancer, resulting in response rates of up to 40% in this patient population.', 'Based on the abstract, the most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer is nivolumab plus ipilimumab. This combination therapy demonstrated a high objective response rate (ORR) of 55%, with a disease control rate of 80% and a median duration of response that was not reached at a median follow-up of 13.4 months. Additionally, the regimen showed encouraging progression-free survival rates of 76% at 9 months and 71% at 12 months, as well as overall survival rates of 87% and 85% at 9 and 12 months, respectively. The safety profile was manageable, with grade 3-4 treatment-related adverse events occurring in 32% of patients.', '2015 saw FDA approval of pembrolizumab in patients with MSI-H/dMMR advanced colorectal cancer. This was based on impressive results of the phase II KEYNOTE-016 trial. Since then, studies such as the AGEO study have investigated the efficacy of immunotherapy regimens in real-world clinical practice. According to the AGEO study, in patients with MSI-H advanced colorectal cancer, pembrolizumab monotherapy is the most effective immunotherapy regimen.', 'The most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer is the use of immune checkpoint inhibitors (ICIs) such as pembrolizumab and nivolumab. Pembrolizumab is strongly recommended as first-line therapy for MSI-H metastatic colorectal cancer. Observed deep and durable responses with the use of ICIs in advanced-stage disease have stimulated the development of clinical trials with ICIs for patients with early-stage MMR-D/MSI-H CRC. Most recently, neoadjuvant dostarlimab monotherapy for nonoperative management of MMR-D/MSI-H rectal cancer and neoadjuvant NICHE trial with nivolumab and ipilimumab for MMR-D/MSI-H colon cancer resulted in groundbreaking results. Preoperative PD-1 blockade immunotherapy in dMMR/MSI-H gastrointestinal malignancies can achieve a high CR, especially in patients with duodenal or low rectal cancer, and can achieve high organ function protection. However, the benefit of immunotherapy is limited to a minority of patients with mismatch-repair-deficient (dMMR) and microsatellite instability-high (MSI-H) (dMMR-MSI-H) colorectal cancer (CRC). Identifying immune subtypes will improve understanding of complex CRC tumor heterogeneity and refine current immunotherapeutic strategies.', 'Nivolumab plus ipilimumab demonstrated high response rates, encouraging progression-free survival and overall survival (OS) at 12 months, manageable safety, and meaningful improvements in key patient-reported outcomes. Indirect comparisons suggest combination therapy provides improved efficacy relative to anti-programmed death-1 monotherapy and has a favorable benefit-risk profile. Nivolumab plus ipilimumab provides a promising new treatment option for patients with MSI-H advanced colorectal cancer.', 'The most effective immunotherapy regimen for patients with MSI-H advanced colorectal cancer is PD-1 inhibitors pembrolizumab or nivolumab. A phase II clinical trial of pembrolizumab in patients with previously treated, progressive, metastatic MSI-H colorectal cancer showed an overall response rate of 40% and a median duration of response of 8.2 months.', 'The most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer is the combination of Nivolumab and Ipilimumab, as it has demonstrated high response rates, encouraging progression-free survival and overall survival at 12 months, manageable safety, and meaningful improvements in patient-reported outcomes, suggesting improved efficacy relative to anti-programmed death-1 monotherapy.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/30343509",
"http://www.ncbi.nlm.nih.gov/pubmed/31139574",
"http://www.ncbi.nlm.nih.gov/pubmed/36896306",
"http://www.ncbi.nlm.nih.gov/pubmed/35958603",
"http://www.ncbi.nlm.nih.gov/pubmed/29355075",
"http://www.ncbi.nlm.nih.gov/pubmed/31383813",
"http://www.ncbi.nlm.nih.gov/pubmed/37668816",
"http://www.ncbi.nlm.nih.gov/pubmed/31147488",
"http://www.ncbi.nlm.nih.gov/pubmed/37246506",
"http://www.ncbi.nlm.nih.gov/pubmed/37821934",
"http://www.ncbi.nlm.nih.gov/pubmed/31322663",
"http://www.ncbi.nlm.nih.gov/pubmed/35433988",
"http://www.ncbi.nlm.nih.gov/pubmed/31079031",
"http://www.ncbi.nlm.nih.gov/pubmed/36111897",
"http://www.ncbi.nlm.nih.gov/pubmed/35371084",
"http://www.ncbi.nlm.nih.gov/pubmed/34970153",
"http://www.ncbi.nlm.nih.gov/pubmed/36217119",
"http://www.ncbi.nlm.nih.gov/pubmed/33812497",
"http://www.ncbi.nlm.nih.gov/pubmed/33537496",
"http://www.ncbi.nlm.nih.gov/pubmed/37259600",
"http://www.ncbi.nlm.nih.gov/pubmed/36998297",
"http://www.ncbi.nlm.nih.gov/pubmed/37569431",
"http://www.ncbi.nlm.nih.gov/pubmed/36528470",
"http://www.ncbi.nlm.nih.gov/pubmed/35720492",
"http://www.ncbi.nlm.nih.gov/pubmed/33671871",
"http://www.ncbi.nlm.nih.gov/pubmed/35351582",
"http://www.ncbi.nlm.nih.gov/pubmed/32090113",
"http://www.ncbi.nlm.nih.gov/pubmed/34431576",
"http://www.ncbi.nlm.nih.gov/pubmed/33183114",
"http://www.ncbi.nlm.nih.gov/pubmed/34391139",
"http://www.ncbi.nlm.nih.gov/pubmed/35340169",
"http://www.ncbi.nlm.nih.gov/pubmed/35340168",
"http://www.ncbi.nlm.nih.gov/pubmed/37114536",
"http://www.ncbi.nlm.nih.gov/pubmed/33846198",
"http://www.ncbi.nlm.nih.gov/pubmed/33264544",
"http://www.ncbi.nlm.nih.gov/pubmed/32160138",
"http://www.ncbi.nlm.nih.gov/pubmed/34775366",
"http://www.ncbi.nlm.nih.gov/pubmed/38091773",
"http://www.ncbi.nlm.nih.gov/pubmed/33563194"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29355075",
"endSection": "abstract",
"offsetInBeginSection": 1607,
"offsetInEndSection": 2075,
"text": "Nivolumab plus ipilimumab demonstrated high response rates, encouraging progression-free survival and OS at 12 months, manageable safety, and meaningful improvements in key patient-reported outcomes. Indirect comparisons suggest combination therapy provides improved efficacy relative to anti-programmed death-1 monotherapy and has a favorable benefit-risk profile. Nivolumab plus ipilimumab provides a promising new treatment option for patients with dMMR/MSI-H mCRC."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/38091773",
"endSection": "abstract",
"offsetInBeginSection": 12,
"offsetInEndSection": 273,
"text": "To determine the clinical predictors of response rate, progression-free survival (PFS), and overall survival (OS) to pembrolizumab in advanced or recurrent, mismatch repair deficient (MMRd) or Microsatellite Instability-High (MSI-H) endometrial adenocarcinomas."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34970153",
"endSection": "abstract",
"offsetInBeginSection": 1255,
"offsetInEndSection": 1490,
"text": "Conclusion: For patients with MSI-H/dMMR advanced colorectal cancer, reserving pembrolizumab for second-line line use is dominated by its first-line use, and first-line use of pembrolizumab is cost-effective compared with chemotherapy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34970153",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 682,
"text": "Background: Pembrolizumab is a guideline-recommended, both first- and second-line treatment option for microsatellite-instability-high (MSI-H)/mismatch repair-deficient (dMMR)advanced colorectal cancer patients. The aim of the present study is to investigates the health and economic outcomes of three treatment strategies with or without pembrolizumab in MSI-H/dMMR advanced colorectal cancer to define the best treatment strategy from the perspective of the US payer. Methods: A microsimulation model was developed to estimate the cost and effectiveness of three treatment strategies: 1) pembrolizumab used as first-line, 2) pembrolizumab used as second-line and, 3) chemotherapy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34970153",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 469,
"text": "Background: Pembrolizumab is a guideline-recommended, both first- and second-line treatment option for microsatellite-instability-high (MSI-H)/mismatch repair-deficient (dMMR)advanced colorectal cancer patients. The aim of the present study is to investigates the health and economic outcomes of three treatment strategies with or without pembrolizumab in MSI-H/dMMR advanced colorectal cancer to define the best treatment strategy from the perspective of the US payer."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33846198",
"endSection": "abstract",
"offsetInBeginSection": 1468,
"offsetInEndSection": 1653,
"text": "Approval of pembrolizumab is likely to change the treatment paradigm for first-line treatment with MSI-H advanced colorectal cancer given the study results and different safety profile."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34970153",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 211,
"text": "Background: Pembrolizumab is a guideline-recommended, both first- and second-line treatment option for microsatellite-instability-high (MSI-H)/mismatch repair-deficient (dMMR)advanced colorectal cancer patients."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33846198",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 223,
"text": "The FDA approved pembrolizumab on June 29, 2020, for the treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) colorectal cancer with no prior systemic treatment for advanced disease."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35371084",
"endSection": "abstract",
"offsetInBeginSection": 359,
"offsetInEndSection": 864,
"text": "The 2015 KEYNOTE-016 trial identified MSI-H/dMMR as a biomarker indicative of immunotherapy efficacy, and pointed to the potential use of immune checkpoint inhibitors (ICIs). In 2017, the FDA approved two ICIs (pembrolizumab and nivolumab) for treatment of MSI-H/dMMR metastatic CRC (mCRC). In 2018, the CheckMate-142 trial demonstrated successful treatment of mCRC based on \"double immunity\" provided by nivolumab with ipilimumab, a regimen that may become a standard first-line treatment for MSI-H mCRC."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31383813",
"endSection": "abstract",
"offsetInBeginSection": 2117,
"offsetInEndSection": 2319,
"text": "Combination therapy (e.g., nivolumab with low-dose ipilimumab) has demonstrated numerically higher response rates and improved long-term clinical benefit relative to anti-programmed death-1 monotherapy."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34775366",
"endSection": "abstract",
"offsetInBeginSection": 218,
"offsetInEndSection": 489,
"text": "The use of immunotherapy, like nivolumab and pembrolizumab (which are monoclonal antibodies against programmed cell death 1) has shown prosperous outcomes in a group of CRC patients who represent mismatch-repair-deficient and microsatellite instability-high (dMMR-MSI-H)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33671871",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 172,
"text": "Nivolumab (NIVO) plus low-dose ipilimumab (IPI) has shown a promising survival benefit in first-line treatment of microsatellite instability-high (MSI-H) colorectal cancer."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33671871",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 221,
"text": "An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35433988",
"endSection": "abstract",
"offsetInBeginSection": 92,
"offsetInEndSection": 788,
"text": "bility-high (dMMR/MSI-H) colorectal cancer exhibits better immune activity, and patients with dMMR/MSI-H colorectal cancer benefit from immunotherapy with programmed death-1 (PD-1)/PD-1 ligand (PD-L1) inhibitors and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) inhibitors as a first-line treatment. However, for microsatellite-stable (MSS) colorectal cancer, which accounts for the majority of the cases of colorectal cancer, immunotherapy has yielded little success, especially in cases of patients with advanced colorectal cancer in whom multiple lines of chemotherapy have failed. Hence, safe and effective targeted treatment strategies are urgently needed to achieve greater survival "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33537496",
"endSection": "abstract",
"offsetInBeginSection": 8,
"offsetInEndSection": 1307,
"text": "the recent advances in the systemic treatment of metastatic colorectal cancer (mCRC), prognostic outcomes have remained to be poor. Thus, what is needed is an innovative treatment approach. Immune checkpoint inhibitors (ICIs) targeting programmed death-1 (PD-1) and anti-programmed cell death ligand 1 (PD-L1) have exhibited a durable response and dominated the treatment of various tumor types. However, in mCRC, the clinical benefit is limited in patients with deficient mismatch repair (dMMR)/high levels of microsatellite instability (MSI-H), comprising approximately 5% of mCRC cases, and some do not respond to ICI treatment. Thus, further research is needed to identify predictive biomarkers. The most urgent need is developing effective immunotherapy for patients with proficient mismatch repair (pMMR)/microsatellite stable (MSS) cancer, which comprises 95% of mCRC cases. Tumors with the pMMR/MSS phenotype often exhibit a lower tumor mutation burden and fewer tumor-infiltrating lymphocytes than dMMR/MSI-H, leading to immune tolerance and evasion in the tumor microenvironment. Therefore, a number of investigative studies aimed at overcoming tumor resistance in current immunotherapy approaches are underway. A better understanding on the complexity and diversity of the immune system's"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35371084",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1802,
"text": "Patients with locally advanced colorectal cancer (LACRC) have a high risk of recurrence and metastasis, although neoadjuvant therapy may provide some benefit. However, patients with high microsatellite instability/deficient mismatch repair (MSI-H/dMMR) LACRC receive little benefit from neoadjuvant chemoradiotherapy (nCRT) or neoadjuvant chemotherapy (nCT). The 2015 KEYNOTE-016 trial identified MSI-H/dMMR as a biomarker indicative of immunotherapy efficacy, and pointed to the potential use of immune checkpoint inhibitors (ICIs). In 2017, the FDA approved two ICIs (pembrolizumab and nivolumab) for treatment of MSI-H/dMMR metastatic CRC (mCRC). In 2018, the CheckMate-142 trial demonstrated successful treatment of mCRC based on \"double immunity\" provided by nivolumab with ipilimumab, a regimen that may become a standard first-line treatment for MSI-H mCRC. In 2018, the FDA approved nivolumab alone or with ipilimumab for patients who progressed to MSI-H/dMMR mCRC after standard chemotherapy. The FDA then approved pembrolizumab alone as a first-line treatment for patients with MSI-H/dMMR CRC that was unresectable or metastatic. There is now interest in using these drugs in neoadjuvant immunotherapy (nIT) for patients with MSI-H/dMMR non-mCRC. In 2020, the NICHE trial marked the start of using nIT for CRC. This novel treatment of MSI-H/dMMR LACRC may change the approaches used for neoadjuvant therapy of other cancers. Our review of immunotherapy for CRC covers diagnosis and treatment, clinical prognostic characteristics, the mechanism of nIT, analysis of completed prospective and retrospective studies, and ongoing clinical trials, and the clinical practice of using nIT for MSI-H/dMMR LACRC. Our team also proposes a new organ-preservation strategy for patients with MSI-H/dMMR low"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37259600",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 229,
"text": "OBJECTIVE: The immune checkpoint inhibitor pembrolizumab has recently been recognized as a standard treatment regimen for patients with metastatic colorectal cancer and the microsatellite-instability-high/mismatch repair-deficien"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30343509",
"endSection": "abstract",
"offsetInBeginSection": 1097,
"offsetInEndSection": 1391,
"text": "ess ratios (ICERs).RESULTS: Ipilimumab with nivolumab was the most effective strategy (10.69 life-years and 9.25 QALYs for the third line; 10.69 life-years and 9.44 QALYs for the first line) in comparison with nivolumab (8.21 life-years and 6.76 QALYs for the third line; 8.21 life-years and 7."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37569431",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 521,
"text": "DNA mismatch repair deficient (dMMR) and microsatellite instable (MSI) metastatic colorectal cancer (mCRC) can be successfully treated with FDA- and EMA-approved immune checkpoint inhibitors (ICI) pembrolizumab and nivolumab (as single agents targeting the anti-programmed cell death protein-1 (PD-1)) or combinations of a PD-1 inhibitor with ipilimumab, a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)-targeting antibody. The best treatment strategy beyond progression on single-agent ICI therapy remains unclear."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35340169",
"endSection": "abstract",
"offsetInBeginSection": 559,
"offsetInEndSection": 732,
"text": "The success of KEYNOTE-177 study has changed the guidelines with pembrolizumab becoming a standard treatment in the first-line treatment of MSI-H advanced colorectal cancer."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33563194",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 825,
"text": "Immunotherapy has revolutionized the treatment landscape in a number of solid tumors. In colorectal cancer, evidence suggests that microsatellite high (MSI-H) tumors are the most responsive to immune checkpoint blockade due to increased neo-antigen load and a favorable tumor microenvironment. Indeed, Pembrolizumab now represents a first-line option in such patients. However, MSI-H tumors represent the minority and a proportion of patients' progress despite initially responding. Trials are investigating different immunotherapy combinatorial strategies to enhance immune response in less immunogenic colorectal tumors. Such strategies include dual immune checkpoint blockade, combining immune checkpoint inhibitors with other treatment modalities such as radiotherapy, chemotherapy or other biological or targeted agents."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36998297",
"endSection": "abstract",
"offsetInBeginSection": 121,
"offsetInEndSection": 862,
"text": "immunotherapy has become widely recognized as a new standard treatment for cancers including microsatellite instability-high (MSI-H) colorectal cancer. Immune checkpoint inhibitors such as pembrolizumab and nivolumab (anti-PD-1 antibodies) that act in the effector phase of T cells and ipilimumab (anti-CTLA-4 antibody) that acts mainly in the priming phase are now in clinical use. These antibodies have shown therapeutic efficacy in MSI colorectal cancer patients who have failed to respond to existing standard therapies. Pembrolizumab is also strongly recommended as first-line therapy for MSI-H metastatic colorectal cancer. Therefore, the MSI status and tumor mutation burden of the tumor should be clarified before starting treatment."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34391139",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 656,
"text": "Immunotherapy has recently become a major treatment modality for several types of solid tumours, achieving remarkable and long-lasting remissions. In metastatic colorectal cancer patients (mCRC), immune checkpoint inhibitors (ICIs) were found to be effective as treatment for deficient mismatch repair (dMMR)/ microsatellite instability high (MSI-H) tumours and received regulatory approval for this indication. However, mCRC is a complex disease and dMMR/MSI-H tumours represent a minority of the cases; therefore, new strategies are needed to extend the benefits of immunotherapy to a larger population of patients. This review explores the immunological"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31322663",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 1408,
"text": "Colorectal cancer (CRC) remains a leading cause of cancer-related deaths in the United States. Although immunotherapy has dramatically changed the landscape of treatment for many advanced cancers, the benefit in CRC has thus far been limited to patients with microsatellite instability high (MSI-H):DNA mismatch repair-deficient (dMMR) tumors. Recent studies in the refractory CRC setting have led to US Food and Drug Administration approvals for pembrolizumab as well as nivolumab (with or without ipilimumab) for tumors harboring an MSI-H:dMMR molecular profile. Several randomized controlled trials are underway to move immunotherapy into the frontline for metastatic cancer (with or without chemotherapy) and the adjuvant setting. Awareness of these studies is critical given the relatively low incidence (approximately 3%-5%) of MSI-H:dMMR in advanced or metastatic CRC to support study completion, because the results could be potentially practice changing. The real challenge in this disease is related to demonstrating the benefit of immunotherapy for the vast majority of patients with CRC not harboring MSI-H:dMMR. Given the rapid pace of scientific changes, this article provides a narrative review regarding the current landscape of immunotherapy for CRC. Particular attention is paid to the currently available data that inform today's clinical practice along with upcoming randomized controlled"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32090113",
"endSection": "abstract",
"offsetInBeginSection": 196,
"offsetInEndSection": 1760,
"text": "metastatic colorectal cancer (mCRC). As a result of their dramatic and durable response rates in patients with chemorefractory, mismatch repair-deficient-microsatellite instability-high (dMMR-MSI-H) mCRC, ICIs have become potential alternatives to classical systemic therapies. The anti-programmed death-1 (PD-1) agents, Pembrolizumab and Nivolumab, have been granted FDA approval for this subset of patients. Unfortunately, however, not all CRC cases with the dMMR-MSI-H phenotype respond well to ICIs, and ongoing studies are currently exploring biomarkers that can predict good response to them. Another challenge lies in developing novel treatment strategies for the subset of patients with the mismatch repair-proficient-microsatellite instability-low (pMMR-MSI-L) phenotype that comprises 95% of all mCRC cases in whom treatment with currently approved ICIs has been largely unsuccessful. Approaches aiming at overcoming the resistance of tumors in this subset of patients are being developed including combining different checkpoint inhibitors with either chemotherapy, anti-angiogenic agents, cancer vaccines, adoptive cell transfer (ACT), or bispecific T-cell (BTC) antibodies. This review describes the rationale behind using immunotherapeutics in CRC. It sheds light on the progress made in the use of immunotherapy in the treatment of patients with dMMR-MSI-H CRC. It also discusses emerging approaches and proposes potential strategies for targeting the immune microenvironment in patients with pMMR-MSI-L CRC tumors in an attempt to complement immune"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35340168",
"endSection": "abstract",
"offsetInBeginSection": 406,
"offsetInEndSection": 1212,
"text": "The advent of PD-1 antibodies has significantly improved the prognosis and changed treatment landscape in this population, not only achieving good outcomes in late-line therapy, but also significantly outperforming traditional chemotherapy combined with targeted therapy in first-line therapy. How to overcome primary and secondary drug resistance is a key issue in improving the outcome of MSI-H metastatic colorectal cancer, and commonly used approaches include changing chemotherapy regimens, combining with other immunotherapies, combining with anti-angiogenesis, and local treatments (surgery, radiotherapy, or interventional therapy). It is worth noting that immunotherapy has certain lifelong or even lethal toxicity, and the indications for neoadjuvant immunotherapy must be evaluated with caution."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34431576",
"endSection": "abstract",
"offsetInBeginSection": 1313,
"offsetInEndSection": 1813,
"text": "TS: Immune checkpoint inhibitors are more active in treatment-naïve patients than in patients with refractory high-grade microsatellite instability (MSI-H)/deficiency in mismatch repair (dMMR) colorectal cancer. Standard neoadjuvant chemoradiation is less effective in MSI-H/dMMR rectal cancer patients than in patients with proficient mismatch repair. A young patient with Lynch syndrome and MSI-H/dMMR locally advanced rectal cancer refused chemoradiation in order to preserve his fertility. After "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32160138",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 499,
"text": "Recent studies have identified durable responses with the use of immune checkpoint inhibitors in patients with mismatch repair-deficient (MMR-D)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (CRC). The dramatic improvement in clinical outcomes led to the US Food and Drug Administration approval of pembrolizumab, nivolumab, and nivolumab in combination with ipilimumab in metastatic patients with MSI-H/MMR-D CRC who previously experienced progression on cytotoxic therapies."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35351582",
"endSection": "abstract",
"offsetInBeginSection": 585,
"offsetInEndSection": 837,
"text": "In subsequent lines, both these immunotherapeutic regimens (e.g., pembrolizumab and nivolumab+/-ipilimumab) as well as dostarlimab-gxly are currently recommended for patients with dMMR/MSI-H chemo-resistant mCRC who have not previously received an ICI."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37668816",
"endSection": "abstract",
"offsetInBeginSection": 542,
"offsetInEndSection": 827,
"text": "For metastatic colorectal cancer, pembrolizumab and nivolumab, with or without ipilimumab, are recommended for chemotherapy-refractory patients, and pembrolizumab is recommended for chemotherapy-naive patients with mismatch repair deficiency and microsatellite instability-high tumors."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31147488",
"endSection": "abstract",
"offsetInBeginSection": 148,
"offsetInEndSection": 532,
"text": "e outcomes. In CheckMate 142, nivolumab (3 mg/kg) plus low-dose ipilimumab (1 mg/kg) provided durable clinical benefit (objective response rate [ORR] 55%, median duration of response not reached, 12-month overall survival [OS] rate 85%) and manageable safety for previously treated microsatellite instability-high and/or mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal ca"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29355075",
"endSection": "abstract",
"offsetInBeginSection": 1605,
"offsetInEndSection": 1970,
"text": "n Nivolumab plus ipilimumab demonstrated high response rates, encouraging progression-free survival and OS at 12 months, manageable safety, and meaningful improvements in key patient-reported outcomes. Indirect comparisons suggest combination therapy provides improved efficacy relative to anti-programmed death-1 monotherapy and has a favorable benefit-risk profil"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33812497",
"endSection": "abstract",
"offsetInBeginSection": 3648,
"offsetInEndSection": 4022,
"text": "48 [95% CI 0·33-0·69]; one-sided nominal p<0·0001).INTERPRETATION: Pembrolizumab monotherapy led to clinically meaningful improvements in HRQOL compared with chemotherapy in patients with previously untreated microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer. These data, along with the previously reported clinical benefits, support "
}
] | 13
|
BioASQ-training13b
| null | null |
660999e7fdcbea915f00001c
| 5,357
|
factoid
|
What is the cause of autosomal dominant Polycystic Kidney Disease?
|
['mutations in the PKD1 or PKD2 genes']
|
[
"PKD1 gene",
"PKD2 gene",
"polycystic kidney disease 1",
"polycystic kidney disease 2",
"PKD1",
"PKD2",
"mutations in PKD1",
"mutations in PKD2",
"mutations in the PKD1 gene",
"mutations in the PKD2 gene"
] |
['Autosomal dominant Polycystic Kidney Disease is caused by mutations in the PKD1 gene or PKD2 gene.', 'Autosomal dominant Polycystic Kidney Disease is caused by mutations in PKD1 or PKD2 genes.', 'Autosomal dominant Polycystic Kidney Disease is primarily caused by mutations in either the PKD1 or PKD2 genes.', '85% of the autosomal dominant polycystic kidney disease cases are due to mutation in the PKD1 gene on chromosome 16 and 15% are due to mutation in the PKD2 gene on chromosome 4.', 'Autosomal dominant polycystic kidney disease (ADPKD) is a common monogenic multisystem disease caused primarily by mutations in the PKD1 gene or PKD2 gene', 'Autosomal dominant polycystic kidney disease (ADPKD) is caused primarily by mutations in the PKD1 gene or PKD2 gene.', 'Autosomal dominant Polycystic Kidney Disease is caused by a mutation in either the PKD1 or PKD2 gene.', 'Autosomal dominant polycystic kidney disease (ADPKD) is primarily caused by mutations in the PKD1 gene or PKD2 gene.', 'Autosomal dominant Polycystic Kidney Disease is caused by mutations in polycystic kidney disease genes such as PKD1, pathogenic variants affecting polycystin-2, and Monoallelic IFT140.', 'Autosomal dominant Polycystic Kidney Disease is primarily caused by mutations in the PKD1 gene or PKD2 gene.', 'Autosomal dominant Polycystic Kidney Disease (ADPKD) is caused primarily by mutations in the PKD1 gene or PKD2 gene.', 'Autosomal dominant Polycystic Kidney Disease is primarily caused by mutations in the PKD1 or PKD2 genes, with specific variants in the NEK8 gene also identified as a cause.', 'Autosomal dominant Polycystic Kidney Disease is caused by mutations in the PKD1 or PKD2 genes.', 'Autosomal dominant polycystic kidney disease (ADPKD) is a common monogenic multisystem disease caused primarily by mutations in the PKD1 gene or PKD2 gene.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/31056860",
"http://www.ncbi.nlm.nih.gov/pubmed/22383692",
"http://www.ncbi.nlm.nih.gov/pubmed/10322638",
"http://www.ncbi.nlm.nih.gov/pubmed/30792735",
"http://www.ncbi.nlm.nih.gov/pubmed/27067213",
"http://www.ncbi.nlm.nih.gov/pubmed/11336705",
"http://www.ncbi.nlm.nih.gov/pubmed/31668373",
"http://www.ncbi.nlm.nih.gov/pubmed/37664187",
"http://www.ncbi.nlm.nih.gov/pubmed/23496908",
"http://www.ncbi.nlm.nih.gov/pubmed/26788466",
"http://www.ncbi.nlm.nih.gov/pubmed/21115670",
"http://www.ncbi.nlm.nih.gov/pubmed/9889186",
"http://www.ncbi.nlm.nih.gov/pubmed/15775720",
"http://www.ncbi.nlm.nih.gov/pubmed/27016049",
"http://www.ncbi.nlm.nih.gov/pubmed/10655152",
"http://www.ncbi.nlm.nih.gov/pubmed/37468838",
"http://www.ncbi.nlm.nih.gov/pubmed/34542828",
"http://www.ncbi.nlm.nih.gov/pubmed/29860066",
"http://www.ncbi.nlm.nih.gov/pubmed/36035467",
"http://www.ncbi.nlm.nih.gov/pubmed/37598857",
"http://www.ncbi.nlm.nih.gov/pubmed/10602361",
"http://www.ncbi.nlm.nih.gov/pubmed/37028763",
"http://www.ncbi.nlm.nih.gov/pubmed/36469907",
"http://www.ncbi.nlm.nih.gov/pubmed/30644092",
"http://www.ncbi.nlm.nih.gov/pubmed/24374109",
"http://www.ncbi.nlm.nih.gov/pubmed/29633482",
"http://www.ncbi.nlm.nih.gov/pubmed/18947299",
"http://www.ncbi.nlm.nih.gov/pubmed/17100995",
"http://www.ncbi.nlm.nih.gov/pubmed/25491204",
"http://www.ncbi.nlm.nih.gov/pubmed/29767557",
"http://www.ncbi.nlm.nih.gov/pubmed/21392578",
"http://www.ncbi.nlm.nih.gov/pubmed/26718059",
"http://www.ncbi.nlm.nih.gov/pubmed/31160911",
"http://www.ncbi.nlm.nih.gov/pubmed/22508176",
"http://www.ncbi.nlm.nih.gov/pubmed/20219615"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37468838",
"endSection": "abstract",
"offsetInBeginSection": 12,
"offsetInEndSection": 167,
"text": "Autosomal dominant polycystic kidney disease (ADPKD) is a common monogenic multisystem disease caused primarily by mutations in the PKD1 gene or PKD2 gene."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22508176",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 627,
"text": "Autosomal dominant polycystic kidney disease (ADPKD), the most common inherited kidney disorder, is caused by mutations in PKD1 or PKD2. The molecular diagnosis of ADPKD is complicated by extensive allelic heterogeneity and particularly by the presence of six highly homologous sequences of PKD1 exons 1-33. Here, we screened PKD1 and PKD2 for both conventional mutations and gross genomic rearrangements in up to 700 unrelated ADPKD patients--the largest patient cohort to date--by means of direct sequencing, followed by quantitative fluorescent multiplex polymerase chain reaction or array-comparative genomic hybridization."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21115670",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 283,
"text": "BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is a common genetic renal disorder with an incidence of 1:1000. Mutations in two genes (PKD1 and PKD2) have been identified as causative. Eighty-five percent of patients with ADPKD carry their mutation in the PKD1 gene"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21115670",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 201,
"text": "BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is a common genetic renal disorder with an incidence of 1:1000. Mutations in two genes (PKD1 and PKD2) have been identified as causative"
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21115670",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 86,
"text": "Novel PKD1 and PKD2 mutations in autosomal dominant polycystic kidney disease (ADPKD)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37598857",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 214,
"text": "Autosomal dominant polycystic kidney disease (ADPKD) resulting from pathogenic variants in PKD1 and PKD2 is the most common form of PKD, but other genetic causes tied to primary cilia function have been identified."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37028763",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 90,
"text": "Autosomal dominant polycystic kidney disease is caused by mutations in PKD1 or PKD2 genes."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36035467",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 176,
"text": "Autosomal dominant polycystic kidney disease (ADPKD) is caused by mutations in the PKD1 or PKD2 gene which encodes membrane receptor PKD1 and cation channel PKD2, respectively."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25491204",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 244,
"text": "BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder. It is caused by mutations in the PKD1 and PKD2 genes, and manifests as progressive cyst growth and renal enlargement, resulting in re"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36469907",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 146,
"text": "ABSTRACT: Autosomal dominant polycystic kidney disease (ADPKD) is a systemic, irreversible, genetic condition caused by mutations in the PKD1 and "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23496908",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 348,
"text": "BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is the most common form of inherited kidney disease that results in renal failure. ADPKD is a systemic disorder with cysts and connective tissue abnormalities involving many organs. ADPKD caused by mutations in PKD1 gene is significantly more severe than the cases caused by PKD2 gen"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29633482",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 159,
"text": "AIM: Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary renal disease in humans and is caused by mutations in the PKD1 or PKD2 "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29860066",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 284,
"text": "Autosomal Dominant Polycystic Kidney Disease (ADPKD), the most frequent genetic disorder of the kidneys, is characterized by a typical presenting symptoms include cysts development in different organs and a non-cysts manifestations. ADPKD is caused by mutations in PKD1 or PKD2 genes."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/17100995",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 135,
"text": "Autosomal dominant polycystic kidney disease (ADPKD) is genetically heterogeneous and is caused by mutations in the PKD1 or PKD2 genes."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31056860",
"endSection": "abstract",
"offsetInBeginSection": 78,
"offsetInEndSection": 221,
"text": "ey disease. The main mutational genes causing autosomal dominant polycystic kidney disease (ADPKD) are PKD1 and PKD2 as well as some rare patho"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/10602361",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 179,
"text": "Autosomal Dominant Polycystic Kidney Disease (ADPKD), a common inherited disease leading to progressive renal failure, can be caused by a mutation in either the PKD1 or PKD2 gene."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18947299",
"endSection": "abstract",
"offsetInBeginSection": 66,
"offsetInEndSection": 226,
"text": "The most common form, autosomal dominant polycystic kidney disease (ADPKD), is a disorder most often diagnosed in adults and caused by mutation in PKD1 or PKD2."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21392578",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 326,
"text": "Autosomal dominant polycystic kidney disease (ADPKD) is a common, monogenic multi-systemic disorder characterized by the development of renal cysts and various extrarenal manifestations. Worldwide, it is a common cause of end-stage renal disease. ADPKD is caused by mutation in either one of two principal genes, PKD1 and PKD2"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26718059",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 198,
"text": "Autosomal-dominant polycystic kidney disease (ADPKD) is caused by mutations in PKD1 and PKD2 and is characterized by proliferation of renal tubular epithelium and progressive chronic kidney disease."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27016049",
"endSection": "abstract",
"offsetInBeginSection": 162,
"offsetInEndSection": 312,
"text": "sease include autosomal dominant polycystic kidney diseases (caused by mutations in PKD1 or PKD2), autosomal recessive polycystic kidney disease, tube"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/9889186",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 112,
"text": "Most cases of autosomal dominant polycystic kidney disease (ADPKD) are the result of mutations in the PKD1 gene."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29767557",
"endSection": "abstract",
"offsetInBeginSection": 144,
"offsetInEndSection": 222,
"text": "Mutations in PKD1 lead to autosomal dominant polycystic kidney disease (ADPKD)"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/11336705",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 127,
"text": "The PKD1 gene accounts for 85% of autosomal dominant polycystic kidney disease (ADPKD), the most common human genetic disorder."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/10322638",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 103,
"text": "Mutations in the PKD1 gene cause the majority of cases of autosomal dominant polycystic kidney disease."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26788466",
"endSection": "abstract",
"offsetInBeginSection": 252,
"offsetInEndSection": 399,
"text": "Approximately 85% of ADPKD cases are caused by mutations in the PKD1 gene, while mutations in the PKD2 gene account for the remaining 15% of cases."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34542828",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 167,
"text": "OBJECTIVE: Autosomal dominant polycystic kidney disease (ADPKD) is mainly caused by the pathogenic mutation of PKD1 or PKD2 gene and usually affects bilateral kidneys."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27016049",
"endSection": "abstract",
"offsetInBeginSection": 114,
"offsetInEndSection": 426,
"text": "Some of the inherited causes of cystic kidney disease include autosomal dominant polycystic kidney diseases (caused by mutations in PKD1 or PKD2), autosomal recessive polycystic kidney disease, tuberous sclerosis complex, von Hippel-Lindau disease, oral-facial-digital syndrome type I, and Hadju-Cheney syndrome."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30644092",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 497,
"text": "Autosomal dominant polycystic kidney disease (ADPKD) is a monogenic inherited renal cystic disease that occurs in different races worldwide. It is characterized by the development of a multitude of renal cysts, which leads to massive enlargement of the kidney and often to renal failure in adulthood. ADPKD is caused by a mutation in PKD1 or PKD2 genes encoding the proteins polycystin-1 and polycystin-2, respectively. Recent studies showed that cyst formation and growth result from deregulation"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36469907",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 330,
"text": "ABSTRACT: Autosomal dominant polycystic kidney disease (ADPKD) is a systemic, irreversible, genetic condition caused by mutations in the PKD1 and PKD2 genes, and the most common form of inherited kidney disease in the United States, affecting more than 600,000 individuals. Because the condition is autosomal dominant, there is a "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37664187",
"endSection": "abstract",
"offsetInBeginSection": 151,
"offsetInEndSection": 555,
"text": "Autosomal Dominant Polycystic Kidney Disease (ADPKD), one of the most common genetic kidney diseases. Approaches including both phenotype first and genotype first allows some interesting and informative observations within this disease population. PKD1 and PKD2 are the most frequent genetic causes of ADPKD accounting for 78% and 15% respectively, whilst around 7-8% of cases have an alternative genetic"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21392578",
"endSection": "abstract",
"offsetInBeginSection": 247,
"offsetInEndSection": 480,
"text": "ADPKD is caused by mutation in either one of two principal genes, PKD1 and PKD2, but has large phenotypic variability among affected individuals, attributable to PKD genic and allelic variability and, possibly, modifier gene effects."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22383692",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 115,
"text": "Mutations in two large multi-exon genes, PKD1 and PKD2, cause autosomal dominant polycystic kidney disease (ADPKD)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/15775720",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 104,
"text": "Autosomal dominant polycystic kidney disease (ADPKD) is caused by mutations in two genes, PKD1 and PKD2."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/10655152",
"endSection": "abstract",
"offsetInBeginSection": 145,
"offsetInEndSection": 247,
"text": "ADPKD is a heterogeneous human disease resulting from mutations in either of two genes, PKD1 and PKD2."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24374109",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 93,
"text": "Autosomal dominant polycystic kidney disease (ADPKD) is caused by mutations in PKD1 and PKD2."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21115670",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 190,
"text": "BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is a common genetic renal disorder with an incidence of 1:1000. Mutations in two genes (PKD1 and PKD2) have been identified a"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31668373",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 168,
"text": "Autosomal dominant polycystic kidney disease (ADPKD) is caused by mutations in PKD1 or PKD2, the genes encoding polycystin 1 (PC1) and polycystin 2 (PC2), respectively."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30792735",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 306,
"text": "Autosomal Dominant Polycystic Kidney Disease (ADPKD) typically results from a mutation in the PKD1 and PKD2 genes, which code for polycystin-1 (PC1) and polycystin-2 (PC2), respectively. Mutations in these genes promote renal cystic dysplasia and are a significant cause of End-Stage Kidney Disease (ESKD)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/20219615",
"endSection": "abstract",
"offsetInBeginSection": 129,
"offsetInEndSection": 263,
"text": "The understanding of the pathogenesis of ADPKD has advanced significantly since the discovery of the 2 causative genes, PKD1 and PKD2."
}
] | 13
|
BioASQ-training13b
| null | null |
661d6252eac11fad33000025
| 5,361
|
factoid
|
By which method do micro RNAs (miRNAs) primarily aid in transcriptional and post-transcriptional regulation?
|
['Target degradation and/or repression', 'Degradation', 'Repression', 'translational repression', 'mRNA degradation']
|
[
"Target degradation and/or repression",
"Degradation",
"Repression",
"Translational repression",
"mRNA degradation",
"Target repression",
"mRNA decay",
"RNA degradation",
"mRNA turnover"
] |
['Micro RNAs (miRNAs) are small non-coding RNAs that regulate gene expression by binding to mRNA and mediating its degradation or inhibiting translation.', 'MicroRNAs (miRNAs) are small, single-stranded non-coding RNAs that are widely found in plants and animals. They primarily aid in transcriptional and post-transcriptional regulation of gene expression through sequence-specific interaction with target mRNAs leading to translational repression or target mRNA degradation.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/34155810",
"http://www.ncbi.nlm.nih.gov/pubmed/34979040",
"http://www.ncbi.nlm.nih.gov/pubmed/24075926",
"http://www.ncbi.nlm.nih.gov/pubmed/36552307",
"http://www.ncbi.nlm.nih.gov/pubmed/19841878",
"http://www.ncbi.nlm.nih.gov/pubmed/21832809",
"http://www.ncbi.nlm.nih.gov/pubmed/27754357",
"http://www.ncbi.nlm.nih.gov/pubmed/22336708",
"http://www.ncbi.nlm.nih.gov/pubmed/26761000",
"http://www.ncbi.nlm.nih.gov/pubmed/20036482",
"http://www.ncbi.nlm.nih.gov/pubmed/23447695",
"http://www.ncbi.nlm.nih.gov/pubmed/34432271",
"http://www.ncbi.nlm.nih.gov/pubmed/27525292",
"http://www.ncbi.nlm.nih.gov/pubmed/16957368",
"http://www.ncbi.nlm.nih.gov/pubmed/29058542",
"http://www.ncbi.nlm.nih.gov/pubmed/18533097",
"http://www.ncbi.nlm.nih.gov/pubmed/29959194",
"http://www.ncbi.nlm.nih.gov/pubmed/19643113",
"http://www.ncbi.nlm.nih.gov/pubmed/29471827",
"http://www.ncbi.nlm.nih.gov/pubmed/26673698",
"http://www.ncbi.nlm.nih.gov/pubmed/28837599",
"http://www.ncbi.nlm.nih.gov/pubmed/23445489",
"http://www.ncbi.nlm.nih.gov/pubmed/36069329",
"http://www.ncbi.nlm.nih.gov/pubmed/28602827",
"http://www.ncbi.nlm.nih.gov/pubmed/35247033",
"http://www.ncbi.nlm.nih.gov/pubmed/17507929",
"http://www.ncbi.nlm.nih.gov/pubmed/29187891",
"http://www.ncbi.nlm.nih.gov/pubmed/17538623",
"http://www.ncbi.nlm.nih.gov/pubmed/26257769",
"http://www.ncbi.nlm.nih.gov/pubmed/36040583",
"http://www.ncbi.nlm.nih.gov/pubmed/26308709",
"http://www.ncbi.nlm.nih.gov/pubmed/33381822",
"http://www.ncbi.nlm.nih.gov/pubmed/29989022",
"http://www.ncbi.nlm.nih.gov/pubmed/21893463",
"http://www.ncbi.nlm.nih.gov/pubmed/17127242",
"http://www.ncbi.nlm.nih.gov/pubmed/37958433",
"http://www.ncbi.nlm.nih.gov/pubmed/31179855",
"http://www.ncbi.nlm.nih.gov/pubmed/20940025",
"http://www.ncbi.nlm.nih.gov/pubmed/11896390",
"http://www.ncbi.nlm.nih.gov/pubmed/32949853",
"http://www.ncbi.nlm.nih.gov/pubmed/24367289",
"http://www.ncbi.nlm.nih.gov/pubmed/25086339",
"http://www.ncbi.nlm.nih.gov/pubmed/38075204",
"http://www.ncbi.nlm.nih.gov/pubmed/22622804",
"http://www.ncbi.nlm.nih.gov/pubmed/26616332",
"http://www.ncbi.nlm.nih.gov/pubmed/21807045",
"http://www.ncbi.nlm.nih.gov/pubmed/30374521",
"http://www.ncbi.nlm.nih.gov/pubmed/30333195",
"http://www.ncbi.nlm.nih.gov/pubmed/36316086",
"http://www.ncbi.nlm.nih.gov/pubmed/23559250",
"http://www.ncbi.nlm.nih.gov/pubmed/26662984",
"http://www.ncbi.nlm.nih.gov/pubmed/19112830",
"http://www.ncbi.nlm.nih.gov/pubmed/20545570",
"http://www.ncbi.nlm.nih.gov/pubmed/25914709",
"http://www.ncbi.nlm.nih.gov/pubmed/21532838",
"http://www.ncbi.nlm.nih.gov/pubmed/18333757",
"http://www.ncbi.nlm.nih.gov/pubmed/31752361",
"http://www.ncbi.nlm.nih.gov/pubmed/37397550",
"http://www.ncbi.nlm.nih.gov/pubmed/37505443",
"http://www.ncbi.nlm.nih.gov/pubmed/19800023",
"http://www.ncbi.nlm.nih.gov/pubmed/24938790",
"http://www.ncbi.nlm.nih.gov/pubmed/20371515"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37505443",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 131,
"text": "Small non-coding RNAs (miRNAs) regulate gene expression by binding to mRNA and mediating its degradation or inhibiting translation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32949853",
"endSection": "abstract",
"offsetInBeginSection": 252,
"offsetInEndSection": 409,
"text": "MicroRNAs (miRNAs) are small non-coding RNAs mediating gene expression at the post-transcriptional level through mRNA degradation or translational repression"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21832809",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 215,
"text": "Micro-RNAs (miRNAs) play a crucial role in post-transcriptional gene regulation by pairing with target mRNAs to repress protein production. It has been shown that over one-third of human genes are targeted by miRNA."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21832809",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 139,
"text": "Micro-RNAs (miRNAs) play a crucial role in post-transcriptional gene regulation by pairing with target mRNAs to repress protein production."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/20940025",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 147,
"text": "Micro RNAs (miRNAs) are a recently discovered class of small, non-coding RNAs with the function of post-transcriptional gene expression regulation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26673698",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 139,
"text": "MicroRNAs (miRNAs) play a major role in the post-transcriptional regulation of target genes, especially in development and differentiation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36316086",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 252,
"text": "MicroRNAs (miRNAs) are small non-coding RNAs (sncRNAs) that function in post-transcriptional gene regulation through imperfect base pairing with mRNA targets which results in inhibition of translation and typically destabilization of bound transcripts."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36040583",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 223,
"text": "MicroRNA (miRNA) is a small, non-coding RNA molecule (~22 nucleotides) that acts as a post-transcriptional gene regulator, primarily by inhibiting the translation of target mRNA transcripts or affecting cell mRNA stability."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/16957368",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 563,
"text": "Although initially believed to act exclusively as translational repressors, microRNAs (miRNAs) are now known to target complementary messenger RNA (mRNA) transcripts for either translational repression or cleavage via the RNA-induced silencing complex (RISC) ([1], reviewed in ref. 2). The current model postulates that mature miRNAs are incorporated into the RISC, bind target mRNAs based on complementarity, and guide cleavage of mRNA targets with perfect or nearly perfect complementarity and translational repression of targets with lower complementarity (2)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/17507929",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 129,
"text": "MicroRNAs (miRNAs) are a class of small RNAs that act post-transcriptionally to regulate messenger RNA stability and translation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27754357",
"endSection": "abstract",
"offsetInBeginSection": 729,
"offsetInEndSection": 866,
"text": "miRNAs act as post-transcriptional regulators of their messenger RNA (mRNA) targets via mRNA degradation and/or translational repression."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26662984",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 174,
"text": "MicroRNAs (miRNAs) are short (~22 nucleotides) single-stranded RNA molecules that primarily function to negatively regulate gene expression at the post-transcriptional level."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37958433",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 140,
"text": "MicroRNAs (MiRNAs) are small, non-coding RNA molecules that function in RNA silencing and post-transcriptional regulation of gene expression"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22622804",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 406,
"text": "MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression in animals and in plants. In recent years, miRNAs have been shown to be important biological molecules for regulating various cellular functions. miRNAs function post-transcriptionally usually by base-pairing to the mRNA 3'-untranslated regions of the mRNAs and repress protein synthesis by mechanisms that are not fully understood."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29989022",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 201,
"text": "MicroRNA (miRNA) is a small non-coding RNA with an established function to regulate genes at the post-transcriptional level leading to suppression or degradation of its messenger RNA expression (mRNA)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37397550",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 342,
"text": "MicroRNAs (miRNAs) are small non-coding single-stranded RNAs of about 22 nucleotides in length that act as post-transcriptional regulators of gene expression. Depending on the complementarity between miRNA and target mRNA, cleavage, destabilization, or translational suppression of mRNA occurs within the RISC (RNA-induced silencing complex)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22336708",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 269,
"text": "microRNAs (miRNAs), defined as 21-24 nucleotide non-coding RNAs, are important regulators of gene expression. Initially, the functions of miRNAs were recognized as post-transcriptional regulators on mRNAs that result in mRNA degradation and/or translational repression."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21893463",
"endSection": "abstract",
"offsetInBeginSection": 105,
"offsetInEndSection": 194,
"text": "MiRNAs regulate gene expression by inhibiting protein translation from the messenger RNA."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25914709",
"endSection": "abstract",
"offsetInBeginSection": 97,
"offsetInEndSection": 285,
"text": "Generally, miRNAs that are 20-24 nucleotides long bind to specific complementary transcripts, attenuating gene expression at the post-transcriptional level or via translational inhibition."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30333195",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 129,
"text": "MicroRNAs (miRNAs) are important regulators of gene expression that bind complementary target mRNAs and repress their expression."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26257769",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 347,
"text": "MicroRNAs (miRNAs) are important post-transcriptional regulators of gene expression that act by degrading their RNA targets or by repressing the translation of messenger RNAs (mRNAs). Initially thought to primarily target the 3' untranslated region (3'UTR) of mRNAs, miRNAs have since been shown to also target the 5'UTR and coding sequence (CDS)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26257769",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 183,
"text": "MicroRNAs (miRNAs) are important post-transcriptional regulators of gene expression that act by degrading their RNA targets or by repressing the translation of messenger RNAs (mRNAs)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35247033",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 452,
"text": "Post-transcriptional regulation of messenger RNAs (mRNAs) (i.e., mechanisms that control translation, stability and localization) is a critical focal point in spatiotemporal regulation of gene expression in response to changes in environmental conditions. The human genome encodes ~ 2000 microRNAs (miRNAs), each of which could control the expression of hundreds of protein-coding mRNAs by inducing translational repression and/or promoting mRNA decay."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29058542",
"endSection": "abstract",
"offsetInBeginSection": 143,
"offsetInEndSection": 213,
"text": "miRNAs degrade or repress target mRNAs by targeting the 3' UTR region."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/18533097",
"endSection": "abstract",
"offsetInBeginSection": 396,
"offsetInEndSection": 471,
"text": "miRNAs modulate gene expression by affecting mRNA translation or stability."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/20371515",
"endSection": "abstract",
"offsetInBeginSection": 114,
"offsetInEndSection": 245,
"text": "miRNAs act by binding to the 3' untranslated region (3'UTR) of an mRNA, affecting the stability and translation of the target mRNA."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/19841878",
"endSection": "abstract",
"offsetInBeginSection": 514,
"offsetInEndSection": 644,
"text": "miRNAs regulate gene expression at the post-transcriptional level, through both translational inhibition and mRNA destabilization."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26308709",
"endSection": "abstract",
"offsetInBeginSection": 258,
"offsetInEndSection": 553,
"text": "miRNAs are incorporated into the RNA-induced silencing complexes (RISCs) that contain Argonaute (AGO) family proteins and guide RISC to target RNAs via complementary base pairing, leading to post-transcriptional gene silencing by a combination of translation inhibition and mRNA destabilization."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21532838",
"endSection": "abstract",
"offsetInBeginSection": 1003,
"offsetInEndSection": 1199,
"text": "The degree and nature of the complementarity between the microRNA and target determine the gene silencing mechanism, slicer-dependent mRNA degradation or slicer-independent translation inhibition."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23559250",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 130,
"text": "MicroRNAs (miRNAs) control gene expression through both translational repression and degradation of target messenger RNAs (mRNAs)."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24938790",
"endSection": "abstract",
"offsetInBeginSection": 162,
"offsetInEndSection": 351,
"text": "To repress gene expression, miRNAs are packaged into RNA-induced silencing complexes (RISCs) that target mRNAs for degradation and/or translational repression in a sequence-specific manner."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34155810",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 233,
"text": "MicroRNAs (miRNAs) are major post-transcriptional regulators of gene expression. They base pair with the complementary target mRNA at the 3'UTR and modulate cellular processes by repressing the mRNA translation or degrading the mRNA."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28837599",
"endSection": "abstract",
"offsetInBeginSection": 805,
"offsetInEndSection": 965,
"text": "MicroRNAs (miRNAs) have emerged as a class of post-transcriptional regulators that control gene expression through translational repression or mRNA degradation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/19643113",
"endSection": "abstract",
"offsetInBeginSection": 142,
"offsetInEndSection": 256,
"text": "There are two main outcomes for the transcripts targeted by miRNAs: mRNA degradation and translational repression."
}
] | 13
|
BioASQ-training13b
| null | null |
661c424588784bab31000001
| 5,366
|
factoid
|
What is the cause of Autosomal Recessive Polycystic Kidney Disease?
|
['polycystic kidney and hepatic disease 1 gene', 'PKHD1 gene']
|
[
"polycystic kidney and hepatic disease 1 gene",
"PKHD1 gene",
"PKHD1",
"polycystic kidney and hepatic disease 1",
"polycystic kidney disease 1 gene",
"polycystic kidney and liver disease 1 gene"
] |
['The cause of Autosomal Recessive Polycystic Kidney Disease is mutations in the polycystic kidney and hepatic disease 1 (PKHD1) gene.', 'Autosomal Recessive Polycystic Kidney Disease is caused by variants of the PKHD1 gene.', 'Variants of the PKHD1 gene are the cause of Autosomal Recessive Polycystic Kidney Disease.', 'Autosomal recessive polycystic kidney disease is caused by mutations in both alleles of the PKHD1 gene.', 'Variants of the polycystic kidney and hepatic disease 1 (PKHD1) gene are associated with autosomal recessive polycystic kidney disease (ARPKD)', 'Autosomal Recessive Polycystic Kidney Disease is caused by variants of the polycystic kidney and hepatic disease 1 (PKHD1) gene.', 'Autosomal Recessive Polycystic Kidney Disease (ARPKD) is caused by variants in the PKHD1 gene.', 'Autosomal Recessive Polycystic Kidney Disease is caused by mutations in the PKHD1 gene.', 'Autosomal Recessive Polycystic Kidney Disease is caused by variants in the PKHD1 gene.', 'Autosomal Recessive Polycystic Kidney Disease (ARPKD) is caused by variants of the polycystic kidney and hepatic disease 1 (PKHD1) gene.', 'Autosomal recessive polycystic kidney disease (ARPKD) is caused by variants of the polycystic kidney and hepatic disease 1 (PKHD1) gene.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/37456659"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37456659",
"endSection": "abstract",
"offsetInBeginSection": 11,
"offsetInEndSection": 154,
"text": "Variants of the polycystic kidney and hepatic disease 1 (PKHD1) gene are associated with autosomal recessive polycystic kidney disease (ARPKD)."
}
] | 13
|
BioASQ-training13b
| null | null |
661d6473eac11fad33000027
| 5,367
|
factoid
|
What causes Mucormycosis?
|
['Mucorales', 'Zygomycetes', 'mucormycetes']
|
[
"Mucorales",
"Zygomycetes",
"mucormycetes",
"Mucoromycetes",
"Mucorales fungi",
"Zygomycete fungi"
] |
['Mucormycosis is caused by fungi of the family Mucoraceae.', 'Mucormycosis is a serious and invasive fungal infection caused by Mucorales fungi.', 'Mucormycosis is a serious, life-threatening fungal infection caused by the exposure to mucorales.', 'Mucormycosis is caused by a fungal infection, particularly by fungi of the family Mucoraceae, and is often seen as a side effect in post-COVID-19 patients.', 'Mucormycosis is caused by the mucormycetes group of molds, which are filamentous molds within the Class Zygomycetes and Order Mucorales.', 'Mucormycosis is caused by a ubiquitous saprophytic filamentous fungus that belongs to the class Zygomycosis, specifically from the family Mucoraceae.', 'Mucormycosis is caused by a group of fungi belonging to the order Mucorales.', 'Mucormycosis is caused by fungi of the family Mucoraceae, which are ubiquitous saprophytic filamentous fungi that belong to the class Zygomycosis.', 'Fungi of the family Mucoraceae causes Mucormycosis.', 'Mucormycosis is caused by fungi belonging to the family Mucoraceae.', 'Mucormycosis is caused by filamentous molds within the Class Zygomycetes and Order Mucorales.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/36159045",
"http://www.ncbi.nlm.nih.gov/pubmed/21891908",
"http://www.ncbi.nlm.nih.gov/pubmed/23510521",
"http://www.ncbi.nlm.nih.gov/pubmed/38034231",
"http://www.ncbi.nlm.nih.gov/pubmed/34226483",
"http://www.ncbi.nlm.nih.gov/pubmed/25386533",
"http://www.ncbi.nlm.nih.gov/pubmed/35887511",
"http://www.ncbi.nlm.nih.gov/pubmed/36224039",
"http://www.ncbi.nlm.nih.gov/pubmed/30574450",
"http://www.ncbi.nlm.nih.gov/pubmed/33222179",
"http://www.ncbi.nlm.nih.gov/pubmed/34881204",
"http://www.ncbi.nlm.nih.gov/pubmed/37608614",
"http://www.ncbi.nlm.nih.gov/pubmed/8848770",
"http://www.ncbi.nlm.nih.gov/pubmed/33107473",
"http://www.ncbi.nlm.nih.gov/pubmed/36005264",
"http://www.ncbi.nlm.nih.gov/pubmed/37367595",
"http://www.ncbi.nlm.nih.gov/pubmed/35986111",
"http://www.ncbi.nlm.nih.gov/pubmed/30875744",
"http://www.ncbi.nlm.nih.gov/pubmed/20305117",
"http://www.ncbi.nlm.nih.gov/pubmed/35360784",
"http://www.ncbi.nlm.nih.gov/pubmed/36227854",
"http://www.ncbi.nlm.nih.gov/pubmed/35219907",
"http://www.ncbi.nlm.nih.gov/pubmed/10756000",
"http://www.ncbi.nlm.nih.gov/pubmed/35433396",
"http://www.ncbi.nlm.nih.gov/pubmed/36566630",
"http://www.ncbi.nlm.nih.gov/pubmed/35447883",
"http://www.ncbi.nlm.nih.gov/pubmed/21879155",
"http://www.ncbi.nlm.nih.gov/pubmed/35220559",
"http://www.ncbi.nlm.nih.gov/pubmed/37937225",
"http://www.ncbi.nlm.nih.gov/pubmed/2782563",
"http://www.ncbi.nlm.nih.gov/pubmed/36226007",
"http://www.ncbi.nlm.nih.gov/pubmed/36625576",
"http://www.ncbi.nlm.nih.gov/pubmed/14748801",
"http://www.ncbi.nlm.nih.gov/pubmed/33282040",
"http://www.ncbi.nlm.nih.gov/pubmed/37262298",
"http://www.ncbi.nlm.nih.gov/pubmed/36751448",
"http://www.ncbi.nlm.nih.gov/pubmed/19201393",
"http://www.ncbi.nlm.nih.gov/pubmed/15131477",
"http://www.ncbi.nlm.nih.gov/pubmed/36569440",
"http://www.ncbi.nlm.nih.gov/pubmed/27284399",
"http://www.ncbi.nlm.nih.gov/pubmed/36571098",
"http://www.ncbi.nlm.nih.gov/pubmed/28560130",
"http://www.ncbi.nlm.nih.gov/pubmed/21482731",
"http://www.ncbi.nlm.nih.gov/pubmed/36604110",
"http://www.ncbi.nlm.nih.gov/pubmed/36452533",
"http://www.ncbi.nlm.nih.gov/pubmed/36941816",
"http://www.ncbi.nlm.nih.gov/pubmed/29326525",
"http://www.ncbi.nlm.nih.gov/pubmed/9475685",
"http://www.ncbi.nlm.nih.gov/pubmed/23391952",
"http://www.ncbi.nlm.nih.gov/pubmed/21761152",
"http://www.ncbi.nlm.nih.gov/pubmed/15487636",
"http://www.ncbi.nlm.nih.gov/pubmed/34322352",
"http://www.ncbi.nlm.nih.gov/pubmed/35532252",
"http://www.ncbi.nlm.nih.gov/pubmed/32000287"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36566630",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 92,
"text": "Mucormycosis is a fungal infection which got worsens with time if not diagnosed and treated."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36569440",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 310,
"text": "Mucormycosis, which is a life threatening condition, is one of the side effects experienced by post-COVID-19 patients. Early identification and timely treatment are essential to stop the dissemination of the disease, since invasive mucormycosis has a very high fatality rate and significant disease dispersion."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36571098",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 150,
"text": "Mucormycosis is an emerging angioinvasive fungal infection caused by ubiquitous saprophytic filamentous fungus that belongs to the class Zygomycosis. "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36751448",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 198,
"text": "Background: Mucormycosis is a life-threatening infection of the paranasal sinuses and nasal cavities that can easily spread to the orbit and the brain. It is caused by fungi of the family Mucoraceae"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35219907",
"endSection": "abstract",
"offsetInBeginSection": 116,
"offsetInEndSection": 382,
"text": "Mucormycosis, is a severe but rare fungal infection caused by a group of molds called mucormycetes. Diabetes, use of corticosteroids, metabolic/diabetic acidosis and Covid-19 mediated immunosuppression are reported in more than 70% of cases in mucormycosis patients."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35219907",
"endSection": "abstract",
"offsetInBeginSection": 116,
"offsetInEndSection": 483,
"text": "Mucormycosis, is a severe but rare fungal infection caused by a group of molds called mucormycetes. Diabetes, use of corticosteroids, metabolic/diabetic acidosis and Covid-19 mediated immunosuppression are reported in more than 70% of cases in mucormycosis patients. Coexisting mucormycosis, Covid-19 along with diabetes mellitus increase the likelihood of mortality."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21891908",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 435,
"text": "Mucormycosis, caused by saprophytic fungi of the order Mucorales of the class Zygomycetes, is a rare opportunistic fungal infection, which has a rapidly progressive and fulminant course with fatal outcome. These fungi are ubiquitous, found in soil, bread molds, decaying fruits and vegetables. The most common form of mucormycosis is rhinocerebral and is usually seen in uncontrolled diabetes mellitus or in immunocompromised patients."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35360784",
"endSection": "abstract",
"offsetInBeginSection": 133,
"offsetInEndSection": 451,
"text": "Mucormycosis is caused by the mucormycetes group of molds. Immunocompromised states such as diabetes, chronic steroid use, and patients receiving immunosuppressant drugs are the risk factors for mucormycosis. The second wave of the COVID-19 pandemic has also invited the notorious mucormycosis in the current scenario."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35433396",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 249,
"text": "Mucormycosis is a rare but life-threatening opportunistic fungal infection caused by a group of molds that belong to Zygomycetes of the order Mucorales. These fungi are found in the environment such as soil, decaying vegetation, and organic matters."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37262298",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 113,
"text": "INTRODUCTION: Mucormycosis (MCR) is caused by filamentous molds within the Class Zygomycetes and Order Mucorales."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37262298",
"endSection": "abstract",
"offsetInBeginSection": 1076,
"offsetInEndSection": 1364,
"text": "A literature search of mucormycosis was performed via PubMed (up to November 2022), using the key words: invasivefungal infections; mold; mucormycosis;Mucorales; Zyzomyces; Zygomycosis; Rhizopus, diagnosis.EXPERT OPINION: Mucormycosis occurs primarily in severely immunocompromised hosts."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36005264",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 99,
"text": "Mucormycosis is a rare but serious fungal infection caused by a mold family known as the Mucorales."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35360784",
"endSection": "abstract",
"offsetInBeginSection": 133,
"offsetInEndSection": 191,
"text": "Mucormycosis is caused by the mucormycetes group of molds."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36159045",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 94,
"text": "Saprophytic molds such as Mucor, Rhizopus, and Absidia cause mucormycosis, a fungal infection."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35532252",
"endSection": "abstract",
"offsetInBeginSection": 365,
"offsetInEndSection": 601,
"text": "Mucormycosis is an invasive fungal disease that primarily affects immunosuppressant patients, mainly caused by mold fungi of the genus mucor, rhizopus, rhizomucor, and absidia, which are in the zygomycetes class and the Mucorales order."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/15131477",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 202,
"text": "Mucormycosis (zygomycosis) normally occurs among individuals with predisposing factors such as prematurity, use of broad spectrum antibiotics, metabolic acidosis or advanced stages of immunosuppression."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21761152",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 147,
"text": "Mucormycosis (Zygomycosis) is a rare, invasive, opportunistic fungal infection of the paranasal sinuses, caused by a fungus of the order Mucorales."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36604110",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 92,
"text": "Zygomycosis is a fungal infection in humans caused by orders Mucorales and Entomophthorales."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36226007",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 91,
"text": "Mucormycosis is a rare, aggressive angioinvasive deep fungal infection caused by mucorales."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/8848770",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 371,
"text": "Mucormycosis (zygomycosis) is an uncommon mycosis which can be contracted from the environment and which is responsible for rhino-orbital, pulmonary, gastrointestinal, cerebral or disseminated infections. Severe immunodepression, such as that caused by leukemia, lymphomata and organ graft, or treatment by desferrioxamine, may predispose to pulmonary and systemic forms."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36941816",
"endSection": "abstract",
"offsetInBeginSection": 343,
"offsetInEndSection": 457,
"text": "Mucormycosis is a fungal infection that invades the blood vessels and is caused by Mucormycetes, a group of fungi."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32000287",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 95,
"text": "Mucormycosis is an infection caused by a group of filamentous molds within the order Mucorales."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/14748801",
"endSection": "abstract",
"offsetInBeginSection": 142,
"offsetInEndSection": 311,
"text": "Genera from the order Mucorales (Rhizopus, Mucor, Rhizomucor, Absidia, Apophysomyces, Cunninghamella and Saksenaea) cause an angioinvasive infection called mucormycosis."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23510521",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 80,
"text": "Mucormycosis is an infection caused by filamentous fungi of the Mucorales order."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30875744",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 82,
"text": "Mucormycosis is an emerging life-threatening fungal infection caused by Mucorales."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21482731",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 92,
"text": "Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35220559",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 94,
"text": "Mucormycosis is a deadly opportunistic disease caused by a group of fungus named mucormycetes."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/2782563",
"endSection": "abstract",
"offsetInBeginSection": 9,
"offsetInEndSection": 185,
"text": "mucormycosis is a rare disorder caused by several genera of the family Mucoraceae. The genera Rhizopus, Absidia, and Mucor are the predominant pathogenic groups. Disease caused"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34226483",
"endSection": "abstract",
"offsetInBeginSection": 106,
"offsetInEndSection": 214,
"text": "The saprophytic fungi of Mucorales species cause the disease, Mucormycosis, only in immunocompromised hosts."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/19201393",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 434,
"text": "Mucormycosis or zygomycosis is a group of infections caused by filamentous fungi of the mucorales order belonging to the zygomycetes family. They generally appear in patients with uncontrolled diabetes or immunodepression, especially neutropenic immunodepression. Incidence has increased with progress in immunosuppressive therapy and chemotherapy and the absence of the use of antifungal prophylactic agents effective against mucors."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27284399",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 109,
"text": "BACKGROUND: The Mucorales are an important opportunistic fungi that can cause mucormycosis in immunocompromis"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30574450",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 314,
"text": "PURPOSE OF REVIEW: Mucormycosis is an emerging opportunistic fungal infection whose causative agents are found within the Mucorales family. A recent increase in immunocompromised cohorts with solid organ transplants, diabetes mellitus, and other medical conditions have resulted in increased fungal infections incl"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21879155",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 459,
"text": "Mucormycosis or zygomycosis is a rare opportunistic infection caused by aerobic saprophytic fungus that belongs to the class of Zygomycetes Mucorales family. These organisms live in the environment and enter the body by air, gastrointestinal or skin routes, through solutions of continuity of the skin. This microorganism is generally not pathogenic for immunocompetent hosts, being the development of the disease linked with the immune status of the subject."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28560130",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 111,
"text": "Mucormycosis is an opportunistic infection caused by the fungi of the Mucorales order of the class Zygomycetes."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34322352",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 150,
"text": "Mucormycosis is a rare infection caused by fungi of the order Mucorales. The infection frequently involves the rhino-cerebral or respiratory system an"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21891908",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 150,
"text": "Mucormycosis, caused by saprophytic fungi of the order Mucorales of the class Zygomycetes, is a rare opportunistic fungal infection, which has a rapid"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34881204",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 150,
"text": "Mucormycosis (also known as black fungus) is caused by fungi of the Zygomycetes class and is the third most common invasive mycosis after candidiasis "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25386533",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 150,
"text": "Mucormycosis are a group of invasive infections caused by filamentous fungi of the Mucoraceae family. Mucormycosis is essentially limited to immunocom"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35447883",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 121,
"text": "Mucormycoses are rare but serious opportunistic fungal infections caused by filamentous organisms of the order Mucorales."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35986111",
"endSection": "abstract",
"offsetInBeginSection": 901,
"offsetInEndSection": 1077,
"text": "Mucormycosis is a rare fungal infection induced by exposure to a fungus called mucormycete. The most typically implicated genera are Mucor rhyzuprhizopusdia and Cunninghamella."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36604110",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 211,
"text": "Zygomycosis is a fungal infection in humans caused by orders Mucorales and Entomophthorales. The incidence of Mucorales causing mucormycosis is on a rise and is well documented, whereas Entomophthorales is rare."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/9475685",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 237,
"text": "Mucormycosis is an uncommon infection caused by fungi of the order Mucorales, family Mucoraceae, and almost always occurs in individuals with predisposing factors such as diabetes mellitus, metabolic acidosis, or immunodeficiency states."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/15487636",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 190,
"text": "Mucormycosis is a form of fulminant invasive fungal infection of the sinonasal tract that often extends to the orbit, brain, palate, and skin. It is caused by members of the order Mucorales,"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/38034231",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 137,
"text": "Introduction Mucormycosis is a rare opportunistic fungal infection caused by fungi belonging to the Mucorales order and Mucoraceae family"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34881204",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 168,
"text": "Mucormycosis (also known as black fungus) is caused by fungi of the Zygomycetes class and is the third most common invasive mycosis after candidiasis and aspergillosis."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36227854",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 144,
"text": "Mucormycosis (previously called zygomycosis) is a serious but rare fungal infection caused by a group of fungi belonging to the order Mucorales."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37367595",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 97,
"text": "Mucormycosis is an uncommon, yet deadly invasive fungal infection caused by the Mucorales moulds."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21891908",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 205,
"text": "Mucormycosis, caused by saprophytic fungi of the order Mucorales of the class Zygomycetes, is a rare opportunistic fungal infection, which has a rapidly progressive and fulminant course with fatal outcome."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25386533",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 101,
"text": "Mucormycosis are a group of invasive infections caused by filamentous fungi of the Mucoraceae family."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32000287",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 117,
"text": "Mucormycosis is an infection caused by a group of filamentous molds within the order Mucorales. Infections may result"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37608614",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 193,
"text": "Mucormycosis is a serious and invasive fungal infection caused by Mucorales fungi. This review article provides a concise overview of the pathogenesis, epidemiology, microbiology, and diagnosis"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36224039",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 105,
"text": "Mucormycosis is a fungal disease caused by fibrous saprophytic fungi called mucorales. The most important"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37937225",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 233,
"text": "Mucormycosis is a devastating fungal infection that is usually seen in immunocompromised hosts. It is caused by fungi of the subphylum Mucoromycotina, order Mucorales, with most cases caused by Mucor, Rhizopus, or Rhizomucor species."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29326525",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 433,
"text": "Mucormycosis is one of the most rapidly progressing and fulminant forms of fungal infection which usually begins in the nose and paranasal sinuses following inhalation of fungal spores. It is caused by organisms of the subphylum Mucormycotina, including genera as Absidia, Mucor, Rhizomucor, and Rhizopus. The incidence of mucormycosis is approximately 1.7 cases per 1,000,000 inhabitants per year. Mucormycosis affecting the maxilla"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/20305117",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 110,
"text": "Mucormycosis is an aggressive, opportunistic infection caused by fungi belonging to the class of Phycomycetes."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25386533",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 455,
"text": "Mucormycosis are a group of invasive infections caused by filamentous fungi of the Mucoraceae family. Mucormycosis is essentially limited to immunocompromised patients with poorly controlled diabetes mellitus, hematologic malignancy, organ transplant, chemotherapy, chronic renal insufficiency, malnutrition, deferoxamine therapy and severe burns. The fungi invade arteries leading to thrombosis that subsequently causes necrosis of hard and soft tissues."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25386533",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 347,
"text": "Mucormycosis are a group of invasive infections caused by filamentous fungi of the Mucoraceae family. Mucormycosis is essentially limited to immunocompromised patients with poorly controlled diabetes mellitus, hematologic malignancy, organ transplant, chemotherapy, chronic renal insufficiency, malnutrition, deferoxamine therapy and severe burns."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/20305117",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 237,
"text": "Mucormycosis is an aggressive, opportunistic infection caused by fungi belonging to the class of Phycomycetes. Rhino-oculo-cerebral mucormycosis is the commonest anatomical presentation of mucormycosis and is a potentially fatal disease."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33107473",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 449,
"text": "Mucormycosis, caused by saprophytic fungi of the order Mucorales of the class zygomycetes, is a rare opportunistic fungal infection, which has a rapidly progressive and fulminant course with fatal outcome. Mucormycosis can result in an acute, rapidly advancing and occasionally fatal disease caused by different fungi typically found in the soil in association with decaying organic matter such as leaves, compost piles, or bread molds. Mucormycosis"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37262298",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 307,
"text": "INTRODUCTION: Mucormycosis (MCR) is caused by filamentous molds within the Class Zygomycetes and Order Mucorales. Infections can result from inhalation of spores into the nares, oropharynx, or lungs, ingestion of contaminated food or water, or inoculation into disrupted skin or wounds. In developed countri"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36452533",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 109,
"text": "Mucormycosis is a dreaded clinical entity caused by filamentous fungi of the order Mucorales mainly affecting"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33222179",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 114,
"text": "BACKGROUND/OBJECTIVES: Cutaneous mucormycosis is an emerging opportunistic mycosis caused by Mucorales. It can be "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36625576",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 104,
"text": "Mucormycosis is an invasive fungal infection caused by certain members of the fungal order of Mucorales."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33282040",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 110,
"text": "Mucormycosis is a rare and severe invasive fungal infection caused by ubiquitous fungi of the order Mucorales."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23391952",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 143,
"text": "Mucormycosis, also known as phycomycosis or zygomycosis, is caused by common Zygomycete fungi frequently found in soil and decaying vegetation."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35887511",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 120,
"text": "Mucormycosis is a highly aggressive angio-invasive disease of humans caused by fungi in the zygomycete order, Mucorales."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/10756000",
"endSection": "abstract",
"offsetInBeginSection": 864,
"offsetInEndSection": 1295,
"text": "Human zygomycosis caused by the Mucorales generally occurs in immunocompromised hosts as opportunistic infections. Host risk factors include diabetes mellitus, neutropenia, sustained immunosuppressive therapy, chronic prednisone use, iron chelation therapy, broad-spectrum antibiotic use, severe malnutrition, and primary breakdown in the integrity of the cutaneous barrier such as trauma, surgical wounds, needle sticks, or burns."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21891908",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 293,
"text": "Mucormycosis, caused by saprophytic fungi of the order Mucorales of the class Zygomycetes, is a rare opportunistic fungal infection, which has a rapidly progressive and fulminant course with fatal outcome. These fungi are ubiquitous, found in soil, bread molds, decaying fruits and vegetables."
}
] | 13
|
BioASQ-training13b
| null | null |
65ef8502dffffb9b6b000003
| 5,370
|
factoid
|
When was the first case of human monkey pox diagnosed?
|
['1970']
|
[
"1970"
] |
['The first case of human monkeypox was diagnosed in September 1970 in the Democratic Republic of the Congo.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/36403582"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36403582",
"endSection": "abstract",
"offsetInBeginSection": 150,
"offsetInEndSection": 235,
"text": "the detection of the first human case in the Democratic Republic of the Congo in 1970"
}
] | 13
|
BioASQ-training13b
| null | null |
66165f2afdcbea915f000051
| 5,371
|
factoid
|
What type of colorectal cancer screening is the most cost-effective for general population?
|
['Colonoscopy']
|
[
"Colonoscopy",
"Colonic endoscopy",
"Colon examination",
"Colonic inspection"
] |
['Colonoscopy every 10 years is the most cost-effective primary colorectal cancer (CRC) screening strategy in the general population according to a decision tree modeling study. Flexible sigmoidoscopy, fecal occult blood test (FOBT), and fecal immunochemical tests (FIT) were more effective than standard care, while colonoscopy and FIT-DNA were cost-effective. Screening at 40 years old is recommended for average risk individuals as it increases QALYs compared to starting at 50 years old, with flexible sigmoidoscopy being the most preferred option.', 'Based on the provided information, colonoscopy appears to be the most cost-effective colorectal cancer screening strategy for the general population. The summary states that modeling studies suggest fecal occult blood testing (FOBT) every 1-2 years, sigmoidoscopy every 5 years with FOBT every 2-3 years, and colonoscopy every 10 years are all considered cost-effective compared to no screening. However, the additional evidence specifically highlights that colonoscopy was found to be cost-effective compared to no screening and even compared to FIT (fecal immunochemical testing, a type of FOBT), with an incremental cost-effectiveness ratio of $28,071 per life-year gained. So while all three main screening strategies are cost-effective, colonoscopy seems to be the preferred choice from a cost-effectiveness perspective for average-risk individuals.', 'Colonoscopy every 10 years is the most cost-effective primary screening strategy for colorectal cancer in the general population, according to a decision tree modeling study. The study compared five common and effective CRC screening modalities in average-risk 40-year olds versus deferring screening until 50 (standard of care) under a limited societal perspective. Flexible sigmoidoscopy, FOBT, and FIT all dominated the current standard of care, while colonoscopy and FIT-DNA were cost-effective. Regardless of screening modality, CRC screening at 40 years old is cost-effective with increased QALYs compared to current screening initiation at 50 years old, with flexible sigmoidoscopy being the most preferred option. Therefore, consideration should be given for a general recommendation to start screening at age 40 for average risk individuals.', 'According to a systematic review, colorectal cancer (CRC) screening techniques such as flexible sigmoidoscopy, fecal occult blood test (FOBT), and fecal immunochemical test (FIT) have been found to be cost-effective compared to no-screening. Among these, flexible sigmoidoscopy had the lowest incremental cost-effectiveness ratio (ICER) of $PPP -16265/quality-adjusted life-year (QALY). However, the cost-effectiveness of various screening techniques may vary depending on context-specific parameters and the framework of the cost-effectiveness analysis. It is important to adopt a reference-based methodology for economic evaluation studies to make them comparable.', 'Colonoscopy is considered the most cost-effective strategy for colorectal cancer screening in the general population. It has an incremental cost-effectiveness ratio of $28,071 per life-year gained, making it a preferred choice compared to other methods like FIT (fecal immunochemical test)', 'Colonoscopy is considered the most cost-effective strategy for colorectal cancer screening in the general population. It is preferred due to its effectiveness in screening for adenoma, advanced neoplasia, and a composite endpoint of advanced neoplasia or stage I CRC, with an incremental cost-effectiveness ratio of $28,071 per life-year gained.', 'Colorectal cancer screening is a cost-effective method for reducing colorectal cancer incidence and mortality in the general population. The most cost-effective method is likely to be a combination of screening tests, such as fecal occult blood test (FOBT) and flexible sigmoidoscopy (FS). These tests have been shown to be effective in reducing colorectal cancer incidence and mortality, and they are relatively inexpensive compared to other screening methods. Additionally, risk-stratification based on genetic and phenotypic factors can help identify individuals who are at high risk for colorectal cancer and target screening efforts accordingly. Overall, colorectal cancer screening is a valuable investment in public health, as it can save lives and reduce healthcare costs in the long run.', 'The most cost-effective colorectal cancer screening strategy for the general population is colonoscopy every 10 years. This method reduces mortality at relatively low incremental costs. However, if compliance rates are low, annual fecal occult blood testing (FOBT) becomes a more cost-effective option. Flexible sigmoidoscopy every 5 or 10 years is less cost-effective than the other two screening methods. These conclusions are based on computer models of a Markov process that compare the cost-effectiveness of fecal occult blood testing, flexible sigmoidoscopy, and colonoscopy by using U.S. vital statistics, cancer statistics, published data on the sensitivity, specificity, and efficacy of various screening techniques, and Medicare reimbursement data for costs.', 'Colonoscopy is recognized as the most cost-effective strategy for colorectal cancer screening in the general population, with an incremental cost-effectiveness ratio of $28,071 per life-year gained.', 'The most cost-effective colorectal cancer screening strategy for the general population is likely to be a combination of flexible sigmoidoscopy and faecal occult blood test (FOBT) every 5 years. This approach has been shown to be highly effective in reducing colorectal cancer incidence and mortality, while also being cost-effective compared to other screening strategies.', 'Screening for colorectal cancer in the general population can be done using different methods, including fecal occult blood testing, flexible sigmoidoscopy, and colonoscopy. Colonoscopy is considered the most cost-effective strategy for colorectal cancer screening in the general population.', 'A systematic review of cost-effectiveness analyses of colorectal cancer screening in Europe suggests that fecal occult blood testing (FOBT) has shown to be cost-effective in most European countries. However, the review points out that most studies have not evaluated optimal screening intervals and may therefore have overestimated the cost-effectiveness of screening.', 'Colonoscopy is considered the most cost-effective strategy for colorectal cancer screening in the general population. This is based on a comparison to fecal immunochemical testing (FIT) where colonoscopy was found to be cost-effective for screening adenoma, advanced neoplasia, and a composite endpoint of advanced neoplasia or stage I colorectal cancer. The incremental cost-effectiveness ratio for colonoscopy was $28,071 per life-year gained.', 'According to a systematic review, colorectal cancer (CRC) screening techniques such as flexible sigmoidoscopy, fecal occult blood test (FOBT), and fecal immunochemical test (FIT) have been found to be cost-effective compared to no screening. However, the cost-effectiveness of various screening techniques may vary depending on the context-specific parameters and the framework of the cost-effectiveness analysis. A one-time colonoscopy at age 60 may also be a more cost-effective method for some individuals. It is important to adopt a reference-based methodology for economic evaluation studies to make them comparable.', 'Colonoscopy is the most cost-effective strategy for colorectal cancer screening in the general population.', 'Colonoscopy and flexible sigmoidoscopy are cost-effective strategies for colorectal cancer (CRC) screening in the general population, with colonoscopy having an incremental cost-effectiveness ratio of $28,071 per life-year gained, while flexible sigmoidoscopy has a cost-utility of $32,284 per person and offers the greatest net monetary benefit among all screening modalities assessed. Both procedures are considered cost-effective options for CRC screening.', 'Summary: Colonoscopy is the most cost-effective strategy for colorectal cancer screening in the general population, with an incremental cost-effectiveness ratio of $28,071 per life-year gained according to one abstract. The inclusion of liquid biopsy was not found to be cost-effective at its current cost and performance. Comparing colonoscopy vs. faecal immunochemical test (FIT), colonoscopy detects more adenomas, advanced lesions, or cancer than FIT with a varying incremental cost-effectiveness ratio.', 'Based on the abstracts provided, colonoscopy is the most cost-effective strategy for colorectal cancer screening in the general population. According to the first abstract, colonoscopy had an incremental cost-effectiveness ratio of $28,071 per life-year gained, making it a cost-effective strategy. The inclusion of liquid biopsy as a first- or second-line screening strategy was not cost-effective at its current cost and screening performance. In contrast, the second abstract compared the cost-effectiveness of faecal immunochemical test (FIT) vs. colonoscopy and found that colonoscopy detected more adenomas and advanced lesions or cancer than FIT, with an incremental cost-effectiveness ratio ranging from $3,489 to $922,762 depending on the outcome measured. Overall, colonoscopy is the most cost-effective strategy for colorectal cancer screening in the general population.', 'The most cost-effective colorectal cancer screening strategy for the general population is not definitively established, as it depends on various factors such as the specific population, healthcare system, and available resources. However, several studies suggest that flexible sigmoidoscopy, fecal occult blood testing (FOBT), and fecal immunochemical testing (FIT) are cost-effective screening options. In particular, flexible sigmoidoscopy has been found to be the most favorable intervention by net monetary benefit in some studies. It is important to note that the cost-effectiveness of a screening strategy can vary depending on the context-specific parameters and the framework of the cost-effectiveness analysis. Therefore, it is recommended to adopt a reference-based methodology for economic evaluation studies to make the results more comparable.', 'A comparison of colonoscopy and FIT (fecal immunochemical test) as strategies for colorectal cancer screening in the general population suggests that colonoscopy is a cost-effective strategy for colorectal cancer screening, particularly when considering adenoma, advanced neoplasia, and a composite endpoint of advanced neoplasia or stage I CRC. Compared to FIT, colonoscopy is the preferred or cost-effective strategy, with an incremental cost-effectiveness ratio of $28,071 per life-year gained. Therefore colonoscopy is the most cost-effective type of colorectal cancer screening for the general population.', 'colonoscopy was the preferred, or cost-effective, strategy with an incremental cost-effectiveness ratio of $28\u202f071 per life-year gained', 'The most cost-effective colorectal cancer screening strategy for the general population is not definitively established, as it depends on various factors such as the specific population, healthcare system, and available resources. However, several studies suggest that flexible sigmoidoscopy, fecal immunochemical test (FIT), and fecal occult blood test (FOBT) are cost-effective screening strategies. The American Cancer Society recommends a combination of FOBT and flexible sigmoidoscopy, while some experts believe that a one-time colonoscopy at age 60 may be a more cost-effective method. A systematic review found that all colorectal cancer screening techniques were cost-effective compared to no-screening methods, but the cost-effectiveness of the various screening techniques mainly depended on context-specific parameters and was highly affected by the framework of the cost-effectiveness analysis.', 'Colonoscopy every 10 years is considered the most cost-effective CRC screening strategy for the general population, achieving nearly half of the reduction in CRC mortality obtainable with colonoscopy every 10 years. The combination of annual FOBT plus sigmoidoscopy every 5 years is also cost-effective but less effective than colonoscopy every 10 years. Compliance rates significantly affect incremental CE ratios, and mathematical modeling used to inform clinical guidelines needs to take this into account.', 'Colonoscopy is considered to be the most cost-effective strategy for colorectal cancer screening in the general population. This was found in multiple studies, including one from 2023 which reported that colonoscopy was the preferred, or cost-effective, strategy with an incremental cost-effectiveness ratio of $28,071 per life-year gained. Another study from 2014 found that when compared to FIT, colonoscopy is considered cost-effective for screening adenoma, advanced neoplasia, and a composite endpoint of advanced neoplasia or stage I CRC.', 'The most cost-effective type of colorectal cancer screening for the general population is colonoscopy, as it has an incremental cost-effectiveness ratio of $28,071 per life-year gained, according to an economic evaluation comparing no screening and five colorectal cancer screening strategies including colonoscopy, liquid biopsy, liquid biopsy following nonadherence to colonoscopy, stool DNA, and fecal immunochemical test.', 'The most cost-effective type of colorectal cancer screening for the general population is colonoscopy, as it is the preferred strategy with an incremental cost-effectiveness ratio of $28,071 per life-year gained, and is particularly effective for screening adenoma, advanced neoplasia, and stage I colorectal cancer.', 'colonoscopy was the preferred, or cost-effective, strategy with an incremental cost-effectiveness ratio of $28\u202f071 per life-year gained.', 'The most cost-effective colorectal cancer (CRC) screening strategy in a general population is a subject of multiple cost-effectiveness analyses, and the results can vary depending on regional epidemiology, available screening strategies, and local healthcare systems. However, several studies suggest that some screening methods are more cost-effective than others. Fecal immunochemical tests (FIT) and colonoscopy are frequently reported as cost-effective options. For instance, in a systematic review, CRC screening with colonoscopy and FIT was found to be cost-effective compared to no screening. Another study found that, under the assumption of perfect adherence, annual mSEPT9 screening resulted in more quality-adjusted life-years gained and averted more CRC cases and deaths than annual FIT screening, but it led to a higher rate of colonoscopy referrals. Ultimately, the choice of the most cost-effective CRC screening strategy should consider factors such as effectiveness, harms, cost, screening interval, patient preferences, and test availability.']
|
[
"http://www.ncbi.nlm.nih.gov/pubmed/33840520",
"http://www.ncbi.nlm.nih.gov/pubmed/25285526",
"http://www.ncbi.nlm.nih.gov/pubmed/31790657",
"http://www.ncbi.nlm.nih.gov/pubmed/37971743",
"http://www.ncbi.nlm.nih.gov/pubmed/26685321",
"http://www.ncbi.nlm.nih.gov/pubmed/30788122",
"http://www.ncbi.nlm.nih.gov/pubmed/19807403",
"http://www.ncbi.nlm.nih.gov/pubmed/32439083",
"http://www.ncbi.nlm.nih.gov/pubmed/33953799",
"http://www.ncbi.nlm.nih.gov/pubmed/11297120",
"http://www.ncbi.nlm.nih.gov/pubmed/28976679",
"http://www.ncbi.nlm.nih.gov/pubmed/28561259",
"http://www.ncbi.nlm.nih.gov/pubmed/12118964",
"http://www.ncbi.nlm.nih.gov/pubmed/34958279",
"http://www.ncbi.nlm.nih.gov/pubmed/32294848",
"http://www.ncbi.nlm.nih.gov/pubmed/37012077",
"http://www.ncbi.nlm.nih.gov/pubmed/20624866",
"http://www.ncbi.nlm.nih.gov/pubmed/11028135",
"http://www.ncbi.nlm.nih.gov/pubmed/37594967",
"http://www.ncbi.nlm.nih.gov/pubmed/11095350",
"http://www.ncbi.nlm.nih.gov/pubmed/33088680",
"http://www.ncbi.nlm.nih.gov/pubmed/33014138",
"http://www.ncbi.nlm.nih.gov/pubmed/34129408",
"http://www.ncbi.nlm.nih.gov/pubmed/11916165",
"http://www.ncbi.nlm.nih.gov/pubmed/37968075",
"http://www.ncbi.nlm.nih.gov/pubmed/19779203",
"http://www.ncbi.nlm.nih.gov/pubmed/32761199",
"http://www.ncbi.nlm.nih.gov/pubmed/21361717",
"http://www.ncbi.nlm.nih.gov/pubmed/32001308",
"http://www.ncbi.nlm.nih.gov/pubmed/16434595",
"http://www.ncbi.nlm.nih.gov/pubmed/24672652",
"http://www.ncbi.nlm.nih.gov/pubmed/22901118",
"http://www.ncbi.nlm.nih.gov/pubmed/20059779",
"http://www.ncbi.nlm.nih.gov/pubmed/21444171",
"http://www.ncbi.nlm.nih.gov/pubmed/29702900",
"http://www.ncbi.nlm.nih.gov/pubmed/31891647",
"http://www.ncbi.nlm.nih.gov/pubmed/12943152",
"http://www.ncbi.nlm.nih.gov/pubmed/23865368",
"http://www.ncbi.nlm.nih.gov/pubmed/14986736",
"http://www.ncbi.nlm.nih.gov/pubmed/34789653",
"http://www.ncbi.nlm.nih.gov/pubmed/18341782",
"http://www.ncbi.nlm.nih.gov/pubmed/36852204",
"http://www.ncbi.nlm.nih.gov/pubmed/35954499",
"http://www.ncbi.nlm.nih.gov/pubmed/29904156",
"http://www.ncbi.nlm.nih.gov/pubmed/37099816",
"http://www.ncbi.nlm.nih.gov/pubmed/35974390",
"http://www.ncbi.nlm.nih.gov/pubmed/1599742",
"http://www.ncbi.nlm.nih.gov/pubmed/32982508",
"http://www.ncbi.nlm.nih.gov/pubmed/8898453",
"http://www.ncbi.nlm.nih.gov/pubmed/31939431",
"http://www.ncbi.nlm.nih.gov/pubmed/9177140",
"http://www.ncbi.nlm.nih.gov/pubmed/16514382",
"http://www.ncbi.nlm.nih.gov/pubmed/27538046",
"http://www.ncbi.nlm.nih.gov/pubmed/16314648",
"http://www.ncbi.nlm.nih.gov/pubmed/26338314",
"http://www.ncbi.nlm.nih.gov/pubmed/16723013",
"http://www.ncbi.nlm.nih.gov/pubmed/21623557",
"http://www.ncbi.nlm.nih.gov/pubmed/24735237",
"http://www.ncbi.nlm.nih.gov/pubmed/11863113",
"http://www.ncbi.nlm.nih.gov/pubmed/28988790",
"http://www.ncbi.nlm.nih.gov/pubmed/36276354",
"http://www.ncbi.nlm.nih.gov/pubmed/28117881",
"http://www.ncbi.nlm.nih.gov/pubmed/35081762",
"http://www.ncbi.nlm.nih.gov/pubmed/35803353",
"http://www.ncbi.nlm.nih.gov/pubmed/29977160",
"http://www.ncbi.nlm.nih.gov/pubmed/32686116",
"http://www.ncbi.nlm.nih.gov/pubmed/23247579",
"http://www.ncbi.nlm.nih.gov/pubmed/10998669",
"http://www.ncbi.nlm.nih.gov/pubmed/22898146",
"http://www.ncbi.nlm.nih.gov/pubmed/32167186",
"http://www.ncbi.nlm.nih.gov/pubmed/11033584",
"http://www.ncbi.nlm.nih.gov/pubmed/37380865",
"http://www.ncbi.nlm.nih.gov/pubmed/35361332",
"http://www.ncbi.nlm.nih.gov/pubmed/33307024",
"http://www.ncbi.nlm.nih.gov/pubmed/15699893",
"http://www.ncbi.nlm.nih.gov/pubmed/38088946",
"http://www.ncbi.nlm.nih.gov/pubmed/12489279",
"http://www.ncbi.nlm.nih.gov/pubmed/31748260",
"http://www.ncbi.nlm.nih.gov/pubmed/28973514",
"http://www.ncbi.nlm.nih.gov/pubmed/11035892",
"http://www.ncbi.nlm.nih.gov/pubmed/37050991",
"http://www.ncbi.nlm.nih.gov/pubmed/19575496",
"http://www.ncbi.nlm.nih.gov/pubmed/21633092",
"http://www.ncbi.nlm.nih.gov/pubmed/10094264",
"http://www.ncbi.nlm.nih.gov/pubmed/37752872",
"http://www.ncbi.nlm.nih.gov/pubmed/11274533"
] |
[
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37971743",
"endSection": "abstract",
"offsetInBeginSection": 2255,
"offsetInEndSection": 2354,
"text": "colonoscopy was a cost-effective strategy for colorectal cancer screening in the general population"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26338314",
"endSection": "abstract",
"offsetInBeginSection": 1289,
"offsetInEndSection": 1457,
"text": "When compared to FIT, colonoscopy is considered cost-effective for screening adenoma, advanced neoplasia, and a composite endpoint of advanced neoplasia or stage I CRC."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37971743",
"endSection": "abstract",
"offsetInBeginSection": 1749,
"offsetInEndSection": 1885,
"text": "colonoscopy was the preferred, or cost-effective, strategy with an incremental cost-effectiveness ratio of $28 071 per life-year gained."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37971743",
"endSection": "abstract",
"offsetInBeginSection": 2177,
"offsetInEndSection": 2505,
"text": "In this economic evaluation of liquid biopsy for colorectal cancer screening, colonoscopy was a cost-effective strategy for colorectal cancer screening in the general population, and the inclusion of liquid biopsy as a first- or second-line screening strategy was not cost-effective at its current cost and screening performance"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37594967",
"endSection": "abstract",
"offsetInBeginSection": 14,
"offsetInEndSection": 105,
"text": "Screening for colorectal cancer (CRC) is effective in reducing both incidence and mortality"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37050991",
"endSection": "abstract",
"offsetInBeginSection": 197,
"offsetInEndSection": 340,
"text": "Screening for colorectal cancer is a rational and cost-effective strategy for reducing the incidence of colorectal cancer and related mortality"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37968075",
"endSection": "abstract",
"offsetInBeginSection": 238,
"offsetInEndSection": 685,
"text": "However, due to the invasiveness, high cost and the need for professional endoscopists of colonoscopy, it is not feasible to directly use this method for mass population screening. Fecal immunochemical test (FIT) is one of the screening techniques recommended by authoritative international guidelines for colorectal cancer screening, and has been widely used in population-based colorectal cancer screening programs in countries around the world."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37968075",
"endSection": "abstract",
"offsetInBeginSection": 238,
"offsetInEndSection": 909,
"text": "However, due to the invasiveness, high cost and the need for professional endoscopists of colonoscopy, it is not feasible to directly use this method for mass population screening. Fecal immunochemical test (FIT) is one of the screening techniques recommended by authoritative international guidelines for colorectal cancer screening, and has been widely used in population-based colorectal cancer screening programs in countries around the world. This paper elaborates on the value of FIT in colorectal cancer screening from different aspects, such as the technical principles, the screening efficiency, the screening strategies, and the population effects and benefits."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/11033584",
"endSection": "abstract",
"offsetInBeginSection": 1781,
"offsetInEndSection": 2230,
"text": "Other assumptions about the sensitivity and specificity of fecal occult blood testing, screening frequency, efficacy of colonoscopy in preventing cancer, and polyp incidence have a lesser influence on the differences in cost-effectiveness between colonoscopy and fecal occult blood testing.CONCLUSIONS: Colonoscopy represents a cost-effective means of screening for colorectal cancer because it reduces mortality at relatively low incremental costs."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/11033584",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 369,
"text": "BACKGROUND: Fecal occult blood testing, flexible sigmoidoscopy, and colonoscopy are used to screen patients for colorectal cancer.OBJECTIVE: To compare the cost-effectiveness of fecal occult blood testing, flexible sigmoidoscopy, and colonoscopy.DESIGN: The cost-effectiveness of the three screening strategies was compared by using computer models of a Markov process."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32982508",
"endSection": "abstract",
"offsetInBeginSection": 736,
"offsetInEndSection": 2121,
"text": "e authors' consensus. The main outcome measures in this systematic review were the incremental cost-effectiveness ratio (ICER) of screening versus no-screening and then in comparison with other screening techniques. The ICER is defined by the difference in cost between two possible interventions, divided by the difference in their effect.RESULTS: Eight studies were identified and retained for the final analysis. In this study, when screening techniques were compared to no-screening, all CRC screening techniques showed to be cost-effective. The lowest ICER calculated was $PPP -16265/quality-adjusted life-year (QALY) (the negative ICERs were between purchasing power parity in US dollar ($PPP) -16265/QALY to $PPP -1988/QALY, whereas the positive ICERs were between $PPP 1257/QALY to $PPP 55987/QALY). For studies comparing various screening techniques, there was great heterogeneity in terms of the structures of the analyses, leading to diverse conclusions about their incremental cost-effectiveness.CONCLUSION: All CRC screening techniques were cost-effective, compared with the no-screening methods. The cost-effectiveness of the various screening techniques mainly was dependent on the context-specific parameters and highly affected by the framework of the cost-effectiveness analysis. In order to make the studies comparable, it is important to adopt a reference-based met"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21623557",
"endSection": "abstract",
"offsetInBeginSection": 145,
"offsetInEndSection": 2010,
"text": "g in Europe are available, generating uncertainty over its efficiency. Although immunochemical fecal tests (FIT) and guaiac-based fecal occult blood tests (g-FOBT) have been shown to be cost-effective in France, cost-effectiveness of endoscopic screening has not yet been addressed.METHODS: Cost-effectiveness of screening strategies using colonoscopy, flexible sigmoidoscopy, second-generation colon capsule endoscopy (CCE), FIT and g-FOBT were compared using a Markov model. A 40 % adherence rate was assumed for all strategies. Colonoscopy costs included anesthesiologist assistance. Incremental cost-effectiveness ratios (ICERs) were calculated. Probabilistic and value-of-information analyses were used to estimate the expected benefit of future research. A third-payer perspective was adopted.RESULTS: In the reference case analysis, FIT repeated every year was the most cost-effective strategy, with an ICER of €48165 per life-year gained vs. FIT every 2 years, which was the next most cost-effective strategy. Although CCE every 5 years was as effective as FIT 1-year, it was not a cost-effective alternative. Colonoscopy repeated every 10 years was substantially more costly, and slightly less effective than FIT 1-year. When projecting the model outputs onto the French population, the least (g-FOBT 2-years) and most (FIT 1-year) effective strategies reduced the absolute number of annual CRC deaths from 16037 to 12916 and 11217, respectively, resulting in an annual additional cost of €26 million and €347 million, respectively. Probabilistic sensitivity analysis demonstrated that FIT 1-year was the optimal choice in 20% of the simulated scenarios, whereas sigmoidoscopy 5-years, colonoscopy, and FIT 2-years were the optimal choices in 40%, 26%, and 14%, respectively.CONCLUSIONS: A screening program based on FIT 1-year appeared to be the most cost"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22901118",
"endSection": "abstract",
"offsetInBeginSection": 1470,
"offsetInEndSection": 1620,
"text": "ch lower than that for repeat screening colonoscopy (474 RMB). Single colonoscopy was a more cost-effective strategy, which was not sensitive to the c"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/11297120",
"endSection": "abstract",
"offsetInBeginSection": 200,
"offsetInEndSection": 350,
"text": "rent screening strategies of faecal occult blood testing (FOBT), flexible sigmoidoscopy combined with FOBT and colonoscopy are all cost effective. In "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/11916165",
"endSection": "abstract",
"offsetInBeginSection": 1222,
"offsetInEndSection": 1641,
"text": "The models discussed in this article suggested that colorectal cancer screening using annual FOBT, flexible sigmoidoscopy at 3 or 5 years, the combination of FOBT and flexible sigmoidoscopy, barium enema, colonoscopy, and even virtual colonoscopy had incremental cost-effectiveness ratios ranging from $6300 to $92,900 per LY saved with most of the cost-effectiveness ratio ranging from $10,000 to $40,000 per LY saved."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/10998669",
"endSection": "abstract",
"offsetInBeginSection": 481,
"offsetInEndSection": 654,
"text": "Colonoscopy-first programs are more expensive initially, but their cost effectiveness may prove to be comparable with the currently recommended programs in certain settings."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/11028135",
"endSection": "abstract",
"offsetInBeginSection": 900,
"offsetInEndSection": 1028,
"text": " published studies.RESULTS: Cost per life-year saved was $12,636 for flexible sigmoidoscopy every 5 years and $14,394 for annual"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/16514382",
"endSection": "abstract",
"offsetInBeginSection": 810,
"offsetInEndSection": 1150,
"text": "Most of these trials were performed by US or UK authors and demonstrate that the incremental cost-effectiveness ratio varies between 5 000 and 15 000 US dollars/one year life gained, with wide variations: these results were highly dependent on the unit costs of the different devices as well as the predictive values of the screening tests."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32439083",
"endSection": "abstract",
"offsetInBeginSection": 608,
"offsetInEndSection": 802,
"text": "Cost-effectiveness analysis informs decisions in ongoing debates, including preferred age to begin average-risk CRC screening, and implementation of CRC screening tailored to predicted CRC risk."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/36276354",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 104,
"text": "Cost-effectiveness analysis of a community-based colorectal cancer screening program in Shanghai, China."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/34958279",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 111,
"text": "Cost-Effectiveness of Outreach Strategies for Stool-Based Colorectal Cancer Screening in a Medicaid Population."
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35081762",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 179,
"text": "Cost-Effectiveness of Community-to-Clinic Tailored Navigation for Colorectal Cancer Screening in an Underserved Population: Economic Evaluation Alongside a Group-Randomized Trial."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33953799",
"endSection": "abstract",
"offsetInBeginSection": 1922,
"offsetInEndSection": 2825,
"text": "Sigmoidoscopy and FIT at lower thresholds (10 µg/g) and a higher uptake should be given consideration as cost-effective alternatives.PLAIN LANGUAGE SUMMARY: Cost-effectiveness analysis of colorectal cancer screening strategies in high-risk individuals Fecal occult blood testing with an immunochemical test (FIT) is generally considered as the most cost-effective alternative in colorectal cancer screening programs for average risk individuals without family history.Current screening guidelines for high-risk individuals with familial history recommend colonoscopy every 3-5 years.Colonoscopy every 3-5 years for individuals with familial history is the most effective strategy but is associated with a high incremental cost-effectiveness ratio.Compared with colonoscopy, if screening based on FIT is associated with a higher participation rate, it can achieve a similar effectiveness at a lower cost."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33840520",
"endSection": "abstract",
"offsetInBeginSection": 1289,
"offsetInEndSection": 1528,
"text": "Under varied adherence scenarios, MT-sDNA either dominates or is cost-effective (ICERs, $1740-$75,868 per QALY saved) compared with FIT and colonoscopy.CONCLUSION: Each strategy reduced costs and increased QALYs compared with no screening."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37752872",
"endSection": "abstract",
"offsetInBeginSection": 1625,
"offsetInEndSection": 1985,
"text": "In the threshold analyses, at equivalent rates to stool-based screening, mt-sDNA was always cost-effective at a willingness-to-pay threshold of $100,000 per QALY versus FIT and FOBT.CONCLUSIONS: Initiating average-risk CRC screening at age 45 instead of age 50 increases the estimated clinical benefit by reducing disease burden while remaining cost-effective."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/19779203",
"endSection": "abstract",
"offsetInBeginSection": 2012,
"offsetInEndSection": 2308,
"text": "Colonoscopy did not become cost saving, but the total net costs of this strategy decreased from $1317 to $296 per individual in the population.CONCLUSIONS: With the increase in chemotherapy costs for advanced colorectal cancer, most colorectal cancer screening strategies have become cost saving."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33953799",
"endSection": "abstract",
"offsetInBeginSection": 1536,
"offsetInEndSection": 1921,
"text": "With a lower threshold (10 µg/g) and a higher uptake of 45%, FIT was more effective and less costly than colonoscopy at a 30% uptake and was associated with an incremental cost-effectiveness ratio (ICER) of €4240/QALY versus no screening.CONCLUSION: At 30% uptake, current screening is the most effective screening strategy for high-risk individuals but is associated with a high ICER."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26685321",
"endSection": "abstract",
"offsetInBeginSection": 1482,
"offsetInEndSection": 1632,
"text": "procedures than the other strategies.CONCLUSIONS: The total colonoscopy-based strategy could be the most cost-effective for population-based colorecta"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32982508",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 445,
"text": "INTRODUCTION: Colorectal cancer (CRC) is a significant health problem with an increasing incidence worldwide. Screening is one of the ways, in which cases and deaths of CRC can be prevented. The objective of this systematic review was to evaluate the cost-effectiveness of the different CRC screening techniques and to specify the efficient technique from a cost-effectiveness perspective.METHODS: The economic studies of CRC screening in genera"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29977160",
"endSection": "abstract",
"offsetInBeginSection": 233,
"offsetInEndSection": 348,
"text": "fectiveness of colorectal cancer screening. We aim to analyze the cost-effectiveness of colorectal cancer screening"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28988790",
"endSection": "abstract",
"offsetInBeginSection": 281,
"offsetInEndSection": 1027,
"text": "discuss the cost-effectiveness of colorectal cancer screening procedures, in particular, the recent ones through the last eight years. The effectiveness of screening estimated by discounted life years gained (LYGs) compared to no screening, differed considerably between the studies. Despite these differences, all studies consistently emphasized that screening for CRC was cost-effective compared with no screening for each of the recognized screening strategies. Newer technologies for colorectal cancer screening, including computed tomographic colonography (CTC), faecal DNA test, and Pillcam Colon are less invasive and accurate, however, they are not cost-effective, as their cost was higher than all other established screening strategies."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/33014138",
"endSection": "abstract",
"offsetInBeginSection": 431,
"offsetInEndSection": 1469,
"text": "as 34%. The objective of this study was to compare the cost effectiveness of screening alternatives taking real-world participation rates into account.METHODS: Eight screening strategies were compared, based either on a screening test (Guaiac or FIT testing, blood-based, stool DNA, computed tomography colonography, colon capsules, and sigmoidoscopy) followed by full colonoscopy if positive or direct colonoscopy. A microsimulation model was used to estimate the cost effectiveness associated with each strategy.RESULTS: Compared with no screening, FIT was associated with a 14.0 quality-adjusted life year (QALY) increase of €50,520 per 1000 individuals, giving an incremental cost-effectiveness ratio (ICER) of €3600/QALY. Only stool DNA and blood-based testing were associated with a QALY increase compared with FIT, with stool DNA weakly dominated by blood-based testing, and the latter associated with an ICER of €154,600/QALY compared with FIT. All other strategies were dominated by FIT.CONCLUSION: FIT every 2 years appears to b"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/29702900",
"endSection": "abstract",
"offsetInBeginSection": 134,
"offsetInEndSection": 412,
"text": " a Markov model to compare the clinical and economic impact in terms of reducing the incidence and mortality from colorectal cancer (CRC). Six screening strategies for adults were compared: fecal occult blood (FOBT) immunochemical and guaiac type, conventional colonoscopy, flex"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28976679",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 655,
"text": "Colorectal cancer is the second most common cancer killer of Americans. Recently developed and tested methods of screening and surveillance can effectively diagnose and treat the disease in most patients before symptoms develop when the chance of cure is high. It is also possible to prevent colorectal cancer by detecting and resecting premalignant adenomatous polyps. Evidence-based guidelines recommend that the average-risk population greater than age 50 be screened with annual faecal occult blood tests plus periodic flexible sigmoidoscopy. This approach is feasible, efficacious, affordable and cost-effective in a high-risk country such as the US."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28988790",
"endSection": "abstract",
"offsetInBeginSection": 746,
"offsetInEndSection": 1183,
"text": "Newer technologies for colorectal cancer screening, including computed tomographic colonography (CTC), faecal DNA test, and Pillcam Colon are less invasive and accurate, however, they are not cost-effective, as their cost was higher than all other established screening strategies. When compliance and adherence to such new techniques are increased more than the established strategies they would be more cost-effective particularly CTC."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37050991",
"endSection": "abstract",
"offsetInBeginSection": 196,
"offsetInEndSection": 512,
"text": " Screening for colorectal cancer is a rational and cost-effective strategy for reducing the incidence of colorectal cancer and related mortality. Despite endorsement by academic and healthcare organizations, patient awareness and compliance with screening are low, partly due to patient-related barriers to screening"
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/1599742",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 58,
"text": "Cost-effective screening strategies for colorectal cancer."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37050991",
"endSection": "abstract",
"offsetInBeginSection": 92,
"offsetInEndSection": 512,
"text": " Numerous studies have shown the benefit of early screening for colorectal cancer in reducing mortality. Screening for colorectal cancer is a rational and cost-effective strategy for reducing the incidence of colorectal cancer and related mortality. Despite endorsement by academic and healthcare organizations, patient awareness and compliance with screening are low, partly due to patient-related barriers to screening"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/28988790",
"endSection": "abstract",
"offsetInBeginSection": 746,
"offsetInEndSection": 1027,
"text": "Newer technologies for colorectal cancer screening, including computed tomographic colonography (CTC), faecal DNA test, and Pillcam Colon are less invasive and accurate, however, they are not cost-effective, as their cost was higher than all other established screening strategies."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37050991",
"endSection": "abstract",
"offsetInBeginSection": 196,
"offsetInEndSection": 625,
"text": " Screening for colorectal cancer is a rational and cost-effective strategy for reducing the incidence of colorectal cancer and related mortality. Despite endorsement by academic and healthcare organizations, patient awareness and compliance with screening are low, partly due to patient-related barriers to screening.AIM: This study aimed to explore the preferred screening method for colorectal cancer in Saudi Arabia in general"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37971743",
"endSection": "abstract",
"offsetInBeginSection": 2162,
"offsetInEndSection": 2517,
"text": "and Relevance: In this economic evaluation of liquid biopsy for colorectal cancer screening, colonoscopy was a cost-effective strategy for colorectal cancer screening in the general population, and the inclusion of liquid biopsy as a first- or second-line screening strategy was not cost-effective at its current cost and screening performance. Liquid bio"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/11033584",
"endSection": "abstract",
"offsetInBeginSection": 2091,
"offsetInEndSection": 2249,
"text": "copy represents a cost-effective means of screening for colorectal cancer because it reduces mortality at relatively low incremental costs. Low compliance rat"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37971743",
"endSection": "abstract",
"offsetInBeginSection": 2032,
"offsetInEndSection": 2515,
"text": "py-liquid biopsy hybrid had a greater gain in life-years if liquid biopsy could detect polyps but remained too costly.Conclusions and Relevance: In this economic evaluation of liquid biopsy for colorectal cancer screening, colonoscopy was a cost-effective strategy for colorectal cancer screening in the general population, and the inclusion of liquid biopsy as a first- or second-line screening strategy was not cost-effective at its current cost and screening performance. Liquid b"
},
{
"beginSection": "title",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/11033584",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 69,
"text": "Cost-effectiveness of colonoscopy in screening for colorectal cancer."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37971743",
"endSection": "abstract",
"offsetInBeginSection": 1631,
"offsetInEndSection": 1894,
"text": "his study used a simulated cohort of patients aged 45 years with average risk of colorectal cancer. In the base case, colonoscopy was the preferred, or cost-effective, strategy with an incremental cost-effectiveness ratio of $28 071 per life-year gained. Colonosc"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/37594967",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 389,
"text": "INTRODUCTION: Screening for colorectal cancer (CRC) is effective in reducing both incidence and mortality. Colonoscopy and stool tests are most frequently used for this purpose. Sigmoidoscopy is an alternative screening measure with a strong evidence base. Due to its distinct characteristics, it might be preferred by subgroups. The aim of this systematic review is to analyze the cost-ef"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35974390",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 358,
"text": "INTRODUCTION: Colorectal cancer (CRC) is the second leading cause of death worldwide and the use of CRC screening tests can reduce the incidence and mortality of the disease by early detection. This study aims to review cost-effectiveness strategies in different ages and countries, systematically.METHODS: We searched ProQuest, Web of Science, Scopus, Cochr"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32001308",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 187,
"text": "The incidence of colorectal cancer (CRC) is increasing in patients under the age of 50. The purpose of this study was to assess the cost-utility of available screening modalities starting"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/31891647",
"endSection": "abstract",
"offsetInBeginSection": 1090,
"offsetInEndSection": 2028,
"text": "ted States (24,2%) and Asia (24,2%). The main screening modalities considered were fecal immunochemical tests (70%), colonoscopy (67%), guaiac fecal occult blood test (42%) and flexible sigmoidoscopy (30%). In most studies, CRC screening was deemed cost-effective compared to no screening. Sensitivity analyses indicated that cost of CRC screening tests, adherence to screening, screening test sensitivity, and cost of CRC treatment had the greatest impact on cost-effectiveness results across studies. The majority of studies (73%) adequately reported at least 50% of the items included in the CHEERS checklist. Least well reported items included setting, study perspective, discount rate, model choice, and methods to identify effectiveness data or to estimate resource use and costs.CONCLUSIONS: CRC screening is an efficient alternative to no screening. Nevertheless, it is not possible to conclude which strategy should be preferred "
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/35361332",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 493,
"text": "Colorectal cancer screening incorporates various testing modalities. Factors including effectiveness, harms, cost, screening interval, patient preferences, and test availability should be considered when determining which test to use. Fecal occult blood testing and endoscopic screening have the most robust evidence, while newer blood- and imaging-based techniques require further evaluation. In this review, we compare the effectiveness, harms, and costs of the various screening strategies."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32761199",
"endSection": "abstract",
"offsetInBeginSection": 695,
"offsetInEndSection": 1571,
"text": "ing and colonoscopy screening every 10 years. Quality-adjusted life-years gained (QALYG), number of colonoscopies, and incremental cost-effectiveness ratios were projected. We assumed a willingness-to-pay threshold of $100 000 per QALYG.RESULTS: Among the alternative tests, computed tomographic colonography every 5 years, annual mSEPT9, and annual multi-target stool DNA screening had incremental cost-effectiveness ratios of $1092, $63 253, and $214 974 per QALYG, respectively. Other screening strategies were more costly and less effective than (a combination of) these 3. Under the assumption of perfect adherence, annual mSEPT9 screening resulted in more QALYG, CRC cases averted, and CRC deaths averted than annual FIT screening but led to a high rate of colonoscopy referral (51% after 3 years, 69% after 5 years). The alternative tests were not cost-effective compar"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32439083",
"endSection": "abstract",
"offsetInBeginSection": 110,
"offsetInEndSection": 607,
"text": "Alternatives are compared based on an incremental cost-effectiveness ratio reported in terms of cost per quality-adjusted life-year gained. Multiple cost-effectiveness analyses of colorectal cancer (CRC) screening have been performed. Although regional epidemiology of CRC, relevant screening strategies, regional health system, and applicable medical costs in local currencies differ by country and region, several overarching points emerge from literature on cost-effectiveness of CRC screening."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22898146",
"endSection": "abstract",
"offsetInBeginSection": 744,
"offsetInEndSection": 987,
"text": "All economic evaluations, despite some differences between studies, add further arguments to support the opinion that the immunochemical faecal occult blood test is currently the most cost-effective screening test for average-risk populations."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23865368",
"endSection": "abstract",
"offsetInBeginSection": 1883,
"offsetInEndSection": 2045,
"text": "nal levels of WTP (Willingness to Pay). Annual high-sensitivity fecal occult blood testing, such as a fecal immunochemical test, or colonoscopy every 10 years off"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/30788122",
"endSection": "abstract",
"offsetInBeginSection": 1444,
"offsetInEndSection": 1653,
"text": "mical test programme or 31% for colonoscopy.Conclusion: Biennial faecal immunochemical test screening is better than colonoscopy as it is cost-effective, allows more individuals to get screened, and provides a"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/11863113",
"endSection": "abstract",
"offsetInBeginSection": 127,
"offsetInEndSection": 414,
"text": "The best evidence for the effectiveness of screening for colorectal cancer is with annual or biennial fecal occult blood testing. While the benefit of fecal occult blood testing is small in absolute terms, the incremental cost-effectiveness of this screening strategy appears acceptable."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/27538046",
"endSection": "abstract",
"offsetInBeginSection": 313,
"offsetInEndSection": 842,
"text": "Decision models using Markov or microsimulation modelling that compare the cost-effectiveness of different screening strategies are useful in this regard. We have reviewed recent decision models that compare the cost-effectiveness of one-off flexible sigmoidoscopy screening with immunochemical faecal occult blood (FIT) based screening. Models consistently show that any population-based screening is cost-effective compared with no screening, and that FIT-based screening is more effective than one-off sigmoidoscopy screening."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/32001308",
"endSection": "abstract",
"offsetInBeginSection": 1386,
"offsetInEndSection": 1590,
"text": "Regardless of screening modality, CRC screening at 40 years old is cost-effective with increased QALYs compared to current screening initiation at 50 years old, with flexible sigmoidoscopy most preferred."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/11863113",
"endSection": "abstract",
"offsetInBeginSection": 127,
"offsetInEndSection": 256,
"text": "The best evidence for the effectiveness of screening for colorectal cancer is with annual or biennial fecal occult blood testing."
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/19779203",
"endSection": "abstract",
"offsetInBeginSection": 1363,
"offsetInEndSection": 2127,
"text": "wed up until death.RESULTS: Compared with no screening, the treatment savings from preventing advanced colorectal cancer and colorectal cancer deaths by screening more than doubled with the widespread use of new chemotherapies. The lifetime average treatment savings were larger than the lifetime average screening costs for screening with Hemoccult II, immunochemical FOBT, sigmoidoscopy, and the combination of sigmoidoscopy and Hemoccult II (average savings vs costs per individual in the population: Hemoccult II, $1398 vs $859; immunochemical FOBT, $1756 vs $1565; sigmoidoscopy, $1706 vs $1575; sigmoidoscopy and Hemoccult II $1931 vs $1878). Colonoscopy did not become cost saving, but the total net costs of this strategy decreased from $1317 to $296 per i"
},
{
"beginSection": "abstract",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/11095350",
"endSection": "abstract",
"offsetInBeginSection": 0,
"offsetInEndSection": 295,
"text": "OBJECTIVES: Fecal occult blood testing has been shown to reduce mortality from colorectal cancer in large randomized, controlled trials conducted in the United States, Denmark, and the United Kingdom, and mathematical simulation modeling found it to be cost-effective relative to other health ca"
}
] | 13
|
BioASQ-training13b
| null | null |
65f774a4c4010b4d78000029
| 5,375
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.